Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - GAMG [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - hTERT-RPE1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - JURKAT [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - OE19 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - SuSa [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" "Single Cell Type RNA - Alveolar cells type 1 [NX]" "Single Cell Type RNA - Alveolar cells type 2 [NX]" "Single Cell Type RNA - B-cells [NX]" "Single Cell Type RNA - Basal glandular cells [NX]" "Single Cell Type RNA - Basal keratinocytes [NX]" "Single Cell Type RNA - Bipolar cells [NX]" "Single Cell Type RNA - Cardiomyocytes [NX]" "Single Cell Type RNA - Cholangiocytes [NX]" "Single Cell Type RNA - Ciliated cells [NX]" "Single Cell Type RNA - Club cells [NX]" "Single Cell Type RNA - Collecting duct cells [NX]" "Single Cell Type RNA - Cone photoreceptor cells [NX]" "Single Cell Type RNA - Cytotrophoblasts [NX]" "Single Cell Type RNA - Distal tubular cells [NX]" "Single Cell Type RNA - Ductal cells [NX]" "Single Cell Type RNA - Early spermatids [NX]" "Single Cell Type RNA - Endothelial cells [NX]" "Single Cell Type RNA - Enterocytes [NX]" "Single Cell Type RNA - Erythroid cells [NX]" "Single Cell Type RNA - Exocrine glandular cells [NX]" "Single Cell Type RNA - Extravillous trophoblasts [NX]" "Single Cell Type RNA - Fibroblasts [NX]" "Single Cell Type RNA - Glandular cells [NX]" "Single Cell Type RNA - granulocytes [NX]" "Single Cell Type RNA - Hepatocytes [NX]" "Single Cell Type RNA - Hofbauer cells [NX]" "Single Cell Type RNA - Horizontal cells [NX]" "Single Cell Type RNA - Intestinal endocrine cells [NX]" "Single Cell Type RNA - Ito cells [NX]" "Single Cell Type RNA - Kupffer cells [NX]" "Single Cell Type RNA - Late spermatids [NX]" "Single Cell Type RNA - Leydig cells [NX]" "Single Cell Type RNA - Macrophages [NX]" "Single Cell Type RNA - Melanocytes [NX]" "Single Cell Type RNA - monocytes [NX]" "Single Cell Type RNA - Mucus-secreting cells [NX]" "Single Cell Type RNA - Muller glia cells [NX]" "Single Cell Type RNA - Pancreatic endocrine cells [NX]" "Single Cell Type RNA - Paneth cells [NX]" "Single Cell Type RNA - Peritubular cells [NX]" "Single Cell Type RNA - Proximal tubular cells [NX]" "Single Cell Type RNA - Rod photoreceptor cells [NX]" "Single Cell Type RNA - Sertoli cells [NX]" "Single Cell Type RNA - Smooth muscle cells [NX]" "Single Cell Type RNA - Spermatocytes [NX]" "Single Cell Type RNA - Spermatogonia [NX]" "Single Cell Type RNA - Suprabasal keratinocytes [NX]" "Single Cell Type RNA - Syncytiotrophoblasts [NX]" "Single Cell Type RNA - T-cells [NX]" "Single Cell Type RNA - Undifferentiated cells [NX]" "Single Cell Type RNA - Urothelial cells [NX]" ABI1 "ABI-1, E3B1, SSH3BP1" ENSG00000136754 "Abl interactor 1" Q8IZP0 10 26746593-26861087 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Basal keratinocytes: 218.7;Suprabasal keratinocytes: 236.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008375, HPA068407" Approved Approved "Plasma membrane" NA NA 400000 "Plasma membrane" "CAB008375: AB_592744, HPA068407: AB_2685983" "unprognostic (2.83e-3)" "unprognostic (8.69e-2)" "unprognostic (1.12e-1)" "unprognostic (3.96e-1)" "unprognostic (2.51e-2)" "unprognostic (9.24e-3)" "unprognostic (1.88e-3)" "unprognostic (2.03e-1)" "unprognostic (6.04e-2)" "unprognostic (4.38e-1)" "unprognostic (2.40e-2)" "unprognostic (5.48e-2)" "unprognostic (1.98e-1)" "unprognostic (1.07e-1)" "unprognostic (1.79e-1)" "unprognostic (1.37e-1)" "unprognostic (1.18e-1)" 24.0 14.0 32.0 28.1 32.6 54.1 21.4 28.2 35.5 22.5 22.7 19.8 14.8 24.8 23.9 15.4 45.1 20.3 21.6 14.1 47.3 23.1 21.9 17.8 22.5 32.1 25.0 26.4 25.3 17.0 19.1 14.4 22.7 20.9 19.1 24.8 26.7 30.9 17.0 16.6 33.0 26.0 21.6 27.5 25.5 23.9 12.4 20.5 43.5 18.8 27.3 40.9 25.2 30.3 36.1 26.8 51.5 28.0 20.5 44.5 31.5 23.7 13.3 10.9 10.7 16.6 20.4 16.4 24.1 16.4 17.8 20.8 15.6 28.1 43.6 12.4 25.5 11.4 26.7 13.1 15.6 19.9 29.1 11.7 19.1 9.1 11.0 11.3 9.2 19.4 13.9 19.9 17.4 10.4 20.8 21.5 14.6 14.1 27.9 18.2 10.2 21.7 8.8 9.0 14.8 6.4 23.6 20.3 28.1 18.9 11.0 9.1 9.7 20.0 19.6 20.1 14.6 12.6 14.8 26.7 13.7 16.8 17.3 12.3 6.3 10.0 51.9 19.7 23.8 9.8 35.5 23.8 51.5 27.0 28.0 25.8 36.1 25.9 30.0 26.8 28.6 24.4 26.5 37.9 20.5 26.7 22.3 44.5 31.5 32.0 32.6 28.2 31.9 47.3 23.1 25.0 26.4 20.9 20.5 38.7 33.6 47.0 115.9 218.7 9.0 20.7 33.1 77.6 58.0 24.4 2.0 30.2 11.6 46.6 9.9 39.4 52.3 0.0 46.0 39.6 47.2 106.9 56.6 23.6 68.6 15.9 43.1 35.0 76.6 4.2 20.4 67.7 87.7 83.8 48.7 42.6 61.4 46.3 20.8 31.5 9.7 32.3 49.1 12.1 8.5 236.6 64.5 62.5 39.1 163.3 ABL1 "ABL, c-ABL, JTK7, p150" ENSG00000097007 "ABL proto-oncogene 1, non-receptor tyrosine kinase" P00519 9 130713946-130887675 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis" "DNA-binding, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002686, HPA027251, HPA027280, HPA028409" Supported Enhanced "Nucleoplasm,Nuclear bodies" Yes No Nucleoplasm "Nuclear bodies" "CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011" "unprognostic (4.82e-2)" "unprognostic (3.99e-2)" "unprognostic (5.55e-2)" "unprognostic (4.72e-2)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (3.75e-3)" "unprognostic (1.89e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-2)" "unprognostic (1.09e-2)" "unprognostic (1.48e-1)" "unprognostic (3.96e-3)" "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" 20.1 11.6 12.4 15.0 18.1 10.7 22.0 6.7 16.0 28.9 34.3 29.1 12.1 11.9 26.6 16.9 21.4 20.8 30.9 14.2 10.3 8.4 9.9 6.7 13.8 8.7 24.1 9.4 24.2 12.2 27.7 14.5 13.6 17.1 27.3 15.8 19.4 14.6 18.0 10.8 14.2 17.0 66.6 14.3 10.8 21.9 9.8 21.2 5.8 19.5 11.4 9.1 35.8 31.9 3.1 3.1 1.1 5.0 2.4 2.6 1.6 7.2 16.1 17.2 20.8 25.3 30.9 6.3 12.7 19.9 14.9 12.6 12.6 9.4 11.9 7.3 16.8 15.3 14.0 8.7 11.7 11.0 7.4 5.4 7.8 27.4 10.7 17.3 11.9 10.9 22.5 12.9 26.6 16.5 20.8 20.6 15.4 43.5 9.5 18.1 13.7 15.1 9.8 19.1 11.3 11.9 17.5 22.3 12.8 15.1 8.5 16.1 20.1 21.3 8.3 10.2 10.5 16.2 11.0 23.6 57.2 14.8 21.8 19.9 2.9 6.8 15.9 23.5 9.9 18.1 0.2 2.1 1.1 2.0 1.2 2.6 3.1 2.0 1.9 2.0 1.4 1.9 1.7 0.2 2.4 5.0 3.1 0.9 1.6 12.4 18.1 6.7 16.0 10.3 8.4 24.1 9.4 17.1 21.2 8.9 9.9 4.2 6.4 8.1 6.2 5.8 12.7 5.3 5.7 14.0 11.8 11.3 1.7 12.6 3.1 14.3 15.4 0.0 9.5 3.5 27.8 8.1 2.3 13.4 13.7 9.5 21.2 20.3 13.7 7.4 25.9 6.5 5.0 3.6 15.7 15.7 14.3 20.3 24.1 8.4 9.7 19.4 21.0 11.9 13.6 5.9 12.7 7.9 19.1 6.4 ABL2 "ABLL, ARG" ENSG00000143322 "ABL proto-oncogene 2, non-receptor tyrosine kinase" P42684 1 179099327-179229684 "Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Cone photoreceptor cells: 157.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTERT-HME1: 32.3;TIME: 30.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001866, CAB017106, HPA072754" Uncertain Approved Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "CAB017106: , HPA001866: AB_1078082, HPA072754: AB_2732212" "unprognostic (3.05e-1)" "prognostic unfavorable (3.50e-4)" "unprognostic (1.07e-1)" "unprognostic (4.71e-2)" "unprognostic (9.45e-2)" "unprognostic (8.23e-3)" "unprognostic (1.91e-2)" "unprognostic (4.81e-3)" "unprognostic (1.26e-1)" "unprognostic (6.98e-2)" "unprognostic (1.12e-1)" "unprognostic (3.73e-1)" "prognostic unfavorable (1.78e-7)" "unprognostic (4.76e-2)" "unprognostic (4.14e-2)" "unprognostic (6.08e-2)" "prognostic unfavorable (8.40e-4)" 14.3 5.2 8.6 7.4 13.7 3.7 8.3 14.9 10.6 9.2 6.6 5.8 4.5 4.0 5.4 4.7 3.9 4.3 18.8 6.8 9.7 3.9 4.9 4.3 11.5 3.7 6.5 6.1 5.6 8.4 9.2 8.4 6.1 8.1 5.1 5.2 5.8 4.5 4.4 5.2 6.6 3.7 6.9 6.2 3.9 4.7 9.2 8.6 3.6 5.8 3.1 3.6 6.7 11.2 2.8 2.0 3.8 1.2 1.8 2.2 0.6 10.1 5.6 3.7 2.5 3.2 7.4 2.3 11.3 9.3 13.9 10.1 4.1 3.1 5.9 8.4 8.0 9.6 5.1 5.4 3.8 19.8 3.7 4.9 2.8 5.1 2.0 5.9 3.1 0.9 6.8 5.0 19.8 32.3 6.0 15.4 3.0 6.7 1.7 18.1 2.7 2.5 1.7 3.6 2.0 1.8 3.7 6.3 2.9 4.7 1.6 2.3 5.2 9.4 3.0 23.2 5.9 2.7 2.6 30.1 14.5 10.8 6.9 18.1 3.1 3.9 6.1 6.8 1.8 13.9 3.8 1.2 0.4 2.2 0.4 1.0 1.8 1.4 1.4 0.9 2.8 1.9 2.0 2.6 1.8 0.5 2.0 0.8 0.6 8.6 13.7 14.9 10.6 9.7 3.9 6.5 6.1 8.1 8.6 20.8 26.6 12.4 33.8 41.7 36.0 7.0 17.8 6.7 10.3 10.4 157.1 7.7 10.0 12.7 14.0 46.7 9.7 0.0 11.9 6.7 36.0 32.7 16.2 14.5 21.0 23.8 25.9 33.7 32.7 21.4 14.1 36.5 65.8 12.6 9.6 9.8 30.1 14.4 12.7 8.4 34.1 6.5 29.3 18.2 26.3 33.5 8.7 10.1 13.9 20.7 ACKR3 "CMKOR1, CXCR7, GPR159, RDC1" ENSG00000144476 "Atypical chemokine receptor 3" P25106 2 236567787-236582358 "Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Basal keratinocytes: 19.6;Club cells: 21.6;Endothelial cells: 44.5;Fibroblasts: 27.8;Ito cells: 17.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "NK-cells: 6.1;T-cells: 6.1" "Cell line enhanced" "Detected in some" "HeLa: 23.4;MCF7: 17.2;RT4: 68.3;SiHa: 20.9;U-2197: 71.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA032003, HPA049718" Approved Supported "Vesicles,Plasma membrane" NA NA "Vesicles, Plasma membrane" "HPA032003: AB_2674107, HPA049718: AB_2680859" "unprognostic (1.65e-2)" "prognostic unfavorable (4.64e-4)" "unprognostic (2.50e-1)" "unprognostic (1.92e-3)" "unprognostic (2.10e-1)" "unprognostic (1.23e-1)" "unprognostic (7.34e-3)" "unprognostic (1.55e-2)" "unprognostic (1.85e-2)" "unprognostic (1.35e-1)" "unprognostic (9.70e-3)" "unprognostic (6.69e-2)" "prognostic unfavorable (1.76e-6)" "prognostic unfavorable (2.01e-4)" "unprognostic (9.71e-2)" "unprognostic (8.57e-3)" "prognostic unfavorable (2.93e-4)" 56.1 2.9 5.4 6.9 5.6 1.7 28.5 2.2 6.4 10.7 15.2 8.9 9.1 5.7 9.9 20.4 23.6 14.6 15.3 30.2 8.4 3.0 3.8 29.6 10.9 7.2 3.8 6.5 19.3 25.7 2.2 10.7 59.6 8.4 14.2 12.8 25.2 8.9 8.9 36.4 16.0 15.7 32.6 7.2 70.9 12.6 9.4 5.5 0.2 34.3 22.3 8.6 59.2 17.8 1.0 0.2 0.1 0.5 6.1 6.1 0.6 0.0 0.0 1.4 0.0 2.4 0.0 10.0 0.5 0.3 0.5 1.0 0.1 0.0 0.0 1.1 0.0 3.8 14.7 0.0 5.2 0.0 0.0 0.0 0.0 23.4 0.0 0.0 0.0 0.0 0.6 13.4 0.0 0.0 3.3 2.4 0.0 0.2 0.0 0.0 17.2 0.0 0.0 2.3 0.0 0.1 0.0 1.6 0.1 0.0 68.3 0.0 0.0 20.9 0.1 0.0 5.5 0.0 0.0 0.0 0.1 5.4 71.8 0.0 0.3 0.0 0.0 0.2 1.4 0.1 0.0 0.1 0.0 4.1 0.3 6.1 0.6 2.1 5.0 0.2 1.0 1.8 2.3 0.1 6.1 0.5 0.0 3.1 0.6 5.4 5.6 2.2 6.4 8.4 3.0 3.8 6.5 8.4 5.5 8.9 4.5 0.5 0.1 19.6 1.3 6.9 0.0 6.7 21.6 0.0 0.0 0.0 0.0 0.2 1.0 44.5 0.7 0.0 9.3 0.2 27.8 0.2 5.8 0.9 0.8 0.0 0.0 17.8 2.5 0.2 1.4 4.0 1.7 1.0 0.0 0.0 0.9 0.8 1.1 0.6 0.0 0.0 15.0 0.3 0.4 13.9 0.2 0.0 0.0 0.9 ACSL3 "ACS3, FACL3, PRO2194" ENSG00000123983 "Acyl-CoA synthetase long chain family member 3" O95573 2 222860934-222944639 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Fatty acid metabolism, Lipid metabolism" Ligase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "parathyroid gland: 206.1" "Cell type enhanced" "Detected in all" 9 "Horizontal cells: 494.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-MEL-30: 94.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011315, HPA071021" Approved Approved "Nucleoli,Nucleoli rim,Lipid droplets" NA NA "Nucleoli, Nucleoli rim" "Lipid droplets" "HPA011315: AB_1848344, HPA071021: AB_2686335" "unprognostic (1.87e-1)" "unprognostic (5.64e-2)" "unprognostic (2.36e-1)" "unprognostic (9.35e-3)" "unprognostic (7.53e-2)" "unprognostic (2.07e-2)" "prognostic unfavorable (2.75e-4)" "prognostic unfavorable (8.78e-4)" "unprognostic (3.90e-2)" "unprognostic (2.50e-1)" "unprognostic (2.64e-1)" "unprognostic (4.26e-2)" "unprognostic (1.17e-3)" "unprognostic (1.36e-1)" "unprognostic (2.72e-1)" "unprognostic (2.65e-1)" "unprognostic (1.60e-1)" 14.7 17.0 22.8 9.9 26.0 16.3 51.5 19.4 45.9 15.3 16.5 16.1 11.6 12.7 10.9 18.4 28.3 9.0 11.8 22.7 20.9 22.8 17.9 22.3 15.6 10.5 19.6 21.2 11.7 10.3 206.1 8.8 19.1 24.4 44.4 16.7 14.4 34.2 15.5 19.1 11.4 12.7 12.2 22.2 9.7 28.3 13.7 14.2 13.5 17.3 11.2 8.7 14.6 15.4 15.0 22.5 21.8 16.8 16.6 20.1 16.5 10.1 17.9 27.4 29.8 12.0 29.8 7.6 12.9 33.6 15.5 32.7 16.1 26.1 4.8 7.5 12.3 33.5 29.9 5.9 28.7 20.1 8.7 11.2 11.4 14.5 17.9 26.5 7.5 5.6 15.3 40.8 25.6 44.7 11.9 16.8 8.5 21.5 18.6 21.8 21.5 14.6 8.8 13.9 23.0 9.3 8.0 23.2 8.2 22.3 41.6 14.5 10.7 7.6 20.6 94.2 22.1 10.3 18.4 11.6 10.4 16.6 8.9 9.4 6.6 3.2 16.8 11.1 7.1 31.4 16.6 14.6 21.8 20.1 16.8 19.3 11.6 12.8 14.6 15.7 15.0 18.7 16.7 21.8 16.6 15.9 22.5 9.5 16.5 22.8 26.0 19.4 45.9 20.9 22.8 19.6 21.2 24.4 14.2 32.8 58.5 16.4 65.8 41.3 91.7 51.2 40.8 37.5 44.3 34.9 72.6 32.9 6.6 28.6 31.0 38.3 33.1 23.3 27.3 8.4 36.3 113.5 26.5 47.9 33.5 494.2 20.1 36.2 50.2 18.9 24.2 42.9 45.5 32.5 32.3 205.8 32.5 38.6 33.6 12.5 51.8 45.3 51.8 50.2 49.9 42.7 50.7 27.7 46.5 102.1 ACVR1 "ACVR1A, ACVRLK2, ALK2, SKR1" ENSG00000115170 "Activin A receptor type 1" Q04771 2 157736444-157875862 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007505, HPA046514" Approved Uncertain Nucleoli,Cytosol NA NA Nucleoli Cytosol "HPA007505: AB_1844752, HPA046514: AB_2732526" "unprognostic (6.99e-2)" "unprognostic (3.32e-2)" "unprognostic (3.02e-1)" "unprognostic (1.19e-2)" "unprognostic (2.73e-1)" "unprognostic (6.09e-2)" "unprognostic (3.66e-3)" "unprognostic (1.08e-1)" "unprognostic (3.99e-1)" "unprognostic (3.20e-1)" "unprognostic (2.65e-2)" "unprognostic (4.29e-2)" "unprognostic (2.42e-1)" "unprognostic (3.43e-3)" "unprognostic (3.17e-1)" "unprognostic (1.76e-2)" "prognostic unfavorable (5.17e-4)" 18.9 9.2 18.0 10.0 12.7 1.6 38.7 15.3 12.2 25.2 14.4 7.4 8.4 8.9 24.8 26.8 11.0 16.6 20.5 18.8 18.7 8.6 21.7 18.9 22.5 15.1 10.4 7.9 18.5 12.3 11.3 17.0 14.2 12.3 16.8 10.5 14.3 18.1 13.6 15.6 12.8 11.5 29.2 12.3 9.2 11.8 8.8 10.9 7.5 34.0 14.6 6.9 16.1 32.5 1.4 2.4 3.8 2.6 1.9 10.0 1.6 2.1 4.3 5.0 6.5 25.4 26.5 7.0 15.4 25.6 12.4 13.2 3.4 4.8 0.0 7.1 16.6 12.0 6.0 3.6 8.3 13.3 14.7 3.1 8.7 2.5 4.9 20.1 0.6 10.4 33.2 15.8 25.3 32.3 16.2 13.4 2.4 3.2 2.4 15.5 3.8 0.1 0.2 7.5 3.0 7.8 1.4 6.7 1.8 16.0 8.1 4.4 5.5 5.9 3.4 21.1 8.2 1.8 2.3 19.3 18.8 6.2 9.2 5.8 1.6 1.2 0.1 19.3 0.5 20.2 3.8 2.6 0.2 1.1 1.7 1.2 1.4 7.8 2.5 1.8 0.8 3.1 1.5 0.8 1.9 2.3 2.4 10.0 1.6 18.0 12.7 15.3 12.2 18.7 8.6 10.4 7.9 12.3 10.9 8.9 7.0 0.8 6.8 8.8 7.5 9.2 12.7 6.7 9.1 7.0 0.0 7.0 5.0 8.4 0.5 13.5 3.1 0.0 15.5 4.4 11.6 8.9 4.7 12.1 6.5 3.2 4.1 17.2 11.6 1.1 18.7 7.7 3.3 3.6 5.2 6.1 14.7 3.5 14.9 15.3 1.5 12.9 15.5 0.5 2.5 6.6 8.8 1.0 3.5 7.6 ACVR2A "ACTRII, ACVR2" ENSG00000121989 "Activin A receptor type 2A" P27037 2 147844517-147930826 "Cancer-related genes, Enzymes, Predicted membrane proteins" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HHSteC: 21.0;RH-30: 17.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA046997 Approved Approved Cytosol NA NA Cytosol "HPA046997: AB_10970077" "unprognostic (4.55e-2)" "unprognostic (2.26e-2)" "unprognostic (2.09e-1)" "unprognostic (7.34e-3)" "unprognostic (2.75e-1)" "unprognostic (1.17e-1)" "unprognostic (4.41e-3)" "unprognostic (8.73e-3)" "unprognostic (1.30e-2)" "unprognostic (3.61e-1)" "unprognostic (1.34e-2)" "unprognostic (1.52e-1)" "prognostic favorable (1.62e-4)" "unprognostic (1.16e-1)" "unprognostic (1.40e-1)" "unprognostic (3.95e-1)" "unprognostic (3.99e-2)" 12.0 6.0 13.6 8.2 9.9 3.8 10.7 14.5 14.2 10.2 14.1 4.7 9.7 10.4 9.3 9.9 13.6 7.6 17.7 5.6 10.0 9.0 9.0 10.3 7.5 4.7 5.9 10.6 7.6 9.8 8.6 15.9 10.6 7.3 12.2 9.1 7.6 12.2 12.0 19.6 29.5 17.8 13.8 5.4 6.5 9.3 11.0 6.4 1.5 9.5 6.9 6.8 13.5 11.8 0.7 3.0 0.5 3.6 7.7 4.6 1.4 1.3 1.6 10.0 3.7 5.9 3.8 4.1 3.1 3.7 5.3 9.3 4.3 6.0 0.0 2.8 4.9 1.9 4.7 9.1 4.5 6.8 1.0 5.5 0.6 2.8 7.4 21.0 0.6 0.7 6.3 5.7 3.4 6.8 4.1 4.0 1.2 1.4 2.6 3.6 3.5 0.3 0.5 11.3 4.0 2.6 0.1 17.5 0.9 4.2 8.5 9.9 5.6 2.6 3.1 3.8 4.5 1.9 1.0 3.1 4.9 5.8 4.6 2.1 0.7 0.2 1.8 3.0 0.3 3.9 0.4 3.0 0.5 1.2 3.6 0.5 0.3 4.6 2.1 2.3 0.7 3.0 0.7 0.1 7.7 3.1 3.0 0.4 1.4 13.6 9.9 14.5 14.2 10.0 9.0 5.9 10.6 7.3 6.4 6.0 6.5 0.5 6.7 26.4 15.8 7.8 10.2 8.1 11.4 7.0 13.7 3.9 1.7 5.0 4.1 9.8 13.2 0.0 5.6 2.1 13.5 6.7 0.0 8.6 4.7 11.1 8.6 12.9 9.4 0.8 9.2 7.6 10.1 8.2 13.8 3.7 6.3 8.6 10.6 5.0 8.5 32.3 14.4 13.8 12.8 26.1 4.5 5.1 8.5 7.1 AFDN "AF-6, AF6, MLLT4" ENSG00000130396 "Afadin, adherens junction formation factor" P55196 6 167826922-167972023 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Cell adhesion" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Alveolar cells type 1: 157.8;Alveolar cells type 2: 72.9;Ciliated cells: 85.6;Club cells: 75.1;Collecting duct cells: 90.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868" Approved Enhanced "Nucleoplasm,Plasma membrane,Cell Junctions" NA NA "Plasma membrane, Cell Junctions" Nucleoplasm "CAB013496: , HPA030212: AB_10599291, HPA030213: AB_10601340, HPA030214: AB_10601005, HPA030215: AB_10601556, HPA049868: AB_2680924" "prognostic unfavorable (7.43e-5)" "unprognostic (2.66e-3)" "unprognostic (2.07e-2)" "unprognostic (2.61e-1)" "unprognostic (1.13e-1)" "unprognostic (9.06e-2)" "unprognostic (4.12e-1)" "unprognostic (3.12e-2)" "unprognostic (4.12e-1)" "unprognostic (1.09e-3)" "unprognostic (1.75e-1)" "unprognostic (1.73e-2)" "unprognostic (5.56e-2)" "unprognostic (5.43e-3)" "unprognostic (1.59e-1)" "unprognostic (4.72e-2)" "unprognostic (5.68e-2)" 17.0 7.4 14.9 13.0 17.2 1.8 23.5 17.8 19.3 19.6 26.3 16.1 25.5 22.2 15.8 17.7 59.5 27.9 18.2 13.9 15.6 7.2 20.6 29.3 26.3 5.1 17.1 12.5 16.2 29.7 16.4 27.4 18.7 16.1 20.9 27.2 15.3 38.6 18.6 12.7 24.8 42.3 17.4 13.0 13.5 21.1 16.3 15.2 2.1 25.7 13.7 24.5 16.3 27.9 3.5 0.6 2.9 0.5 0.0 1.2 0.0 18.9 5.9 41.5 14.8 4.0 3.4 30.9 7.7 4.0 6.7 8.3 25.3 11.9 3.4 14.3 4.6 10.5 9.1 17.2 15.8 12.0 21.4 17.8 0.1 2.5 19.1 6.1 2.1 9.1 2.4 10.7 11.2 26.5 10.7 12.3 7.4 38.0 13.3 4.3 8.1 0.2 0.1 10.1 27.1 2.7 12.3 10.9 14.4 12.2 9.3 19.2 11.7 7.8 29.8 11.8 40.5 3.5 0.8 18.0 3.1 15.1 13.4 12.7 0.2 16.1 6.9 9.3 4.4 27.2 0.0 0.5 0.0 1.0 0.5 0.6 3.5 1.2 0.4 0.6 2.7 0.0 0.5 2.9 0.0 0.3 0.0 0.6 0.0 14.9 17.2 17.8 19.3 15.6 7.2 17.1 12.5 16.1 15.2 157.8 72.9 0.0 0.0 0.0 0.0 0.0 0.0 85.6 75.1 90.7 0.0 27.0 18.3 58.2 0.0 0.0 0.0 0.0 34.2 28.5 0.0 0.0 8.1 0.0 16.2 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 19.0 0.0 0.0 52.1 0.0 0.0 23.8 0.0 0.0 0.0 0.0 0.0 0.0 35.2 0.0 0.0 0.0 AFF1 "AF-4, AF4, MLLT2, PBM1" ENSG00000172493 "AF4/FMR2 family member 1" P51825 4 86935002-87141054 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 121.7" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 212.1;Rod photoreceptor cells: 150.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA069947 Approved Nucleoplasm,Mitochondria No No "Nucleoplasm, Mitochondria" "HPA069947: AB_2686219" "unprognostic (1.01e-1)" "unprognostic (7.56e-2)" "unprognostic (2.57e-3)" "unprognostic (1.53e-1)" "unprognostic (1.33e-1)" "unprognostic (1.55e-2)" "unprognostic (1.79e-1)" "unprognostic (6.23e-2)" "unprognostic (6.09e-2)" "unprognostic (7.13e-2)" "unprognostic (1.24e-1)" "unprognostic (8.32e-3)" "unprognostic (5.86e-2)" "unprognostic (1.33e-2)" "unprognostic (4.41e-1)" "unprognostic (2.55e-1)" "unprognostic (2.71e-2)" 33.7 16.6 8.0 11.8 9.5 19.5 26.5 6.5 12.2 20.2 21.0 10.5 18.9 11.1 27.4 16.6 15.8 18.6 15.3 22.4 10.3 5.3 27.6 15.5 18.4 12.9 9.3 5.5 24.7 19.0 28.6 18.5 121.7 9.5 16.8 14.3 27.0 16.0 25.6 58.8 18.6 16.2 20.3 11.5 13.9 15.0 6.7 10.3 17.0 38.8 21.1 13.9 19.5 26.5 11.3 14.6 21.1 5.4 5.1 8.8 2.8 7.9 7.3 6.1 6.4 10.1 12.1 8.6 8.0 11.8 6.1 9.2 7.7 14.8 9.0 11.0 9.8 7.8 3.6 9.6 12.1 8.5 15.4 3.8 18.8 19.1 6.4 7.8 18.0 14.9 9.8 8.8 10.5 9.3 8.9 22.5 7.6 11.5 25.6 2.6 2.1 16.2 5.2 8.1 13.3 2.6 12.9 3.6 11.5 18.1 7.6 13.9 2.5 12.3 8.1 3.9 13.4 4.8 15.1 11.3 11.4 10.4 6.9 4.4 22.2 12.3 15.6 9.4 20.8 4.1 3.5 5.4 11.7 6.7 4.1 7.4 8.0 8.8 6.6 6.0 11.3 4.7 4.4 21.1 5.1 2.2 14.6 7.5 2.8 8.0 9.5 6.5 12.2 10.3 5.3 9.3 5.5 9.5 10.3 38.7 57.2 25.4 12.5 21.4 44.7 96.4 40.8 40.2 31.8 87.2 212.1 0.9 3.3 11.6 6.6 38.8 30.8 46.7 10.9 3.8 14.6 24.9 23.3 27.7 11.3 17.5 31.0 65.1 43.0 5.4 27.0 25.6 21.9 8.2 40.8 22.0 11.1 31.7 26.9 40.9 150.1 25.8 15.6 3.5 6.4 27.7 27.5 15.2 25.3 14.4 AFF3 "LAF4, MLLT2-like" ENSG00000144218 "AF4/FMR2 family member 3" P51826 2 99545419-100142739 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 43.6" "Cell type enhanced" "Detected in many" 10 "B-cells: 79.7;Horizontal cells: 44.5" "Cancer enhanced" "Detected in many" "breast cancer: 11.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "memory B-cell: 16.2;naive B-cell: 27.5;plasmacytoid DC: 12.8" "Group enriched" "Detected in many" 16 "B-cells: 27.5;dendritic cells: 12.8" "Cell line enhanced" "Detected in many" "Daudi: 23.7;U-698: 35.1" "Low region specificity" "Detected in all" "HPA044512, HPA053379" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA044512: AB_10795984, HPA053379: AB_2682133" "unprognostic (1.05e-2)" "unprognostic (3.01e-2)" "unprognostic (2.30e-1)" "unprognostic (4.88e-3)" "unprognostic (1.02e-1)" "unprognostic (4.98e-5)" "unprognostic (1.11e-3)" "unprognostic (3.04e-2)" "unprognostic (8.75e-2)" "unprognostic (3.07e-1)" "unprognostic (1.95e-3)" "unprognostic (7.57e-2)" "prognostic unfavorable (5.64e-4)" "unprognostic (6.40e-3)" "unprognostic (6.79e-2)" "unprognostic (3.69e-2)" "unprognostic (7.87e-3)" 3.2 2.4 6.0 40.2 6.1 10.3 16.6 20.5 9.9 4.2 4.2 1.8 0.8 1.2 8.9 1.7 4.1 4.1 2.3 4.9 6.3 6.2 1.8 2.4 7.6 23.3 5.4 6.8 7.5 1.1 0.3 5.2 6.9 4.4 18.9 2.3 5.5 6.6 3.3 1.0 1.0 5.9 8.6 6.6 43.6 4.8 6.0 2.5 34.7 1.7 0.7 42.0 7.4 2.7 27.5 12.8 0.2 0.2 0.9 1.2 0.4 0.1 0.0 10.0 3.5 0.0 0.4 0.0 1.4 0.3 3.0 1.0 0.0 0.0 23.7 0.1 1.5 7.6 0.1 0.2 0.0 1.8 6.0 2.9 0.0 0.1 0.0 0.2 0.1 6.8 0.6 0.0 6.2 0.1 7.7 0.0 1.3 0.1 0.0 0.0 0.1 1.9 0.3 1.3 0.0 1.6 3.2 0.0 0.1 0.0 0.0 9.9 3.5 0.1 0.1 6.4 1.3 11.9 10.9 3.9 9.5 2.6 0.3 1.5 0.2 0.0 35.1 8.8 0.8 0.8 0.2 0.2 0.0 0.0 0.2 0.2 16.2 0.1 0.0 2.9 27.5 1.2 0.0 0.1 0.9 0.2 12.8 0.0 0.4 6.0 6.1 20.5 9.9 6.3 6.2 5.4 6.8 4.4 2.5 6.0 29.7 79.7 0.4 1.5 15.0 9.6 0.0 0.0 6.8 0.0 11.8 0.2 0.0 0.0 25.7 1.2 0.0 0.0 0.0 0.1 4.7 14.7 0.0 0.8 1.4 44.5 22.0 0.6 7.0 28.0 10.0 12.9 13.5 0.0 0.3 8.9 0.0 0.0 19.8 0.8 1.4 0.0 6.9 5.1 7.0 1.1 0.1 2.2 0.0 0.1 AFF4 "AF5Q31, MCEF" ENSG00000072364 "AF4/FMR2 family member 4" Q9UHB7 5 132875379-132963634 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Disease mutation, Dwarfism, Obesity, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023690, HPA029634" Approved Supported "Nucleoplasm,Nucleoli fibrillar center" NA NA "Nucleoplasm, Nucleoli fibrillar center" "HPA023690: AB_1844633, HPA029634: AB_2673129" "unprognostic (3.24e-2)" "unprognostic (1.86e-2)" "unprognostic (6.17e-3)" "unprognostic (1.45e-1)" "unprognostic (1.99e-1)" "unprognostic (1.10e-1)" "unprognostic (2.56e-2)" "unprognostic (7.37e-2)" "unprognostic (1.18e-1)" "unprognostic (6.13e-2)" "unprognostic (4.94e-2)" "unprognostic (3.52e-1)" "unprognostic (1.16e-2)" "unprognostic (2.77e-2)" "unprognostic (3.25e-2)" "prognostic unfavorable (6.44e-4)" "unprognostic (1.69e-1)" 22.9 29.6 22.8 19.1 38.7 38.3 23.6 37.8 25.6 26.2 21.8 25.2 22.1 14.6 27.6 19.5 29.8 20.8 26.8 21.3 18.7 18.7 25.7 24.2 24.8 19.6 19.0 19.7 34.0 24.9 48.8 40.1 20.4 18.3 26.7 18.5 27.5 25.2 25.1 32.1 22.2 17.8 24.4 18.8 17.3 24.8 17.6 24.4 26.6 33.9 15.7 19.2 26.3 24.7 8.7 5.2 12.2 4.9 3.8 5.5 1.5 16.8 13.6 18.7 20.7 14.4 17.5 14.7 18.2 19.6 16.8 21.5 20.0 11.1 8.5 21.7 23.8 20.4 8.4 15.0 22.5 28.2 6.1 9.7 10.6 18.5 7.1 18.5 3.7 11.0 20.4 15.1 29.1 29.6 18.1 16.1 7.8 7.5 7.3 20.9 6.4 10.2 3.9 7.2 5.0 5.5 6.8 18.3 3.2 14.6 23.7 14.6 15.4 20.7 5.1 20.6 27.0 10.7 6.0 22.6 20.2 17.2 17.8 19.3 10.1 17.2 7.8 19.0 6.9 13.8 12.2 2.4 3.8 5.5 2.0 4.1 7.7 5.1 3.7 2.9 8.7 5.3 4.6 5.2 3.8 4.9 5.2 2.5 1.5 22.8 38.7 37.8 25.6 18.7 18.7 19.0 19.7 18.3 24.4 74.5 31.6 45.5 71.7 70.7 71.8 55.7 68.8 48.2 73.9 55.8 149.2 32.2 6.6 46.4 222.1 55.8 54.9 0.0 40.0 37.0 72.8 98.0 41.6 20.2 36.3 74.7 93.7 57.1 46.7 140.8 64.2 53.7 65.8 30.7 46.2 72.9 61.9 60.4 63.3 26.2 136.3 77.6 56.1 34.9 20.1 75.7 58.5 51.1 37.9 92.8 AKT1 "AKT, PKB, PRKBA, RAC" ENSG00000142208 "AKT serine/threonine kinase 1" P31749 14 104769349-104795751 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Neurogenesis, Sugar transport, Translation regulation, Transport" "Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 30.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 30.7" "Cell line enhanced" "Detected in all" "MCF7: 115.3" "Low region specificity" "Detected in all" "HPA002891, CAB003765" Supported Supported Nucleoplasm,Microtubules NA NA Nucleoplasm Microtubules "CAB003765: AB_562035, HPA002891: AB_1078123" "unprognostic (3.30e-2)" "unprognostic (4.27e-2)" "unprognostic (1.98e-1)" "unprognostic (1.84e-1)" "unprognostic (3.70e-1)" "unprognostic (9.17e-3)" "unprognostic (1.55e-3)" "unprognostic (1.21e-1)" "unprognostic (1.47e-1)" "prognostic favorable (4.83e-4)" "unprognostic (3.58e-2)" "unprognostic (1.90e-2)" "prognostic favorable (2.12e-4)" "unprognostic (7.14e-2)" "unprognostic (1.28e-1)" "unprognostic (1.06e-1)" "unprognostic (2.41e-1)" 31.7 45.4 22.9 24.2 23.6 20.3 40.0 20.9 29.5 24.7 32.6 20.0 30.8 22.5 27.0 21.5 33.0 25.5 30.3 47.7 22.9 19.1 26.3 49.2 31.3 21.0 22.1 14.7 25.9 43.0 20.3 16.7 28.4 21.5 31.1 18.2 25.3 30.4 36.1 23.8 20.4 24.0 40.5 17.5 35.4 32.6 16.2 18.8 26.3 32.7 22.4 29.3 36.7 35.9 3.2 5.2 30.7 5.8 5.7 6.2 3.0 15.4 30.8 25.5 37.9 19.7 20.5 28.5 28.4 34.6 42.0 33.7 20.2 18.7 18.7 21.9 38.9 21.4 20.1 18.0 26.4 18.3 42.6 7.3 14.1 18.4 21.7 21.9 23.0 36.9 29.3 22.3 21.0 14.0 20.2 31.4 18.4 12.3 20.8 26.9 115.3 28.9 29.4 6.6 30.3 22.1 27.3 23.6 12.7 19.4 38.4 29.3 24.3 23.7 31.0 17.8 11.9 40.6 34.3 25.0 28.2 13.5 40.1 28.5 22.6 10.9 16.1 23.8 19.5 33.9 3.3 5.3 30.7 5.4 5.2 4.0 2.9 4.8 6.2 3.6 3.2 2.5 5.7 11.8 5.7 5.8 5.2 4.7 3.0 22.9 23.6 20.9 29.5 22.9 19.1 22.1 14.7 21.5 18.8 14.9 24.3 13.4 13.8 11.0 24.3 13.8 40.8 5.3 11.4 21.0 11.8 15.1 11.6 21.0 1.2 19.6 22.2 0.0 30.3 25.7 18.8 34.2 2.3 38.4 20.2 39.7 28.8 24.5 23.7 3.1 26.4 18.1 10.1 17.2 36.1 35.8 43.4 17.3 29.0 13.9 24.0 25.8 11.8 0.9 5.1 12.2 19.6 18.1 26.9 30.8 AKT2 ENSG00000105221 "AKT serine/threonine kinase 2" P31751 19 40230317-40285536 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Sugar transport, Translation regulation, Transport" "Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Diabetes mellitus, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Rod photoreceptor cells: 109.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004204, HPA064521" Uncertain Supported Nucleoplasm,Vesicles,Cytosol NA NA "Nucleoplasm, Vesicles, Cytosol" "CAB004204: AB_626659, HPA064521: AB_2685278" "unprognostic (6.13e-2)" "unprognostic (2.21e-1)" "unprognostic (1.56e-1)" "prognostic unfavorable (1.05e-6)" "unprognostic (2.85e-1)" "unprognostic (6.40e-3)" "unprognostic (9.59e-2)" "unprognostic (1.22e-2)" "unprognostic (2.98e-2)" "unprognostic (2.49e-2)" "unprognostic (3.02e-1)" "prognostic unfavorable (4.74e-4)" "unprognostic (1.30e-2)" "unprognostic (1.89e-1)" "unprognostic (3.28e-1)" "unprognostic (6.16e-2)" "unprognostic (2.00e-1)" 31.1 20.3 15.4 17.6 15.2 21.3 18.2 46.3 18.2 23.3 18.2 23.4 21.2 12.3 22.8 28.0 22.1 22.7 14.0 23.1 15.4 10.0 23.0 62.5 14.6 17.8 17.9 13.3 27.8 24.5 21.1 24.0 17.5 14.7 19.7 12.3 26.8 18.5 24.3 48.5 18.3 17.1 20.0 16.8 18.7 15.5 21.3 15.7 26.6 52.6 29.5 23.6 19.6 19.9 6.3 8.8 7.7 4.4 3.2 4.9 2.4 22.8 56.3 21.5 22.1 26.8 32.8 11.9 15.3 22.6 31.7 28.3 24.8 21.3 23.3 13.6 33.6 13.3 10.0 23.8 31.8 20.4 22.3 27.1 15.3 35.7 15.5 16.8 17.5 18.4 30.2 19.1 21.5 20.4 25.1 6.9 25.7 19.6 24.5 17.6 19.0 27.8 8.5 11.6 25.4 15.1 18.5 11.7 16.8 24.7 37.4 29.6 18.1 15.7 26.8 12.7 23.0 21.2 22.6 6.8 19.4 19.2 17.3 23.9 22.8 19.5 19.1 18.9 20.8 15.8 7.6 4.4 3.6 4.5 2.0 4.5 3.9 3.6 3.0 3.0 6.3 3.5 4.9 7.7 3.2 2.6 8.8 2.7 2.4 15.4 15.2 46.3 18.2 15.4 10.0 17.9 13.3 14.7 15.7 14.9 12.8 36.4 20.9 21.2 67.1 26.8 28.1 12.0 10.3 57.6 39.3 25.4 18.3 18.1 2.9 17.0 18.8 0.0 26.0 20.6 22.1 24.5 13.9 74.6 19.3 57.2 18.5 12.9 19.7 7.4 39.7 13.5 21.9 19.8 19.0 52.5 20.4 19.2 25.1 18.3 109.8 19.4 23.3 11.6 16.2 24.0 32.4 17.1 20.1 24.4 AL035425.2 ENSG00000260548 X 108722070-108732687 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "ovary: 13.0;pituitary gland: 7.4;thyroid gland: 8.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEK 293: 19.0;NTERA-2: 2.7;RT4: 4.9;WM-115: 5.0" NA NA 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.6 2.9 0.0 0.0 3.9 0.9 0.0 0.5 0.0 0.0 0.1 5.1 0.0 0.0 0.0 0.0 0.5 13.0 0.9 0.0 7.4 0.0 0.1 0.0 0.0 0.7 0.0 1.1 0.0 1.5 0.1 0.0 0.4 0.0 8.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 19.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.1 0.0 0.1 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921566 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 8.1;pituitary gland: 17.9" "Group enriched" "Detected in some" 12 "Early spermatids: 36.6;Late spermatids: 30.9" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 27.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" NA NA "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 1.8 3.1 3.6 1.2 4.4 0.3 1.1 0.5 8.1 0.7 2.1 2.0 0.0 0.7 0.5 0.5 0.6 0.5 1.2 0.4 3.4 4.9 0.4 0.5 1.1 0.5 2.7 4.2 0.6 0.4 0.4 17.9 0.5 5.5 0.5 1.2 2.4 0.9 0.8 0.3 0.9 1.5 0.9 2.1 0.5 0.8 4.9 0.9 0.0 1.6 0.0 0.3 0.6 1.2 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 3.6 0.0 0.0 0.1 0.3 27.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.2 0.0 4.1 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.6 4.4 0.5 5.9 3.4 4.9 2.7 4.2 5.5 0.9 0.0 0.0 0.0 0.0 0.0 1.5 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 30.9 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.0 0.0 AMER1 "FAM123B, FLJ39827, RP11-403E24.2, WTX" ENSG00000184675 "APC membrane recruitment protein 1" Q5JTC6 X 64185117-64205744 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Bipolar cells: 4.5;Cholangiocytes: 5.1;Sertoli cells: 6.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.0" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "NTERA-2: 15.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA065214, HPA065265" Approved Supported "Nuclear bodies,Vesicles,Plasma membrane" NA NA "Nuclear bodies" "Vesicles, Plasma membrane" "HPA065214: AB_2685435, HPA065265: AB_2685450" "unprognostic (1.56e-2)" "unprognostic (8.85e-2)" "unprognostic (6.86e-2)" "unprognostic (2.74e-1)" "unprognostic (2.12e-2)" "unprognostic (1.86e-1)" "unprognostic (3.57e-2)" "unprognostic (1.48e-1)" "unprognostic (8.02e-2)" "unprognostic (1.75e-1)" "unprognostic (6.31e-2)" "unprognostic (3.43e-1)" "unprognostic (4.69e-4)" "unprognostic (1.26e-1)" "unprognostic (1.13e-1)" "unprognostic (6.19e-2)" "unprognostic (2.89e-1)" 3.0 3.4 3.0 2.8 5.6 2.3 3.0 8.8 4.9 6.8 4.7 3.1 7.8 3.3 9.8 11.3 6.9 5.2 2.4 3.5 3.0 3.4 4.2 7.1 2.8 2.6 4.5 1.6 15.5 8.1 5.1 3.9 2.0 6.3 4.5 3.2 6.8 7.0 5.3 9.0 4.8 3.7 6.6 2.9 3.7 5.1 1.4 4.3 2.4 3.4 6.5 3.4 4.3 5.7 0.4 0.2 0.0 0.3 2.0 1.0 0.1 3.0 2.2 5.8 4.6 2.2 2.2 4.6 1.4 1.2 2.1 1.3 7.2 1.0 5.7 1.9 2.9 1.6 4.2 12.2 4.0 2.0 2.6 2.4 3.5 4.5 4.6 1.6 7.4 0.9 3.0 5.3 1.6 3.2 1.7 1.2 4.5 5.3 5.8 1.1 3.5 4.8 4.0 15.4 3.8 4.3 11.5 9.4 4.1 1.0 0.9 2.6 3.9 3.6 4.9 1.9 5.0 1.6 2.1 0.8 2.6 5.9 6.6 1.9 3.0 2.0 4.4 1.2 8.4 0.0 0.0 0.3 0.0 0.4 0.1 0.0 0.4 0.0 0.4 0.0 0.3 1.0 0.0 0.0 2.0 0.0 0.2 0.9 0.1 3.0 5.6 8.8 4.9 3.0 3.4 4.5 1.6 6.3 4.3 0.0 0.0 0.0 0.6 1.9 4.5 2.3 5.1 0.0 0.0 0.0 2.0 0.8 0.0 1.0 0.0 1.0 0.5 0.0 1.4 0.6 0.8 0.4 0.0 1.9 0.3 0.0 1.2 2.5 1.5 0.0 2.3 0.1 1.7 0.0 0.9 0.2 0.5 0.0 3.9 0.6 0.7 6.5 1.2 0.0 0.2 2.3 0.6 0.5 1.3 0.7 APC "DP2, DP2.5, DP3, PPP1R46" ENSG00000134982 "APC, WNT signaling pathway regulator" P25054 5 112707498-112846239 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 40.9" "Cell type enhanced" "Detected in many" 8 "Bipolar cells: 169.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013349, HPA013362" Supported Approved "Nucleoplasm,Golgi apparatus,Plasma membrane" NA NA "Plasma membrane" "Nucleoplasm, Golgi apparatus" "HPA013349: AB_1844913, HPA013362: " "unprognostic (4.80e-2)" "unprognostic (1.19e-1)" "unprognostic (3.72e-2)" "unprognostic (1.14e-1)" "unprognostic (1.10e-1)" "unprognostic (7.09e-3)" "unprognostic (1.62e-1)" "unprognostic (8.10e-3)" "unprognostic (2.35e-1)" "unprognostic (4.85e-3)" "unprognostic (1.27e-1)" "unprognostic (4.18e-2)" "unprognostic (1.02e-2)" "unprognostic (1.07e-1)" "unprognostic (3.35e-1)" "unprognostic (2.23e-2)" "unprognostic (1.96e-1)" 7.2 5.4 40.9 6.4 21.7 8.5 6.3 19.1 39.7 6.8 7.1 10.3 2.0 6.6 6.3 3.9 8.4 5.0 5.5 7.4 37.9 12.9 6.9 6.2 6.7 5.6 23.6 20.7 7.6 4.6 13.8 7.2 5.5 39.1 5.9 6.9 4.0 4.0 4.9 7.0 6.1 8.8 8.1 19.1 6.2 5.4 5.3 20.6 3.6 6.5 2.7 6.2 6.2 3.9 3.8 3.0 12.9 2.9 3.0 3.4 1.1 8.3 7.7 12.9 9.4 10.6 8.9 5.3 13.6 6.5 7.6 9.0 6.1 6.8 16.2 13.2 17.3 11.7 6.9 13.2 11.1 12.5 9.7 9.0 12.3 11.2 4.7 5.2 6.2 6.7 7.4 7.7 12.8 8.5 5.3 10.5 7.8 15.1 5.6 10.9 5.8 7.1 3.1 4.6 4.6 2.8 6.0 16.0 7.9 7.0 10.7 13.1 7.9 12.9 5.0 5.5 5.5 7.0 5.1 16.7 15.4 7.4 15.1 10.3 4.4 6.6 6.4 8.5 11.5 8.6 10.4 2.9 5.0 3.4 1.4 2.9 3.1 1.8 2.1 2.3 3.8 2.9 2.8 12.9 3.0 2.5 3.0 1.6 1.1 40.9 21.7 19.1 31.4 37.9 12.9 23.6 20.7 39.1 20.6 47.6 17.6 10.8 8.3 10.0 169.9 48.4 12.7 20.1 26.1 0.0 62.8 4.4 0.0 16.7 6.3 21.0 24.6 0.0 17.0 5.3 10.2 10.3 18.5 12.1 13.8 74.7 26.4 28.8 14.9 4.4 16.4 14.8 16.9 19.0 15.5 21.8 16.3 25.9 18.4 4.2 37.9 38.8 14.3 14.9 26.7 10.2 2.4 10.7 14.2 7.6 AR "AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1" ENSG00000169083 "Androgen receptor" P10275 X 67544032-67730619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 49.0" "Cell type enhanced" "Detected in many" 14 "Hepatocytes: 189.5;Leydig cells: 72.2;Peritubular cells: 81.3;Sertoli cells: 64.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 5.4" "Lineage enriched" "Detected in single" 16 "dendritic cells: 5.4" "Cell line enhanced" "Detected in some" "AF22: 11.3;BJ hTERT+: 9.8;HAP1: 14.4;LHCN-M2: 12.6;RH-30: 20.9;T-47d: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000001, HPA004733, CAB065764" Enhanced Supported Cytosol NA NA Cytosol "CAB000001: AB_2060174, CAB065764: AB_10620739, HPA004733: " "unprognostic (1.34e-1)" "unprognostic (8.10e-3)" "unprognostic (2.49e-2)" "unprognostic (5.95e-2)" "unprognostic (1.04e-2)" "unprognostic (3.35e-2)" "prognostic favorable (8.77e-4)" "unprognostic (4.99e-2)" "unprognostic (1.72e-1)" "unprognostic (7.79e-2)" "unprognostic (2.30e-1)" "unprognostic (2.29e-1)" "prognostic favorable (1.03e-8)" "unprognostic (8.23e-3)" "unprognostic (8.90e-2)" "unprognostic (4.23e-2)" "unprognostic (7.97e-2)" 10.1 1.2 0.9 1.6 0.9 0.1 10.7 0.4 1.6 34.4 1.9 2.4 25.4 0.2 20.5 20.5 2.2 17.5 4.3 5.7 0.9 1.5 6.3 49.0 1.5 0.2 1.2 0.7 14.4 1.0 0.1 2.3 0.3 1.9 28.0 0.5 3.8 1.6 36.1 8.1 3.9 1.1 7.6 1.9 0.9 1.6 9.3 1.2 5.4 3.1 2.0 1.2 6.3 13.1 0.0 5.4 0.3 0.0 0.1 0.0 0.1 0.0 4.7 11.3 0.0 0.0 0.1 0.0 6.0 9.8 0.4 0.1 0.2 0.0 0.0 0.0 0.7 0.0 0.0 14.4 0.0 0.1 0.0 1.9 0.0 1.1 0.0 0.7 0.0 0.0 4.6 0.0 1.7 0.0 0.0 3.5 0.1 4.1 1.9 12.6 1.2 0.0 0.0 4.5 0.0 0.0 0.0 20.9 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 3.2 8.8 5.3 0.2 0.2 2.0 0.1 3.0 0.0 0.0 0.0 4.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 5.4 0.0 0.1 0.9 0.9 0.4 1.6 0.9 1.5 1.2 0.7 1.9 1.2 0.0 5.3 0.0 18.1 8.7 0.6 31.3 12.7 6.7 19.4 3.5 0.0 1.9 1.7 7.5 0.9 4.9 0.0 0.0 0.0 0.1 9.4 31.9 1.1 189.5 0.7 0.0 0.0 14.7 1.6 1.6 72.2 2.1 10.1 2.8 0.0 0.2 1.0 0.0 81.3 22.3 0.3 64.7 12.3 0.5 1.0 14.1 0.8 0.0 0.0 15.9 ARHGAP26 "GRAF, KIAA0621, OPHN1L, OPHN1L1" ENSG00000145819 "Rho GTPase activating protein 26" Q9UNA1 5 142770377-143229011 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Late spermatids: 105.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "neutrophil: 19.6;NK-cell: 5.8" "Group enriched" "Detected in many" 4 "granulocytes: 19.6;NK-cells: 5.8" "Cell line enhanced" "Detected in many" "Karpas-707: 39.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035106, HPA035107" Enhanced Approved Cytosol NA NA Cytosol "HPA035106: AB_2674465, HPA035107: AB_10669855" "prognostic favorable (2.05e-4)" "prognostic favorable (1.36e-4)" "prognostic favorable (6.95e-4)" "prognostic favorable (5.93e-6)" "unprognostic (1.19e-1)" "unprognostic (1.93e-2)" "unprognostic (4.19e-3)" "unprognostic (5.93e-2)" "unprognostic (2.22e-1)" "unprognostic (9.43e-3)" "unprognostic (7.19e-3)" "unprognostic (8.65e-2)" "unprognostic (3.21e-3)" "unprognostic (5.67e-2)" "unprognostic (2.70e-2)" "unprognostic (2.95e-2)" "prognostic favorable (2.88e-6)" 13.3 5.7 18.4 18.6 22.7 33.9 13.0 29.2 23.9 15.9 14.2 7.5 9.9 13.2 9.4 10.9 7.6 18.5 16.4 17.0 12.8 10.5 8.0 7.7 20.0 8.8 12.9 15.4 4.8 5.5 4.8 15.1 22.4 11.9 8.5 14.8 8.8 14.6 11.2 14.0 8.5 12.6 11.1 12.6 18.9 17.0 16.1 12.2 10.3 10.0 5.4 13.6 9.4 10.6 0.3 2.0 19.6 2.8 5.8 3.0 1.0 6.9 14.0 3.9 3.6 5.8 6.4 6.0 0.8 1.2 3.4 5.9 19.1 15.8 1.0 6.9 2.2 10.3 3.3 1.9 6.6 4.2 14.3 2.2 0.0 1.8 12.1 3.7 10.2 1.4 2.3 11.6 6.2 14.3 2.7 5.0 4.8 0.2 39.7 1.0 1.1 5.8 4.2 1.8 10.3 3.6 2.2 5.8 16.6 9.9 10.7 1.5 2.4 1.8 1.9 3.2 3.1 1.0 3.1 9.6 1.8 2.6 0.2 3.6 1.8 5.7 0.2 4.8 9.7 2.5 2.9 2.8 1.6 3.0 1.7 1.3 0.2 0.6 1.8 2.0 0.3 0.2 0.8 19.6 5.8 1.0 0.5 0.2 1.0 18.4 22.7 29.2 23.9 12.8 10.5 12.9 15.4 11.9 12.2 14.9 22.7 2.9 13.9 6.2 9.5 33.7 25.5 12.0 12.5 0.0 7.9 1.1 0.0 15.6 62.7 31.7 30.5 0.0 18.9 0.7 11.6 26.2 25.5 4.3 21.6 71.5 3.5 30.1 49.8 105.1 6.1 31.8 10.1 6.4 26.2 6.3 16.0 21.5 13.4 4.4 54.5 45.3 12.7 1.9 11.3 4.8 1.6 22.7 21.7 31.9 ARHGEF12 "KIAA0382, LARG" ENSG00000196914 "Rho guanine nucleotide exchange factor 12" Q9NZN5 11 120336914-120489936 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 2.2" "Group enriched" "Detected in many" 5 "granulocytes: 2.2;NK-cells: 1.5;T-cells: 1.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018911, CAB025581" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" Nucleoplasm "CAB025581: , HPA018911: AB_1845003" "unprognostic (1.55e-1)" "unprognostic (1.29e-1)" "unprognostic (6.91e-3)" "unprognostic (1.28e-1)" "unprognostic (7.28e-2)" "unprognostic (5.39e-2)" "unprognostic (1.56e-1)" "unprognostic (5.55e-2)" "unprognostic (4.79e-2)" "unprognostic (7.77e-2)" "unprognostic (4.34e-3)" "unprognostic (4.78e-2)" "prognostic favorable (5.43e-6)" "unprognostic (1.29e-1)" "unprognostic (4.38e-2)" "unprognostic (2.13e-1)" "unprognostic (1.48e-1)" 17.6 19.2 27.6 8.3 32.5 5.9 19.6 40.4 41.5 21.7 16.4 12.4 15.7 14.9 17.5 15.9 17.8 18.6 17.3 23.4 21.8 17.7 41.2 38.8 24.1 6.5 15.8 26.3 16.3 16.9 55.8 17.2 25.4 21.1 16.8 17.8 20.7 16.7 20.0 24.1 29.0 14.8 18.6 10.8 12.4 19.0 6.7 13.0 3.0 31.3 15.0 10.9 19.4 22.9 0.3 0.3 2.2 0.1 1.5 1.0 0.4 13.2 11.1 14.9 14.3 20.2 20.2 6.2 15.6 17.7 9.5 12.1 13.0 9.7 1.1 19.2 27.8 16.8 9.9 19.1 19.7 18.6 10.9 9.4 21.5 12.0 9.9 18.1 0.0 16.0 19.3 14.3 20.8 23.2 21.0 28.7 11.7 18.1 44.1 23.9 9.2 0.0 0.0 4.1 17.1 9.6 4.7 17.1 4.2 23.3 23.0 11.0 13.6 21.8 18.3 5.7 9.3 15.6 1.7 28.4 21.1 9.0 13.7 11.3 13.0 5.2 7.3 8.7 2.8 15.9 2.2 0.0 0.0 1.0 0.1 0.2 0.3 0.6 0.6 0.0 0.3 0.0 0.5 0.0 1.5 0.1 0.3 0.7 0.4 27.6 32.5 40.4 41.5 21.8 17.7 15.8 26.3 21.1 13.0 68.5 79.7 12.3 48.8 80.4 124.2 79.1 58.6 52.2 67.1 92.5 174.7 13.7 29.9 34.0 5.0 74.1 47.9 23.3 43.8 8.3 45.2 80.8 10.5 105.8 6.1 85.8 36.4 81.0 27.2 11.5 27.6 17.4 49.0 10.8 44.1 42.4 44.6 49.0 31.5 60.7 84.8 25.8 70.9 13.5 11.9 74.4 24.0 17.5 34.8 95.3 ARID1A "B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1" ENSG00000117713 "AT-rich interaction domain 1A" O14497 1 26693236-26782110 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005456, CAB016334" Supported Enhanced Nucleoplasm NA Yes Nucleoplasm "CAB016334: AB_673396, HPA005456: AB_1078205" "unprognostic (2.83e-1)" "unprognostic (1.81e-1)" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (2.44e-1)" "unprognostic (1.89e-2)" "prognostic unfavorable (4.18e-4)" "unprognostic (3.02e-1)" "unprognostic (3.66e-2)" "unprognostic (1.34e-1)" "unprognostic (9.69e-2)" "unprognostic (7.76e-2)" "unprognostic (1.01e-2)" "unprognostic (1.62e-2)" "unprognostic (6.05e-2)" "unprognostic (2.66e-1)" "unprognostic (6.54e-2)" 18.6 18.4 17.4 24.9 17.0 33.8 27.8 23.6 19.1 20.3 23.7 21.7 23.9 15.8 24.1 17.3 23.2 20.6 21.9 15.5 14.8 12.8 13.7 15.9 18.8 35.6 20.3 19.2 24.1 23.9 27.5 15.8 19.3 17.2 16.5 16.4 18.9 21.4 23.1 22.6 20.6 20.7 18.4 15.4 25.9 19.5 16.5 19.8 57.3 24.8 14.2 24.5 24.4 20.4 4.3 5.3 7.4 3.3 4.7 5.1 3.5 19.2 18.3 25.9 27.0 7.5 7.2 12.2 9.0 7.9 12.4 8.8 13.3 13.0 27.2 7.9 11.7 7.8 11.7 22.5 10.0 14.5 33.6 8.8 23.1 11.9 8.9 6.2 34.2 7.4 8.3 7.1 14.6 10.5 6.9 10.6 19.7 27.6 30.5 8.0 9.1 28.8 13.3 27.4 12.5 8.5 30.1 17.1 15.4 7.7 13.0 24.3 20.0 15.8 13.4 10.9 15.0 3.9 19.4 18.7 13.3 12.9 12.4 14.6 14.5 19.1 12.5 8.1 21.9 11.7 0.4 3.3 2.9 4.0 2.9 5.1 4.3 3.2 4.9 3.1 4.3 4.0 4.4 7.4 4.7 2.8 5.3 1.5 3.5 17.4 17.0 23.6 19.1 14.8 12.8 20.3 19.2 17.2 19.8 56.6 36.8 33.6 18.1 65.3 60.2 31.1 28.1 25.4 28.4 36.6 49.1 31.8 1.7 31.8 14.2 37.2 28.4 0.0 32.5 32.1 42.6 39.3 56.9 53.9 43.0 69.9 45.7 51.0 93.5 7.5 35.6 45.4 38.8 34.3 56.1 31.2 40.3 31.6 39.3 14.5 37.1 51.8 27.2 46.0 55.3 82.4 30.7 41.2 46.0 27.7 ARID1B "6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R" ENSG00000049618 "AT-rich interaction domain 1B" Q8NFD5 6 156777374-157210779 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Neurogenesis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016511, HPA075291" Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA016511: AB_1845008, HPA075291: AB_2686743" "prognostic unfavorable (1.04e-4)" "unprognostic (9.82e-2)" "unprognostic (1.73e-1)" "unprognostic (5.42e-2)" "unprognostic (7.47e-2)" "unprognostic (1.40e-2)" "unprognostic (2.73e-2)" "unprognostic (2.89e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (4.16e-4)" "unprognostic (2.53e-1)" "unprognostic (5.33e-2)" "unprognostic (1.07e-3)" "unprognostic (2.46e-1)" "unprognostic (1.80e-1)" "unprognostic (3.53e-1)" "unprognostic (1.16e-1)" 18.3 15.0 20.2 18.8 20.9 25.8 19.3 42.1 32.8 20.0 17.4 26.3 21.7 15.3 23.0 14.2 18.6 20.7 15.9 16.8 20.4 11.3 14.2 10.6 17.0 18.3 19.4 16.7 30.2 18.5 47.4 29.2 12.2 17.7 17.7 13.3 24.0 20.0 20.2 30.6 27.3 17.8 21.7 14.9 21.1 15.0 10.7 24.6 24.0 23.8 13.3 26.3 23.5 21.0 9.5 11.9 5.6 3.0 2.7 5.6 1.6 7.2 11.1 16.4 22.3 13.5 12.4 11.2 7.7 10.1 10.0 10.0 9.8 10.5 22.8 4.8 13.0 12.3 9.2 14.0 12.5 9.9 22.9 9.8 16.5 11.2 11.6 9.5 13.7 12.1 14.0 10.1 15.2 13.6 10.9 13.8 14.9 19.4 17.8 7.1 8.5 15.9 15.5 8.3 9.6 5.9 36.3 7.0 12.3 6.9 13.4 15.0 19.2 15.4 16.2 9.0 9.0 10.9 21.6 14.2 12.6 13.4 11.6 15.0 12.3 11.0 29.2 11.0 16.5 16.9 5.6 3.0 2.5 5.4 2.4 5.0 6.8 4.7 3.8 2.3 9.5 4.0 5.6 5.5 2.7 2.6 11.9 4.6 1.6 20.2 20.9 42.1 32.8 20.4 11.3 19.4 16.7 17.7 24.6 44.7 46.7 59.6 18.3 42.2 35.6 27.8 28.1 28.1 36.4 120.4 27.5 10.8 6.6 33.6 12.1 27.8 19.2 0.0 29.8 6.4 27.7 23.2 38.1 23.3 12.3 44.5 39.2 37.4 29.2 13.0 52.6 28.8 28.7 72.1 38.0 23.8 39.9 21.0 59.1 12.2 30.1 45.3 28.2 6.3 14.9 48.7 14.6 23.2 34.9 20.2 ARID2 "BAF200, DKFZp686G052, FLJ30619, KIAA1557" ENSG00000189079 "AT-rich interaction domain 2" Q68CP9 12 45729665-45908040 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "Early spermatids: 522.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063044 Supported "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "HPA063044: AB_2684929" "unprognostic (8.41e-2)" "unprognostic (1.03e-1)" "unprognostic (4.02e-2)" "unprognostic (3.94e-2)" "unprognostic (4.15e-2)" "prognostic favorable (5.75e-4)" "unprognostic (1.26e-2)" "unprognostic (9.71e-2)" "unprognostic (9.04e-2)" "unprognostic (5.57e-2)" "unprognostic (1.34e-1)" "unprognostic (2.47e-1)" "unprognostic (1.12e-2)" "unprognostic (9.21e-2)" "unprognostic (3.02e-1)" "unprognostic (2.00e-1)" "unprognostic (6.53e-2)" 9.0 7.9 7.1 14.6 7.2 14.0 11.8 15.7 8.8 10.2 11.4 8.2 17.9 6.4 12.2 10.7 11.5 8.8 10.6 8.2 7.4 5.8 8.7 6.9 10.2 13.0 9.6 3.8 12.2 10.7 18.4 15.1 10.3 7.5 9.9 8.1 10.1 9.7 20.6 8.6 13.5 12.6 12.5 7.3 10.2 9.0 30.9 11.0 33.3 11.5 8.2 11.2 10.0 10.0 2.1 5.3 10.5 4.9 3.1 4.4 1.3 5.4 7.8 14.0 6.1 6.0 4.2 7.6 3.8 5.4 5.3 5.0 11.1 5.6 10.5 7.1 5.2 3.9 6.6 11.3 6.5 7.7 4.6 5.4 13.9 8.6 5.4 4.1 10.9 6.4 3.4 4.9 6.7 10.8 7.5 5.4 15.9 11.7 10.9 4.7 7.1 15.6 7.8 8.4 0.0 4.2 12.1 10.0 10.1 5.1 9.1 7.6 9.7 6.2 7.2 6.0 8.4 11.0 21.9 6.4 5.7 6.9 3.8 4.9 7.3 6.1 29.4 4.4 28.8 4.0 10.5 1.7 4.2 4.1 2.2 4.3 1.7 3.7 4.4 2.4 2.1 3.6 3.3 2.4 3.1 4.9 5.3 3.1 1.3 7.1 7.2 15.7 8.8 7.4 5.8 9.6 3.8 7.5 11.0 26.8 27.9 10.2 11.5 30.0 49.0 12.6 5.1 9.4 12.5 27.9 64.8 11.9 6.6 11.2 522.0 21.5 15.0 0.0 8.7 8.9 17.5 17.9 20.9 13.1 9.9 30.2 20.2 16.5 27.5 122.6 23.0 20.0 13.5 12.6 19.9 19.7 15.6 24.6 21.2 6.9 67.9 25.8 22.7 61.7 16.5 36.1 19.6 24.5 16.0 16.5 ARNT "bHLHe2, HIF-1beta" ENSG00000143437 "Aryl hydrocarbon receptor nuclear translocator" P27540 1 150809705-150876768 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in many" 7 "U-698: 97.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001759, CAB004318" Supported Supported "Nucleoplasm,Nuclear bodies" NA NA "Nucleoplasm, Nuclear bodies" "CAB004318: AB_626698, HPA001759: AB_1078213" "unprognostic (1.81e-1)" "unprognostic (8.14e-2)" "unprognostic (6.87e-2)" "unprognostic (5.76e-2)" "unprognostic (1.86e-1)" "unprognostic (4.10e-2)" "unprognostic (9.43e-2)" "unprognostic (5.27e-3)" "unprognostic (5.05e-1)" "unprognostic (3.42e-2)" "unprognostic (1.22e-1)" "unprognostic (9.52e-2)" "unprognostic (1.85e-3)" "unprognostic (2.68e-1)" "unprognostic (4.67e-1)" "unprognostic (6.45e-2)" "unprognostic (6.92e-2)" 23.5 20.8 12.1 14.5 12.6 11.3 25.1 25.4 14.4 28.0 17.2 18.7 12.8 10.9 26.1 14.4 16.6 20.4 17.9 20.0 10.2 8.2 14.4 32.2 21.6 12.0 11.6 9.5 31.8 22.4 16.5 22.9 31.7 12.3 18.2 16.4 28.3 15.2 16.3 25.5 21.9 15.2 22.6 14.0 19.2 16.5 14.9 12.3 18.8 16.1 13.9 18.0 23.0 24.4 6.6 12.7 23.9 15.6 8.0 8.8 9.7 4.0 4.2 6.4 4.8 13.7 13.2 8.6 4.6 9.2 6.4 5.8 3.6 4.2 4.3 4.2 8.3 3.1 4.7 5.8 5.2 5.6 6.9 3.5 5.2 7.2 4.2 7.9 6.1 6.1 10.3 4.9 7.7 6.8 7.7 7.8 5.9 6.6 8.7 6.5 8.0 4.9 3.4 5.2 7.4 3.3 6.2 7.7 6.1 5.0 4.2 4.2 6.3 9.0 6.2 3.6 9.0 7.8 13.4 5.5 5.3 4.8 4.2 4.0 9.9 7.2 97.0 6.5 0.2 3.6 23.9 15.6 13.9 8.8 14.7 7.9 6.2 7.2 8.4 12.7 6.6 7.0 7.1 8.1 8.0 14.7 5.2 7.2 9.7 12.1 12.6 25.4 14.4 10.2 8.2 11.6 9.5 12.3 12.3 11.9 9.3 9.7 7.8 12.6 20.9 10.6 22.9 6.7 11.4 10.4 51.1 20.7 3.3 8.1 4.2 11.7 8.6 0.0 8.5 31.6 20.3 7.2 3.5 36.0 17.1 6.4 19.5 31.9 35.9 2.1 30.0 15.7 10.1 14.4 15.1 7.7 8.6 7.0 30.8 9.3 37.6 12.9 15.0 18.6 15.7 13.4 24.7 10.1 8.0 8.6 ASPSCR1 "ASPL, ASPS, TUG, UBXD9, UBXN9" ENSG00000169696 "ASPSCR1, UBX domain containing tether for SLC2A4" Q9BZE9 17 81976807-82017406 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Extravillous trophoblasts: 151.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in all" 5 "Hep G2: 82.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA026749 Approved Supported "Nucleoplasm,Vesicles,Plasma membrane" NA NA Nucleoplasm "Vesicles, Plasma membrane" "HPA026749: AB_1845114" "unprognostic (5.01e-2)" "unprognostic (1.19e-3)" "unprognostic (7.61e-2)" "unprognostic (1.34e-1)" "unprognostic (1.36e-1)" "prognostic favorable (8.55e-4)" "unprognostic (2.02e-1)" "unprognostic (2.07e-2)" "unprognostic (3.43e-1)" "unprognostic (1.71e-3)" "prognostic favorable (2.67e-4)" "unprognostic (1.13e-1)" "prognostic unfavorable (1.26e-4)" "unprognostic (3.16e-2)" "unprognostic (1.13e-1)" "unprognostic (2.27e-1)" "unprognostic (1.01e-2)" 10.3 12.6 14.3 12.6 14.5 16.8 10.6 16.5 20.8 9.9 12.9 16.7 11.8 17.5 10.1 15.8 11.9 9.3 15.1 11.5 13.1 12.6 15.8 31.9 14.1 14.8 18.9 12.9 8.8 17.8 17.0 19.7 21.8 14.8 13.2 7.1 14.4 22.6 9.9 25.1 15.5 14.4 9.1 12.6 13.2 13.0 16.9 14.6 9.8 16.4 12.9 13.0 9.7 8.3 8.1 14.6 15.7 11.3 7.2 10.5 5.2 5.1 9.0 3.5 5.1 2.2 2.8 15.3 4.9 3.7 5.9 5.8 5.2 5.9 5.2 5.0 3.5 4.5 2.5 3.8 3.7 1.8 3.6 11.5 5.8 7.3 82.6 7.3 5.1 8.5 3.2 4.0 2.9 2.1 3.1 5.6 4.4 5.8 7.5 3.3 17.3 4.7 11.1 4.4 9.5 6.6 5.2 5.1 10.6 5.7 4.7 9.4 9.6 3.9 12.6 9.0 4.2 7.5 12.2 4.6 10.1 7.0 7.4 6.1 5.4 3.2 5.8 5.4 5.2 6.0 15.7 11.3 8.0 6.7 7.6 4.0 7.9 10.5 9.0 14.6 8.1 8.0 6.0 2.9 7.2 9.3 9.1 4.9 5.2 14.3 14.5 16.5 20.8 13.1 12.6 18.9 12.9 14.8 14.6 8.9 46.0 18.6 20.7 11.8 21.4 11.4 17.8 10.7 9.1 14.0 39.3 64.7 33.2 21.2 40.2 16.0 26.7 0.0 22.9 151.3 16.6 19.3 20.8 45.6 39.1 47.7 24.0 15.4 16.6 63.2 10.9 17.1 18.6 18.0 24.4 56.7 16.2 20.1 16.6 44.0 32.8 12.9 15.3 43.6 48.7 12.5 49.7 23.6 23.8 19.7 ASXL1 KIAA0978 ENSG00000171456 "Additional sex combs like 1, transcriptional regulator" Q8IXJ9 20 32358330-32439319 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Chromatin regulator, Repressor" "Cancer-related genes, Craniosynostosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064156 Approved Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA064156: AB_2685200" "unprognostic (1.49e-1)" "unprognostic (5.97e-2)" "unprognostic (8.36e-2)" "prognostic unfavorable (2.86e-4)" "unprognostic (6.69e-2)" "prognostic favorable (9.16e-4)" "unprognostic (2.01e-3)" "unprognostic (2.89e-1)" "unprognostic (1.49e-1)" "unprognostic (1.38e-1)" "unprognostic (4.32e-2)" "unprognostic (3.21e-2)" "unprognostic (1.84e-3)" "unprognostic (5.47e-2)" "unprognostic (1.90e-1)" "unprognostic (4.82e-2)" "unprognostic (1.06e-1)" 24.3 19.6 19.0 35.0 18.2 39.0 24.7 28.3 23.8 32.4 22.7 17.7 16.9 15.6 32.4 22.2 14.3 20.5 21.6 17.9 19.7 10.7 21.2 25.2 27.3 26.7 20.3 14.7 28.1 27.1 21.2 16.3 19.8 18.2 20.6 16.4 16.6 17.4 23.3 25.5 18.2 21.8 21.8 12.2 28.2 19.7 32.1 23.0 47.4 26.8 15.8 29.0 23.2 35.3 9.8 3.1 1.3 0.8 1.7 14.6 1.9 22.9 13.3 20.9 11.6 9.6 12.0 18.2 15.4 13.2 26.9 19.9 39.6 14.8 21.7 9.9 19.0 25.6 16.0 17.6 14.8 22.0 32.5 9.6 34.6 21.1 21.6 8.6 14.4 14.4 13.3 9.9 18.7 14.1 13.3 14.8 17.9 16.7 11.8 12.5 7.0 19.7 11.6 5.0 10.7 15.4 11.5 25.1 9.4 11.0 11.1 9.6 15.1 27.9 9.3 12.2 11.6 13.3 10.2 15.3 28.6 25.0 13.2 17.1 13.8 14.7 16.0 14.5 38.4 10.9 0.0 0.8 1.3 4.4 0.7 3.5 9.8 5.2 5.6 0.7 5.8 5.8 5.9 0.9 1.7 0.7 3.1 14.6 1.9 19.0 18.2 28.3 23.8 19.7 10.7 20.3 14.7 18.2 23.0 47.6 38.1 41.7 41.8 35.5 18.7 18.5 15.3 21.4 25.0 26.2 49.1 16.2 21.6 12.4 73.4 61.8 21.2 0.0 10.8 12.8 37.0 40.7 17.4 29.3 18.3 17.5 6.9 34.4 16.8 61.5 23.6 23.6 74.2 10.0 12.1 12.6 14.1 11.5 13.8 22.1 30.4 6.5 44.0 25.6 13.5 26.7 4.9 41.5 15.5 32.6 ATF1 TREB36 ENSG00000123268 "Activating transcription factor 1" P18846 12 50763710-50821122 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016222, HPA055069, HPA055406" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB016222: AB_2290030, HPA055069: AB_2682688, HPA055406: AB_2682807" "unprognostic (1.71e-1)" "unprognostic (1.50e-3)" "unprognostic (1.50e-1)" "unprognostic (9.05e-2)" "unprognostic (6.68e-2)" "unprognostic (1.58e-1)" "prognostic unfavorable (1.53e-5)" "unprognostic (3.65e-1)" "unprognostic (8.17e-3)" "unprognostic (5.94e-2)" "unprognostic (4.31e-3)" "unprognostic (5.52e-2)" "unprognostic (1.73e-1)" "unprognostic (2.74e-2)" "unprognostic (2.46e-1)" "unprognostic (2.27e-1)" "unprognostic (8.75e-2)" 24.4 20.7 9.8 13.7 9.5 10.2 16.2 28.1 10.6 22.4 19.7 8.1 14.6 12.3 19.2 14.2 16.2 15.5 13.4 20.0 10.8 8.0 17.7 19.8 15.1 15.8 12.2 6.0 24.7 11.8 18.1 15.2 36.1 11.9 20.7 15.1 12.5 16.3 14.2 37.9 12.9 18.8 13.4 12.3 22.9 12.7 9.3 13.9 34.4 30.8 16.3 16.2 21.6 20.0 13.3 13.6 26.3 12.3 12.2 18.8 11.6 13.5 9.8 10.4 10.6 15.0 16.0 25.9 14.4 24.8 22.8 18.0 20.1 21.5 18.7 23.8 16.6 10.0 11.3 12.3 14.8 24.4 18.4 12.7 20.6 22.2 10.7 28.8 29.6 19.8 17.0 23.5 16.3 26.8 23.8 11.0 13.2 25.1 18.1 16.9 20.1 18.6 18.8 15.1 15.7 15.7 17.9 16.2 22.1 17.3 9.3 14.0 7.6 30.5 13.3 21.7 14.9 18.5 18.1 7.6 16.1 19.5 13.5 11.4 10.0 11.8 29.9 15.5 16.7 7.6 4.2 11.5 26.3 13.9 12.3 15.8 13.0 15.1 16.4 13.6 13.3 18.8 14.3 7.3 12.2 7.7 6.2 17.9 11.6 9.8 9.5 28.1 10.6 10.8 8.0 12.2 6.0 11.9 13.9 50.6 14.4 34.4 42.6 66.9 12.0 12.9 10.2 18.7 23.9 12.2 0.0 27.2 44.7 20.3 6.5 18.6 17.3 70.0 18.5 60.0 36.0 33.7 9.3 15.7 24.6 12.7 5.8 15.4 21.9 4.9 29.7 29.4 21.9 18.0 13.9 12.9 18.2 14.0 26.2 25.4 6.9 38.8 32.0 9.3 10.2 47.7 67.4 30.9 21.2 30.7 ATIC "AICARFT, IMPCHASE, PURH" ENSG00000138363 "5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase" P31939 2 215311817-215349773 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Hydrolase, Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cytotrophoblasts: 144.4;Extravillous trophoblasts: 132.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013462, HPA021012" Supported Approved "Plasma membrane,Cytosol" NA NA 3400000 Cytosol "Plasma membrane" "CAB013462: , HPA021012: AB_1845169" "unprognostic (1.41e-2)" "unprognostic (2.18e-1)" "unprognostic (1.13e-2)" "unprognostic (8.46e-2)" "unprognostic (2.90e-1)" "unprognostic (3.81e-2)" "prognostic unfavorable (1.99e-7)" "unprognostic (1.86e-2)" "unprognostic (5.07e-2)" "unprognostic (1.83e-1)" "unprognostic (6.31e-3)" "unprognostic (9.21e-2)" "prognostic unfavorable (8.77e-4)" "unprognostic (1.00e-1)" "unprognostic (1.30e-1)" "unprognostic (4.18e-2)" "unprognostic (4.39e-3)" 19.4 27.4 21.1 23.0 28.4 16.9 24.8 12.1 32.3 20.6 26.7 29.1 18.1 23.4 27.9 15.6 19.1 21.9 19.1 18.2 20.3 21.1 23.1 35.6 17.3 36.1 29.7 19.9 23.4 32.9 25.1 21.1 31.1 24.4 21.9 35.9 19.5 14.4 29.4 35.5 17.0 20.6 26.7 21.7 29.0 20.4 15.0 28.0 46.3 16.1 13.5 35.3 27.6 18.0 21.7 13.4 2.9 8.9 19.6 22.8 10.0 20.5 31.1 17.4 29.5 23.4 23.7 8.7 21.0 18.3 24.0 27.6 60.0 32.2 29.9 26.0 21.9 33.8 21.6 38.2 31.7 34.5 22.3 36.9 36.4 26.7 53.7 30.3 45.6 18.7 20.0 24.3 32.1 38.8 16.6 16.0 29.0 47.0 25.0 33.0 30.3 39.7 22.2 66.8 32.9 17.5 36.9 25.0 26.8 25.5 33.2 27.3 18.9 16.9 20.8 23.7 40.4 34.1 16.2 14.1 20.4 21.1 26.3 13.2 31.6 41.2 62.1 17.7 25.4 29.4 2.9 6.0 0.1 13.2 8.9 22.8 21.7 18.6 20.0 13.4 13.2 18.9 17.5 0.7 19.6 7.4 11.7 17.7 10.0 21.1 28.4 12.1 32.3 20.3 21.1 29.7 19.9 24.4 28.0 11.9 17.1 19.3 23.5 13.4 9.6 18.5 25.5 26.8 19.4 22.7 3.9 144.4 23.2 32.2 0.8 6.3 13.5 0.0 42.8 132.7 23.3 16.1 24.3 18.7 46.4 9.5 18.5 4.3 15.0 0.0 22.2 18.7 28.7 32.5 29.9 20.6 30.0 21.0 32.2 44.0 12.8 25.8 19.8 3.2 40.3 7.4 79.8 21.5 52.7 17.4 ATM "ATA, ATC, ATD, ATDC, TEL1, TELO1" ENSG00000149311 "ATM serine/threonine kinase" Q13315 11 108222484-108369102 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell cycle, DNA damage" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Neurodegeneration, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 198.3;Rod photoreceptor cells: 196.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 48.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000102, HPA067142" Supported Enhanced Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "CAB000102: , HPA067142: AB_2685789" "unprognostic (9.77e-2)" "unprognostic (1.47e-1)" "unprognostic (3.04e-1)" "unprognostic (2.36e-1)" "unprognostic (5.70e-2)" "unprognostic (2.86e-2)" "unprognostic (6.32e-3)" "unprognostic (1.05e-1)" "unprognostic (8.19e-2)" "unprognostic (1.63e-1)" "unprognostic (7.68e-2)" "unprognostic (6.16e-2)" "unprognostic (2.17e-3)" "unprognostic (3.10e-1)" "unprognostic (7.87e-2)" "unprognostic (1.21e-1)" "unprognostic (2.81e-1)" 8.3 10.9 12.7 26.5 19.3 16.8 9.4 17.7 14.4 10.9 8.5 10.9 8.8 6.0 11.2 11.4 6.9 9.5 9.2 9.6 12.4 8.5 7.7 9.5 10.1 33.4 19.6 6.7 20.5 20.7 15.7 29.2 8.8 14.5 9.1 7.9 7.2 15.1 9.8 6.2 8.4 16.5 10.6 23.4 22.6 8.9 6.1 17.9 19.5 10.7 5.1 26.9 10.7 10.7 13.7 6.1 13.5 12.5 7.6 18.5 4.4 2.7 3.9 7.7 4.1 10.0 14.6 2.0 6.1 6.8 3.5 5.9 4.8 6.5 9.6 9.1 4.9 5.6 4.1 5.8 5.1 5.5 7.7 3.4 8.7 4.8 4.8 5.3 10.5 9.4 9.4 3.2 5.4 10.4 7.7 7.4 8.2 8.4 6.6 6.9 2.0 7.1 9.7 6.3 4.1 3.9 5.6 5.3 15.1 4.0 5.5 5.2 6.4 7.1 3.3 10.5 7.1 5.0 5.9 11.5 8.8 4.9 5.0 5.7 4.4 4.6 48.5 5.8 11.5 9.8 13.5 5.7 3.8 14.9 5.3 10.4 11.1 10.5 11.3 2.7 13.7 18.5 17.9 10.8 7.6 12.5 6.1 5.3 4.4 12.7 19.3 17.7 14.4 12.4 8.5 19.6 6.7 14.5 17.9 35.7 21.0 122.7 17.4 11.2 101.7 35.4 10.2 13.4 19.4 21.0 198.3 14.8 5.0 7.7 12.8 18.8 4.9 0.0 10.6 10.5 26.4 9.5 12.7 21.2 26.0 57.2 19.5 36.8 82.2 2.7 36.5 48.1 25.3 9.0 15.9 35.9 7.6 10.5 26.2 10.3 196.6 25.8 17.3 18.7 33.6 10.8 3.5 111.7 11.7 9.9 ATP1A1 ENSG00000163399 "ATPase Na+/K+ transporting subunit alpha 1" P05023 1 116372668-116410261 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" Translocase "Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 195.4;parathyroid gland: 194.4" "Cell type enhanced" "Detected in all" 5 "Enterocytes: 917.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-MEL-30: 254.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018702, CAB069993" Enhanced NA NA 380000 "CAB018702: AB_626713, CAB069993: AB_2060979" "unprognostic (6.18e-2)" "unprognostic (2.18e-1)" "unprognostic (6.91e-2)" "unprognostic (1.42e-2)" "unprognostic (6.80e-2)" "unprognostic (2.15e-1)" "prognostic unfavorable (1.42e-4)" "unprognostic (1.80e-1)" "unprognostic (1.21e-2)" "unprognostic (6.32e-2)" "unprognostic (1.61e-2)" "unprognostic (1.65e-1)" "prognostic favorable (8.98e-8)" "unprognostic (4.75e-2)" "unprognostic (1.17e-1)" "unprognostic (3.11e-2)" "prognostic unfavorable (4.01e-4)" 17.4 25.6 22.4 16.2 40.3 10.5 26.9 74.2 67.4 17.8 121.9 14.2 56.1 92.3 13.1 38.3 34.9 17.7 65.8 41.1 26.1 18.7 162.7 34.6 35.1 9.6 19.2 27.6 17.4 78.6 194.4 25.0 19.2 34.1 22.1 65.7 24.1 84.4 53.7 19.0 40.5 195.4 17.7 20.7 13.7 25.0 17.0 13.9 9.1 101.2 13.7 16.2 14.2 23.1 10.3 22.0 6.4 29.7 10.4 30.2 17.2 33.7 12.4 12.9 6.5 26.0 25.3 66.6 20.2 40.3 24.9 35.4 49.8 24.2 26.7 28.6 23.9 25.3 44.1 25.5 42.6 36.3 9.8 28.3 15.5 23.5 42.0 19.9 38.9 21.9 28.1 71.5 29.0 38.3 35.2 30.5 16.3 25.6 25.8 22.0 67.0 15.7 14.1 30.4 53.6 25.0 15.2 30.3 23.6 90.1 34.8 12.7 11.2 31.4 59.6 254.2 33.2 15.7 22.6 26.9 14.2 19.9 36.7 40.9 12.5 9.7 20.5 43.6 22.5 83.4 6.4 13.3 6.1 23.2 20.9 24.8 10.3 26.4 24.9 22.0 5.3 30.2 22.0 1.6 10.4 29.7 11.1 20.3 17.2 22.4 40.3 74.2 67.4 26.1 18.7 19.2 27.6 34.1 13.9 256.1 246.7 58.7 265.3 245.9 76.0 62.7 540.1 113.8 203.6 731.0 375.0 70.1 316.7 432.8 25.0 117.9 917.6 93.5 278.3 130.8 110.9 297.5 43.8 66.4 114.8 96.9 169.4 90.9 77.6 11.5 109.0 130.5 197.4 47.7 304.0 513.0 192.4 264.8 94.7 289.6 141.6 32.3 179.2 17.9 27.5 235.0 56.5 95.6 365.5 236.0 ATP2B3 "CFAP39, CLA2, PMCA3, SCAX1" ENSG00000067842 "ATPase plasma membrane Ca2+ transporting 3" Q16720 X 153517676-153582939 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Calcium transport, Ion transport, Transport" "Calmodulin-binding, Translocase" "Cancer-related genes, Disease mutation, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 18.6;brain: 23.2" "Group enriched" "Detected in some" 4 "Bipolar cells: 5.0;Extravillous trophoblasts: 8.3;Rod photoreceptor cells: 2.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "SCLC-21H: 14.6;SH-SY5Y: 4.3;THP-1: 3.5;U-937: 3.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001583 Enhanced Supported NA NA "HPA001583: AB_1079641" "unprognostic (1.35e-1)" "unprognostic (3.07e-2)" "unprognostic (3.28e-1)" "unprognostic (6.82e-2)" "unprognostic (1.30e-1)" "unprognostic (4.32e-2)" "unprognostic (2.67e-1)" "unprognostic (6.34e-2)" "unprognostic (2.68e-2)" "unprognostic (8.58e-2)" "unprognostic (1.38e-3)" "unprognostic (3.44e-1)" "unprognostic (2.71e-12)" "unprognostic (1.44e-3)" "unprognostic (2.04e-1)" "unprognostic (2.42e-2)" 0.8 18.6 5.4 0.9 11.3 0.8 0.8 16.1 23.2 0.8 0.9 3.9 0.0 0.9 0.9 2.6 0.8 3.1 0.8 0.8 7.8 5.5 1.0 0.8 0.8 0.8 4.3 11.5 0.8 0.9 0.8 1.2 1.7 13.6 0.8 0.8 1.4 1.3 1.3 0.8 0.9 0.9 0.9 1.4 0.8 0.8 1.1 0.9 0.0 0.8 0.0 0.8 0.8 0.1 0.0 0.5 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.6 4.3 0.0 0.0 0.0 0.1 0.0 3.5 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.4 11.3 16.1 20.7 7.8 5.5 4.3 11.5 13.6 0.9 0.0 0.0 0.0 0.0 0.0 5.0 1.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 ATR "FRP1, MEC1, SCKL, SCKL1" ENSG00000175054 "ATR serine/threonine kinase" Q13535 3 142449235-142578826 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair" "DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cone photoreceptor cells: 35.3;Spermatocytes: 42.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054320 Supported "Nucleoplasm,Golgi apparatus" No No Nucleoplasm "Golgi apparatus" "HPA054320: AB_2682448" "unprognostic (1.47e-1)" "unprognostic (8.90e-2)" "unprognostic (2.90e-1)" "unprognostic (4.23e-2)" "unprognostic (2.25e-2)" "unprognostic (6.42e-2)" "prognostic unfavorable (8.39e-5)" "unprognostic (3.44e-1)" "unprognostic (1.67e-1)" "unprognostic (3.02e-1)" "prognostic unfavorable (1.23e-5)" "unprognostic (1.94e-1)" "unprognostic (5.61e-2)" "unprognostic (1.06e-1)" "unprognostic (3.55e-1)" "unprognostic (1.69e-2)" "unprognostic (1.43e-1)" 10.5 24.3 7.7 11.4 15.9 10.1 14.8 11.3 14.6 10.1 8.5 10.0 10.4 6.0 14.7 16.8 9.4 12.1 9.3 8.8 9.8 7.1 9.6 12.0 10.3 16.0 10.0 8.1 12.3 13.6 18.0 22.5 8.8 12.5 11.0 11.2 9.5 12.5 10.8 7.7 11.2 10.9 9.8 8.8 14.2 9.0 15.3 9.7 19.0 13.8 7.7 15.1 10.9 10.6 5.8 2.8 2.2 4.0 6.7 6.0 0.8 22.7 11.2 7.5 8.5 10.7 11.8 8.9 12.6 7.1 9.4 9.7 5.2 7.3 18.6 13.0 8.9 12.3 14.8 11.0 11.6 14.2 5.9 7.2 10.2 8.5 5.1 4.7 17.1 5.7 9.2 6.4 8.9 10.6 6.4 9.7 9.7 7.1 8.4 9.6 10.0 12.9 7.1 7.2 14.9 8.0 10.7 10.9 13.5 9.5 10.6 5.3 5.4 23.2 8.4 8.2 7.1 12.2 6.9 12.5 9.6 4.8 12.4 13.5 11.0 6.5 17.3 12.5 6.7 7.6 0.7 2.7 2.2 4.4 4.0 6.0 3.1 3.2 4.2 2.8 5.8 4.1 4.0 1.7 6.7 2.5 2.5 2.4 0.8 7.7 15.9 11.3 14.6 9.8 7.1 10.0 8.1 12.5 9.7 6.0 8.8 13.4 6.5 3.5 14.7 7.1 7.6 18.7 6.8 3.5 35.3 6.6 0.0 5.3 12.0 7.1 2.1 0.0 4.3 3.3 4.8 6.7 1.1 6.0 5.7 7.9 7.5 8.6 9.1 6.9 6.1 6.9 10.1 4.6 5.4 4.8 6.2 0.0 6.7 4.1 23.4 0.0 6.4 42.3 15.8 4.0 4.2 5.1 7.0 5.2 ATRX "JMS, MRX52, RAD54, XH2, XNP" ENSG00000085224 "ATRX, chromatin remodeler" P46100 X 77504878-77786269 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "DNA damage, DNA repair, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001906, CAB009372, HPA064684, CAB068176" Supported Supported "Nuclear bodies" NA NA "Nuclear bodies" "CAB009372: AB_2061023, CAB068176: AB_2665665, HPA001906: AB_1078249, HPA064684: AB_2685321" "unprognostic (1.77e-2)" "unprognostic (1.55e-1)" "unprognostic (6.65e-2)" "unprognostic (4.37e-2)" "unprognostic (1.67e-1)" "unprognostic (9.69e-2)" "unprognostic (8.11e-2)" "unprognostic (1.15e-2)" "unprognostic (6.04e-2)" "unprognostic (2.35e-2)" "unprognostic (1.09e-1)" "unprognostic (5.80e-2)" "unprognostic (5.14e-3)" "unprognostic (1.50e-1)" "unprognostic (6.19e-2)" "unprognostic (1.76e-2)" "unprognostic (2.24e-1)" 16.4 16.6 24.5 18.9 29.3 24.3 16.3 48.2 26.4 20.6 15.4 7.1 18.9 10.2 20.2 17.1 13.5 13.8 13.4 15.1 22.9 15.8 16.6 12.2 15.9 18.6 21.1 21.3 25.4 18.3 35.7 28.1 15.9 20.2 18.4 12.6 7.1 15.8 16.5 20.1 14.1 13.5 22.3 15.3 20.1 15.6 6.5 22.4 23.7 19.8 12.7 16.5 19.9 21.1 21.9 12.8 21.5 11.5 14.6 17.7 5.7 15.3 24.7 25.4 17.1 12.7 17.1 9.0 13.3 12.3 9.9 11.7 8.4 13.5 21.4 13.7 14.1 18.6 13.7 20.4 7.9 16.8 12.0 13.3 12.9 29.4 6.2 6.9 16.7 4.4 11.2 7.8 14.5 13.9 12.3 17.4 13.5 15.1 24.6 12.3 12.1 12.9 8.7 18.4 7.1 19.2 21.0 35.2 10.9 9.6 20.6 14.5 25.1 26.8 10.5 8.8 17.2 8.5 8.6 24.0 14.0 21.6 15.6 9.3 7.3 22.7 19.2 10.2 13.3 12.3 21.3 6.9 13.8 17.7 8.7 17.1 19.2 16.3 13.7 5.1 21.9 16.8 13.5 21.5 14.6 11.5 12.8 12.8 5.7 24.5 29.3 48.2 26.4 22.9 15.8 21.1 21.3 20.2 22.4 148.9 213.6 88.0 96.7 82.1 217.2 263.3 58.6 120.5 117.2 68.0 200.3 58.0 19.9 72.8 3.1 123.5 43.3 23.3 72.0 39.7 90.3 99.7 106.6 45.6 60.7 149.4 121.7 91.4 84.5 4.9 150.4 86.3 59.1 120.0 68.3 114.7 80.3 40.3 195.6 28.6 231.4 90.5 113.3 13.6 49.5 73.8 50.0 94.4 62.6 104.6 AXIN1 PPP1R49 ENSG00000103126 "Axin 1" O15169 16 287440-352673 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Wnt signaling pathway" "Developmental protein" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB012987 Approved Supported Nucleoli,Vesicles NA NA "Nucleoli, Vesicles" "CAB012987: AB_2533178" "unprognostic (3.81e-2)" "unprognostic (1.56e-1)" "unprognostic (1.90e-1)" "unprognostic (7.64e-2)" "unprognostic (1.90e-1)" "unprognostic (1.06e-1)" "prognostic unfavorable (3.38e-5)" "unprognostic (1.23e-1)" "unprognostic (3.58e-1)" "unprognostic (1.56e-1)" "unprognostic (4.58e-2)" "unprognostic (2.02e-2)" "unprognostic (1.57e-1)" "unprognostic (4.41e-2)" "unprognostic (1.94e-1)" "unprognostic (1.23e-2)" "unprognostic (1.03e-1)" 10.8 8.3 13.7 18.9 17.1 28.1 21.0 26.4 13.6 10.4 15.8 12.7 9.4 17.3 12.6 8.5 14.1 10.7 12.7 11.0 11.5 7.7 9.8 9.6 13.6 13.4 15.6 10.6 13.3 17.7 11.1 11.9 8.4 13.9 11.4 10.2 9.6 13.9 9.5 17.7 16.9 17.6 18.9 9.6 15.1 15.2 9.6 14.6 17.5 12.7 7.5 14.5 11.9 22.9 1.8 1.4 5.5 1.1 3.6 10.4 2.4 9.6 14.0 7.5 13.2 5.6 5.2 15.8 6.5 6.0 9.1 7.8 20.6 11.3 15.0 10.1 6.7 10.9 13.9 11.7 10.2 4.1 14.7 19.2 9.7 11.8 14.9 9.6 11.1 10.8 5.1 17.8 9.3 11.5 8.0 6.0 11.0 24.1 8.3 4.1 25.8 12.0 7.7 17.1 11.7 8.6 22.7 6.8 20.8 6.8 5.7 17.1 10.5 12.4 13.9 20.5 5.9 9.2 14.2 6.7 9.0 9.7 10.3 9.4 9.6 9.3 18.3 4.3 7.4 8.8 1.4 1.1 5.5 10.4 0.9 9.5 1.8 3.0 7.0 0.8 1.6 3.2 4.3 3.2 3.6 0.7 1.4 3.0 2.4 13.7 17.1 26.4 13.6 11.5 7.7 15.6 10.6 13.9 14.6 3.0 11.3 5.2 5.3 16.4 4.9 5.0 5.1 6.7 6.8 3.5 0.0 3.1 0.0 6.1 1.0 6.7 18.6 0.0 6.1 20.3 5.9 9.4 10.4 4.7 6.5 4.8 10.4 4.3 7.5 1.3 4.9 5.9 10.1 3.6 14.5 3.7 8.8 11.9 4.6 2.1 5.4 12.9 5.3 4.4 7.6 13.2 3.1 7.7 11.8 8.7 AXIN2 "DKFZp781B0869, MGC126582" ENSG00000168646 "Axin 2" Q9Y2T1 17 65528563-65561647 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 12 "Extravillous trophoblasts: 87.1" "Cancer enhanced" "Detected in all" "colorectal cancer: 33.4" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 5.1" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 11.8;CACO-2: 22.1;Hep G2: 32.9;OE19: 36.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012283, CAB017783" Approved Uncertain "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane" Cytosol "CAB012283: AB_2290204, CAB017783: " "unprognostic (1.31e-2)" "unprognostic (1.29e-1)" "unprognostic (1.05e-2)" "unprognostic (3.45e-3)" "unprognostic (4.48e-1)" "unprognostic (9.81e-2)" "unprognostic (1.12e-2)" "unprognostic (1.82e-1)" "unprognostic (4.57e-2)" "unprognostic (8.84e-3)" "prognostic favorable (6.58e-4)" "unprognostic (1.98e-1)" "unprognostic (1.42e-1)" "unprognostic (3.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.74e-1)" "unprognostic (1.25e-1)" 7.4 10.1 9.0 7.0 8.9 0.9 5.2 8.2 13.1 16.5 12.2 8.7 10.5 7.2 29.0 7.7 6.5 18.6 6.9 7.3 7.9 5.7 3.5 2.5 15.2 3.4 5.3 10.3 14.7 3.9 3.2 5.8 18.2 10.6 14.8 15.2 7.8 4.6 9.8 12.4 14.9 7.5 18.0 4.8 6.9 14.6 6.8 9.0 27.6 11.3 3.6 3.8 11.8 8.7 4.1 0.0 4.4 0.0 1.9 5.1 0.8 0.0 5.9 11.8 0.2 4.3 1.8 5.2 0.1 0.5 0.4 0.7 22.1 2.1 0.4 0.7 3.4 0.4 0.1 2.4 0.0 0.8 1.0 1.3 0.0 1.0 32.9 0.4 0.0 0.0 1.0 0.9 0.9 0.2 0.7 1.0 2.2 0.0 0.5 0.6 0.1 5.7 0.0 2.3 36.5 0.2 4.1 0.6 0.0 1.1 0.1 3.7 2.4 0.2 0.1 2.0 9.1 0.4 0.1 2.6 2.3 4.3 3.3 0.7 0.0 1.2 1.5 1.1 0.2 1.1 4.4 0.0 0.0 0.3 0.0 0.8 1.0 2.3 0.4 0.0 4.1 5.1 0.8 0.0 1.9 0.0 0.0 0.0 0.8 9.0 8.9 8.2 13.1 7.9 5.7 5.3 10.3 10.6 9.0 0.0 7.0 0.0 1.2 10.0 3.8 8.1 2.5 1.4 10.3 0.0 3.9 14.3 0.0 1.0 27.8 3.8 2.8 0.0 0.7 87.1 17.5 4.1 0.0 1.9 3.3 1.6 5.2 1.3 0.0 11.2 6.1 0.3 16.9 1.8 18.7 3.5 0.7 3.5 10.3 0.6 1.9 12.9 5.9 5.4 12.6 4.8 11.9 0.0 16.8 1.1 B2M ENSG00000166710 Beta-2-microglobulin P61769 15 44711477-44718877 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" Immunity "Amyloidosis, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 9 "monocytes: 43079.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "THP-1: 178.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002572, HPA006361" Enhanced Enhanced "Golgi apparatus,Plasma membrane,Cytosol" "Intracellular and membrane" NA NA 1790000000 3200000000 "Golgi apparatus, Plasma membrane" Cytosol "CAB002572: AB_563434, HPA006361: AB_1078278" "unprognostic (9.45e-2)" "unprognostic (5.63e-2)" "unprognostic (3.02e-1)" "unprognostic (8.14e-2)" "unprognostic (1.18e-1)" "unprognostic (4.82e-2)" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (2.69e-2)" "unprognostic (1.12e-1)" "unprognostic (2.44e-3)" "unprognostic (2.02e-2)" "unprognostic (4.77e-2)" "unprognostic (2.39e-1)" "unprognostic (5.25e-2)" "unprognostic (1.97e-2)" "unprognostic (2.17e-2)" 127.2 50.9 24.2 109.2 29.8 131.1 85.2 11.8 23.1 70.5 111.4 29.1 43.3 79.1 72.7 74.7 80.5 36.8 112.8 73.6 26.0 23.1 109.7 140.3 191.2 172.1 42.2 18.8 54.8 42.7 7.8 40.5 91.9 33.1 78.7 128.9 53.5 121.5 40.9 45.7 94.1 178.5 55.1 56.7 272.8 52.5 30.0 29.5 108.0 97.7 71.5 131.6 135.9 73.5 138.9 74.9 341.3 132.8 128.8 215.8 323.7 33.7 14.9 1.4 8.4 55.5 74.8 52.9 22.3 45.6 36.4 61.8 19.4 78.7 16.1 31.6 21.7 34.6 29.7 5.6 9.9 17.5 112.5 13.2 61.2 90.6 22.5 42.2 34.2 36.7 37.8 9.3 11.1 12.0 49.2 24.8 9.3 15.5 2.2 40.2 18.0 14.0 90.3 2.5 9.7 31.9 17.1 36.6 101.9 31.7 139.7 5.9 2.1 23.3 18.9 26.3 8.0 6.3 178.1 49.3 71.4 7.9 94.1 43.6 41.7 95.3 29.9 69.6 113.1 34.1 221.2 90.4 210.9 126.8 132.8 125.9 138.9 171.7 141.1 58.9 109.4 137.0 167.5 341.3 128.8 106.5 74.9 215.8 323.7 24.2 29.8 11.8 23.1 26.0 23.1 42.2 18.8 33.1 29.5 3147.5 4324.0 5959.3 2738.0 6967.5 30.8 1001.8 3658.6 2584.4 1819.9 1992.5 25.5 1178.5 880.3 10047.2 36.4 7847.2 5137.6 1074.6 7941.0 3388.9 4495.5 5043.9 2851.5 3441.9 11377.9 4.8 2180.6 6477.0 10376.7 71.4 2794.5 10340.1 6397.4 43079.4 4753.5 280.0 9393.5 5334.1 1587.5 2212.2 49.3 3951.7 5055.6 55.6 68.2 7534.8 673.0 11479.7 3001.5 5867.1 BAP1 "hucep-6, KIAA0272, UCHL2" ENSG00000163930 "BRCA1 associated protein 1" Q92560 3 52401013-52410350 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Chromatin regulator, Hydrolase, Protease, Thiol protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 81.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004322, HPA028814, HPA028815, HPA055560" Approved Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB004322: AB_626723, HPA028814: AB_10602393, HPA028815: AB_2672785, HPA055560: AB_2682850" "unprognostic (1.52e-1)" "unprognostic (7.96e-2)" "unprognostic (1.96e-2)" "unprognostic (6.04e-2)" "unprognostic (1.74e-1)" "unprognostic (2.55e-2)" "unprognostic (9.41e-3)" "unprognostic (8.53e-3)" "unprognostic (1.33e-1)" "unprognostic (3.15e-1)" "unprognostic (4.64e-3)" "unprognostic (3.30e-3)" "prognostic favorable (3.29e-7)" "unprognostic (6.37e-2)" "unprognostic (1.91e-1)" "unprognostic (5.54e-2)" "unprognostic (2.92e-1)" 13.8 17.6 35.6 14.7 33.3 37.3 13.5 21.8 50.4 12.5 17.0 16.3 11.5 12.4 14.7 14.6 21.2 12.1 15.7 16.4 41.5 15.5 16.6 19.0 14.9 15.2 19.4 27.6 16.9 16.3 30.0 11.1 14.8 19.6 14.4 14.9 15.6 17.9 14.6 24.8 40.5 13.9 14.5 10.0 16.1 13.3 37.3 14.7 18.6 15.3 12.9 16.0 14.1 11.7 5.5 8.4 11.3 5.0 3.0 8.5 3.9 14.8 16.9 20.6 17.4 19.9 12.8 23.2 14.7 19.1 24.0 18.6 20.5 13.9 21.4 7.4 20.5 27.1 12.1 21.6 23.8 15.3 21.1 20.5 26.4 35.8 21.2 18.5 24.8 23.5 19.1 31.9 26.5 14.2 13.2 19.1 41.2 22.6 18.9 18.0 12.9 29.4 34.0 23.2 11.8 20.6 12.7 16.7 21.1 14.8 24.1 7.8 25.3 18.1 5.3 21.5 12.1 14.8 34.3 20.4 21.7 20.0 26.0 27.3 28.7 37.7 30.6 23.7 26.2 25.6 3.4 5.0 7.4 8.5 3.9 4.0 5.0 6.8 6.9 3.3 5.5 4.9 6.4 11.3 3.0 3.1 8.4 6.0 3.9 35.6 33.3 21.8 50.4 41.5 15.5 19.4 27.6 19.6 14.7 0.0 13.6 15.0 8.8 28.0 15.3 19.3 10.2 5.3 9.1 24.4 0.0 12.2 10.0 12.0 81.1 12.4 17.6 0.0 14.3 13.1 11.8 9.7 20.7 25.8 11.0 9.5 10.4 15.4 19.3 32.6 9.5 10.2 11.8 11.8 12.9 9.9 12.6 15.3 11.0 14.6 11.3 19.4 13.2 30.9 12.4 20.6 10.1 11.3 16.4 8.5 BARD1 ENSG00000138376 "BRCA1 associated RING domain 1" Q99728 2 214725646-214809711 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Basal glandular cells: 54.9;Basal keratinocytes: 60.9;Spermatogonia: 54.9;Suprabasal keratinocytes: 65.1;Urothelial cells: 57.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "CAB034106, HPA035354, HPA044864" Enhanced Supported "Nuclear speckles,Cytoplasmic bodies" No No "Nuclear speckles" "Cytoplasmic bodies" "CAB034106: AB_2061237, HPA035354: AB_2674585, HPA044864: AB_2679119" "unprognostic (4.85e-2)" "unprognostic (1.87e-2)" "unprognostic (1.74e-2)" "unprognostic (8.37e-3)" "unprognostic (2.57e-2)" "unprognostic (1.03e-2)" "unprognostic (6.25e-4)" "unprognostic (1.99e-1)" "unprognostic (2.16e-2)" "unprognostic (3.92e-3)" "unprognostic (2.80e-2)" "unprognostic (7.41e-2)" "unprognostic (1.94e-8)" "unprognostic (3.94e-2)" "unprognostic (2.28e-1)" "unprognostic (1.57e-1)" "unprognostic (1.08e-1)" 4.4 1.9 3.2 11.8 4.8 16.1 4.9 1.2 5.8 7.3 5.4 5.4 3.6 3.7 6.8 5.0 10.0 4.1 3.9 3.6 3.4 2.8 2.2 2.1 5.3 8.2 5.1 1.9 5.8 3.7 3.6 6.3 3.8 4.5 5.7 6.1 1.9 4.7 6.5 12.4 16.3 4.5 7.5 5.3 4.7 3.8 9.5 3.9 25.8 4.0 8.0 9.9 8.3 7.8 9.7 6.6 6.0 3.4 6.1 16.0 2.0 7.8 4.3 11.9 6.1 1.6 2.0 8.2 9.6 5.6 9.4 10.9 5.5 7.8 8.5 4.6 3.9 5.8 8.6 8.5 5.6 13.5 6.7 4.4 8.4 8.0 5.8 0.6 9.4 8.5 2.7 0.8 8.3 4.6 3.2 3.2 9.4 4.7 23.9 9.1 6.5 16.8 9.8 9.4 4.9 2.2 14.5 12.0 7.7 2.8 6.6 3.7 6.0 8.8 10.1 3.5 7.1 10.3 9.4 2.7 12.2 8.6 7.1 8.6 7.2 8.0 17.2 4.9 7.2 8.1 2.9 1.7 6.0 4.8 3.4 3.1 8.9 5.3 5.2 3.0 9.7 2.5 3.6 0.5 6.1 2.9 6.6 16.0 2.0 3.2 4.8 1.2 5.8 3.4 2.8 5.1 1.9 4.5 3.9 6.0 2.1 9.5 54.9 60.9 3.3 12.5 15.3 12.0 9.1 8.7 0.0 9.4 3.3 6.8 8.1 7.5 3.4 23.3 6.0 13.6 7.7 21.0 15.0 3.6 10.6 1.6 1.2 12.3 8.8 3.6 5.8 8.8 3.3 17.2 11.3 3.3 5.6 5.8 9.6 0.6 6.8 19.4 15.5 19.7 54.9 65.1 4.2 8.6 11.0 57.3 BAX BCL2L4 ENSG00000087088 "BCL2 associated X, apoptosis regulator" Q07812 19 48954815-48961798 "Cancer-related genes, Predicted intracellular proteins, Transporters" "Apoptosis, Host-virus interaction" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "monocytes: 382.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004206, HPA027878" Approved NA NA 1300000 "CAB004206: AB_626729, HPA027878: AB_10601687" "unprognostic (4.11e-2)" "unprognostic (4.70e-2)" "unprognostic (1.50e-1)" "unprognostic (6.23e-2)" "unprognostic (1.70e-1)" "unprognostic (2.82e-1)" "prognostic unfavorable (1.63e-5)" "unprognostic (4.92e-2)" "unprognostic (1.09e-1)" "unprognostic (4.71e-2)" "unprognostic (3.66e-2)" "unprognostic (8.10e-2)" "unprognostic (1.19e-2)" "unprognostic (7.83e-2)" "unprognostic (1.08e-1)" "unprognostic (4.47e-3)" "unprognostic (6.22e-2)" 15.2 20.0 12.3 26.0 13.2 25.3 20.2 7.6 13.6 14.9 33.3 15.1 13.5 30.7 19.3 11.2 21.4 15.5 40.4 14.9 11.3 10.2 19.5 26.1 26.6 25.9 18.7 12.5 16.4 16.2 8.8 10.0 21.5 14.9 16.6 27.8 10.3 16.5 13.3 11.6 17.1 28.7 16.3 15.1 37.8 19.6 10.7 13.2 37.8 17.7 16.3 26.5 19.1 19.5 6.6 10.6 11.1 16.5 9.1 6.4 6.6 34.3 57.2 34.6 30.3 34.6 33.9 57.1 23.5 47.2 31.0 43.4 15.1 33.7 42.1 11.0 35.9 28.9 18.7 15.7 45.8 25.8 32.4 36.2 17.9 11.6 56.0 55.6 18.6 57.5 46.4 32.9 25.7 15.5 37.7 71.3 16.7 17.5 17.3 53.1 24.3 30.1 29.2 26.8 33.6 16.4 21.2 23.0 16.1 32.5 33.5 19.9 23.5 19.8 14.1 10.8 51.5 11.3 33.6 41.7 40.0 43.4 24.4 32.2 20.0 25.4 27.3 24.2 25.3 55.2 4.3 10.4 10.5 6.0 15.3 4.3 6.6 3.4 6.4 10.4 5.8 2.3 5.3 11.1 9.1 16.5 10.6 6.3 6.6 12.3 13.2 7.6 13.6 11.3 10.2 18.7 12.5 14.9 13.2 3.0 4.5 117.5 48.9 48.7 17.5 7.3 79.0 5.3 3.4 57.6 9.8 113.9 63.0 111.1 0.9 69.9 164.3 0.0 84.3 129.6 73.3 76.7 44.8 26.7 232.2 28.6 109.5 54.0 114.6 1.6 44.5 121.4 79.2 382.3 86.5 32.3 116.8 161.4 36.0 172.3 13.7 45.3 56.6 12.6 35.8 49.3 85.2 119.3 131.1 73.4 BCL10 "c-E10, CARMEN, CIPER, CLAP, mE10" ENSG00000142867 "B cell CLL/lymphoma 10" O95999 1 85266248-85277090 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Immunity" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Basal keratinocytes: 172.4;Urothelial cells: 313.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 40.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001944, HPA017925" Approved NA NA "CAB001944: , HPA017925: AB_1845312" "unprognostic (3.78e-3)" "unprognostic (2.53e-1)" "prognostic favorable (2.51e-4)" "unprognostic (1.61e-1)" "unprognostic (3.47e-1)" "unprognostic (2.61e-2)" "prognostic unfavorable (7.21e-7)" "unprognostic (7.06e-2)" "unprognostic (2.36e-1)" "unprognostic (9.46e-2)" "unprognostic (1.27e-2)" "unprognostic (1.73e-1)" "unprognostic (4.92e-3)" "unprognostic (3.18e-2)" "unprognostic (1.06e-1)" "unprognostic (1.63e-1)" "unprognostic (1.07e-1)" 17.2 10.7 5.8 16.4 6.0 19.6 20.7 5.8 8.6 14.7 21.5 7.5 9.5 12.2 14.8 10.0 29.0 8.5 16.7 7.5 5.9 5.4 11.9 11.4 20.4 21.5 6.5 5.2 11.6 9.1 5.4 6.3 11.8 5.9 11.6 20.4 6.4 11.8 12.4 5.0 14.6 27.6 9.9 6.1 18.5 13.0 8.5 5.1 18.3 11.3 12.7 22.1 14.3 17.6 22.4 14.2 37.5 18.2 10.4 13.3 9.0 16.0 3.4 4.6 5.0 6.7 10.0 7.9 12.3 11.2 8.9 12.4 4.0 6.5 7.2 8.7 9.6 16.9 8.7 5.3 13.1 13.0 6.1 4.0 7.6 3.3 5.6 10.5 7.4 7.1 7.9 14.5 13.3 11.9 10.8 40.6 4.2 5.3 6.5 14.9 3.0 7.1 6.1 8.2 9.0 11.3 5.1 10.7 4.6 31.0 12.4 3.1 4.2 3.7 12.7 11.7 6.7 4.3 5.0 20.2 9.2 6.5 11.2 12.2 5.3 2.9 7.0 4.6 6.5 6.3 25.2 15.1 20.1 10.0 18.2 11.1 22.4 13.1 11.3 14.2 20.3 12.4 11.4 37.5 10.4 13.5 12.0 13.3 9.0 5.8 6.0 5.8 8.6 5.9 5.4 6.5 5.2 5.9 5.1 20.8 18.6 32.1 121.5 172.4 5.3 3.6 15.3 24.1 36.4 22.7 0.0 13.1 14.9 59.3 42.4 34.3 75.1 0.0 39.3 23.1 20.1 72.2 39.2 15.3 19.5 9.5 47.0 20.9 28.8 8.6 10.3 35.3 15.1 19.0 59.4 9.9 56.0 60.3 10.6 16.3 5.4 0.0 22.0 7.6 12.4 149.7 19.8 24.9 40.5 313.8 BCL11A "BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856" ENSG00000119866 "B cell CLL/lymphoma 11A" Q9H165 2 60450520-60555154 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 107.1" "Cell type enhanced" "Detected in many" 8 "B-cells: 89.5;Erythroid cells: 93.5;Horizontal cells: 49.3;Suprabasal keratinocytes: 61.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "memory B-cell: 39.6;naive B-cell: 53.7;plasmacytoid DC: 107.1" "Group enriched" "Detected in many" 16 "B-cells: 53.7;dendritic cells: 107.1" "Cell line enhanced" "Detected in many" "Daudi: 20.7;MOLT-4: 19.1;REH: 19.5;U-698: 42.7;U-937: 13.7" "Group enriched" "Detected in all" 5 "amygdala: 42.3;basal ganglia: 57.1;cerebral cortex: 62.7;hippocampal formation: 65.3;olfactory region: 101.8" "Group enriched" "Detected in all" 4 "basal ganglia: 58.3;cerebral cortex: 93.2;hippocampal formation: 97.2;olfactory region: 128.9" "CAB014891, HPA029003, HPA075941" Enhanced Supported "Nucleoplasm,Nuclear bodies" NA NA Nucleoplasm "Nuclear bodies" "CAB014891: , HPA029003: AB_2672863, HPA075941: " "unprognostic (4.10e-3)" "unprognostic (6.72e-2)" "unprognostic (4.50e-2)" "unprognostic (9.41e-3)" "unprognostic (2.37e-1)" "unprognostic (4.47e-3)" "unprognostic (2.53e-2)" "unprognostic (1.68e-2)" "unprognostic (1.02e-1)" "unprognostic (2.45e-1)" "unprognostic (4.27e-4)" "unprognostic (1.23e-2)" "unprognostic (2.35e-2)" "unprognostic (3.59e-2)" "unprognostic (2.26e-1)" "unprognostic (4.40e-2)" "unprognostic (2.99e-2)" 1.5 2.4 6.6 13.9 14.6 17.0 5.5 1.8 34.5 3.9 8.6 0.2 0.1 7.6 1.8 1.4 13.6 4.8 2.2 4.7 14.5 3.4 1.7 1.5 3.0 21.2 3.5 14.4 1.6 11.3 1.2 3.9 0.9 9.6 4.8 5.1 0.0 11.4 2.0 1.4 24.9 11.4 2.9 2.0 13.5 3.3 2.0 2.6 20.9 2.4 4.0 30.4 3.6 7.8 53.7 107.1 1.3 5.1 1.0 0.1 1.2 0.2 0.0 1.7 0.0 0.3 0.3 0.1 0.6 0.0 0.0 0.0 0.0 0.0 20.7 0.1 0.0 0.0 4.2 6.4 3.0 0.0 0.3 6.2 0.0 0.2 0.1 0.0 7.4 0.0 0.7 1.7 0.0 1.0 1.7 1.0 7.0 0.3 0.1 0.0 0.0 19.1 7.6 11.8 3.0 0.1 19.5 0.5 7.9 0.0 0.3 8.4 2.0 0.1 0.1 0.1 3.5 0.1 3.6 0.5 0.1 4.9 0.1 0.0 0.3 0.0 42.7 0.0 13.7 0.6 0.4 2.9 0.5 0.0 5.1 0.1 39.6 0.0 0.0 10.7 53.7 0.1 0.1 1.3 1.0 3.7 107.1 0.1 1.2 6.6 14.6 1.8 34.5 14.5 3.4 3.5 14.4 9.6 2.6 0.0 9.0 89.5 14.8 41.1 0.5 12.2 5.1 5.3 7.9 1.8 0.0 0.5 5.0 7.7 9.4 1.2 8.4 93.5 5.6 0.7 5.1 4.2 9.3 0.0 32.9 49.3 19.0 0.6 8.2 3.6 0.3 17.9 15.1 6.4 11.7 0.1 5.4 13.6 0.0 0.3 0.1 0.0 1.3 1.6 5.9 61.1 0.7 0.0 24.2 4.1 BCL11B "CTIP-2, CTIP2, hRIT1-alpha, ZNF856B" ENSG00000127152 "B cell CLL/lymphoma 11B" Q9C0K0 14 99169287-99271524 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Repressor "Cancer-related genes, Disease mutation, Mental retardation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 13.7;lymphoid tissue: 25.4;skin 1: 17.6" "Group enriched" "Detected in many" 8 "Basal keratinocytes: 55.8;Suprabasal keratinocytes: 62.4;T-cells: 48.4" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 13.7" "Group enriched" "Detected in many" 8 "gdT-cell: 3.3;MAIT T-cell: 3.0;memory CD4 T-cell: 4.5;memory CD8 T-cell: 3.7;naive CD4 T-cell: 7.4;naive CD8 T-cell: 4.9;T-reg: 3.0" "Lineage enriched" "Detected in single" 14 "T-cells: 7.4" "Group enriched" "Detected in some" 6 "JURKAT: 24.7;MOLT-4: 29.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA049117 Enhanced Supported Approved "Nucleoplasm,Nucleoli fibrillar center" NA NA Nucleoplasm "Nucleoli fibrillar center" "HPA049117: AB_2680639" "unprognostic (1.64e-5)" "unprognostic (4.66e-2)" "unprognostic (2.35e-2)" "unprognostic (1.87e-2)" "unprognostic (9.37e-2)" "unprognostic (5.97e-2)" "unprognostic (4.75e-2)" "unprognostic (6.07e-2)" "unprognostic (1.74e-1)" "unprognostic (1.40e-2)" "unprognostic (1.90e-1)" "unprognostic (1.12e-1)" "unprognostic (1.60e-6)" "unprognostic (1.07e-3)" "unprognostic (1.61e-1)" "unprognostic (3.31e-3)" "prognostic favorable (7.48e-4)" 0.3 0.4 4.4 6.6 13.7 5.2 1.3 0.3 3.8 0.8 1.3 0.1 0.0 2.3 1.9 0.8 3.9 0.3 3.0 0.8 4.8 1.0 0.3 0.5 1.1 10.8 0.8 2.6 0.2 0.1 0.0 0.1 0.0 0.6 0.6 1.7 0.3 5.0 0.7 0.1 17.6 3.0 0.2 0.7 4.9 2.1 0.4 1.6 25.4 0.9 1.5 8.8 2.0 2.3 0.0 0.0 0.1 0.0 0.5 7.4 1.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.2 1.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.1 0.0 0.1 0.0 0.0 24.7 0.0 2.8 0.0 1.6 29.5 0.4 0.3 2.2 0.0 4.6 0.0 0.0 0.0 1.6 2.4 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.1 0.1 0.0 1.8 0.0 0.0 1.2 0.4 0.0 0.0 0.0 0.1 3.3 0.0 3.0 0.0 4.5 3.7 0.0 0.0 7.4 4.9 0.0 0.5 0.0 0.0 3.0 1.1 4.4 13.7 0.3 3.8 4.8 1.0 0.8 2.6 0.6 1.6 3.0 0.0 2.7 1.6 55.8 0.1 3.1 5.1 0.0 1.2 0.0 0.0 0.1 1.7 0.3 0.0 0.1 4.3 0.0 0.4 0.0 1.1 0.2 4.7 0.0 0.2 0.0 1.2 4.3 1.2 0.2 0.6 0.7 5.0 0.0 2.6 0.0 0.7 4.3 0.0 0.3 0.0 0.0 3.3 0.7 4.9 62.4 0.0 48.4 6.9 0.6 BCL2 "Bcl-2, PPP1R50" ENSG00000171791 "BCL2, apoptosis regulator" P10415 18 63123346-63320128 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Apoptosis "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7" "Group enriched" "Detected in many" 8 "B-cells: 5.2;T-cells: 7.6" "Cell line enhanced" "Detected in many" "Karpas-707: 22.8;U-266/70: 79.4" "Low region specificity" "Detected in all" "CAB000003, HPA055295" Enhanced Supported "Nucleoplasm,Nuclear membrane" NA NA "Nuclear membrane" Nucleoplasm "CAB000003: AB_2064429, HPA055295: AB_2682776" "unprognostic (1.11e-3)" "prognostic favorable (5.13e-5)" "unprognostic (5.49e-2)" "unprognostic (1.19e-1)" "unprognostic (1.89e-1)" "unprognostic (3.05e-3)" "unprognostic (2.88e-1)" "unprognostic (1.93e-3)" "unprognostic (4.78e-2)" "unprognostic (2.08e-1)" "unprognostic (2.23e-2)" "unprognostic (8.51e-2)" "prognostic favorable (1.29e-8)" "unprognostic (6.67e-2)" "unprognostic (1.19e-1)" "prognostic unfavorable (2.47e-4)" "unprognostic (2.63e-1)" 12.9 3.0 10.1 15.7 9.4 5.3 24.6 4.7 8.4 14.8 7.8 7.4 9.1 5.0 17.1 9.3 4.7 12.2 9.2 6.5 10.0 8.1 8.5 2.3 5.0 14.6 10.8 5.6 18.2 2.9 19.6 7.0 22.4 9.2 8.4 5.9 10.8 5.4 15.7 20.0 6.3 10.5 8.6 9.3 17.8 5.4 3.5 10.5 21.0 35.6 2.9 13.4 7.9 16.4 5.2 0.3 0.7 0.2 0.7 7.6 1.9 0.5 0.1 2.3 1.8 2.8 0.4 0.8 0.2 0.2 0.8 0.5 1.1 0.1 0.0 0.4 0.2 1.5 0.1 2.1 0.3 0.4 13.6 0.4 0.1 0.6 0.2 0.5 12.4 1.8 0.5 0.2 0.9 1.9 0.3 0.2 1.4 0.2 22.8 0.4 0.4 2.6 5.4 0.5 0.2 0.4 11.7 0.5 8.8 3.9 1.9 1.9 1.8 0.0 0.0 2.8 0.5 0.1 10.5 0.1 3.0 1.0 0.3 1.5 79.4 10.4 0.9 0.5 8.8 1.7 0.7 0.0 0.0 2.3 0.0 7.6 5.2 6.3 3.8 0.1 4.1 5.1 4.5 0.1 0.7 0.2 0.3 6.7 1.9 10.1 9.4 4.7 8.4 10.0 8.1 10.8 5.6 9.2 10.5 0.0 0.6 41.9 30.2 17.3 1.0 15.4 17.8 0.0 3.4 7.0 0.0 8.5 13.3 2.5 0.2 3.5 0.8 0.0 0.0 0.9 10.3 31.5 15.1 1.5 8.3 0.0 5.2 3.7 10.4 2.1 8.1 16.9 43.9 29.7 9.9 18.9 0.3 0.0 13.1 13.5 0.5 25.8 10.8 0.3 0.6 15.4 41.1 28.7 10.6 39.2 BCL3 "BCL4, D19S37" ENSG00000069399 "B cell CLL/lymphoma 3" P20749 19 44747705-44760044 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "neutrophil: 16.5" "Lineage enriched" "Detected in all" 6 "granulocytes: 16.5" "Cell line enhanced" "Detected in many" "HDLM-2: 27.0;Karpas-707: 22.4;SiHa: 28.7;U-266/70: 21.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB002051, HPA047514" Approved Supported Nucleoplasm,Vesicles,Midbody Yes No Nucleoplasm "Vesicles, Midbody" "CAB002051: AB_563428, HPA047514: AB_2680074" "prognostic favorable (9.67e-4)" "unprognostic (8.82e-2)" "unprognostic (2.81e-1)" "unprognostic (7.54e-2)" "prognostic unfavorable (4.01e-4)" "unprognostic (3.49e-2)" "unprognostic (2.34e-3)" "unprognostic (2.79e-1)" "prognostic favorable (3.74e-4)" "unprognostic (2.09e-2)" "unprognostic (9.23e-2)" "unprognostic (1.81e-1)" "prognostic unfavorable (3.13e-14)" "unprognostic (8.24e-2)" "unprognostic (1.36e-1)" "unprognostic (3.77e-2)" "unprognostic (3.04e-2)" 17.7 13.0 4.0 21.1 5.6 35.2 18.7 1.4 4.7 11.7 14.9 2.4 5.9 24.5 10.4 9.7 27.1 12.5 22.7 20.1 3.9 2.0 17.8 52.1 36.4 20.5 4.3 0.5 26.5 13.2 2.4 9.2 9.5 5.6 16.0 8.0 8.8 13.7 13.7 20.2 9.0 35.5 11.5 6.5 41.6 15.0 8.3 4.0 6.5 13.9 22.9 37.0 18.7 11.9 1.3 2.6 16.5 2.4 1.8 1.5 0.7 3.9 13.6 0.3 7.2 2.6 5.5 0.7 2.4 2.6 1.5 2.2 2.8 7.2 3.9 5.6 4.8 8.0 4.4 0.9 4.1 1.0 27.0 0.2 0.5 7.1 3.6 6.3 0.3 11.6 9.6 3.2 3.4 4.3 7.1 4.1 0.0 0.5 22.4 0.9 3.3 0.0 3.0 0.3 6.0 5.7 1.8 2.7 1.4 6.9 8.2 0.0 0.4 28.7 14.7 0.7 0.5 5.1 3.0 6.9 4.9 5.1 7.6 0.9 21.3 8.3 4.0 9.1 0.5 3.7 0.2 2.4 4.2 0.7 1.6 1.0 1.3 0.9 1.1 2.1 1.1 0.5 0.6 16.5 1.8 0.9 2.6 1.5 0.7 4.0 5.6 1.4 4.7 3.9 2.0 4.3 0.5 5.6 4.0 17.9 53.0 18.6 32.7 41.4 1.7 2.4 25.5 18.7 31.8 12.2 0.0 0.3 8.3 26.4 9.3 39.0 55.4 0.0 58.8 5.9 33.8 37.5 36.9 31.7 13.9 7.9 20.6 35.6 31.1 1.3 12.4 45.8 38.8 36.9 31.6 2.3 42.1 35.1 4.2 17.7 0.5 6.5 57.5 0.5 1.2 53.3 1.1 14.6 22.9 44.4 BCL6 "BCL5, BCL6A, LAZ3, ZBTB27, ZNF51" ENSG00000113916 "B cell CLL/lymphoma 6" P41182 3 187721377-187745727 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Immunity, Inflammatory response, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 114.3" "Cell type enhanced" "Detected in many" 5 "Smooth muscle cells: 96.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 4 "neutrophil: 63.4" "Lineage enriched" "Detected in many" 4 "granulocytes: 63.4" "Cell line enhanced" "Detected in many" "ASC diff: 27.3;Daudi: 42.9;HSkMC: 31.1;U-698: 59.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000307, HPA004899, HPA050645" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB000307: AB_2063451, HPA004899: AB_1078273, HPA050645: AB_2681199" "unprognostic (5.36e-2)" "unprognostic (3.29e-2)" "unprognostic (1.63e-3)" "unprognostic (2.49e-1)" "unprognostic (2.85e-1)" "unprognostic (6.34e-3)" "unprognostic (2.62e-2)" "unprognostic (3.33e-3)" "unprognostic (8.75e-2)" "unprognostic (2.04e-2)" "unprognostic (1.63e-3)" "unprognostic (1.29e-1)" "prognostic unfavorable (1.27e-9)" "unprognostic (5.22e-2)" "unprognostic (7.82e-2)" "unprognostic (5.67e-2)" "unprognostic (2.58e-2)" 47.1 14.3 21.8 23.2 25.9 50.6 48.0 58.7 23.7 21.2 21.2 19.2 11.5 4.1 17.7 8.8 20.9 28.3 22.3 18.6 21.5 8.0 10.1 20.1 26.3 24.5 31.6 9.3 20.2 15.6 9.1 23.3 7.5 28.5 17.3 5.8 15.9 19.1 11.8 114.3 36.4 8.1 24.4 50.1 27.2 16.1 10.2 26.6 18.9 14.8 10.4 22.4 24.9 20.0 3.9 5.6 63.4 15.4 0.9 1.3 5.2 1.2 3.6 3.6 0.8 27.3 21.8 3.9 4.3 10.5 5.0 5.3 2.6 2.0 42.9 3.1 5.4 3.1 2.1 1.2 2.8 4.3 9.0 1.4 0.0 1.8 6.1 14.2 0.5 0.2 31.1 18.2 6.1 9.4 16.3 2.8 1.1 0.4 7.4 4.8 1.4 1.4 0.3 0.3 0.7 2.7 11.9 1.8 0.2 3.5 6.3 0.8 0.0 5.0 2.1 2.8 8.3 9.4 1.5 5.6 12.1 1.9 4.4 2.0 5.5 1.8 59.6 6.6 1.6 8.5 1.6 6.9 4.1 1.3 8.7 1.3 1.4 0.8 1.2 5.6 3.9 0.5 0.6 63.4 0.9 15.4 0.9 0.6 5.2 21.8 25.9 58.7 23.7 21.5 8.0 31.6 9.3 28.5 26.6 17.9 76.9 6.5 13.3 42.0 11.0 60.5 17.8 25.4 22.7 15.7 19.6 1.1 0.0 9.2 12.3 27.7 1.6 0.0 10.6 2.0 36.2 28.7 10.5 44.4 11.2 0.0 4.6 9.8 56.3 6.2 26.7 26.7 33.7 3.6 1.1 40.1 8.7 0.0 17.7 1.1 9.6 32.3 96.4 0.4 0.7 53.8 3.4 10.7 1.9 21.9 BCL7A BCL7 ENSG00000110987 "BCL tumor suppressor 7A" Q4VC05 12 122019422-122062044 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Horizontal cells: 101.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "naive B-cell: 8.4;plasmacytoid DC: 9.7" "Group enriched" "Detected in many" 10 "B-cells: 8.4;dendritic cells: 9.7" "Cell line enhanced" "Detected in many" "Daudi: 26.2;MOLT-4: 19.2;U-698: 30.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019762 Approved Approved Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "HPA019762: AB_10962489" "unprognostic (3.27e-1)" "unprognostic (2.97e-2)" "prognostic unfavorable (6.81e-4)" "unprognostic (1.35e-1)" "unprognostic (1.46e-1)" "unprognostic (1.23e-1)" "prognostic unfavorable (2.04e-4)" "unprognostic (5.18e-1)" "unprognostic (5.13e-2)" "unprognostic (1.06e-2)" "unprognostic (3.13e-1)" "unprognostic (3.11e-1)" "prognostic favorable (1.54e-6)" "unprognostic (4.86e-2)" "unprognostic (8.56e-2)" "unprognostic (6.16e-3)" "unprognostic (1.51e-2)" 3.8 3.7 13.0 9.8 14.5 9.9 6.5 19.8 18.2 6.7 4.2 6.8 3.3 3.6 6.0 7.4 3.3 10.3 4.3 9.4 9.5 7.5 10.7 5.3 5.1 19.4 6.6 15.9 4.9 11.7 8.3 6.1 2.8 6.8 6.3 3.8 3.8 8.2 7.2 12.8 8.2 3.4 4.1 5.1 6.5 4.4 3.1 7.9 26.4 11.1 3.5 15.8 6.9 5.4 8.4 9.7 0.1 0.1 0.5 0.9 0.6 1.7 2.4 8.0 5.6 0.5 0.3 1.7 1.0 1.1 1.7 1.5 1.0 0.7 26.2 2.9 0.8 1.0 2.3 5.8 5.5 1.5 0.0 9.5 1.3 0.2 1.4 1.7 4.0 2.3 1.3 5.3 1.2 7.2 2.0 2.1 12.3 5.9 0.0 1.0 3.6 19.2 0.3 2.9 2.4 4.1 10.6 2.8 0.3 3.2 4.5 8.0 9.0 1.3 0.3 3.3 2.0 5.4 3.3 1.9 0.3 1.7 3.0 1.7 2.7 1.8 30.3 0.5 2.6 1.8 0.1 0.0 0.0 0.1 0.0 0.0 2.9 0.2 0.2 2.2 8.4 0.9 0.6 0.1 0.5 0.1 9.7 0.0 0.6 13.0 14.5 19.8 18.0 9.5 7.5 6.6 15.9 6.8 7.9 20.8 8.6 37.2 47.6 31.9 38.8 25.8 38.2 14.7 22.7 36.6 17.7 1.0 49.7 25.7 6.1 3.1 1.7 0.0 9.5 0.8 8.7 26.5 10.4 16.8 3.2 101.7 20.6 4.3 3.5 9.8 13.0 8.5 11.8 5.4 8.0 5.6 10.5 7.0 7.4 18.9 13.5 6.5 15.6 0.5 4.3 26.3 0.5 0.0 11.4 26.0 BCL9 ENSG00000116128 "B cell CLL/lymphoma 9" O00512 1 147541412-147626216 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Wnt signaling pathway" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Intestinal endocrine cells: 27.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "NTERA-2: 24.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020274 Approved Approved "Nucleoplasm,Nuclear bodies" No No "Nucleoplasm, Nuclear bodies" "HPA020274: AB_2670400" "unprognostic (2.31e-1)" "unprognostic (1.52e-2)" "unprognostic (5.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.04e-1)" "unprognostic (1.65e-1)" "prognostic unfavorable (6.74e-4)" "unprognostic (1.03e-1)" "unprognostic (2.78e-1)" "unprognostic (2.29e-1)" "unprognostic (4.78e-3)" "unprognostic (3.92e-2)" "unprognostic (1.64e-3)" "unprognostic (2.58e-1)" "unprognostic (2.20e-1)" "unprognostic (1.37e-1)" "unprognostic (1.60e-2)" 4.5 7.8 10.2 5.9 9.2 3.1 4.8 22.3 12.6 18.2 9.4 8.1 10.9 5.3 23.9 15.9 6.8 18.9 5.2 8.3 8.0 7.4 9.6 4.3 5.0 4.0 5.9 8.7 17.0 6.1 14.6 10.6 4.5 6.8 10.5 7.9 11.8 8.1 13.2 7.9 7.8 5.5 15.7 5.4 3.8 7.6 6.1 6.5 22.4 7.8 8.0 6.0 9.6 8.0 0.4 0.0 0.6 0.3 0.1 2.6 1.0 2.9 2.9 20.6 15.3 2.3 2.8 4.0 2.4 3.9 2.7 2.6 3.8 4.5 2.8 5.5 2.3 4.5 2.4 13.0 4.4 2.5 6.7 3.6 1.3 3.1 2.5 2.0 0.8 4.1 2.7 3.8 3.2 2.3 4.8 4.1 9.4 2.6 4.6 2.3 6.7 7.0 0.6 24.3 6.0 6.4 7.5 5.2 5.5 10.4 3.3 5.6 12.2 2.7 5.1 4.7 19.8 6.4 1.3 3.0 1.9 9.0 5.3 3.8 20.9 5.3 5.4 4.8 0.8 9.1 0.0 0.3 0.6 1.0 0.0 0.9 0.2 1.2 1.2 0.0 0.4 2.6 1.6 0.2 0.1 0.1 0.0 0.9 1.0 10.2 9.2 22.3 12.6 8.0 7.4 5.9 8.7 6.8 6.5 0.0 2.1 0.0 5.2 2.7 7.9 4.7 7.6 2.7 2.3 12.2 2.0 1.8 10.0 3.4 9.0 2.8 1.8 0.0 4.0 2.0 4.6 7.6 8.1 2.6 1.1 6.4 27.2 6.2 2.8 4.2 8.9 0.4 0.0 1.0 10.9 4.3 3.8 0.0 7.4 4.9 2.8 0.0 3.8 3.2 6.8 3.1 1.7 0.5 6.9 2.7 BCL9L DLNB11 ENSG00000186174 "B cell CLL/lymphoma 9 like" Q86UU0 11 118893875-118925608 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049370, HPA053421" Uncertain Enhanced Nucleoplasm NA NA Nucleoplasm "HPA049370: AB_2680732, HPA053421: AB_2682145" "unprognostic (1.67e-2)" "unprognostic (1.48e-2)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (2.87e-1)" "unprognostic (1.90e-1)" "unprognostic (6.61e-3)" "unprognostic (1.17e-3)" "unprognostic (1.03e-1)" "unprognostic (4.61e-2)" "unprognostic (4.66e-3)" "unprognostic (1.39e-1)" "unprognostic (2.83e-3)" "unprognostic (4.85e-3)" "unprognostic (2.24e-2)" "unprognostic (2.14e-1)" "unprognostic (2.90e-3)" 18.4 18.9 10.2 17.2 10.0 13.3 23.8 31.7 9.9 27.4 16.4 6.7 15.8 13.2 22.3 12.8 18.9 22.2 21.2 15.6 9.0 4.1 10.9 9.0 17.1 13.8 9.5 7.7 22.2 16.4 9.0 6.5 31.9 9.1 16.1 4.1 14.5 21.5 14.7 19.1 19.9 14.6 22.8 7.9 13.9 14.0 9.0 8.6 13.0 12.2 11.9 16.7 21.9 25.6 0.6 0.6 1.1 0.5 0.7 2.2 0.8 12.3 22.5 3.2 5.9 10.5 10.2 20.7 17.1 13.2 5.4 3.2 23.9 24.7 3.4 22.9 17.9 22.2 24.0 1.5 31.4 1.4 4.1 0.8 3.3 12.6 8.2 11.9 1.1 3.2 12.9 19.6 6.5 13.1 10.5 4.8 2.0 4.3 3.9 3.7 20.8 2.5 0.9 3.8 7.4 13.0 5.3 1.4 2.3 5.7 8.6 1.7 2.6 24.1 36.6 3.4 6.0 28.8 1.4 16.0 17.5 13.3 5.2 14.5 0.8 0.0 1.0 9.4 3.9 9.9 0.0 0.5 0.0 2.2 0.0 1.5 0.3 1.2 1.3 0.1 0.6 1.9 1.5 1.1 0.7 0.0 0.6 0.2 0.8 10.2 10.0 31.7 9.9 9.0 4.1 9.5 7.7 9.1 8.6 14.9 11.5 2.4 8.8 34.5 18.4 2.0 15.3 4.0 11.4 7.0 3.9 9.8 0.0 11.8 0.1 10.1 8.0 0.0 12.7 7.0 11.6 18.2 2.3 10.0 3.8 12.7 5.2 11.1 5.2 0.0 13.6 2.6 6.8 19.8 5.0 6.9 20.3 7.0 13.4 2.2 2.8 25.8 14.7 0.5 1.0 39.5 29.6 11.8 6.3 9.1 BCOR "FLJ20285, KIAA1575" ENSG00000183337 "BCL6 corepressor" Q6W2J9 X 40049815-40177329 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA056308, HPA073591" Enhanced Nucleoplasm NA NA Nucleoplasm "HPA056308: AB_2683095, HPA073591: AB_2732227" "unprognostic (2.75e-2)" "unprognostic (2.83e-1)" "unprognostic (2.45e-1)" "unprognostic (9.26e-2)" "unprognostic (1.55e-1)" "unprognostic (9.80e-3)" "prognostic unfavorable (1.30e-5)" "unprognostic (3.82e-3)" "unprognostic (6.86e-2)" "unprognostic (1.86e-1)" "unprognostic (4.08e-2)" "unprognostic (1.18e-1)" "unprognostic (3.91e-3)" "unprognostic (6.83e-2)" "unprognostic (9.57e-2)" "unprognostic (2.63e-1)" "unprognostic (1.55e-1)" 9.1 12.8 8.7 8.7 10.5 20.6 13.3 11.5 12.0 10.0 12.6 22.7 11.9 7.8 11.1 13.9 13.6 10.4 8.6 13.0 7.1 5.4 11.2 13.3 11.4 15.2 12.9 8.4 19.8 13.6 19.7 11.9 12.5 10.7 13.2 8.2 13.7 11.1 16.5 28.8 13.6 10.3 12.9 8.6 11.4 11.5 9.8 15.8 18.4 16.0 11.4 13.5 13.8 25.5 6.5 7.3 7.6 7.1 8.2 6.8 11.8 13.1 8.7 17.8 21.7 2.0 1.6 3.1 4.5 7.1 5.7 4.7 3.7 5.3 12.0 5.3 8.3 3.7 12.4 29.0 3.8 5.1 20.9 26.4 13.4 13.4 14.4 3.4 10.8 7.7 2.6 5.6 6.3 3.6 8.4 7.7 7.9 34.3 29.0 7.0 8.4 24.4 22.6 17.5 6.2 13.6 11.9 18.4 13.5 10.5 8.3 12.8 23.1 9.4 8.3 7.0 9.1 8.9 23.8 6.4 6.2 7.8 9.1 5.0 17.2 13.3 12.5 5.4 9.9 9.5 7.6 5.0 4.5 6.8 6.1 4.3 6.5 4.7 3.9 7.3 5.5 4.7 4.8 1.1 8.2 7.1 3.1 5.5 11.8 8.7 10.5 11.5 12.0 7.1 5.4 12.9 8.4 10.7 15.8 20.8 23.2 12.3 3.2 13.1 34.2 7.6 10.2 6.7 5.7 10.4 11.8 3.7 1.7 4.5 2.1 17.4 4.9 0.0 9.1 5.5 13.6 7.9 23.2 9.5 6.4 14.3 15.6 19.0 11.0 2.1 9.8 8.6 5.0 7.2 11.7 7.7 6.6 0.0 7.4 4.0 22.0 0.0 26.4 1.1 13.5 12.2 1.7 7.5 7.6 2.6 BCORL1 "CXorf10, FLJ11362" ENSG00000085185 "BCL6 corepressor like 1" Q5H9F3 X 129981107-130058083 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enriched" "Detected in many" 7 "Syncytiotrophoblasts: 78.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AN3-CA: 20.4;HAP1: 30.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031775, HPA031777, HPA068568" Uncertain Approved "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "HPA031775: AB_10602332, HPA031777: AB_10671578, HPA068568: AB_2686007" "unprognostic (8.07e-2)" "unprognostic (2.78e-2)" "unprognostic (7.09e-2)" "prognostic unfavorable (2.20e-5)" "unprognostic (4.58e-1)" "unprognostic (1.68e-3)" "unprognostic (1.96e-3)" "unprognostic (5.56e-3)" "unprognostic (2.39e-1)" "unprognostic (8.02e-2)" "unprognostic (4.46e-2)" "unprognostic (2.04e-1)" "prognostic unfavorable (5.00e-4)" "unprognostic (9.18e-2)" "unprognostic (2.60e-2)" "unprognostic (3.09e-1)" "unprognostic (1.41e-2)" 7.5 7.9 7.7 5.2 9.1 9.8 9.1 19.8 10.5 8.7 8.3 10.7 8.1 5.4 9.2 5.4 5.8 9.3 4.2 6.9 8.4 4.5 7.5 4.7 6.7 5.3 7.6 5.9 11.4 8.9 13.4 15.0 28.9 7.5 8.1 4.5 6.0 6.5 8.4 6.0 6.5 6.0 8.8 5.3 7.7 6.6 26.1 8.1 6.8 10.3 2.2 5.1 6.7 8.5 1.2 1.6 3.5 1.3 0.8 1.3 0.7 2.2 5.5 12.9 20.4 7.6 5.5 3.6 3.0 3.5 3.9 4.5 6.6 1.4 1.0 6.7 6.0 3.7 1.3 30.8 1.2 3.7 2.2 4.5 10.6 2.7 2.2 3.8 2.6 3.1 3.4 2.5 7.7 0.4 5.8 4.7 3.5 5.1 10.8 2.5 1.3 3.9 8.0 3.5 1.8 3.9 8.3 5.2 1.4 2.2 0.3 2.1 7.3 1.6 0.4 2.0 7.2 4.5 4.0 3.9 3.2 4.1 3.8 2.9 3.5 6.3 1.6 2.1 5.4 1.5 0.1 1.3 2.8 1.3 0.2 1.0 1.2 0.9 0.8 1.6 1.0 0.6 0.7 3.5 0.8 0.5 0.7 0.2 0.7 7.7 9.1 19.8 10.5 8.4 4.5 7.6 5.9 7.5 8.1 0.0 3.2 0.0 2.3 10.5 1.8 6.4 5.1 2.7 1.2 7.0 0.0 10.7 0.0 3.2 0.4 7.1 2.7 0.0 0.9 4.2 5.8 2.9 6.9 3.0 2.8 7.9 11.5 3.1 2.6 1.0 4.4 1.8 6.8 1.0 1.7 3.1 2.3 0.0 3.5 2.2 1.0 6.5 4.5 3.5 5.3 10.0 78.1 1.5 2.8 2.5 BCR "ALL, BCR1, CML, D22S11, D22S662, PHL" ENSG00000186716 "BCR, RhoGEF and GTPase activating protein" P11274 22 23179704-23318037 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Ito cells: 62.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "K-562: 44.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010421, CAB018545, HPA038337" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" Nucleoplasm "CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795" "unprognostic (7.46e-3)" "unprognostic (2.43e-2)" "unprognostic (2.15e-3)" "unprognostic (1.16e-1)" "unprognostic (5.35e-2)" "unprognostic (1.45e-1)" "unprognostic (5.08e-2)" "unprognostic (1.44e-1)" "unprognostic (7.55e-2)" "unprognostic (1.81e-1)" "unprognostic (9.46e-2)" "unprognostic (2.39e-2)" "prognostic favorable (9.15e-10)" "unprognostic (1.47e-1)" "unprognostic (7.10e-2)" "unprognostic (4.10e-2)" "unprognostic (7.43e-2)" 14.5 8.4 24.0 9.1 41.2 26.7 10.5 14.2 26.5 13.6 9.7 10.3 10.6 8.7 9.2 13.9 19.3 10.8 8.3 7.8 20.9 13.0 16.3 8.3 11.3 10.9 16.0 15.6 8.8 12.9 14.5 14.9 15.7 14.2 7.0 6.8 8.3 15.5 9.7 3.4 12.8 8.7 9.0 9.5 9.1 14.0 9.6 15.4 11.8 16.6 5.5 9.2 9.2 8.8 1.5 0.8 1.2 1.0 2.8 6.6 2.5 19.0 8.2 12.7 13.0 7.6 5.2 19.2 6.9 6.5 6.4 5.2 14.4 7.7 13.3 12.9 5.9 6.2 19.6 1.3 19.2 1.8 25.4 13.2 11.6 11.3 11.4 9.9 10.7 6.1 4.4 13.0 9.5 8.4 11.4 22.3 9.6 44.4 6.3 2.9 12.5 10.0 8.4 10.7 15.1 8.1 13.2 5.1 8.7 9.9 12.1 11.7 11.1 12.6 10.9 5.2 8.5 6.9 8.8 25.1 3.8 0.4 6.2 5.7 1.4 5.8 4.7 9.9 8.1 5.9 0.0 1.0 0.0 6.6 0.4 2.3 1.4 3.3 3.3 0.8 1.5 2.6 3.6 1.2 2.8 1.0 0.8 1.6 2.5 24.0 41.2 14.2 24.9 20.9 13.0 16.0 15.6 14.2 15.4 8.9 11.5 3.0 9.5 13.7 24.0 7.3 20.4 2.7 19.4 17.4 21.6 10.5 8.3 12.4 3.9 22.4 11.1 0.0 14.1 5.9 7.3 10.2 10.4 18.4 6.0 22.3 19.1 62.0 10.8 7.7 8.1 5.4 5.0 6.4 12.0 13.4 21.8 5.8 5.3 14.3 8.0 0.0 8.6 1.6 6.8 13.8 9.0 9.2 11.2 11.5 BIRC3 "API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49" ENSG00000023445 "Baculoviral IAP repeat containing 3" Q13489 11 102317450-102339403 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 46.0;lymphoid tissue: 46.3" "Cell type enhanced" "Detected in many" 16 "granulocytes: 530.1;monocytes: 1925.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "memory B-cell: 32.9;naive B-cell: 32.9" "Group enriched" "Detected in many" 10 "B-cells: 32.9;T-cells: 17.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 38.4;Daudi: 33.7;HDLM-2: 31.9;hTERT-HME1: 33.6;U-266/70: 22.5;U-266/84: 19.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002317 Enhanced Approved Supported Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "HPA002317: AB_1846748" "prognostic favorable (3.60e-4)" "unprognostic (2.89e-1)" "prognostic favorable (9.35e-4)" "unprognostic (3.28e-2)" "prognostic unfavorable (7.28e-4)" "unprognostic (5.83e-3)" "unprognostic (2.23e-1)" "unprognostic (3.88e-3)" "unprognostic (9.62e-2)" "unprognostic (1.29e-1)" "prognostic unfavorable (3.03e-4)" "unprognostic (3.21e-1)" "prognostic unfavorable (6.66e-6)" "unprognostic (6.42e-2)" "unprognostic (6.23e-3)" "unprognostic (1.00e-1)" "unprognostic (3.85e-2)" 6.9 3.3 1.4 43.9 2.3 5.1 5.4 0.5 2.0 5.3 13.1 0.5 2.8 6.8 2.9 3.7 8.4 3.9 13.9 6.0 2.2 1.3 10.8 12.5 21.8 46.3 2.8 1.2 3.4 7.0 1.1 14.5 0.9 2.2 8.7 6.2 1.1 9.2 4.7 2.2 5.5 46.0 7.3 3.0 34.9 15.9 3.2 2.7 34.2 3.0 4.1 34.0 12.6 6.2 32.9 0.8 2.0 2.6 2.5 17.1 2.8 6.5 5.3 0.0 0.1 0.1 0.7 0.6 0.5 4.4 0.6 0.7 0.9 38.4 33.7 17.4 0.3 5.5 3.6 0.0 0.9 2.1 31.9 0.1 0.1 1.6 0.2 6.6 0.5 0.7 0.7 4.7 2.1 33.6 1.2 0.1 2.7 0.1 0.0 0.8 0.0 2.3 0.3 0.1 3.1 0.2 0.0 0.3 1.7 8.7 3.4 0.0 0.1 0.5 0.6 0.3 0.2 1.7 0.3 1.7 7.3 0.8 0.4 6.7 22.5 19.2 11.9 1.3 1.9 0.9 2.0 0.9 0.4 1.4 2.2 2.5 32.9 10.7 3.5 0.8 32.9 7.5 2.2 0.5 2.5 2.6 0.3 17.1 2.8 1.4 2.3 0.5 2.0 2.2 1.3 2.8 1.2 2.2 2.7 134.0 68.1 285.1 318.0 89.9 0.3 12.0 76.5 30.8 73.9 38.4 0.0 1.7 6.6 193.4 1.3 50.1 284.0 46.7 153.8 0.5 71.9 371.3 530.1 3.4 11.1 0.0 14.5 7.4 18.1 1.3 4.6 71.9 182.2 1925.2 27.1 0.1 190.8 361.2 2.1 8.8 0.0 0.0 133.5 0.5 0.4 73.9 0.5 89.3 29.9 164.7 BRAF BRAF1 ENSG00000157764 "B-Raf proto-oncogene, serine/threonine kinase" P15056 7 140719327-140924928 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001328, CAB004552, HPA071048" Approved Approved Vesicles,Cytosol No No Vesicles Cytosol "CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: AB_2686336" "unprognostic (2.98e-3)" "unprognostic (5.66e-2)" "unprognostic (2.20e-2)" "unprognostic (2.66e-3)" "unprognostic (2.44e-1)" "unprognostic (1.48e-2)" "unprognostic (2.07e-2)" "unprognostic (4.23e-2)" "unprognostic (4.07e-2)" "unprognostic (1.58e-2)" "unprognostic (6.53e-2)" "unprognostic (1.91e-2)" "unprognostic (3.79e-3)" "unprognostic (2.08e-1)" "unprognostic (1.76e-1)" "unprognostic (8.01e-2)" "unprognostic (5.46e-2)" 13.1 12.1 20.1 16.5 20.4 27.8 14.2 29.9 21.5 12.4 12.3 9.5 12.5 9.3 15.3 17.0 11.8 11.5 12.0 13.6 13.2 12.2 13.7 12.8 15.9 13.3 9.9 17.8 16.8 13.2 28.9 24.8 13.7 15.3 14.5 11.0 10.7 11.6 16.6 12.9 15.6 10.5 13.0 10.9 12.3 12.0 24.9 12.2 13.5 16.6 7.5 12.1 18.6 18.1 2.6 1.9 7.5 2.4 7.0 5.6 1.1 5.5 4.7 6.9 8.3 8.4 11.0 11.1 6.2 6.6 5.0 7.2 5.1 6.0 9.5 4.8 6.4 8.0 3.1 6.1 4.9 9.3 8.8 5.0 6.2 4.6 4.7 7.2 10.0 6.2 7.3 5.6 5.3 11.1 7.4 5.8 7.1 9.7 17.1 8.8 2.9 13.3 10.5 6.4 5.4 3.0 8.7 5.9 7.7 4.9 10.7 8.1 6.8 7.2 4.4 6.5 7.1 4.1 6.8 8.6 5.5 4.2 11.7 5.0 19.8 11.2 15.2 8.9 10.1 5.9 3.3 2.0 7.5 3.1 1.7 2.1 2.6 3.0 2.4 1.6 2.6 5.6 2.8 4.1 7.0 2.4 1.9 2.7 1.1 20.1 20.4 29.9 21.5 13.2 12.2 9.9 17.8 15.3 12.2 20.8 34.2 19.5 20.3 19.2 29.1 12.7 5.1 24.1 25.0 24.4 33.4 12.4 6.6 10.9 55.6 17.1 7.5 0.0 8.6 10.3 13.1 23.9 24.3 8.7 7.9 23.8 18.4 8.6 14.8 30.8 15.3 17.2 15.1 10.0 8.1 11.8 12.5 6.6 9.6 9.6 32.5 6.5 17.3 33.7 23.0 21.0 63.2 17.5 8.1 23.8 BRCA1 "BRCC1, FANCS, PPP1R53, RNF53" ENSG00000012048 "BRCA1, DNA repair associated" P38398 17 43044295-43170245 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA recombination, DNA repair, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, DNA-binding, Transferase" "Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Spermatocytes: 64.7;Spermatogonia: 61.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in all" 5 "dendritic cells: 9.1;granulocytes: 9.7;monocytes: 12.7" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB001946, HPA004840, HPA034966, HPA057371" Approved Supported "Nucleoplasm,Nuclear bodies" NA Yes "Nucleoplasm, Nuclear bodies" "CAB001946: , HPA004840: , HPA034966: AB_10795287, HPA057371: AB_2732611" "unprognostic (7.87e-3)" "unprognostic (6.97e-2)" "unprognostic (3.53e-3)" "unprognostic (2.39e-1)" "unprognostic (5.42e-2)" "unprognostic (7.07e-3)" "unprognostic (1.56e-3)" "unprognostic (4.14e-3)" "unprognostic (9.62e-3)" "unprognostic (2.47e-1)" "unprognostic (5.53e-3)" "unprognostic (1.28e-1)" "unprognostic (1.08e-4)" "unprognostic (1.08e-3)" "unprognostic (1.48e-1)" "unprognostic (2.12e-1)" "unprognostic (8.31e-2)" 4.8 4.3 6.0 9.6 11.3 15.3 5.1 12.9 10.6 5.4 9.2 3.4 6.8 4.3 5.4 5.5 9.1 5.5 3.3 6.5 6.6 5.3 4.2 7.7 4.9 13.0 7.5 5.9 5.1 4.7 4.2 11.0 5.3 10.5 4.1 10.4 3.7 5.4 7.4 7.3 8.3 6.7 5.5 9.2 5.9 5.1 17.6 7.0 10.9 15.6 7.3 14.6 5.5 5.6 2.0 9.1 9.7 12.7 1.4 1.3 10.7 15.7 25.6 14.1 11.2 2.3 5.2 13.8 18.6 8.0 15.6 14.9 15.5 12.3 36.4 3.4 7.1 18.5 18.3 19.1 10.4 26.2 16.6 14.0 17.1 20.1 13.4 0.5 30.5 14.9 1.4 1.7 23.5 7.5 4.0 8.1 17.0 25.8 15.6 14.7 10.5 25.5 10.1 7.7 10.6 6.8 17.6 29.7 14.9 5.8 15.3 9.7 10.4 14.3 4.7 7.0 10.0 12.6 14.1 5.2 14.0 11.4 18.1 19.3 7.3 17.8 28.0 11.3 18.1 14.6 4.6 12.7 1.8 1.3 4.0 1.3 1.1 1.3 1.0 9.1 2.0 1.2 1.3 9.7 1.4 1.5 1.4 0.4 10.7 6.0 11.3 12.9 10.6 6.6 5.3 7.5 5.9 10.5 7.0 0.0 3.2 5.2 3.8 2.6 8.3 10.4 7.6 13.4 5.7 1.8 21.6 7.0 0.0 2.6 11.1 2.9 1.0 0.0 1.0 17.5 2.9 2.4 8.1 16.1 8.6 11.1 0.0 5.5 4.0 5.2 2.3 5.3 0.0 3.6 3.7 2.8 1.6 3.1 1.4 0.8 21.1 6.5 1.4 64.7 61.1 1.9 3.3 2.5 3.5 2.5 BRCA2 "BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11" ENSG00000139618 "BRCA2, DNA repair associated" P51587 13 32315474-32400266 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 23.2;testis: 16.9" "Group enriched" "Detected in many" 4 "Erythroid cells: 23.3;monocytes: 31.5;Spermatocytes: 75.1;Spermatogonia: 82.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA026815 Uncertain Supported Nucleoplasm,Cytosol Yes No Nucleoplasm Cytosol "HPA026815: AB_10602692" "unprognostic (9.36e-2)" "unprognostic (2.50e-1)" "unprognostic (4.50e-3)" "unprognostic (1.06e-2)" "unprognostic (5.40e-2)" "unprognostic (2.26e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-1)" "unprognostic (1.60e-2)" "unprognostic (2.01e-1)" "unprognostic (6.97e-3)" "unprognostic (4.06e-2)" "unprognostic (3.07e-9)" "unprognostic (2.36e-2)" "unprognostic (1.18e-1)" "unprognostic (1.88e-1)" "unprognostic (1.32e-1)" 2.4 1.0 0.6 13.8 0.6 11.6 3.2 0.6 0.6 1.8 4.0 0.2 0.2 1.4 1.5 2.7 3.0 1.0 0.7 2.1 0.6 0.7 1.0 1.4 3.5 5.3 0.7 0.5 1.4 3.3 0.4 0.7 7.0 0.8 0.9 2.0 0.1 1.8 0.3 3.3 1.8 3.2 0.8 2.1 6.6 1.5 16.9 0.1 23.2 0.9 4.8 4.2 1.3 1.7 1.3 1.9 0.4 0.2 1.5 0.8 0.0 4.0 3.5 6.1 4.6 0.6 1.6 6.2 4.3 2.7 5.0 4.6 8.3 5.3 14.2 2.9 2.1 6.9 5.4 5.0 2.5 9.7 9.2 2.7 9.0 2.2 3.2 0.2 12.8 4.5 0.4 0.3 9.2 6.4 0.5 4.1 7.2 5.9 4.9 5.7 4.6 10.3 7.6 7.2 4.6 1.9 10.1 15.7 2.7 1.3 4.3 2.3 4.4 5.2 2.3 2.1 2.2 2.7 6.4 3.2 5.8 6.2 6.4 6.0 1.9 2.9 7.3 3.0 5.1 5.5 0.1 0.2 0.2 0.3 0.2 0.1 0.9 0.4 0.2 0.2 1.3 0.6 0.8 0.4 1.5 0.2 1.9 0.4 0.0 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.5 0.8 0.1 8.9 1.6 1.9 2.8 2.3 0.0 1.6 0.0 4.0 2.3 0.0 0.0 9.1 0.0 1.8 4.3 3.6 1.0 23.3 1.4 9.1 3.5 0.6 3.5 0.8 8.2 0.0 1.2 2.5 6.7 2.5 2.0 13.2 3.3 31.5 3.0 0.2 1.1 1.5 1.1 0.6 0.0 12.9 2.0 75.1 82.4 1.1 4.6 3.8 5.3 1.4 BRD3 "KIAA0043, ORFX, RING3L" ENSG00000169925 "Bromodomain containing 3" Q15059 9 134030305-134068535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051830 Approved Approved "Nuclear bodies" NA NA "Nuclear bodies" "HPA051830: AB_2681627" "unprognostic (3.53e-2)" "unprognostic (2.17e-1)" "unprognostic (1.55e-2)" "unprognostic (1.90e-1)" "unprognostic (6.20e-2)" "unprognostic (2.60e-2)" "unprognostic (2.98e-2)" "unprognostic (3.48e-2)" "unprognostic (1.11e-2)" "unprognostic (6.75e-2)" "unprognostic (2.79e-1)" "unprognostic (1.98e-1)" "prognostic favorable (2.71e-7)" "unprognostic (1.00e-1)" "unprognostic (4.71e-2)" "unprognostic (2.57e-2)" "unprognostic (1.42e-1)" 16.3 15.7 18.0 12.0 20.0 12.3 14.2 21.8 21.8 21.0 20.3 26.7 17.3 13.8 21.7 17.4 14.6 17.7 12.6 17.1 19.9 14.8 11.3 14.5 14.6 11.9 15.8 15.8 19.1 18.7 21.8 15.8 15.7 15.6 19.9 10.3 16.6 16.5 22.5 29.2 19.6 12.9 16.3 17.8 20.1 14.8 17.8 18.2 35.4 18.7 9.2 10.3 17.9 14.1 7.3 16.6 14.6 12.9 15.4 11.9 7.8 4.1 12.6 16.1 12.5 8.9 7.3 14.7 4.2 4.8 4.7 4.8 10.5 6.9 1.6 4.5 3.8 5.3 14.4 14.9 5.8 3.7 9.8 8.3 9.0 14.3 11.8 8.0 11.7 8.1 7.8 7.2 5.4 6.2 7.7 7.7 15.1 8.1 4.7 4.8 13.9 21.7 15.8 21.4 10.8 9.8 16.1 23.2 7.8 6.6 4.4 23.6 21.8 18.9 7.2 5.0 10.1 10.3 19.6 9.8 11.6 6.5 7.5 3.7 2.5 2.7 1.4 5.8 8.1 7.6 5.9 12.9 14.5 11.9 9.8 10.0 7.1 9.6 10.6 12.5 7.3 9.1 9.7 14.6 15.4 7.9 16.6 4.4 7.8 18.0 20.0 21.8 21.8 19.9 14.8 15.8 15.8 15.6 18.2 29.8 21.6 14.1 17.5 28.7 54.2 17.9 25.5 24.1 29.6 22.7 35.3 22.4 16.6 37.3 34.3 26.7 15.2 93.5 21.3 17.8 30.4 33.1 16.1 25.1 15.9 54.0 51.9 27.0 25.1 14.1 52.9 20.6 21.9 19.0 24.6 41.9 25.2 21.0 63.3 13.0 54.0 58.2 32.6 13.7 61.1 31.1 27.3 25.8 30.3 14.7 BRD4 "CAP, HUNK1, HUNKI, MCAP" ENSG00000141867 "Bromodomain containing 4" O60885 19 15235519-15332545 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA damage, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015055, HPA061646, CAB068177, CAB068178" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB068177: AB_2665685, CAB068178: AB_2665686, HPA015055: AB_1845435, HPA061646: AB_2684575" "unprognostic (2.83e-3)" "unprognostic (2.39e-2)" "unprognostic (6.37e-3)" "unprognostic (3.38e-2)" "unprognostic (2.15e-1)" "unprognostic (9.53e-3)" "unprognostic (3.03e-3)" "unprognostic (6.13e-2)" "unprognostic (7.63e-2)" "unprognostic (2.72e-2)" "unprognostic (3.98e-2)" "unprognostic (5.26e-2)" "unprognostic (1.83e-3)" "unprognostic (2.43e-1)" "unprognostic (2.73e-1)" "unprognostic (1.28e-1)" "unprognostic (1.22e-1)" 23.0 20.7 27.8 25.6 30.1 25.2 20.4 32.1 29.9 20.8 19.6 17.2 18.9 17.6 23.4 12.5 22.9 18.6 15.8 21.3 20.3 12.4 18.1 25.3 22.5 22.7 14.8 17.6 27.3 31.3 19.1 18.8 34.0 17.6 20.8 10.7 18.9 22.0 19.3 47.7 27.3 21.0 20.3 13.9 26.8 20.2 20.1 16.8 34.2 21.5 11.6 23.7 20.9 24.8 6.9 4.3 11.6 4.4 4.9 3.5 2.0 20.4 20.7 12.9 24.3 12.3 8.7 15.6 15.1 12.3 11.9 12.6 21.8 30.9 25.7 25.0 16.4 11.7 20.5 15.0 14.2 10.4 25.7 9.9 24.3 18.1 19.0 18.8 24.0 27.1 12.8 14.7 14.8 29.2 7.9 11.5 17.3 41.1 26.1 7.6 26.5 22.5 17.3 26.3 9.4 24.3 28.3 13.6 16.1 9.5 22.1 15.6 14.1 19.9 14.6 17.0 11.0 14.6 16.4 18.3 31.2 14.9 27.7 23.7 21.3 18.8 13.1 17.2 19.5 24.2 5.2 3.6 3.9 3.5 4.4 2.7 5.4 3.1 2.9 2.1 6.9 3.1 2.9 11.6 4.9 3.9 4.3 2.2 2.0 27.8 30.1 32.1 29.9 20.3 12.4 14.8 17.6 17.6 16.8 59.6 53.2 59.1 104.0 104.5 62.2 73.0 56.0 22.7 28.4 24.4 78.5 177.3 21.6 46.6 107.0 73.3 66.9 93.5 57.8 59.0 72.1 110.7 34.8 77.4 51.9 74.7 109.2 55.3 67.7 148.2 71.7 51.2 42.2 43.3 47.3 38.6 55.1 44.4 75.0 28.3 85.9 71.1 85.8 52.5 37.5 125.2 212.7 56.7 51.5 128.6 BTG1 APRO2 ENSG00000133639 "BTG anti-proliferation factor 1" P62324 12 92140278-92145897 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 190.7" "Cell type enhanced" "Detected in all" 5 "Basal keratinocytes: 2444.1;Suprabasal keratinocytes: 2626.0" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 5 "cerebellum: 66.8" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC TERT1: 50.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005972 Approved Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA005972: AB_1078303" "prognostic favorable (4.36e-5)" "unprognostic (1.43e-1)" "unprognostic (2.32e-1)" "unprognostic (1.37e-2)" "unprognostic (1.07e-1)" "unprognostic (3.61e-3)" "unprognostic (1.10e-1)" "unprognostic (5.51e-2)" "unprognostic (1.46e-1)" "unprognostic (1.34e-2)" "unprognostic (2.50e-1)" "unprognostic (4.94e-2)" "prognostic unfavorable (1.95e-7)" "unprognostic (1.14e-1)" "unprognostic (1.56e-1)" "unprognostic (5.79e-2)" "unprognostic (9.81e-2)" 52.0 22.1 11.5 58.3 13.4 126.9 114.4 66.8 10.4 41.7 40.1 5.5 21.9 15.5 30.1 22.0 28.7 27.9 39.9 49.2 11.9 8.1 22.2 58.1 85.6 190.7 10.4 8.2 29.1 64.2 17.6 17.1 23.4 13.3 28.7 18.1 21.0 19.0 25.9 31.6 70.6 34.3 26.0 24.6 77.1 26.4 19.0 8.9 148.9 15.7 14.3 58.2 54.2 35.2 58.3 6.6 94.3 14.0 47.1 95.2 26.1 7.0 8.8 9.7 1.1 36.3 50.4 4.2 7.9 17.4 5.3 5.3 5.2 2.4 7.5 1.6 8.3 8.4 4.8 3.2 8.8 9.9 9.0 6.8 1.5 6.1 2.7 36.8 5.5 2.6 43.0 26.7 12.1 37.5 23.5 10.6 5.0 5.2 10.0 6.0 7.2 3.9 17.7 2.3 7.7 10.0 13.4 5.4 2.3 16.3 14.6 5.4 10.8 9.8 7.6 25.5 7.8 32.0 12.8 3.4 6.0 1.8 4.6 4.8 13.8 7.4 12.5 4.7 4.4 6.7 22.3 13.6 94.3 17.0 10.6 20.1 44.5 34.3 29.8 6.6 58.3 95.2 39.1 52.3 47.1 14.0 6.2 39.2 26.1 11.5 13.4 66.8 10.4 11.9 8.1 10.4 8.2 13.3 8.9 89.3 164.0 1133.8 898.4 2444.1 509.3 99.7 695.5 18.7 63.7 165.7 184.6 344.9 271.9 357.5 306.7 258.8 666.0 140.2 222.2 261.3 225.7 728.6 288.8 235.3 359.2 400.5 434.2 206.2 468.4 134.9 265.8 682.9 933.0 1485.2 192.1 767.8 308.3 596.2 227.4 96.3 342.5 530.3 1116.5 68.9 113.5 2626.0 1122.8 1563.2 226.0 1040.3 BTK "AGMX1, ATK, IMD1, PSCTK1, XLA" ENSG00000010671 "Bruton tyrosine kinase" Q06187 X 101349447-101390796 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 77.5;lymphoid tissue: 37.0" "Cell type enhanced" "Detected in some" 19 "B-cells: 86.8;granulocytes: 203.6;Hofbauer cells: 50.3;Kupffer cells: 53.4;Macrophages: 53.0;monocytes: 52.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 77.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "Daudi: 29.5;HEL: 40.9;HMC-1: 147.5;U-937: 21.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001198, HPA002028, CAB016689" Enhanced Supported "Plasma membrane,Cytosol" NA NA 610000 "Plasma membrane, Cytosol" "CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306" "unprognostic (3.19e-2)" "unprognostic (2.51e-3)" "unprognostic (1.06e-2)" "unprognostic (3.66e-2)" "unprognostic (5.69e-2)" "unprognostic (3.76e-3)" "unprognostic (6.55e-2)" "unprognostic (3.58e-3)" "unprognostic (6.02e-2)" "unprognostic (3.12e-1)" "unprognostic (1.02e-1)" "unprognostic (1.41e-1)" "unprognostic (2.08e-3)" "unprognostic (7.80e-2)" "unprognostic (1.29e-2)" "unprognostic (1.56e-2)" "unprognostic (8.14e-2)" 7.3 2.4 3.3 23.5 5.6 14.0 2.6 0.8 3.6 2.3 3.0 4.7 0.3 2.2 1.9 2.6 2.4 2.0 3.7 3.3 3.3 2.5 2.2 2.5 10.7 25.1 5.4 1.2 1.2 1.5 0.2 1.4 3.2 4.1 2.5 4.5 1.5 3.2 1.0 1.0 2.5 12.9 3.3 10.8 37.0 3.1 1.3 6.3 4.0 1.7 1.8 36.7 5.8 2.0 13.7 13.2 77.5 20.7 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 40.9 0.0 0.0 0.0 16.4 147.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.6 0.3 0.0 0.0 0.0 11.5 0.2 0.0 0.0 12.3 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 9.8 0.0 0.0 0.0 0.0 0.0 0.3 0.2 14.0 0.0 21.4 0.0 77.5 11.3 19.3 0.0 18.1 0.0 13.7 0.0 0.0 13.2 13.7 0.0 0.0 4.5 0.0 20.7 6.0 0.0 6.1 3.3 5.6 0.8 3.6 3.3 2.5 5.4 1.2 4.1 6.3 3.0 12.8 86.8 0.1 0.9 0.0 0.4 0.0 0.0 1.2 0.0 0.0 1.1 0.0 0.0 0.2 0.6 0.0 23.3 0.0 0.4 0.5 0.0 203.6 0.0 50.3 0.0 0.0 1.3 53.4 0.0 0.3 53.0 3.3 52.3 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.3 0.4 1.6 0.3 1.6 0.8 0.0 0.1 CACNA1D "CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2" ENSG00000157388 "Calcium voltage-gated channel subunit alpha1 D" Q01668 3 53328963-53813733 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 9 "Alveolar cells type 2: 45.9;Cone photoreceptor cells: 33.4;Intestinal endocrine cells: 57.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 9 "basophil: 7.2" "Lineage enriched" "Detected in single" 20 "granulocytes: 7.2" "Cell line enhanced" "Detected in some" "HMC-1: 14.4;RPMI-8226: 33.6;SK-BR-3: 6.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA020215 Uncertain Approved "Nuclear membrane" NA NA "Nuclear membrane" "HPA020215: AB_1845860" "unprognostic (5.85e-2)" "unprognostic (4.90e-3)" "unprognostic (5.09e-2)" "unprognostic (2.24e-2)" "unprognostic (7.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.92e-1)" "unprognostic (2.32e-2)" "unprognostic (2.95e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-3)" "unprognostic (1.53e-1)" "prognostic favorable (8.34e-8)" "unprognostic (1.14e-1)" "unprognostic (3.05e-2)" "unprognostic (8.09e-3)" "unprognostic (6.70e-3)" 0.6 13.4 10.0 0.8 12.6 1.4 3.6 12.2 16.5 11.2 2.8 3.7 0.1 3.3 6.8 13.2 1.2 14.9 6.2 1.8 5.3 3.5 4.2 3.0 9.0 0.5 2.5 9.6 1.2 5.3 3.0 13.6 1.4 8.7 5.7 3.1 10.1 1.1 3.5 0.6 1.5 4.2 1.7 2.2 4.4 1.8 3.0 1.6 0.0 5.2 0.0 0.6 2.3 0.6 0.1 0.3 7.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 0.0 1.6 1.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 14.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.2 0.5 0.0 0.0 0.1 33.6 0.3 2.2 3.1 1.3 0.2 6.3 0.7 0.0 1.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 7.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 10.0 12.6 12.2 16.5 5.3 3.5 2.5 9.6 8.7 1.6 3.0 45.9 0.0 0.6 0.8 23.0 1.2 12.7 14.7 14.8 1.8 33.4 0.6 0.0 5.5 3.6 0.5 3.3 0.0 2.0 0.1 1.0 2.6 11.6 2.4 0.2 7.9 57.1 0.0 1.0 4.9 4.0 0.3 5.0 0.0 2.7 2.5 2.6 3.5 25.5 1.6 13.0 0.0 2.8 1.1 2.5 0.9 0.2 1.3 4.5 0.6 CALR "cC1qR, CRT, FLJ26680, RO, SSA" ENSG00000179218 Calreticulin P27797 19 12938578-12944489 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Extravillous trophoblasts: 1318.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001513, HPA002242, CAB019952, CAB079775" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" NA NA 450000000 "Endoplasmic reticulum" "CAB001513: , CAB019952: AB_2069792, CAB079775: AB_303403, HPA002242: AB_1078384" "unprognostic (1.49e-1)" "unprognostic (1.57e-1)" "unprognostic (8.46e-2)" "unprognostic (4.25e-2)" "unprognostic (9.44e-3)" "unprognostic (6.93e-2)" "unprognostic (2.47e-2)" "unprognostic (4.60e-2)" "unprognostic (2.61e-1)" "prognostic favorable (1.10e-4)" "unprognostic (2.07e-1)" "unprognostic (3.76e-1)" "prognostic unfavorable (1.11e-16)" "unprognostic (2.37e-1)" "unprognostic (1.96e-1)" "unprognostic (1.37e-1)" "unprognostic (5.27e-2)" 67.5 55.5 31.9 58.9 36.1 86.4 64.6 20.9 38.9 50.2 52.3 42.5 65.7 44.1 61.6 108.4 65.2 49.1 67.5 62.5 31.6 35.2 81.9 302.6 61.8 83.6 33.5 33.4 59.6 124.3 56.4 60.3 98.0 35.7 53.1 60.0 43.2 121.0 68.6 25.1 34.2 53.8 56.9 42.1 66.6 49.7 65.0 32.7 61.6 250.6 55.0 65.2 39.4 68.0 25.1 57.2 16.1 38.6 26.3 48.4 16.2 118.3 46.8 64.3 140.1 81.3 73.4 58.9 158.3 130.0 95.4 139.0 71.5 95.3 76.0 146.2 183.6 85.6 47.2 70.3 100.9 96.7 56.5 40.1 63.3 57.0 108.7 192.1 254.0 85.9 68.0 46.8 88.4 74.9 126.5 114.8 52.2 54.1 38.6 77.4 81.7 70.4 166.1 57.2 66.7 66.4 54.6 54.5 92.0 83.8 67.8 24.5 52.3 98.1 54.0 32.3 79.5 72.2 105.4 99.3 79.7 50.2 113.4 70.7 48.2 42.9 76.4 112.3 110.8 87.6 16.1 19.5 10.1 48.4 38.6 34.3 25.1 29.2 36.7 20.4 22.4 21.6 39.2 6.6 26.3 30.8 57.2 21.5 16.2 31.9 36.1 20.9 38.9 31.6 35.2 33.5 33.4 35.7 32.7 137.0 125.9 216.1 284.2 232.4 67.7 39.5 168.2 151.3 164.9 211.1 119.8 557.7 54.7 494.3 20.8 202.2 487.4 140.2 249.9 1318.6 319.8 346.7 204.2 513.5 724.5 33.4 339.2 328.4 165.0 18.8 295.1 261.1 202.4 256.1 263.3 298.5 397.7 287.1 292.4 139.9 115.0 200.5 213.6 255.0 394.6 186.7 806.5 193.7 294.0 285.1 CAMTA1 KIAA0833 ENSG00000171735 "Calmodulin binding transcription activator 1" Q9Y6Y1 1 6785324-7769706 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036342, HPA036343" Approved Supported Cytosol NA NA Cytosol "HPA036342: AB_2675072, HPA036343: AB_10671839" "unprognostic (1.11e-1)" "unprognostic (6.31e-2)" "unprognostic (5.80e-2)" "unprognostic (4.14e-3)" "unprognostic (3.10e-2)" "unprognostic (1.47e-2)" "prognostic unfavorable (5.25e-4)" "unprognostic (1.08e-2)" "unprognostic (3.59e-1)" "prognostic favorable (4.10e-4)" "unprognostic (3.90e-3)" "unprognostic (8.84e-2)" "unprognostic (1.35e-3)" "unprognostic (2.17e-2)" "unprognostic (9.19e-3)" "unprognostic (1.42e-1)" "unprognostic (9.03e-3)" 18.4 24.3 31.6 12.2 30.7 12.1 21.7 24.4 37.1 16.5 30.2 19.9 13.2 28.3 20.0 46.7 22.7 16.8 17.7 58.1 26.4 27.6 36.7 37.2 16.5 13.3 31.2 26.5 17.1 18.6 22.0 17.6 14.3 47.5 22.2 27.1 25.0 27.1 29.6 48.0 12.9 30.4 38.4 23.9 15.7 21.5 23.0 19.4 14.7 30.8 20.5 17.5 31.3 18.7 19.8 32.3 28.3 32.4 10.3 18.1 18.9 22.0 12.4 34.6 17.5 17.9 27.4 9.7 23.9 18.4 25.8 21.9 15.0 28.0 18.3 18.8 25.0 17.3 13.7 18.0 24.7 36.9 13.7 19.6 20.6 29.4 29.2 29.1 15.6 15.0 18.3 17.2 18.6 28.7 22.3 28.7 26.1 14.4 24.9 29.7 21.3 20.7 42.9 23.9 28.1 14.6 13.9 30.8 40.5 34.8 12.9 35.8 28.9 16.9 25.2 36.8 26.0 13.6 19.6 16.7 18.4 15.6 18.9 14.8 19.0 23.5 49.2 27.5 35.2 10.3 27.5 32.4 28.3 11.5 19.4 12.5 19.8 18.0 14.2 30.6 16.2 14.7 12.8 6.6 10.3 14.7 32.3 18.1 18.9 31.6 30.7 24.4 37.1 26.4 27.6 31.2 26.5 47.5 19.4 50.6 45.6 87.6 306.4 275.2 103.9 495.7 107.0 68.3 46.6 181.5 237.6 60.6 354.8 147.0 138.1 160.0 190.4 46.7 180.4 116.8 142.3 320.6 54.3 215.1 94.9 149.4 125.6 81.6 94.6 111.6 70.8 142.3 226.0 196.6 153.7 60.0 175.4 166.1 120.9 611.1 144.7 135.8 271.7 133.0 213.0 247.2 73.7 58.9 164.9 354.7 CANT1 "SCAN-1, SHAPY" ENSG00000171302 "Calcium activated nucleotidase 1" Q8WVQ1 17 78991717-79009867 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" Hydrolase "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 6 "Mucus-secreting cells: 134.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "OE19: 92.2;T-47d: 60.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019627, HPA019639, HPA022818" Enhanced Supported "Golgi apparatus" NA NA 2300000 "Golgi apparatus" "HPA019627: AB_1845969, HPA019639: AB_1845970, HPA022818: AB_1845971" "unprognostic (1.98e-2)" "unprognostic (2.49e-2)" "unprognostic (1.50e-2)" "unprognostic (5.36e-2)" "unprognostic (2.13e-2)" "unprognostic (2.21e-2)" "prognostic unfavorable (1.41e-4)" "prognostic unfavorable (2.90e-4)" "unprognostic (1.76e-1)" "unprognostic (9.00e-2)" "unprognostic (3.30e-1)" "unprognostic (2.49e-1)" "prognostic unfavorable (6.21e-4)" "unprognostic (7.04e-2)" "unprognostic (5.06e-2)" "unprognostic (1.16e-1)" "unprognostic (7.23e-2)" 13.8 15.3 9.6 13.1 10.2 8.1 13.0 12.2 10.8 17.7 43.8 12.3 25.4 25.5 12.0 14.3 27.5 10.0 19.5 10.8 9.0 6.9 10.3 17.7 11.1 11.5 12.5 7.7 10.4 14.7 13.1 11.8 33.0 12.0 36.7 41.5 7.9 30.3 41.4 9.0 8.9 27.2 8.0 12.4 18.1 25.8 19.0 10.3 14.1 12.4 8.9 14.4 10.3 13.7 4.1 3.8 17.5 4.4 3.1 6.2 4.4 22.2 24.4 6.8 9.9 6.5 7.8 8.8 13.8 12.1 14.8 12.6 11.6 21.1 5.4 8.1 9.6 18.1 11.3 5.8 10.8 14.9 9.0 10.6 7.0 7.4 9.6 5.6 6.7 11.1 8.0 7.0 13.7 7.5 8.8 25.6 9.1 8.8 9.2 9.8 12.1 10.1 4.0 4.7 92.2 26.0 5.7 11.2 6.1 6.5 11.2 9.9 9.9 7.3 48.8 10.4 11.4 60.2 8.0 12.7 22.2 20.1 9.9 17.2 10.9 9.0 5.3 14.2 5.2 13.9 6.1 3.8 8.1 6.2 4.4 6.1 4.1 4.6 5.2 3.8 2.9 4.5 4.4 17.5 3.1 2.9 2.7 3.8 4.4 9.6 10.2 12.2 10.8 9.0 6.9 12.5 7.7 12.0 10.3 26.8 19.4 13.7 13.8 14.7 5.9 11.6 15.3 6.7 10.3 12.2 13.7 30.3 3.3 30.3 11.4 14.3 61.6 23.3 25.4 31.5 12.3 34.8 5.7 12.1 21.5 4.8 49.0 54.6 9.2 10.4 10.9 11.3 13.5 11.8 134.8 6.7 27.4 49.1 7.1 6.1 8.5 6.5 7.2 23.2 5.5 11.4 84.9 10.2 83.2 16.5 CARD11 "BIMP3, CARMA1" ENSG00000198286 "Caspase recruitment domain family member 11" Q9BXL7 7 2906141-3043945 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 21.4;lymphoid tissue: 44.7" "Cell type enhanced" "Detected in some" 13 "B-cells: 19.1;Pancreatic endocrine cells: 15.2;T-cells: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 21.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Daudi: 40.6;K-562: 16.2;RT4: 30.6;U-698: 36.2" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA052984 Approved NA NA "HPA052984: AB_2682005" "unprognostic (3.12e-2)" "unprognostic (1.75e-1)" "unprognostic (2.17e-1)" "unprognostic (8.46e-3)" "unprognostic (4.81e-1)" "unprognostic (3.44e-2)" "unprognostic (1.71e-1)" "unprognostic (2.31e-1)" "unprognostic (5.65e-2)" "unprognostic (5.11e-2)" "unprognostic (2.09e-2)" "unprognostic (3.09e-1)" "prognostic unfavorable (6.68e-8)" "unprognostic (3.74e-2)" "unprognostic (4.75e-2)" "unprognostic (1.31e-1)" "prognostic favorable (1.10e-4)" 1.2 1.7 1.4 44.7 1.0 9.0 0.9 0.7 1.4 1.7 1.4 1.2 0.6 1.9 0.8 0.5 2.7 1.2 11.4 0.8 1.4 2.3 1.9 1.4 3.8 25.0 2.1 0.5 0.9 1.4 0.1 1.0 0.5 1.1 2.8 1.2 1.2 6.7 1.0 0.3 0.5 14.2 1.4 2.9 27.4 3.9 1.4 1.5 22.8 1.3 1.7 28.6 9.4 5.2 4.6 21.4 0.3 0.0 3.3 5.5 1.8 5.4 0.8 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.2 0.0 10.7 12.0 40.6 10.1 0.0 0.0 9.1 0.0 0.1 0.1 13.8 0.4 0.0 1.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 7.8 4.5 16.2 0.0 0.0 0.1 1.5 0.0 15.3 6.8 0.0 1.9 0.0 10.1 3.9 30.6 0.1 0.5 0.0 0.0 0.0 6.4 0.0 0.8 5.1 0.0 4.1 0.0 0.0 4.2 0.0 36.2 0.0 0.0 0.0 0.3 0.0 0.0 5.5 0.0 5.2 3.8 3.2 3.6 0.6 4.6 2.1 3.8 0.1 3.3 0.0 21.4 2.2 1.8 1.4 1.0 0.7 1.4 1.4 2.3 2.1 0.5 1.1 1.5 0.0 0.0 19.1 0.3 0.0 0.4 1.7 0.0 0.0 0.0 1.8 0.0 0.0 0.0 4.6 0.1 0.0 0.0 0.0 4.7 0.0 0.5 0.3 5.7 0.0 1.5 0.0 0.0 0.0 1.5 0.0 0.3 2.2 3.3 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 0.4 1.4 0.0 0.3 0.0 24.5 0.0 3.1 CARS CARS1 ENSG00000110619 "Cysteinyl-tRNA synthetase" P49589 11 3000922-3057613 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Protein biosynthesis" "Aminoacyl-tRNA synthetase, Ligase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Ciliated cells: 92.3;Early spermatids: 93.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737" Enhanced Enhanced Cytosol NA NA 110000 Cytosol "CAB075734: AB_2665740, CAB075735: AB_2665741, CAB075736: AB_2665742, CAB075737: AB_2665743, HPA002383: AB_1078399, HPA002384: AB_1846033" "unprognostic (9.10e-3)" "unprognostic (1.83e-1)" "unprognostic (4.16e-3)" "unprognostic (1.43e-1)" "unprognostic (1.00e-2)" "unprognostic (7.97e-2)" "prognostic unfavorable (5.16e-4)" "unprognostic (1.41e-2)" "unprognostic (1.05e-1)" "unprognostic (8.00e-2)" "unprognostic (5.51e-2)" "unprognostic (2.45e-1)" "prognostic unfavorable (0.00e+0)" "unprognostic (5.37e-2)" "unprognostic (1.71e-1)" "unprognostic (1.48e-1)" "unprognostic (3.46e-1)" 24.9 15.9 15.8 15.8 17.7 9.0 15.9 9.5 29.1 13.4 16.3 19.1 11.1 15.9 14.0 10.7 16.0 10.8 14.2 12.5 15.3 18.7 10.7 22.1 15.1 17.2 23.3 15.9 14.5 42.5 14.9 15.9 14.0 23.0 10.8 17.6 7.4 20.3 14.8 24.6 18.8 17.8 21.0 16.1 14.8 22.8 13.4 17.3 9.8 23.0 14.5 22.7 14.4 19.4 8.3 13.3 18.0 23.9 16.4 18.1 11.6 7.4 3.8 4.9 14.8 19.3 17.8 4.4 19.1 21.8 13.2 23.9 9.3 17.9 11.6 5.6 24.1 0.0 19.2 16.2 21.7 18.2 33.8 3.7 6.5 6.5 7.1 46.3 13.5 14.4 29.3 17.1 11.4 12.7 0.0 17.4 28.8 10.9 41.0 13.0 11.3 9.5 0.0 18.5 26.5 6.8 4.6 8.2 14.5 0.0 12.5 10.6 14.1 4.7 13.4 20.9 3.8 0.0 0.0 6.0 5.4 5.1 13.5 0.2 30.5 27.8 7.4 0.0 7.1 10.7 7.7 12.0 8.8 15.2 10.5 13.0 8.3 13.6 13.6 13.3 6.0 7.5 12.1 18.0 16.4 23.9 5.2 18.1 11.6 15.8 17.7 9.5 29.1 15.3 18.7 23.3 15.9 23.0 17.3 17.9 31.5 21.7 25.4 12.8 11.7 6.7 2.5 92.3 27.3 10.4 5.9 18.8 8.3 35.4 93.7 13.7 18.6 0.0 34.2 34.8 12.6 16.1 20.7 16.8 18.9 14.3 18.3 13.5 15.1 39.9 11.5 14.7 8.5 14.4 16.9 10.8 37.5 21.0 18.0 13.4 10.0 6.5 14.1 39.5 24.2 10.5 27.0 24.2 14.3 35.5 CASP8 "Casp-8, FLICE, MACH, MCH5" ENSG00000064012 "Caspase 8" Q14790 2 201233443-201287711 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Host-virus interaction" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 52.5" "Cell type enhanced" "Detected in many" 5 "T-cells: 55.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001302, CAB002047, HPA005688, HPA006191" Approved Supported Nucleoplasm,Cytosol No No Cytosol Nucleoplasm "CAB002047: AB_563465, HPA001302: AB_1846057, HPA005688: AB_1846056, HPA006191: AB_2667535" "unprognostic (5.21e-3)" "unprognostic (2.10e-1)" "unprognostic (1.83e-2)" "unprognostic (9.69e-3)" "unprognostic (2.09e-1)" "unprognostic (5.60e-2)" "prognostic unfavorable (3.02e-4)" "unprognostic (2.10e-1)" "unprognostic (4.79e-2)" "prognostic favorable (1.25e-4)" "unprognostic (7.75e-2)" "unprognostic (5.11e-2)" "prognostic unfavorable (1.27e-6)" "unprognostic (7.67e-3)" "unprognostic (2.43e-1)" "unprognostic (2.53e-1)" "unprognostic (4.53e-3)" 14.1 10.6 2.0 31.6 2.6 27.1 10.2 1.4 1.8 7.9 18.5 3.9 7.0 9.6 9.6 12.0 11.7 9.1 12.1 4.4 2.1 2.3 16.4 14.8 17.1 28.3 3.9 1.1 8.2 7.6 1.8 5.9 12.3 3.2 9.8 8.7 4.4 9.6 8.4 2.7 7.4 34.7 5.1 5.0 37.7 7.4 3.8 2.7 43.7 6.7 10.7 43.4 9.6 7.3 13.8 13.7 52.5 17.0 22.2 26.4 12.0 14.5 12.4 3.6 10.1 10.1 14.8 5.6 6.4 6.3 7.6 12.6 16.6 25.4 1.6 14.1 4.9 13.7 7.4 7.9 7.6 15.1 9.4 7.2 14.2 10.1 15.8 8.2 11.0 15.4 12.8 18.8 14.4 11.3 6.4 7.2 12.3 12.7 31.6 6.9 6.0 14.3 11.6 5.9 8.0 11.1 10.8 7.5 25.9 14.3 16.2 1.1 0.5 8.3 13.8 8.2 3.5 3.6 8.6 9.0 8.2 8.6 4.3 5.0 28.7 12.8 9.9 12.3 14.8 7.7 20.7 13.0 24.9 25.0 17.0 23.1 13.8 20.5 26.4 13.7 7.8 13.3 16.9 52.5 22.2 15.6 6.1 24.0 12.0 2.0 2.6 1.4 1.8 2.1 2.3 3.9 1.1 3.2 2.7 23.8 26.1 34.1 10.1 6.6 1.5 1.6 7.6 16.0 18.2 5.2 9.8 7.5 13.3 9.0 5.6 7.1 19.8 0.0 7.3 10.3 3.8 8.1 23.2 10.4 11.2 0.0 4.1 5.5 25.6 0.7 2.3 21.7 6.8 19.8 13.0 0.1 9.6 12.7 0.7 20.0 0.4 0.0 1.4 0.7 0.4 6.8 2.9 55.4 12.1 12.7 CBFA2T3 "ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4" ENSG00000129993 "CBFA2/RUNX1 translocation partner 3" O75081 16 88874858-88977204 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 75.9" "Cell type enhanced" "Detected in many" 7 "B-cells: 11.5;Mucus-secreting cells: 13.5;Sertoli cells: 19.4;Smooth muscle cells: 11.2" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "cerebellum: 26.0" "Cell type enhanced" "Detected in many" "plasmacytoid DC: 11.6" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HEL: 21.4;K-562: 37.4;MCF7: 17.3;MOLT-4: 19.0;NB-4: 23.1;REH: 37.6;T-47d: 17.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA059931, HPA062423, HPA065890" Approved Enhanced Nucleoplasm NA NA Nucleoplasm "HPA059931: AB_2684168, HPA062423: AB_2684758, HPA065890: AB_2685575" "unprognostic (2.47e-1)" "unprognostic (2.03e-2)" "unprognostic (9.24e-3)" "unprognostic (2.62e-1)" "unprognostic (1.98e-1)" "prognostic favorable (3.95e-4)" "unprognostic (1.13e-3)" "unprognostic (1.69e-2)" "unprognostic (1.25e-1)" "unprognostic (2.10e-1)" "unprognostic (7.30e-3)" "unprognostic (2.38e-1)" "unprognostic (7.04e-5)" "unprognostic (2.18e-1)" "unprognostic (4.08e-2)" "unprognostic (4.62e-2)" "unprognostic (9.35e-3)" 10.0 1.7 3.6 11.3 7.4 8.2 6.1 26.0 5.4 2.3 3.9 1.3 1.4 3.9 3.2 2.1 2.1 1.9 2.5 6.2 3.0 3.0 0.7 2.0 6.4 9.5 2.0 3.8 0.9 24.9 0.7 2.7 3.8 2.3 3.7 1.5 3.1 4.5 2.9 14.2 2.6 5.5 1.5 1.2 14.7 3.5 3.2 2.2 75.9 2.4 2.0 10.3 3.6 4.8 3.7 11.6 3.6 4.9 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 21.4 0.0 0.0 0.0 5.6 10.6 0.0 0.0 0.0 0.0 0.0 0.0 10.3 37.4 0.2 0.0 17.3 19.0 23.1 0.4 0.0 0.0 37.6 0.3 3.7 0.0 0.0 7.4 1.6 0.8 0.1 0.1 0.1 17.1 6.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 12.4 0.0 6.5 0.0 1.1 2.7 2.7 0.0 3.2 0.0 3.7 0.0 0.0 7.1 2.1 0.0 0.0 3.6 0.1 4.9 11.6 0.0 1.7 3.6 7.4 26.0 5.4 3.0 3.0 2.0 3.8 2.3 2.2 0.0 1.4 11.5 5.1 2.3 7.7 1.6 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.2 0.0 3.6 0.9 0.0 2.4 0.1 1.6 2.5 5.8 5.7 2.4 0.0 3.5 2.5 2.8 0.0 2.0 6.4 0.0 1.0 13.5 0.1 1.4 0.0 0.7 0.5 1.2 19.4 11.2 0.2 4.5 1.9 0.2 1.0 0.8 3.8 CBFB PEBP2B ENSG00000067955 "Core-binding factor beta subunit" Q13951 16 67029116-67101058 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 101.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038852 Uncertain Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "HPA038852: AB_10795358" "unprognostic (1.05e-1)" "unprognostic (1.18e-2)" "unprognostic (1.30e-1)" "unprognostic (3.22e-2)" "unprognostic (4.66e-2)" "unprognostic (3.80e-3)" "prognostic unfavorable (2.83e-4)" "unprognostic (1.63e-2)" "unprognostic (1.47e-1)" "unprognostic (1.11e-1)" "unprognostic (4.46e-3)" "unprognostic (1.88e-2)" "prognostic unfavorable (2.89e-8)" "unprognostic (1.03e-1)" "unprognostic (4.31e-2)" "unprognostic (1.37e-1)" "unprognostic (1.20e-1)" 15.9 10.9 15.9 26.4 25.1 20.5 15.0 9.5 14.3 15.4 10.6 23.3 11.8 8.8 15.3 10.2 20.5 14.3 16.3 21.5 16.2 13.2 12.1 14.4 16.1 32.6 23.6 12.4 17.3 13.6 40.4 18.8 13.2 17.5 14.6 11.1 13.7 19.6 10.3 33.3 14.8 12.2 11.7 22.4 18.2 17.1 7.3 24.2 42.2 17.0 14.8 31.0 15.9 18.8 6.5 9.1 20.5 9.2 14.8 7.0 5.1 15.6 10.5 9.2 14.9 6.7 8.6 14.7 18.2 10.9 17.2 15.2 21.0 18.0 34.7 17.4 15.5 7.2 15.6 16.4 10.2 23.2 11.9 9.4 24.1 9.0 16.7 9.6 31.4 51.9 8.7 7.0 19.2 14.8 9.1 13.9 17.2 25.6 12.4 17.8 11.9 32.3 16.8 9.0 8.3 14.8 65.6 39.7 29.5 12.1 14.0 13.5 12.1 46.7 7.1 18.6 11.3 6.4 22.6 19.3 26.7 18.3 15.1 24.4 17.0 30.2 101.5 20.3 21.6 24.0 20.5 7.4 7.4 6.7 9.2 7.0 6.5 6.6 7.0 9.1 6.4 6.3 5.3 4.6 14.8 6.1 3.3 7.0 5.1 15.9 25.1 9.5 14.3 16.2 13.2 23.6 12.4 17.5 24.2 8.9 19.8 29.2 37.0 49.9 4.5 15.4 15.3 13.4 17.0 38.4 11.8 12.1 23.2 14.4 4.4 17.4 7.3 0.0 24.0 26.0 32.1 38.3 26.6 14.0 33.8 9.5 18.2 27.0 43.0 5.7 22.2 46.5 49.0 10.8 12.4 12.3 47.8 5.8 19.8 9.8 14.2 12.9 24.7 13.4 16.3 55.2 14.2 54.9 11.5 52.5 CBL "c-Cbl, CBL2, RNF55" ENSG00000110395 "Cbl proto-oncogene" P22681 11 119206276-119313926 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.9" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.8" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004350, HPA027956" Enhanced Supported Cytosol NA NA Cytosol "CAB004350: AB_2244054, HPA027956: AB_10601094" "unprognostic (2.52e-1)" "unprognostic (1.32e-3)" "unprognostic (1.60e-1)" "unprognostic (1.15e-1)" "unprognostic (1.50e-2)" "unprognostic (2.92e-1)" "unprognostic (4.10e-3)" "unprognostic (9.75e-2)" "unprognostic (1.72e-1)" "unprognostic (1.52e-1)" "unprognostic (1.03e-2)" "unprognostic (5.23e-2)" "unprognostic (5.21e-2)" "unprognostic (5.27e-2)" "unprognostic (1.52e-1)" "unprognostic (1.12e-1)" "unprognostic (5.85e-2)" 9.9 5.5 9.1 17.0 11.1 11.1 8.8 10.7 12.0 6.2 7.5 8.7 3.0 5.7 9.9 5.3 7.5 7.4 6.3 5.9 8.0 9.6 5.5 4.0 10.3 16.3 8.1 6.9 6.3 5.6 16.6 4.1 9.1 9.3 5.3 7.5 6.4 5.4 7.1 3.9 7.4 8.6 10.6 8.9 13.3 7.3 32.3 5.1 40.9 6.0 5.5 15.6 7.6 7.7 1.8 3.3 11.8 3.7 0.6 1.9 1.0 6.3 4.8 16.9 10.6 5.1 6.0 10.0 6.9 7.2 6.7 6.6 10.3 7.9 15.1 6.2 8.7 13.8 9.3 11.6 5.9 14.7 8.6 2.7 15.5 3.7 3.1 6.2 18.0 17.7 5.3 6.5 17.0 18.4 7.1 16.5 14.8 12.5 6.3 12.0 6.9 9.6 10.1 8.8 5.7 5.4 10.4 8.5 2.8 5.9 5.1 2.3 7.1 12.8 5.6 4.6 12.1 5.8 15.2 13.7 10.4 7.4 7.2 9.0 2.1 3.1 12.3 4.2 15.6 7.4 0.8 3.2 2.4 1.3 3.7 1.1 1.8 1.6 1.3 3.3 1.8 1.8 1.9 11.8 0.6 3.1 1.8 1.4 1.0 9.1 11.1 10.7 12.0 8.0 9.6 8.1 6.9 9.3 5.1 8.9 8.8 18.8 4.9 16.0 12.4 5.9 7.6 1.4 4.5 10.4 43.2 5.2 1.7 5.8 22.7 17.8 6.3 0.0 5.8 8.0 8.0 6.2 3.5 2.6 15.0 12.7 8.1 19.0 52.9 32.8 7.2 29.9 15.1 5.4 4.3 17.5 8.7 8.6 12.0 3.1 33.8 25.8 17.6 38.1 26.2 19.2 5.8 20.0 4.5 9.5 CBLB "Cbl-b, RNF56" ENSG00000114423 "Cbl proto-oncogene B" Q13191 3 105655461-105869552 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-138 MG: 23.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018327, HPA019880" Approved Supported Nucleoplasm,Cytosol NA NA Cytosol Nucleoplasm "HPA018327: AB_1846097, HPA019880: AB_1846099" "unprognostic (2.65e-1)" "unprognostic (9.42e-2)" "unprognostic (1.72e-2)" "unprognostic (2.38e-1)" "unprognostic (5.89e-3)" "unprognostic (2.80e-2)" "unprognostic (8.18e-2)" "unprognostic (1.10e-1)" "unprognostic (7.05e-2)" "unprognostic (1.66e-1)" "unprognostic (9.29e-2)" "unprognostic (1.50e-2)" "unprognostic (1.43e-2)" "unprognostic (8.21e-2)" "unprognostic (2.83e-1)" "unprognostic (1.20e-2)" "unprognostic (3.09e-2)" 38.4 9.0 3.7 19.5 4.9 15.5 16.3 24.4 3.8 13.7 18.7 5.9 7.7 9.3 13.8 12.2 8.3 12.5 13.4 27.5 3.8 4.8 7.4 6.7 16.3 19.1 4.4 1.9 17.7 6.8 3.4 13.5 25.4 7.9 12.9 8.0 11.6 9.1 6.3 10.3 8.5 13.8 25.6 5.7 16.4 12.4 9.2 5.2 11.6 13.5 7.0 18.0 24.9 24.1 5.1 3.1 2.8 2.1 10.3 9.9 1.6 1.6 2.3 7.7 3.8 8.9 9.0 5.0 5.8 2.9 1.7 2.7 2.9 2.0 3.6 4.0 3.0 2.7 2.9 1.0 1.0 2.1 2.8 2.9 2.0 12.0 1.9 13.1 1.4 1.5 8.6 3.1 4.5 12.3 6.4 5.6 3.7 2.1 11.7 3.6 2.1 2.0 0.9 2.7 2.0 3.3 4.2 2.3 0.6 4.1 7.4 6.0 6.5 6.8 0.8 8.9 5.6 1.7 2.9 3.1 23.9 2.0 3.2 1.4 6.6 0.6 5.7 6.4 1.2 1.5 0.7 1.5 2.8 9.9 0.9 8.8 2.2 5.1 5.6 1.3 5.1 4.4 8.0 1.0 10.3 2.1 3.1 5.6 1.6 3.7 4.9 24.4 3.8 3.8 4.8 4.4 1.9 7.9 5.2 14.9 6.7 21.6 6.8 9.6 44.8 39.9 0.0 10.7 6.8 12.2 25.5 8.9 5.0 6.0 27.4 22.6 8.7 0.0 6.9 53.5 21.6 9.6 8.1 6.7 12.2 3.2 12.1 39.3 11.3 9.0 6.9 10.4 15.1 5.4 16.2 7.4 11.7 7.0 10.3 3.1 27.4 6.5 19.9 9.8 15.8 6.0 38.0 52.3 10.7 3.0 CBLC "CBL-3, CBL-SL, RNF57" ENSG00000142273 "Cbl proto-oncogene C" Q9ULV8 19 44777869-44800634 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 66.8" "Cell type enhanced" "Detected in many" 8 "Enterocytes: 105.9;Pancreatic endocrine cells: 67.6;Paneth cells: 84.2;Undifferentiated cells: 54.6;Urothelial cells: 56.4" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A-431: 19.0;BEWO: 13.1;CACO-2: 12.9;CAPAN-2: 26.3;HaCaT: 18.4;HBEC3-KT: 16.0;hTCEpi: 12.3;OE19: 16.9;RT4: 16.0;SK-BR-3: 14.6;T-47d: 10.5" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB008087, HPA035266" Approved Approved Nucleoplasm,Aggresome NA NA Nucleoplasm Aggresome "CAB008087: AB_2228531, HPA035266: AB_2674542" "unprognostic (1.58e-1)" "unprognostic (2.25e-1)" "unprognostic (8.21e-3)" "unprognostic (1.55e-1)" "unprognostic (3.04e-2)" "unprognostic (3.91e-2)" "unprognostic (1.67e-1)" "unprognostic (2.13e-2)" "unprognostic (3.82e-1)" "unprognostic (7.39e-2)" "unprognostic (1.06e-2)" "unprognostic (1.85e-1)" "prognostic favorable (3.11e-6)" "unprognostic (3.50e-1)" "unprognostic (8.25e-3)" "unprognostic (2.90e-2)" "unprognostic (2.21e-3)" 0.1 0.0 0.5 8.5 0.2 0.0 4.8 0.1 0.4 4.4 39.5 0.1 3.2 29.5 1.7 1.7 22.0 1.4 18.8 0.1 0.6 0.0 4.9 15.1 1.3 0.1 0.1 0.3 0.8 18.1 0.9 0.7 4.1 0.2 6.9 6.9 0.5 11.4 5.2 0.1 20.8 66.8 0.4 0.1 0.1 10.2 1.6 0.1 0.5 1.9 13.2 15.7 7.6 8.9 0.0 0.0 0.0 0.0 0.0 0.8 0.0 19.0 0.0 0.0 0.0 0.0 0.0 13.1 0.0 0.0 0.0 0.0 12.9 26.3 0.0 0.0 0.0 0.0 18.4 0.0 16.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 12.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 16.9 0.0 0.0 0.0 0.0 0.0 16.0 0.1 0.0 0.0 14.6 0.0 0.1 10.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.1 0.4 0.6 0.0 0.1 0.3 0.2 0.1 0.0 1.6 0.0 28.6 13.4 0.0 0.2 5.1 5.3 11.4 7.0 0.0 4.6 1.7 37.5 0.0 0.1 105.9 0.0 42.7 1.3 0.4 14.4 0.0 8.5 0.3 0.0 16.7 0.0 0.0 0.0 0.0 0.9 0.0 1.0 35.8 0.0 67.6 84.2 0.0 9.9 0.0 0.0 0.4 0.0 1.7 22.5 2.1 0.7 54.6 56.4 CCDC6 "D10S170, H4, PTC, TPC, TST1" ENSG00000108091 "Coiled-coil domain containing 6" Q16204 10 59788763-59906656 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019049, HPA019051" Enhanced Supported Cytosol No No Cytosol "HPA019049: AB_1846163, HPA019051: AB_1846164" "unprognostic (1.88e-2)" "unprognostic (1.72e-2)" "unprognostic (4.41e-2)" "unprognostic (1.25e-3)" "unprognostic (5.98e-3)" "prognostic favorable (5.48e-4)" "prognostic unfavorable (1.11e-4)" "unprognostic (7.39e-2)" "unprognostic (2.45e-1)" "unprognostic (2.28e-1)" "prognostic unfavorable (3.95e-4)" "unprognostic (4.08e-1)" "unprognostic (4.69e-2)" "unprognostic (2.23e-1)" "unprognostic (2.56e-1)" "unprognostic (9.95e-2)" "unprognostic (4.19e-2)" 13.7 13.3 22.8 11.7 41.8 12.8 20.7 13.8 27.1 23.0 23.9 11.3 10.7 20.4 28.4 16.6 33.2 23.6 16.2 11.2 17.0 18.1 19.4 10.9 15.5 18.7 13.8 17.6 19.8 22.5 16.8 13.7 13.3 14.5 18.7 18.4 9.6 25.5 14.0 18.2 26.0 20.4 28.1 11.8 14.5 16.6 12.6 12.3 10.6 19.1 14.8 20.7 21.7 23.8 7.1 7.3 0.2 3.4 1.2 2.3 1.4 16.0 14.5 7.3 16.3 11.1 16.8 14.9 7.9 10.5 7.9 9.4 28.2 31.6 13.8 12.0 13.2 4.6 23.9 14.6 14.4 11.9 20.7 7.3 11.2 11.8 17.1 13.5 12.8 10.6 12.1 19.1 13.2 32.5 11.2 11.7 7.9 8.4 8.9 10.3 21.6 5.3 7.4 11.7 15.2 9.9 7.2 12.0 8.7 13.3 13.8 7.5 6.5 10.0 42.1 8.8 9.9 26.7 6.9 11.9 7.4 13.6 11.4 13.2 4.7 5.4 6.3 11.7 24.5 4.6 0.0 2.9 0.0 1.5 3.4 1.8 6.7 2.3 2.1 7.3 7.1 2.2 1.6 0.2 1.2 1.9 1.9 2.1 1.4 22.8 41.8 13.8 27.1 17.0 18.1 13.8 17.6 14.5 12.3 92.3 20.4 12.6 42.6 84.3 14.0 14.2 28.1 20.1 47.8 24.4 39.3 32.1 24.9 42.8 25.1 15.7 40.4 0.0 56.0 14.6 20.6 38.1 27.8 19.1 20.3 15.9 25.9 19.6 29.9 60.3 22.7 22.5 15.1 11.8 37.1 11.8 47.6 17.5 18.4 30.5 42.9 19.4 21.8 2.6 20.8 70.0 22.5 13.4 39.3 38.3 CCNB1IP1 "C14orf18, HEI10" ENSG00000100814 "Cyclin B1 interacting protein 1" Q9NPC3 14 20311368-20333312 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Meiosis, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTERT-HME1: 88.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (4.79e-2)" "unprognostic (1.35e-1)" "unprognostic (1.29e-1)" "unprognostic (9.37e-2)" "unprognostic (5.46e-3)" "unprognostic (2.79e-2)" "unprognostic (8.43e-2)" "unprognostic (5.88e-2)" "unprognostic (1.56e-1)" "unprognostic (1.88e-2)" "unprognostic (4.87e-2)" "unprognostic (4.77e-2)" "prognostic favorable (5.18e-6)" "unprognostic (2.12e-1)" "unprognostic (1.54e-2)" "unprognostic (4.43e-1)" "unprognostic (1.52e-1)" 12.6 9.7 10.9 9.8 13.7 14.2 27.2 14.5 16.4 20.3 13.4 13.2 17.2 9.9 20.4 24.2 17.4 18.8 12.4 33.8 11.1 11.2 31.2 34.4 15.4 11.2 13.4 11.1 49.1 20.6 14.5 12.1 14.4 15.9 18.0 14.5 15.8 14.0 12.3 20.6 14.6 10.0 27.6 15.8 11.3 13.0 9.7 13.9 11.2 35.8 15.3 16.1 33.6 17.7 9.3 13.7 3.5 3.1 4.4 10.7 3.0 6.7 5.5 31.5 30.2 16.1 22.2 25.4 8.2 16.6 12.7 16.9 18.7 7.5 23.4 5.5 6.0 12.9 12.1 21.8 15.6 17.3 6.7 18.5 13.8 5.2 17.6 47.5 25.4 13.0 30.2 26.4 9.1 88.5 15.5 9.6 28.4 16.8 18.6 8.3 10.7 14.7 17.3 18.9 14.7 10.6 18.2 15.6 9.8 13.3 9.9 25.1 26.1 5.7 13.3 37.0 18.2 4.2 18.7 4.0 7.3 9.3 8.7 10.7 8.7 10.9 16.0 2.4 21.5 8.3 3.5 3.1 0.0 6.7 1.1 9.1 9.3 7.4 8.3 13.7 8.4 7.7 10.7 0.5 4.4 1.1 13.7 9.9 3.0 10.9 13.7 14.5 16.4 11.1 11.2 13.4 11.1 15.9 13.9 26.8 25.6 34.4 63.5 51.6 3.2 25.0 56.0 4.0 18.2 22.7 19.6 34.7 87.9 23.7 47.1 18.0 13.1 0.0 33.0 56.8 32.0 34.6 34.6 30.1 15.8 1.6 39.6 16.5 17.5 58.8 47.8 23.1 49.0 8.2 37.0 24.9 27.7 14.0 41.4 71.2 15.5 45.3 24.0 49.1 59.6 35.0 28.5 27.7 41.7 43.6 CCND1 "BCL1, D11S287E, PRAD1, U21B31" ENSG00000110092 "Cyclin D1" P24385 11 69641087-69654474 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation" "Cyclin, Repressor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Ductal cells: 534.1;Pancreatic endocrine cells: 367.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 3.0;myeloid DC: 3.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/70: 96.3;WM-115: 134.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000024, HPA027802" Uncertain Supported Nucleoplasm Yes No Nucleoplasm "CAB000024: AB_563678, HPA027802: AB_2672390" "unprognostic (4.90e-2)" "unprognostic (1.54e-1)" "unprognostic (7.62e-2)" "unprognostic (1.39e-2)" "unprognostic (2.18e-1)" "prognostic unfavorable (5.51e-4)" "unprognostic (1.38e-1)" "unprognostic (2.53e-2)" "unprognostic (9.46e-2)" "unprognostic (4.84e-3)" "prognostic unfavorable (1.96e-4)" "unprognostic (4.39e-2)" "unprognostic (2.61e-3)" "unprognostic (4.38e-3)" "unprognostic (1.16e-1)" "unprognostic (6.40e-3)" "unprognostic (2.57e-1)" 52.0 11.6 9.7 6.0 9.7 0.7 22.8 3.4 7.7 15.4 8.9 15.4 19.9 8.4 18.8 23.1 37.7 11.8 31.0 23.9 10.8 8.8 14.5 68.1 22.2 3.7 12.4 5.6 6.5 31.5 83.2 16.6 38.1 10.0 30.7 6.8 24.8 25.6 21.7 2.0 43.6 10.4 16.5 12.6 12.9 19.2 4.0 7.5 9.0 17.1 23.1 23.6 21.4 22.1 3.0 3.4 0.8 0.0 0.0 0.9 0.3 48.7 19.5 6.5 0.2 20.0 21.1 14.0 77.2 28.8 9.0 5.3 21.9 37.8 0.0 35.1 40.1 15.1 35.7 0.7 21.0 16.2 0.1 3.9 0.0 4.8 22.2 4.8 0.3 0.7 11.9 4.1 12.7 4.9 21.3 15.4 0.0 0.0 0.1 71.0 20.6 0.0 2.8 11.9 20.2 21.5 0.1 20.6 1.1 41.9 30.1 1.1 25.5 0.9 18.3 48.0 16.5 11.1 1.0 64.4 44.3 12.3 19.2 52.4 96.3 57.5 0.1 37.9 0.6 134.1 0.8 0.0 0.0 0.9 0.0 0.1 3.0 0.4 0.2 3.4 2.5 0.8 0.2 0.2 0.0 0.0 0.0 0.0 0.3 9.7 9.7 3.4 7.7 10.8 8.8 12.4 5.6 10.0 7.5 169.7 99.5 5.9 202.5 179.8 2.2 68.0 124.9 78.9 155.8 118.7 2.0 6.4 26.6 534.1 0.2 134.5 22.2 0.0 128.5 1.1 63.9 195.1 27.8 148.1 60.6 0.0 54.3 108.1 18.0 0.9 3.7 17.9 49.0 3.6 40.4 66.7 367.2 54.7 54.1 42.3 2.0 129.4 220.1 0.2 19.0 306.9 2.1 7.0 62.1 326.2 CCND2 ENSG00000118971 "Cyclin D2" P30279 12 4273772-4305350 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Cardiomyocytes: 305.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 32.3;HBEC3-KT: 29.5;HDLM-2: 49.7;Karpas-707: 71.8;RH-30: 47.0;SuSa: 37.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA049138, HPA054196" Approved Enhanced Nucleoplasm Yes Yes Nucleoplasm "HPA049138: AB_2680650, HPA054196: AB_2682412" "unprognostic (2.98e-3)" "unprognostic (1.15e-1)" "unprognostic (7.21e-2)" "unprognostic (1.65e-2)" "unprognostic (1.70e-2)" "unprognostic (4.82e-2)" "unprognostic (4.94e-2)" "unprognostic (2.01e-3)" "unprognostic (3.16e-2)" "unprognostic (1.66e-2)" "prognostic favorable (2.52e-4)" "unprognostic (1.75e-1)" "unprognostic (1.25e-1)" "unprognostic (8.23e-2)" "unprognostic (4.52e-1)" "prognostic favorable (9.76e-5)" "unprognostic (7.06e-2)" 13.7 39.3 20.8 12.0 15.9 23.6 10.4 6.1 22.3 14.4 28.3 8.1 24.3 18.5 21.9 41.9 12.2 16.5 9.1 36.9 17.5 7.3 6.0 5.7 12.8 24.5 7.9 17.0 11.6 18.4 8.3 19.2 23.5 9.3 16.4 24.2 14.1 8.3 22.4 2.0 9.2 19.6 45.5 14.0 16.5 11.1 5.2 8.6 6.2 18.5 6.9 13.6 22.3 16.3 3.9 2.1 4.6 1.0 9.1 14.8 5.4 0.0 0.0 32.3 0.0 5.6 0.8 0.0 0.0 0.0 0.0 0.0 13.9 0.0 0.0 0.2 0.0 0.0 4.1 0.9 29.5 0.0 49.7 0.8 0.3 0.0 0.2 0.1 12.6 2.7 10.8 4.9 0.0 22.3 0.2 0.0 0.9 3.4 71.8 6.3 0.0 0.0 16.6 13.3 0.2 0.0 0.0 47.0 23.4 0.0 2.8 0.0 0.0 0.0 0.0 0.0 37.8 0.0 0.1 2.3 0.0 9.4 0.0 0.0 1.2 12.2 0.0 0.1 9.1 0.0 4.1 1.0 4.6 9.1 0.2 13.7 3.9 13.0 11.0 2.1 1.5 8.2 9.8 1.5 9.1 0.1 1.0 14.8 5.4 20.8 15.9 6.1 22.3 17.5 7.3 7.9 17.0 9.3 8.6 56.6 49.3 25.1 24.4 94.8 6.8 305.9 0.0 9.4 43.3 12.2 0.0 2.6 0.0 2.5 0.7 38.4 26.9 46.7 59.7 1.7 135.6 5.7 54.3 0.8 12.0 3.2 62.3 17.8 13.3 0.9 48.6 38.9 37.1 6.4 146.6 155.3 32.6 35.1 116.7 1.0 3.7 25.8 50.5 0.7 3.6 34.6 5.3 61.2 109.0 7.0 CCND3 ENSG00000112576 "Cyclin D3" P30281 6 41934933-42050357 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 129.2;lymphoid tissue: 142.5" "Cell type enhanced" "Detected in all" 5 "Syncytiotrophoblasts: 197.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MOLT-4: 94.2;REH: 89.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000116, HPA042871" Approved Supported Nucleoplasm NA Yes Nucleoplasm "CAB000116: , HPA042871: " "unprognostic (4.53e-2)" "unprognostic (4.45e-2)" "unprognostic (2.45e-1)" "unprognostic (4.40e-3)" "unprognostic (1.01e-1)" "unprognostic (9.80e-2)" "unprognostic (3.40e-2)" "unprognostic (5.25e-2)" "unprognostic (7.76e-2)" "unprognostic (3.45e-1)" "unprognostic (9.17e-2)" "unprognostic (6.39e-2)" "unprognostic (2.45e-3)" "unprognostic (9.12e-2)" "unprognostic (1.71e-1)" "prognostic favorable (8.08e-6)" "unprognostic (2.11e-1)" 20.2 39.8 16.1 28.9 17.5 74.7 36.0 13.3 19.8 13.3 17.3 11.3 14.1 16.0 10.8 10.4 13.5 13.4 19.0 16.3 15.4 14.5 13.7 8.0 32.1 83.8 14.1 15.5 11.1 10.9 5.0 10.1 21.9 9.3 14.2 11.4 10.2 18.1 14.4 6.5 14.6 22.0 11.7 11.5 51.2 18.0 7.4 10.0 142.5 26.8 9.3 32.8 13.0 16.6 24.1 42.4 129.2 45.8 39.0 52.8 66.2 9.2 33.7 3.5 7.8 6.4 13.2 40.9 10.8 6.2 11.2 8.2 6.3 4.2 39.7 18.4 7.2 10.0 5.7 9.4 13.2 5.8 6.7 6.1 62.9 15.0 5.1 14.1 10.2 55.6 12.5 8.7 10.8 4.1 3.4 13.7 26.7 31.7 3.9 16.0 12.5 94.2 49.4 1.5 28.4 7.2 89.5 13.7 4.4 25.9 6.2 12.0 3.1 9.2 11.8 5.3 4.7 7.3 40.2 22.9 12.5 6.9 10.7 12.1 2.5 2.0 62.1 7.3 21.7 7.5 129.2 30.5 87.7 52.8 35.1 37.0 16.4 36.4 42.5 42.4 24.1 42.8 45.0 42.8 39.0 45.8 27.8 23.2 66.2 16.1 17.5 13.3 19.8 15.4 14.5 14.1 15.5 9.3 10.0 56.6 64.8 78.2 82.2 24.0 9.3 21.8 56.0 16.0 18.2 19.2 5.9 150.0 24.9 17.1 12.1 47.0 34.6 93.5 21.5 66.5 22.6 44.0 25.5 3.9 39.8 11.1 9.2 55.9 111.4 7.4 38.3 68.6 35.4 7.2 16.9 35.9 21.6 28.8 48.8 13.2 14.6 45.3 26.8 1.7 5.7 19.7 197.8 130.7 19.5 56.2 CCNE1 CCNE ENSG00000105173 "Cyclin E1" P24864 19 29811898-29824308 "Cancer-related genes, Predicted intracellular proteins" "Cell cycle, Cell division" Cyclin "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 23.3;placenta: 46.7" "Cell type enriched" "Detected in many" 14 "Extravillous trophoblasts: 1526.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BEWO: 81.6" "Low region specificity" "Detected in all" "CAB000308, CAB016682, HPA018169" Approved Enhanced Nucleoplasm Yes Yes Nucleoplasm "CAB000308: , CAB016682: AB_1614564, HPA018169: AB_1847384" "unprognostic (2.90e-3)" "unprognostic (1.33e-2)" "unprognostic (1.47e-3)" "prognostic unfavorable (6.35e-6)" "unprognostic (5.78e-2)" "unprognostic (4.77e-2)" "prognostic unfavorable (3.89e-5)" "unprognostic (1.26e-3)" "unprognostic (3.14e-3)" "prognostic unfavorable (2.97e-4)" "unprognostic (3.29e-2)" "unprognostic (7.07e-2)" "unprognostic (1.11e-16)" "unprognostic (5.61e-2)" "unprognostic (1.92e-1)" "unprognostic (6.63e-2)" "unprognostic (1.46e-1)" 1.6 6.8 2.4 4.5 2.9 23.3 0.6 6.3 3.3 0.8 3.0 1.7 1.1 2.3 1.2 0.6 4.7 0.7 2.2 4.4 2.3 2.8 1.2 0.7 1.1 4.6 1.9 1.9 0.9 1.4 1.7 1.0 46.7 2.8 1.1 3.8 1.5 3.2 1.2 2.2 4.4 2.5 3.0 1.7 4.6 2.0 12.3 1.6 4.1 1.6 2.1 5.9 2.7 2.5 2.7 1.6 1.6 1.9 0.0 1.4 0.5 4.1 8.6 6.6 9.4 1.4 1.6 81.6 6.6 1.4 2.9 3.6 8.7 8.4 3.5 15.7 2.9 3.8 1.3 7.8 3.4 4.2 11.1 4.8 2.9 8.4 9.1 1.1 11.5 7.9 1.7 1.9 4.0 0.5 0.9 3.5 3.5 11.8 1.6 4.4 6.2 6.3 3.3 11.0 9.4 2.0 9.5 7.7 2.6 2.2 6.6 5.6 4.7 9.5 11.7 1.0 10.1 2.6 8.6 2.0 6.9 25.9 4.1 4.4 6.6 4.6 23.9 3.9 1.4 3.7 0.0 0.1 0.0 0.6 1.9 1.1 2.7 0.5 0.4 1.6 0.2 0.1 0.9 1.6 0.0 1.9 0.0 1.4 0.5 2.4 2.9 6.3 3.3 2.3 2.8 1.9 1.9 2.8 1.6 0.0 1.1 0.8 1.0 4.2 2.4 2.8 0.0 0.0 2.3 0.0 0.0 112.5 0.0 0.4 7.1 1.1 1.7 0.0 0.6 1526.8 4.8 1.9 0.0 0.0 37.5 3.2 2.9 1.3 0.3 2.6 1.1 1.1 1.7 0.0 2.7 1.8 1.0 2.9 2.1 0.2 0.8 6.5 3.1 14.1 19.5 5.3 96.8 2.2 3.8 2.4 CD274 "B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1" ENSG00000120217 "CD274 molecule" Q9NZQ7 9 5450503-5470566 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 23.9;placenta: 56.0" "Cell type enhanced" "Detected in many" 14 "granulocytes: 26.7;monocytes: 73.9;Syncytiotrophoblasts: 37.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 8.4" "Group enriched" "Detected in many" 6 "granulocytes: 8.4;T-cells: 2.4" "Cell line enhanced" "Detected in many" "HDLM-2: 34.2;HHSteC: 22.8;U-251 MG: 37.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003528, CAB076385" Enhanced Approved "Nucleoplasm,Plasma membrane,Actin filaments" NA NA "Plasma membrane, Actin filaments" Nucleoplasm "CAB076385: AB_2687655, HPA003528: " "prognostic favorable (8.89e-4)" "unprognostic (4.54e-2)" "prognostic favorable (1.64e-5)" "unprognostic (1.27e-2)" "unprognostic (2.96e-2)" "unprognostic (1.08e-1)" "unprognostic (4.61e-2)" "unprognostic (1.44e-1)" "unprognostic (1.68e-2)" "unprognostic (5.67e-4)" "unprognostic (7.39e-3)" "unprognostic (1.69e-2)" "unprognostic (1.24e-2)" "unprognostic (1.35e-1)" "unprognostic (1.49e-2)" "unprognostic (2.67e-1)" "unprognostic (9.02e-2)" 3.4 2.1 1.7 10.8 3.2 1.4 2.2 2.5 3.3 2.0 2.3 2.5 2.8 2.6 1.7 2.4 3.0 1.9 4.3 9.5 1.4 3.7 3.0 3.6 23.9 6.4 2.3 0.7 1.7 2.7 3.8 7.4 56.0 3.2 2.9 2.2 3.3 1.7 1.6 4.3 1.3 2.7 2.3 2.4 12.8 1.9 1.2 1.0 11.6 3.7 2.1 5.8 3.1 1.9 0.9 0.0 8.4 0.1 0.4 2.4 0.7 5.9 0.1 0.0 0.2 0.0 0.0 0.0 11.9 10.1 3.0 4.2 0.0 1.9 0.0 0.2 0.3 1.5 0.2 0.0 5.2 9.9 34.2 0.0 3.4 0.1 0.0 22.8 0.0 0.0 0.2 0.0 6.3 9.3 3.1 5.9 0.3 0.0 1.1 9.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 1.7 0.3 0.6 0.1 0.0 0.1 0.1 0.9 0.7 0.9 0.0 0.1 10.9 6.5 2.0 0.2 37.9 0.2 0.1 0.1 2.1 0.1 0.0 8.4 0.1 0.3 1.2 0.1 2.1 0.9 2.4 1.8 0.0 0.2 1.3 0.7 5.7 0.4 0.0 0.0 1.1 0.7 1.7 3.2 2.5 3.3 1.4 3.7 2.3 0.7 3.2 1.0 11.9 10.7 0.5 1.2 4.0 1.4 6.5 0.0 4.0 3.4 0.0 0.0 4.9 0.0 6.4 0.2 6.3 0.8 0.0 3.7 20.2 1.9 0.9 26.7 1.0 4.9 0.0 0.0 10.4 1.9 0.0 0.3 7.7 3.3 73.9 0.1 0.6 12.0 0.0 0.4 0.4 0.1 0.0 0.9 0.5 0.7 2.3 37.2 1.3 0.2 2.2 CD74 DHLAG ENSG00000019582 "CD74 molecule" P04233 5 150401637-150412929 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 504.7" "Cell type enhanced" "Detected in many" 16 "Hofbauer cells: 4588.2;Macrophages: 7133.7;monocytes: 15196.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2" "Group enriched" "Detected in all" 5 "B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5" "Cell line enhanced" "Detected in many" "CAPAN-2: 118.2;Daudi: 181.9;HDLM-2: 261.1;REH: 157.4;RPMI-8226: 107.2;U-266/70: 87.7;U-698: 100.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB002506, HPA010592" Enhanced Supported "Golgi apparatus" NA NA 90000 "Golgi apparatus" "CAB002506: AB_563630, HPA010592: AB_1078482" "prognostic favorable (1.06e-4)" "unprognostic (1.48e-2)" "unprognostic (4.80e-3)" "prognostic favorable (6.53e-6)" "unprognostic (1.41e-1)" "unprognostic (4.53e-2)" "unprognostic (2.05e-1)" "unprognostic (3.69e-3)" "unprognostic (1.54e-2)" "unprognostic (3.48e-2)" "unprognostic (2.20e-2)" "unprognostic (2.64e-1)" "unprognostic (5.44e-3)" "unprognostic (1.73e-1)" "unprognostic (4.95e-2)" "unprognostic (2.05e-1)" "unprognostic (4.24e-2)" 137.8 95.7 53.2 177.0 81.4 40.7 104.2 8.4 43.5 89.6 68.2 79.0 30.0 98.3 60.0 73.9 43.6 68.1 81.3 104.1 46.9 43.5 168.3 60.1 222.5 310.1 78.3 23.1 53.4 34.1 15.1 51.0 27.9 79.8 72.6 63.6 72.9 123.0 55.4 40.5 56.6 182.8 55.1 123.1 372.1 77.3 23.7 68.1 201.1 83.4 45.6 288.2 91.7 47.0 504.7 437.9 76.1 303.5 42.2 41.2 238.1 1.9 0.0 0.0 0.1 0.1 0.1 0.7 0.0 0.0 0.0 0.0 23.6 118.2 181.9 7.3 0.0 0.5 0.5 0.0 0.0 0.0 261.1 0.0 5.9 0.1 14.4 0.3 0.4 0.3 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 72.4 0.0 0.0 0.2 0.8 0.3 0.0 0.0 157.4 0.2 107.2 0.5 7.7 0.3 0.5 0.3 0.2 5.2 1.2 4.8 21.8 0.2 0.6 0.5 0.5 0.2 87.7 9.4 100.8 42.2 8.2 38.5 6.3 191.6 76.1 16.8 303.5 18.7 467.7 14.8 24.8 437.9 504.7 7.8 13.5 16.8 42.2 140.0 303.2 41.2 238.1 53.2 81.4 8.4 43.5 46.9 43.5 78.3 23.1 79.8 68.1 390.1 2012.6 3694.0 133.2 635.9 0.3 57.9 405.1 591.6 683.6 476.3 0.0 29.1 99.5 571.4 6.9 1116.8 170.9 23.3 476.1 19.5 234.4 182.3 395.1 56.2 4588.2 1.6 233.2 353.6 3259.2 11.0 108.4 7133.7 1135.4 15196.0 331.4 14.5 306.9 131.5 16.6 759.6 8.0 161.7 171.2 2.3 7.6 503.4 34.8 370.6 168.2 195.9 CD79A "IGA, MB-1" ENSG00000105369 "CD79a molecule" P11912 19 41877120-41881372 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2" "Cell type enriched" "Detected in some" 6 "B-cells: 739.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 38 "memory B-cell: 106.4;naive B-cell: 125.3" "Lineage enriched" "Detected in many" 41 "B-cells: 125.3" "Group enriched" "Detected in some" 24 "Daudi: 159.2;REH: 49.5;U-698: 138.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" CAB000019 Enhanced NA NA "CAB000019: AB_2244527" "prognostic favorable (8.45e-5)" "unprognostic (1.63e-3)" "unprognostic (4.13e-3)" "unprognostic (1.31e-3)" "unprognostic (2.02e-1)" "prognostic favorable (1.18e-5)" "unprognostic (1.23e-2)" "unprognostic (8.11e-3)" "unprognostic (9.41e-3)" "unprognostic (1.12e-2)" "unprognostic (2.53e-1)" "unprognostic (2.32e-1)" "prognostic unfavorable (2.15e-5)" "unprognostic (6.08e-2)" "unprognostic (3.39e-1)" "unprognostic (1.17e-1)" "unprognostic (1.46e-1)" 1.3 0.6 0.5 103.8 0.5 5.4 1.3 0.5 0.5 1.8 6.3 0.1 0.1 4.9 0.6 0.2 4.4 1.0 2.3 0.8 0.5 0.5 2.3 0.9 4.3 114.9 0.5 0.1 0.6 0.6 0.0 0.5 0.5 0.1 1.0 3.4 1.8 13.6 1.2 0.5 0.5 43.5 0.2 0.5 108.1 9.7 0.8 0.1 32.0 2.4 1.9 119.2 6.8 1.0 125.3 3.0 0.7 0.3 0.2 2.3 4.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 159.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.1 0.1 0.9 0.0 0.0 0.0 49.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.4 0.0 0.0 0.8 0.1 138.6 0.0 4.7 0.0 0.7 0.1 0.5 0.1 0.1 0.0 106.4 0.3 0.1 0.2 125.3 0.4 2.3 0.4 0.2 0.3 3.0 0.8 4.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.1 0.1 0.1 0.0 3.7 739.3 0.4 1.5 0.0 0.2 2.5 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.2 0.0 0.0 0.0 22.3 0.2 0.6 0.2 0.0 0.0 0.8 0.0 0.0 1.8 3.1 0.0 0.3 1.7 131.6 2.8 0.3 0.0 105.8 0.0 0.4 0.6 0.0 0.0 0.4 0.0 0.6 1.3 0.1 6.5 0.6 0.1 CD79B "B29, IGB" ENSG00000007312 "CD79b molecule" P40259 17 63928740-63932354 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 138.8;lymphoid tissue: 56.6" "Cell type enriched" "Detected in many" 8 "B-cells: 486.9" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 100.6;naive B-cell: 138.8" "Lineage enriched" "Detected in many" 6 "B-cells: 138.8" "Cell line enhanced" "Detected in some" "Daudi: 117.7;REH: 38.7;U-698: 161.1" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009178, CAB009751, HPA044107" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane" "Nucleoplasm, Cytosol" "CAB009751: AB_2275844, HPA009178: AB_1078483, HPA044107: " "unprognostic (3.90e-3)" "unprognostic (1.61e-3)" "unprognostic (5.21e-2)" "unprognostic (3.45e-3)" "unprognostic (4.22e-3)" "prognostic favorable (2.35e-4)" "unprognostic (1.82e-1)" "unprognostic (9.25e-3)" "unprognostic (3.89e-2)" "unprognostic (1.48e-1)" "unprognostic (1.04e-1)" "unprognostic (2.87e-2)" "unprognostic (2.50e-3)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (4.28e-2)" "unprognostic (2.75e-1)" 1.7 0.7 0.4 50.6 0.4 11.1 1.2 0.3 0.4 0.6 1.7 0.3 0.3 0.7 0.6 0.5 2.6 0.6 1.4 3.4 0.4 0.2 2.3 1.7 1.3 56.6 0.4 0.3 0.6 1.6 0.0 9.0 0.5 0.3 1.0 1.3 0.8 8.9 0.9 1.2 0.9 22.4 0.5 0.4 56.0 1.8 0.6 0.3 3.7 1.4 1.7 46.6 4.5 0.9 138.8 4.2 0.5 25.0 3.4 9.2 9.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 117.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 6.5 0.0 0.0 0.0 2.5 0.0 0.0 0.0 38.7 0.1 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 1.8 0.1 0.0 0.4 0.0 0.0 5.9 5.7 161.1 0.0 0.2 0.0 0.5 1.1 0.0 4.2 16.5 4.8 100.6 5.4 2.8 4.2 138.8 3.7 2.2 0.5 3.4 25.0 0.6 9.2 9.0 0.4 0.4 0.3 0.4 0.4 0.2 0.4 0.3 0.3 0.3 0.0 2.2 486.9 0.3 3.9 0.0 0.8 2.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 7.1 0.0 23.3 0.0 0.4 4.3 0.3 15.0 0.5 4.7 0.0 1.2 62.0 14.1 1.1 1.1 3.5 20.3 1.0 0.0 0.0 0.0 0.0 1.8 0.8 0.0 0.0 3.3 0.7 0.1 2.8 0.3 34.6 0.0 0.1 CDC73 "C1orf28, FIHP, HRPT1, HRPT2, parafibromin" ENSG00000134371 "Cell division cycle 73" Q6P1J9 1 193121997-193253901 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Transcription, Transcription regulation, Wnt signaling pathway" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002326, CAB016359, HPA069324" Supported Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB016359: AB_628102, HPA002326: , HPA069324: " "unprognostic (4.41e-2)" "unprognostic (6.22e-2)" "unprognostic (1.90e-2)" "unprognostic (5.30e-2)" "unprognostic (2.88e-3)" "unprognostic (3.53e-2)" "unprognostic (2.48e-3)" "unprognostic (5.74e-2)" "unprognostic (1.25e-1)" "unprognostic (1.40e-1)" "unprognostic (7.23e-3)" "unprognostic (2.17e-1)" "unprognostic (5.44e-3)" "unprognostic (3.47e-1)" "unprognostic (2.49e-1)" "unprognostic (6.73e-3)" "unprognostic (2.98e-3)" 23.4 20.0 18.1 16.8 22.9 21.0 20.1 25.6 22.6 20.4 20.1 14.5 16.3 12.0 26.8 15.2 20.6 14.9 16.4 21.4 18.4 15.0 18.8 17.1 17.2 16.6 19.7 15.9 23.3 14.5 27.1 24.8 17.3 19.4 26.9 16.2 13.6 17.3 19.0 44.5 15.0 14.5 25.6 23.9 16.0 15.7 16.3 22.1 20.6 27.1 14.1 15.8 26.8 35.0 6.6 6.7 10.2 7.0 9.0 12.5 5.2 13.4 12.1 16.0 10.3 15.0 14.6 12.3 14.5 14.1 17.6 15.4 8.3 16.0 17.5 10.3 17.8 9.7 13.2 14.5 13.7 21.5 11.1 6.9 12.7 10.9 8.0 14.1 17.2 12.7 11.9 13.3 16.5 15.8 15.6 14.9 10.0 19.2 14.2 23.5 12.4 14.1 8.5 15.4 19.8 4.5 12.6 9.7 16.7 20.6 9.4 4.8 13.2 18.1 22.4 20.7 18.6 19.2 12.5 16.6 17.1 4.0 14.5 14.8 13.3 9.9 14.4 10.3 10.6 29.9 6.6 7.0 10.2 9.3 6.8 12.5 6.6 9.2 9.2 6.7 5.4 8.4 8.7 7.4 9.0 5.7 4.9 9.3 5.2 18.1 22.9 25.6 22.6 18.4 15.0 19.7 15.9 19.4 22.1 32.8 20.1 34.3 31.1 33.1 31.2 36.4 20.4 20.1 19.4 31.4 33.4 21.8 28.2 29.4 11.9 30.1 16.2 23.3 28.5 34.0 29.2 33.5 39.4 14.3 28.0 20.6 10.9 22.1 25.9 6.1 31.1 38.8 27.0 47.7 15.3 33.5 28.2 13.1 33.9 26.4 36.3 25.8 57.1 56.5 32.0 30.6 31.8 29.8 16.1 23.2 CDH1 "CD324, UVO, uvomorulin" ENSG00000039068 "Cadherin 1" P12830 16 68737225-68835548 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 125.5" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 12 "myeloid DC: 2.8;plasmacytoid DC: 8.5" "Lineage enriched" "Detected in single" 18 "dendritic cells: 8.5" "Cell line enhanced" "Detected in some" "BEWO: 107.1;CACO-2: 36.0;CAPAN-2: 50.3;HaCaT: 48.6;hTCEpi: 34.3;MCF7: 29.7;OE19: 31.7;RT4: 37.0;T-47d: 32.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857" Enhanced Supported "Golgi apparatus,Plasma membrane,Cell Junctions" NA NA 22000000 "Plasma membrane, Cell Junctions" "Golgi apparatus" "CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: AB_2665698, CAB072856: AB_2665699, CAB072857: AB_2665700, HPA004812: AB_1078369" "unprognostic (3.95e-2)" "unprognostic (1.91e-1)" "unprognostic (1.12e-3)" "unprognostic (1.13e-1)" "unprognostic (1.42e-1)" "unprognostic (2.78e-1)" "unprognostic (5.04e-3)" "unprognostic (1.63e-1)" "unprognostic (5.47e-2)" "unprognostic (2.85e-1)" "unprognostic (1.19e-2)" "unprognostic (3.61e-1)" "prognostic favorable (2.06e-4)" "unprognostic (1.21e-1)" "unprognostic (2.62e-1)" "unprognostic (2.51e-1)" "unprognostic (5.92e-2)" 1.1 0.7 1.3 14.8 1.5 0.5 15.3 0.8 1.1 14.4 63.8 1.8 42.4 25.5 4.7 18.6 48.5 9.7 48.9 0.8 1.5 1.0 24.2 64.9 24.4 0.5 1.8 0.9 5.6 71.5 62.2 13.2 55.2 2.8 28.9 25.9 11.8 66.6 43.7 0.8 30.5 125.5 1.5 1.1 3.5 21.6 2.1 1.8 11.7 83.0 26.2 32.6 16.8 21.7 0.0 8.5 0.0 0.0 0.3 0.4 0.1 21.6 2.2 0.0 0.0 0.0 0.0 107.1 0.0 0.0 0.0 0.0 36.0 50.3 0.0 0.4 0.0 0.0 48.6 0.0 24.1 0.0 4.2 0.6 0.0 0.1 7.7 0.0 0.0 0.2 0.0 34.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.7 0.0 0.1 0.8 31.7 0.1 0.0 0.0 0.3 8.8 37.0 1.3 0.1 0.2 0.0 9.1 15.2 32.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 2.8 0.0 0.0 0.0 0.0 0.3 0.0 8.5 0.1 0.1 1.3 1.5 0.8 1.1 1.5 1.0 1.8 0.9 2.8 1.8 122.1 58.7 0.9 101.9 83.6 0.0 0.8 152.8 73.6 64.8 155.3 0.0 97.3 1.7 107.7 0.0 1.2 202.1 0.0 98.3 22.3 4.1 170.0 1.1 44.7 10.1 0.0 83.2 0.6 1.5 0.0 0.3 6.3 50.6 5.4 180.9 0.0 193.9 160.9 0.4 3.3 0.0 0.0 4.7 0.0 0.1 114.9 42.2 0.0 125.1 204.2 CDH11 "CAD11, OB" ENSG00000140937 "Cadherin 11" P55287 16 64943753-65126112 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 71.0" "Group enriched" "Detected in many" 5 "Fibroblasts: 97.0;Ito cells: 32.5;Leydig cells: 48.6;Muller glia cells: 51.3;Peritubular cells: 72.9;Sertoli cells: 25.8;Smooth muscle cells: 24.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 48.0;BJ hTERT+: 27.9;fHDF/TERT166: 65.6;HSkMC: 45.2;PC-3: 56.5;U-2197: 38.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013072 Enhanced NA NA 70000 "CAB013072: AB_2533068" "unprognostic (1.77e-1)" "unprognostic (1.51e-1)" "unprognostic (1.50e-1)" "unprognostic (6.93e-2)" "unprognostic (6.00e-2)" "unprognostic (1.02e-1)" "unprognostic (6.96e-2)" "unprognostic (1.28e-1)" "unprognostic (2.09e-1)" "unprognostic (2.30e-2)" "unprognostic (3.74e-2)" "unprognostic (6.75e-2)" "prognostic unfavorable (2.48e-9)" "unprognostic (1.43e-3)" "unprognostic (3.20e-2)" "unprognostic (1.26e-1)" "unprognostic (5.07e-3)" 8.1 3.6 5.5 9.2 12.1 0.3 6.1 5.5 8.8 24.1 4.3 7.5 2.4 2.7 25.9 5.9 3.0 6.8 22.4 4.6 7.3 5.1 4.8 1.0 20.8 5.9 7.8 8.5 71.0 1.7 1.2 6.0 44.2 8.3 8.0 4.9 22.2 7.3 9.7 2.5 5.7 3.4 20.5 10.6 35.1 5.1 4.0 5.4 0.1 4.8 1.9 4.9 18.4 11.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 10.4 0.0 7.4 16.3 0.0 48.0 27.9 12.4 7.1 0.9 0.0 0.0 0.0 65.6 0.0 0.0 0.0 0.3 8.9 0.0 0.4 0.0 0.2 0.0 6.2 0.0 2.9 45.2 0.0 15.1 3.0 0.0 3.5 0.0 0.0 0.0 6.6 0.0 0.0 0.0 3.8 7.2 56.5 0.1 7.5 0.0 0.0 0.0 0.1 7.2 0.0 0.0 0.0 13.7 0.0 0.0 0.0 25.6 3.5 38.6 13.6 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 12.1 5.5 8.8 7.3 5.1 7.8 8.5 8.3 5.4 3.0 0.0 0.0 1.1 3.4 11.0 2.8 2.5 0.0 4.5 0.0 0.0 1.8 0.0 0.0 2.4 9.0 0.0 0.0 0.0 1.4 97.0 0.8 0.0 0.0 4.2 0.0 0.0 32.5 0.0 3.1 48.6 1.1 5.0 0.0 0.0 51.3 0.6 0.0 72.9 1.0 1.1 25.8 24.7 0.6 1.1 2.8 4.7 0.0 0.0 0.4 CDK12 "CRK7, CRKR, CRKRS, KIAA0904" ENSG00000167258 "Cyclin dependent kinase 12" Q9NYV4 17 39461511-39564907 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-BR-3: 87.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008038, HPA073305" Supported Enhanced "Nucleoplasm,Nuclear speckles" NA NA "Nucleoplasm, Nuclear speckles" "HPA008038: AB_1078570, HPA073305: " "unprognostic (2.02e-1)" "unprognostic (1.80e-1)" "unprognostic (2.61e-2)" "unprognostic (7.56e-2)" "unprognostic (1.05e-1)" "unprognostic (3.19e-1)" "unprognostic (2.56e-3)" "unprognostic (2.37e-2)" "unprognostic (3.86e-2)" "unprognostic (3.00e-3)" "unprognostic (6.87e-3)" "unprognostic (1.86e-1)" "unprognostic (3.06e-2)" "unprognostic (9.10e-2)" "unprognostic (1.24e-1)" "unprognostic (2.22e-2)" "unprognostic (5.32e-1)" 16.0 13.1 12.4 17.4 9.2 32.4 14.0 23.4 17.8 18.2 17.6 9.6 15.7 11.1 15.7 12.0 16.9 12.2 12.5 11.0 10.1 6.7 10.2 18.5 13.5 15.2 10.9 14.3 17.4 11.3 19.0 12.2 18.4 9.5 12.7 11.7 10.4 15.6 11.1 11.1 17.0 16.5 11.0 10.6 16.3 11.8 18.9 8.3 29.0 15.0 5.4 17.3 16.3 20.5 5.1 4.0 10.4 2.9 6.6 4.0 0.9 8.9 11.1 6.7 6.2 4.9 5.5 6.2 8.1 6.9 11.1 8.3 13.6 5.5 12.7 7.1 8.5 11.3 14.6 13.3 10.2 10.8 8.3 11.4 13.7 7.5 10.5 4.8 18.7 9.6 5.9 7.1 13.5 10.7 4.6 6.7 7.7 23.2 8.4 6.3 4.2 15.3 4.8 7.0 4.4 5.0 10.1 14.4 7.2 4.2 10.7 7.2 4.6 10.3 87.5 7.0 10.1 11.2 8.1 7.2 10.1 8.1 7.0 10.4 6.9 4.9 17.9 7.2 7.9 6.6 10.4 2.9 4.1 4.0 2.2 3.0 2.9 2.5 2.7 1.8 5.1 2.9 2.7 9.7 6.6 1.8 4.0 2.0 0.9 12.4 9.2 23.4 17.8 10.1 6.7 10.9 14.3 9.5 8.3 23.8 26.1 37.7 45.0 57.5 45.4 12.1 35.7 29.4 40.9 36.6 60.9 27.7 11.6 24.4 15.9 29.6 32.0 23.3 23.8 24.7 35.7 62.9 27.8 38.9 23.9 33.4 29.9 27.6 37.0 14.0 34.5 34.5 25.3 27.9 26.9 31.5 36.1 31.6 31.8 12.9 67.7 32.3 33.0 113.1 90.5 60.3 48.7 42.9 28.8 77.9 CDK6 PLSTIRE ENSG00000105810 "Cyclin dependent kinase 6" Q00534 7 92604921-92836594 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 74.6" "Cell type enhanced" "Detected in many" 8 "Early spermatids: 219.8;Late spermatids: 186.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "MOLT-4: 93.5;REH: 45.7" "Low region specificity" "Detected in all" "HPA002637, CAB004363" Enhanced Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB004363: AB_627242, HPA002637: AB_1846432" "unprognostic (1.29e-1)" "unprognostic (5.98e-3)" "unprognostic (9.07e-2)" "unprognostic (2.78e-3)" "unprognostic (2.56e-2)" "unprognostic (3.24e-2)" "unprognostic (3.39e-1)" "unprognostic (2.42e-3)" "unprognostic (7.19e-2)" "unprognostic (7.78e-3)" "prognostic unfavorable (3.86e-6)" "unprognostic (4.06e-2)" "unprognostic (4.09e-3)" "unprognostic (1.09e-1)" "unprognostic (7.88e-2)" "unprognostic (1.93e-1)" "prognostic unfavorable (2.33e-5)" 6.6 11.3 6.0 9.1 7.5 22.5 5.9 2.4 6.0 7.8 10.0 9.6 5.7 7.5 6.0 5.9 8.5 4.6 7.8 6.6 6.9 4.2 6.5 7.5 7.3 7.4 7.0 5.2 5.0 10.0 25.7 4.2 20.5 7.5 6.1 9.2 4.4 10.9 6.1 2.0 11.6 9.4 9.8 7.5 6.3 10.8 5.4 8.0 74.6 4.3 9.2 10.3 6.7 9.0 3.6 5.6 6.5 4.8 3.9 7.1 2.3 6.2 2.9 8.0 5.1 2.3 2.6 1.7 6.4 4.0 3.2 3.0 7.8 4.8 4.8 3.7 4.3 2.0 3.8 4.4 9.2 7.6 10.5 3.1 12.0 5.5 7.5 1.4 7.4 0.6 2.6 5.0 4.3 20.4 3.0 1.2 19.6 11.5 13.3 5.7 1.2 93.5 0.8 2.5 7.9 2.6 45.7 28.1 8.1 4.4 0.1 4.2 27.3 0.7 2.2 3.7 6.1 0.1 12.3 4.7 10.5 16.5 4.1 12.9 7.1 0.1 6.4 1.5 25.5 13.9 4.9 1.9 6.5 5.2 3.9 5.9 2.0 5.5 5.6 4.0 3.6 7.1 4.0 1.1 3.9 4.8 5.6 2.8 2.3 6.0 7.5 2.4 6.0 6.9 4.2 7.0 5.2 7.5 8.0 23.8 3.0 11.9 19.5 53.5 0.2 14.8 25.5 4.0 27.3 21.0 0.0 42.7 8.3 31.7 219.8 24.1 11.0 0.0 20.1 3.4 21.6 18.1 24.3 18.4 15.0 0.0 16.1 7.4 23.4 186.0 4.6 21.9 18.6 20.8 46.7 0.5 63.1 14.0 3.2 5.1 0.0 6.5 22.1 2.6 46.4 44.2 14.8 20.3 68.3 23.3 CDKN1B "KIP1, P27KIP1" ENSG00000111276 "Cyclin dependent kinase inhibitor 1B" P46527 12 12715058-12722371 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle" "Protein kinase inhibitor" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Muller glia cells: 157.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003691, CAB021888, HPA059086" Approved Supported Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "CAB003691: AB_425362, CAB021888: , HPA059086: AB_2683900" "unprognostic (5.67e-2)" "unprognostic (9.76e-2)" "prognostic favorable (5.15e-4)" "unprognostic (6.90e-3)" "unprognostic (5.84e-3)" "unprognostic (1.03e-2)" "prognostic unfavorable (3.25e-4)" "unprognostic (4.04e-2)" "unprognostic (1.11e-1)" "unprognostic (2.85e-3)" "unprognostic (9.23e-3)" "unprognostic (2.96e-1)" "prognostic unfavorable (8.39e-4)" "unprognostic (1.23e-1)" "unprognostic (8.68e-2)" "unprognostic (2.88e-1)" "unprognostic (1.15e-1)" 29.8 30.9 30.2 25.0 30.0 40.2 45.3 64.5 50.6 31.6 34.4 35.6 19.9 29.2 33.1 19.8 26.0 24.3 24.3 21.2 33.0 29.5 20.8 23.3 29.2 38.5 42.9 25.1 46.2 15.1 22.2 15.9 26.8 26.3 25.1 22.2 31.4 23.5 24.2 48.8 26.1 26.4 19.4 46.0 34.3 19.4 19.2 39.0 43.0 29.4 21.4 25.5 34.1 29.1 6.2 3.3 19.2 4.5 6.2 10.6 2.9 12.4 6.2 33.2 5.8 11.4 6.5 16.3 11.7 18.6 16.2 20.0 17.7 14.1 0.1 4.4 6.6 5.8 11.9 15.5 5.7 14.5 21.1 11.0 9.7 17.1 17.8 15.3 8.2 6.9 7.1 12.4 5.3 15.6 38.1 9.6 18.8 10.4 35.5 5.7 15.9 11.5 11.8 13.3 10.8 5.8 8.5 10.8 20.9 7.8 13.5 12.6 20.7 16.8 12.1 21.9 12.4 6.4 18.5 6.5 8.0 12.8 7.2 11.3 30.8 20.3 11.2 10.0 12.4 7.7 4.5 3.1 6.8 5.4 3.1 5.6 6.2 6.9 6.5 3.2 4.8 7.4 5.2 19.2 6.2 4.5 3.3 10.6 2.9 30.2 30.0 64.5 50.6 33.0 29.5 42.9 25.1 26.3 39.0 41.7 24.0 37.6 14.6 46.8 43.1 37.8 20.4 48.2 27.3 8.7 25.5 36.5 13.3 8.0 57.9 56.5 24.9 23.3 8.0 38.1 31.0 32.5 30.1 26.7 22.7 9.5 43.9 46.6 57.3 37.2 51.8 41.9 70.9 14.4 35.8 157.6 10.4 17.5 25.1 12.1 25.0 90.5 40.9 7.7 4.9 45.9 32.6 76.1 40.2 13.6 CDKN2A "ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf" ENSG00000147889 "Cyclin dependent kinase inhibitor 2A" "P42771, Q8N726" 9 21967753-21995301 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway" DNA-binding "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 22.6;pituitary gland: 39.3" "Cell type enhanced" "Detected in many" 13 "Early spermatids: 178.1;Late spermatids: 275.2;Pancreatic endocrine cells: 259.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 22.6" "Group enriched" "Detected in many" 8 "B-cells: 7.2;T-cells: 22.6" "Cell line enhanced" "Detected in many" "CAPAN-2: 50.2;HEK 293: 56.9;HeLa: 53.2;SK-MEL-30: 53.1" "Low region specificity" "Detected in some" "CAB000093, CAB000445, CAB018232, HPA047838" Enhanced Supported Nucleoli NA NA Nucleoli "CAB000093: AB_442119, CAB000445: , CAB018232: AB_785018, HPA047838: AB_2680174" "unprognostic (3.41e-2)" "unprognostic (4.51e-2)" "unprognostic (3.00e-3)" "prognostic unfavorable (1.82e-7)" "unprognostic (5.22e-2)" "prognostic favorable (5.19e-4)" "prognostic unfavorable (2.17e-4)" "unprognostic (1.25e-2)" "unprognostic (1.05e-1)" "unprognostic (1.04e-1)" "unprognostic (1.71e-1)" "unprognostic (1.56e-2)" "prognostic unfavorable (5.76e-7)" "unprognostic (9.41e-2)" "unprognostic (1.22e-2)" "unprognostic (3.05e-2)" "unprognostic (3.55e-1)" 5.4 8.6 2.9 4.5 3.9 1.8 5.3 1.7 3.1 1.2 2.5 4.4 0.1 1.2 1.2 1.9 6.3 3.0 2.6 0.7 1.7 1.0 0.9 1.2 3.0 3.0 3.6 1.6 1.5 1.5 8.5 39.3 6.7 5.0 1.9 1.1 1.2 2.4 2.9 0.9 1.3 3.7 1.0 3.0 8.9 6.0 13.0 1.9 3.9 1.4 3.0 14.0 2.7 1.5 7.2 0.2 0.8 1.8 0.4 22.6 2.2 2.1 0.0 0.3 14.1 0.1 0.1 6.1 2.3 0.0 19.7 35.1 3.5 50.2 7.2 32.3 1.6 0.0 6.0 5.9 36.5 15.9 31.0 56.9 0.0 53.2 2.3 1.5 3.6 3.0 3.8 0.0 19.8 11.0 42.3 2.0 0.0 0.0 33.0 18.0 0.1 0.3 0.0 0.4 4.0 29.3 0.0 13.4 26.5 4.0 0.0 33.1 2.3 38.2 6.3 53.1 1.7 7.5 0.1 6.6 0.1 0.4 0.0 0.1 14.7 8.3 29.5 0.0 9.5 0.1 0.8 1.3 0.2 6.2 0.6 9.7 7.2 8.0 11.0 0.2 7.0 0.5 4.7 0.4 0.4 1.8 0.0 22.6 2.2 2.9 3.9 1.7 3.1 1.7 1.0 3.6 1.6 5.0 1.9 0.0 0.0 1.5 0.7 1.5 0.2 4.0 0.0 14.7 1.2 10.4 0.0 20.9 0.0 32.4 178.1 2.2 6.9 0.0 22.9 52.3 3.6 10.0 4.6 0.0 6.6 0.0 68.2 0.6 8.2 275.2 2.8 1.8 8.5 26.2 6.2 0.8 259.8 10.5 1.8 0.0 0.0 0.0 1.0 5.7 4.1 0.4 7.7 12.5 2.3 34.0 CDKN2C "INK4C, p18" ENSG00000123080 "Cyclin dependent kinase inhibitor 2C" P42773 1 50960745-50974633 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Erythroid cells: 70.0;Sertoli cells: 84.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-937: 53.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB005303, CAB018398, HPA019057, HPA019764" Approved Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB005303: AB_2078729, CAB018398: AB_2078731, HPA019057: AB_1854865, HPA019764: AB_1854866" "unprognostic (4.07e-2)" "unprognostic (1.47e-3)" "unprognostic (2.89e-1)" "unprognostic (4.86e-2)" "unprognostic (6.70e-2)" "unprognostic (4.76e-3)" "prognostic unfavorable (1.58e-4)" "unprognostic (1.59e-2)" "unprognostic (1.59e-1)" "unprognostic (1.71e-1)" "unprognostic (2.28e-1)" "unprognostic (2.38e-1)" "prognostic unfavorable (1.70e-10)" "unprognostic (2.55e-2)" "unprognostic (2.12e-1)" "unprognostic (6.45e-2)" "unprognostic (1.24e-1)" 42.1 12.6 5.9 10.7 7.9 14.9 31.7 4.3 5.7 13.1 13.0 8.7 7.7 6.6 17.1 13.9 11.5 8.4 13.7 20.1 5.7 3.1 7.4 3.3 7.9 11.0 13.7 5.3 22.5 9.4 23.1 5.7 3.1 3.9 10.3 5.7 6.0 5.4 12.2 9.2 8.5 7.9 15.1 7.5 8.5 5.3 5.3 8.9 54.2 8.0 4.9 9.8 17.4 21.7 3.4 7.4 12.2 2.5 6.0 14.1 3.8 14.0 5.8 1.1 19.4 20.0 2.9 0.2 13.4 13.6 22.5 19.8 0.3 4.8 27.6 12.1 11.4 8.2 1.7 13.0 1.7 11.1 16.7 17.5 20.9 44.3 3.5 1.0 14.5 9.6 1.0 0.3 6.1 2.6 8.5 5.9 22.9 9.4 0.0 13.0 3.5 18.7 7.0 0.0 5.3 14.2 22.3 18.3 0.0 7.1 5.9 9.8 23.0 18.3 12.8 4.3 0.1 6.3 49.3 4.7 25.8 10.0 15.6 0.2 28.3 26.9 22.7 0.0 53.0 22.8 12.2 2.5 11.0 5.2 1.4 6.0 3.4 7.7 6.8 6.1 1.9 4.3 4.1 0.2 6.0 0.6 7.4 14.1 3.8 5.9 7.9 4.3 5.7 5.7 3.1 13.7 5.3 3.9 8.9 0.0 4.6 5.3 2.5 9.0 4.2 12.5 2.5 2.7 2.3 3.5 15.7 1.1 14.9 3.3 3.6 5.3 3.9 70.0 3.1 11.0 20.6 2.5 16.1 6.0 22.5 4.8 8.1 17.2 19.7 5.3 36.5 11.2 6.8 24.4 4.8 27.8 4.0 4.0 44.9 26.6 9.7 84.1 18.6 5.1 6.8 9.8 1.6 33.8 3.9 1.0 CDX2 CDX3 ENSG00000165556 "Caudal type homeobox 2" Q99626 13 27962137-27971139 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "intestine: 21.2" "Group enriched" "Detected in some" 7 "Enterocytes: 190.4;Intestinal endocrine cells: 60.0;Mucus-secreting cells: 200.2;Paneth cells: 129.8;Undifferentiated cells: 183.4" "Cancer enriched" "Detected in many" 6 "colorectal cancer: 63.7" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "CACO-2: 14.7;CAPAN-2: 4.9;HEK 293: 8.1" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002221, HPA045669, HPA049580" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB002221: AB_563649, HPA045669: AB_2679413, HPA049580: AB_2680823" "unprognostic (1.42e-1)" "unprognostic (2.41e-1)" "unprognostic (2.92e-1)" "unprognostic (8.11e-3)" "unprognostic (4.19e-6)" "unprognostic (1.73e-4)" "unprognostic (1.71e-1)" "unprognostic (1.58e-1)" "unprognostic (5.51e-2)" "unprognostic (6.07e-3)" "unprognostic (1.13e-1)" "unprognostic (1.09e-1)" 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 21.2 13.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.1 14.3 0.0 0.0 0.0 0.0 16.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 14.7 4.9 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 8.1 0.0 0.2 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 2.3 0.0 20.8 0.0 0.0 190.4 0.0 0.6 0.3 0.0 0.2 0.0 0.0 0.4 0.0 60.0 0.0 0.0 0.0 0.0 0.0 0.0 11.8 200.2 0.0 1.1 129.8 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.2 0.0 183.4 0.1 CEBPA "C/EBP-alpha, CEBP" ENSG00000245848 "CCAAT/enhancer binding protein alpha" P49715 19 33299934-33302564 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 52.3;liver: 44.3" "Cell type enhanced" "Detected in many" 10 "Hepatocytes: 84.7;Hofbauer cells: 76.1;Suprabasal keratinocytes: 150.2;Syncytiotrophoblasts: 177.5" "Cancer enhanced" "Detected in all" "liver cancer: 70.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 11.0;non-classical monocyte: 11.8" "Group enriched" "Detected in many" 13 "dendritic cells: 4.1;granulocytes: 11.0;monocytes: 11.8" "Cell line enhanced" "Detected in some" "BEWO: 43.5;Hep G2: 23.3;NB-4: 24.0;THP-1: 86.8;U-937: 27.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA052734, HPA065037, HPA067937" Approved Approved Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "HPA052734: AB_2681931, HPA065037: AB_2685410, HPA067937: AB_2685927" "unprognostic (1.80e-1)" "unprognostic (7.62e-3)" "unprognostic (2.09e-3)" "unprognostic (2.21e-2)" "unprognostic (3.38e-1)" "unprognostic (3.99e-2)" "unprognostic (1.94e-1)" "unprognostic (2.43e-3)" "unprognostic (5.95e-2)" "unprognostic (3.96e-2)" "unprognostic (3.09e-1)" "unprognostic (9.45e-2)" "unprognostic (8.02e-3)" "unprognostic (2.19e-1)" "unprognostic (1.98e-1)" "unprognostic (2.49e-2)" "unprognostic (2.72e-2)" 40.7 1.5 2.3 7.6 4.6 8.4 52.3 2.1 4.0 3.5 9.0 5.2 1.1 9.0 2.2 2.1 6.1 2.4 6.4 6.6 3.9 2.4 2.0 44.3 39.9 10.3 4.1 3.1 1.3 9.0 4.5 1.7 17.4 2.7 3.8 5.1 1.9 5.6 1.6 15.4 23.7 12.7 2.9 6.6 3.0 3.5 1.2 2.6 2.2 2.5 10.7 3.5 5.4 7.9 0.1 4.1 11.0 11.8 0.0 0.6 1.5 0.5 1.1 0.0 1.5 12.5 0.0 43.5 0.0 0.3 0.0 0.0 5.3 0.0 0.0 0.6 0.0 0.2 2.0 1.2 0.1 0.0 7.5 1.5 0.0 0.0 23.3 0.2 7.6 9.3 0.5 5.6 0.0 0.0 0.0 0.0 0.6 0.5 0.0 0.0 2.6 0.0 24.0 1.1 13.1 0.6 0.0 0.0 0.2 0.0 3.8 0.0 0.3 0.1 0.1 0.1 1.4 3.0 86.8 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 27.8 0.0 11.0 6.0 0.0 0.6 9.4 0.6 0.0 0.1 0.4 4.1 0.1 0.2 0.4 2.1 0.0 11.8 0.2 0.0 1.5 2.3 4.6 2.1 4.0 3.9 2.4 4.1 3.1 2.7 2.6 14.9 27.8 1.4 20.5 33.2 0.7 0.4 25.5 6.7 5.7 0.0 0.0 27.5 3.3 0.6 0.0 0.6 62.2 0.0 5.0 35.2 6.1 11.7 1.1 84.7 76.1 0.0 4.1 1.3 21.4 0.0 2.8 23.2 5.0 1.0 22.1 8.0 2.1 31.3 1.4 3.7 0.3 0.0 4.1 0.2 0.7 150.2 177.5 1.0 26.9 9.5 CHCHD7 "COX23, MGC2217" ENSG00000170791 "Coiled-coil-helix-coiled-coil-helix domain containing 7" Q9BUK0 8 56211686-56218798 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050783 Approved Approved "Cell Junctions,Aggresome" NA NA "Cell Junctions" Aggresome "HPA050783: AB_2681236" "unprognostic (1.64e-2)" "unprognostic (3.23e-2)" "unprognostic (3.18e-2)" "prognostic unfavorable (1.39e-6)" "unprognostic (4.46e-2)" "unprognostic (2.43e-1)" "unprognostic (5.04e-2)" "unprognostic (8.38e-3)" "unprognostic (1.62e-1)" "unprognostic (9.03e-2)" "unprognostic (2.24e-1)" "unprognostic (1.15e-1)" "prognostic favorable (9.47e-5)" "unprognostic (1.94e-1)" "unprognostic (5.07e-1)" "unprognostic (1.77e-2)" "unprognostic (2.50e-1)" 16.6 14.8 24.1 19.6 29.4 17.6 18.9 27.1 23.3 17.6 20.7 18.3 22.8 22.5 13.1 34.3 15.7 17.6 12.3 27.0 21.0 19.5 23.4 18.0 19.4 24.4 27.0 16.0 36.3 20.0 22.5 48.3 13.3 26.7 19.2 21.3 19.2 34.5 18.0 23.2 14.6 26.2 14.8 32.0 33.0 17.7 7.6 24.8 27.4 19.8 18.3 24.9 15.5 16.4 31.0 33.6 26.2 20.6 24.2 31.1 17.3 18.7 6.0 13.5 4.4 35.9 25.5 13.9 13.4 12.7 10.7 8.0 15.4 23.0 17.8 11.9 7.9 14.8 10.6 13.9 20.7 13.3 7.7 26.8 27.1 14.3 21.2 18.2 23.1 17.4 30.4 19.1 7.6 34.1 15.2 11.1 33.4 13.2 11.7 25.3 9.4 23.1 34.3 11.8 30.0 8.7 26.5 4.1 14.8 19.8 20.3 3.5 2.3 7.0 11.0 9.9 16.9 11.5 13.0 16.1 5.7 12.1 18.3 12.6 12.3 12.6 29.6 15.9 34.4 9.7 21.5 20.6 26.2 23.2 19.0 22.5 31.0 26.0 23.6 22.8 26.4 31.1 27.8 7.9 24.2 16.6 33.6 29.7 17.3 24.1 29.4 27.1 23.3 21.0 19.5 27.0 16.0 26.7 24.8 17.9 68.8 75.2 36.1 18.4 31.3 84.5 48.4 44.2 40.9 47.1 13.7 38.6 106.1 35.3 16.9 29.6 88.5 23.3 65.0 72.3 25.3 33.7 52.0 63.7 129.2 12.7 38.1 46.6 72.1 9.6 34.2 55.9 50.6 69.5 53.7 38.5 58.7 54.7 29.0 49.6 34.8 12.9 36.3 52.6 37.9 20.8 35.2 57.5 63.2 39.1 CHD4 "Mi-2b, Mi2-BETA" ENSG00000111642 "Chromodomain helicase DNA binding protein 4" Q14839 12 6570082-6614524 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Helicase, Hydrolase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA012008 Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA012008: AB_1846633" "unprognostic (6.11e-2)" "unprognostic (2.26e-2)" "unprognostic (1.71e-2)" "unprognostic (6.40e-3)" "unprognostic (8.99e-2)" "unprognostic (3.36e-3)" "prognostic unfavorable (6.03e-6)" "unprognostic (2.66e-2)" "unprognostic (1.05e-1)" "unprognostic (6.85e-2)" "unprognostic (3.15e-1)" "unprognostic (3.94e-1)" "unprognostic (2.06e-1)" "unprognostic (3.33e-1)" "unprognostic (1.82e-1)" "unprognostic (9.84e-2)" "unprognostic (1.66e-1)" 23.5 34.9 21.9 50.0 33.5 27.2 25.9 29.4 25.1 28.1 29.5 29.3 38.5 18.6 37.2 35.4 29.1 28.0 40.3 52.8 23.5 19.2 29.5 25.0 25.5 30.9 33.6 19.4 34.6 27.4 58.4 25.3 29.5 27.2 21.5 26.0 26.5 24.8 46.2 33.7 31.1 24.4 36.6 30.3 29.4 27.2 29.7 28.9 75.7 38.4 33.7 38.4 34.7 24.3 12.6 16.8 12.8 9.1 13.5 16.7 5.8 20.4 18.7 46.4 17.4 19.0 21.4 27.3 22.7 22.2 25.1 23.2 31.2 15.9 44.1 9.0 25.7 16.4 18.3 43.5 25.0 33.9 33.0 22.4 61.6 29.1 19.4 16.5 48.3 29.6 20.7 12.4 24.3 17.0 31.7 29.3 24.7 48.4 22.0 23.8 25.6 45.8 15.8 44.4 19.0 17.7 39.3 28.5 24.1 15.9 24.2 22.0 28.3 29.2 32.6 22.6 53.2 14.9 27.5 27.2 25.7 54.7 18.8 26.5 35.7 21.2 56.3 17.0 29.5 18.7 9.0 7.7 9.2 12.2 9.1 12.0 10.5 10.3 11.1 7.9 12.6 13.0 12.3 12.8 13.5 8.1 16.8 16.7 5.8 21.9 33.5 29.4 25.1 23.5 19.2 33.6 19.4 27.2 28.9 56.6 102.0 59.1 45.6 60.9 103.2 110.8 66.2 96.4 79.6 83.7 66.8 38.6 11.6 71.4 71.8 70.5 43.4 23.3 62.1 41.7 66.9 40.2 81.1 60.6 61.2 131.9 93.2 49.7 44.2 45.3 60.9 57.6 45.5 56.9 59.2 71.6 76.6 24.6 70.0 30.3 60.2 51.8 73.5 97.0 107.1 59.1 56.9 61.8 61.8 37.3 CIC KIAA0306 ENSG00000079432 "Capicua transcriptional repressor" Q96RK0 19 42268537-42295797 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB026388, HPA044341, HPA064725" Approved Supported Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "CAB026388: , HPA044341: AB_2678901, HPA064725: AB_2685335" "unprognostic (2.02e-2)" "unprognostic (4.08e-1)" "unprognostic (1.41e-2)" "unprognostic (3.54e-3)" "unprognostic (3.67e-1)" "unprognostic (4.17e-3)" "unprognostic (1.49e-1)" "unprognostic (2.06e-1)" "unprognostic (4.87e-1)" "unprognostic (1.85e-2)" "unprognostic (1.72e-3)" "unprognostic (3.10e-1)" "unprognostic (4.23e-2)" "unprognostic (1.00e-1)" "unprognostic (2.38e-1)" "unprognostic (1.88e-2)" "unprognostic (1.56e-1)" 18.6 15.7 30.5 22.8 29.9 28.1 20.3 46.8 31.6 17.5 14.7 24.7 13.0 16.5 28.6 12.3 12.3 22.1 17.4 12.1 25.5 15.2 14.9 15.1 15.8 21.5 25.2 20.1 31.5 22.6 16.6 22.6 13.2 20.4 14.4 6.2 19.0 23.8 20.8 21.0 34.1 16.1 16.3 16.5 24.7 14.5 31.5 25.6 13.6 16.8 10.6 13.4 13.6 17.4 2.3 2.0 5.0 2.6 0.6 2.5 1.6 17.7 32.1 12.4 17.0 8.0 15.2 6.1 13.6 11.3 11.5 10.6 9.1 11.0 12.3 12.9 10.7 9.5 8.7 6.9 20.5 3.7 29.9 9.3 10.4 20.3 10.8 10.1 5.8 29.5 18.0 12.1 13.0 7.6 12.1 10.5 7.8 10.1 26.0 6.4 16.9 11.5 11.2 7.7 5.7 18.3 9.9 10.5 7.4 9.6 16.7 16.0 13.1 12.8 8.1 10.1 4.1 9.5 12.5 20.0 27.5 22.3 9.4 16.5 21.6 14.8 8.4 21.3 9.2 16.2 3.4 1.8 1.0 2.5 2.6 1.9 1.7 1.3 1.6 1.7 2.3 0.9 1.5 5.0 0.6 1.9 2.0 0.5 1.6 30.5 29.9 46.8 31.6 25.5 15.2 25.2 20.1 20.4 25.6 0.0 4.0 8.0 14.4 23.0 32.4 5.6 22.9 2.7 1.2 8.7 19.6 5.9 3.3 11.2 3.5 17.5 10.7 0.0 13.1 4.3 11.3 8.6 11.5 17.4 10.3 39.7 14.3 12.3 18.4 2.5 20.1 10.7 23.6 10.8 9.4 17.4 13.4 10.5 17.0 5.0 18.3 25.8 13.7 10.2 22.9 16.9 10.9 11.7 8.4 9.8 CIITA "C2TA, MHC2TA, NLRA" ENSG00000179583 "Class II major histocompatibility complex transactivator" P33076 16 10866222-10943021 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Acyltransferase, Kinase, Transferase" "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 67.2" "Cell type enhanced" "Detected in many" 14 "Alveolar cells type 2: 17.9;Macrophages: 36.9;monocytes: 58.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HDLM-2: 23.3;REH: 40.9;U-266/70: 8.6;U-698: 12.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB016084, HPA054757" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB016084: AB_627261, HPA054757: " "unprognostic (1.45e-3)" "unprognostic (1.38e-2)" "unprognostic (8.22e-3)" "unprognostic (1.12e-2)" "unprognostic (5.66e-2)" "unprognostic (2.88e-3)" "unprognostic (2.92e-2)" "unprognostic (1.55e-2)" "unprognostic (1.15e-2)" "unprognostic (1.85e-1)" "unprognostic (1.23e-1)" "unprognostic (3.72e-1)" "unprognostic (1.64e-2)" "unprognostic (2.72e-2)" "unprognostic (6.33e-3)" "unprognostic (2.74e-1)" "unprognostic (1.05e-2)" 8.0 5.9 4.6 47.7 7.1 4.3 6.8 1.5 5.5 6.3 3.7 10.6 4.2 10.4 8.1 10.4 4.8 5.2 8.1 4.9 4.7 3.5 8.8 2.9 15.0 27.0 9.4 1.1 2.5 3.5 1.9 4.0 1.2 6.6 5.5 4.3 5.5 13.3 4.3 2.9 4.4 17.4 3.7 15.6 25.9 6.2 1.5 7.4 12.6 6.1 5.2 67.2 6.3 6.8 27.3 19.0 6.5 11.9 0.7 0.5 1.7 0.1 0.2 0.3 0.3 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.3 5.6 5.1 0.8 0.0 0.9 0.9 0.0 0.0 0.1 23.3 0.3 2.9 1.1 0.6 0.0 0.5 0.4 1.0 0.0 0.1 0.0 0.9 0.0 0.3 0.3 2.0 0.1 0.3 0.2 0.4 0.1 0.2 0.1 40.9 0.3 3.6 0.0 1.7 0.9 0.1 0.9 0.3 0.9 0.3 0.5 1.7 0.3 2.1 0.3 0.6 0.2 8.6 0.6 12.1 7.7 0.5 6.9 0.2 11.9 6.5 0.3 9.5 0.1 17.9 0.1 0.5 17.7 27.3 0.1 0.2 2.8 0.7 10.0 19.0 0.4 1.7 4.6 7.1 1.5 5.5 4.7 3.5 9.4 1.1 6.6 7.4 6.0 17.9 12.3 0.3 2.1 0.6 2.8 2.5 2.7 1.2 3.5 0.0 0.1 0.0 2.5 0.6 4.2 3.4 0.0 1.7 0.2 1.0 0.3 10.4 1.0 9.1 0.0 2.4 2.5 15.6 0.0 0.6 36.9 6.8 58.7 0.7 0.4 1.7 0.0 0.0 3.3 0.9 0.0 0.9 0.0 0.0 2.5 0.1 1.0 0.4 0.3 CLIP1 "CLIP, CLIP-170, CLIP170, CYLN1, RSN" ENSG00000130779 "CAP-Gly domain containing linker protein 1" P30622 12 122271432-122422632 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 96.5" "Cell type enhanced" "Detected in many" 6 "Syncytiotrophoblasts: 400.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004399, HPA026678" Approved Supported "Microtubule ends,Cytosol" NA NA 7700 "Microtubule ends, Cytosol" "CAB004399: AB_671001, HPA026678: AB_1846954" "unprognostic (1.18e-1)" "unprognostic (2.01e-1)" "unprognostic (1.72e-1)" "unprognostic (4.91e-2)" "unprognostic (6.28e-2)" "unprognostic (2.28e-1)" "unprognostic (1.20e-1)" "unprognostic (4.73e-2)" "unprognostic (2.51e-1)" "unprognostic (7.62e-2)" "unprognostic (2.31e-2)" "unprognostic (8.97e-2)" "unprognostic (3.26e-2)" "unprognostic (5.50e-2)" "unprognostic (2.63e-1)" "unprognostic (3.37e-1)" "unprognostic (2.52e-3)" 14.4 12.6 9.8 9.1 10.9 6.4 11.7 44.5 11.5 11.6 19.5 4.3 13.9 5.7 14.3 10.1 24.8 7.5 7.7 11.8 9.3 7.5 10.0 15.2 10.0 5.8 6.5 9.5 6.3 9.1 37.8 10.9 36.5 8.7 13.2 7.1 6.7 11.8 15.1 96.5 16.8 9.1 31.1 7.2 5.9 9.6 6.1 6.9 3.7 24.1 25.9 10.1 22.2 16.6 5.3 5.4 18.2 10.6 3.9 7.2 3.7 15.5 19.7 12.2 12.3 10.4 16.1 21.3 22.3 21.2 15.1 9.5 9.1 7.7 7.0 15.0 28.8 19.4 20.0 7.7 9.1 17.1 29.3 5.6 2.3 13.1 9.6 20.8 8.1 12.9 10.6 31.5 17.4 26.3 20.2 15.1 6.2 8.7 4.8 15.1 9.0 5.0 2.8 4.6 6.7 17.5 4.6 9.4 3.5 13.6 17.9 4.7 3.0 47.7 11.7 19.5 11.0 10.1 4.8 29.2 11.5 12.4 26.9 14.5 5.3 4.2 4.2 19.7 4.1 7.9 3.6 6.5 5.2 7.2 10.6 5.4 5.3 6.7 6.5 5.4 3.6 5.0 3.7 18.2 3.9 8.6 3.5 5.8 3.7 9.8 10.9 44.5 11.5 9.3 7.5 6.5 9.5 8.7 6.9 125.0 126.6 21.9 132.8 59.6 59.4 113.6 43.3 131.2 134.2 41.8 41.2 101.8 6.6 54.0 137.2 49.6 24.3 0.0 56.4 29.4 46.1 121.3 69.5 39.3 33.9 125.5 13.4 48.5 34.8 68.2 33.1 51.6 52.3 30.7 18.9 36.4 75.0 24.6 58.4 10.5 41.9 71.1 40.1 21.2 29.5 125.3 400.9 27.1 21.5 189.8 CLTC "CLTCL2, Hc" ENSG00000141367 "Clathrin heavy chain" Q00610 17 59619689-59696956 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Autophagy, Cell cycle, Cell division, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB010389, CAB011571, CAB017155, HPA059143" Approved Enhanced "Vesicles,Endosomes,Lysosomes,Mitotic spindle,Cytosol" Yes No 51000000 "Vesicles, Endosomes, Lysosomes" "Mitotic spindle, Cytosol" "CAB010389: AB_2083184, CAB011571: AB_2083165, CAB017155: , HPA059143: AB_2683924" "unprognostic (1.56e-1)" "prognostic unfavorable (7.35e-4)" "prognostic favorable (7.65e-4)" "unprognostic (1.03e-1)" "unprognostic (2.62e-1)" "unprognostic (5.23e-3)" "prognostic unfavorable (5.54e-4)" "unprognostic (1.11e-1)" "unprognostic (6.43e-2)" "unprognostic (1.09e-1)" "unprognostic (3.34e-2)" "unprognostic (2.69e-1)" "unprognostic (1.49e-1)" "unprognostic (1.18e-1)" "unprognostic (9.22e-2)" "unprognostic (1.10e-1)" "prognostic unfavorable (2.02e-4)" 39.5 45.7 47.4 35.1 57.6 30.7 57.9 59.1 83.6 38.1 45.0 25.1 47.7 27.9 38.7 52.3 32.1 30.9 34.1 39.9 47.1 53.7 48.6 46.0 46.5 60.7 53.9 59.3 29.8 23.3 96.1 30.0 51.5 57.0 38.9 48.9 22.7 28.6 54.4 44.2 30.5 27.7 45.8 47.8 28.0 34.2 29.4 28.8 28.0 43.7 26.6 31.2 37.1 40.6 10.0 24.6 13.9 24.6 12.3 15.6 13.1 47.4 71.8 35.4 35.0 59.8 48.8 40.5 51.0 53.8 45.7 47.8 44.0 29.2 33.0 58.6 72.4 50.6 31.3 52.8 42.4 61.1 35.5 28.4 54.1 45.4 68.2 45.7 37.0 31.3 46.1 26.0 69.5 44.8 36.0 50.5 16.9 53.9 46.8 71.2 84.6 21.9 11.0 30.5 43.4 41.9 19.5 59.3 40.0 51.2 67.3 31.8 37.8 31.6 20.7 30.2 47.8 49.2 23.3 64.5 83.9 50.1 40.0 52.2 36.8 51.7 30.5 61.5 25.1 51.2 10.5 20.9 13.9 12.7 24.6 15.6 10.0 11.7 13.7 24.6 9.1 10.0 11.0 13.4 12.3 20.7 16.1 14.5 13.1 47.4 57.6 59.1 83.6 47.1 53.7 53.9 59.3 57.0 28.8 92.3 94.7 38.0 37.2 56.7 86.7 68.8 86.6 72.3 81.9 73.3 56.9 86.9 23.2 67.8 20.6 66.0 118.0 93.5 84.2 40.6 77.3 84.0 65.9 162.9 151.0 81.0 115.9 156.5 173.7 53.1 68.4 90.2 50.6 62.3 109.9 47.7 89.2 73.7 88.1 105.0 55.3 77.6 61.2 51.7 37.2 69.4 90.3 33.1 108.8 72.3 CLTCL1 "CHC22, CLH22, CLTCL, CLTD" ENSG00000070371 "Clathrin heavy chain like 1" P53675 22 19179473-19291716 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 53.0" "Cell type enhanced" "Detected in many" 7 "Cardiomyocytes: 11.2;Cone photoreceptor cells: 13.7;Early spermatids: 15.7;Late spermatids: 12.9;Spermatocytes: 13.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 8 "classical monocyte: 3.3;neutrophil: 8.4" "Group enriched" "Detected in many" 15 "granulocytes: 8.4;monocytes: 3.3" "Cell line enhanced" "Detected in many" "HMC-1: 34.9;K-562: 16.3" "HPA075327, HPA075795" Enhanced Approved Vesicles NA NA Vesicles "HPA075327: , HPA075795: AB_2686764" "unprognostic (1.29e-2)" "unprognostic (3.13e-2)" "unprognostic (1.93e-2)" "unprognostic (3.16e-3)" "unprognostic (8.20e-2)" "unprognostic (6.93e-3)" "unprognostic (1.60e-1)" "unprognostic (3.28e-1)" "unprognostic (4.42e-2)" "unprognostic (2.93e-3)" "unprognostic (3.14e-1)" "unprognostic (1.02e-1)" "unprognostic (1.20e-1)" "unprognostic (8.71e-4)" "unprognostic (1.61e-1)" "unprognostic (2.10e-2)" "unprognostic (1.06e-1)" 2.9 3.3 1.1 0.9 2.0 9.7 1.6 3.4 1.8 1.3 1.0 3.7 1.2 0.4 2.3 3.1 2.2 1.4 0.9 5.6 1.3 1.7 1.0 1.7 1.2 0.6 2.7 1.4 1.4 0.9 2.1 14.9 1.1 4.1 1.8 0.8 4.2 1.5 1.1 53.0 2.1 0.9 2.4 3.6 0.9 1.0 17.2 1.2 1.3 2.7 10.4 0.7 1.2 1.3 0.2 0.3 8.4 3.3 0.0 0.3 0.6 2.3 2.4 1.6 2.6 5.9 3.2 0.7 1.6 1.7 2.3 3.4 0.8 0.7 0.9 0.2 3.6 1.7 0.8 2.5 4.6 1.9 0.1 2.4 0.1 2.2 2.7 3.0 3.3 34.9 13.9 3.7 4.2 5.9 6.7 1.4 1.3 16.3 0.9 5.3 1.8 0.4 11.6 2.0 9.4 2.0 1.2 13.3 0.0 1.8 0.9 3.8 0.6 3.5 2.2 0.2 2.0 4.7 14.1 0.4 4.1 8.7 2.3 2.7 1.8 4.2 0.4 2.4 9.0 0.8 0.0 3.3 0.3 0.1 0.7 0.0 0.0 0.1 0.3 0.3 0.2 0.3 0.0 8.4 0.0 0.0 0.1 0.0 0.6 1.1 2.0 3.4 1.8 1.3 1.7 2.7 1.4 4.1 1.2 3.0 0.3 0.0 0.5 0.6 1.6 11.2 2.5 0.0 2.3 0.0 13.7 0.3 0.0 0.7 15.7 0.4 0.0 0.0 0.0 0.1 0.9 1.4 0.0 1.5 0.3 0.0 0.0 1.3 1.5 12.9 2.3 0.0 0.0 0.0 1.2 1.7 1.0 0.0 3.9 0.6 2.1 0.0 2.1 13.4 5.3 0.6 0.9 0.0 0.9 0.0 CNBP "CNBP1, DM2, RNF163, ZCCHC22, ZNF9" ENSG00000169714 "CCHC-type zinc finger nucleic acid binding protein" P62633 3 129169484-129183922 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063097 Approved Nucleoplasm,Cytosol NA NA 43000 Nucleoplasm Cytosol "HPA063097: AB_2684939" "unprognostic (1.74e-1)" "unprognostic (3.11e-2)" "unprognostic (4.84e-1)" "unprognostic (3.35e-2)" "unprognostic (6.28e-2)" "unprognostic (7.38e-2)" "unprognostic (7.02e-3)" "unprognostic (1.23e-1)" "unprognostic (1.06e-3)" "unprognostic (6.39e-2)" "prognostic unfavorable (3.51e-4)" "unprognostic (4.72e-3)" "unprognostic (4.62e-3)" "unprognostic (1.89e-1)" "unprognostic (2.03e-1)" "unprognostic (2.51e-1)" "unprognostic (1.58e-1)" 54.2 52.8 36.4 33.6 33.7 35.9 46.6 43.5 35.6 58.1 47.1 34.5 40.5 32.4 54.5 49.4 55.6 40.9 48.5 78.2 33.0 32.0 38.0 71.6 47.5 40.6 39.7 30.3 67.4 65.4 39.3 33.5 41.5 33.3 62.3 37.1 41.3 48.9 50.9 182.1 46.7 40.6 71.9 38.0 43.2 43.1 32.1 33.1 39.0 67.3 81.1 41.2 76.1 63.5 74.3 60.3 120.1 84.1 61.7 83.4 172.9 61.7 36.6 53.4 42.3 53.4 45.8 42.2 48.6 77.1 53.0 60.9 53.6 43.5 82.2 41.7 45.2 38.9 46.5 69.8 56.3 71.9 55.1 50.8 79.4 37.8 57.7 53.2 85.1 45.7 44.3 66.2 37.1 134.1 36.1 46.7 46.4 59.4 56.6 55.5 73.9 78.8 62.6 65.1 55.1 61.9 69.3 49.6 97.9 54.9 59.5 72.8 58.3 38.3 37.9 103.0 32.6 43.6 58.6 49.2 39.3 38.7 53.9 49.1 53.2 48.4 129.3 40.5 58.4 51.8 93.4 84.1 96.8 64.1 63.8 80.6 74.3 77.4 68.9 60.3 62.7 83.4 72.0 120.1 61.7 48.9 35.1 73.9 172.9 36.4 33.7 43.5 35.6 33.0 32.0 39.7 30.3 33.3 33.1 241.2 236.8 168.8 346.4 466.2 151.2 559.4 112.1 211.5 257.0 75.0 31.4 228.5 316.7 172.7 25.7 265.4 148.7 46.7 254.5 331.1 308.6 248.1 302.0 134.8 219.0 87.4 164.4 125.8 185.1 30.7 292.6 305.9 301.9 415.6 158.2 306.6 196.4 147.3 300.5 191.8 122.5 258.7 447.2 255.1 271.9 512.9 243.9 251.4 182.3 305.2 CNOT3 "KIAA0691, LENG2, NOT3, NOT3H" ENSG00000088038 "CCR4-NOT transcription complex subunit 3" O75175 19 54137717-54155708 "Cancer-related genes, Predicted intracellular proteins" "RNA-mediated gene silencing, Transcription, Transcription regulation, Translation regulation" "Developmental protein, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEK 293: 72.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006408 Approved Approved Cytosol NA NA Cytosol "HPA006408: AB_1078543" "unprognostic (1.23e-1)" "unprognostic (2.54e-1)" "unprognostic (1.75e-2)" "unprognostic (1.40e-1)" "unprognostic (4.86e-2)" "unprognostic (1.90e-1)" "prognostic unfavorable (2.22e-4)" "unprognostic (9.06e-2)" "unprognostic (1.43e-2)" "unprognostic (2.65e-2)" "unprognostic (9.30e-3)" "unprognostic (4.08e-3)" "prognostic unfavorable (2.77e-4)" "unprognostic (2.18e-1)" "unprognostic (1.73e-1)" "unprognostic (2.11e-1)" "unprognostic (2.66e-2)" 18.1 25.2 25.5 23.6 26.4 21.4 20.2 46.8 27.9 22.1 20.7 24.5 27.7 21.3 25.0 26.5 22.1 23.6 19.7 16.2 21.9 15.6 21.3 20.2 17.9 23.9 25.5 20.8 28.0 22.7 27.6 30.2 24.2 20.3 23.3 17.5 20.7 22.4 31.4 20.2 25.2 21.4 22.0 16.7 26.3 21.9 34.4 26.9 33.6 26.3 14.3 23.3 23.8 29.9 3.2 6.7 8.4 3.1 1.6 3.6 2.9 13.8 22.3 23.2 13.3 8.6 8.8 16.2 13.0 22.5 17.4 15.6 14.3 12.0 17.1 8.3 15.0 14.3 14.6 25.7 12.6 18.1 17.6 72.5 26.5 14.5 12.7 15.0 15.1 18.6 11.0 12.2 15.5 26.3 12.6 13.8 13.0 19.5 16.0 12.8 17.1 18.7 8.9 14.1 28.5 17.9 18.7 17.8 11.1 11.7 28.1 15.0 12.6 25.1 18.1 8.2 18.0 10.3 16.2 12.3 14.8 17.1 7.9 17.6 15.1 16.4 23.6 12.9 11.6 15.6 1.4 3.1 5.2 3.6 2.2 2.5 2.9 2.4 3.2 2.8 3.2 2.7 2.6 8.4 1.6 2.6 6.7 2.5 2.9 25.5 26.4 46.8 27.9 21.9 15.6 25.5 20.8 20.3 26.9 11.9 9.0 17.1 14.7 8.9 17.3 1.7 12.7 12.0 11.4 7.0 15.7 23.7 8.3 12.8 7.4 10.5 14.4 0.0 12.6 22.9 13.5 16.1 3.5 7.6 14.1 15.9 13.8 12.9 7.9 5.4 15.8 7.2 5.0 16.2 15.2 11.3 13.1 20.1 8.9 8.1 17.8 6.5 11.2 44.2 39.9 8.7 41.9 12.5 11.9 14.8 CNTRL "CEP1, CEP110" ENSG00000119397 Centriolin Q7Z7A1 9 121074863-121177610 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 13 "Ciliated cells: 156.6;Spermatocytes: 334.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HL-60: 35.4" "Low region specificity" "Detected in all" "HPA020468, HPA020480, HPA051583" Approved Supported Centrosome,Cytosol NA NA Centrosome Cytosol "HPA020468: AB_2670455, HPA020480: AB_2670457, HPA051583: AB_2681542" "unprognostic (4.33e-3)" "unprognostic (2.89e-3)" "unprognostic (2.09e-2)" "unprognostic (7.97e-2)" "unprognostic (1.17e-2)" "prognostic favorable (9.21e-5)" "unprognostic (1.05e-2)" "unprognostic (3.22e-3)" "unprognostic (3.74e-3)" "unprognostic (2.02e-1)" "unprognostic (1.78e-2)" "unprognostic (5.47e-2)" "unprognostic (3.60e-3)" "unprognostic (9.83e-3)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" "unprognostic (1.13e-2)" 7.7 4.7 5.5 22.2 11.7 24.0 6.8 10.9 8.7 8.4 5.5 4.9 5.9 3.8 7.3 6.4 5.6 8.4 5.1 4.4 6.6 4.3 4.0 3.8 9.3 20.3 8.1 4.1 10.6 5.2 4.0 17.3 5.8 7.0 7.2 5.5 4.4 6.3 8.6 2.8 5.2 8.8 5.7 9.7 14.8 7.1 30.2 9.8 26.7 6.2 4.2 19.2 8.6 7.1 12.7 10.5 15.0 6.9 4.8 10.4 2.5 5.4 3.6 10.2 7.3 1.5 2.3 1.8 3.8 2.8 3.0 2.6 2.1 6.0 25.1 1.5 2.7 5.4 11.5 3.4 2.3 4.9 15.1 2.6 13.1 6.7 2.5 2.1 35.4 15.9 1.4 1.7 3.1 7.6 1.3 6.5 10.4 8.4 14.3 2.9 3.5 13.9 12.1 3.5 7.0 3.0 13.1 15.4 7.2 1.4 2.5 3.8 5.8 12.9 2.3 2.9 1.8 4.9 17.0 4.8 3.2 5.5 4.9 7.0 10.0 10.9 17.0 2.6 14.6 7.2 12.2 6.9 15.0 7.5 4.5 5.7 10.8 7.7 5.5 3.4 12.7 9.3 6.6 2.7 4.8 5.8 10.5 10.4 2.5 5.5 11.7 10.9 8.7 6.6 4.3 8.1 4.1 7.0 9.8 26.8 26.2 35.1 12.7 3.0 28.2 7.0 5.1 156.6 48.9 3.5 35.3 1.5 3.3 3.8 56.2 14.4 2.1 0.0 5.2 2.1 5.9 3.8 49.9 2.0 22.5 28.6 8.1 12.3 34.6 27.0 12.7 37.9 8.5 22.6 7.3 7.0 5.3 3.5 11.3 1.1 64.1 38.8 5.1 334.4 72.6 5.0 0.7 29.8 5.2 4.7 COL1A1 OI4 ENSG00000108821 "Collagen type I alpha 1 chain" P02452 17 50183289-50201632 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 415.7" "Cell type enhanced" "Detected in many" 22 "Fibroblasts: 2038.6;Ito cells: 615.0;Leydig cells: 514.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enriched" "Detected in single" 5 "naive CD8 T-cell: 1.1" "Lineage enriched" "Detected in single" 5 "T-cells: 1.1" "Cell line enhanced" "Detected in many" "ASC TERT1: 91.8;BJ: 176.2;fHDF/TERT166: 266.1;HHSteC: 71.8;HSkMC: 134.8;U-138 MG: 143.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "HPA011795, HPA012111" Approved Approved "Endoplasmic reticulum,Vesicles" "Secreted to extracellular matrix" NA NA 58000000 "Endoplasmic reticulum, Vesicles" "HPA011795: AB_1847088, HPA012111: " "unprognostic (1.61e-1)" "unprognostic (3.60e-3)" "unprognostic (8.29e-2)" "unprognostic (5.52e-2)" "unprognostic (7.74e-2)" "unprognostic (2.22e-1)" "unprognostic (6.01e-2)" "prognostic unfavorable (4.43e-4)" "unprognostic (1.23e-2)" "unprognostic (2.55e-2)" "unprognostic (8.53e-2)" "unprognostic (9.90e-2)" "prognostic unfavorable (7.19e-12)" "unprognostic (2.74e-2)" "unprognostic (4.73e-2)" "unprognostic (7.26e-2)" "unprognostic (3.87e-3)" 30.2 5.7 0.7 28.2 4.0 0.1 31.7 0.6 0.9 415.7 25.7 1.6 23.9 3.0 121.8 70.9 17.4 33.0 110.3 43.9 0.7 0.1 7.5 4.6 18.8 38.5 0.7 1.2 73.6 10.5 1.0 10.7 89.1 2.2 31.5 4.0 9.2 9.1 21.0 11.0 35.5 10.6 88.0 1.3 13.7 15.0 44.6 0.7 7.7 6.7 15.5 8.7 67.3 49.7 0.2 0.0 0.0 0.0 0.0 1.1 0.0 0.3 0.2 0.9 0.1 37.7 91.8 1.6 176.2 47.9 43.9 27.6 3.5 0.8 0.0 0.4 266.1 0.3 0.5 0.4 0.1 7.9 0.2 0.3 0.0 4.4 0.2 71.8 0.0 0.0 134.8 2.6 53.7 0.2 7.3 0.0 0.2 0.1 0.0 22.1 0.4 0.0 0.0 0.9 0.6 0.5 0.3 0.1 0.1 0.2 0.0 0.1 0.5 0.3 0.2 0.0 13.7 2.2 0.0 0.0 143.2 31.3 21.4 0.8 0.1 0.3 0.0 10.7 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 4.0 0.6 0.9 0.7 0.1 0.7 1.2 2.2 0.7 8.9 14.4 0.5 11.0 166.9 0.0 4.8 0.0 5.3 12.5 7.0 0.0 29.5 0.0 11.2 0.9 5.1 0.0 0.0 3.7 26.1 2038.6 12.1 2.3 1.9 59.9 0.0 2.9 615.0 0.8 4.5 514.8 7.7 178.8 0.0 2.2 2.8 25.7 0.0 252.1 0.5 0.1 77.6 273.4 4.2 1.7 142.9 93.5 0.5 1.3 7.5 COL2A1 "AOM, SEDC, STL1" ENSG00000139219 "Collagen type II alpha 1 chain" P02458 12 47972965-48004554 "Cancer-related genes, Disease related genes, Predicted secreted proteins" "Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Stickler syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "epididymis: 22.7;pituitary gland: 11.0;retina: 8.1;stomach 1: 11.3" "Cell type enhanced" "Detected in some" 24 "Early spermatids: 12.7;Intestinal endocrine cells: 42.2;Muller glia cells: 19.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 55.2;HAP1: 34.6;HEK 293: 12.8" "Not detected" "Not detected" "Not detected" "Not detected" "CAB002214, HPA055753" Approved Approved Nucleoplasm "Secreted to extracellular matrix" No NA Nucleoplasm "CAB002214: AB_563666, HPA055753: AB_2682908" "unprognostic (7.25e-2)" "unprognostic (1.20e-1)" "unprognostic (2.58e-1)" "unprognostic (3.44e-1)" "unprognostic (2.88e-2)" "unprognostic (3.08e-2)" "unprognostic (8.63e-2)" "unprognostic (2.77e-1)" "unprognostic (1.22e-1)" "unprognostic (3.12e-2)" "unprognostic (1.31e-4)" "unprognostic (2.64e-1)" "unprognostic (3.44e-3)" "unprognostic (1.89e-1)" "unprognostic (2.93e-1)" "unprognostic (2.07e-1)" "unprognostic (1.02e-1)" 0.0 0.0 0.1 2.2 0.3 0.0 0.7 0.9 0.9 0.0 0.2 0.3 0.0 0.0 0.3 22.7 0.0 0.0 0.0 0.0 0.5 1.3 0.0 0.0 1.4 0.0 0.0 0.7 1.3 0.0 0.0 11.0 0.4 1.9 2.6 0.4 8.1 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 11.3 2.8 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.2 0.0 0.0 0.0 34.6 0.0 0.0 0.0 12.8 0.0 0.0 1.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 4.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.9 0.9 0.5 1.3 0.0 0.7 1.9 0.0 0.0 0.0 0.0 0.2 0.1 0.6 0.8 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 12.7 0.0 0.0 0.0 0.0 0.2 0.4 0.1 0.0 0.0 0.2 0.0 42.2 0.0 0.0 7.1 0.9 0.0 0.0 0.0 0.3 19.5 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.5 0.7 0.0 0.7 0.0 0.9 0.1 CREB1 ENSG00000118260 "CAMP responsive element binding protein 1" P16220 2 207529737-207603431 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Differentiation, Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enriched" "Detected in many" 6 "Early spermatids: 355.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003803, HPA019150" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB003803: AB_562092, HPA019150: AB_1847220" "unprognostic (1.20e-1)" "unprognostic (3.15e-1)" "unprognostic (3.30e-2)" "unprognostic (2.69e-2)" "unprognostic (3.16e-2)" "unprognostic (1.03e-1)" "prognostic unfavorable (2.77e-5)" "unprognostic (8.41e-2)" "unprognostic (1.04e-2)" "unprognostic (2.53e-1)" "unprognostic (9.58e-2)" "unprognostic (1.74e-2)" "unprognostic (4.82e-3)" "unprognostic (5.53e-3)" "unprognostic (1.06e-1)" "unprognostic (1.77e-1)" "unprognostic (8.45e-2)" 21.2 12.9 19.4 24.8 17.0 22.9 16.7 25.5 18.7 17.6 15.7 14.3 14.7 12.6 19.3 14.9 17.9 15.4 15.5 14.4 15.4 14.5 14.6 13.1 17.7 21.7 15.8 17.7 20.5 12.9 19.8 20.0 19.8 16.1 16.3 16.2 11.2 16.2 14.9 11.6 14.3 15.2 19.5 19.8 19.0 13.3 39.2 18.5 38.4 19.7 13.3 27.7 16.1 23.6 22.1 20.7 34.8 19.1 28.4 22.5 14.5 15.3 13.8 25.5 9.8 15.0 15.4 14.6 9.9 14.8 17.2 18.1 13.9 15.6 10.0 13.3 14.5 20.2 13.4 23.1 13.5 25.3 15.9 8.3 18.3 12.3 14.2 12.6 17.3 13.5 11.1 10.0 14.2 21.1 17.2 24.1 18.7 12.8 14.6 21.2 10.6 26.2 10.2 18.2 15.4 8.4 20.5 13.9 13.1 15.4 15.9 17.6 15.3 13.7 10.1 11.9 25.5 11.3 18.9 11.5 14.1 15.1 14.7 12.6 13.2 16.7 23.0 17.3 15.9 14.7 16.9 17.0 16.8 17.3 18.0 15.4 22.1 16.6 16.7 20.7 20.2 19.9 13.5 34.8 28.4 19.1 11.3 22.5 14.5 19.4 17.0 25.5 18.7 15.4 14.5 15.8 17.7 16.1 18.5 17.9 12.8 45.4 39.6 63.0 36.1 22.1 12.7 9.4 25.0 12.2 31.4 24.5 19.9 20.2 355.9 44.6 20.0 0.0 17.9 21.7 32.3 41.9 42.7 14.3 25.7 38.1 31.2 31.3 43.4 27.4 24.2 38.0 42.2 36.9 24.2 40.0 21.9 23.5 27.6 15.6 36.9 38.8 34.1 24.7 27.5 50.6 15.6 31.9 23.0 54.8 CREB3L1 OASIS ENSG00000157613 "CAMP responsive element binding protein 3 like 1" Q96BA8 11 46277661-46321422 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation, Unfolded protein response" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Osteogenesis imperfecta" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 60.7" "Cell type enhanced" "Detected in many" 14 "Mucus-secreting cells: 277.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 30.1;BJ hTERT+: 29.5;BJ hTERT+ SV40 Large T+: 27.6;fHDF/TERT166: 71.5;OE19: 28.4" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "HPA024069, CAB026151" Enhanced NA NA "CAB026151: , HPA024069: AB_1854750" "unprognostic (2.46e-2)" "unprognostic (2.80e-1)" "unprognostic (1.34e-1)" "prognostic favorable (3.92e-4)" "unprognostic (1.66e-3)" "unprognostic (2.93e-1)" "unprognostic (5.41e-2)" "unprognostic (2.75e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-1)" "unprognostic (1.54e-1)" "unprognostic (1.87e-1)" "prognostic unfavorable (2.97e-4)" "unprognostic (2.62e-1)" "unprognostic (1.93e-1)" "prognostic unfavorable (8.59e-4)" "unprognostic (1.12e-2)" 2.5 3.6 3.7 3.1 2.3 0.0 3.0 1.6 2.9 17.2 13.1 0.9 9.5 8.6 9.7 9.2 2.2 1.7 37.6 4.8 3.3 3.5 1.4 1.5 10.4 0.5 3.4 1.7 9.7 60.7 0.0 3.3 8.2 0.6 17.6 14.1 1.8 28.3 14.3 1.6 2.3 12.9 12.8 1.8 2.2 22.1 3.8 0.2 0.4 1.8 2.2 13.0 15.1 3.4 0.0 0.1 0.0 0.4 0.1 0.0 0.0 0.2 0.1 0.3 5.9 19.1 18.3 0.1 30.1 29.5 27.6 19.2 3.0 0.0 0.0 0.1 71.5 1.9 0.0 0.3 0.0 15.4 0.0 0.3 0.4 0.1 0.0 26.6 0.0 0.4 17.6 0.0 15.6 0.5 25.1 0.2 0.1 2.4 0.0 23.1 0.0 0.0 0.0 3.8 28.4 3.1 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 5.6 0.0 1.0 0.0 14.5 4.3 11.1 18.3 0.0 0.0 0.0 17.3 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 3.7 2.3 1.6 2.9 3.3 3.5 3.4 1.7 0.6 0.2 0.0 39.0 0.0 35.2 1.3 0.0 14.6 15.3 5.3 4.5 27.9 0.0 0.7 3.3 38.7 1.0 1.3 18.0 0.0 79.2 1.7 61.0 50.4 4.6 0.0 1.7 0.0 8.7 5.5 0.0 3.9 77.3 1.8 10.1 3.6 277.8 0.0 45.1 42.1 41.8 0.5 0.0 0.0 3.6 0.9 1.1 1.9 2.9 0.0 48.7 36.7 CREB3L2 "BBF2H7, TCAG_1951439" ENSG00000182158 "CAMP responsive element binding protein 3 like 2" Q70SY1 7 137874979-138002067 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Unfolded protein response" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 81.6" "Cell type enhanced" "Detected in many" 5 "Syncytiotrophoblasts: 120.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA015068, HPA015534" Enhanced Supported "Nucleoplasm,Endoplasmic reticulum" NA NA "Nucleoplasm, Endoplasmic reticulum" "HPA015068: AB_1847224, HPA015534: AB_2669210" "unprognostic (8.50e-2)" "unprognostic (3.70e-2)" "unprognostic (2.77e-1)" "unprognostic (1.50e-3)" "unprognostic (9.88e-2)" "unprognostic (9.09e-2)" "unprognostic (5.17e-2)" "unprognostic (4.50e-1)" "unprognostic (4.77e-1)" "unprognostic (8.93e-2)" "unprognostic (9.48e-2)" "unprognostic (9.65e-2)" "unprognostic (2.42e-1)" "unprognostic (3.08e-3)" "unprognostic (7.65e-2)" "unprognostic (2.59e-2)" "unprognostic (1.32e-2)" 14.9 19.8 4.7 17.1 9.8 10.8 15.7 1.9 6.0 25.4 16.7 11.4 18.7 11.6 28.2 25.5 12.8 16.2 16.2 20.4 5.6 4.3 17.0 11.7 14.6 15.2 11.8 3.7 25.9 16.0 38.4 28.8 81.6 9.8 15.9 9.5 24.9 26.5 23.3 5.0 6.9 17.5 17.7 6.2 12.1 14.1 9.8 9.1 7.0 35.8 10.9 18.1 21.3 15.7 4.6 12.4 7.4 5.6 6.5 11.8 3.2 4.0 6.3 12.0 0.2 20.5 20.4 9.0 20.4 33.0 14.3 14.5 8.6 3.7 0.8 5.5 22.1 7.8 2.2 7.0 14.9 28.0 5.9 3.5 25.7 8.6 20.5 13.6 7.7 36.9 8.4 9.5 18.0 21.1 14.7 18.8 2.1 13.2 12.0 16.7 7.3 2.4 9.5 4.3 5.6 4.5 5.4 6.5 6.8 11.2 4.2 3.1 7.2 6.6 17.1 9.1 7.3 2.5 5.8 20.0 19.2 2.9 23.1 7.4 14.2 4.9 5.3 23.0 21.8 42.5 7.4 5.6 5.9 8.2 2.9 10.6 4.0 6.0 8.6 5.8 4.6 2.2 3.8 2.1 6.5 1.5 12.4 11.8 3.2 4.7 9.8 1.9 6.0 5.6 4.3 11.8 3.7 9.8 9.1 6.0 20.4 20.6 8.1 10.9 7.2 14.1 20.4 10.7 18.2 22.7 9.8 50.6 11.6 9.3 48.0 20.2 32.0 0.0 15.3 76.5 40.4 27.0 48.5 24.5 49.4 14.3 15.1 30.1 33.2 14.1 57.2 25.1 25.3 10.0 17.0 6.7 15.1 17.3 96.9 9.1 12.4 38.8 42.4 1.1 4.3 6.1 120.8 27.3 14.9 17.2 CREBBP "CBP, KAT3A, RSTS, RTS" ENSG00000005339 "CREB binding protein" Q92793 16 3725054-3880726 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004212, HPA055861" Supported Enhanced "Nucleoplasm,Nuclear bodies" No No Nucleoplasm "Nuclear bodies" "CAB004212: AB_626817, HPA055861: AB_2682948" "unprognostic (1.17e-1)" "unprognostic (8.51e-2)" "unprognostic (1.60e-1)" "unprognostic (1.63e-1)" "unprognostic (1.49e-1)" "unprognostic (5.09e-2)" "unprognostic (9.59e-3)" "unprognostic (6.98e-2)" "unprognostic (8.96e-2)" "unprognostic (1.08e-1)" "unprognostic (1.76e-1)" "unprognostic (2.84e-1)" "prognostic favorable (6.24e-5)" "unprognostic (1.47e-1)" "unprognostic (1.74e-1)" "unprognostic (3.97e-2)" "unprognostic (8.23e-2)" 18.5 10.9 17.2 22.8 17.5 37.0 17.4 42.6 18.8 20.1 17.2 16.8 17.1 9.9 25.1 15.2 14.1 18.9 21.3 14.5 17.1 8.7 11.1 12.3 16.9 14.4 20.5 12.0 31.6 23.4 24.3 13.0 13.3 15.8 18.4 11.6 14.6 14.9 16.7 28.2 20.4 16.4 17.0 13.6 17.4 14.7 29.1 20.2 29.6 19.5 13.8 16.1 19.0 29.9 4.7 2.3 10.6 3.8 2.0 2.7 1.1 5.6 14.5 18.8 8.3 11.5 11.4 9.8 8.1 13.7 14.0 13.7 13.1 10.6 15.6 9.7 15.5 9.0 10.9 21.6 6.7 16.0 26.3 8.7 12.2 13.4 8.3 12.8 12.2 17.6 10.1 6.8 15.6 18.9 8.7 10.5 8.0 13.9 21.4 7.6 19.3 8.1 5.9 15.4 5.4 6.0 38.3 14.9 11.9 5.4 7.6 15.7 10.3 13.9 13.7 8.2 12.7 12.2 12.0 16.3 17.2 17.2 8.8 7.4 10.0 10.8 30.3 3.5 7.3 12.1 2.9 1.7 1.3 2.7 2.2 1.4 4.7 1.3 2.0 1.0 3.3 1.4 1.7 10.6 2.0 3.8 2.3 1.3 1.1 17.2 17.5 42.6 18.8 17.1 8.7 20.5 12.0 15.8 20.2 41.7 45.9 13.8 25.5 49.9 31.9 37.0 43.3 32.1 33.0 10.4 23.6 14.6 5.0 17.4 38.0 35.3 24.0 0.0 17.7 9.4 24.3 32.2 30.0 25.1 17.8 27.0 14.5 32.5 38.7 57.1 52.3 33.5 16.9 27.9 22.4 31.4 22.7 17.3 48.1 10.7 15.8 45.3 36.0 33.1 46.0 51.4 25.7 35.9 23.8 31.6 CRLF2 "CRL2, TSLPR" ENSG00000205755 "Cytokine receptor like factor 2" Q9HC73 X 1187549-1212750 "Cancer-related genes, Predicted membrane proteins" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 7.8" "Cell type enriched" "Detected in some" 9 "monocytes: 174.9" "Cancer enhanced" "Detected in single" "thyroid cancer: 1.0" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 43 "plasmacytoid DC: 4.3" "Lineage enriched" "Detected in single" 43 "dendritic cells: 4.3" "Cell line enhanced" "Detected in some" "GAMG: 2.4;HMC-1: 18.5;RPMI-8226: 4.7;U-698: 4.0" "Intracellular and membrane" NA NA "unprognostic (7.84e-2)" "unprognostic (7.99e-4)" "unprognostic (6.02e-3)" "unprognostic (2.01e-2)" "unprognostic (1.15e-3)" "unprognostic (2.31e-6)" "unprognostic (1.72e-1)" "unprognostic (5.10e-2)" "unprognostic (4.59e-3)" "unprognostic (1.09e-1)" "unprognostic (1.46e-2)" "unprognostic (9.72e-3)" "unprognostic (6.88e-5)" "unprognostic (7.09e-3)" "unprognostic (4.81e-2)" "unprognostic (2.89e-2)" "unprognostic (1.62e-1)" 0.8 0.0 0.2 4.1 0.2 4.1 0.6 0.2 0.2 3.0 0.7 0.2 0.2 0.2 7.8 0.2 0.9 0.2 3.7 0.2 0.2 0.1 0.9 0.2 1.9 0.2 0.2 0.2 0.2 0.2 0.0 0.2 1.0 0.2 0.6 0.9 0.2 0.8 0.2 0.2 0.7 1.5 0.3 0.2 0.6 1.0 0.2 0.2 0.2 0.2 0.2 1.4 1.3 0.6 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.5 0.0 0.6 1.0 0.2 0.3 2.4 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 18.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.5 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.7 1.0 4.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 3.0 3.4 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 19.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 174.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CRTC1 "FLJ14027, KIAA0616, MECT1, TORC1" ENSG00000105662 "CREB regulated transcription coactivator 1" Q6UUV9 19 18683677-18782333 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 40.7" "Cell type enhanced" "Detected in many" 6 "Horizontal cells: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA022035, HPA063619" Enhanced Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Nuclear bodies" "Plasma membrane, Cytosol" "HPA022035: AB_1847255, HPA063619: " "unprognostic (5.95e-3)" "unprognostic (2.57e-1)" "unprognostic (9.94e-2)" "unprognostic (8.62e-3)" "unprognostic (9.07e-2)" "unprognostic (1.57e-2)" "unprognostic (1.04e-1)" "unprognostic (5.57e-2)" "unprognostic (2.27e-1)" "unprognostic (6.68e-2)" "prognostic favorable (1.80e-5)" "unprognostic (3.37e-2)" "prognostic favorable (3.83e-5)" "unprognostic (6.83e-3)" "unprognostic (1.02e-1)" "unprognostic (2.51e-2)" "unprognostic (2.03e-2)" 8.6 7.7 26.0 7.4 38.8 3.2 3.8 40.7 30.1 5.0 4.4 6.5 4.3 6.5 6.8 5.6 3.1 10.5 5.5 5.6 17.7 7.8 6.6 4.5 5.7 6.3 6.4 18.1 6.7 10.0 8.4 11.3 6.4 6.0 7.0 2.6 5.1 8.8 9.4 12.4 5.5 6.2 4.3 4.8 8.1 8.0 7.5 10.2 1.9 7.4 1.1 3.7 4.6 3.5 4.1 3.8 1.8 3.4 1.1 3.0 1.3 4.4 8.1 5.9 9.4 5.5 4.6 16.7 4.9 3.3 4.7 4.5 5.4 5.8 6.2 10.4 4.6 3.3 4.8 1.8 3.0 1.1 2.7 14.1 5.2 7.2 8.9 5.3 7.1 14.6 7.5 2.9 4.0 1.2 6.2 2.6 6.4 4.1 5.7 2.6 16.1 4.6 8.1 7.6 2.3 11.9 7.3 2.6 6.8 2.9 7.9 10.8 9.7 5.5 5.2 5.8 2.0 5.8 4.3 4.7 5.3 8.2 9.7 5.6 3.8 3.0 4.1 6.2 7.7 4.0 1.5 3.4 1.8 1.7 1.3 1.8 2.3 2.7 3.0 3.0 4.1 2.3 1.8 1.7 1.1 1.9 3.8 1.8 1.3 26.0 38.8 40.7 30.1 17.7 7.8 6.4 18.1 6.0 10.2 0.0 4.0 4.2 9.5 2.4 24.9 14.0 5.1 2.7 2.3 17.4 25.5 8.5 10.0 3.6 0.7 4.5 5.1 0.0 5.3 2.1 5.4 3.0 2.3 3.4 7.8 41.3 18.4 1.3 5.4 1.7 8.6 3.7 3.3 1.8 6.9 8.9 2.6 8.6 4.6 4.3 14.1 0.0 8.2 2.9 7.2 1.8 8.7 5.1 4.8 2.5 CRTC3 FLJ21868 ENSG00000140577 "CREB regulated transcription coactivator 3" Q6UUV7 15 90529925-90645345 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 16.0" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 40.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043735, HPA063691" Uncertain Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA043735: AB_10794286, HPA063691: AB_2685092" "unprognostic (7.60e-2)" "unprognostic (6.13e-2)" "unprognostic (1.35e-1)" "unprognostic (2.31e-2)" "unprognostic (5.12e-2)" "unprognostic (3.51e-1)" "unprognostic (1.75e-2)" "unprognostic (1.69e-1)" "unprognostic (6.48e-2)" "unprognostic (3.60e-1)" "unprognostic (1.47e-1)" "unprognostic (2.23e-1)" "unprognostic (5.22e-3)" "unprognostic (4.67e-2)" "unprognostic (9.32e-2)" "unprognostic (9.51e-2)" "unprognostic (2.30e-1)" 22.3 14.0 13.7 17.0 20.9 11.4 26.6 15.0 16.2 21.2 22.2 27.5 15.3 8.9 23.9 14.5 15.1 19.4 21.5 17.2 14.0 9.7 10.7 11.7 19.2 21.7 24.1 10.9 45.9 13.9 17.1 9.6 20.2 15.7 18.2 11.7 17.4 19.9 22.0 16.1 15.8 13.7 31.8 20.3 13.1 14.2 15.3 23.6 12.8 22.7 9.2 18.1 24.0 29.6 5.3 2.1 16.0 2.5 3.3 6.6 3.0 4.8 8.0 5.5 8.9 11.9 8.8 25.1 6.2 9.0 9.8 9.3 6.6 4.9 0.1 4.5 12.8 8.1 8.2 8.8 5.4 7.7 8.4 10.2 12.3 40.0 3.0 13.5 3.2 21.1 9.9 8.7 8.1 10.9 7.2 7.0 5.5 6.5 2.8 7.2 5.6 1.3 4.6 2.0 1.4 3.7 4.2 8.8 0.2 3.5 10.3 10.1 8.9 18.1 6.0 10.1 6.0 6.0 6.0 8.6 10.9 8.0 10.0 7.1 3.8 5.1 3.7 4.5 6.4 5.2 16.0 2.5 1.4 3.7 0.8 4.2 3.1 4.5 4.0 1.6 5.3 6.6 4.1 0.5 3.3 0.3 2.1 4.2 3.0 13.7 20.9 15.0 16.2 14.0 9.7 24.1 10.9 15.7 23.6 6.0 8.6 37.4 23.2 20.9 21.6 13.4 17.8 0.0 4.5 12.2 25.5 12.1 1.7 12.0 22.9 18.0 6.4 0.0 9.4 36.5 23.1 23.5 23.1 13.5 13.5 54.0 15.0 20.9 19.7 14.7 24.7 21.3 16.9 8.2 10.0 20.4 9.0 10.5 41.1 8.4 55.7 45.3 38.4 7.7 16.5 21.0 14.9 30.5 11.3 31.1 CSF3R "CD114, GCSFR" ENSG00000119535 "Colony stimulating factor 3 receptor" Q99062 1 36466043-36483278 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7" "Cell type enhanced" "Detected in many" 27 "Alveolar cells type 2: 228.0;Cytotrophoblasts: 271.6;Syncytiotrophoblasts: 999.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 8 "neutrophil: 167.3" "Lineage enriched" "Detected in many" 8 "granulocytes: 167.3" "Group enriched" "Detected in some" 18 "BEWO: 34.9;NB-4: 9.4;THP-1: 22.9;U-937: 22.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB017116, HPA048086" Enhanced "Intracellular and membrane" NA NA "CAB017116: , HPA048086: AB_2680257" "unprognostic (5.57e-3)" "unprognostic (8.05e-2)" "unprognostic (7.23e-2)" "unprognostic (3.87e-2)" "unprognostic (2.88e-1)" "unprognostic (2.92e-2)" "unprognostic (2.86e-2)" "unprognostic (1.35e-1)" "unprognostic (1.83e-1)" "unprognostic (5.65e-2)" "unprognostic (2.47e-1)" "unprognostic (3.44e-1)" "prognostic unfavorable (5.72e-4)" "unprognostic (6.33e-2)" "prognostic unfavorable (3.79e-4)" "unprognostic (2.03e-1)" "unprognostic (2.31e-2)" 8.5 1.5 2.9 39.5 3.2 88.9 2.4 0.7 2.9 1.1 1.1 4.2 0.4 0.6 0.7 1.1 1.2 6.9 4.3 5.6 2.6 2.0 1.7 4.5 26.9 27.5 7.2 1.1 1.1 1.3 0.3 1.1 152.7 3.8 1.3 0.5 2.1 1.6 0.5 0.6 0.3 1.6 3.1 7.1 71.4 2.2 1.4 3.3 1.1 1.0 0.4 0.9 4.6 3.9 0.0 8.2 167.3 22.1 0.2 0.0 10.3 0.0 0.0 0.0 0.0 0.0 0.0 34.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.9 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 9.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.0 22.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 22.1 0.0 0.0 22.1 0.6 0.0 4.8 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 167.3 0.2 1.8 0.2 0.0 10.3 2.9 3.2 0.7 2.9 2.6 2.0 7.2 1.1 3.8 3.3 23.8 228.0 2.4 0.6 0.9 0.0 1.4 0.0 12.0 18.2 0.0 0.0 271.6 0.0 0.0 0.4 1.9 0.0 0.0 0.0 49.1 3.0 0.2 17.4 0.8 60.8 0.0 0.0 3.7 146.3 0.4 0.3 62.6 0.0 3.6 0.0 0.2 0.1 0.0 0.0 0.4 0.2 0.0 0.3 0.0 0.2 0.1 999.2 0.5 0.0 2.2 CTCF ENSG00000102974 "CCCTC-binding factor" P49711 16 67562407-67639185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Chromosome partition, Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004122, CAB062550, CAB068181, CAB068182" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB062550: AB_2665624, CAB068181: AB_2665625, CAB068182: AB_2665626, HPA004122: AB_2667139" "unprognostic (2.70e-1)" "unprognostic (4.21e-2)" "unprognostic (3.41e-2)" "unprognostic (4.70e-2)" "unprognostic (4.41e-2)" "unprognostic (2.70e-1)" "prognostic unfavorable (4.21e-4)" "unprognostic (1.71e-2)" "unprognostic (1.29e-1)" "unprognostic (1.14e-1)" "unprognostic (1.36e-2)" "unprognostic (1.99e-2)" "prognostic favorable (4.06e-4)" "unprognostic (3.47e-1)" "unprognostic (5.99e-2)" "unprognostic (4.58e-2)" "unprognostic (1.11e-2)" 19.1 17.5 22.3 35.0 24.3 32.2 20.2 31.6 26.6 23.0 19.4 20.5 21.0 16.5 24.2 15.4 23.1 21.7 20.3 17.6 21.8 16.7 19.5 19.5 17.2 27.9 22.3 21.0 24.6 21.2 42.4 21.8 23.5 17.9 19.4 23.2 14.3 19.9 24.9 29.4 25.2 21.4 22.0 20.2 26.1 18.5 14.8 22.9 68.8 20.7 16.2 35.5 22.6 26.7 10.1 7.9 9.6 6.2 4.9 7.2 1.9 11.0 17.1 22.8 9.0 10.4 8.9 18.5 10.6 11.3 15.7 15.0 14.0 11.5 34.7 8.6 9.2 8.9 14.4 21.9 11.9 17.7 12.3 14.4 21.1 9.7 16.0 7.1 23.8 20.2 7.2 14.5 11.7 13.1 9.4 11.9 27.9 18.4 14.5 13.0 21.7 50.0 9.1 19.8 12.7 11.5 36.6 18.7 19.1 9.6 16.1 19.5 13.5 19.2 11.2 9.3 12.5 13.8 14.8 11.3 13.6 14.1 10.3 11.6 12.7 15.9 50.6 7.8 14.3 14.5 9.4 3.4 4.9 6.7 3.4 6.3 7.9 7.2 5.4 3.1 10.1 5.9 6.7 9.6 4.9 6.2 7.9 5.4 1.9 22.3 24.3 31.6 26.6 21.8 16.7 22.3 21.0 17.9 22.9 20.8 28.0 26.8 21.6 19.8 33.6 32.3 38.2 17.4 38.7 22.7 7.9 20.9 16.6 25.5 0.9 30.1 18.7 46.7 29.1 27.5 18.8 26.1 18.5 21.3 20.8 42.9 30.0 20.3 23.2 2.0 23.0 23.7 11.8 24.4 25.6 30.4 26.6 14.0 26.9 19.5 27.1 19.4 21.7 15.8 25.6 21.7 24.7 32.3 21.2 29.4 CTNNB1 "armadillo, beta-catenin, CTNNB" ENSG00000168036 "Catenin beta 1" P35222 3 41194741-41260096 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation, Wnt signaling pathway" Activator "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Syncytiotrophoblasts: 451.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000108, CAB001950, HPA029159, HPA029160" Supported Enhanced "Plasma membrane" NA NA 1000000 "Plasma membrane" "CAB000108: , CAB001950: , HPA029159: AB_10599619, HPA029160: AB_10600996" "unprognostic (2.47e-1)" "unprognostic (3.48e-2)" "prognostic favorable (7.54e-4)" "unprognostic (1.61e-1)" "unprognostic (9.55e-2)" "unprognostic (1.05e-2)" "unprognostic (3.20e-3)" "unprognostic (2.79e-1)" "unprognostic (1.57e-1)" "unprognostic (1.80e-2)" "unprognostic (1.88e-2)" "unprognostic (9.05e-2)" "unprognostic (1.97e-3)" "unprognostic (1.82e-2)" "unprognostic (1.17e-1)" "unprognostic (2.61e-1)" "unprognostic (9.79e-2)" 52.9 54.5 38.8 33.5 45.9 46.3 70.5 78.8 59.3 71.7 49.6 57.3 34.2 48.7 79.2 42.5 46.3 49.8 45.0 42.1 38.6 41.5 46.9 53.2 53.6 31.6 37.0 47.0 84.2 38.6 59.2 44.0 82.6 41.5 50.8 50.1 75.9 53.9 49.7 31.2 44.7 70.4 66.5 39.4 41.0 37.3 29.0 39.3 40.1 62.3 44.5 36.6 46.9 54.2 10.1 13.5 7.5 14.5 11.1 13.5 4.8 22.5 30.0 63.3 35.4 34.1 28.0 48.6 25.4 36.1 42.5 42.3 20.7 32.2 18.5 23.2 44.9 19.1 16.9 45.8 73.4 45.6 17.1 31.2 29.8 39.9 73.8 25.5 16.9 14.4 40.8 33.3 50.8 30.9 34.8 37.3 8.9 21.1 11.5 47.1 22.8 11.8 9.1 57.6 30.1 23.3 8.9 41.2 12.3 26.3 70.4 15.1 25.6 42.1 21.5 113.0 78.5 35.2 35.2 48.1 32.0 24.5 20.5 37.2 7.2 11.1 19.7 32.8 21.3 53.4 4.3 8.1 6.9 11.2 14.5 13.5 9.6 10.5 12.1 13.5 10.1 10.7 10.8 7.5 11.1 13.7 11.7 12.6 4.8 38.8 45.9 78.8 59.3 38.6 41.5 37.0 47.0 41.5 39.3 128.1 177.9 34.4 112.8 189.7 38.8 66.6 99.3 119.1 161.5 59.3 31.4 274.7 29.9 114.0 5.5 164.1 147.7 46.7 68.4 90.6 121.0 101.1 113.2 146.9 108.7 12.7 90.0 114.2 130.0 5.0 55.3 139.8 192.3 115.4 132.0 103.7 102.3 182.4 81.7 57.4 56.6 45.3 106.2 71.5 40.7 152.9 451.2 62.8 118.4 109.3 CUX1 "CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6" ENSG00000257923 "Cut like homeobox 1" "P39880, Q13948" 7 101815904-102283958 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation, Transport" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "non-classical monocyte: 21.0" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003277, HPA003317" Approved Supported "Nucleoplasm,Golgi apparatus" NA NA "Nucleoplasm, Golgi apparatus" "HPA003277: AB_10601804, HPA003317: AB_2666891" "unprognostic (5.86e-2)" "unprognostic (5.39e-3)" "unprognostic (9.62e-3)" "unprognostic (1.73e-1)" "prognostic unfavorable (7.51e-4)" "unprognostic (5.85e-2)" "unprognostic (1.54e-1)" "unprognostic (1.04e-1)" "unprognostic (1.50e-1)" "unprognostic (2.89e-3)" "unprognostic (2.20e-1)" "unprognostic (2.50e-1)" "prognostic favorable (5.72e-7)" "unprognostic (1.12e-1)" "unprognostic (8.85e-2)" "unprognostic (1.97e-2)" "unprognostic (2.97e-1)" 19.3 12.7 22.9 19.2 24.4 19.5 12.3 48.6 29.9 31.6 26.4 23.1 17.3 22.2 52.1 17.4 23.9 24.5 23.2 53.8 18.8 18.3 27.4 16.0 22.0 11.8 20.4 11.7 33.0 41.4 34.4 30.2 24.4 16.9 22.8 17.2 26.8 26.3 16.9 31.0 15.9 25.3 27.5 31.6 15.0 23.4 8.3 17.1 44.0 33.5 23.2 24.1 31.8 21.9 2.0 12.1 4.7 21.0 3.0 2.2 4.5 14.5 15.6 11.0 13.7 9.0 18.6 6.9 14.7 15.6 6.2 4.1 9.3 9.4 18.9 23.6 14.5 11.5 12.0 7.0 11.8 3.7 9.0 7.8 6.6 11.6 7.7 23.9 8.5 3.6 12.9 24.1 4.8 10.9 17.9 8.0 12.2 15.3 16.0 5.8 30.0 27.8 10.5 4.5 22.5 16.4 18.4 9.2 22.3 10.2 16.7 10.2 30.3 12.8 32.2 12.5 9.6 6.3 10.3 11.9 26.3 17.8 19.8 8.3 10.5 4.9 40.8 24.3 7.9 18.3 2.1 8.6 1.5 2.1 8.8 2.2 2.0 1.6 2.2 7.0 1.7 1.6 2.2 4.7 3.0 21.0 12.1 1.5 4.5 22.9 24.4 48.6 29.9 18.8 18.3 20.4 11.7 16.9 17.1 92.3 45.5 28.3 27.6 23.4 53.5 101.2 28.1 46.8 45.5 38.4 64.8 44.1 8.3 29.7 7.2 31.1 49.5 0.0 20.8 48.4 40.9 44.0 11.5 30.9 29.9 50.9 40.8 32.5 70.3 7.4 38.3 36.4 16.9 25.2 44.2 49.6 28.5 54.3 57.3 53.1 57.1 25.8 24.5 12.0 13.8 37.9 73.6 20.8 37.2 42.8 CXCR4 "CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R" ENSG00000121966 "C-X-C motif chemokine receptor 4" P61073 2 136114349-136118165 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 149.9;lymphoid tissue: 186.3" "Cell type enhanced" "Detected in many" 14 "B-cells: 772.9;Macrophages: 299.5;monocytes: 255.1;T-cells: 588.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 76.4;JURKAT: 43.5;Karpas-707: 41.0;MOLT-4: 69.2;REH: 36.7;U-266/70: 88.9;U-698: 89.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "unprognostic (1.19e-1)" "unprognostic (1.46e-2)" "unprognostic (2.69e-1)" "unprognostic (5.97e-2)" "unprognostic (1.29e-2)" "unprognostic (1.12e-2)" "unprognostic (4.99e-2)" "unprognostic (9.25e-2)" "unprognostic (6.06e-2)" "prognostic favorable (2.05e-4)" "unprognostic (1.23e-1)" "unprognostic (2.66e-1)" "prognostic unfavorable (1.41e-7)" "prognostic unfavorable (5.67e-4)" "unprognostic (1.57e-1)" "unprognostic (3.47e-2)" "unprognostic (9.33e-2)" 15.4 26.5 3.0 39.1 3.4 149.9 9.7 0.8 2.1 7.7 8.7 6.8 1.5 1.6 8.3 3.8 16.4 9.1 12.0 5.4 4.1 4.7 8.2 7.1 29.3 94.5 6.5 1.3 6.3 3.1 0.7 8.1 7.8 6.1 6.8 7.0 10.0 10.6 2.2 3.2 2.3 57.8 3.8 22.9 82.4 8.0 7.2 3.4 186.3 9.2 4.6 97.5 50.0 6.6 47.3 16.8 37.8 7.2 4.0 32.0 11.9 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 76.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 3.8 0.9 4.6 12.1 0.0 0.0 10.5 8.3 0.0 0.0 0.0 0.0 0.0 7.3 43.5 0.1 41.0 0.0 0.2 69.2 9.4 1.2 5.9 0.4 36.7 8.5 13.3 0.6 0.0 4.2 3.5 0.0 0.2 0.0 0.4 0.0 20.7 1.0 0.0 0.2 0.0 0.0 88.9 15.0 89.4 0.0 17.4 0.0 17.9 7.2 29.6 22.9 3.8 18.7 30.1 21.1 21.7 6.6 47.3 32.0 30.1 37.8 4.0 2.1 16.8 18.9 11.9 3.0 3.4 0.8 2.1 4.1 4.7 6.5 1.3 6.1 3.4 14.9 64.2 772.9 4.0 36.5 4.4 3.6 2.5 4.0 6.8 3.5 0.0 1.4 11.6 3.6 0.9 19.0 0.0 46.7 0.8 2.2 30.2 4.8 11.6 5.5 168.4 0.0 1.7 22.7 175.5 1.7 1.4 299.5 108.0 255.1 0.1 1.0 1.6 0.0 2.5 2.1 0.6 45.3 16.3 0.5 5.5 31.1 5.3 588.4 0.4 3.2 CYLD "CYLD1, KIAA0849, USPL2" ENSG00000083799 "CYLD lysine 63 deubiquitinase" Q9NQC7 16 50742050-50801935 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Immunity, Innate immunity, Ubl conjugation pathway, Wnt signaling pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 47.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011713, HPA050095" Approved Supported "Nucleoplasm,Centriolar satellite" Yes No "Centriolar satellite" Nucleoplasm "CAB011713: AB_731794, HPA050095: AB_2681013" "unprognostic (9.83e-2)" "unprognostic (1.17e-2)" "unprognostic (5.01e-2)" "unprognostic (2.83e-2)" "unprognostic (3.84e-1)" "unprognostic (5.06e-2)" "unprognostic (3.87e-2)" "unprognostic (3.24e-2)" "unprognostic (9.46e-2)" "unprognostic (1.11e-1)" "unprognostic (1.18e-2)" "unprognostic (2.32e-1)" "unprognostic (1.03e-1)" "unprognostic (1.07e-1)" "unprognostic (3.43e-2)" "unprognostic (6.83e-2)" "unprognostic (8.42e-2)" 9.3 16.2 13.9 22.9 26.4 51.1 9.1 14.2 20.9 9.2 10.3 18.8 12.8 10.2 16.1 8.1 15.3 8.5 13.3 12.7 15.7 17.0 9.4 13.2 15.6 30.7 16.3 14.3 11.5 12.2 20.3 27.8 9.8 20.0 11.0 12.7 13.3 12.6 10.9 31.7 12.4 14.2 12.5 16.3 23.4 12.4 22.6 13.7 16.9 16.2 8.0 29.3 14.1 12.6 9.2 10.2 31.4 9.8 13.6 19.1 10.2 9.3 2.9 3.4 3.8 5.4 7.8 3.1 13.8 20.2 14.4 8.5 2.4 4.4 10.7 5.0 13.5 15.7 3.6 4.0 8.4 21.5 47.2 6.1 5.3 5.2 2.0 10.7 5.3 25.3 8.5 6.8 17.4 18.2 13.7 5.8 7.6 2.2 9.4 20.1 1.4 5.2 7.7 3.6 2.9 4.9 4.7 6.9 10.3 4.7 3.2 4.4 3.3 11.7 4.0 3.4 5.4 4.0 6.7 6.5 24.7 5.6 8.6 5.6 24.8 23.5 12.0 18.1 6.0 5.2 31.4 8.6 20.8 10.7 9.8 12.9 9.2 15.8 14.4 10.2 6.2 14.7 11.4 19.4 13.6 9.5 6.2 19.1 10.2 13.9 26.4 14.2 20.9 15.7 17.0 16.3 14.3 20.0 13.7 41.7 25.6 39.6 48.8 106.7 75.4 32.7 25.5 12.0 19.4 17.4 88.4 5.4 5.0 18.3 32.8 37.9 13.4 46.7 16.5 3.8 37.2 52.3 78.5 22.1 19.0 63.5 29.9 21.5 32.3 24.7 23.6 47.1 70.9 34.3 10.3 22.6 15.2 18.7 19.8 10.3 49.3 6.5 34.4 52.6 13.8 135.9 3.4 73.4 12.0 56.3 DAXX DAP6 ENSG00000204209 "Death domain associated protein" Q9UER7 6 33318558-33323016 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Host-virus interaction, Transcription, Transcription regulation" "Chaperone, Chromatin regulator, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002224, HPA008736, HPA008797, CAB025546, HPA065779" Enhanced Enhanced "Nucleoplasm,Nuclear bodies" NA NA "Nucleoplasm, Nuclear bodies" "CAB002224: AB_563688, CAB025546: , HPA008736: AB_1078625, HPA008797: AB_2797218, HPA065779: AB_2685558" "prognostic favorable (6.05e-4)" "unprognostic (2.90e-1)" "unprognostic (9.66e-2)" "unprognostic (4.04e-2)" "unprognostic (8.55e-2)" "unprognostic (1.36e-1)" "unprognostic (1.46e-3)" "unprognostic (3.48e-1)" "unprognostic (1.92e-1)" "unprognostic (8.58e-3)" "unprognostic (1.34e-1)" "unprognostic (2.01e-2)" "prognostic unfavorable (6.32e-7)" "unprognostic (2.43e-1)" "unprognostic (5.37e-1)" "unprognostic (1.26e-1)" "unprognostic (1.04e-1)" 10.4 14.3 10.7 13.5 11.9 8.8 10.8 11.3 14.8 11.8 12.2 9.4 7.3 11.2 13.2 43.7 13.5 12.6 12.1 9.1 9.7 7.3 9.2 12.0 10.3 18.3 10.2 8.5 13.8 18.6 24.4 10.4 11.6 11.6 13.0 14.1 7.3 10.7 15.2 14.8 11.6 12.7 15.5 8.1 20.4 10.5 20.2 11.5 25.0 16.1 6.8 30.9 11.5 10.9 17.0 5.9 12.6 11.2 15.3 18.2 21.8 2.1 0.0 7.1 2.8 1.2 2.3 4.7 7.0 22.9 17.9 13.2 0.8 2.4 6.9 2.5 5.4 20.5 1.3 0.1 5.7 16.6 8.2 15.6 9.0 12.4 11.1 3.9 9.6 2.6 6.0 8.5 2.0 5.3 5.3 0.5 4.5 5.0 4.5 5.5 5.2 3.8 21.3 0.4 0.1 3.3 5.9 0.1 7.7 1.4 0.7 8.5 2.2 0.0 0.4 3.7 3.5 2.2 0.2 5.9 4.4 5.6 0.2 0.1 7.8 16.2 14.9 3.3 4.4 4.7 7.8 7.5 12.6 16.3 8.0 18.2 16.6 15.4 15.8 5.9 17.0 13.9 14.1 7.4 15.3 11.2 5.9 17.1 21.8 10.7 11.9 11.3 14.8 9.7 7.3 10.2 8.5 11.6 11.5 6.0 21.4 27.0 17.6 52.0 17.3 7.5 15.3 14.7 25.0 12.2 17.7 21.7 19.9 29.4 9.8 20.6 18.0 0.0 33.3 29.5 26.3 21.9 35.9 13.5 21.9 14.3 20.2 11.6 13.7 4.7 16.4 20.8 23.6 60.5 19.5 17.7 46.9 21.0 21.9 11.9 73.3 12.9 23.7 48.8 34.9 53.2 20.7 51.7 20.9 30.2 DCTN1 ENSG00000204843 "Dynactin subunit 1" Q14203 2 74361154-74392087 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Mitosis, Transport" "Amyotrophic lateral sclerosis, Cancer-related genes, Neurodegeneration, Neuropathy, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009108, HPA034635, HPA071875" Approved Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" Yes No 220000 Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB009108: AB_2090601, HPA034635: AB_2674256, HPA071875: " "unprognostic (1.14e-1)" "unprognostic (7.19e-2)" "unprognostic (1.33e-3)" "unprognostic (4.08e-2)" "unprognostic (1.20e-1)" "unprognostic (2.67e-1)" "unprognostic (4.61e-3)" "unprognostic (2.11e-2)" "unprognostic (2.79e-1)" "unprognostic (3.73e-3)" "unprognostic (1.87e-1)" "unprognostic (2.26e-1)" "prognostic favorable (2.34e-7)" "unprognostic (5.41e-2)" "unprognostic (3.11e-1)" "unprognostic (7.86e-3)" "unprognostic (1.12e-3)" 20.7 21.1 36.0 13.7 54.6 11.1 14.0 45.9 70.9 23.5 17.1 37.8 8.9 11.8 18.5 9.8 22.9 19.7 15.1 37.7 39.5 35.8 13.5 10.0 18.9 10.9 37.7 40.3 21.9 15.2 70.2 21.6 17.2 54.6 16.5 14.0 13.2 23.5 21.7 39.5 19.9 13.7 26.5 32.2 12.4 16.0 25.5 26.7 9.4 17.0 9.5 12.8 17.2 18.0 11.6 12.1 12.9 15.8 9.8 16.7 15.5 19.1 22.5 21.1 22.0 38.8 29.0 17.1 30.9 32.3 39.5 28.2 29.9 14.8 26.4 12.7 64.2 21.8 19.2 25.8 39.3 30.2 32.9 26.0 27.4 18.1 25.1 30.0 14.9 34.0 34.7 19.2 42.9 25.6 27.1 33.7 24.2 11.8 18.9 29.7 16.4 27.1 15.5 22.8 23.5 24.0 24.4 37.2 18.9 21.9 11.9 26.1 23.1 17.3 20.8 18.6 19.2 13.4 10.9 25.5 36.0 26.1 15.4 23.0 11.7 9.3 24.0 33.7 24.4 25.2 7.3 11.4 12.9 16.7 14.2 13.5 11.6 9.5 12.4 12.1 8.6 6.8 7.5 9.8 9.8 15.8 9.6 8.1 15.5 36.0 54.6 45.9 70.9 39.5 35.8 37.7 40.3 54.6 26.7 29.8 20.1 9.7 8.2 9.0 26.0 50.1 12.7 12.0 15.9 27.9 23.6 24.7 16.6 19.4 5.8 25.5 38.3 23.3 17.1 23.3 20.8 9.2 28.8 17.0 24.6 85.8 16.0 25.8 15.9 3.9 41.4 16.7 15.1 27.9 26.4 15.6 21.6 24.6 48.8 16.1 43.6 19.4 27.1 28.4 35.7 10.3 21.1 13.8 20.7 9.5 DDIT3 "CHOP, CHOP10, GADD153" ENSG00000175197 "DNA damage inducible transcript 3" P35638 12 57516588-57521737 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Growth arrest, Stress response, Transcription, Transcription regulation, Unfolded protein response, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 50.8" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HHSteC: 125.3;hTERT-HME1: 63.0;SK-MEL-30: 58.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058416, HPA068416" Uncertain Supported Nucleoplasm No No Nucleoplasm "HPA058416: AB_2683712, HPA068416: AB_2685985" "unprognostic (1.12e-1)" "unprognostic (5.33e-2)" "unprognostic (2.20e-3)" "unprognostic (4.92e-2)" "unprognostic (7.86e-3)" "unprognostic (2.28e-1)" "prognostic unfavorable (6.55e-4)" "unprognostic (8.55e-2)" "unprognostic (1.26e-3)" "unprognostic (9.40e-3)" "unprognostic (4.92e-2)" "unprognostic (4.16e-2)" "unprognostic (3.52e-2)" "unprognostic (3.70e-1)" "unprognostic (1.62e-1)" "unprognostic (2.56e-1)" "unprognostic (6.76e-2)" 19.1 25.5 15.9 8.3 29.9 82.2 21.4 16.7 25.2 14.8 13.5 20.1 15.7 10.6 19.5 55.8 13.0 13.1 16.0 25.8 18.6 19.8 28.8 26.1 17.1 8.8 34.4 15.5 27.3 13.0 13.5 26.8 18.0 32.1 22.8 13.9 27.3 20.7 13.9 18.0 16.3 10.9 15.4 21.8 11.2 14.7 14.3 35.3 2.9 88.9 12.6 9.4 30.2 17.0 13.8 4.6 50.8 5.4 9.2 10.9 5.1 2.6 2.4 1.5 5.3 14.4 9.8 8.4 7.3 16.3 10.9 10.3 8.6 7.0 3.8 7.4 2.1 29.4 3.2 5.9 1.1 11.3 3.1 2.4 2.9 2.7 6.2 125.3 4.6 4.6 27.9 23.7 18.4 63.0 12.8 2.6 4.0 12.6 14.5 4.8 1.6 3.1 6.1 3.0 5.6 5.8 1.7 34.4 3.2 3.8 3.4 3.2 2.4 2.1 2.5 58.5 6.1 5.3 12.5 1.5 7.5 3.2 7.0 6.3 25.7 8.6 4.0 9.0 4.4 13.1 27.5 5.4 13.5 8.0 4.6 7.0 13.8 5.7 7.3 3.7 13.1 10.9 9.9 50.8 9.2 5.1 4.6 6.5 5.1 15.9 29.9 16.7 25.2 18.6 19.8 34.4 15.5 32.1 35.3 17.9 66.4 36.9 73.0 50.0 111.0 146.3 38.2 24.1 25.0 21.0 86.4 37.7 97.8 32.3 4.8 25.9 67.5 0.0 13.8 18.0 63.8 157.0 198.7 17.9 39.8 52.4 221.2 23.4 24.7 5.5 25.9 50.7 84.4 8.2 36.5 118.8 35.9 70.2 35.7 34.7 135.4 12.9 94.3 83.5 13.4 40.0 90.2 46.8 32.1 42.1 DDR2 "NTRKR3, TKT, TYRO10" ENSG00000162733 "Discoidin domain receptor tyrosine kinase 2" Q16832 1 162631373-162787400 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Osteogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Fibroblasts: 84.7;Leydig cells: 58.4;Peritubular cells: 83.1;Smooth muscle cells: 68.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 1.1;MAIT T-cell: 1.3" "Lineage enriched" "Detected in single" 5 "T-cells: 1.3" "Cell line enhanced" "Detected in many" "ASC diff: 61.7;ASC TERT1: 61.0;BJ hTERT+: 45.1;fHDF/TERT166: 32.3;HSkMC: 43.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070112 Supported "Plasma membrane,Actin filaments" Yes No 850000 "Plasma membrane, Actin filaments" "HPA070112: AB_2686229" "unprognostic (4.12e-2)" "unprognostic (2.73e-1)" "unprognostic (6.97e-3)" "unprognostic (4.52e-2)" "unprognostic (1.17e-1)" "unprognostic (8.16e-2)" "unprognostic (1.81e-1)" "unprognostic (1.19e-1)" "unprognostic (6.62e-2)" "unprognostic (2.24e-2)" "unprognostic (1.00e-1)" "unprognostic (1.15e-1)" "prognostic unfavorable (1.73e-7)" "unprognostic (1.56e-3)" "unprognostic (8.26e-3)" "unprognostic (7.57e-2)" "unprognostic (4.10e-3)" 42.1 43.5 4.7 10.9 6.9 0.2 15.6 7.9 7.1 30.3 30.4 9.0 18.6 3.3 24.2 17.7 25.0 13.4 16.6 15.4 7.9 4.7 4.0 3.3 8.9 5.1 12.9 3.4 26.4 2.2 2.1 4.0 6.6 12.7 21.8 9.1 30.7 6.4 19.3 5.2 6.1 10.1 34.3 19.7 3.4 14.1 8.3 7.5 0.0 8.6 12.8 4.1 29.0 18.3 0.1 0.2 0.0 0.0 0.2 1.3 0.0 0.1 0.0 0.0 16.3 61.7 61.0 0.2 24.0 45.1 10.5 15.1 0.0 0.0 0.0 0.0 32.3 2.1 0.0 0.0 0.1 14.4 12.9 0.1 0.0 0.1 0.0 26.8 0.0 0.0 43.3 0.1 18.5 0.5 17.0 12.1 0.1 0.1 5.1 9.6 0.0 0.0 0.0 0.1 0.0 0.1 0.0 6.9 0.1 0.0 0.0 0.0 9.9 0.0 0.0 0.8 0.9 0.0 0.0 0.6 16.8 3.7 8.5 3.3 0.7 1.3 0.0 15.2 0.0 17.0 0.0 0.0 0.0 1.1 0.0 1.3 0.0 0.8 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 4.7 6.9 7.9 7.1 7.9 4.7 12.9 3.4 12.7 7.5 3.0 2.9 0.0 2.4 11.2 3.1 23.3 2.5 4.0 1.2 0.0 0.0 0.5 0.0 0.5 6.9 21.3 2.0 0.0 1.5 0.4 84.7 4.1 1.1 3.0 1.1 0.0 1.2 24.5 2.1 4.0 58.4 1.5 21.9 0.0 0.7 19.0 1.5 1.7 83.1 0.9 2.9 38.8 68.4 0.9 0.9 7.5 0.8 1.3 0.6 3.3 DDX10 "Dbp4, HRH-J8" ENSG00000178105 "DEAD-box helicase 10" Q13206 11 108665025-108940930 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cone photoreceptor cells: 90.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 58.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004691 Approved Approved Nucleoli NA NA Nucleoli "HPA004691: AB_1078629" "unprognostic (9.49e-2)" "unprognostic (9.32e-2)" "unprognostic (1.34e-1)" "unprognostic (2.58e-1)" "unprognostic (7.97e-2)" "unprognostic (1.48e-2)" "prognostic unfavorable (2.52e-5)" "unprognostic (2.86e-2)" "unprognostic (1.23e-2)" "unprognostic (1.06e-1)" "prognostic unfavorable (5.75e-4)" "unprognostic (1.00e-1)" "prognostic favorable (2.14e-5)" "unprognostic (5.20e-2)" "unprognostic (1.98e-1)" "unprognostic (4.64e-1)" "unprognostic (2.43e-3)" 14.0 11.9 17.3 15.0 20.3 10.4 15.5 20.5 18.3 14.3 12.2 8.1 11.7 8.8 18.4 12.8 12.6 16.8 8.8 12.1 13.5 11.5 19.6 12.5 10.6 13.1 12.2 16.3 18.6 18.0 16.7 22.2 12.9 13.1 12.4 13.3 7.9 10.6 14.7 13.6 14.8 9.1 16.8 13.3 15.0 11.3 25.1 12.6 13.8 13.4 8.8 14.2 14.3 18.8 11.6 8.4 1.4 6.7 9.4 11.3 4.3 7.4 7.3 6.9 9.7 6.9 5.6 7.2 8.0 4.3 9.7 9.6 20.8 10.9 25.3 15.1 6.1 10.5 8.3 19.8 9.7 14.0 9.6 8.9 17.1 4.3 7.7 12.3 17.4 8.2 5.0 7.6 11.0 13.8 5.8 8.8 6.6 24.0 2.8 9.5 4.8 14.6 14.7 9.0 14.0 11.1 12.5 11.3 23.6 6.0 6.4 12.9 6.8 11.2 9.9 4.2 9.7 12.0 6.1 9.2 10.2 10.4 9.7 10.8 4.3 7.5 58.4 3.5 21.1 10.3 1.4 5.0 1.0 8.6 6.7 11.3 10.4 7.5 10.1 8.4 11.6 8.1 7.8 0.7 9.4 6.4 8.2 6.3 4.3 17.3 20.3 20.5 18.3 13.5 11.5 12.2 16.3 13.1 12.6 14.9 30.3 22.6 17.3 25.2 21.1 18.2 7.6 18.7 22.7 3.5 90.3 21.4 16.6 13.2 28.6 19.8 2.9 0.0 18.3 17.8 17.6 12.7 13.9 10.2 13.1 17.5 14.5 9.2 9.2 5.9 27.3 18.2 6.8 18.0 7.8 8.9 15.1 3.5 20.1 46.2 25.2 12.9 15.6 64.4 44.6 25.3 21.6 14.4 13.6 12.2 DDX3X "DBX, DDX14, DDX3, HLP2" ENSG00000215301 "DEAD-box helicase 3, X-linked" O00571 X 41333284-41364472 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Chromosome partition, Host-virus interaction, Immunity, Innate immunity, Ribosome biogenesis, Transcription, Transcription regulation, Translation regulation" "DNA-binding, Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Late spermatids: 631.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001648, HPA005631, HPA059585" Supported Supported Approved Nucleoplasm,Cytosol NA NA 110000 Cytosol Nucleoplasm "HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059585: AB_2684073" "unprognostic (2.42e-2)" "unprognostic (1.11e-1)" "unprognostic (8.01e-3)" "unprognostic (1.66e-1)" "unprognostic (8.12e-2)" "unprognostic (6.43e-2)" "unprognostic (1.17e-3)" "unprognostic (1.88e-1)" "unprognostic (9.80e-2)" "unprognostic (1.40e-1)" "unprognostic (3.25e-2)" "unprognostic (2.05e-1)" "unprognostic (1.51e-1)" "unprognostic (2.95e-1)" "unprognostic (4.77e-1)" "unprognostic (9.44e-2)" "unprognostic (2.93e-2)" 80.9 49.3 26.1 40.0 34.5 49.3 46.5 31.1 36.2 52.4 43.3 35.1 21.3 29.5 56.4 25.9 53.5 56.3 42.6 47.6 30.8 24.5 55.6 77.9 45.3 40.4 41.4 29.0 60.1 30.9 68.7 60.2 79.9 37.9 30.0 29.2 30.8 37.4 26.5 63.4 42.2 54.0 57.2 53.9 46.1 43.0 27.0 39.0 49.2 45.6 44.0 42.6 55.8 50.2 13.1 20.5 32.0 21.6 17.3 21.5 17.9 45.8 51.1 47.7 26.2 56.2 47.7 29.1 33.5 47.1 34.4 27.6 52.5 30.9 0.5 23.9 37.4 41.4 31.0 58.3 47.1 57.3 27.2 45.4 29.2 50.8 31.5 29.2 54.7 52.5 34.5 33.4 57.9 56.0 38.5 53.9 25.7 53.6 28.9 31.9 34.7 34.4 17.1 45.9 24.4 20.6 40.4 50.8 37.4 32.4 61.9 32.6 49.4 75.8 38.9 40.1 50.2 35.0 37.2 48.6 35.5 37.9 37.9 39.7 33.7 40.0 45.3 35.7 33.2 33.6 22.5 20.2 17.5 14.8 21.1 21.5 13.1 14.5 16.3 20.5 9.0 16.3 15.1 32.0 17.3 21.6 6.9 14.3 17.9 26.1 34.5 31.1 36.2 30.8 24.5 41.4 29.0 37.9 39.0 80.4 161.8 98.4 138.2 234.8 74.1 130.3 81.5 65.6 85.3 55.8 123.7 79.4 36.5 59.8 317.8 170.8 178.1 116.8 73.8 80.3 155.2 122.4 162.7 142.1 107.7 57.2 176.3 120.3 200.6 631.6 61.5 160.4 121.4 72.1 136.1 88.8 86.2 143.8 59.1 71.7 117.4 71.1 155.5 15.7 55.7 291.5 144.6 132.3 100.9 182.7 DDX5 "G17P1, HLR1, p68" ENSG00000108654 "DEAD-box helicase 5" P17844 17 64499616-64508199 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005868, HPA020043, HPA071154" Supported Supported Nucleoplasm,Nucleoli No No 150000 "Nucleoplasm, Nucleoli" "CAB005868: AB_446484, HPA020043: AB_1847572, HPA071154: " "unprognostic (6.64e-2)" "unprognostic (6.98e-2)" "prognostic favorable (2.12e-4)" "unprognostic (8.94e-2)" "unprognostic (5.08e-2)" "unprognostic (9.85e-2)" "unprognostic (5.80e-2)" "unprognostic (1.61e-2)" "unprognostic (3.17e-2)" "unprognostic (4.71e-2)" "unprognostic (3.03e-3)" "unprognostic (1.44e-1)" "unprognostic (4.00e-1)" "unprognostic (2.08e-1)" "unprognostic (2.37e-1)" "unprognostic (2.17e-1)" "unprognostic (9.28e-3)" 91.6 61.4 46.9 80.0 68.0 108.3 94.7 61.6 58.9 81.6 81.1 53.3 104.2 27.4 106.7 94.5 64.5 96.9 101.4 53.9 48.5 30.6 53.1 68.0 84.8 70.9 62.8 44.1 74.0 49.3 88.9 110.5 56.6 73.1 59.5 55.4 50.9 62.2 103.6 77.6 59.7 54.7 113.1 71.0 67.6 69.0 39.7 57.8 82.1 81.1 77.7 69.3 91.0 63.9 46.9 59.6 66.4 66.2 40.3 60.8 109.8 55.1 20.8 63.0 39.9 58.4 55.0 40.1 54.7 70.6 67.1 67.2 22.5 33.8 80.9 31.4 71.8 47.8 32.9 67.8 62.9 75.9 28.7 48.7 52.6 15.9 17.2 42.8 66.9 56.1 61.9 54.3 61.3 47.8 37.4 71.6 69.9 41.7 69.1 51.7 32.8 139.9 19.5 36.7 50.9 64.3 87.6 66.6 56.9 41.1 26.5 44.3 74.3 53.1 51.5 66.6 56.7 48.2 37.7 50.3 40.8 45.6 43.9 56.6 38.6 76.1 142.8 43.2 32.9 48.1 66.4 62.5 66.4 53.7 56.9 60.8 46.9 42.9 51.7 59.6 46.8 44.5 43.1 37.8 40.3 66.2 37.0 50.2 109.8 46.9 68.0 61.6 58.9 48.5 30.6 62.8 44.1 73.1 57.8 497.3 661.1 481.3 1231.3 781.2 369.6 221.7 262.4 725.4 624.4 350.7 316.1 372.7 283.5 416.6 432.3 643.3 503.6 116.8 366.6 307.8 528.8 417.0 836.7 222.3 399.0 397.3 638.0 483.1 539.2 80.3 384.6 631.0 410.0 779.1 366.4 576.1 376.0 445.4 411.5 208.8 514.0 485.0 599.5 374.0 341.8 652.0 741.9 719.3 310.9 1106.4 DDX6 "HLR2, RCK" ENSG00000110367 "DEAD-box helicase 6" P26196 11 118747766-118791149 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Helicase, Hydrolase, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004668, HPA024201, HPA026644" Approved Supported "Cytosol,Cytoplasmic bodies" NA NA "Cytoplasmic bodies" Cytosol "CAB004668: AB_436960, HPA024201: AB_10603562, HPA026644: AB_1847582" "unprognostic (1.26e-1)" "unprognostic (1.40e-1)" "unprognostic (1.89e-1)" "unprognostic (3.40e-2)" "unprognostic (4.12e-2)" "unprognostic (5.82e-2)" "prognostic unfavorable (6.56e-4)" "unprognostic (3.43e-1)" "unprognostic (1.48e-2)" "unprognostic (1.16e-1)" "unprognostic (1.00e-1)" "unprognostic (7.76e-2)" "unprognostic (1.98e-1)" "unprognostic (4.91e-3)" "unprognostic (1.88e-1)" "unprognostic (9.58e-2)" "unprognostic (4.55e-2)" 29.8 23.0 25.0 24.1 41.0 43.3 25.1 41.9 39.2 26.9 23.2 29.4 14.5 17.1 30.1 22.9 31.8 23.4 17.5 26.8 25.5 25.1 22.8 24.6 23.4 32.2 21.9 27.1 38.2 27.9 30.9 43.2 26.1 29.6 24.9 20.8 25.4 26.8 22.9 43.8 23.9 24.1 27.8 30.4 30.6 21.2 19.9 24.0 46.0 27.9 19.4 42.8 33.0 25.7 12.2 6.5 17.8 10.3 7.2 12.6 5.7 11.9 16.3 26.3 25.9 23.1 23.7 17.2 16.2 21.3 15.1 14.4 23.7 18.4 27.4 17.1 26.5 15.1 19.1 30.6 23.7 24.4 20.6 6.1 52.9 10.5 19.3 15.3 37.9 20.4 25.0 17.5 22.4 36.4 19.9 24.0 18.5 24.3 39.8 21.3 32.6 27.5 17.6 18.7 16.9 12.0 30.3 21.3 21.9 17.7 31.0 17.4 24.0 30.6 24.6 9.7 20.6 28.7 14.9 27.4 25.1 13.8 14.3 16.3 12.4 16.1 32.7 10.0 18.2 21.4 10.5 4.1 11.6 10.1 5.7 12.6 11.4 9.9 10.4 4.7 12.2 12.4 10.8 17.8 7.2 10.3 6.5 8.9 5.7 25.0 41.0 41.9 39.2 25.5 25.1 21.9 27.1 29.6 24.0 56.6 60.1 71.3 62.3 26.9 78.4 105.7 35.7 40.2 43.3 41.8 47.1 31.3 26.6 28.5 3.7 65.3 48.0 46.7 30.5 30.1 37.5 44.5 49.8 37.6 33.8 58.8 82.4 58.9 51.1 8.2 50.0 42.0 32.1 73.1 55.4 81.3 38.8 65.4 42.5 35.6 75.0 38.8 41.9 66.1 72.8 26.7 64.0 103.8 45.4 65.9 DEK D6S231E ENSG00000124795 "DEK proto-oncogene" P35659 6 18223868-18264823 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Chromatin regulator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB015226, HPA054505, HPA057799" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB015226: , HPA054505: AB_2682508, HPA057799: AB_2683530" "unprognostic (6.35e-2)" "unprognostic (6.11e-2)" "unprognostic (5.04e-3)" "unprognostic (1.40e-2)" "unprognostic (3.66e-1)" "unprognostic (5.02e-3)" "prognostic unfavorable (9.65e-4)" "unprognostic (1.76e-1)" "unprognostic (1.48e-2)" "unprognostic (1.61e-3)" "unprognostic (6.49e-3)" "unprognostic (1.12e-2)" "prognostic unfavorable (3.45e-4)" "unprognostic (1.59e-1)" "unprognostic (1.68e-1)" "unprognostic (2.31e-1)" "unprognostic (3.78e-1)" 30.9 20.0 22.9 41.8 29.5 50.8 28.9 41.5 30.2 31.0 35.8 11.4 24.0 28.2 32.9 19.7 31.0 23.8 19.2 33.5 26.8 14.1 19.3 23.8 29.2 42.7 30.7 17.6 28.3 19.3 20.5 27.8 24.3 27.7 33.9 29.9 11.0 26.8 21.4 40.2 23.2 35.9 51.3 28.1 29.8 24.2 12.6 32.9 58.8 44.9 33.9 38.4 45.1 43.3 40.0 40.2 57.7 49.3 34.0 46.3 35.0 60.9 18.0 47.6 39.7 9.6 16.7 27.7 56.2 31.0 50.7 68.8 29.4 22.9 69.4 59.6 25.3 40.8 36.6 35.2 27.9 85.4 46.7 33.6 42.9 32.3 34.2 9.3 65.3 34.9 8.2 13.9 35.0 27.7 24.0 24.2 25.6 52.1 0.0 32.3 21.9 47.1 29.3 29.2 24.3 20.1 62.8 63.2 40.7 24.4 35.3 29.2 26.8 50.7 44.1 30.6 32.6 39.6 26.9 24.6 59.5 33.0 33.1 69.9 4.2 10.2 73.2 14.2 33.3 55.1 51.1 49.3 21.9 41.4 39.3 46.3 40.0 42.1 42.5 40.2 33.2 33.5 32.0 57.7 34.0 43.9 31.0 40.6 35.0 22.9 29.5 41.5 30.2 26.8 14.1 30.7 17.6 27.7 32.9 113.2 133.1 112.0 157.1 241.0 64.8 174.2 152.8 109.7 146.7 75.0 76.6 208.5 69.6 136.5 15.9 140.0 115.1 443.9 150.2 201.0 139.1 206.8 105.4 107.1 166.8 25.4 84.9 75.5 163.3 15.6 175.4 212.2 96.2 259.7 117.1 119.5 110.8 110.4 180.0 82.7 127.2 207.0 187.2 63.1 177.2 204.1 90.8 150.3 203.5 166.1 DICER1 "Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1" ENSG00000100697 "Dicer 1, ribonuclease III" Q9UPY3 14 95086228-95158010 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "RNA-mediated gene silencing" "Endonuclease, Helicase, Hydrolase, Nuclease, RNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000694, CAB068185" Approved Supported Cytosol NA NA Cytosol "CAB068185: AB_2665650, HPA000694: AB_1078661" "unprognostic (2.97e-1)" "unprognostic (2.70e-2)" "unprognostic (1.21e-1)" "unprognostic (1.72e-1)" "unprognostic (6.75e-2)" "unprognostic (9.62e-2)" "unprognostic (1.96e-2)" "unprognostic (7.73e-2)" "unprognostic (1.21e-1)" "unprognostic (8.52e-3)" "unprognostic (5.73e-2)" "unprognostic (9.22e-2)" "unprognostic (4.22e-2)" "unprognostic (9.07e-2)" "unprognostic (2.58e-1)" "unprognostic (6.04e-3)" "unprognostic (3.74e-2)" 23.2 12.5 18.4 22.4 33.3 20.5 23.2 28.5 29.9 19.0 18.1 31.4 22.4 13.0 20.8 20.6 23.4 18.5 16.2 15.3 22.0 14.1 19.5 23.6 22.4 20.3 29.7 19.6 23.8 19.8 26.9 30.9 29.9 23.2 20.3 19.7 14.5 19.5 18.9 28.0 20.7 17.3 19.0 26.8 20.7 17.1 20.6 32.0 17.0 23.8 14.7 20.3 20.7 24.1 2.5 1.8 10.7 7.2 1.2 3.3 1.0 12.9 13.6 25.4 9.4 6.6 9.9 20.1 10.7 6.5 6.8 8.3 17.2 10.0 14.7 11.6 10.0 7.1 15.3 20.1 10.1 14.4 22.7 9.0 22.2 7.4 12.4 6.6 13.6 13.6 9.2 8.3 9.2 14.1 5.9 10.2 11.6 9.3 13.1 11.5 18.2 15.2 9.0 7.2 9.1 6.7 12.1 20.8 8.1 9.1 20.7 21.1 11.9 10.8 11.1 12.2 14.1 12.6 10.0 10.1 5.3 10.5 10.2 12.0 14.9 21.3 20.8 5.5 11.0 9.4 3.1 3.0 1.2 1.6 3.1 3.3 1.9 1.5 1.2 1.8 2.5 1.5 1.3 10.7 1.2 7.2 1.6 1.6 1.0 18.4 33.3 28.5 29.9 22.0 14.1 29.7 19.6 23.2 32.0 50.6 47.2 32.6 39.2 24.4 99.7 34.3 38.2 32.1 51.2 43.6 53.0 39.4 5.0 30.3 19.8 39.1 29.6 23.3 19.9 20.7 34.6 55.9 11.5 50.5 41.7 101.7 44.3 41.1 94.2 12.0 50.3 46.8 21.9 19.0 30.6 35.0 28.4 23.0 49.5 22.6 68.5 32.3 35.0 34.9 52.5 24.1 21.5 23.0 31.6 49.7 DNAJB1 "Hsp40, HSPF1, RSPH16B, Sis1" ENSG00000132002 "DnaJ heat shock protein family (Hsp40) member B1" P25685 19 14514770-14529770 "Cancer-related genes, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 291.1" "Cell type enhanced" "Detected in many" 4 "Smooth muscle cells: 802.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 110.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017450, HPA063247" Enhanced Supported Nucleoplasm NA Yes 9600 Nucleoplasm "CAB017450: AB_10631418, HPA063247: AB_2684971" "unprognostic (3.75e-2)" "unprognostic (2.23e-1)" "unprognostic (1.46e-1)" "unprognostic (2.12e-1)" "unprognostic (1.60e-1)" "unprognostic (1.32e-1)" "unprognostic (1.52e-1)" "unprognostic (1.74e-2)" "unprognostic (3.83e-1)" "unprognostic (1.85e-1)" "unprognostic (7.91e-3)" "unprognostic (2.17e-1)" "prognostic favorable (5.96e-4)" "unprognostic (2.20e-2)" "unprognostic (4.44e-2)" "unprognostic (2.00e-2)" "unprognostic (6.77e-2)" 29.2 76.9 28.5 13.2 30.0 36.2 67.0 41.4 29.4 19.3 15.5 21.5 14.5 10.5 20.4 11.8 72.3 21.7 56.4 23.5 28.2 31.6 23.4 37.7 35.7 10.7 53.4 12.0 32.3 22.6 18.3 25.0 33.5 45.8 29.6 13.1 12.2 18.4 40.8 16.1 25.3 9.5 24.0 40.2 9.4 19.1 37.5 37.9 15.0 28.9 18.0 31.1 19.2 291.1 19.7 15.2 28.2 31.6 23.0 61.6 56.7 36.9 39.3 14.2 15.1 26.2 21.1 8.9 24.6 18.3 39.0 29.5 23.2 20.9 10.2 28.2 20.9 25.5 28.1 29.1 17.7 27.7 10.7 14.4 16.3 26.0 48.6 17.9 11.5 15.5 11.7 42.4 15.1 13.2 20.4 12.8 6.9 24.1 110.7 21.4 23.4 18.5 10.7 15.1 48.9 42.4 14.2 20.0 23.0 17.7 12.7 13.1 9.7 22.3 44.2 24.2 16.6 12.1 11.2 13.3 31.7 19.1 36.5 51.6 49.3 30.2 13.4 22.6 19.9 28.2 11.5 18.9 22.3 36.6 31.1 38.9 19.4 52.5 45.4 15.2 19.7 61.6 47.6 28.2 23.0 31.6 9.1 51.8 56.7 28.5 30.0 41.4 29.4 28.2 31.6 53.4 12.0 45.8 37.9 145.9 105.3 114.6 695.7 378.2 47.1 335.7 48.4 87.0 71.7 22.7 111.9 123.3 34.9 105.0 377.6 275.7 133.0 0.0 143.2 142.5 617.3 678.1 342.8 50.4 134.5 49.3 390.0 73.1 71.9 368.9 58.7 232.5 477.5 35.1 126.4 109.5 97.8 108.7 34.6 43.9 149.2 25.8 802.9 139.1 31.8 418.7 229.9 251.4 123.6 238.8 DNM2 "CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII" ENSG00000079805 "Dynamin 2" P50570 19 10718079-10833488 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Endocytosis, Phagocytosis" "Hydrolase, Motor protein" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054246 Supported Approved "Golgi apparatus,Cytosol" NA NA 500000 "Golgi apparatus, Cytosol" "HPA054246: AB_2682427" "unprognostic (2.30e-1)" "unprognostic (5.23e-2)" "unprognostic (4.72e-2)" "unprognostic (1.23e-1)" "unprognostic (1.76e-1)" "prognostic favorable (8.91e-4)" "prognostic unfavorable (3.63e-4)" "unprognostic (1.03e-1)" "unprognostic (3.79e-1)" "unprognostic (1.89e-1)" "unprognostic (4.75e-2)" "unprognostic (5.35e-2)" "unprognostic (5.47e-2)" "unprognostic (5.40e-3)" "unprognostic (2.68e-1)" "unprognostic (1.61e-1)" "unprognostic (1.99e-3)" 23.8 32.6 18.5 29.3 31.2 53.4 20.4 25.7 29.7 20.1 51.4 57.5 46.0 32.1 20.4 16.8 29.9 19.7 27.0 35.0 20.8 18.0 38.5 25.1 39.2 28.2 48.3 18.0 17.9 32.2 19.5 20.0 32.3 32.2 24.0 42.5 24.5 24.7 37.7 46.6 40.6 50.8 18.6 43.1 37.6 48.2 23.3 36.4 39.1 23.5 21.1 41.5 35.7 31.5 3.4 11.1 8.6 9.8 10.1 5.8 4.6 35.0 29.0 21.3 16.9 22.0 21.5 27.3 23.5 22.3 34.8 29.6 28.9 23.2 25.5 42.3 25.3 16.6 30.8 29.0 25.5 29.2 31.2 23.0 48.9 25.9 32.3 27.1 26.8 46.4 22.1 19.7 26.6 25.1 21.2 33.8 26.3 39.3 43.9 21.4 42.5 37.3 25.6 24.2 41.6 35.2 37.9 23.1 28.7 22.9 52.9 30.7 20.1 26.8 23.0 16.8 24.8 18.4 32.0 30.6 38.3 13.0 53.7 31.0 36.4 37.1 23.5 28.6 41.1 18.9 3.0 4.5 8.6 5.6 8.2 5.1 3.4 4.2 5.8 5.3 3.1 2.4 4.1 8.5 10.1 9.8 11.1 4.8 4.6 18.5 31.2 25.7 29.7 20.8 18.0 48.3 18.0 32.2 36.4 29.8 21.1 33.5 15.2 20.6 26.5 23.8 15.3 5.3 18.2 48.8 21.6 21.9 43.1 30.7 37.5 27.5 130.4 0.0 27.6 96.1 18.2 17.4 18.5 18.7 42.3 41.3 20.7 20.3 22.9 75.8 15.5 40.5 18.6 50.5 92.3 16.0 35.8 87.7 26.2 31.5 27.7 25.8 19.8 8.0 13.3 27.6 26.5 39.9 56.9 19.7 DNMT3A ENSG00000119772 "DNA methyltransferase 3 alpha" Q9Y6K1 2 25227855-25342590 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Cone photoreceptor cells: 119.8;Horizontal cells: 90.6;Rod photoreceptor cells: 144.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NTERA-2: 25.7;REH: 25.4;SH-SY5Y: 31.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009469, HPA026588" Approved Supported Nucleoplasm NA NA Nucleoplasm "CAB009469: AB_2093990, HPA026588: AB_1847812" "unprognostic (2.38e-1)" "unprognostic (2.94e-1)" "unprognostic (5.65e-2)" "prognostic unfavorable (1.55e-4)" "unprognostic (8.38e-2)" "unprognostic (7.27e-2)" "prognostic unfavorable (1.58e-4)" "unprognostic (2.24e-1)" "unprognostic (7.25e-2)" "unprognostic (2.72e-1)" "prognostic favorable (1.18e-4)" "unprognostic (2.35e-2)" "prognostic unfavorable (2.49e-4)" "unprognostic (1.43e-1)" "unprognostic (1.87e-1)" "unprognostic (1.14e-1)" "unprognostic (2.70e-2)" 7.8 12.4 13.7 12.7 15.5 10.8 8.6 21.6 20.1 9.0 12.7 14.5 7.6 9.1 13.0 12.2 8.0 9.6 8.9 8.2 12.3 6.7 9.4 6.9 9.5 13.6 15.3 10.1 18.3 12.1 6.3 12.6 20.8 10.7 9.3 9.2 12.0 8.5 9.2 29.1 6.6 11.4 11.3 7.9 17.5 11.6 6.6 15.2 20.8 9.1 10.5 11.8 9.8 8.4 3.0 4.1 4.9 4.1 8.7 8.3 2.3 1.1 3.5 14.9 3.6 1.6 1.2 19.5 1.0 0.9 2.0 1.6 8.8 5.7 0.0 2.2 1.9 1.6 1.0 1.6 2.2 1.2 3.7 2.6 6.4 5.3 10.5 3.9 1.3 4.1 3.6 1.1 2.6 0.9 3.9 8.3 14.5 7.3 1.4 1.5 8.5 13.9 15.1 25.7 5.9 1.9 25.4 16.4 2.1 1.2 1.5 8.8 31.3 1.2 8.4 2.6 13.4 1.0 6.7 2.8 2.5 3.3 0.6 1.3 3.2 2.2 8.6 0.9 3.8 2.6 4.7 1.8 3.1 5.2 3.0 7.0 2.3 3.4 4.9 2.0 3.0 8.3 6.6 4.9 8.7 4.1 4.1 2.8 2.3 13.7 15.5 21.6 20.1 12.3 6.7 15.3 10.1 10.7 15.2 6.0 13.3 10.0 8.3 4.6 74.9 13.7 5.1 9.4 12.5 19.2 119.8 30.2 5.0 13.8 1.5 14.6 5.3 0.0 8.5 9.4 14.7 11.7 36.9 5.5 19.8 90.6 12.6 6.2 10.5 1.1 17.8 11.9 6.8 4.6 11.5 22.7 9.2 10.5 14.5 5.6 144.9 19.4 8.2 2.3 13.4 2.3 26.9 18.7 11.0 6.7 DROSHA "Etohi2, HSA242976, RN3, RNASE3L, RNASEN" ENSG00000113360 "Drosha ribonuclease III" Q9NRR4 5 31400497-31532196 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Ribosome biogenesis, RNA-mediated gene silencing" "Endonuclease, Hydrolase, Nuclease, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031150 Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA031150: AB_2673761" "unprognostic (8.37e-3)" "unprognostic (1.81e-1)" "unprognostic (9.56e-2)" "prognostic unfavorable (6.79e-4)" "unprognostic (5.40e-2)" "unprognostic (6.03e-2)" "prognostic unfavorable (1.39e-4)" "unprognostic (3.11e-1)" "unprognostic (4.08e-2)" "unprognostic (9.08e-2)" "unprognostic (1.86e-1)" "unprognostic (5.43e-2)" "unprognostic (1.12e-1)" "unprognostic (1.74e-1)" "unprognostic (2.39e-1)" "unprognostic (6.94e-2)" "unprognostic (2.32e-2)" 15.7 16.8 18.4 17.7 32.1 12.2 16.1 33.7 33.7 17.4 16.3 19.1 12.2 15.9 22.3 25.8 16.0 18.2 14.1 15.2 16.6 15.1 15.3 11.7 13.9 17.8 13.6 16.4 26.7 17.8 23.9 38.9 17.0 18.9 17.2 19.2 23.7 17.5 19.2 23.6 16.0 17.5 16.9 19.4 16.8 16.0 12.8 16.4 25.6 21.9 13.4 19.8 18.2 16.2 4.7 6.4 3.3 4.8 4.8 6.4 3.1 12.4 15.7 17.4 23.6 9.3 11.4 25.1 16.5 8.1 15.4 11.5 16.5 16.2 14.0 19.0 12.1 17.9 10.9 21.4 12.5 17.2 13.1 15.1 17.2 51.6 11.9 8.4 19.2 51.4 8.9 8.8 17.2 8.3 11.8 13.1 15.0 21.8 6.6 13.4 12.4 18.5 14.4 16.4 10.1 12.6 16.8 33.3 10.1 8.7 14.2 9.1 12.0 41.9 17.2 10.1 16.2 15.8 11.1 11.4 14.9 17.3 13.3 15.6 12.1 19.8 15.4 10.3 21.7 14.2 1.8 2.4 3.3 5.2 2.6 5.5 4.2 5.4 6.0 5.2 4.7 6.4 4.4 0.8 4.8 4.8 6.4 5.1 3.1 18.4 32.1 33.7 33.7 16.6 15.1 13.6 16.4 18.9 16.4 11.9 14.7 3.0 4.6 3.2 18.2 21.0 7.6 20.1 15.9 5.2 0.0 6.6 3.3 7.2 2.5 6.2 7.3 0.0 7.0 6.4 7.4 5.0 9.2 5.1 6.7 6.4 10.9 9.2 7.8 4.3 10.0 3.2 1.7 9.0 10.1 10.5 7.8 8.6 12.4 4.2 16.8 6.5 4.7 5.8 8.4 3.0 4.1 5.7 10.0 5.1 EBF1 "EBF, OLF1" ENSG00000164330 "Early B cell factor 1" Q9UH73 5 158695916-159099761 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 16 "Leydig cells: 264.3;Peritubular cells: 114.2;Sertoli cells: 97.0;Smooth muscle cells: 110.4" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "cerebellum: 23.6" "Group enriched" "Detected in some" 62 "memory B-cell: 11.8;naive B-cell: 10.4" "Lineage enriched" "Detected in single" 66 "B-cells: 11.8" "Cell line enhanced" "Detected in some" "ASC diff: 19.4;HSkMC: 15.1;REH: 40.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA061169 Approved Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "HPA061169: AB_2684441" "unprognostic (7.86e-2)" "unprognostic (3.08e-2)" "unprognostic (7.29e-2)" "unprognostic (4.70e-2)" "unprognostic (2.63e-1)" "unprognostic (1.39e-2)" "unprognostic (1.78e-1)" "unprognostic (1.60e-1)" "unprognostic (5.75e-2)" "unprognostic (1.60e-1)" "unprognostic (4.58e-2)" "unprognostic (1.02e-1)" "prognostic unfavorable (9.62e-7)" "prognostic unfavorable (7.80e-4)" "unprognostic (5.75e-2)" "unprognostic (5.81e-2)" "unprognostic (4.37e-3)" 33.7 3.3 1.9 9.7 2.5 3.1 25.0 23.6 2.0 15.9 5.8 1.1 9.0 1.2 19.7 13.0 5.0 8.5 9.4 15.5 2.0 2.4 3.3 0.9 5.2 12.7 3.2 1.2 7.4 3.7 1.8 2.6 10.7 4.7 8.5 3.4 10.4 4.7 10.8 15.5 4.8 4.5 25.7 6.6 5.4 3.4 8.4 1.0 0.1 6.8 13.2 9.1 11.7 12.5 11.8 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 6.2 0.0 19.4 8.4 0.0 0.0 0.0 0.2 0.6 0.0 0.0 5.6 0.0 2.3 1.2 0.0 0.2 0.0 0.1 1.3 0.0 0.0 1.6 0.0 0.3 0.0 0.0 15.1 0.0 6.0 0.2 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 40.6 0.2 0.0 0.0 0.0 3.3 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.8 8.5 0.1 0.0 0.0 5.6 4.9 0.4 6.7 0.1 0.0 0.1 0.0 0.0 0.0 11.8 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.9 2.5 23.6 1.6 2.0 2.4 3.2 1.2 4.7 1.0 0.0 0.3 44.7 0.4 10.9 4.1 4.3 0.0 1.4 1.2 1.8 0.0 0.1 0.0 2.4 15.8 55.5 0.0 0.0 0.0 0.3 40.4 0.6 0.0 1.0 0.7 0.0 0.0 2.5 0.8 15.5 264.3 1.0 13.5 16.2 0.0 1.7 0.2 0.0 114.2 0.0 2.0 97.0 110.4 2.2 0.4 6.0 0.3 1.3 0.0 0.5 EGFR "ERBB, ERBB1" ENSG00000146648 "Epidermal growth factor receptor" P00533 7 55019021-55211628 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Host-virus interaction" "Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 102.3" "Cell type enhanced" "Detected in many" 8 "Cytotrophoblasts: 207.2;Syncytiotrophoblasts: 315.1" "Cancer enhanced" "Detected in all" "glioma: 136.0" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in many" 12 "A-431: 345.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000035, HPA001200, HPA018530, CAB068186, CAB073534" Enhanced Enhanced "Plasma membrane,Cell Junctions" "Secreted to blood" NA NA 4740000 93000000 "Plasma membrane, Cell Junctions" "CAB000035: , CAB068186: AB_2665679, CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044" "unprognostic (2.62e-2)" "unprognostic (9.56e-3)" "unprognostic (1.59e-1)" "unprognostic (7.51e-2)" "unprognostic (1.08e-1)" "unprognostic (1.27e-2)" "unprognostic (6.11e-2)" "unprognostic (4.88e-2)" "unprognostic (2.85e-2)" "unprognostic (3.30e-3)" "unprognostic (1.78e-3)" "unprognostic (1.04e-1)" "unprognostic (1.93e-3)" "unprognostic (6.98e-3)" "unprognostic (1.72e-1)" "unprognostic (6.62e-2)" "prognostic unfavorable (2.04e-5)" 16.2 8.4 4.9 7.5 6.8 0.1 39.8 5.1 8.5 13.8 7.8 3.3 10.7 3.6 8.2 11.7 15.6 8.8 8.5 4.8 6.8 2.7 7.6 23.5 14.2 2.3 4.1 3.9 10.4 10.1 1.8 2.1 102.3 5.6 10.9 6.7 9.2 15.4 12.9 10.7 32.5 6.3 15.5 3.5 3.3 7.8 5.5 5.9 3.2 12.8 15.5 8.0 10.2 28.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 345.9 4.4 1.1 1.5 7.1 4.4 1.2 3.4 4.6 2.1 1.6 0.8 3.7 0.2 0.8 2.9 9.0 13.9 0.0 15.3 2.5 0.1 0.2 0.0 1.9 0.2 1.8 0.0 0.0 2.1 14.0 5.3 28.6 3.1 0.2 0.0 0.0 0.0 4.5 0.2 0.0 0.0 0.3 1.3 2.2 0.0 0.6 0.0 2.6 3.7 0.0 1.3 2.9 3.5 0.7 1.2 0.3 0.8 1.0 1.9 0.5 14.9 3.2 0.0 0.3 0.2 2.6 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 6.8 5.1 6.6 6.8 2.7 4.1 3.9 5.6 5.9 89.3 37.5 4.2 67.7 76.2 1.5 7.3 53.5 16.0 59.1 21.0 5.9 207.2 0.0 30.6 4.6 10.9 15.9 23.3 21.0 36.6 45.3 37.8 0.0 77.4 24.2 0.0 4.1 6.7 7.0 2.2 118.8 1.3 16.9 2.8 25.3 106.1 41.7 17.3 125.5 14.0 2.3 77.6 23.1 1.6 2.7 78.5 315.1 0.0 20.0 46.4 EIF3E "eIF3-p48, eIF3e, EIF3S6, INT6" ENSG00000104408 "Eukaryotic translation initiation factor 3 subunit E" P60228 8 108201216-108435333 "Cancer-related genes, Predicted intracellular proteins" "Protein biosynthesis" "Initiation factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023973 Approved Supported Cytosol NA NA Cytosol "HPA023973: AB_1848083" "unprognostic (8.18e-2)" "unprognostic (4.28e-2)" "unprognostic (6.26e-2)" "unprognostic (1.51e-1)" "unprognostic (3.52e-3)" "unprognostic (6.93e-3)" "unprognostic (2.29e-2)" "unprognostic (2.57e-2)" "unprognostic (3.47e-1)" "unprognostic (1.96e-1)" "unprognostic (1.67e-3)" "unprognostic (3.63e-1)" "prognostic unfavorable (3.06e-7)" "unprognostic (2.46e-1)" "unprognostic (1.60e-1)" "unprognostic (1.81e-1)" "unprognostic (2.77e-2)" 88.2 44.0 27.6 49.2 38.2 57.8 75.1 41.5 25.2 101.6 73.6 14.6 47.2 34.4 55.5 47.6 111.2 45.4 41.0 39.5 23.9 22.4 51.8 63.6 60.3 75.3 33.0 19.5 127.6 90.2 29.2 72.5 54.6 28.9 100.1 40.3 22.8 56.9 45.5 100.4 46.7 56.3 73.7 38.4 63.9 49.7 52.7 31.5 100.5 93.8 70.8 50.7 121.7 69.2 49.0 51.7 14.0 39.5 38.7 78.1 59.4 61.5 30.3 40.7 50.3 69.5 146.9 27.8 32.2 50.3 47.9 50.1 38.0 62.1 106.1 42.3 36.2 25.9 38.4 53.7 63.1 63.8 41.7 54.6 84.7 32.2 54.3 55.6 50.4 39.8 110.9 93.4 36.1 100.3 95.8 72.8 68.0 71.3 44.1 53.9 60.9 65.4 95.7 40.6 101.8 48.5 60.8 50.4 82.6 62.5 37.1 46.1 42.0 18.1 15.3 71.7 49.3 65.1 73.2 46.2 28.0 48.4 29.0 40.4 33.3 24.9 60.8 34.6 88.2 31.2 14.0 39.5 7.4 26.6 36.2 52.0 49.0 52.6 37.7 51.7 40.4 78.1 56.1 3.7 38.7 33.6 27.3 45.2 59.4 27.6 38.2 41.5 25.2 23.9 22.4 33.0 19.5 28.9 31.5 125.0 164.2 521.1 900.1 920.2 60.0 77.3 196.1 124.5 205.9 150.1 51.1 533.6 514.0 289.5 296.8 388.9 107.5 70.0 306.5 673.2 507.3 554.3 369.5 167.4 375.7 55.6 285.6 304.5 609.8 52.5 420.5 585.5 490.9 376.1 360.5 84.2 309.4 241.9 308.0 535.0 54.4 187.5 536.7 231.2 100.5 976.5 518.8 456.1 516.4 811.5 EIF4A2 "BM-010, DDX2B, EIF4A, EIF4F" ENSG00000156976 "Eukaryotic translation initiation factor 4A2" Q14240 3 186783205-186789900 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Protein biosynthesis" "Helicase, Hydrolase, Initiation factor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB011690, HPA068286" Uncertain Approved Cytosol NA NA 1000000 Cytosol "CAB011690: AB_732123, HPA068286: AB_2685968" "unprognostic (1.49e-1)" "unprognostic (9.62e-2)" "unprognostic (3.78e-2)" "unprognostic (9.50e-3)" "unprognostic (2.82e-2)" "unprognostic (1.10e-2)" "unprognostic (4.46e-2)" "unprognostic (6.27e-2)" "unprognostic (4.32e-3)" "unprognostic (1.00e-1)" "unprognostic (6.39e-2)" "unprognostic (3.99e-2)" "unprognostic (6.36e-2)" "unprognostic (3.22e-1)" "unprognostic (3.03e-1)" "unprognostic (4.67e-2)" "unprognostic (2.62e-2)" 34.6 66.1 61.2 27.7 79.9 1.9 53.5 121.1 111.5 65.1 52.1 26.5 30.1 30.3 73.1 45.5 44.5 73.9 45.1 83.7 58.4 71.9 63.9 43.5 33.7 36.1 48.9 61.7 142.0 59.0 30.9 84.1 47.3 69.6 57.9 40.1 31.8 43.7 62.8 126.7 19.8 35.6 57.1 41.9 32.5 39.0 32.9 39.5 23.9 67.8 36.4 35.4 61.1 51.7 55.1 19.3 39.4 24.8 33.0 63.4 51.3 10.1 5.1 21.4 3.5 82.7 78.0 6.6 18.3 16.5 19.4 25.6 18.9 3.7 22.7 102.5 26.2 35.9 17.1 31.5 7.7 34.3 21.2 16.6 36.6 6.8 25.3 32.4 7.7 25.7 52.2 37.0 5.6 46.7 98.7 34.4 19.2 12.3 38.3 63.1 1.7 12.2 3.8 21.3 41.0 24.6 15.7 15.2 13.8 38.5 12.4 42.2 8.5 29.7 20.5 38.9 56.7 32.0 28.2 25.1 15.4 7.7 14.8 11.2 30.5 43.2 10.4 10.6 8.1 7.2 39.4 16.0 18.5 28.5 18.2 45.3 55.1 41.9 34.8 19.3 46.1 63.4 50.2 11.0 33.0 24.8 17.4 38.6 51.3 61.2 79.9 121.1 111.5 58.4 71.9 48.9 61.7 69.6 39.5 110.2 187.7 337.3 695.6 613.2 269.9 244.1 206.4 220.8 192.2 247.7 60.9 410.2 560.3 199.1 25.8 233.7 293.3 23.3 81.4 227.6 351.3 637.4 309.0 119.2 199.9 368.7 391.5 183.0 192.6 37.8 357.2 230.1 327.3 376.9 296.7 294.3 160.6 364.6 444.5 452.5 161.0 232.8 455.3 100.9 174.0 540.1 514.8 331.3 287.0 611.0 ELF4 "ELFR, MEF" ENSG00000102034 "E74 like ETS transcription factor 4" Q99607 X 130064874-130110716 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Extravillous trophoblasts: 31.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA058595, HPA060277" Enhanced Supported "Nucleoplasm,Nuclear bodies" NA NA "Nuclear bodies" Nucleoplasm "HPA058595: AB_2683768, HPA060277: AB_2684239" "unprognostic (1.33e-1)" "unprognostic (8.51e-2)" "unprognostic (3.83e-1)" "unprognostic (2.13e-2)" "unprognostic (1.14e-1)" "unprognostic (1.80e-1)" "unprognostic (4.43e-3)" "unprognostic (7.86e-3)" "unprognostic (3.50e-2)" "unprognostic (1.80e-1)" "unprognostic (1.29e-2)" "unprognostic (3.95e-1)" "prognostic unfavorable (6.49e-6)" "unprognostic (1.43e-1)" "unprognostic (5.46e-2)" "unprognostic (2.51e-1)" "prognostic favorable (1.42e-4)" 16.9 3.6 2.0 18.1 2.5 27.6 16.9 0.5 3.0 7.7 10.8 3.1 7.0 8.4 10.5 8.1 10.5 9.5 11.0 7.3 3.1 1.2 5.9 2.5 21.9 33.3 3.8 0.9 12.7 4.5 3.8 4.2 23.5 3.0 6.6 10.9 3.6 5.4 7.9 5.7 9.1 16.3 6.4 4.2 18.9 12.3 3.5 2.9 18.1 3.9 7.4 11.5 11.7 14.4 3.9 6.1 9.4 10.3 8.4 10.3 5.1 22.8 8.5 1.5 0.1 3.9 8.5 22.3 10.7 13.6 13.0 14.4 11.8 16.3 11.7 21.4 14.4 18.0 14.9 8.5 12.5 12.7 12.5 7.0 23.0 11.4 5.4 8.8 20.0 29.5 8.8 14.1 20.8 20.6 8.1 12.5 2.6 8.8 3.2 7.0 13.2 3.2 11.4 1.0 11.6 8.4 7.1 2.7 5.0 7.9 26.4 5.9 2.5 9.5 9.3 2.9 8.4 4.6 19.3 11.6 9.1 7.2 16.9 19.6 1.8 0.7 9.4 10.7 18.5 2.1 1.6 5.4 7.8 10.3 10.3 8.3 3.9 6.2 8.8 6.1 3.5 6.2 7.2 9.4 8.4 7.0 3.7 6.3 5.1 2.0 2.5 0.5 3.0 3.1 1.2 3.8 0.9 3.0 2.9 8.9 4.1 0.5 8.0 12.0 0.0 0.6 0.0 6.7 5.7 0.0 0.0 9.1 0.0 2.2 0.1 4.5 15.6 0.0 3.6 31.1 5.6 5.4 1.1 0.4 8.7 0.0 8.6 6.7 10.2 0.4 1.7 8.9 3.3 7.2 6.6 0.0 5.7 14.0 1.1 0.3 0.0 6.5 3.8 0.0 3.8 9.2 9.4 5.3 5.9 15.5 ELK4 SAP1 ENSG00000158711 "ELK4, ETS transcription factor" P28324 1 205597556-205631962 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Bipolar cells: 95.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 8.7" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028863 Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA028863: AB_10602492" "unprognostic (2.08e-1)" "unprognostic (2.71e-2)" "unprognostic (1.98e-1)" "unprognostic (1.59e-1)" "unprognostic (2.15e-1)" "prognostic favorable (4.65e-4)" "unprognostic (2.97e-1)" "unprognostic (1.48e-1)" "unprognostic (1.19e-1)" "unprognostic (3.53e-1)" "unprognostic (1.27e-2)" "unprognostic (2.64e-1)" "prognostic unfavorable (2.94e-6)" "unprognostic (2.21e-2)" "unprognostic (1.26e-1)" "unprognostic (1.08e-1)" "unprognostic (5.58e-3)" 14.1 7.1 10.0 14.7 12.7 12.0 13.8 16.2 10.4 10.1 8.9 10.4 8.6 7.3 11.3 9.2 11.7 9.5 11.4 10.8 10.6 5.0 15.2 15.6 13.8 19.1 10.0 6.9 13.1 12.4 13.6 16.8 9.5 9.5 32.6 8.7 12.2 12.4 8.2 14.7 17.6 13.5 10.5 8.2 18.3 9.4 8.4 11.0 24.4 10.8 8.3 19.6 15.1 13.2 2.2 1.5 8.7 1.1 1.2 3.1 0.6 8.2 7.5 2.9 7.7 7.1 9.1 7.5 5.6 5.8 4.4 5.2 3.2 8.4 17.6 5.3 6.9 3.3 10.4 6.2 6.8 7.7 20.0 4.4 7.6 12.2 6.8 9.7 14.2 30.3 8.0 8.5 7.0 14.4 8.6 18.6 8.4 6.9 14.8 6.2 11.2 11.7 5.3 4.9 1.9 4.5 8.7 18.3 14.3 5.9 18.2 3.5 4.1 14.4 7.9 9.5 5.4 7.3 4.8 13.4 9.0 10.6 8.0 10.5 11.1 10.1 11.9 7.8 5.8 10.5 8.7 0.8 1.2 1.6 1.1 2.1 1.4 1.8 2.1 1.1 2.2 2.2 3.1 0.4 1.2 0.6 1.5 1.8 0.6 10.0 12.7 16.2 10.4 10.6 5.0 10.0 6.9 9.5 11.0 8.9 11.5 21.4 29.2 34.9 95.4 18.7 28.1 17.4 15.9 29.6 11.8 11.3 3.3 12.9 11.6 35.7 9.8 0.0 15.6 5.2 25.6 62.3 27.7 28.9 8.9 23.8 12.6 25.8 20.0 14.0 23.6 18.5 28.7 5.4 15.8 10.6 12.9 3.5 14.5 13.9 26.7 25.8 23.4 20.0 9.8 42.4 15.3 37.4 17.3 61.0 ELL "C19orf17, ELL1, Men, PPP1R68" ENSG00000105656 "Elongation factor for RNA polymerase II" P55199 19 18442663-18522127 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "Early spermatids: 301.9;Late spermatids: 183.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004202, HPA046076" Uncertain Supported "Nucleoplasm,Nuclear bodies,Cytosol" NA NA Nucleoplasm "Nuclear bodies, Cytosol" "HPA004202: , HPA046076: AB_2679526" "unprognostic (9.49e-2)" "unprognostic (1.38e-1)" "unprognostic (3.26e-3)" "unprognostic (2.07e-1)" "unprognostic (1.64e-1)" "unprognostic (2.10e-1)" "unprognostic (8.26e-2)" "unprognostic (2.71e-1)" "unprognostic (2.34e-1)" "unprognostic (3.00e-2)" "unprognostic (6.28e-3)" "unprognostic (2.38e-2)" "unprognostic (1.57e-1)" "unprognostic (2.07e-1)" "unprognostic (5.12e-1)" "unprognostic (2.46e-1)" "unprognostic (1.06e-1)" 19.9 7.7 5.1 13.4 9.9 38.4 10.8 17.0 9.7 11.9 13.5 7.7 8.6 10.4 12.6 9.5 9.3 9.1 10.9 9.5 5.8 4.4 9.8 11.6 14.2 10.7 6.2 3.5 12.7 14.6 6.2 10.5 27.0 6.3 10.4 4.4 9.1 10.6 9.0 20.3 13.3 10.9 10.0 5.1 15.9 9.3 31.7 7.7 11.0 7.8 7.2 13.6 18.5 13.2 3.1 8.6 17.2 5.6 2.1 7.9 3.3 8.9 4.4 2.3 4.9 2.5 3.2 17.0 7.1 6.3 5.4 5.2 5.0 7.1 11.3 8.8 4.7 3.7 6.3 3.4 7.8 2.7 9.2 8.0 6.8 4.4 4.3 3.8 7.4 8.7 6.5 6.7 7.0 5.5 4.2 3.8 6.2 9.4 15.6 2.8 7.6 8.7 8.1 7.7 5.4 12.6 7.5 3.7 11.9 3.8 6.3 4.2 4.6 5.2 9.0 7.7 3.1 4.5 9.3 6.3 6.3 4.9 8.6 6.6 25.5 16.0 8.4 8.3 12.6 8.9 0.3 5.6 3.8 4.7 4.1 7.9 3.1 2.9 4.2 4.7 2.3 1.9 2.9 17.2 2.1 2.1 8.6 3.0 3.3 5.1 9.9 17.0 9.7 5.8 4.4 6.2 3.5 6.3 7.7 6.0 6.7 6.0 22.3 24.8 4.1 4.0 10.2 6.7 3.4 3.5 3.9 37.4 10.0 7.0 301.9 11.7 10.5 0.0 7.0 14.6 16.0 13.8 10.5 13.4 16.6 1.6 18.9 8.6 11.5 183.8 6.1 13.8 6.8 11.8 9.0 4.2 8.8 2.9 2.8 5.7 3.5 19.4 28.8 19.0 21.8 26.6 57.4 11.4 6.4 18.6 EML4 "C2orf2, ELP120, ROPP120" ENSG00000143924 "Echinoderm microtubule associated protein like 4" Q9HC35 2 42169350-42332548 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 60.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036687, HPA036688, HPA065337" Enhanced Supported "Intermediate filaments,Microtubules,Cytosol" NA NA 41000 Microtubules "Intermediate filaments, Cytosol" "HPA036687: AB_2675251, HPA036688: AB_10671968, HPA065337: AB_2685474" "unprognostic (1.70e-1)" "unprognostic (1.38e-1)" "unprognostic (8.17e-2)" "unprognostic (3.53e-3)" "unprognostic (1.79e-2)" "unprognostic (9.19e-2)" "unprognostic (8.61e-3)" "unprognostic (1.61e-2)" "unprognostic (2.96e-3)" "unprognostic (6.80e-2)" "unprognostic (7.44e-2)" "unprognostic (1.60e-2)" "unprognostic (1.86e-2)" "unprognostic (1.27e-1)" "unprognostic (1.05e-1)" "unprognostic (1.39e-1)" "unprognostic (2.13e-2)" 11.3 17.3 5.8 29.3 6.8 19.2 10.5 4.6 5.2 9.4 21.6 6.7 6.8 20.3 13.6 11.6 10.7 8.7 20.3 6.5 5.1 3.9 11.7 26.4 19.3 27.7 4.6 4.0 12.5 37.8 10.8 11.6 26.9 6.5 8.5 12.8 12.1 17.7 8.9 4.3 17.9 33.5 9.2 5.0 30.9 11.7 14.2 5.3 17.4 13.2 6.9 30.0 14.0 9.0 11.5 4.2 10.0 11.0 9.4 17.5 5.9 14.6 25.5 14.9 11.8 5.4 8.9 16.3 9.1 7.2 10.1 9.8 26.6 18.5 13.4 6.3 8.9 15.6 7.6 12.7 8.8 17.7 26.2 10.7 12.3 7.9 60.9 6.9 9.3 12.7 9.7 3.3 13.4 9.1 4.9 7.0 4.6 12.1 13.6 10.9 8.6 8.7 2.5 15.2 18.9 7.4 9.0 23.6 7.9 8.3 21.3 14.7 29.6 9.0 9.4 6.9 14.1 4.9 3.7 8.2 10.4 13.9 8.3 8.2 15.3 10.6 11.6 9.0 8.9 7.2 4.4 3.9 7.7 7.8 10.9 16.3 11.5 13.0 12.7 3.3 7.9 11.4 8.3 10.0 9.4 11.0 4.2 17.5 5.9 5.8 6.8 4.6 5.2 5.1 3.9 4.6 4.0 6.5 5.3 56.6 103.1 87.1 59.5 59.8 36.4 5.7 40.8 32.1 69.4 38.4 45.2 112.3 14.9 30.5 25.2 34.6 46.7 0.0 65.3 37.0 71.8 58.2 46.2 54.6 62.4 15.9 98.2 48.5 34.8 23.1 22.2 58.2 15.1 24.4 56.5 34.1 37.0 58.3 21.5 31.5 48.1 6.5 46.2 40.3 39.2 69.6 99.4 95.6 60.7 86.1 EP300 "KAT3B, p300" ENSG00000100393 "E1A binding protein p300" Q09472 22 41091786-41180079 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Acyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000146, HPA003128, HPA004112" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000146: AB_2533138, HPA003128: AB_1078745, HPA004112: AB_1078746" "unprognostic (7.67e-2)" "unprognostic (5.56e-2)" "unprognostic (2.29e-1)" "unprognostic (2.52e-1)" "unprognostic (6.10e-3)" "unprognostic (1.66e-1)" "unprognostic (2.21e-2)" "unprognostic (2.13e-1)" "unprognostic (1.54e-1)" "unprognostic (8.97e-2)" "unprognostic (1.74e-2)" "unprognostic (8.54e-2)" "prognostic favorable (7.45e-5)" "unprognostic (7.97e-2)" "unprognostic (1.41e-1)" "unprognostic (1.01e-1)" "unprognostic (8.66e-2)" 16.8 14.8 19.1 13.9 15.5 45.3 14.5 33.0 20.6 14.8 16.8 15.6 18.9 11.1 18.1 11.6 16.8 15.7 16.5 10.7 16.6 8.3 11.5 12.2 14.1 12.9 16.9 12.7 20.2 15.7 26.4 14.5 27.7 13.8 13.2 12.2 12.3 15.3 17.9 19.5 18.2 17.4 13.8 12.7 15.9 14.7 20.6 18.6 29.3 16.9 10.9 14.1 18.7 22.5 4.3 4.4 9.8 3.9 5.7 3.9 2.3 15.7 11.3 19.2 11.9 12.2 13.2 17.2 7.6 11.0 11.4 11.0 14.4 5.8 16.4 6.7 15.0 10.5 12.7 27.7 10.4 12.7 15.9 18.4 12.3 13.0 11.2 13.9 29.2 13.9 12.9 10.9 16.5 13.8 10.0 12.6 9.5 13.0 22.6 9.0 5.8 8.4 9.1 13.8 19.8 7.9 17.3 9.0 10.2 10.8 20.9 6.1 6.5 26.9 13.7 13.1 16.7 9.7 17.0 16.3 11.4 13.8 8.1 10.8 15.5 7.3 25.6 8.4 9.0 10.8 5.0 3.2 3.0 3.7 3.9 3.2 4.3 3.6 3.9 4.4 2.9 3.1 2.6 9.8 5.7 2.1 3.0 2.6 2.3 19.1 15.5 33.0 20.6 16.6 8.3 16.9 12.7 13.8 18.6 62.5 45.1 44.7 19.0 21.9 43.6 25.4 53.5 29.4 18.2 24.4 33.4 15.3 3.3 13.2 12.6 27.2 22.2 46.7 16.0 15.4 23.4 24.1 24.3 24.1 15.9 23.8 23.7 34.4 59.8 3.4 26.7 31.6 8.5 20.8 23.1 31.8 20.2 26.6 28.7 9.2 31.1 25.8 15.6 20.6 29.9 22.6 25.3 26.6 20.3 30.6 EPAS1 "bHLHe73, HIF2A, HLF, MOP2, PASD2" ENSG00000116016 "Endothelial PAS domain protein 1" Q99814 2 46293667-46386703 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Angiogenesis, Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Congenital erythrocytosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 200.8" "Cell type enhanced" "Detected in many" 6 "Endothelial cells: 341.0;Ito cells: 438.9;Smooth muscle cells: 281.4;Syncytiotrophoblasts: 292.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 16 "basophil: 14.9;eosinophil: 7.1" "Lineage enriched" "Detected in single" 21 "granulocytes: 14.9" "Cell line enhanced" "Detected in many" "BEWO: 46.9;BJ hTERT+: 46.2;HHSteC: 58.7;RT4: 58.1;TIME: 58.0;U-138 MG: 50.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA031200, HPA069697" Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA031200: AB_2673785, HPA069697: AB_2732139" "unprognostic (1.74e-1)" "unprognostic (9.47e-2)" "unprognostic (1.29e-2)" "unprognostic (2.74e-1)" "unprognostic (5.25e-2)" "unprognostic (1.75e-1)" "unprognostic (2.22e-2)" "unprognostic (8.67e-2)" "unprognostic (6.00e-2)" "unprognostic (9.72e-2)" "unprognostic (1.55e-2)" "unprognostic (9.29e-2)" "prognostic favorable (2.63e-4)" "unprognostic (6.66e-3)" "unprognostic (7.75e-2)" "unprognostic (7.56e-2)" "unprognostic (1.36e-1)" 71.2 14.2 12.5 17.1 15.7 0.8 101.7 5.3 13.9 24.9 20.9 8.9 11.3 12.0 28.8 13.0 21.6 24.8 35.2 40.0 12.8 11.0 35.2 31.2 200.8 27.2 14.3 11.1 20.2 15.5 18.1 9.4 119.6 18.4 20.7 11.5 41.2 13.3 18.7 25.2 13.0 15.6 19.2 12.5 20.5 12.8 13.8 8.0 1.1 43.8 15.2 10.3 32.2 39.3 0.0 0.0 14.9 0.1 0.7 0.1 0.1 5.3 5.7 0.3 0.4 27.6 17.8 46.9 16.9 46.2 9.7 10.6 1.0 0.9 0.0 4.2 32.2 9.7 2.6 0.1 13.5 7.3 0.1 0.2 0.0 1.8 12.0 58.7 0.0 3.4 26.0 18.7 19.0 13.4 7.2 33.4 0.1 0.5 0.0 5.9 4.6 0.1 0.1 0.2 3.7 3.2 0.1 0.6 1.7 6.0 58.1 0.2 12.0 13.3 30.6 3.6 12.5 2.0 2.3 58.0 50.4 1.4 6.7 1.4 0.0 0.0 0.0 36.7 0.9 1.2 14.9 0.1 7.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.0 0.1 0.1 12.5 15.7 5.3 12.6 12.8 11.0 14.3 11.1 18.4 8.0 71.5 137.9 8.1 61.5 42.7 3.5 58.5 50.9 30.8 96.7 3.5 9.8 93.6 1.7 15.5 12.6 341.0 66.4 0.0 45.9 256.0 104.5 46.7 40.4 77.4 47.9 0.0 4.1 438.9 58.4 41.8 11.5 23.9 27.0 0.0 13.6 89.1 25.9 40.4 6.0 24.0 57.7 278.1 281.4 1.2 1.7 29.1 292.5 9.6 11.6 58.0 EPS15 "AF-1P, MLLT5" ENSG00000085832 "Epidermal growth factor receptor pathway substrate 15" P42566 1 51354263-51519328 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Endocytosis, Host-virus interaction, Protein transport, Transport" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008451, CAB010164, HPA061431" Approved Enhanced Vesicles,Cytosol "Intracellular and membrane" NA NA 67000 "Vesicles, Cytosol" "CAB010164: AB_631445, HPA008451: AB_1848221, HPA061431: AB_2732662" "unprognostic (1.45e-2)" "prognostic unfavorable (6.44e-4)" "unprognostic (1.05e-2)" "unprognostic (7.72e-3)" "unprognostic (3.99e-1)" "unprognostic (1.42e-1)" "unprognostic (4.96e-3)" "unprognostic (9.26e-2)" "unprognostic (4.13e-2)" "unprognostic (5.80e-2)" "unprognostic (1.17e-1)" "unprognostic (1.41e-1)" "unprognostic (5.36e-2)" "unprognostic (8.73e-3)" "unprognostic (2.13e-1)" "unprognostic (1.21e-1)" "unprognostic (1.24e-1)" 39.0 26.9 35.5 25.3 27.8 13.2 19.3 22.2 41.0 25.7 16.7 35.7 16.2 11.4 21.8 21.3 19.6 14.1 19.3 18.9 40.7 26.0 21.0 19.1 24.4 30.7 36.2 11.2 22.4 10.9 17.0 14.6 22.8 20.3 22.5 15.5 25.7 24.3 16.4 30.9 18.1 19.3 18.2 36.8 33.8 15.2 32.4 33.1 25.0 20.3 23.4 32.1 25.3 17.0 16.1 10.8 14.9 12.2 10.7 18.7 8.0 14.8 4.4 9.6 9.0 22.3 22.3 24.0 10.4 16.4 8.5 12.6 6.1 8.3 30.3 10.7 16.2 17.4 14.1 12.4 9.9 12.9 34.2 7.8 26.9 7.6 7.2 21.0 15.3 24.9 18.1 9.2 14.9 20.3 14.8 15.8 10.8 16.7 13.8 12.9 7.3 12.3 8.3 13.2 10.4 7.2 10.1 14.6 6.6 11.2 18.4 6.6 9.2 12.3 22.0 17.9 27.7 8.9 10.9 21.9 7.9 8.6 15.9 8.6 16.5 16.7 20.4 11.8 17.4 7.0 14.9 10.1 11.6 10.1 10.7 15.3 16.1 12.2 15.6 10.8 10.0 7.3 10.5 7.8 10.7 12.2 7.1 18.7 8.0 35.5 27.8 22.2 41.0 40.7 26.0 36.2 11.2 20.3 33.1 32.8 43.7 52.2 25.1 38.1 16.1 53.7 20.4 26.8 21.6 41.8 29.5 17.7 16.6 12.4 21.7 42.7 20.1 0.0 16.4 15.6 33.6 48.2 23.2 33.7 65.6 27.0 27.6 74.9 76.1 45.1 60.9 39.3 97.8 33.3 31.1 41.6 19.4 24.1 45.3 22.7 26.0 38.8 31.5 70.5 36.4 44.5 23.8 47.5 19.5 42.3 ERBB2 "CD340, HER-2, HER2, NEU, NGL" ENSG00000141736 "Erb-b2 receptor tyrosine kinase 2" P04626 17 39687914-39730426 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Collecting duct cells: 129.1;Enterocytes: 93.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.8" "Lineage enriched" "Detected in many" 4 "T-cells: 8.8" "Group enriched" "Detected in many" 41 "OE19: 366.2;SK-BR-3: 179.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555" Enhanced Enhanced "Plasma membrane,Cytosol" NA NA 430000 "Plasma membrane" Cytosol "CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: AB_2665610, HPA001060: AB_2666185, HPA001338: AB_2666279, HPA001383: AB_1078500" "unprognostic (1.97e-1)" "unprognostic (6.60e-3)" "unprognostic (6.21e-2)" "prognostic unfavorable (8.99e-8)" "unprognostic (2.96e-2)" "unprognostic (1.40e-2)" "unprognostic (1.97e-2)" "unprognostic (9.04e-2)" "unprognostic (1.79e-2)" "unprognostic (1.20e-3)" "prognostic unfavorable (9.17e-4)" "unprognostic (3.92e-1)" "prognostic favorable (2.41e-14)" "unprognostic (9.29e-2)" "unprognostic (1.40e-1)" "unprognostic (3.75e-2)" "unprognostic (1.96e-1)" 5.8 2.4 5.2 10.4 7.0 0.1 20.1 4.2 7.0 19.1 46.5 9.1 55.2 21.6 14.9 18.7 40.9 22.7 26.6 24.8 6.3 3.1 37.5 21.5 17.6 3.7 5.1 5.6 19.3 16.2 27.7 8.1 60.8 7.5 23.6 16.6 15.9 28.7 58.1 8.9 35.3 47.2 10.9 4.5 4.0 17.1 6.5 3.7 2.8 35.7 20.8 22.9 19.7 20.3 1.3 0.3 2.1 0.4 0.9 8.8 2.2 2.1 2.5 2.9 1.8 3.5 2.4 3.9 1.5 2.5 3.3 2.8 1.9 5.8 0.1 3.1 3.5 1.8 6.7 0.1 3.4 1.5 0.2 2.2 0.1 2.0 3.1 2.0 0.0 0.0 2.4 3.2 2.0 1.2 3.2 1.3 0.1 0.3 0.1 2.4 3.3 0.3 0.1 5.2 366.2 0.6 0.2 1.1 0.3 3.4 6.7 0.5 0.1 2.9 179.8 0.9 3.7 5.0 0.1 0.1 1.7 2.2 2.1 0.9 0.3 0.1 0.1 0.1 0.0 5.6 1.6 0.4 0.8 8.8 0.3 0.7 0.9 0.5 2.5 0.3 1.3 1.0 2.5 2.1 0.9 0.2 0.2 0.4 2.2 5.2 7.0 4.2 7.0 6.3 3.1 5.1 5.6 7.5 3.7 38.7 34.4 1.3 21.0 12.5 4.3 13.5 30.6 10.7 15.9 129.1 11.8 9.7 6.6 27.1 0.3 4.6 93.2 0.0 22.3 75.4 11.0 33.4 0.0 10.4 3.5 6.4 15.0 12.3 2.4 0.7 17.0 1.8 10.1 1.0 56.6 30.9 26.2 42.1 21.5 20.7 5.9 0.0 10.3 7.1 5.3 16.6 19.0 2.2 63.0 28.1 ERBB3 "HER3, LCCS2" ENSG00000065361 "Erb-b2 receptor tyrosine kinase 3" P21860 12 56076799-56103505 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Cholangiocytes: 180.9;Enterocytes: 163.1;Paneth cells: 165.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.3" "Lineage enriched" "Detected in many" 4 "granulocytes: 5.3" "Cell line enhanced" "Detected in many" "Hep G2: 30.9;MCF7: 20.2;OE19: 31.8;RT4: 24.2;SK-BR-3: 28.4;SK-MEL-30: 37.9;T-47d: 31.5;WM-115: 40.2" "Low region specificity" "Detected in many" "CAB025331, HPA045396" Uncertain Supported "Plasma membrane,Actin filaments" "Secreted - unknown location" NA NA 420000 "Plasma membrane" "Actin filaments" "CAB025331: , HPA045396: AB_2679312" "unprognostic (2.97e-1)" "unprognostic (2.71e-2)" "unprognostic (1.91e-1)" "unprognostic (8.97e-2)" "unprognostic (1.63e-1)" "unprognostic (1.07e-3)" "unprognostic (2.31e-3)" "unprognostic (2.66e-2)" "unprognostic (9.89e-2)" "unprognostic (4.30e-2)" "unprognostic (4.76e-3)" "unprognostic (5.77e-2)" "unprognostic (1.06e-2)" "unprognostic (4.56e-2)" "unprognostic (1.57e-1)" "unprognostic (6.72e-3)" "unprognostic (2.07e-2)" 1.1 1.4 11.6 12.6 16.5 0.6 26.8 2.0 16.7 6.8 40.5 40.3 12.0 37.7 2.8 7.5 29.4 5.7 22.9 3.4 18.6 9.0 16.5 33.9 13.4 0.5 23.5 9.3 0.9 21.5 11.4 1.0 15.4 14.9 16.8 29.7 5.5 36.8 22.3 1.1 30.7 41.3 3.2 27.4 0.5 32.9 1.2 23.8 0.0 4.5 7.4 8.5 11.8 14.4 0.9 0.7 5.3 0.6 1.2 1.2 0.2 10.0 0.6 0.8 0.3 0.0 0.0 16.4 0.8 1.9 1.1 1.1 5.5 18.2 0.0 0.2 0.2 0.1 8.6 1.2 1.9 0.6 0.2 0.8 0.0 0.3 30.9 0.0 0.0 0.1 0.4 2.5 0.2 0.0 0.2 0.0 0.1 0.7 0.3 0.1 20.2 0.1 0.3 2.8 31.8 0.4 0.1 1.9 0.5 2.1 24.2 0.9 0.3 0.7 28.4 37.9 2.7 31.5 0.1 0.0 0.1 1.1 0.6 0.1 0.2 0.1 0.1 0.1 0.0 40.2 5.3 0.4 0.8 0.9 0.4 0.4 0.4 0.7 0.3 0.3 0.9 0.6 1.2 3.3 1.2 0.6 0.7 0.8 0.2 11.6 16.5 2.0 16.7 18.6 9.0 23.5 9.3 14.9 23.8 110.2 61.2 1.3 13.0 16.3 1.5 1.4 180.9 21.4 61.4 33.2 2.0 44.4 1.7 41.9 0.9 2.2 163.1 0.0 77.1 73.6 2.7 83.4 1.1 83.9 5.5 0.0 89.5 6.7 1.9 0.0 1.4 1.7 52.3 2.8 134.3 11.3 75.9 165.5 0.0 31.8 1.1 6.5 1.7 2.4 2.3 32.2 84.1 1.5 124.3 62.5 ERBB4 "ALS19, HER4" ENSG00000178568 "Erb-b2 receptor tyrosine kinase 4" Q15303 2 211375717-212538841 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Lactation, Transcription, Transcription regulation" "Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 24.5" "Cell type enhanced" "Detected in many" 10 "Bipolar cells: 11.2;Cardiomyocytes: 15.3;Ciliated cells: 26.8;Club cells: 17.0;Collecting duct cells: 12.2;Muller glia cells: 12.4" "Cancer enhanced" "Detected in many" "breast cancer: 4.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 9.6;EFO-21: 7.2;HEK 293: 5.3;RPTEC TERT1: 7.8;SCLC-21H: 4.4;T-47d: 7.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000276, HPA012016, CAB025522" Enhanced NA NA 140000 "CAB000276: , CAB025522: , HPA012016: AB_1846541" "unprognostic (1.48e-1)" "unprognostic (3.28e-1)" "unprognostic (4.31e-3)" "unprognostic (1.76e-3)" "unprognostic (3.59e-1)" "unprognostic (2.75e-1)" "unprognostic (2.88e-1)" "unprognostic (9.56e-2)" "unprognostic (2.07e-1)" "unprognostic (4.67e-3)" "unprognostic (1.07e-1)" "unprognostic (3.61e-1)" "unprognostic (7.14e-3)" "unprognostic (1.49e-3)" "unprognostic (1.41e-1)" "unprognostic (1.14e-1)" "unprognostic (4.11e-2)" 1.6 1.9 15.1 1.2 15.0 1.0 13.4 18.6 14.1 7.8 1.1 7.6 8.8 1.1 1.5 1.2 1.3 24.5 1.2 7.0 14.3 6.5 11.9 1.1 2.9 1.2 7.8 10.7 1.3 2.4 10.8 5.1 1.3 8.8 1.7 1.1 2.0 9.7 18.1 3.8 1.8 1.2 1.1 7.3 1.2 1.5 7.6 12.0 0.0 4.5 1.1 1.2 1.4 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 9.6 0.2 0.0 0.0 0.0 0.0 0.3 0.5 0.1 0.0 0.0 0.0 7.2 1.0 0.0 0.4 0.2 0.0 0.0 0.1 5.3 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.8 0.0 0.0 0.5 0.0 7.8 0.4 4.4 0.2 0.0 0.1 0.1 0.1 7.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 15.0 18.6 14.1 14.3 6.5 7.8 10.7 8.8 12.0 0.0 9.3 0.0 0.8 0.6 11.2 15.3 0.0 26.8 17.0 12.2 0.0 0.0 5.0 0.4 4.1 0.1 0.0 0.0 0.4 0.1 0.2 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.3 1.7 0.0 3.3 0.0 0.0 12.4 0.0 0.0 0.4 0.0 1.4 6.5 3.1 1.9 1.5 1.1 0.0 0.0 0.0 1.0 ERC1 "CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2" ENSG00000082805 "ELKS/RAB6-interacting/CAST family member 1" Q8IUD2 12 990509-1495933 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Horizontal cells: 174.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019513, HPA019523, HPA024130" Approved Supported "Vesicles,Plasma membrane,Cytosol" NA NA Cytosol "Vesicles, Plasma membrane" "HPA019513: AB_1856012, HPA019523: AB_1856013, HPA024130: AB_1856014" "unprognostic (2.41e-1)" "unprognostic (4.00e-2)" "unprognostic (2.14e-1)" "unprognostic (5.70e-2)" "unprognostic (2.81e-1)" "unprognostic (1.32e-1)" "unprognostic (5.50e-2)" "unprognostic (8.49e-2)" "unprognostic (2.53e-1)" "unprognostic (3.26e-2)" "unprognostic (1.04e-1)" "unprognostic (6.79e-2)" "unprognostic (3.75e-3)" "unprognostic (4.19e-2)" "unprognostic (3.01e-1)" "unprognostic (7.37e-2)" "prognostic unfavorable (7.01e-4)" 12.6 11.4 10.3 12.5 14.7 7.4 15.1 41.7 10.4 11.2 11.9 8.5 9.2 4.3 17.1 11.0 13.7 9.8 9.9 14.7 10.0 11.2 11.2 8.0 8.8 5.4 9.0 6.4 12.5 8.6 24.3 19.4 13.2 10.7 11.4 7.5 10.1 9.3 14.4 9.2 9.9 6.4 22.1 8.5 7.3 8.6 11.0 9.9 9.8 15.3 7.2 8.6 15.7 15.3 8.6 2.9 2.1 3.8 1.1 3.5 0.5 2.9 7.3 3.9 2.6 10.4 8.8 5.4 9.2 7.4 6.3 5.8 6.4 3.6 4.5 1.3 11.9 6.3 4.9 8.3 7.1 8.8 9.5 4.2 11.1 7.3 3.2 7.9 5.7 2.6 7.1 6.2 11.1 20.8 7.6 8.1 2.9 3.3 8.9 4.7 3.2 1.8 1.2 6.2 2.8 3.5 3.6 14.8 1.4 6.2 5.3 2.3 4.6 14.4 3.3 5.2 14.7 3.4 2.4 15.0 10.9 11.1 8.0 8.6 2.4 4.5 6.7 7.1 3.4 4.8 1.4 2.8 2.1 1.6 1.0 2.2 8.6 2.4 2.4 2.4 5.6 3.5 2.6 2.1 1.1 3.8 2.9 2.2 0.5 10.3 14.7 41.7 10.4 10.0 11.2 9.0 6.4 10.7 9.9 23.8 21.4 15.2 22.2 18.7 34.0 51.9 15.3 14.7 23.9 19.2 45.2 25.8 1.7 17.5 29.4 26.3 7.0 0.0 11.7 14.8 17.3 21.4 13.9 15.3 10.8 174.8 28.8 24.5 10.7 24.2 23.0 11.3 13.5 16.2 8.4 47.3 15.2 9.0 29.0 3.3 34.7 19.4 16.5 15.6 28.4 24.0 65.8 7.4 7.6 29.2 ERG "erg-3, p55" ENSG00000157554 "ERG, ETS transcription factor" P11308 21 38380027-38661780 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 6 "Endothelial cells: 84.3;granulocytes: 22.1;Ito cells: 63.3" "Cancer enhanced" "Detected in all" "prostate cancer: 18.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "myeloid DC: 1.7;NK-cell: 1.0" "Group enriched" "Detected in many" 5 "dendritic cells: 1.7;NK-cells: 1.0" "Group enriched" "Detected in some" 5 "HUVEC TERT2: 43.7;MOLT-4: 14.3;REH: 46.4;TIME: 35.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB018377, HPA046598" Approved Approved Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB018377: AB_675518, HPA046598: AB_2679715" "unprognostic (2.14e-1)" "prognostic unfavorable (6.18e-6)" "unprognostic (6.44e-3)" "unprognostic (8.64e-3)" "unprognostic (5.65e-2)" "unprognostic (1.91e-1)" "unprognostic (9.03e-4)" "unprognostic (4.30e-2)" "unprognostic (2.63e-2)" "unprognostic (1.29e-1)" "unprognostic (3.42e-2)" "unprognostic (2.89e-1)" "prognostic unfavorable (3.94e-4)" "unprognostic (4.31e-3)" "unprognostic (3.88e-2)" "unprognostic (2.64e-2)" "unprognostic (5.63e-3)" 39.1 4.2 5.7 6.5 8.5 6.6 20.5 3.6 7.0 17.9 5.2 2.3 5.6 3.3 16.9 9.0 6.2 9.2 11.6 10.1 6.2 3.6 10.8 6.0 19.9 7.4 8.0 1.8 7.7 4.8 2.3 3.9 23.2 8.0 8.1 3.6 7.8 4.2 5.6 13.5 5.3 6.2 11.8 4.7 32.5 5.0 4.8 5.0 2.4 10.8 9.1 3.6 9.6 15.8 0.0 1.7 0.0 0.2 1.0 0.0 0.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 7.1 0.0 0.0 0.3 0.0 0.0 43.7 0.0 0.0 0.0 0.0 0.3 14.3 0.0 0.1 0.0 0.0 46.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 35.4 0.2 0.7 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.4 5.7 8.5 3.6 7.0 6.2 3.6 8.0 1.8 8.0 5.0 0.0 4.6 1.9 1.5 3.1 0.0 2.5 7.6 0.0 2.3 0.0 0.0 0.0 0.0 0.1 0.5 84.3 0.0 0.0 0.0 0.0 2.1 0.4 22.1 0.8 0.2 0.0 0.0 63.3 9.8 1.5 0.9 1.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.2 0.9 3.0 0.0 0.0 0.0 0.6 ESR1 "ER-alpha, Era, ESR, NR3A1" ENSG00000091831 "Estrogen receptor 1" P03372 6 151656691-152129619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 64.5;endometrium 1: 68.9" "Group enriched" "Detected in many" 6 "Early spermatids: 36.0;Hepatocytes: 48.4;Horizontal cells: 58.8" "Group enriched" "Detected in many" 9 "breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.5" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 9 "MCF7: 24.9;T-47d: 32.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB000037, HPA000449, HPA000450, CAB055099, CAB072858" Enhanced Approved Nucleoplasm,Vesicles NA NA Vesicles Nucleoplasm "CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: AB_2665701, HPA000449: AB_1078753, HPA000450: AB_1078754" "unprognostic (8.28e-2)" "unprognostic (3.02e-2)" "unprognostic (1.43e-2)" "prognostic favorable (5.47e-7)" "unprognostic (4.79e-1)" "unprognostic (2.43e-3)" "unprognostic (4.10e-5)" "unprognostic (9.92e-2)" "unprognostic (2.20e-1)" "unprognostic (7.17e-2)" "unprognostic (7.35e-2)" "unprognostic (3.45e-1)" "unprognostic (1.20e-2)" "unprognostic (7.91e-3)" "unprognostic (6.45e-2)" "unprognostic (1.25e-1)" "unprognostic (1.52e-1)" 3.0 0.9 0.5 1.6 0.5 0.2 16.2 0.8 0.4 64.5 1.5 0.2 2.2 0.1 68.9 27.7 1.1 26.7 1.9 1.1 0.5 0.8 1.5 6.6 3.6 1.6 0.4 0.1 14.2 0.4 0.0 9.3 0.9 0.6 3.6 0.1 2.6 1.6 4.1 2.0 0.6 0.5 20.8 0.4 1.6 0.3 1.9 0.4 1.9 1.3 2.2 2.5 3.8 23.7 0.6 1.0 0.0 0.8 0.3 2.5 1.0 0.3 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.4 0.0 0.0 0.0 0.6 0.0 24.9 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 1.8 0.0 0.0 0.0 0.3 0.0 0.1 32.2 0.0 0.0 0.1 0.1 0.3 0.0 3.0 0.5 0.0 0.1 0.3 0.0 0.0 0.8 0.0 0.3 0.2 1.0 0.6 1.3 0.4 1.0 0.4 2.5 0.9 0.0 0.3 0.0 0.0 0.3 1.0 0.5 0.5 0.8 0.4 0.5 0.8 0.4 0.1 0.6 0.4 0.0 0.6 0.0 1.4 0.9 3.8 4.5 0.0 1.4 1.2 0.0 7.9 0.1 1.7 0.0 36.0 0.6 0.0 0.0 0.2 0.1 4.7 0.6 2.3 48.4 0.9 58.8 1.7 6.7 4.7 6.9 3.7 2.4 1.7 0.0 0.0 2.7 0.2 0.0 2.1 3.3 4.0 0.0 1.4 1.6 1.2 1.5 0.1 0.0 0.0 8.4 ETNK1 "EKI, EKI1" ENSG00000139163 "Ethanolamine kinase 1" Q9HBU6 12 22625075-22690665 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Lipid biosynthesis, Lipid metabolism, Phospholipid biosynthesis, Phospholipid metabolism" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Early spermatids: 201.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010712, HPA029407" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane, Cytosol" "HPA010712: AB_2668349, HPA029407: AB_2673026" "unprognostic (2.06e-1)" "unprognostic (7.48e-2)" "unprognostic (1.23e-3)" "unprognostic (2.19e-1)" "unprognostic (8.79e-3)" "unprognostic (1.31e-2)" "prognostic unfavorable (5.85e-4)" "unprognostic (3.98e-3)" "unprognostic (8.30e-2)" "unprognostic (7.97e-3)" "unprognostic (2.01e-1)" "unprognostic (1.64e-2)" "unprognostic (4.53e-3)" "unprognostic (2.77e-1)" "unprognostic (2.91e-1)" "unprognostic (3.01e-1)" "prognostic favorable (1.75e-4)" 15.7 17.7 15.2 41.1 19.4 13.7 16.9 19.7 22.2 12.9 33.2 16.4 14.6 27.2 16.6 24.1 14.7 13.1 27.3 10.4 15.6 23.9 22.0 30.2 19.6 18.5 17.2 15.8 17.2 14.9 15.8 30.6 13.4 18.9 13.8 19.5 15.9 16.7 14.7 8.2 17.8 24.5 10.0 17.1 18.3 53.7 22.3 17.5 33.4 17.6 8.2 16.5 14.2 18.6 16.2 10.7 28.1 17.6 14.0 15.7 13.4 6.7 14.0 15.6 14.4 11.3 11.4 11.6 8.0 6.0 8.3 8.6 10.8 17.1 20.1 7.2 5.2 8.7 5.1 13.7 3.8 15.0 16.7 11.1 16.6 6.2 9.3 10.8 15.9 15.3 7.4 3.7 11.2 9.5 13.3 10.3 7.9 19.9 8.5 11.0 4.6 17.3 32.4 30.2 8.7 9.2 15.6 13.8 16.1 13.8 9.2 5.0 8.8 8.7 7.6 12.5 22.4 11.8 15.4 8.8 6.6 10.6 8.9 12.0 6.2 7.7 21.6 8.4 10.4 11.0 28.1 11.7 12.1 12.9 17.5 12.7 16.2 14.1 11.9 10.7 13.0 15.7 15.5 11.5 14.0 17.6 9.7 15.3 13.4 15.2 19.4 19.7 22.2 15.6 23.9 17.2 15.8 18.9 17.5 44.7 25.1 40.9 63.3 128.1 40.4 11.0 53.5 72.3 35.2 41.8 47.1 27.9 23.2 26.3 201.9 28.7 55.0 0.0 39.6 20.3 28.6 70.5 33.5 38.4 37.5 25.4 103.9 27.6 78.9 26.1 22.5 44.7 64.1 22.6 52.6 21.4 29.0 46.1 20.1 26.4 35.5 38.8 44.3 47.7 15.1 148.8 63.0 39.2 36.0 60.2 ETV1 ER81 ENSG00000006468 "ETS variant 1" P50549 7 13891228-13991425 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 90.0;salivary gland: 45.8" "Cell type enhanced" "Detected in many" 16 "Alveolar cells type 2: 112.4;Cardiomyocytes: 72.8;Intestinal endocrine cells: 190.4" "Cancer enhanced" "Detected in all" "glioma: 22.5" "Region enriched" "Detected in all" 8 "cerebellum: 90.0" "Cell type enriched" "Detected in single" 5 "T-reg: 3.1" "Lineage enriched" "Detected in single" 5 "T-cells: 3.1" "Cell line enhanced" "Detected in many" "AN3-CA: 22.2;hTERT-RPE1: 25.6;SCLC-21H: 26.3;U-87 MG: 51.8;WM-115: 25.6" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 418.9" "HPA068389, HPA077249" Supported Approved Nucleoplasm No No Nucleoplasm "HPA068389: , HPA077249: AB_2686829" "unprognostic (2.45e-1)" "unprognostic (1.01e-1)" "unprognostic (6.98e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-2)" "unprognostic (2.13e-2)" "unprognostic (1.64e-7)" "unprognostic (7.08e-3)" "unprognostic (7.21e-2)" "unprognostic (2.36e-1)" "unprognostic (2.01e-1)" "unprognostic (3.02e-1)" "unprognostic (1.51e-3)" "unprognostic (2.21e-2)" "unprognostic (2.05e-1)" "unprognostic (1.05e-1)" "unprognostic (1.20e-2)" 2.5 12.4 8.1 1.1 11.7 0.2 4.4 90.0 35.2 1.4 2.4 3.1 0.1 1.2 2.4 1.3 1.5 1.1 9.2 18.0 7.0 4.5 2.1 2.0 14.9 0.7 4.5 6.9 1.0 1.6 11.4 7.4 1.9 8.3 3.1 2.4 0.9 45.8 7.1 0.9 1.5 1.9 2.0 3.5 4.5 1.7 4.5 2.9 0.3 6.5 0.9 4.7 1.8 1.3 0.0 0.0 0.0 0.6 0.0 3.1 0.2 0.0 1.6 11.6 22.2 4.1 12.2 0.0 1.0 3.9 0.6 2.6 0.0 5.3 0.0 1.2 1.8 3.2 0.1 0.4 1.2 1.4 0.3 0.5 0.6 1.0 0.0 2.4 3.8 1.5 3.6 0.0 7.6 0.6 25.6 5.0 0.3 3.4 0.1 4.7 0.0 0.0 0.0 17.5 0.6 11.8 0.0 7.1 0.9 7.9 0.1 26.3 5.1 0.0 0.4 6.3 4.2 0.4 0.1 2.7 2.3 0.7 4.5 4.3 4.0 1.2 0.0 51.8 0.2 25.6 0.0 0.2 0.0 0.1 0.6 0.3 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.2 8.1 11.7 90.0 10.9 7.0 4.5 4.5 6.9 8.3 2.9 17.9 112.4 0.0 2.5 0.9 4.2 72.8 38.2 1.4 1.2 3.5 0.0 0.4 5.0 2.7 18.7 5.2 0.0 0.0 0.8 0.3 4.2 0.2 2.3 11.0 2.6 4.8 190.4 1.8 6.0 6.6 1.4 0.8 11.8 0.0 0.7 12.2 0.9 0.0 32.5 2.7 0.4 19.4 8.2 0.5 1.0 1.1 0.2 0.7 1.1 0.3 ETV4 "E1A-F, E1AF, PEA3" ENSG00000175832 "ETS variant 4" P43268 17 43527844-43579620 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 38.4" "Cell type enhanced" "Detected in many" 6 "Cholangiocytes: 10.2;Distal tubular cells: 14.9;Extravillous trophoblasts: 11.2;Intestinal endocrine cells: 14.3;Syncytiotrophoblasts: 12.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in single" "neutrophil: 1.3" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "AN3-CA: 45.2;Hep G2: 42.4;SK-MEL-30: 48.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA005768 Approved Supported "Nucleoli rim,Mitotic chromosome" Yes No "Nucleoli rim" "Mitotic chromosome" "HPA005768: AB_1848294" "unprognostic (2.32e-1)" "unprognostic (7.33e-2)" "unprognostic (2.14e-1)" "unprognostic (2.51e-1)" "unprognostic (1.97e-2)" "unprognostic (3.14e-3)" "prognostic unfavorable (2.48e-4)" "unprognostic (1.58e-2)" "unprognostic (5.34e-2)" "unprognostic (8.13e-2)" "unprognostic (7.05e-2)" "unprognostic (3.01e-1)" "unprognostic (7.79e-2)" "unprognostic (2.03e-1)" "unprognostic (7.08e-2)" "prognostic favorable (7.60e-4)" "unprognostic (1.69e-1)" 0.6 2.4 1.4 0.9 1.4 0.0 6.8 1.6 8.3 3.6 3.3 0.4 1.3 5.7 3.4 2.2 9.9 2.4 38.4 2.6 1.8 1.3 7.8 1.4 2.5 0.4 2.3 1.1 1.2 23.8 19.3 19.7 11.6 2.7 4.7 1.6 1.7 4.9 4.5 1.3 6.7 3.8 1.2 1.8 0.5 3.6 1.3 0.5 0.3 6.6 15.0 12.1 3.1 5.3 0.2 0.0 1.3 0.2 0.0 0.6 0.1 5.9 16.8 20.6 45.2 0.8 5.3 4.6 1.9 5.3 3.8 3.9 9.4 8.6 0.0 1.1 1.0 9.4 10.9 0.7 10.1 3.4 0.2 0.1 0.5 2.7 42.4 1.1 11.4 5.4 0.9 0.3 14.6 9.1 4.3 8.1 0.0 11.8 0.0 7.8 2.4 0.0 20.3 29.8 30.4 28.2 24.5 2.5 14.4 8.5 4.3 0.0 18.4 0.5 1.1 48.9 11.8 0.2 3.4 3.7 2.7 13.5 4.0 5.4 1.8 11.3 0.0 4.9 2.2 15.9 0.0 0.0 0.0 0.0 0.2 0.5 0.2 0.1 0.0 0.0 0.0 0.2 0.6 1.3 0.0 0.0 0.0 0.0 0.1 1.4 1.4 1.6 3.6 1.8 1.3 2.3 1.1 2.7 0.5 0.0 0.0 0.0 2.1 1.6 1.1 0.6 10.2 1.4 3.4 0.0 0.0 2.2 14.9 6.8 2.8 0.6 0.9 0.0 0.9 11.2 1.7 0.4 0.0 0.0 0.7 0.0 14.3 0.6 0.0 3.9 0.3 0.0 3.3 0.0 0.8 7.7 2.7 2.3 0.4 0.0 0.3 0.0 0.8 0.0 0.0 1.0 12.5 0.0 2.5 3.1 ETV5 ERM ENSG00000244405 "ETS variant 5" P41161 3 186046308-186110318 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 55.3" "Cell type enhanced" "Detected in many" 5 "Muller glia cells: 62.8;Syncytiotrophoblasts: 74.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 3.1" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "SK-MEL-30: 56.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009590, HPA063065, HPA073889" Approved Supported Nucleoplasm NA NA Nucleoplasm "CAB009590: AB_2101008, HPA063065: AB_2684936, HPA073889: " "unprognostic (3.85e-1)" "unprognostic (5.81e-2)" "unprognostic (1.54e-2)" "unprognostic (3.30e-1)" "unprognostic (9.00e-2)" "unprognostic (2.56e-3)" "prognostic unfavorable (7.85e-9)" "unprognostic (3.52e-3)" "unprognostic (2.97e-1)" "unprognostic (1.22e-2)" "unprognostic (4.18e-2)" "unprognostic (1.48e-1)" "unprognostic (1.57e-3)" "unprognostic (6.80e-2)" "unprognostic (1.57e-1)" "unprognostic (3.58e-2)" "unprognostic (3.84e-3)" 5.8 30.3 13.2 5.5 21.7 1.6 11.3 12.1 35.2 4.7 3.0 15.7 1.3 5.1 6.8 6.2 3.8 4.6 4.8 8.8 13.6 9.4 7.1 6.2 21.9 8.9 9.9 11.0 2.5 25.4 55.3 28.1 24.3 11.5 6.3 3.1 7.4 5.5 5.1 9.8 5.3 2.8 6.1 9.6 10.0 11.9 7.2 6.1 2.0 16.6 1.7 3.6 3.6 3.6 0.6 1.8 0.9 3.1 0.1 0.3 0.5 13.0 9.0 11.6 25.3 7.2 7.4 0.8 11.2 12.6 8.9 9.6 9.9 8.0 0.3 15.1 10.8 13.4 2.2 0.2 8.5 13.2 2.8 0.3 3.8 0.3 11.1 11.9 9.5 7.1 6.5 1.4 14.2 17.4 10.6 13.0 1.3 3.5 4.7 15.1 6.0 1.2 14.5 17.3 3.7 10.2 26.7 11.6 8.7 7.3 3.1 0.5 14.9 2.7 0.1 56.7 4.8 0.0 5.3 12.6 4.9 8.0 12.3 21.9 3.6 14.7 0.1 14.9 7.6 29.1 0.0 0.3 0.1 0.3 3.1 0.0 0.6 0.0 0.0 1.8 0.1 0.0 0.0 0.9 0.1 1.5 1.6 0.0 0.5 13.2 21.7 12.1 31.7 13.6 9.4 9.9 11.0 11.5 6.1 3.0 55.6 4.2 10.8 14.0 15.6 4.7 20.4 1.4 2.3 0.0 11.8 53.9 3.3 8.2 19.2 8.3 1.0 0.0 8.0 16.2 11.4 2.6 8.1 8.5 45.7 4.8 10.3 14.7 47.8 37.8 8.3 13.5 15.1 2.8 0.3 62.8 9.4 0.0 14.5 11.8 15.8 0.0 15.7 17.4 9.3 4.5 74.3 0.9 0.4 1.6 ETV6 TEL ENSG00000139083 "ETS variant 6" P41212 12 11649854-11895402 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 39.7;NB-4: 21.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA000264 Enhanced Approved Nucleoli,Cytosol NA NA Nucleoli Cytosol "HPA000264: AB_611466" "unprognostic (4.03e-3)" "unprognostic (3.08e-2)" "unprognostic (7.54e-3)" "unprognostic (2.60e-1)" "unprognostic (2.07e-1)" "unprognostic (1.35e-3)" "unprognostic (2.74e-2)" "unprognostic (4.02e-2)" "unprognostic (3.16e-1)" "unprognostic (9.46e-2)" "prognostic unfavorable (9.38e-5)" "unprognostic (1.15e-1)" "prognostic unfavorable (4.66e-8)" "unprognostic (1.33e-2)" "unprognostic (5.99e-2)" "unprognostic (8.92e-2)" "prognostic favorable (1.54e-5)" 17.2 8.9 5.1 20.0 7.6 32.8 20.4 1.6 9.1 10.5 14.5 6.0 9.8 7.2 10.8 14.2 11.3 8.9 15.3 6.7 5.6 3.8 9.2 9.6 16.0 13.4 6.0 3.1 10.5 10.4 8.4 8.7 7.7 7.4 14.9 11.0 8.0 41.9 12.4 6.9 23.9 14.6 25.0 9.4 17.8 9.7 4.7 5.7 30.6 10.0 10.0 19.9 19.0 15.8 2.9 6.2 11.4 7.1 2.4 2.2 1.3 2.6 3.5 3.2 5.6 2.5 2.3 3.9 1.9 3.3 2.5 3.0 0.2 12.4 2.2 1.9 3.3 3.0 3.4 1.4 5.9 3.1 39.7 0.7 14.0 1.9 1.3 3.1 14.7 15.3 4.6 3.7 2.5 5.2 4.9 7.6 10.2 1.0 7.4 2.3 1.7 8.3 21.1 5.3 2.7 0.9 2.3 3.1 5.7 5.8 16.5 0.6 3.3 3.8 3.7 3.6 5.4 1.2 9.3 8.6 5.7 4.9 1.9 4.1 3.3 2.5 1.2 3.7 0.1 6.5 5.6 5.7 6.6 1.5 6.6 2.0 2.9 2.2 1.4 4.1 2.3 1.3 0.8 11.4 2.4 7.1 6.2 1.4 1.3 5.1 7.6 1.6 9.1 5.6 3.8 6.0 3.1 7.4 5.7 6.0 8.1 21.4 28.1 13.3 1.9 7.5 17.8 28.1 22.7 14.0 5.9 11.8 1.7 15.2 4.5 23.5 22.5 0.0 30.8 3.6 10.8 33.7 10.4 9.3 17.1 0.0 31.2 38.6 48.1 3.6 7.2 48.8 27.0 40.5 26.8 4.8 31.2 24.9 10.3 7.9 4.0 19.4 28.8 0.6 7.0 19.6 7.2 14.6 20.4 60.6 EWSR1 EWS ENSG00000182944 "EWS RNA binding protein 1" Q01844 22 29268009-29300525 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Calmodulin-binding, Repressor, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004230, HPA051771, HPA062953" Enhanced Enhanced "Nucleoplasm,Nucleoli rim" No No Nucleoplasm "Nucleoli rim" "CAB004230: AB_675526, HPA051771: AB_2681602, HPA062953: AB_2684910" "unprognostic (1.96e-1)" "unprognostic (6.39e-3)" "unprognostic (1.32e-1)" "unprognostic (3.93e-2)" "unprognostic (3.59e-1)" "unprognostic (3.15e-2)" "prognostic unfavorable (1.27e-6)" "unprognostic (1.33e-1)" "unprognostic (1.09e-2)" "unprognostic (2.71e-2)" "unprognostic (7.04e-2)" "unprognostic (9.30e-2)" "prognostic unfavorable (1.21e-5)" "unprognostic (7.33e-3)" "unprognostic (1.79e-1)" "unprognostic (3.67e-2)" "unprognostic (1.50e-3)" 35.3 43.2 45.3 41.3 51.3 67.5 32.1 58.2 48.6 32.4 39.8 43.2 31.3 41.0 45.1 38.5 40.8 37.6 25.9 40.7 40.1 32.8 33.0 48.5 33.4 50.5 32.7 49.9 38.4 32.0 47.2 44.3 34.0 41.7 35.0 39.9 41.5 32.3 38.2 52.8 34.8 36.6 40.5 33.8 44.1 34.5 85.6 32.5 39.9 32.5 30.9 55.4 36.4 34.5 52.0 65.8 50.6 81.1 58.4 67.8 76.1 57.2 44.6 61.4 47.7 31.3 26.0 42.2 34.9 55.8 57.9 49.7 50.8 29.8 78.3 22.1 53.5 44.0 45.0 87.4 71.4 59.7 53.3 62.3 59.1 39.5 48.6 46.9 90.9 42.3 39.7 30.1 48.3 78.4 27.8 44.8 37.5 44.2 35.4 42.8 57.5 91.2 34.8 43.1 47.4 34.0 64.1 59.1 47.3 53.2 60.9 50.3 48.1 43.4 50.9 37.6 42.2 32.7 49.5 45.7 35.4 39.3 22.2 50.6 46.0 36.9 72.6 33.7 40.5 43.0 48.4 57.9 50.6 60.2 81.1 60.7 50.4 56.6 59.6 65.8 52.0 55.8 53.6 43.3 58.4 78.6 35.3 67.8 76.1 45.3 51.3 58.2 48.6 40.1 32.8 32.7 49.9 41.7 32.5 95.3 103.6 96.6 120.0 61.7 71.3 60.0 89.2 124.5 102.4 61.1 70.7 120.3 56.3 106.1 87.5 78.6 71.5 70.0 93.8 108.0 78.0 80.7 117.8 64.2 85.5 77.9 77.7 82.3 69.0 21.4 57.0 89.6 77.6 112.8 73.3 66.1 95.4 94.7 58.4 59.1 77.8 51.8 86.8 180.0 109.0 51.2 127.5 88.0 89.6 101.6 EZH2 "ENX-1, EZH1, KMT6, KMT6A" ENSG00000106462 "Enhancer of zeste 2 polycomb repressive complex 2 subunit" Q15910 7 148807383-148884321 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 25.5;lymphoid tissue: 44.1" "Cell type enhanced" "Detected in many" 8 "Early spermatids: 72.2;Spermatocytes: 126.7;Spermatogonia: 62.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009589 Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB009589: " "unprognostic (2.42e-1)" "unprognostic (3.95e-3)" "unprognostic (1.57e-1)" "unprognostic (3.30e-3)" "unprognostic (1.33e-1)" "unprognostic (3.85e-3)" "prognostic unfavorable (2.11e-6)" "unprognostic (2.21e-2)" "prognostic unfavorable (1.96e-4)" "unprognostic (2.32e-3)" "unprognostic (1.58e-3)" "unprognostic (1.69e-3)" "prognostic unfavorable (8.18e-12)" "prognostic favorable (6.97e-4)" "unprognostic (1.83e-1)" "unprognostic (2.12e-1)" "unprognostic (6.67e-2)" 2.0 1.7 1.8 10.6 1.6 25.5 1.4 4.9 2.7 2.6 4.8 1.1 0.1 3.8 1.7 2.8 11.0 0.9 3.0 0.9 0.8 0.6 1.7 3.3 2.3 12.6 1.3 0.3 2.2 3.8 0.6 1.7 3.4 1.4 1.4 5.1 1.8 3.2 1.6 3.7 6.4 4.8 1.5 1.2 5.8 2.7 19.6 1.3 44.1 0.9 5.5 12.4 2.6 3.5 1.5 4.7 1.3 3.9 8.5 10.3 1.7 17.0 8.0 27.3 18.2 0.8 1.4 14.9 13.3 5.4 11.0 11.1 12.0 19.7 30.2 6.5 5.0 10.0 10.5 14.0 4.6 14.0 43.2 14.0 12.9 9.9 9.3 2.2 28.6 10.6 1.2 2.6 8.2 4.4 3.3 6.4 29.3 27.3 20.1 9.8 19.3 55.6 23.9 21.7 15.0 10.8 34.4 15.3 18.7 5.1 8.2 26.1 16.6 16.7 12.7 4.4 7.3 9.3 12.3 3.9 11.7 5.4 23.3 23.8 18.0 19.6 30.4 10.7 19.6 22.9 0.5 2.2 1.3 1.7 1.5 1.3 1.5 3.4 2.9 4.7 0.8 1.9 1.2 0.2 8.5 3.9 1.0 10.3 1.7 1.8 1.6 4.9 2.7 0.8 0.6 1.3 0.3 1.4 1.3 0.0 7.9 6.7 5.7 23.6 4.8 6.5 2.5 14.7 7.9 7.0 33.4 13.6 3.3 9.1 72.2 7.1 6.7 23.3 7.4 29.5 10.8 4.4 21.8 1.3 10.4 14.3 8.6 4.3 8.9 19.2 2.8 10.9 13.5 19.0 10.2 2.0 10.1 9.3 0.7 1.0 21.1 6.5 9.9 126.7 62.4 25.3 25.5 18.7 18.6 4.0 EZR VIL2 ENSG00000092820 Ezrin P15311 6 158765741-158819412 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell shape" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Ciliated cells: 1685.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004035, HPA021616, CAB047324, CAB075739" Enhanced Enhanced "Plasma membrane" NA NA 75000000 "Plasma membrane" "CAB004035: AB_2100309, CAB047324: , CAB075739: AB_2665745, HPA021616: AB_1848342" "unprognostic (4.79e-3)" "unprognostic (1.48e-1)" "unprognostic (1.97e-2)" "unprognostic (2.50e-1)" "unprognostic (1.07e-1)" "unprognostic (1.31e-3)" "unprognostic (1.76e-2)" "unprognostic (2.41e-1)" "unprognostic (1.32e-1)" "unprognostic (7.53e-2)" "prognostic unfavorable (1.70e-4)" "unprognostic (5.59e-2)" "prognostic favorable (9.56e-8)" "unprognostic (1.16e-1)" "unprognostic (1.32e-1)" "unprognostic (1.34e-2)" "unprognostic (9.00e-2)" 22.8 56.4 30.9 31.2 31.4 24.7 13.3 4.0 21.5 18.0 45.5 28.2 35.2 33.8 9.8 25.8 71.8 25.1 30.2 34.3 37.6 13.9 53.5 16.2 44.3 36.7 14.8 19.0 20.7 33.0 77.1 14.6 125.1 23.5 21.7 22.8 37.0 27.4 32.0 13.6 47.5 87.9 22.8 12.8 26.0 55.4 21.4 22.2 41.6 37.1 34.4 75.6 38.2 25.3 81.7 30.0 24.3 31.2 20.7 61.7 41.1 88.1 48.2 11.9 17.1 1.3 1.4 69.7 27.7 9.1 31.3 26.4 56.4 48.9 88.8 27.5 31.6 15.0 67.6 23.5 30.9 36.4 31.0 15.2 1.8 29.2 24.9 31.8 21.9 13.7 2.3 24.0 29.4 28.6 26.8 20.5 12.3 17.5 43.5 18.1 23.2 31.1 26.5 19.9 24.1 16.1 23.4 5.6 20.2 64.3 26.8 21.7 17.7 48.5 69.9 5.2 57.0 17.0 29.0 26.4 10.1 32.5 13.9 42.6 30.0 27.3 76.1 6.3 11.3 12.0 24.3 14.0 16.4 34.8 31.2 41.0 81.7 36.7 42.9 30.0 67.5 19.9 26.5 6.1 20.7 30.6 14.0 61.7 41.1 30.9 31.4 4.0 21.5 37.6 13.9 14.8 19.0 23.5 22.2 884.4 543.1 187.4 615.4 546.1 5.3 247.6 119.8 1685.0 977.1 148.3 0.0 366.9 82.9 222.1 7.9 84.3 679.2 46.7 221.5 488.7 135.0 354.7 114.5 30.6 98.9 0.0 153.2 31.3 77.1 21.1 125.4 213.0 305.4 115.4 206.3 31.3 408.3 238.4 276.5 168.7 4.0 245.8 120.5 46.2 56.6 635.1 1039.8 112.2 143.1 1039.6 FAM46C FLJ20202 ENSG00000183508 "Family with sequence similarity 46 member C" Q5VWP2 1 117605934-117628372 "Cancer-related genes, Predicted intracellular proteins" "Host-virus interaction" "Nucleotidyltransferase, RNA-binding, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pancreas: 114.0" "Group enriched" "Detected in many" 9 "Early spermatids: 418.3;Late spermatids: 1175.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 16.3" "Group enriched" "Detected in many" 17 "B-cells: 9.7;granulocytes: 16.3;T-cells: 9.2" "Cell line enhanced" "Detected in some" "Karpas-707: 74.8;RPMI-8226: 44.6;U-266/70: 20.8;U-266/84: 17.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA054049 Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA054049: AB_2682356" "unprognostic (3.76e-2)" "unprognostic (3.85e-3)" "unprognostic (3.24e-3)" "prognostic favorable (3.75e-5)" "unprognostic (1.17e-1)" "unprognostic (1.55e-3)" "unprognostic (3.29e-1)" "unprognostic (2.88e-2)" "unprognostic (5.75e-2)" "unprognostic (1.36e-3)" "unprognostic (9.41e-3)" "unprognostic (3.91e-2)" "prognostic favorable (2.77e-5)" "unprognostic (6.26e-2)" "unprognostic (3.16e-2)" "unprognostic (3.08e-2)" "unprognostic (1.10e-2)" 3.2 1.8 1.2 24.5 1.1 28.9 4.4 1.1 1.1 8.1 16.1 1.8 8.4 5.6 4.8 16.6 6.9 3.3 9.7 6.4 1.2 1.1 5.0 5.5 11.2 16.3 1.2 0.1 8.3 114.0 7.2 5.3 10.6 3.9 6.4 9.5 4.4 37.8 11.9 10.0 1.8 10.6 4.7 1.4 19.1 12.2 34.0 0.2 1.5 10.3 10.9 37.0 9.5 8.6 9.7 0.2 16.3 0.0 0.6 9.2 2.1 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.1 6.7 0.1 0.0 0.4 0.0 1.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 4.2 0.4 9.2 0.0 0.0 0.0 5.4 11.9 0.0 0.0 0.1 0.0 0.0 0.0 2.5 1.2 74.8 0.0 0.9 0.0 5.5 0.9 1.1 0.6 0.0 0.0 44.6 0.0 0.9 0.5 0.0 0.4 0.6 0.4 0.1 0.4 0.0 0.1 0.0 0.5 0.0 0.1 20.8 17.2 0.4 0.4 1.9 0.6 16.3 0.0 10.5 2.5 0.0 2.2 9.7 2.5 3.1 0.0 8.0 0.3 1.4 1.1 0.6 0.0 0.2 9.2 2.1 1.2 1.1 1.1 1.1 1.2 1.1 1.2 0.1 3.9 0.2 6.0 42.9 52.6 7.5 7.6 0.0 0.0 5.1 21.4 36.4 0.0 0.0 1.9 0.0 0.0 418.3 2.8 12.0 93.5 0.0 2.0 7.3 6.6 7.0 4.3 1.1 0.0 19.0 0.0 1.5 1175.9 13.3 2.0 45.5 0.0 35.3 1.1 0.0 8.6 8.5 0.0 0.0 6.5 9.2 12.5 8.5 5.6 1.8 32.0 26.4 7.9 FAS "APO-1, APT1, CD95, FAS1, TNFRSF6" ENSG00000026103 "Fas cell surface death receptor" P25445 10 88990582-89015785 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins" Apoptosis "Calmodulin-binding, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Basal glandular cells: 100.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 40.1" "Group enriched" "Detected in all" 5 "granulocytes: 40.1;T-cells: 30.9" "Cell line enhanced" "Detected in many" "HDLM-2: 28.0;Karpas-707: 44.7" "Low region specificity" "Detected in all" HPA027444 Uncertain Supported "Nuclear bodies,Plasma membrane,Cytosol" "Secreted to blood" NA NA 11900000 450000 "Plasma membrane" "Nuclear bodies, Cytosol" "HPA027444: AB_10601378" "unprognostic (6.84e-2)" "unprognostic (2.88e-3)" "unprognostic (8.38e-3)" "unprognostic (1.94e-1)" "unprognostic (2.35e-2)" "unprognostic (9.56e-2)" "unprognostic (7.00e-2)" "unprognostic (2.05e-1)" "unprognostic (3.01e-1)" "unprognostic (7.70e-2)" "unprognostic (1.26e-2)" "unprognostic (1.98e-1)" "unprognostic (1.52e-3)" "unprognostic (2.10e-1)" "unprognostic (2.32e-2)" "unprognostic (4.95e-3)" "unprognostic (1.65e-1)" 13.5 26.3 6.1 17.3 7.7 12.4 10.6 2.1 7.2 15.6 14.2 6.1 7.0 5.9 15.7 16.6 14.1 14.2 14.5 8.9 8.2 2.7 11.7 21.9 28.6 15.6 6.0 3.9 24.7 4.1 4.5 4.6 9.0 7.5 22.3 21.3 4.4 7.1 8.5 4.3 9.6 16.3 12.5 10.2 15.3 5.0 7.3 5.1 12.5 10.0 15.8 14.4 14.8 21.4 3.0 4.0 40.1 6.8 1.2 30.9 3.9 8.7 3.4 1.8 5.6 14.5 21.4 0.0 19.2 19.5 0.7 3.8 0.0 9.5 1.7 7.4 18.0 3.2 1.4 0.3 16.2 1.3 28.0 2.8 0.1 1.8 5.7 13.9 0.9 0.4 26.5 14.5 12.0 26.0 9.4 1.7 6.4 0.0 44.7 19.6 0.8 2.8 1.4 0.2 0.0 0.9 0.2 0.1 1.8 27.1 2.8 0.1 0.1 2.8 0.0 0.3 2.8 6.1 0.3 4.2 6.2 3.4 5.7 4.4 17.5 1.8 0.1 5.1 3.5 1.8 11.3 3.2 9.4 3.3 3.9 4.8 3.0 10.4 7.2 4.0 0.7 1.2 3.4 40.1 1.2 6.8 0.0 30.9 3.9 6.1 7.7 2.1 7.2 8.2 2.7 6.0 3.9 7.5 5.1 53.6 14.4 3.7 100.3 40.8 0.0 1.2 15.3 21.4 21.6 8.7 0.0 0.4 0.0 6.7 5.4 8.4 12.0 0.0 3.8 0.2 34.9 22.7 3.5 15.3 5.0 1.6 8.1 2.5 6.9 3.5 17.5 12.7 11.8 20.8 15.0 17.1 4.3 0.0 13.1 11.5 0.7 6.5 33.4 4.8 1.3 38.3 0.3 37.9 23.2 22.7 FAT1 "CDHF7, CDHR8, FAT" ENSG00000083857 "FAT atypical cadherin 1" Q14517 4 186587783-186726722 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 76.4" "Cell type enhanced" "Detected in many" 4 "Basal keratinocytes: 75.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 64.9;LHCN-M2: 47.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001869, HPA023882" Enhanced "Intracellular and membrane" NA NA 120000 "HPA001869: AB_1078818, HPA023882: AB_1848429" "unprognostic (1.98e-1)" "unprognostic (4.91e-2)" "unprognostic (2.50e-2)" "unprognostic (1.86e-1)" "unprognostic (1.53e-2)" "unprognostic (5.82e-3)" "unprognostic (2.31e-1)" "prognostic unfavorable (4.22e-4)" "unprognostic (6.10e-2)" "unprognostic (3.05e-2)" "unprognostic (1.15e-3)" "unprognostic (6.80e-2)" "unprognostic (3.57e-2)" "unprognostic (8.03e-3)" "unprognostic (9.41e-2)" "unprognostic (6.25e-3)" "unprognostic (4.27e-2)" 15.5 1.3 7.9 12.3 9.8 0.4 15.4 11.9 8.4 15.9 40.4 11.8 8.1 17.9 20.6 14.0 9.7 9.6 28.2 21.1 10.0 6.0 29.1 13.3 10.9 1.4 11.4 6.2 9.7 13.8 7.5 10.5 14.6 24.7 15.9 22.9 5.0 13.9 18.2 3.0 13.1 76.4 18.3 12.8 1.7 11.5 7.0 11.2 1.3 10.5 10.2 6.7 17.5 9.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 19.0 18.9 0.0 18.9 22.8 4.6 25.4 41.9 12.4 7.9 11.3 11.2 0.0 6.1 64.9 8.0 9.2 7.4 31.3 16.9 0.0 3.0 0.0 6.7 11.4 9.4 8.2 6.8 8.2 11.3 23.0 15.0 17.0 0.2 10.3 0.1 0.0 47.7 6.0 14.6 0.0 4.2 9.5 3.2 0.0 5.2 0.4 18.6 17.9 2.0 7.6 4.4 7.5 3.0 13.5 0.0 3.0 5.4 35.4 13.7 0.4 15.7 0.1 0.0 0.1 8.1 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.9 9.8 11.9 8.4 10.0 6.0 11.4 6.2 24.7 11.2 14.9 4.1 0.0 25.5 75.6 5.2 20.3 35.7 16.0 25.0 50.6 0.0 1.1 5.0 21.9 0.6 5.1 58.5 0.0 23.2 3.5 24.9 37.8 16.1 22.9 0.3 0.0 13.9 1.8 1.0 0.4 13.6 3.1 11.8 0.0 54.8 4.2 24.0 23.0 35.0 21.4 0.3 38.8 54.6 1.8 7.7 40.9 1.4 0.0 38.7 20.0 FAT4 "CDHF14, CDHR11, FAT-J" ENSG00000196159 "FAT atypical cadherin 4" Q6V0I7 4 125316399-125492932 "Cancer-related genes, Disease related genes, Predicted membrane proteins" "Cell adhesion" "Cancer-related genes, Deafness, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in some" 15 "Endothelial cells: 11.1;Fibroblasts: 9.3;Ito cells: 30.7" "Low cancer specificity" "Detected in many" "Cell type enriched" "Detected in single" 12 "NK-cell: 1.1" "Lineage enriched" "Detected in single" 12 "NK-cells: 1.1" "Cell line enhanced" "Detected in many" "ASC diff: 12.3;ASC TERT1: 9.1;fHDF/TERT166: 8.9;HSkMC: 10.5;HUVEC TERT2: 11.1;TIME: 17.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA052819 Approved Approved Cytosol NA NA 7900000 Cytosol "HPA052819: AB_2681963" "unprognostic (1.18e-1)" "unprognostic (1.77e-1)" "unprognostic (7.99e-2)" "unprognostic (1.09e-1)" "unprognostic (2.31e-1)" "unprognostic (2.81e-4)" "unprognostic (6.17e-3)" "unprognostic (1.28e-1)" "unprognostic (1.77e-2)" "unprognostic (2.78e-2)" "unprognostic (1.63e-1)" "unprognostic (1.39e-1)" "prognostic favorable (1.89e-4)" "unprognostic (2.38e-2)" "unprognostic (1.71e-1)" "unprognostic (1.30e-2)" "unprognostic (2.49e-3)" 3.8 0.5 0.9 0.8 0.7 0.0 3.2 0.0 0.5 4.4 7.1 0.3 2.7 0.6 1.9 2.1 4.1 5.0 1.0 0.4 2.6 2.0 5.3 0.1 0.9 5.3 0.5 6.7 0.4 2.5 3.6 1.9 1.0 2.3 1.1 1.4 2.4 3.3 0.6 2.1 2.4 0.1 3.9 0.2 3.0 2.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.7 6.0 0.6 12.3 9.1 0.0 2.0 2.4 1.0 1.0 0.0 0.3 0.0 2.5 8.9 1.2 0.0 2.2 2.5 0.6 0.0 1.0 1.3 2.5 0.0 4.0 0.8 0.0 10.5 1.4 0.5 5.5 7.2 11.1 0.0 0.0 1.6 5.0 0.1 0.4 0.0 0.4 0.0 0.2 0.7 1.2 0.0 0.1 0.0 0.1 1.2 0.3 0.0 0.0 0.3 0.0 0.0 17.3 6.1 1.7 2.1 0.9 0.2 0.0 0.0 1.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 6.0 0.0 0.0 0.1 1.4 1.3 5.3 0.0 0.0 0.0 5.2 0.0 0.1 0.0 0.7 0.8 11.1 0.0 0.0 0.2 0.0 9.3 0.1 0.0 6.8 0.2 0.0 0.0 30.7 2.4 0.0 5.5 0.0 3.3 0.0 0.0 1.2 0.2 0.0 4.6 0.6 0.1 0.0 3.9 0.0 0.6 0.5 0.0 0.0 0.0 0.0 FBXO11 "FBX11, UBR6" ENSG00000138081 "F-box protein 11" Q86XK2 2 47789316-47905793 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002690 Supported Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA002690: AB_1848448" "unprognostic (1.18e-1)" "unprognostic (8.65e-3)" "unprognostic (3.93e-2)" "unprognostic (2.05e-2)" "unprognostic (7.92e-2)" "unprognostic (1.42e-1)" "unprognostic (3.85e-2)" "unprognostic (1.02e-1)" "unprognostic (2.55e-2)" "unprognostic (9.82e-2)" "unprognostic (5.77e-2)" "unprognostic (2.33e-2)" "unprognostic (3.21e-2)" "unprognostic (1.55e-1)" "unprognostic (3.71e-1)" "unprognostic (2.19e-1)" "unprognostic (3.20e-2)" 18.0 13.8 18.6 15.7 18.8 17.5 26.1 42.2 31.7 21.3 15.3 12.7 15.1 10.4 28.9 16.8 14.5 16.3 15.0 14.1 16.9 13.6 14.3 17.0 22.3 15.0 17.4 21.7 28.9 12.4 25.2 14.4 14.5 19.7 15.3 13.3 12.0 15.6 16.5 22.9 14.5 13.5 19.9 16.4 14.5 13.3 25.1 16.0 14.6 17.3 9.8 17.2 19.3 21.9 4.7 4.3 8.2 2.7 4.8 6.6 2.0 25.5 13.3 31.9 27.2 22.4 21.1 19.0 17.9 24.6 16.7 16.5 11.2 13.0 16.5 23.4 25.1 20.8 12.7 21.8 18.9 24.7 11.0 10.8 15.4 10.9 17.8 21.5 16.0 16.4 20.6 21.3 14.9 25.2 26.6 21.4 8.3 15.0 17.1 20.5 12.3 15.3 15.6 19.4 16.9 13.1 20.0 29.6 12.3 23.9 20.9 22.5 26.6 16.9 15.9 26.1 24.7 7.4 13.7 23.1 20.8 19.2 13.9 19.6 14.8 7.7 30.1 14.1 15.1 21.1 8.2 2.3 4.3 3.8 2.7 3.8 4.7 3.4 4.1 3.1 3.6 6.6 4.1 4.1 4.8 2.4 4.3 3.6 2.0 18.6 18.8 42.2 31.7 16.9 13.6 17.4 21.7 19.7 16.0 14.9 36.6 13.7 38.4 59.5 42.4 7.8 12.7 37.5 23.9 17.4 31.4 16.6 10.0 15.5 22.2 26.9 15.8 0.0 13.2 13.7 43.3 34.1 27.8 17.0 21.7 52.4 23.0 29.4 42.9 29.9 27.9 40.9 33.7 17.2 16.7 30.9 20.6 14.4 37.4 11.3 39.1 19.4 35.3 51.9 40.4 51.6 30.1 26.6 16.9 57.8 FBXW7 "AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10" ENSG00000109670 "F-box and WD repeat domain containing 7" Q969H0 4 152320544-152536063 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 60.1;skin 1: 45.0" "Cell type enhanced" "Detected in many" 7 "Basal keratinocytes: 179.3;Suprabasal keratinocytes: 152.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-266/70: 38.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013793, CAB029987" Supported Supported Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "CAB013793: AB_2533451, CAB029987: AB_2246842" "unprognostic (3.32e-1)" "unprognostic (9.02e-2)" "unprognostic (1.84e-2)" "unprognostic (3.08e-2)" "unprognostic (3.87e-1)" "unprognostic (1.36e-3)" "unprognostic (4.37e-1)" "unprognostic (1.94e-1)" "unprognostic (8.28e-2)" "unprognostic (3.29e-1)" "unprognostic (5.32e-3)" "unprognostic (3.19e-2)" "prognostic unfavorable (1.52e-4)" "unprognostic (3.38e-2)" "unprognostic (1.41e-1)" "unprognostic (5.49e-3)" "unprognostic (2.17e-3)" 9.2 6.8 27.0 8.9 27.9 11.1 9.8 27.2 60.1 5.5 6.1 3.6 3.8 4.9 6.0 18.3 9.8 10.6 6.3 10.9 21.4 10.1 4.1 7.3 6.9 9.8 9.1 40.5 6.4 8.0 6.4 7.3 6.2 37.2 5.1 6.9 2.8 7.6 5.3 15.8 45.0 6.5 6.1 6.4 10.1 8.0 13.7 5.7 6.5 6.8 10.6 12.3 7.9 6.5 2.9 2.2 16.6 3.4 7.8 5.0 1.3 4.9 4.0 10.3 7.5 7.2 5.2 8.6 7.2 6.6 4.5 4.2 8.0 6.4 12.9 2.0 6.9 3.4 3.0 8.9 16.2 6.3 7.3 4.2 6.0 4.9 5.7 7.3 14.6 5.5 8.2 25.8 7.7 13.1 4.7 7.8 10.5 9.4 13.8 5.6 7.0 16.8 5.8 5.0 4.2 3.2 16.9 4.4 2.5 5.5 8.6 6.6 5.7 4.6 6.3 3.9 12.2 3.4 6.9 8.2 6.1 6.9 3.1 4.0 38.0 21.7 12.6 4.9 4.8 4.3 16.6 3.1 1.7 5.0 3.4 3.3 2.9 3.7 3.2 1.8 2.4 3.9 3.2 5.5 7.8 2.5 2.2 3.3 1.3 27.0 27.9 27.2 60.1 21.4 10.1 9.1 40.5 37.2 5.7 8.9 18.5 27.6 32.1 179.3 67.8 54.1 7.6 8.1 13.6 8.7 29.5 9.7 3.3 11.6 13.1 26.4 13.5 0.0 11.7 33.1 24.6 28.4 15.1 15.6 9.4 11.1 13.9 17.8 16.2 7.4 14.1 20.2 27.0 16.2 11.7 30.1 15.8 15.8 10.6 6.0 40.5 12.9 25.6 57.9 80.3 152.9 26.1 34.6 11.3 48.9 FCGR2B "CD32, CD32B, FCG2, FCGR2" ENSG00000072694 "Fc fragment of IgG receptor IIb" P31994 1 161663147-161678654 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins" "Host-virus interaction" "IgG-binding protein, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 53.3;placenta: 83.2" "Group enriched" "Detected in many" 5 "Ito cells: 479.4;Macrophages: 138.2" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in many" "basophil: 53.3;memory B-cell: 42.2" "Group enriched" "Detected in many" 18 "B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3" "Cell line enhanced" "Detected in some" "Daudi: 18.7;HMC-1: 23.5;NB-4: 5.2;RPMI-8226: 8.4" "CAB007796, HPA014730" Enhanced NA NA "CAB007796: AB_562288, HPA014730: AB_2669074" "unprognostic (1.58e-1)" "unprognostic (5.14e-2)" "unprognostic (3.32e-3)" "unprognostic (3.12e-2)" "unprognostic (6.79e-3)" "unprognostic (4.05e-3)" "unprognostic (1.27e-1)" "unprognostic (4.65e-3)" "unprognostic (1.91e-1)" "unprognostic (4.72e-2)" "unprognostic (2.89e-2)" "unprognostic (3.49e-1)" "prognostic unfavorable (8.82e-4)" "unprognostic (3.51e-2)" "unprognostic (6.36e-2)" "unprognostic (4.31e-1)" "unprognostic (3.37e-1)" 11.3 2.4 0.0 2.0 0.2 0.0 4.1 0.0 0.0 1.9 3.4 0.2 0.9 0.2 2.1 2.1 2.3 3.7 0.0 0.2 2.0 9.5 5.6 2.5 0.5 0.8 0.6 0.0 0.3 83.2 0.3 2.0 3.3 0.2 0.5 2.0 4.6 3.1 4.7 6.7 1.5 0.1 1.7 5.6 3.3 1.2 42.2 14.5 53.3 1.9 0.1 0.3 2.4 0.0 0.1 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 5.2 0.1 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.1 0.1 0.0 0.0 1.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 2.2 0.0 53.3 1.8 5.4 0.3 1.9 0.1 42.2 0.1 0.2 14.5 34.3 0.0 0.3 11.2 0.1 1.7 0.0 0.0 2.4 0.0 4.6 57.3 0.0 4.7 0.0 1.9 5.1 0.0 2.3 0.0 0.0 0.2 0.0 0.0 4.2 1.4 0.0 23.3 0.0 0.2 2.7 0.0 2.3 2.5 7.6 0.0 0.0 479.4 63.3 2.3 0.6 138.2 21.9 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.7 0.3 0.2 2.8 0.3 4.9 0.0 0.0 FCRL4 "CD307d, FCRH4, IGFP2, IRTA1" ENSG00000163518 "Fc receptor like 4" Q96PJ5 1 157573749-157598080 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "intestine: 5.4;lymphoid tissue: 15.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 12 "memory B-cell: 1.1" "Lineage enriched" "Detected in single" 12 "B-cells: 1.1" "Cell line enriched" "Detected in single" 104 "U-266/70: 10.4" "Not detected" "Not detected" HPA054030 Approved NA NA "HPA054030: " "unprognostic (6.06e-2)" "unprognostic (3.41e-3)" "unprognostic (2.57e-1)" "unprognostic (5.08e-2)" "unprognostic (4.69e-4)" "unprognostic (2.06e-2)" "unprognostic (6.38e-2)" "unprognostic (1.99e-1)" "unprognostic (2.14e-1)" "unprognostic (3.37e-1)" "unprognostic (6.77e-2)" 0.1 0.1 0.1 15.6 0.1 0.0 0.1 0.1 0.2 0.1 0.3 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 5.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.0 2.5 0.0 0.1 0.1 5.4 0.0 0.1 2.2 0.3 0.1 0.0 1.1 0.1 1.9 14.9 0.4 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 FES FPS ENSG00000182511 "FES proto-oncogene, tyrosine kinase" P07332 15 90883695-90895776 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 60.8;lymphoid tissue: 49.7" "Cell type enhanced" "Detected in many" 11 "Hofbauer cells: 40.6;Kupffer cells: 93.1;Macrophages: 37.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in many" "eosinophil: 60.8" "Group enriched" "Detected in many" 4 "dendritic cells: 32.6;granulocytes: 60.8;monocytes: 30.5" "Cell line enhanced" "Detected in many" "HEL: 21.3;HL-60: 19.0;HMC-1: 40.7;NB-4: 24.9;THP-1: 37.4;U-937: 16.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001376 Approved Approved Nucleoplasm,Vesicles,Cytosol NA NA "Nucleoplasm, Cytosol" Vesicles "HPA001376: AB_1078847" "unprognostic (1.07e-2)" "unprognostic (2.54e-2)" "prognostic unfavorable (5.78e-4)" "unprognostic (2.31e-2)" "unprognostic (4.05e-3)" "unprognostic (7.33e-2)" "unprognostic (1.74e-1)" "unprognostic (2.22e-1)" "unprognostic (1.58e-3)" "unprognostic (1.35e-1)" "unprognostic (4.66e-2)" "unprognostic (5.15e-3)" "unprognostic (1.78e-3)" "unprognostic (2.53e-3)" "unprognostic (6.08e-2)" "unprognostic (1.18e-1)" "unprognostic (1.40e-1)" 14.9 3.4 4.8 9.7 4.1 38.3 12.7 2.4 5.7 6.8 5.4 3.2 4.7 3.0 7.4 5.6 4.9 7.6 7.3 7.9 4.2 2.2 5.2 11.8 12.7 23.3 3.7 0.9 6.4 3.7 1.8 2.7 8.1 7.2 7.7 2.4 5.3 33.8 6.3 3.4 3.5 5.2 5.4 6.9 49.7 4.3 3.2 4.7 3.1 7.2 4.1 4.5 7.2 9.4 1.1 32.6 60.8 30.5 9.3 0.1 13.8 0.1 0.2 0.3 3.6 1.0 3.1 6.1 0.9 0.0 1.8 1.0 0.9 0.0 2.3 0.1 2.0 0.0 0.5 0.6 0.1 0.5 1.2 0.3 21.3 0.0 3.8 2.1 19.0 40.7 3.1 0.0 2.6 0.0 0.0 10.8 3.2 0.6 0.0 0.0 6.9 0.6 24.9 1.0 0.8 0.0 2.8 0.0 0.0 0.0 0.1 0.1 0.0 0.0 1.0 0.9 1.1 0.0 37.4 8.4 0.0 3.7 0.1 0.0 0.0 2.7 0.8 0.1 16.1 0.8 10.4 30.5 60.8 0.1 17.6 0.0 1.1 0.0 0.0 32.6 0.9 0.0 0.0 20.0 9.3 7.3 12.9 0.0 13.8 4.8 4.1 2.4 5.7 4.2 2.2 3.7 0.9 7.2 4.7 3.0 8.0 6.4 4.7 3.4 0.0 2.5 5.1 0.0 0.0 1.8 0.0 4.5 3.3 4.8 1.1 24.5 0.4 0.0 3.9 3.8 6.2 4.0 28.8 8.2 40.6 0.0 2.9 22.7 93.1 4.7 8.3 37.3 6.8 27.1 2.1 2.3 2.0 0.0 9.6 1.3 1.9 12.9 7.2 3.5 9.1 2.5 3.8 10.2 2.6 5.2 FEV Pet-1 ENSG00000163497 "FEV, ETS transcription factor" Q99581 2 218981087-218985657 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9;intestine: 7.0;pituitary gland: 5.4;stomach 1: 6.1" "Cell type enriched" "Detected in some" 123 "Intestinal endocrine cells: 716.0" "Group enriched" "Detected in some" 10 "pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4" "Region enhanced" "Detected in many" "pons and medulla: 6.9" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "HMC-1: 19.1;SH-SY5Y: 24.5" "Group enriched" "Detected in some" 13 "midbrain: 2.3;pons and medulla: 0.9" "Group enriched" "Detected in some" 35 "midbrain: 7.3;pons and medulla: 3.9" HPA067679 Supported Supported "Nuclear speckles" NA NA "Nuclear speckles" "HPA067679: AB_2685884" "unprognostic (4.58e-1)" "unprognostic (1.60e-1)" "unprognostic (7.21e-2)" "prognostic favorable (4.85e-4)" "unprognostic (2.87e-1)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" 0.1 4.1 0.0 1.2 3.5 0.0 0.0 0.0 2.6 0.0 2.0 0.7 0.0 7.0 0.1 0.0 0.0 0.1 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 4.2 0.0 5.4 0.0 6.9 4.0 3.2 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.1 0.0 6.1 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 0.0 19.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 24.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 2.6 1.1 0.2 0.2 0.0 6.9 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 716.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.3 5.8 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.2 0.1 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38411138-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Leydig cells: 177.8;Muller glia cells: 106.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AN3-CA: 111.2;BJ hTERT+: 50.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved NA NA 120000000 "CAB033614: AB_783377, HPA056402: AB_2683118" "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 41.1 8.6 12.5 14.5 12.2 7.2 39.5 45.0 10.5 36.0 31.5 10.1 11.6 5.5 29.3 20.6 22.9 29.4 32.4 31.7 12.8 10.1 11.8 5.4 18.6 9.7 11.4 14.3 42.0 51.2 11.5 22.3 28.4 20.0 28.2 10.8 35.8 14.0 31.6 12.0 12.9 14.4 52.4 15.6 4.5 16.4 16.4 8.5 11.3 12.6 13.0 9.8 39.6 41.2 1.6 0.7 1.8 1.1 0.8 5.7 0.7 2.4 9.4 41.1 111.2 25.5 18.2 27.1 25.3 50.7 17.6 18.4 6.1 1.4 0.3 7.0 24.2 22.6 0.0 19.4 1.2 20.4 6.6 4.3 0.0 1.6 6.0 14.4 5.9 0.1 16.5 0.1 14.3 2.9 9.5 16.9 1.4 2.3 0.1 8.3 2.9 17.4 2.0 28.9 0.3 3.9 16.0 4.3 0.0 8.5 0.0 1.6 3.6 4.5 0.2 1.0 21.5 2.3 1.1 10.6 11.5 6.4 31.8 6.0 0.4 0.8 0.0 13.6 0.3 6.0 1.4 1.1 0.4 5.7 0.3 3.9 0.7 2.7 3.7 0.1 1.6 1.5 4.1 1.8 0.8 0.5 0.7 2.2 0.7 12.5 12.2 45.0 10.5 12.8 10.1 11.4 14.3 20.0 8.5 3.0 12.0 0.0 68.4 27.9 1.3 48.2 17.8 1.4 9.1 8.7 3.9 6.5 0.0 23.4 14.2 57.3 0.0 0.0 56.3 69.1 85.6 80.3 8.1 0.9 19.7 20.6 24.0 47.3 3.2 9.3 177.8 7.5 32.1 2.8 0.0 106.2 29.8 0.0 93.7 8.0 2.4 12.9 68.0 1.4 11.3 17.2 8.7 6.4 0.4 8.4 FGFR1OP FOP ENSG00000213066 "FGFR1 oncogene partner" O95684 6 166999182-167094789 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 50.3" "Cell type enhanced" "Detected in all" 10 "Early spermatids: 225.5;Late spermatids: 194.1;Spermatocytes: 97.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA071876 Approved Supported Centrosome NA NA Centrosome "HPA071876: AB_2686467" "unprognostic (9.14e-2)" "unprognostic (2.24e-1)" "unprognostic (3.98e-2)" "unprognostic (2.39e-1)" "unprognostic (1.30e-1)" "unprognostic (1.69e-2)" "unprognostic (9.59e-2)" "unprognostic (1.00e-1)" "unprognostic (6.95e-2)" "unprognostic (8.83e-2)" "unprognostic (1.08e-3)" "unprognostic (4.06e-2)" "prognostic unfavorable (7.32e-4)" "unprognostic (1.29e-2)" "unprognostic (2.49e-1)" "unprognostic (3.15e-1)" "unprognostic (2.09e-3)" 6.2 12.2 11.2 12.9 12.5 9.8 10.2 11.9 13.0 10.1 9.5 6.9 11.8 10.8 13.6 14.1 8.8 19.1 7.9 6.4 10.8 9.1 12.2 24.9 6.7 9.4 6.4 11.5 11.8 10.2 8.2 17.2 6.6 9.4 7.4 12.1 8.9 8.1 11.6 5.8 7.9 13.0 7.4 7.4 9.4 7.8 50.3 8.0 14.5 12.5 6.2 11.8 7.0 8.2 6.8 10.0 24.1 4.1 3.5 6.8 3.0 11.6 6.5 16.5 11.2 9.7 7.3 20.0 15.1 10.1 12.4 12.0 24.0 9.9 13.9 8.6 9.2 33.0 11.0 14.4 10.7 23.3 8.7 12.4 9.6 11.7 26.0 5.2 17.0 10.1 4.0 7.9 25.3 11.9 7.7 8.5 15.8 31.2 11.9 15.8 10.7 13.7 25.0 14.0 22.5 5.0 15.8 11.2 11.5 12.9 6.3 12.3 12.3 12.3 13.2 5.2 12.1 10.9 21.1 5.5 12.3 20.6 14.7 18.8 10.2 14.0 14.1 13.9 16.0 15.0 0.2 4.1 13.5 3.3 3.6 4.9 6.8 3.9 3.1 6.5 5.0 2.3 3.7 24.1 3.5 3.6 10.0 6.8 3.0 11.2 12.5 11.9 13.0 10.8 9.1 6.4 11.5 9.4 8.0 11.9 15.6 12.7 7.4 5.4 20.9 11.2 15.3 30.8 12.5 5.2 21.6 12.3 10.0 11.1 225.5 5.5 15.2 46.7 6.4 13.6 6.8 4.7 4.7 18.8 9.2 9.5 10.3 6.2 7.6 194.1 12.0 7.7 5.0 15.4 12.7 9.3 8.4 12.9 12.0 14.3 55.1 6.5 6.6 97.9 28.4 5.6 5.3 13.1 13.2 4.3 FGFR2 "BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25" ENSG00000066468 "Fibroblast growth factor receptor 2" P21802 10 121478334-121598458 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.8" "Cell type enhanced" "Detected in many" 16 "Cholangiocytes: 191.1;Club cells: 52.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 15 "basophil: 10.8;eosinophil: 4.6" "Lineage enriched" "Detected in single" 35 "granulocytes: 10.8" "Cell line enhanced" "Detected in some" "AN3-CA: 58.9;BEWO: 19.8;CACO-2: 15.4;HaCaT: 17.8;HAP1: 19.1;NTERA-2: 18.9;T-47d: 15.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010886, HPA035305" Uncertain Supported "Nucleoplasm,Vesicles,Cell Junctions" "Secreted - unknown location" NA NA 500000 "Cell Junctions" "Nucleoplasm, Vesicles" "CAB010886: AB_259379, HPA035305: AB_10672862" "unprognostic (5.53e-2)" "prognostic favorable (8.79e-4)" "unprognostic (1.08e-1)" "unprognostic (5.23e-2)" "unprognostic (1.73e-1)" "prognostic favorable (9.32e-4)" "unprognostic (1.53e-1)" "unprognostic (4.96e-3)" "unprognostic (1.74e-1)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (3.74e-2)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "unprognostic (2.54e-1)" "unprognostic (6.93e-2)" "unprognostic (2.25e-1)" 2.1 8.8 16.4 3.0 30.3 0.0 9.9 15.8 21.3 6.8 14.1 55.7 5.6 4.2 22.0 6.6 10.2 12.5 12.5 1.4 20.6 11.1 11.4 16.1 13.1 1.0 41.2 13.3 7.4 12.8 25.5 2.5 6.2 30.2 11.7 8.7 16.4 23.8 24.3 0.4 45.4 4.7 18.3 74.8 0.5 9.3 2.9 32.1 0.8 23.4 1.6 3.4 6.9 8.5 0.1 0.1 10.8 0.1 0.1 0.3 0.0 2.2 0.1 9.2 58.9 0.0 0.0 19.8 0.1 0.0 0.0 0.0 15.4 0.3 0.0 4.2 0.9 0.0 17.8 19.1 4.0 0.0 0.0 4.1 0.0 0.0 0.3 0.4 0.0 3.8 0.0 8.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 18.9 2.7 0.0 0.0 0.0 2.3 5.7 5.0 0.1 0.1 0.1 10.8 0.0 11.5 15.8 0.0 0.0 0.1 2.9 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 10.8 0.1 4.6 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.1 0.0 0.0 16.4 30.3 15.8 21.3 20.6 11.1 41.2 13.3 30.2 32.1 17.9 31.8 0.0 29.5 35.6 0.0 2.7 191.1 18.7 52.4 34.9 0.0 12.6 0.0 4.0 2.9 0.5 2.6 0.0 0.2 2.7 17.5 9.8 0.0 4.3 2.0 0.0 2.4 3.1 0.3 6.5 1.1 1.3 5.0 1.0 32.0 1.6 0.6 1.4 5.6 11.5 0.1 0.0 2.1 0.9 7.7 24.2 3.3 1.5 3.0 27.7 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "skin 1: 131.7" "Cell type enhanced" "Detected in many" 9 "Basal keratinocytes: 92.2;Cholangiocytes: 94.3;Suprabasal keratinocytes: 77.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CACO-2: 19.3;HaCaT: 15.1;Hep G2: 32.5;NTERA-2: 15.8;RT4: 19.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Intracellular and membrane" NA NA 670000 "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: AB_2685804" "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavorable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.5 1.5 24.7 1.7 30.3 1.6 4.2 10.2 22.0 4.1 4.9 15.8 3.4 9.9 1.8 2.7 26.9 2.0 5.0 2.0 21.6 11.7 9.6 7.4 4.5 1.3 17.6 21.5 1.1 23.0 1.2 3.0 5.6 15.1 3.7 3.8 1.7 3.8 9.0 1.7 131.7 7.4 1.3 9.0 2.1 4.9 8.1 10.6 0.1 1.3 8.5 7.3 8.5 10.1 0.1 0.6 0.1 0.1 0.2 0.3 0.0 0.0 1.5 9.2 2.6 0.0 0.1 9.4 1.1 0.1 0.4 0.2 19.3 0.4 0.0 7.7 0.3 0.4 15.1 2.6 0.1 0.1 0.1 9.7 6.0 1.5 32.5 0.0 0.0 0.2 0.0 5.1 0.1 0.0 0.0 0.0 0.9 6.5 0.0 0.0 9.6 0.4 0.2 15.8 8.8 0.0 0.5 0.5 0.1 1.3 19.3 2.7 0.7 0.8 1.6 0.0 11.1 9.0 1.1 0.4 0.0 0.9 0.2 0.6 0.0 0.0 0.0 0.1 0.7 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.1 0.0 24.7 30.3 10.2 22.0 21.6 11.7 17.6 21.5 15.1 10.6 0.0 23.8 2.4 3.6 92.2 0.0 2.0 94.3 0.0 21.6 14.0 0.0 0.4 0.0 4.8 5.4 0.9 20.6 0.0 0.6 9.2 7.0 3.3 0.0 27.0 0.5 0.0 4.1 14.7 1.2 0.4 0.6 1.2 11.8 1.0 20.7 0.2 0.4 17.3 0.4 7.5 0.6 0.0 2.8 0.4 17.9 77.5 0.7 0.0 13.0 11.8 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086886-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 33.6;kidney: 37.7;liver: 45.3" "Cell type enhanced" "Detected in many" 11 "Cholangiocytes: 50.9;Hepatocytes: 23.7;Proximal tubular cells: 19.5;Sertoli cells: 19.4;Undifferentiated cells: 33.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "neutrophil: 3.0" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "CACO-2: 43.0;Hep G2: 43.0;RH-30: 69.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" NA NA 4300000 "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 0.5 5.7 0.7 14.3 0.6 0.1 1.6 2.6 0.5 2.8 10.4 0.9 0.7 13.5 0.9 4.8 1.6 1.7 33.6 0.7 0.8 0.3 37.7 45.3 25.3 2.5 0.7 1.0 13.6 26.0 0.0 0.7 1.3 0.8 4.0 3.7 2.0 1.6 0.3 4.3 0.5 17.3 1.6 0.8 11.2 5.4 2.9 0.4 0.3 0.8 2.3 0.7 1.9 3.6 1.1 0.9 3.0 1.1 0.4 0.4 0.0 0.7 12.1 0.2 2.9 0.0 0.0 5.9 0.0 0.0 0.0 0.0 43.0 1.6 1.3 5.6 0.0 0.6 0.6 2.4 0.4 0.0 0.7 2.8 0.1 0.6 43.0 1.3 0.1 1.0 0.2 0.0 2.1 0.0 0.0 0.0 0.8 4.0 0.1 0.9 9.8 0.0 0.8 7.3 7.6 1.0 1.9 69.1 7.2 5.8 0.1 0.4 0.7 0.4 3.1 1.4 1.6 2.9 0.6 0.2 0.0 5.8 0.0 0.1 0.4 0.4 0.7 0.0 0.2 0.5 1.5 1.1 0.4 0.4 0.3 0.3 1.1 0.4 0.0 0.1 0.6 0.4 0.4 3.0 0.4 0.3 0.9 0.2 0.0 0.7 0.6 2.6 0.5 0.8 0.3 0.7 1.0 0.8 0.4 0.0 0.0 0.8 0.6 0.6 0.4 0.8 50.9 0.0 0.0 3.5 0.0 1.1 3.3 8.4 0.1 0.1 10.6 0.0 4.4 3.2 1.7 0.3 0.0 23.7 0.3 0.0 4.1 2.5 0.8 0.0 0.6 0.0 0.0 1.0 5.2 0.9 3.6 2.9 1.4 19.5 0.1 19.4 0.5 1.6 12.8 0.4 7.3 0.0 33.6 0.6 FHIT "AP3Aase, FRA3B" ENSG00000189283 "Fragile histidine triad" P49789 3 59749310-61251459 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation" Hydrolase "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Late spermatids: 138.8;Proximal tubular cells: 112.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "naive CD4 T-cell: 38.3" "Lineage enriched" "Detected in all" 14 "T-cells: 38.3" "Cell line enhanced" "Detected in many" "RPMI-8226: 12.1;U-266/70: 24.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002684, HPA018840, HPA018909" Enhanced Approved "Nucleoli fibrillar center,Plasma membrane" NA NA "Nucleoli fibrillar center, Plasma membrane" "CAB002684: , HPA018840: AB_1848538, HPA018909: AB_1848537" "unprognostic (2.36e-3)" "unprognostic (6.38e-2)" "unprognostic (1.59e-1)" "unprognostic (4.42e-2)" "unprognostic (1.10e-1)" "unprognostic (1.08e-2)" "unprognostic (1.18e-1)" "unprognostic (3.16e-2)" "unprognostic (2.77e-2)" "unprognostic (8.49e-2)" "unprognostic (2.36e-1)" "unprognostic (6.77e-2)" "prognostic favorable (1.36e-4)" "unprognostic (1.54e-1)" "unprognostic (5.96e-2)" "unprognostic (1.29e-2)" "unprognostic (1.80e-2)" 6.4 24.0 13.7 8.0 17.5 9.0 12.1 4.7 13.3 7.9 8.0 21.0 12.4 8.2 6.2 9.5 5.1 9.2 13.0 14.9 15.3 13.8 30.9 10.7 5.2 9.3 19.5 9.3 8.9 11.8 16.3 15.2 4.1 14.4 5.8 7.8 14.0 11.4 9.9 11.6 7.0 7.6 9.1 17.1 6.0 8.1 10.5 18.2 3.7 15.6 5.7 6.9 7.3 6.1 1.6 2.4 1.8 1.8 2.6 38.3 4.7 0.0 0.0 1.0 0.0 0.6 0.0 1.7 0.1 0.1 0.0 0.0 1.8 3.1 2.6 0.5 0.1 1.9 0.0 10.1 2.1 0.0 1.4 3.5 2.2 1.3 4.2 2.7 5.7 0.1 6.9 4.2 0.1 5.1 0.2 0.0 2.8 1.7 8.4 0.1 2.5 10.2 4.6 0.8 8.7 0.6 7.6 0.0 12.1 11.3 1.4 2.1 2.9 1.0 7.0 6.6 4.1 0.4 0.1 0.0 1.2 0.4 0.1 1.6 24.7 7.5 0.0 2.7 0.0 1.5 1.8 1.8 0.2 0.9 1.2 0.5 1.6 6.9 0.7 2.2 1.4 38.3 6.7 0.3 2.6 0.4 2.4 7.4 4.7 13.7 17.5 4.7 13.3 15.3 13.8 19.5 9.3 14.4 18.2 6.0 8.8 14.1 16.1 6.8 12.4 9.2 33.1 2.7 3.4 26.2 55.0 33.8 66.3 17.3 41.1 6.2 12.3 0.0 4.1 6.5 4.3 10.2 5.7 20.8 17.6 28.6 7.5 11.6 6.7 138.8 17.8 9.6 11.8 6.4 11.4 17.8 11.6 14.0 9.2 112.3 19.5 0.0 3.1 18.1 6.4 9.8 27.3 7.5 17.2 19.0 FIP1L1 "DKFZp586K0717, FIP1" ENSG00000145216 "Factor interacting with PAPOLA and CPSF1" Q6UN15 4 53377643-53460861 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "mRNA processing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA037475, HPA058202" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA037475: AB_10696933, HPA058202: AB_2683636" "unprognostic (3.80e-1)" "unprognostic (5.46e-2)" "unprognostic (5.60e-3)" "unprognostic (1.40e-1)" "unprognostic (7.18e-2)" "unprognostic (4.71e-2)" "prognostic unfavorable (1.51e-4)" "unprognostic (1.87e-1)" "unprognostic (9.00e-3)" "unprognostic (1.14e-2)" "unprognostic (5.48e-2)" "unprognostic (1.42e-1)" "unprognostic (4.07e-1)" "unprognostic (1.10e-1)" "unprognostic (8.66e-3)" "unprognostic (3.10e-2)" "unprognostic (1.39e-1)" 25.7 24.4 20.2 27.6 25.8 35.8 24.0 23.0 25.1 24.5 18.0 19.4 16.1 16.0 27.4 17.7 23.4 22.4 16.2 19.7 17.1 16.6 19.7 19.0 20.3 24.5 20.1 26.0 32.2 16.9 26.6 26.6 28.2 20.9 21.7 21.0 16.2 21.5 18.0 33.9 24.5 20.0 23.5 19.4 24.5 20.4 40.2 22.4 42.4 22.7 17.8 29.2 26.6 22.6 26.5 32.7 36.5 24.0 33.7 32.4 21.3 18.3 12.1 22.2 13.3 16.8 17.1 28.4 23.3 29.3 19.0 14.7 17.6 17.1 33.7 18.1 24.8 17.8 11.6 24.1 17.3 24.7 11.7 13.1 26.6 10.0 16.2 26.7 39.5 22.8 19.6 15.8 24.0 24.6 18.4 14.0 20.4 30.6 15.8 14.9 13.5 35.6 18.2 14.6 23.5 11.9 32.0 10.1 14.8 15.4 16.6 17.3 18.7 16.3 18.8 26.7 21.8 10.7 14.7 14.7 19.5 17.0 18.1 27.9 19.8 11.5 42.6 16.9 24.8 34.7 25.8 16.9 36.5 25.7 17.8 29.2 26.5 25.8 25.1 22.6 24.2 28.9 25.4 20.7 33.7 24.0 32.7 32.4 21.3 20.2 25.8 23.0 25.1 17.1 16.6 20.1 26.0 20.9 22.4 23.8 20.1 45.5 37.4 34.5 40.5 13.1 17.8 45.5 27.3 26.2 17.7 52.0 31.5 34.1 7.4 26.3 21.3 0.0 30.6 43.6 38.6 25.4 47.4 18.7 28.6 73.1 35.2 33.2 19.4 8.8 61.9 27.7 30.4 46.9 24.6 45.2 30.3 31.7 50.2 19.6 28.8 38.8 24.7 112.4 78.8 29.7 72.2 41.5 25.5 30.3 FLI1 "EWSR2, SIC-1" ENSG00000151702 "Fli-1 proto-oncogene, ETS transcription factor" Q01543 11 128686535-128813267 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 40.2" "Group enriched" "Detected in many" 6 "B-cells: 32.3;Endothelial cells: 76.4;granulocytes: 22.0;Hofbauer cells: 36.1;Ito cells: 49.7;Kupffer cells: 85.1;Macrophages: 24.6;T-cells: 47.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 41.0;HUVEC TERT2: 22.8;REH: 19.2;TIME: 23.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA065030, HPA073099" Approved Supported "Nucleoplasm,Nuclear bodies" Yes NA "Nucleoplasm, Nuclear bodies" "HPA065030: , HPA073099: AB_2686572" "unprognostic (1.38e-2)" "unprognostic (7.46e-2)" "unprognostic (6.16e-2)" "unprognostic (3.74e-2)" "unprognostic (6.22e-2)" "unprognostic (4.26e-3)" "unprognostic (1.33e-1)" "unprognostic (8.32e-3)" "unprognostic (2.97e-1)" "unprognostic (9.91e-2)" "unprognostic (1.60e-2)" "unprognostic (1.42e-1)" "prognostic unfavorable (4.60e-4)" "unprognostic (4.79e-2)" "unprognostic (2.07e-2)" "unprognostic (2.62e-1)" "unprognostic (4.79e-2)" 14.7 2.5 3.5 15.8 4.4 10.6 9.9 1.4 3.2 6.7 5.1 3.8 2.1 3.3 7.8 6.5 4.8 5.3 6.0 7.5 3.8 3.1 4.2 3.6 17.4 24.4 6.2 1.6 4.0 3.2 2.5 2.0 11.4 3.8 4.3 3.1 4.8 4.2 3.3 5.2 3.2 6.9 5.7 6.6 40.2 4.1 2.7 4.6 26.8 5.7 2.8 17.9 6.2 6.7 4.5 13.1 20.1 12.0 7.8 8.8 11.6 0.0 0.0 2.1 0.0 0.2 0.4 0.0 1.2 3.4 1.4 1.2 0.0 0.0 7.0 12.5 4.1 0.4 0.0 0.3 5.1 1.6 3.2 0.1 41.0 0.2 0.0 2.4 4.9 5.8 0.3 0.4 3.0 6.9 4.3 22.8 9.8 0.0 9.0 0.3 0.0 4.9 2.8 0.6 0.0 1.2 19.2 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.0 0.0 7.9 23.6 0.2 0.0 0.1 1.3 2.9 6.0 6.0 0.0 11.9 1.9 20.1 9.5 16.1 7.2 10.3 8.8 4.5 6.2 5.8 13.1 3.6 2.6 5.6 7.8 7.8 12.0 2.2 7.4 11.6 3.5 4.4 1.4 3.2 3.8 3.1 6.2 1.6 3.8 4.6 6.0 7.7 32.3 0.2 4.5 0.0 5.0 5.1 1.4 0.0 1.8 0.0 0.3 0.0 0.0 0.5 76.4 0.0 0.0 0.0 0.2 5.6 0.3 22.0 1.0 36.1 0.0 0.0 49.7 85.1 0.0 1.7 24.6 6.8 6.4 0.0 0.1 0.0 0.0 0.7 0.3 0.0 6.5 2.8 0.3 0.1 3.6 0.2 47.8 0.0 0.4 FLT3 "CD135, FLK2, STK1" ENSG00000122025 "Fms related tyrosine kinase 3" P36888 13 28003274-28100592 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 29.9;brain: 19.3;lymphoid tissue: 15.0" "Cell type enhanced" "Detected in some" 25 "Kupffer cells: 29.6;Macrophages: 12.4;monocytes: 55.9" "Cancer enhanced" "Detected in some" "breast cancer: 1.8" "Region enhanced" "Detected in many" "cerebellum: 19.3" "Group enriched" "Detected in some" 11 "myeloid DC: 29.9;plasmacytoid DC: 12.1" "Lineage enriched" "Detected in many" 16 "dendritic cells: 29.9" "Group enriched" "Detected in some" 11 "REH: 28.5;THP-1: 17.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA047539 Approved "Endoplasmic reticulum" NA NA 180000 "Endoplasmic reticulum" "HPA047539: AB_2680080" "unprognostic (2.19e-3)" "unprognostic (3.16e-3)" "unprognostic (6.54e-3)" "unprognostic (9.96e-2)" "unprognostic (3.88e-1)" "unprognostic (3.96e-7)" "unprognostic (7.99e-3)" "unprognostic (1.65e-2)" "unprognostic (5.37e-2)" "unprognostic (1.01e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-1)" "unprognostic (4.56e-2)" "unprognostic (3.65e-1)" "unprognostic (3.91e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" 0.9 0.6 0.6 7.2 1.1 7.5 2.6 19.3 3.5 0.9 1.2 0.1 0.1 0.4 0.8 0.8 1.0 1.2 4.6 0.5 0.9 1.7 2.8 0.7 2.7 15.0 1.8 1.1 0.5 5.7 0.0 0.4 0.0 7.4 0.6 1.4 0.1 2.3 0.6 0.4 1.2 3.0 1.3 4.4 8.8 0.9 1.2 0.0 8.2 0.6 0.0 5.8 2.4 0.7 0.1 29.9 1.4 1.8 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 2.1 0.5 0.0 0.0 28.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 17.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.8 1.4 0.0 0.3 0.0 0.1 0.0 0.0 29.9 0.0 0.0 0.0 0.0 0.8 0.0 12.1 0.0 1.2 0.6 1.1 19.3 3.5 0.9 1.7 1.8 1.1 7.4 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.3 2.5 0.0 0.0 0.0 0.0 0.0 0.0 2.2 3.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.5 0.0 0.0 1.3 29.6 1.6 0.0 12.4 1.7 55.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.5 0.0 0.0 0.0 0.0 FLT4 "PCL, VEGFR3" ENSG00000037280 "Fms related tyrosine kinase 4" P35916 5 180601506-180649624 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 56.3" "Group enriched" "Detected in some" 5 "Extravillous trophoblasts: 31.7;Ito cells: 65.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "MAIT T-cell: 7.7" "Lineage enriched" "Detected in single" 35 "T-cells: 7.7" "Cell line enhanced" "Detected in some" "AN3-CA: 8.3;BEWO: 10.1;HEK 293: 12.5;HUVEC TERT2: 8.1;JURKAT: 10.0;T-47d: 11.9;TIME: 12.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000099, HPA046519, HPA067906, HPA074389" Approved Supported "Nuclear speckles,Plasma membrane,Cell Junctions" "Secreted to blood" NA NA 270000000 "Nuclear speckles, Plasma membrane" "Cell Junctions" "CAB000099: , HPA046519: AB_2732527, HPA067906: AB_2732775, HPA074389: " "unprognostic (7.35e-2)" "unprognostic (1.63e-1)" "unprognostic (9.45e-3)" "unprognostic (3.81e-1)" "unprognostic (9.26e-2)" "unprognostic (3.20e-3)" "unprognostic (1.13e-2)" "unprognostic (1.80e-2)" "unprognostic (2.19e-1)" "unprognostic (1.70e-1)" "unprognostic (2.13e-2)" "unprognostic (3.69e-1)" "unprognostic (1.88e-2)" "unprognostic (9.41e-3)" "unprognostic (1.83e-1)" "unprognostic (8.26e-2)" "unprognostic (1.32e-1)" 14.8 7.1 1.6 4.9 6.0 0.7 28.5 1.3 2.7 6.3 7.3 1.9 2.1 3.1 7.3 6.2 5.7 9.2 5.3 6.4 1.7 0.9 11.7 10.2 14.1 23.6 2.0 0.8 5.8 2.3 2.3 6.2 56.3 2.1 4.9 1.4 6.7 3.3 4.4 4.8 2.8 4.7 4.7 1.5 14.5 2.4 3.5 2.0 0.3 19.4 4.4 2.3 6.1 14.7 0.0 0.1 0.2 0.0 0.0 7.7 0.2 0.1 2.0 2.7 8.3 0.0 0.0 10.1 0.2 0.1 0.0 0.0 0.3 0.3 0.2 0.8 0.1 0.5 0.3 2.8 0.1 0.2 0.1 12.5 1.0 0.4 0.4 0.1 7.4 0.2 0.2 0.0 0.1 0.3 0.3 8.1 10.0 0.3 0.3 1.7 4.5 0.1 0.4 5.8 0.2 0.5 6.5 0.0 0.1 0.1 0.2 0.2 0.9 0.1 0.2 0.0 2.7 11.9 0.2 12.6 0.1 5.9 0.2 0.1 0.2 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.9 0.0 7.7 0.0 0.4 1.6 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.0 0.2 1.6 6.0 1.3 2.7 1.7 0.9 2.0 0.8 2.1 2.0 0.0 1.7 0.9 0.2 0.8 0.0 4.5 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.2 9.2 0.0 0.0 0.0 31.7 0.6 0.2 2.3 0.4 1.1 0.0 0.0 65.1 5.7 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 4.3 1.0 0.8 0.7 0.0 0.1 FOXA1 HNF3A ENSG00000129514 "Forkhead box A1" P55317 14 37589984-37596059 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 47.0;prostate: 44.4" "Cell type enhanced" "Detected in many" 9 "Basal glandular cells: 103.5;Glandular cells: 100.2;Intestinal endocrine cells: 81.2;Urothelial cells: 133.4" "Cancer enhanced" "Detected in many" "prostate cancer: 127.0" "Region enriched" "Detected in single" 6 "midbrain: 2.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "Hep G2: 16.6;MCF7: 36.1;PC-3: 25.2;RT4: 33.8;SK-BR-3: 34.2;T-47d: 48.4" "Group enriched" "Detected in some" 15 "hypothalamus: 1.0;midbrain: 1.3;thalamus: 1.1" "Region enriched" "Detected in single" 6 "midbrain: 6.1" "CAB011595, HPA050505" Enhanced Supported "Nucleoplasm,Nucleoli fibrillar center" NA NA Nucleoplasm "Nucleoli fibrillar center" "CAB011595: AB_2104842, HPA050505: AB_2681148" "unprognostic (1.61e-1)" "unprognostic (8.80e-2)" "unprognostic (1.12e-1)" "unprognostic (4.65e-1)" "unprognostic (2.58e-1)" "unprognostic (1.51e-1)" "unprognostic (1.74e-1)" "unprognostic (1.78e-1)" "unprognostic (1.71e-1)" "unprognostic (3.01e-1)" "unprognostic (1.54e-2)" "unprognostic (6.30e-2)" "unprognostic (0.00e+0)" "unprognostic (3.67e-1)" "unprognostic (2.58e-1)" "unprognostic (1.69e-2)" "prognostic favorable (1.00e-4)" 0.1 0.0 0.1 6.1 0.1 0.0 23.5 0.1 0.3 1.5 9.4 0.1 0.1 4.6 0.1 0.5 7.2 1.3 6.5 0.1 0.1 0.3 0.4 47.0 13.2 0.1 2.0 0.1 0.6 0.2 0.0 1.1 0.1 0.2 44.4 6.0 0.2 9.4 0.7 0.1 0.7 5.1 2.4 0.1 0.1 13.0 0.6 0.1 0.2 0.1 4.4 9.9 12.5 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.5 0.0 0.9 0.0 0.0 0.2 0.0 0.1 0.0 0.0 7.4 0.9 0.0 0.5 0.0 0.0 8.4 4.7 1.1 0.0 0.0 8.3 0.0 1.4 16.6 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.6 0.0 0.1 0.3 0.0 0.0 36.1 0.0 0.1 0.0 11.0 25.2 0.0 0.4 0.1 3.5 33.8 4.3 0.0 1.6 34.2 0.0 0.0 48.4 0.1 0.0 0.3 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.3 2.0 0.1 0.2 0.1 26.8 38.7 0.0 103.5 0.9 0.0 1.1 25.5 52.2 37.5 3.5 0.0 0.0 0.0 1.8 0.3 0.3 14.7 0.0 2.1 0.0 0.0 100.2 2.3 27.6 0.0 0.0 81.2 1.3 1.2 0.5 0.0 0.1 3.3 1.8 34.4 0.0 3.1 21.0 0.0 0.0 0.0 0.0 0.1 0.5 1.3 0.1 0.0 0.0 25.3 133.4 FOXL2 "BPES, BPES1" ENSG00000183770 "Forkhead box L2" P58012 3 138944224-138947140 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Premature ovarian failure" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 13.9;ovary: 55.5;parathyroid gland: 15.3" "Not detected" "Not detected" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A-431: 5.6;fHDF/TERT166: 6.5;HEL: 9.2;hTCEpi: 8.5;K-562: 9.4;SiHa: 6.5;THP-1: 6.7" "Not detected" "Not detected" HPA069613 Enhanced Supported "Nucleoplasm,Midbody ring" NA NA Nucleoplasm "Midbody ring" "HPA069613: AB_2686160" "unprognostic (1.46e-1)" "unprognostic (3.28e-2)" "unprognostic (4.76e-3)" "unprognostic (2.05e-1)" "unprognostic (5.16e-4)" "unprognostic (3.55e-2)" "unprognostic (2.35e-3)" "unprognostic (5.08e-2)" "unprognostic (3.79e-2)" "unprognostic (2.19e-1)" "unprognostic (9.63e-8)" "unprognostic (2.16e-2)" "unprognostic (4.65e-1)" "unprognostic (2.90e-2)" "unprognostic (1.61e-2)" 0.0 1.5 0.3 0.0 1.2 0.0 0.0 0.3 1.0 13.9 0.0 0.6 0.0 0.0 10.0 0.4 0.1 6.4 0.0 0.1 0.4 0.2 0.0 0.0 0.0 0.0 0.3 0.4 55.5 0.6 15.3 13.1 1.4 0.8 0.2 0.0 1.7 0.0 0.4 0.0 0.2 0.0 0.9 0.3 0.0 0.0 0.8 0.2 0.0 0.2 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 2.2 0.3 4.0 0.1 0.0 1.7 0.2 0.0 0.4 0.1 0.0 0.4 0.0 2.7 6.5 0.2 1.3 0.0 0.0 0.1 0.0 0.0 9.2 1.1 0.0 0.0 0.1 0.0 0.0 8.5 0.0 0.0 1.4 0.0 0.0 9.4 0.0 3.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.5 1.8 0.0 0.0 6.5 0.0 0.0 0.3 0.0 6.7 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.2 0.3 1.0 0.4 0.2 0.3 0.4 0.8 0.2 0.0 0.0 0.0 0.1 0.5 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.9 0.0 0.0 0.0 0.0 FOXO1 "FKH1, FKHR, FOXO1A" ENSG00000150907 "Forkhead box O1" Q12778 13 40469953-40666597 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Autophagy, Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 85.9" "Cell type enhanced" "Detected in many" 6 "Ito cells: 72.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 19.3;Daudi: 20.4;HSkMC: 25.7;U-698: 26.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001252, CAB022326" Approved Approved Supported Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB022326: , HPA001252: AB_1078906" "unprognostic (4.72e-2)" "unprognostic (1.81e-1)" "unprognostic (8.54e-2)" "unprognostic (4.35e-1)" "unprognostic (2.42e-1)" "unprognostic (2.52e-1)" "prognostic favorable (3.74e-4)" "unprognostic (6.35e-2)" "unprognostic (1.60e-1)" "unprognostic (8.65e-3)" "unprognostic (1.71e-1)" "unprognostic (1.31e-1)" "prognostic favorable (1.33e-5)" "unprognostic (1.93e-1)" "unprognostic (5.44e-1)" "unprognostic (9.09e-2)" "unprognostic (9.63e-2)" 41.6 6.9 7.0 18.4 11.2 8.0 35.5 2.3 5.0 21.4 13.4 8.4 7.7 3.5 27.4 9.8 9.5 17.2 13.3 9.9 7.8 3.9 8.3 25.6 15.3 22.4 8.3 3.9 46.0 12.2 3.8 6.2 9.5 6.5 7.9 6.8 5.7 7.5 9.3 85.9 12.3 7.6 18.6 9.7 10.8 7.4 12.3 9.0 9.4 13.1 9.0 15.6 14.4 16.2 6.1 0.5 2.8 1.6 1.1 7.1 1.0 0.3 0.6 5.7 0.1 19.3 3.8 5.5 0.8 1.1 0.2 0.1 1.5 1.3 20.4 3.8 0.5 0.9 4.9 4.5 2.4 0.3 9.2 4.6 0.0 0.6 4.5 9.2 0.1 0.5 25.7 16.7 0.1 3.2 1.1 14.5 1.5 0.3 6.5 1.4 0.7 0.0 0.2 8.3 2.8 1.4 14.5 6.7 1.6 10.7 2.6 1.2 0.3 0.7 3.9 0.8 6.9 0.6 0.5 8.5 0.1 1.1 0.0 0.5 3.7 1.4 26.4 0.5 0.9 2.6 0.9 0.8 0.5 1.5 1.0 2.3 3.2 3.9 2.2 0.5 6.1 7.1 5.3 2.8 1.1 1.6 0.0 5.5 1.0 7.0 11.2 2.3 5.0 7.8 3.9 8.3 3.9 6.5 9.0 0.0 4.1 9.5 18.7 26.1 3.0 9.8 7.6 9.4 9.1 8.7 11.8 0.2 0.0 9.5 5.5 37.9 19.3 0.0 15.3 1.7 28.8 9.2 1.1 39.4 5.7 4.8 50.2 72.4 15.5 2.0 17.3 11.0 11.8 18.0 18.4 5.0 15.9 13.6 12.4 6.3 8.3 6.5 9.3 4.8 14.9 23.3 0.7 12.9 9.8 9.1 FOXO3 "AF6q21, FKHRL1, FOXO2, FOXO3A" ENSG00000118689 "Forkhead box O3" O43524 6 108559835-108684774 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Erythroid cells: 210.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 15.7" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 40.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004074, HPA063104" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB004074: AB_2106672, HPA063104: AB_2684941" "unprognostic (3.42e-2)" "unprognostic (3.76e-2)" "unprognostic (4.28e-2)" "unprognostic (1.96e-2)" "unprognostic (6.68e-2)" "unprognostic (4.63e-2)" "unprognostic (4.08e-3)" "unprognostic (1.73e-1)" "unprognostic (3.81e-2)" "unprognostic (5.18e-2)" "unprognostic (1.98e-2)" "unprognostic (1.75e-1)" "unprognostic (2.54e-2)" "unprognostic (9.09e-2)" "unprognostic (1.13e-1)" "unprognostic (5.81e-2)" "unprognostic (5.68e-2)" 29.6 7.7 11.5 12.2 12.6 36.7 35.4 28.0 18.1 19.9 16.1 12.6 9.8 7.8 17.4 16.1 22.3 16.5 18.0 12.9 9.7 7.7 10.7 14.0 21.1 16.8 12.4 14.0 28.8 52.3 14.3 8.8 13.1 10.3 13.8 11.0 14.3 21.2 10.5 54.7 20.3 11.3 13.9 7.9 14.2 14.8 13.1 13.2 11.6 13.1 12.7 10.2 17.1 20.3 1.8 2.7 15.7 4.6 3.4 4.0 1.0 9.1 3.3 6.0 9.7 18.6 22.3 7.5 7.6 8.0 6.7 9.2 5.9 8.3 5.9 6.5 8.9 9.8 6.7 6.2 9.3 10.0 5.3 9.0 14.7 2.9 4.4 21.7 3.5 10.8 25.4 18.8 13.7 18.8 9.3 5.0 5.4 9.8 40.1 12.1 5.2 4.9 5.4 3.9 4.4 5.0 5.7 17.1 19.7 13.3 7.0 10.6 27.6 6.5 5.3 7.6 11.0 5.8 11.7 8.0 11.4 6.4 7.0 9.8 0.7 6.9 5.6 6.2 7.1 7.8 6.7 2.9 5.7 3.6 1.5 4.0 1.0 1.9 3.0 1.7 1.8 1.7 2.3 15.7 3.4 4.6 2.7 1.8 1.0 11.5 12.6 28.0 18.1 9.7 7.7 12.4 14.0 10.3 13.2 41.7 39.5 22.4 61.6 60.1 55.0 28.2 73.9 44.2 46.6 24.4 66.8 19.2 14.9 43.0 12.5 63.2 36.2 210.2 26.5 31.0 67.9 115.8 15.0 60.6 39.1 49.3 64.2 66.9 66.3 12.1 98.7 35.8 54.0 43.3 49.3 89.6 53.0 33.6 94.4 15.9 67.1 32.3 89.8 7.2 18.1 40.7 34.4 35.5 29.9 108.9 FOXO4 "AFX1, MLLT7" ENSG00000184481 "Forkhead box O4" P98177 X 71096197-71103535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "placenta: 98.6" "Group enriched" "Detected in many" 10 "Cytotrophoblasts: 207.8;Syncytiotrophoblasts: 257.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in many" 5 "BEWO: 61.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039560, HPA040232" Enhanced Supported "Nuclear speckles,Cytosol" NA NA "Nuclear speckles" Cytosol "HPA039560: AB_2676572, HPA040232: AB_2676894" "unprognostic (4.64e-2)" "unprognostic (2.94e-2)" "unprognostic (2.19e-1)" "unprognostic (2.49e-1)" "unprognostic (4.79e-2)" "prognostic favorable (4.61e-4)" "unprognostic (1.09e-1)" "unprognostic (3.20e-2)" "unprognostic (1.58e-1)" "unprognostic (7.18e-2)" "unprognostic (2.13e-2)" "unprognostic (8.16e-2)" "prognostic favorable (3.46e-4)" "unprognostic (2.45e-2)" "unprognostic (2.07e-1)" "unprognostic (1.20e-1)" "unprognostic (1.75e-3)" 8.5 13.2 21.7 3.8 21.5 9.9 5.1 9.1 15.6 4.8 8.4 9.1 11.9 6.3 6.8 10.2 7.3 7.7 5.8 9.7 21.4 14.5 5.2 3.6 5.5 3.6 22.8 8.4 13.4 6.8 8.7 3.0 98.6 9.2 7.0 4.7 4.9 8.5 11.3 33.8 5.5 6.6 9.4 17.3 6.0 5.2 13.9 13.1 4.4 5.9 7.5 4.2 7.5 11.0 0.9 0.2 3.4 0.6 1.0 1.8 0.9 1.8 0.5 1.4 1.8 3.4 2.4 61.2 1.4 1.6 0.7 1.7 1.2 2.4 2.4 1.8 1.8 0.8 0.8 3.7 1.6 0.9 2.4 5.6 3.4 11.4 2.0 1.9 2.0 2.7 2.0 3.9 0.7 0.4 3.3 1.9 3.5 7.0 4.7 0.3 0.4 3.1 3.2 6.6 4.6 2.2 2.1 3.6 3.6 1.2 1.0 1.0 3.0 2.9 0.4 3.2 10.9 0.7 1.2 1.7 0.4 0.9 3.2 0.3 3.1 1.6 0.4 1.6 5.3 0.5 0.2 0.6 3.2 0.9 0.6 0.3 0.8 0.5 0.9 0.2 0.9 0.4 1.8 3.4 1.0 0.3 0.0 1.3 0.9 21.7 21.5 9.1 15.6 21.4 14.5 22.8 8.4 9.2 13.1 0.0 2.4 1.4 4.1 4.7 1.2 6.5 5.1 0.0 1.2 8.7 3.9 207.8 1.7 2.0 0.2 3.8 12.7 23.3 2.6 8.6 4.4 3.4 2.3 2.4 19.4 1.6 5.8 4.3 3.1 0.4 6.4 3.2 3.3 1.0 11.4 2.8 2.6 8.6 14.5 3.3 0.8 6.5 2.5 0.3 0.4 3.0 257.4 5.0 6.0 3.1 FOXP1 "12CC4, hFKH1B, HSPC215, QRF1" ENSG00000114861 "Forkhead box P1" Q9H334 3 70952817-71583993 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 40.2" "HPA003876, CAB011501" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB011501: AB_732428, HPA003876: AB_1078907" "unprognostic (2.31e-1)" "unprognostic (4.35e-3)" "unprognostic (2.09e-2)" "unprognostic (3.54e-2)" "unprognostic (2.69e-1)" "unprognostic (2.81e-3)" "unprognostic (1.68e-1)" "unprognostic (1.00e-1)" "unprognostic (1.23e-1)" "unprognostic (2.03e-1)" "unprognostic (4.38e-3)" "unprognostic (3.40e-1)" "unprognostic (6.14e-2)" "unprognostic (1.05e-1)" "unprognostic (8.65e-2)" "unprognostic (1.27e-1)" "unprognostic (6.05e-2)" 24.6 5.1 7.0 30.2 19.2 32.7 21.9 7.2 13.1 16.3 29.3 8.7 10.3 10.1 19.8 9.9 19.6 13.1 19.3 15.5 8.4 5.9 7.6 12.9 26.1 34.0 7.6 10.2 30.3 14.7 7.2 25.7 11.4 7.4 21.6 21.6 11.3 24.6 11.2 12.7 12.2 16.7 34.3 7.9 18.6 20.4 11.7 10.1 38.1 19.8 13.1 27.0 28.5 31.8 29.9 8.4 14.4 9.9 9.2 29.6 11.2 3.8 2.9 7.1 4.8 3.3 9.6 3.4 11.4 13.1 10.0 7.3 21.3 4.5 10.3 1.7 5.1 7.2 2.6 13.1 9.8 16.9 3.1 5.4 5.3 7.1 20.0 8.3 9.9 13.1 9.8 4.0 40.2 17.8 7.0 14.9 6.1 5.3 15.1 4.5 16.8 4.9 3.9 8.7 2.7 18.6 14.9 12.3 1.8 8.2 12.1 6.0 10.9 11.9 3.3 0.7 7.1 2.3 7.3 18.8 13.9 6.0 19.3 15.7 3.8 2.8 14.6 8.8 12.7 2.9 14.4 5.7 6.0 8.3 5.7 9.3 25.8 18.3 10.3 5.3 29.9 29.6 18.9 8.3 9.2 9.9 8.4 15.9 11.2 7.0 19.2 7.2 13.1 8.4 5.9 7.6 10.2 7.4 10.1 68.5 106.7 181.2 154.9 162.6 27.9 38.3 114.7 87.0 93.3 31.4 17.7 37.3 26.6 65.8 141.2 159.5 75.9 70.0 81.8 13.6 54.0 219.0 213.7 53.9 43.0 6.4 260.7 120.9 97.8 57.5 38.9 86.3 35.4 111.0 226.3 20.3 98.8 101.7 23.3 15.6 38.0 90.5 74.6 10.8 6.4 88.7 43.8 126.3 146.7 116.8 FSTL3 "FLRG, FSRP" ENSG00000070404 "Follistatin like 3" O95633 19 676365-683399 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Osteogenesis, Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 6 "placenta: 201.0" "Cell type enriched" "Detected in many" 4 "Extravillous trophoblasts: 2939.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BEWO: 36.2;hTCEpi: 40.0;SiHa: 73.8;U-2197: 38.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB024899, HPA045378" Approved Supported Nucleoplasm "Secreted in other tissues" NA Yes 6800000 Nucleoplasm "CAB024899: , HPA045378: AB_2679300" "unprognostic (9.86e-3)" "unprognostic (1.32e-3)" "prognostic unfavorable (3.01e-4)" "prognostic unfavorable (3.03e-4)" "unprognostic (2.19e-3)" "unprognostic (1.51e-3)" "unprognostic (8.64e-3)" "prognostic unfavorable (4.61e-7)" "unprognostic (9.50e-2)" "prognostic unfavorable (1.65e-4)" "unprognostic (3.50e-2)" "unprognostic (5.91e-2)" "unprognostic (1.03e-3)" "unprognostic (7.22e-3)" "unprognostic (3.07e-1)" "unprognostic (3.75e-1)" "unprognostic (5.89e-3)" 19.9 29.1 4.0 10.7 6.2 5.6 24.7 1.3 4.2 13.1 14.9 3.8 8.1 3.8 12.8 15.6 12.7 14.1 13.1 27.0 5.0 2.0 13.7 5.1 26.9 8.7 7.3 4.5 16.8 11.7 1.4 5.3 201.0 6.0 14.3 3.1 12.0 4.5 11.0 4.1 6.2 6.5 20.6 10.4 3.9 9.1 34.5 4.9 0.7 7.2 5.5 1.4 16.7 18.3 0.9 2.2 0.1 4.4 0.6 2.6 2.0 1.9 15.9 1.1 0.8 5.0 12.8 36.2 27.0 4.0 6.8 2.5 5.8 3.1 0.8 10.9 18.2 3.9 13.9 0.9 23.0 2.2 1.6 1.9 0.7 22.2 4.7 21.6 1.4 2.6 16.0 40.0 7.5 31.3 17.6 1.2 0.8 1.7 1.1 10.2 7.0 0.5 0.8 1.3 13.1 5.5 1.5 0.7 1.8 9.4 0.3 0.7 1.2 73.8 1.5 0.8 1.4 1.3 0.7 16.2 6.8 23.5 38.1 9.9 1.8 0.8 0.4 1.0 4.2 3.1 0.0 4.4 0.0 1.0 4.4 0.2 0.3 1.4 1.1 2.2 0.9 2.6 1.6 0.1 0.6 3.2 0.9 0.2 2.0 4.0 6.2 1.3 4.2 5.0 2.0 7.3 4.5 6.0 4.9 17.9 3.4 2.2 19.6 12.9 1.6 12.8 30.6 2.7 1.2 8.7 0.0 22.7 6.6 69.7 5.6 4.5 0.9 0.0 56.0 2939.6 52.2 21.7 0.0 0.9 68.4 3.2 1.2 22.1 3.8 6.5 56.7 4.0 5.0 11.8 0.9 7.8 198.1 0.0 25.1 5.6 0.5 45.3 32.5 2.3 7.7 6.8 662.4 2.9 1.7 20.7 FUBP1 "FBP, FUBP" ENSG00000162613 "Far upstream element binding protein 1" Q96AE4 1 77944055-77979110 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006149 Supported Enhanced Nucleoplasm NA NA 200000 Nucleoplasm "HPA006149: AB_1849172" "unprognostic (4.17e-2)" "unprognostic (2.83e-2)" "unprognostic (3.35e-3)" "unprognostic (3.89e-2)" "unprognostic (3.77e-1)" "unprognostic (5.65e-2)" "prognostic unfavorable (9.83e-9)" "unprognostic (2.32e-2)" "unprognostic (2.16e-1)" "unprognostic (1.69e-1)" "unprognostic (3.31e-3)" "unprognostic (9.80e-3)" "unprognostic (9.02e-3)" "unprognostic (1.37e-1)" "unprognostic (1.67e-1)" "unprognostic (6.24e-2)" "unprognostic (9.46e-2)" 23.9 35.5 21.8 42.4 26.9 56.8 27.0 34.0 31.8 24.3 19.6 18.1 23.0 21.8 29.4 35.0 23.5 25.2 18.4 27.5 22.0 22.3 26.6 16.3 27.2 37.6 17.5 28.8 44.4 31.6 36.0 41.5 27.3 26.3 22.4 28.3 22.0 28.2 35.6 27.4 21.3 24.0 22.7 31.3 28.6 22.6 17.6 19.9 64.9 35.0 26.2 40.3 24.0 29.1 16.1 11.3 10.8 16.1 23.5 22.2 12.8 22.3 19.7 46.6 18.5 7.2 9.1 38.2 23.1 13.8 22.2 16.2 19.9 25.0 40.0 10.8 17.1 26.3 22.3 31.2 25.4 29.7 44.0 15.9 25.6 32.7 29.2 15.7 43.8 10.8 11.9 21.0 23.7 18.9 18.2 17.7 27.0 29.3 17.8 17.5 22.5 34.7 21.2 36.4 22.0 14.1 42.7 36.9 15.3 23.0 22.0 24.6 23.2 21.5 20.4 18.2 26.0 24.8 15.9 22.7 21.5 31.3 6.1 27.6 17.1 18.4 51.9 9.3 19.3 21.9 3.8 9.6 10.8 18.7 15.7 22.2 16.1 18.3 19.4 8.7 13.1 17.9 20.9 4.0 23.5 16.1 11.3 21.3 12.8 21.8 26.9 34.0 31.8 22.0 22.3 17.5 28.8 26.3 19.9 68.5 47.3 43.1 67.8 75.3 41.1 65.5 30.6 96.4 89.9 31.4 39.3 42.2 36.5 50.0 27.8 42.8 20.6 0.0 62.7 54.9 40.0 39.3 75.2 20.7 29.1 17.5 52.9 33.7 27.2 15.1 44.5 34.8 37.1 55.9 32.7 36.4 54.2 30.6 28.3 19.7 37.0 32.3 42.4 33.8 40.6 55.2 29.9 54.8 35.4 54.0 FUS "ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS" ENSG00000089280 "FUS RNA binding protein" P35637 16 31180110-31194871 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA-binding, RNA-binding" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008784, CAB033036, CAB058691" Supported Enhanced Nucleoplasm NA NA 190000 Nucleoplasm "CAB033036: AB_2105208, CAB058691: AB_2665583, HPA008784: AB_1849181" "unprognostic (3.06e-2)" "unprognostic (2.53e-1)" "unprognostic (1.86e-2)" "unprognostic (8.68e-2)" "unprognostic (1.44e-1)" "unprognostic (8.03e-2)" "prognostic unfavorable (4.38e-4)" "unprognostic (2.15e-2)" "unprognostic (1.00e-1)" "unprognostic (5.22e-3)" "unprognostic (1.01e-1)" "unprognostic (1.01e-3)" "unprognostic (1.12e-3)" "unprognostic (1.87e-1)" "unprognostic (5.27e-1)" "unprognostic (1.66e-1)" "unprognostic (1.49e-2)" 44.0 24.2 35.0 47.1 43.3 41.7 29.9 64.1 59.0 39.7 32.4 48.6 22.6 28.0 54.5 44.7 29.6 48.6 35.9 32.0 32.7 34.6 30.3 24.4 27.7 51.3 31.1 39.0 66.7 28.8 41.7 24.8 44.1 39.2 29.1 30.2 39.3 27.6 30.5 43.6 24.3 28.7 46.5 33.7 36.2 27.7 40.7 30.7 66.3 29.1 40.1 49.6 30.3 31.4 16.4 22.3 24.2 29.0 14.2 24.8 9.4 48.3 42.0 55.3 35.9 13.6 11.6 58.9 65.2 23.7 29.8 22.8 56.6 32.6 74.6 46.5 32.9 36.9 21.1 55.1 42.2 28.5 44.3 35.8 63.0 31.7 57.0 22.8 67.0 43.4 23.5 11.6 43.0 29.2 14.3 28.4 44.4 66.8 25.4 37.0 59.2 48.6 59.3 84.2 29.4 46.1 79.9 73.7 42.7 33.3 35.5 36.1 64.8 42.8 30.2 32.3 36.7 36.4 74.6 35.2 47.8 48.0 31.5 68.8 23.6 45.2 105.0 26.7 45.6 57.7 5.6 17.5 24.2 24.8 29.0 24.0 12.8 17.4 21.8 19.3 16.4 20.3 21.1 14.9 14.2 25.1 22.3 13.9 9.4 35.0 43.3 64.1 59.0 32.7 34.6 31.1 39.0 39.2 30.7 95.3 108.8 163.2 313.8 128.6 263.0 87.0 94.3 111.1 129.7 99.5 123.7 234.5 58.0 142.1 94.6 197.5 188.3 46.7 133.2 323.0 212.4 178.2 227.1 52.9 180.4 190.7 203.5 174.3 132.4 22.8 284.5 176.9 156.9 172.3 132.7 214.0 132.4 175.4 202.6 57.5 247.1 161.7 222.6 158.2 225.3 134.9 246.8 262.6 169.5 255.7 GAS7 "KIAA0394, MGC1348" ENSG00000007237 "Growth arrest specific 7" O60861 17 9910609-10198551 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 86.2" "Cell type enhanced" "Detected in many" 6 "Early spermatids: 49.9;Kupffer cells: 62.0;Late spermatids: 52.5" "Cancer enhanced" "Detected in all" "melanoma: 54.6" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "classical monocyte: 17.6" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 9 "WM-115: 110.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004838, HPA064678" Enhanced Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Plasma membrane" "Actin filaments, Focal adhesion sites" "HPA004838: AB_2667263, HPA064678: AB_2685319" "unprognostic (1.68e-2)" "unprognostic (2.84e-3)" "unprognostic (1.80e-1)" "unprognostic (1.28e-3)" "unprognostic (1.15e-1)" "unprognostic (1.01e-2)" "unprognostic (7.32e-2)" "unprognostic (7.16e-2)" "unprognostic (2.88e-1)" "unprognostic (1.50e-2)" "unprognostic (2.48e-1)" "unprognostic (1.79e-1)" "unprognostic (1.94e-3)" "unprognostic (6.48e-2)" "unprognostic (8.78e-2)" "unprognostic (3.08e-2)" "prognostic unfavorable (6.89e-4)" 19.1 6.5 22.1 15.4 40.3 18.7 10.8 86.2 64.7 22.6 9.3 33.4 1.7 5.2 9.7 4.4 17.0 12.6 11.5 23.1 25.8 15.0 1.5 2.1 9.9 5.9 28.1 25.0 5.9 2.8 1.4 1.7 11.0 14.2 3.7 8.7 7.7 4.0 8.2 3.9 21.2 7.4 16.3 33.8 10.0 4.2 11.8 22.2 2.7 2.5 2.7 7.2 11.7 7.8 0.4 3.6 11.0 17.6 2.8 2.1 4.4 0.0 0.1 0.1 0.2 3.4 4.9 0.0 0.1 0.0 0.5 0.2 0.0 0.0 1.3 0.4 1.3 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.3 0.1 1.1 0.3 10.1 0.9 0.0 1.0 0.0 0.0 0.0 8.7 0.0 0.1 0.0 0.0 10.7 3.2 0.5 0.4 0.0 2.8 0.0 9.8 0.0 0.0 0.0 0.6 0.0 0.0 12.7 4.7 0.5 5.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 7.1 110.2 0.4 17.6 10.8 2.1 4.7 0.7 0.3 0.2 1.0 3.6 0.4 0.2 1.0 11.0 2.8 3.1 0.6 0.0 4.4 22.1 40.3 86.2 38.8 25.8 15.0 28.1 25.0 14.2 22.2 0.0 6.2 3.2 3.8 7.3 34.5 11.3 0.0 26.8 1.2 5.2 25.5 1.1 0.0 0.6 49.9 7.0 0.0 0.0 0.0 1.1 43.4 1.6 17.3 0.5 34.5 0.0 0.0 7.4 62.0 52.5 9.5 29.6 32.1 1.0 0.0 8.0 0.3 0.0 1.8 0.0 30.3 0.0 5.2 1.1 6.1 14.4 1.6 7.5 0.0 4.3 GATA1 "ERYF1, GATA-1, GF1, NF-E1, NFE1" ENSG00000102145 "GATA binding protein 1" P15976 X 48786554-48794311 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "blood: 78.3;bone marrow: 37.0" "Group enriched" "Detected in some" 10 "Early spermatids: 11.8;Erythroid cells: 23.3;granulocytes: 35.9;Late spermatids: 20.9" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 6 "eosinophil: 78.3" "Lineage enriched" "Detected in single" 784 "granulocytes: 78.3" "Group enriched" "Detected in some" 9 "HEL: 50.8;HMC-1: 52.4;K-562: 54.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA000232, HPA000233, CAB009195" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB009195: AB_2232148, HPA000232: AB_1078949, HPA000233: AB_1078951" "unprognostic (1.93e-1)" "unprognostic (7.54e-2)" "unprognostic (8.95e-3)" "unprognostic (3.84e-3)" "unprognostic (2.25e-1)" "unprognostic (3.00e-4)" "unprognostic (4.87e-2)" "unprognostic (3.48e-2)" "unprognostic (4.44e-2)" "unprognostic (1.95e-2)" "unprognostic (6.04e-2)" "unprognostic (7.71e-3)" "unprognostic (4.13e-2)" "unprognostic (2.24e-1)" "unprognostic (2.78e-1)" "unprognostic (9.10e-2)" "unprognostic (2.71e-2)" 0.7 0.2 0.1 2.4 0.7 37.0 0.3 0.0 0.3 0.7 0.3 0.0 0.0 0.6 4.9 2.4 0.4 0.3 0.6 2.3 0.1 0.3 0.4 0.8 5.6 0.2 0.6 0.0 0.1 0.1 0.1 0.5 2.8 0.3 1.4 0.4 1.6 0.3 0.2 0.1 0.6 0.8 2.4 0.3 4.9 0.5 3.1 0.0 1.5 0.6 1.1 0.6 0.9 0.6 0.0 0.0 78.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 50.8 0.0 0.0 0.0 0.0 52.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.0 0.1 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.2 0.0 78.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.7 0.1 0.7 0.0 0.3 0.1 0.3 0.6 0.0 0.3 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.8 0.0 0.0 23.3 0.0 0.7 0.0 0.0 35.9 0.0 0.5 0.0 0.0 0.0 0.0 20.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 GATA2 NFE1B ENSG00000179348 "GATA binding protein 2" P23769 3 128479427-128493185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Phagocytosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 81.2;ductus deferens: 85.8;seminal vesicle: 209.1" "Group enriched" "Detected in many" 5 "Extravillous trophoblasts: 226.1;granulocytes: 616.3;Syncytiotrophoblasts: 268.8" "Cancer enhanced" "Detected in all" "prostate cancer: 36.7" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 339 "basophil: 81.2" "Lineage enriched" "Detected in single" 813 "granulocytes: 81.2" "Cell line enhanced" "Detected in many" "BEWO: 57.0;HEL: 70.3;HMC-1: 38.1;SH-SY5Y: 66.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "HPA005633, CAB024847" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB024847: , HPA005633: AB_1078954" "unprognostic (1.71e-1)" "unprognostic (8.90e-2)" "unprognostic (1.12e-1)" "unprognostic (8.61e-2)" "unprognostic (8.67e-2)" "unprognostic (4.17e-2)" "unprognostic (5.96e-3)" "unprognostic (7.30e-2)" "unprognostic (3.98e-2)" "unprognostic (4.12e-2)" "unprognostic (3.58e-2)" "unprognostic (3.04e-1)" "prognostic favorable (2.04e-4)" "unprognostic (2.50e-1)" "unprognostic (8.07e-2)" "unprognostic (2.08e-1)" "prognostic favorable (5.22e-5)" 7.0 6.2 2.1 1.5 2.4 2.5 7.9 1.2 1.9 22.4 2.8 1.4 85.8 2.5 20.6 5.4 3.2 23.0 9.7 4.8 1.5 1.0 7.6 0.6 16.1 2.2 1.8 1.1 4.6 5.8 3.4 4.5 51.8 2.4 27.8 1.8 6.1 1.9 209.1 3.5 4.1 3.4 8.4 1.4 5.1 2.9 2.7 1.5 0.4 3.3 2.7 1.5 22.4 12.4 0.0 0.0 81.2 0.0 0.0 0.0 0.4 4.7 1.1 0.2 3.1 0.4 0.1 57.0 10.6 9.1 3.6 1.3 1.9 2.1 0.1 3.0 6.3 0.3 5.0 2.9 0.0 1.5 0.0 1.6 70.3 7.8 3.1 0.8 7.1 38.1 0.0 0.0 0.1 0.0 0.5 5.7 0.0 18.4 0.1 0.0 1.7 0.0 14.4 0.2 0.0 0.3 0.0 1.4 0.0 0.1 4.2 4.4 66.4 2.7 14.1 0.4 3.0 2.7 2.9 10.2 0.2 0.1 2.5 1.4 0.0 0.0 0.0 0.1 0.4 0.7 81.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.1 2.4 1.2 1.9 1.5 1.0 1.8 1.1 2.4 1.5 6.0 48.7 0.5 16.6 4.2 0.2 6.1 0.0 1.4 3.4 71.5 0.0 50.4 1.7 0.3 5.8 56.9 0.0 0.0 12.6 226.1 5.8 36.8 616.3 0.0 9.5 0.0 2.9 34.4 0.8 4.0 0.6 2.9 8.5 0.0 0.0 0.0 1.3 0.0 0.4 0.1 0.2 0.0 7.6 0.5 2.8 2.0 268.8 0.0 0.1 10.0 GATA3 HDR ENSG00000107485 "GATA binding protein 3" P23771 10 8045378-8075203 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 97.8;skin 1: 61.7" "Cell type enhanced" "Detected in many" 19 "Cytotrophoblasts: 243.8;Extravillous trophoblasts: 651.3;Syncytiotrophoblasts: 949.1" "Group enriched" "Detected in many" 24 "breast cancer: 190.0;urothelial cancer: 87.0" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 42 "gdT-cell: 9.7;MAIT T-cell: 13.3;memory CD4 T-cell: 18.2;memory CD8 T-cell: 14.1;naive CD4 T-cell: 10.0;naive CD8 T-cell: 9.0;NK-cell: 16.6;T-reg: 18.9" "Group enriched" "Detected in many" 54 "NK-cells: 16.6;T-cells: 18.9" "Cell line enhanced" "Detected in some" "BEWO: 33.3;MCF7: 79.6;RT4: 32.6;SH-SY5Y: 28.0;T-47d: 103.7" "Region enriched" "Detected in single" 6 "midbrain: 7.3" "Group enriched" "Detected in some" 38 "midbrain: 25.5;pons and medulla: 17.5;thalamus: 20.0" "CAB016217, HPA029730" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB016217: AB_2108591, HPA029730: AB_10601907" "unprognostic (1.70e-1)" "unprognostic (7.23e-2)" "unprognostic (3.58e-2)" "unprognostic (2.00e-1)" "unprognostic (7.03e-3)" "unprognostic (4.68e-3)" "unprognostic (4.23e-2)" "unprognostic (9.65e-2)" "unprognostic (2.06e-1)" "unprognostic (2.55e-1)" "unprognostic (3.83e-1)" "unprognostic (1.17e-1)" "prognostic unfavorable (3.13e-4)" "unprognostic (1.48e-1)" "unprognostic (5.16e-2)" "unprognostic (6.31e-2)" "unprognostic (1.82e-3)" 2.0 2.0 0.3 3.4 0.3 0.9 17.8 0.3 0.3 1.8 0.5 0.1 44.4 0.1 0.4 13.5 0.8 0.4 0.4 0.9 0.3 0.4 12.9 0.7 1.6 2.7 0.8 0.0 0.3 0.4 55.0 3.8 53.4 1.4 8.1 0.0 1.8 8.9 97.8 0.8 61.7 1.2 3.4 0.4 2.7 0.5 0.8 0.1 42.4 3.3 0.6 3.4 26.9 16.4 0.2 0.0 0.3 0.0 16.6 18.9 3.0 5.5 1.3 0.0 0.0 0.0 0.0 33.3 0.1 0.0 0.0 0.0 2.0 5.0 0.0 0.0 0.0 0.0 4.9 0.5 0.1 0.0 16.0 1.7 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.1 0.0 0.3 0.1 2.6 7.8 0.0 0.0 0.0 79.6 8.7 0.0 0.6 1.0 0.7 0.4 0.4 0.1 0.0 32.6 1.6 28.0 0.0 4.5 0.0 6.1 103.7 0.0 0.0 0.4 1.0 0.2 0.7 0.1 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 9.7 0.0 13.3 0.2 18.2 14.1 0.0 0.0 10.0 9.0 0.3 16.6 0.0 0.0 18.9 3.0 0.3 0.3 0.3 0.3 0.3 0.4 0.8 0.0 1.4 0.1 0.0 8.9 0.5 60.9 84.1 0.0 1.2 0.0 0.0 1.2 169.3 0.0 243.8 0.0 0.2 0.0 4.9 0.0 0.0 0.3 651.3 6.9 27.0 2.3 0.5 27.7 0.0 0.0 9.8 4.0 0.0 0.0 2.2 8.5 1.0 0.0 0.0 2.6 0.0 0.0 0.3 0.0 0.0 1.4 0.0 0.2 173.9 949.1 56.1 0.0 68.0 GNA11 "FBH, FBH2, FHH2, HHC2" ENSG00000088256 "G protein subunit alpha 11" P29992 19 3094410-3124004 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 103.3" "Cell type enhanced" "Detected in many" 9 "Enterocytes: 264.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 9.1" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048886 Approved NA NA "HPA048886: AB_2680544" "unprognostic (4.64e-3)" "unprognostic (2.21e-1)" "unprognostic (3.12e-1)" "unprognostic (2.23e-2)" "unprognostic (1.30e-1)" "unprognostic (1.53e-2)" "prognostic unfavorable (4.86e-4)" "unprognostic (2.56e-2)" "unprognostic (1.40e-1)" "unprognostic (6.26e-2)" "unprognostic (7.85e-3)" "unprognostic (2.43e-1)" "prognostic favorable (1.48e-11)" "unprognostic (1.05e-2)" "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (3.02e-1)" 19.3 14.2 17.3 13.7 17.1 5.9 14.2 38.5 28.0 16.1 40.8 18.6 18.3 65.9 19.8 14.5 17.2 19.8 19.5 21.9 16.0 12.8 17.8 16.6 15.1 5.0 11.7 12.6 19.4 19.6 14.2 13.8 20.0 14.1 18.2 23.0 27.1 17.5 30.5 27.3 20.0 103.3 17.6 12.2 10.5 17.2 20.1 12.5 3.9 18.0 13.5 7.6 19.2 22.1 2.4 3.9 9.1 2.4 0.7 2.2 0.4 20.5 12.6 11.4 19.8 16.9 11.2 12.6 20.5 20.4 27.7 22.7 15.7 10.6 5.1 11.3 28.5 17.1 15.0 14.4 16.3 17.7 11.1 8.5 1.4 13.6 9.0 16.7 1.3 4.6 15.4 14.2 18.7 11.3 14.3 22.0 1.7 10.3 1.0 18.5 9.6 1.4 6.1 7.9 14.3 11.3 9.0 10.1 4.7 13.4 16.1 25.8 16.3 14.7 17.6 10.2 7.8 12.7 2.9 18.9 18.3 13.0 33.0 27.3 0.5 1.5 3.3 13.1 1.1 19.8 2.8 2.4 0.5 1.1 1.3 1.4 1.3 0.9 1.1 0.4 2.4 2.2 1.6 9.1 0.7 2.4 3.9 0.3 0.4 17.3 17.1 38.5 28.0 16.0 12.8 11.7 12.6 14.1 12.5 29.8 23.7 9.0 7.9 29.0 17.2 15.5 38.2 22.7 6.8 26.2 35.3 11.2 6.6 18.6 27.8 23.8 264.0 0.0 21.8 10.5 18.3 14.0 4.6 26.3 7.4 42.9 52.5 62.6 6.2 13.4 46.3 3.2 21.9 0.0 73.7 28.4 28.3 80.7 75.7 16.1 14.9 19.4 17.3 17.6 9.1 36.0 17.0 2.2 62.2 12.7 GNAQ "G-ALPHA-q, GAQ" ENSG00000156052 "G protein subunit alpha q" P50148 9 77716087-78031458 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 18.4" "Lineage enriched" "Detected in many" 5 "granulocytes: 18.4" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010036, HPA048886" Uncertain Approved "Nuclear speckles,Plasma membrane,Cytosol" NA NA 28000000 "Nuclear speckles" "Plasma membrane, Cytosol" "CAB010036: AB_631536, HPA048886: AB_2680544" "unprognostic (2.10e-1)" "unprognostic (8.53e-2)" "unprognostic (1.45e-1)" "unprognostic (4.37e-2)" "unprognostic (1.87e-1)" "unprognostic (6.83e-3)" "unprognostic (1.05e-1)" "unprognostic (3.84e-2)" "unprognostic (2.46e-1)" "unprognostic (2.16e-1)" "unprognostic (1.85e-1)" "unprognostic (1.44e-1)" "prognostic favorable (1.11e-7)" "unprognostic (1.90e-1)" "unprognostic (3.13e-1)" "unprognostic (1.05e-1)" "unprognostic (2.01e-1)" 12.7 12.6 24.3 9.9 20.8 21.8 11.6 12.5 29.6 13.1 16.6 17.1 9.1 7.9 13.7 11.2 13.1 10.0 11.6 5.6 24.2 18.3 12.1 12.3 23.1 11.8 19.1 14.6 13.5 8.5 12.7 7.6 12.1 14.3 13.0 16.0 10.4 9.8 15.9 5.9 5.1 9.0 18.2 23.9 5.8 15.5 6.0 14.8 18.6 13.3 4.0 4.8 14.5 13.1 0.8 2.8 18.4 3.5 3.3 2.0 1.2 12.0 13.7 12.2 13.4 15.5 15.9 17.6 16.4 12.4 7.2 8.7 4.2 9.9 0.0 13.3 15.0 10.1 19.8 9.1 9.9 9.0 0.4 5.3 33.0 12.0 8.4 14.0 20.1 12.4 10.8 12.2 13.9 14.2 15.0 17.7 29.8 5.8 0.1 12.6 15.3 23.2 12.8 9.9 19.4 1.9 8.6 15.0 0.1 16.4 25.8 13.7 20.9 11.8 10.0 12.3 12.0 9.1 7.5 22.1 12.7 0.8 17.2 9.5 0.1 0.0 0.1 8.8 11.9 13.1 18.4 2.2 4.6 0.8 1.9 1.6 0.8 1.8 1.0 2.4 0.8 2.0 1.6 7.7 3.3 3.5 2.8 1.9 1.2 24.3 20.8 12.5 24.0 24.2 18.3 19.1 14.6 14.3 14.8 163.8 71.4 6.4 33.6 42.0 29.9 5.9 43.3 42.8 35.2 73.3 15.7 39.3 6.6 28.1 13.1 85.4 69.5 46.7 34.7 42.2 42.9 51.3 49.7 51.3 47.8 77.9 88.6 107.4 139.4 6.8 36.5 92.7 45.5 72.1 90.6 37.0 44.3 48.9 49.1 35.4 4.2 25.8 40.1 4.7 6.6 18.9 24.3 21.8 67.3 50.3 GNAS "GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI" ENSG00000087460 "GNAS complex locus" "O95467, P63092, P84996, Q5JWF2" 20 58839718-58911192 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters" Transducer "Cancer-related genes, Cushing syndrome, Disease mutation, Dwarfism, Obesity, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "pituitary gland: 303.3;thyroid gland: 304.5" "Cell type enhanced" "Detected in all" 5 "Horizontal cells: 1781.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010337, HPA018122, HPA027478, HPA028386" Uncertain Approved "Nucleoplasm,Plasma membrane,Cytosol" "Intracellular and membrane" NA NA Nucleoplasm "Plasma membrane, Cytosol" "CAB010337: AB_631538, HPA018122: AB_1849236, HPA027478: AB_10599284, HPA028386: AB_10601983" "unprognostic (7.48e-2)" "unprognostic (1.41e-1)" "unprognostic (3.90e-2)" "unprognostic (4.77e-2)" "unprognostic (8.37e-3)" "unprognostic (2.82e-2)" "unprognostic (4.53e-3)" "unprognostic (8.01e-2)" "unprognostic (4.29e-2)" "prognostic favorable (8.76e-4)" "unprognostic (2.07e-2)" "unprognostic (1.58e-1)" "prognostic unfavorable (3.49e-4)" "unprognostic (5.24e-3)" "unprognostic (1.61e-1)" "unprognostic (8.25e-2)" "unprognostic (1.36e-1)" 56.2 79.0 84.2 34.4 44.5 42.1 87.4 86.0 107.4 43.2 42.3 25.4 27.0 33.2 37.2 44.7 41.0 43.6 34.4 106.0 71.0 144.0 39.6 35.3 46.6 44.6 75.8 64.7 43.6 118.1 120.9 303.3 49.8 85.6 36.3 31.5 42.7 171.6 31.1 172.9 26.3 34.9 40.5 61.4 36.9 42.4 18.2 27.4 56.0 304.5 80.6 41.0 37.3 44.6 27.3 41.5 29.9 36.2 25.3 24.2 24.6 9.7 32.8 55.4 25.8 94.2 43.0 49.8 56.4 51.6 64.5 46.3 95.8 50.6 32.0 87.9 73.2 46.2 42.3 50.8 75.1 43.7 21.1 30.6 35.6 49.9 62.7 43.5 20.7 22.4 51.3 38.2 31.3 42.2 51.2 48.9 39.5 31.2 43.7 42.5 133.6 105.4 50.6 17.6 6.4 34.7 64.9 48.5 56.5 51.7 38.7 68.7 157.4 78.4 77.9 62.9 50.7 59.5 56.7 53.7 85.7 77.0 30.8 53.1 76.8 49.5 67.6 37.6 10.1 43.7 29.9 24.8 29.5 20.7 35.7 22.1 26.7 22.0 22.2 37.8 27.3 21.3 24.2 29.1 25.3 36.2 41.5 23.3 24.6 84.2 44.5 86.0 107.4 71.0 144.0 75.8 64.7 85.6 27.4 205.4 224.1 189.5 151.9 115.9 363.0 884.0 242.0 250.3 255.9 247.7 53.0 672.6 376.4 220.5 577.5 343.9 323.7 303.7 196.1 292.5 221.9 260.9 133.0 165.2 333.8 1781.3 444.7 335.7 327.9 1338.6 245.7 276.8 210.9 147.9 250.3 861.2 313.5 239.3 185.3 130.9 175.1 207.0 226.4 48.2 25.4 103.0 1013.3 142.4 268.2 212.5 GOLGA5 "golgin-84, GOLIM5, ret-II, rfg5" ENSG00000066455 "Golgin A5" Q8TBA6 14 92794231-92839963 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000992, HPA063876" Enhanced Supported Supported "Golgi apparatus" NA NA "Golgi apparatus" "HPA000992: AB_1079009, HPA063876: AB_2685140" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (1.57e-1)" "unprognostic (2.64e-1)" "unprognostic (1.73e-1)" "unprognostic (2.77e-2)" "unprognostic (1.68e-1)" "unprognostic (3.15e-1)" "unprognostic (1.78e-1)" "unprognostic (5.02e-2)" "unprognostic (1.15e-2)" "unprognostic (2.83e-2)" "unprognostic (7.67e-2)" "unprognostic (6.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.06e-2)" "unprognostic (2.49e-2)" 20.8 20.3 16.8 15.7 17.3 6.5 24.4 11.6 17.5 24.9 20.4 17.2 25.5 16.5 18.2 41.7 21.2 15.3 17.5 18.3 17.5 15.6 21.5 51.0 16.6 18.2 18.6 14.6 18.9 26.8 23.6 27.2 44.4 16.4 23.4 23.7 12.7 24.3 30.2 20.6 18.9 25.6 18.9 19.4 16.9 23.0 23.5 17.6 13.5 24.8 17.8 16.4 20.7 15.8 9.7 9.7 22.2 12.7 8.1 12.4 6.3 12.6 11.7 10.6 9.6 22.2 30.1 18.2 17.6 32.4 17.2 20.3 8.6 17.4 8.2 14.5 27.9 12.0 13.4 9.3 14.3 23.4 10.0 4.5 7.8 5.9 11.5 25.8 9.0 13.1 23.1 26.1 12.0 25.0 19.0 16.9 8.7 6.8 11.1 18.8 23.5 6.9 7.8 6.6 27.7 12.6 5.4 15.5 8.2 17.5 15.5 7.5 10.7 16.0 12.0 17.9 15.3 20.6 10.1 13.9 9.9 6.5 12.8 8.7 13.7 10.5 7.2 22.7 7.2 16.4 9.1 9.8 22.2 10.9 12.7 12.3 9.7 11.1 11.1 9.7 9.2 9.9 8.6 8.7 8.1 10.8 9.1 12.4 6.3 16.8 17.3 11.6 17.5 17.5 15.6 18.6 14.6 16.4 17.6 26.8 19.9 6.7 9.6 6.9 7.5 23.8 12.7 17.4 15.9 14.0 11.8 20.5 24.9 22.5 25.9 13.5 17.1 0.0 28.6 27.4 17.9 21.7 9.2 30.6 13.9 23.8 21.5 11.6 11.6 13.3 21.3 11.3 11.8 17.2 31.9 14.3 22.7 10.5 23.7 17.8 10.9 25.8 17.6 22.4 28.3 9.9 42.1 11.8 16.1 11.2 GOPC "CAL, dJ94G16.2, FIG, GOPC1, PIST" ENSG00000047932 "Golgi associated PDZ and coiled-coil motif containing" Q9HD26 6 117560269-117602542 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "HPA019477, HPA024018" Approved Enhanced "Golgi apparatus" NA NA "Golgi apparatus" "HPA019477: AB_1849890, HPA024018: AB_1849891" "unprognostic (2.48e-2)" "unprognostic (1.63e-3)" "unprognostic (1.71e-1)" "unprognostic (5.56e-2)" "unprognostic (1.84e-2)" "unprognostic (3.17e-2)" "unprognostic (3.12e-2)" "unprognostic (9.21e-2)" "unprognostic (6.22e-2)" "unprognostic (6.77e-2)" "unprognostic (8.23e-2)" "unprognostic (9.46e-2)" "unprognostic (1.40e-2)" "unprognostic (2.67e-2)" "unprognostic (1.38e-1)" "unprognostic (9.55e-2)" "unprognostic (3.01e-2)" 18.4 15.6 17.2 21.1 22.2 6.5 21.5 30.0 27.8 26.9 19.3 17.0 25.7 12.7 25.3 20.1 15.1 20.3 17.3 22.8 18.9 17.8 15.6 19.2 14.1 19.0 18.6 21.8 28.3 16.9 32.6 34.2 21.2 21.2 18.0 21.8 10.7 17.5 24.6 17.6 19.5 17.3 20.7 18.7 18.5 15.5 17.6 18.3 32.1 25.3 13.2 17.4 18.7 26.4 9.9 11.0 9.8 5.5 10.6 11.9 4.9 5.7 6.3 8.2 10.9 18.0 21.4 13.0 24.1 17.8 13.2 13.7 9.6 6.5 17.5 10.5 13.5 26.2 13.1 15.8 11.6 18.6 8.7 8.8 16.0 16.4 15.4 18.8 21.3 10.7 25.3 32.5 9.8 28.7 26.7 11.2 12.3 14.9 7.2 26.6 5.3 8.8 16.6 7.1 9.9 6.8 13.6 15.9 12.6 10.1 5.4 11.7 9.1 24.2 8.4 6.4 16.4 6.1 20.7 13.3 0.9 12.1 12.2 25.9 12.9 11.6 14.9 16.5 18.1 10.1 9.8 5.0 3.8 8.4 4.5 11.9 9.7 9.1 8.9 6.6 9.9 10.7 10.8 3.7 10.6 5.5 11.0 8.9 4.9 17.2 22.2 30.0 27.8 18.9 17.8 18.6 21.8 21.2 18.3 20.8 17.7 13.7 21.2 41.4 55.8 35.1 33.1 33.5 22.7 19.2 21.6 65.0 23.2 23.3 25.7 32.0 27.1 0.0 22.3 50.4 51.1 21.8 31.1 35.0 32.7 69.9 32.2 39.3 19.9 10.2 39.1 21.9 27.0 17.2 57.0 39.5 17.6 37.4 39.6 20.7 34.1 32.3 30.3 106.6 43.2 52.2 43.7 28.7 34.0 22.1 GPHN KIAA1385 ENSG00000171723 Gephyrin Q9NQX3 14 66507407-67181803 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Molybdenum cofactor biosynthesis" "Multifunctional enzyme, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cone photoreceptor cells: 49.1;Hepatocytes: 42.9;Horizontal cells: 41.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003116, CAB004419, HPA024694" Enhanced Uncertain "Cytoplasmic bodies" NA NA "Cytoplasmic bodies" "CAB004419: AB_627670, HPA003116: AB_1078963, HPA024694: AB_1849616" "unprognostic (8.37e-2)" "unprognostic (2.53e-2)" "unprognostic (2.42e-1)" "unprognostic (1.20e-1)" "unprognostic (5.14e-2)" "unprognostic (4.89e-3)" "unprognostic (8.29e-2)" "unprognostic (1.41e-2)" "unprognostic (1.42e-1)" "unprognostic (2.23e-1)" "unprognostic (2.49e-2)" "unprognostic (8.54e-2)" "prognostic favorable (5.25e-12)" "unprognostic (9.81e-2)" "unprognostic (2.27e-1)" "unprognostic (7.50e-2)" "prognostic unfavorable (4.61e-5)" 13.0 12.4 26.1 10.9 31.1 5.2 17.1 40.9 31.2 11.0 18.2 9.3 15.6 11.1 12.3 20.8 8.6 7.5 8.2 11.9 26.4 22.9 34.5 49.0 14.1 7.3 18.3 11.5 7.2 22.9 17.4 24.5 5.8 13.9 11.1 13.2 7.4 10.8 21.3 23.4 10.7 10.8 11.6 16.4 5.6 13.5 7.8 16.2 3.1 12.2 10.0 6.8 7.4 15.1 3.1 3.0 0.5 2.5 2.3 6.2 1.5 22.2 4.4 7.8 8.5 9.2 7.8 5.0 6.3 3.1 6.5 6.5 1.3 10.0 0.0 1.1 3.1 3.3 7.9 7.8 12.3 8.6 6.8 8.4 6.6 6.3 13.6 4.8 3.7 9.8 6.7 7.3 1.8 7.2 2.7 7.5 8.3 4.5 8.4 3.6 11.9 6.5 13.9 3.3 16.8 10.1 0.0 15.0 6.4 10.5 4.4 13.8 5.4 4.3 18.9 6.9 2.2 10.1 6.4 2.8 6.5 14.5 6.4 6.5 11.2 4.8 0.1 5.1 0.5 6.3 0.0 1.3 0.5 3.9 2.5 6.2 2.4 4.9 2.9 1.9 3.1 3.5 3.3 0.0 2.3 1.9 3.0 5.3 1.5 26.1 31.1 40.9 27.0 26.4 22.9 18.3 11.5 13.9 16.2 6.0 9.6 5.4 8.3 4.1 33.5 10.9 7.6 1.4 13.6 1.8 49.1 2.8 11.6 4.1 2.5 9.0 5.1 0.0 4.7 2.1 4.1 6.7 0.0 42.9 3.1 41.3 5.8 19.0 7.6 3.6 10.3 2.7 1.7 0.0 11.9 10.4 2.9 7.0 5.3 14.9 34.2 0.0 6.2 10.9 8.9 5.1 1.7 4.9 8.9 6.0 GRIN2A "GluN2A, NMDAR2A" ENSG00000183454 "Glutamate ionotropic receptor NMDA type subunit 2A" Q12879 16 9753404-10182754 "Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 25.2" "Cell type enhanced" "Detected in some" 9 "Cardiomyocytes: 14.9;Early spermatids: 13.4;Late spermatids: 13.0;Muller glia cells: 17.7;Rod photoreceptor cells: 12.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "fHDF/TERT166: 7.8;hTERT-RPE1: 3.4;RPMI-8226: 2.9;U-138 MG: 8.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB022725 Enhanced NA NA "CAB022725: " "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (5.97e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-2)" "unprognostic (1.59e-2)" "unprognostic (1.62e-1)" "unprognostic (2.10e-1)" "unprognostic (2.08e-1)" "unprognostic (5.39e-2)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (3.75e-3)" "unprognostic (4.79e-3)" "unprognostic (2.05e-1)" "unprognostic (3.92e-3)" "unprognostic (3.33e-2)" 0.9 1.0 5.4 0.5 5.9 0.4 0.6 8.5 25.2 0.6 0.7 1.5 0.0 0.9 0.8 4.5 2.1 4.1 0.5 4.0 8.0 1.9 0.9 0.4 1.0 0.5 1.7 10.3 0.5 0.6 0.4 0.3 0.4 1.4 0.5 0.7 1.4 0.7 1.0 0.5 1.2 0.7 0.9 1.2 0.4 1.1 5.2 0.8 0.0 0.8 0.0 0.7 0.6 0.5 0.6 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 1.9 0.6 1.4 0.0 0.1 0.0 0.0 7.8 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.3 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 8.5 0.8 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 5.4 5.9 8.5 17.9 8.0 1.9 1.7 10.3 1.4 0.8 0.0 0.0 0.0 1.9 1.6 3.6 14.9 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.6 13.4 0.1 0.0 0.0 0.2 0.0 0.2 0.4 0.0 0.0 0.1 1.6 0.0 0.0 0.0 13.0 0.9 0.0 0.0 0.0 0.0 17.7 1.2 0.0 0.0 0.0 12.1 0.0 4.2 3.2 3.8 0.4 0.0 0.0 0.0 0.3 H3F3A "H3.3A, H3F3" ENSG00000163041 "H3 histone family member 3A" P84243 1 226061851-226072001 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 258.7" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 258.7" "Lineage enriched" "Detected in all" 5 "granulocytes: 258.7" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011481, CAB037178, HPA042570" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB011481: AB_880446, CAB037178: AB_532248, HPA042570: AB_2678056" "unprognostic (1.82e-1)" "unprognostic (1.95e-2)" "unprognostic (1.00e-1)" "unprognostic (2.19e-3)" "unprognostic (2.83e-2)" "unprognostic (3.74e-1)" "unprognostic (9.83e-3)" "unprognostic (4.71e-2)" "unprognostic (1.77e-3)" "unprognostic (3.69e-2)" "unprognostic (1.29e-1)" "unprognostic (1.29e-1)" "prognostic unfavorable (1.21e-6)" "unprognostic (3.66e-2)" "unprognostic (8.03e-3)" "unprognostic (2.21e-3)" "unprognostic (6.03e-2)" 39.0 43.4 37.2 83.4 33.4 126.8 67.9 45.0 42.8 44.6 54.0 31.6 62.9 47.9 43.4 60.6 66.3 42.4 49.6 59.4 36.1 31.2 45.9 59.2 73.2 217.9 37.8 23.2 44.4 79.7 30.8 34.8 59.1 29.2 38.4 59.4 42.7 49.0 49.7 37.0 47.1 50.0 42.0 48.6 71.9 41.4 87.6 31.7 148.9 38.5 71.0 84.1 43.5 47.6 39.2 44.6 258.7 56.9 23.6 34.9 60.5 53.9 30.8 120.2 67.8 33.4 38.9 90.3 25.6 31.1 41.6 32.9 32.1 90.0 51.9 56.9 31.4 20.7 51.8 59.4 46.6 40.9 32.1 102.6 64.2 45.6 42.9 33.1 65.9 78.0 35.6 54.0 29.1 38.3 56.4 61.5 67.9 90.4 88.9 47.3 31.2 136.8 122.6 163.0 137.1 61.1 92.6 87.8 133.8 86.0 57.7 117.4 174.5 73.0 92.4 63.2 71.8 104.7 154.7 34.6 30.3 42.3 40.9 74.1 39.6 50.7 90.7 28.9 63.0 64.7 40.0 56.9 80.8 23.1 44.9 23.6 39.2 25.0 24.9 44.6 36.0 23.7 25.7 258.7 23.6 50.8 36.6 34.9 60.5 37.2 33.4 45.0 42.8 36.1 31.2 37.8 23.2 29.2 31.7 485.3 628.9 1112.7 1421.3 1190.0 539.7 34.4 1036.9 1187.2 831.4 919.5 155.1 1193.7 1374.4 1195.9 1414.0 1038.4 1355.7 2359.5 1184.4 1689.1 947.0 1270.6 649.3 699.9 1338.0 554.6 1437.2 842.8 2198.6 1327.8 1016.5 1622.8 1010.6 1191.2 1707.9 908.2 1197.9 2104.2 985.0 1310.8 429.3 976.6 889.6 588.0 858.5 1210.5 1352.2 961.6 1983.9 1893.1 H3F3B H3.3B ENSG00000132475 "H3 histone family member 3B" P84243 17 75776434-75785893 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 570.8;bone marrow: 441.9" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 570.8" "Lineage enriched" "Detected in all" 6 "granulocytes: 570.8" "Low cell line specificity" "Detected in all" "CAB037166, CAB037187, CAB037221, HPA042570" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB037166: AB_2115285, CAB037187: AB_477069, CAB037221: AB_477076, HPA042570: AB_2678056" "unprognostic (1.66e-1)" "unprognostic (8.42e-3)" "unprognostic (3.42e-2)" "unprognostic (1.06e-1)" "unprognostic (1.81e-1)" "unprognostic (1.95e-1)" "unprognostic (2.41e-1)" "unprognostic (2.43e-3)" "unprognostic (3.37e-2)" "unprognostic (1.64e-1)" "unprognostic (5.88e-2)" "unprognostic (1.07e-1)" "unprognostic (1.26e-3)" "unprognostic (9.20e-2)" "unprognostic (4.81e-2)" "unprognostic (2.33e-1)" "unprognostic (1.99e-1)" 57.2 41.2 38.1 58.9 48.6 441.9 71.4 60.2 47.0 86.6 44.6 65.9 42.7 37.9 60.5 77.7 93.2 70.2 75.8 35.1 38.5 33.9 42.8 48.1 64.2 62.3 50.4 41.2 141.0 90.9 33.0 41.5 58.5 42.7 60.5 26.6 65.8 58.4 55.4 71.1 114.0 58.0 63.7 51.8 65.9 45.1 66.9 46.2 78.6 58.9 69.1 55.7 78.5 71.9 78.9 88.1 570.8 98.4 80.0 77.2 203.5 117.9 104.8 43.8 43.2 25.0 39.2 60.6 55.9 49.5 68.7 55.2 112.2 84.0 59.1 53.4 32.5 48.6 46.5 34.6 77.3 39.1 32.2 78.0 52.7 55.9 94.9 56.5 87.5 67.9 42.8 47.9 70.4 90.8 30.6 51.6 38.6 74.6 106.3 35.3 173.6 125.6 73.5 35.1 38.2 117.1 93.6 80.2 64.4 54.2 70.1 88.9 98.7 56.7 83.2 120.0 24.4 65.2 94.6 48.1 123.3 109.1 53.2 148.0 128.6 76.0 71.0 65.2 83.5 67.2 182.8 98.4 259.3 74.4 86.9 70.2 78.9 71.8 70.5 86.7 65.3 77.2 64.5 570.8 80.0 78.9 88.1 76.0 203.5 38.1 48.6 60.2 47.0 38.5 33.9 50.4 41.2 42.7 46.2 851.6 868.5 887.7 3350.2 2457.1 1722.8 361.5 690.4 1184.5 958.9 922.9 382.9 1428.6 1080.9 1926.0 2467.5 1156.8 1059.1 327.1 1563.3 1285.8 1898.2 1719.4 1592.3 352.8 1655.2 575.2 1610.5 672.8 901.1 452.7 934.0 1810.8 1808.5 1233.6 1221.5 2460.8 1745.6 1627.3 545.9 699.9 1161.2 983.1 2751.1 2035.3 943.0 3026.0 2929.8 1269.9 852.2 2611.9 HERPUD1 "HERP, KIAA0025, Mif1, SUP" ENSG00000051108 "Homocysteine inducible ER protein with ubiquitin like domain 1" Q15011 16 56932048-56944863 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Unfolded protein response" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Melanocytes: 899.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RPMI-8226: 78.5;U-266/70: 89.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037041, CAB037104, HPA040754, HPA041219" Approved Uncertain "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "CAB037041: AB_1840910, CAB037104: AB_1840912, HPA040754: AB_10794068, HPA041219: AB_10794268" "unprognostic (1.92e-1)" "unprognostic (3.47e-1)" "unprognostic (8.64e-2)" "unprognostic (3.93e-3)" "unprognostic (3.39e-1)" "unprognostic (5.00e-3)" "unprognostic (1.17e-1)" "unprognostic (9.69e-3)" "unprognostic (3.33e-1)" "unprognostic (2.56e-1)" "unprognostic (2.84e-1)" "unprognostic (3.50e-1)" "prognostic favorable (1.41e-9)" "unprognostic (1.06e-1)" "unprognostic (3.93e-2)" "unprognostic (2.19e-2)" "unprognostic (2.27e-3)" 22.7 38.8 16.2 35.6 20.7 21.6 39.4 17.7 20.0 30.1 32.1 20.0 48.8 21.4 21.6 51.6 15.0 20.2 32.5 28.8 15.8 15.5 42.9 57.7 30.4 40.0 25.6 12.5 44.8 148.6 37.6 26.7 26.2 25.6 49.5 32.3 35.3 108.6 76.1 34.6 18.3 24.7 17.6 24.2 38.3 37.2 10.6 20.8 9.6 64.2 20.4 53.8 24.4 25.9 50.8 121.9 29.0 39.5 22.4 33.4 46.5 4.5 5.0 4.9 10.2 11.4 15.0 17.6 10.8 17.2 14.0 11.0 6.9 10.4 18.5 13.9 10.5 14.3 7.9 8.3 3.8 13.9 10.7 5.0 1.6 8.3 25.0 62.5 3.3 8.3 18.1 36.5 6.3 20.2 16.9 10.6 20.7 2.5 26.5 39.0 3.8 6.2 6.8 3.1 26.5 11.4 4.3 12.5 78.5 30.0 5.1 5.4 6.3 9.4 46.4 47.9 7.3 5.2 12.5 6.5 5.8 5.8 5.1 4.3 89.5 29.1 28.9 8.3 4.6 7.6 23.9 39.5 18.0 16.1 31.0 17.4 50.8 17.5 21.1 30.6 37.8 11.4 17.4 29.0 22.4 21.5 121.9 33.4 46.5 16.2 20.7 17.7 20.0 15.8 15.5 25.6 12.5 25.6 20.8 65.5 113.2 400.7 628.3 323.4 125.0 136.3 71.4 44.2 47.8 68.0 265.1 118.1 144.2 165.3 52.0 119.9 168.3 70.0 173.1 150.4 186.1 478.3 152.0 140.9 178.2 44.5 416.3 118.4 182.3 185.2 96.4 276.3 899.3 227.2 208.8 76.2 141.3 182.4 89.8 157.6 103.7 97.0 210.0 43.1 8.9 223.2 580.2 183.3 123.2 295.1 HEY1 "bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1" ENSG00000164683 "Hes related family bHLH transcription factor with YRPW motif 1" Q9Y5J3 8 79764010-79767863 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Notch signaling pathway, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 60.6" "Cell type enhanced" "Detected in many" 6 "Endothelial cells: 39.4;Extravillous trophoblasts: 39.7;Intestinal endocrine cells: 35.4;Melanocytes: 32.1" "Cancer enhanced" "Detected in all" "glioma: 43.1" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 6 "neutrophil: 9.9" "Lineage enriched" "Detected in many" 6 "granulocytes: 9.9" "Cell line enhanced" "Detected in many" "HEK 293: 49.4;PC-3: 11.2;SK-MEL-30: 33.8;WM-115: 11.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055599, HPA063472" Enhanced Supported "Nucleoplasm,Nuclear membrane,Cytosol" NA NA "Nucleoplasm, Nuclear membrane, Cytosol" "HPA055599: AB_2682858, HPA063472: AB_2685018" "unprognostic (1.15e-1)" "unprognostic (5.06e-2)" "unprognostic (5.13e-3)" "unprognostic (2.12e-1)" "unprognostic (1.86e-3)" "unprognostic (8.47e-2)" "unprognostic (4.21e-3)" "unprognostic (9.56e-2)" "unprognostic (1.72e-1)" "unprognostic (7.22e-2)" "unprognostic (1.25e-2)" "unprognostic (6.71e-3)" "unprognostic (5.92e-3)" "unprognostic (5.77e-2)" "unprognostic (8.53e-2)" "unprognostic (1.74e-2)" "unprognostic (1.00e-1)" 13.3 3.8 13.7 3.6 22.9 1.8 8.8 11.2 60.6 8.9 4.4 10.7 0.0 3.3 3.8 2.4 4.6 3.9 5.7 13.4 11.3 11.6 3.8 2.9 16.4 3.3 11.9 9.3 2.6 4.3 3.0 9.9 20.3 12.5 4.5 3.9 10.3 4.5 3.0 10.3 3.5 3.2 4.4 9.1 2.8 3.6 3.9 10.5 1.3 5.0 3.7 3.7 5.2 2.5 0.0 0.0 9.9 1.7 0.0 0.3 0.1 0.6 0.0 0.4 3.5 0.3 0.3 9.0 0.8 0.8 0.1 0.1 0.1 0.0 1.6 0.9 0.3 0.4 2.2 1.8 0.1 0.2 0.1 49.4 0.0 1.6 0.9 0.5 0.0 0.4 0.5 1.4 0.0 6.2 0.3 1.6 0.0 3.2 1.4 0.5 0.1 0.0 0.2 0.2 0.1 11.2 0.0 1.9 1.4 0.1 1.5 2.0 5.7 0.0 1.0 33.8 8.4 0.0 0.0 1.1 0.2 0.9 0.0 0.6 1.2 0.2 0.0 1.2 0.0 11.5 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 9.9 0.0 1.7 0.0 0.0 0.1 13.7 22.9 11.2 12.3 11.3 11.6 11.9 9.3 12.5 10.5 0.0 2.6 0.0 2.2 2.9 5.3 3.2 0.0 8.1 3.4 0.0 0.0 5.4 13.3 2.1 3.3 39.4 0.9 0.0 1.0 39.7 2.7 1.6 10.4 0.5 1.6 20.6 35.4 13.5 0.6 1.6 0.0 2.1 32.1 0.0 1.9 6.0 0.5 5.8 0.4 0.3 11.5 0.0 6.1 0.7 4.1 2.6 19.6 0.0 2.3 1.8 HIF1A "bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8" ENSG00000100644 "Hypoxia inducible factor 1 alpha subunit" Q16665 14 61695513-61748259 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 47.8" "Lineage enriched" "Detected in all" 6 "granulocytes: 47.8" "Cell line enhanced" "Detected in many" "LHCN-M2: 119.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000907, HPA001275, CAB017442" Approved Enhanced "Nucleoplasm,Nuclear bodies,Plasma membrane" NA NA "Nucleoplasm, Nuclear bodies" "Plasma membrane" "CAB017442: AB_10621732, HPA000907: AB_2666139, HPA001275: AB_1079057" "unprognostic (1.07e-2)" "unprognostic (1.13e-3)" "unprognostic (9.41e-2)" "unprognostic (1.07e-1)" "unprognostic (2.51e-2)" "unprognostic (1.90e-1)" "unprognostic (2.94e-3)" "unprognostic (3.40e-1)" "unprognostic (4.05e-1)" "unprognostic (1.39e-1)" "unprognostic (1.77e-2)" "unprognostic (8.39e-2)" "unprognostic (1.24e-1)" "unprognostic (3.23e-2)" "unprognostic (3.58e-1)" "unprognostic (7.35e-2)" "unprognostic (3.88e-2)" 31.9 62.0 15.6 45.2 17.8 125.2 24.9 22.7 18.5 45.7 15.3 12.3 23.5 10.8 17.7 31.3 31.2 21.7 50.0 19.4 17.5 16.5 76.4 42.7 42.8 27.3 18.3 11.0 34.5 12.7 13.7 26.8 24.2 25.1 17.6 13.9 14.0 24.6 36.2 8.0 17.4 16.9 18.7 27.2 57.3 16.0 21.1 12.4 24.7 26.9 18.4 28.8 37.8 21.5 6.6 6.0 47.8 6.8 6.2 7.9 5.1 38.0 15.2 15.3 43.7 24.3 39.2 20.7 31.7 38.2 39.9 36.0 6.6 12.6 9.3 23.9 39.1 11.4 9.0 9.8 52.0 50.0 4.0 5.1 5.7 14.0 11.4 54.2 2.4 6.2 68.3 16.5 29.3 31.4 53.9 25.1 5.4 3.8 0.0 119.1 7.9 7.4 2.9 13.8 6.0 20.1 0.5 34.3 2.7 51.5 25.3 12.9 14.3 59.4 8.5 20.9 21.8 8.9 4.5 14.9 90.7 20.3 30.0 26.6 5.0 7.2 10.6 47.8 4.7 24.5 11.2 6.8 47.8 3.8 5.5 4.9 6.5 5.0 4.4 6.0 6.6 7.9 5.1 18.2 6.2 5.6 2.9 3.4 5.1 15.6 17.8 22.7 13.2 17.5 16.5 18.3 11.0 25.1 12.4 65.5 115.1 54.6 71.5 94.4 49.4 37.3 86.6 33.5 69.4 247.7 47.1 22.6 87.9 226.7 3.1 113.7 30.7 0.0 216.2 57.6 82.5 54.8 217.2 23.7 123.2 147.8 63.8 177.4 143.9 3.6 22.5 156.8 97.8 76.7 36.5 141.2 213.6 23.0 45.6 116.2 52.0 51.8 129.7 27.4 24.9 76.9 21.3 60.6 34.8 75.6 HIP1 ILWEQ ENSG00000127946 "Huntingtin interacting protein 1" O00291 7 75533300-75738962 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Differentiation, Endocytosis, Transcription, Transcription regulation" "Actin-binding, Activator" "Cancer-related genes, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enriched" "Detected in many" 5 "Late spermatids: 1171.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "A549: 27.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013606, CAB015334, CAB016402, HPA017964" Enhanced Supported Vesicles NA NA Vesicles "CAB015334: AB_2117565, CAB016402: AB_627725, HPA013606: AB_1850717, HPA017964: AB_1850719" "unprognostic (8.23e-2)" "unprognostic (1.22e-1)" "unprognostic (2.20e-2)" "unprognostic (1.64e-1)" "unprognostic (1.04e-1)" "unprognostic (2.59e-1)" "unprognostic (2.73e-3)" "unprognostic (1.03e-2)" "unprognostic (1.11e-2)" "unprognostic (2.02e-2)" "unprognostic (2.70e-2)" "unprognostic (7.98e-2)" "unprognostic (1.73e-3)" "unprognostic (9.67e-2)" "unprognostic (1.75e-1)" "unprognostic (1.00e-2)" "unprognostic (1.09e-1)" 16.5 8.7 14.6 7.2 25.9 5.1 13.5 13.2 20.8 13.2 5.3 34.4 4.9 2.9 13.4 10.1 5.7 13.8 8.7 9.2 17.5 11.9 14.6 9.6 17.7 4.6 27.2 11.8 8.1 4.0 4.9 3.6 20.0 16.1 6.8 4.5 9.9 4.0 12.4 3.9 10.8 4.6 12.6 24.8 10.8 4.6 18.5 29.7 1.6 15.8 5.7 4.6 9.7 8.8 0.5 4.0 8.8 1.1 3.3 1.5 0.3 2.5 27.3 18.6 17.5 7.9 10.7 5.6 4.8 3.1 3.1 2.3 1.5 2.4 1.8 5.6 11.8 10.9 3.1 18.8 3.9 4.2 1.5 3.5 1.4 3.2 2.5 7.8 0.4 7.4 8.2 2.4 10.2 2.1 5.8 13.0 2.0 1.9 1.8 5.0 10.4 1.2 10.6 20.2 0.2 3.3 2.1 7.8 0.1 2.4 9.7 0.9 8.2 4.4 2.8 6.3 17.3 17.2 6.7 4.6 9.2 7.1 3.1 6.6 2.0 0.2 4.4 9.2 3.9 6.2 8.8 1.1 7.6 1.1 1.1 1.0 0.4 0.2 0.9 1.6 0.5 0.1 0.7 7.7 3.3 0.8 4.0 1.5 0.3 14.6 25.9 13.2 16.9 17.5 11.9 27.2 11.8 16.1 29.7 56.6 35.7 6.0 6.3 15.7 7.1 12.5 5.1 0.0 17.0 26.2 11.8 1.3 11.6 10.2 240.8 40.7 0.7 0.0 5.3 7.5 15.4 4.0 13.9 20.2 11.7 22.3 4.6 30.1 15.1 1171.7 20.8 22.9 10.1 1.0 1.4 18.6 2.6 8.5 23.3 2.2 8.2 84.1 37.2 9.3 4.1 8.0 0.7 17.0 2.6 3.1 HIST1H3B "H3/l, H3FL" ENSG00000274267 "Histone cluster 1 H3 family member b" P68431 6 26031650-26032060 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "lymphoid tissue: 343.5" "Cell type enriched" "Detected in some" 5 "Spermatogonia: 5.1" "Low cancer specificity" "Detected in many" "Cell type enhanced" "Detected in some" "T-reg: 1.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-266/84: 12.0" HPA042570 Approved NA NA "HPA042570: AB_2678056" "unprognostic (2.82e-1)" "unprognostic (2.64e-2)" "unprognostic (1.09e-1)" "unprognostic (5.59e-2)" "unprognostic (1.37e-1)" "unprognostic (2.34e-2)" "unprognostic (2.31e-2)" "unprognostic (1.17e-1)" "unprognostic (1.13e-1)" "unprognostic (2.03e-2)" "unprognostic (1.08e-2)" "unprognostic (5.34e-2)" "unprognostic (2.31e-7)" "unprognostic (8.52e-2)" "unprognostic (2.78e-1)" "unprognostic (1.90e-3)" 1.7 0.7 0.0 36.1 0.0 18.1 3.6 0.0 0.3 0.8 6.9 0.0 0.0 0.3 0.8 2.5 11.8 0.5 1.9 2.4 0.0 0.6 0.3 3.4 10.4 0.0 0.0 0.3 0.3 0.3 0.0 7.8 0.0 0.3 0.8 0.0 1.0 0.3 0.3 0.3 6.3 0.8 0.0 14.7 0.5 26.9 0.0 343.5 0.8 18.2 27.7 0.3 0.0 0.8 0.1 1.2 0.0 0.0 1.4 3.1 1.8 4.6 1.3 4.0 0.0 0.4 0.0 0.2 0.8 0.8 0.7 1.1 1.0 3.0 2.0 0.3 1.2 0.7 1.6 1.2 1.7 2.0 4.4 3.2 6.0 1.3 0.0 2.4 2.1 2.9 0.0 0.6 0.0 0.1 1.0 0.9 6.5 5.9 1.1 1.0 7.4 7.4 3.1 0.7 3.2 4.3 2.9 8.5 0.5 0.0 2.1 1.7 5.1 1.6 0.5 0.1 2.8 1.5 1.4 1.4 4.1 0.7 1.7 9.6 12.0 3.9 3.4 4.6 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.8 0.1 0.5 0.0 0.2 1.2 0.0 0.0 0.0 1.4 3.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.1 0.1 0.2 0.0 0.6 0.1 HIST1H4I "H4/m, H4FM" ENSG00000276180 "Histone cluster 1 H4 family member i" P62805 6 27138588-27139881 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "blood: 14.5" "Cell type enhanced" "Detected in some" 11 "Alveolar cells type 2: 1.1;Cardiomyocytes: 1.8;Early spermatids: 2.7;Enterocytes: 1.3" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 29.8;SiHa: 17.9;U-2 OS: 30.7;U-266/84: 31.0" HPA042201 Approved NA NA 30000000 "HPA042201: AB_2677898" "unprognostic (2.49e-2)" "prognostic favorable (9.70e-4)" "unprognostic (1.97e-2)" "unprognostic (2.51e-2)" "unprognostic (2.26e-1)" "unprognostic (2.25e-1)" "unprognostic (1.07e-1)" "unprognostic (2.16e-1)" "unprognostic (2.85e-1)" "unprognostic (1.29e-3)" "unprognostic (1.86e-3)" "unprognostic (1.95e-1)" "prognostic unfavorable (1.32e-5)" "unprognostic (6.28e-2)" "unprognostic (1.49e-1)" "unprognostic (1.80e-1)" "unprognostic (2.02e-2)" 0.1 2.5 2.4 1.7 0.0 0.1 0.0 0.8 2.7 1.1 0.0 1.7 0.0 1.3 0.5 0.0 1.9 0.8 2.6 0.8 2.7 0.0 1.5 2.0 0.0 1.6 0.0 0.0 0.2 2.9 0.0 2.3 3.2 1.8 2.6 0.0 1.9 6.0 5.5 14.5 4.6 2.4 3.4 3.1 1.7 3.5 1.9 1.2 1.3 0.1 2.1 3.3 0.1 0.1 0.1 3.3 2.5 0.5 9.6 0.0 5.3 2.6 0.3 0.1 0.0 2.3 5.1 1.2 5.6 0.1 0.2 1.0 6.2 0.4 0.1 0.0 0.1 3.3 0.1 1.2 29.8 9.2 0.0 5.1 1.5 2.2 0.7 12.3 2.2 1.3 1.1 8.4 0.1 0.9 6.5 2.3 17.9 8.3 1.9 2.3 15.8 0.7 1.1 2.4 30.7 2.8 0.3 9.3 31.0 5.8 1.4 6.7 2.4 9.2 2.6 14.1 1.5 2.0 1.3 4.6 1.3 1.4 2.5 6.0 1.6 1.7 14.5 2.4 4.6 5.5 3.4 3.1 0.0 1.1 0.8 0.2 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.7 0.0 1.3 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.4 0.8 0.1 0.3 0.0 0.6 0.0 HLA-A ENSG00000206503 "Major histocompatibility complex, class I, A" "P04439, P13746, P16188" 6 29941260-29945884 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 6 "monocytes: 4504.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A-431: 158.0;fHDF/TERT166: 42.3;HBEC3-KT: 43.4;RPMI-8226: 41.2;U-266/70: 42.1" CAB078470 Supported "Golgi apparatus,Plasma membrane" NA NA "Plasma membrane" "Golgi apparatus" "CAB078470: AB_10985125" "unprognostic (1.56e-2)" "unprognostic (9.14e-2)" "unprognostic (1.34e-2)" "prognostic favorable (9.59e-4)" "unprognostic (3.49e-1)" "unprognostic (1.21e-1)" "unprognostic (1.12e-1)" "unprognostic (7.28e-2)" "unprognostic (3.42e-2)" "prognostic favorable (6.47e-4)" "unprognostic (2.96e-1)" "unprognostic (3.24e-1)" "unprognostic (1.84e-2)" "unprognostic (1.01e-1)" "unprognostic (2.32e-2)" "unprognostic (1.20e-2)" "unprognostic (1.54e-2)" 69.4 57.5 16.0 69.1 18.2 41.2 40.8 9.1 20.7 54.4 92.6 20.4 28.6 105.7 38.4 76.2 48.4 27.8 92.3 59.1 14.6 16.6 80.5 47.6 112.0 90.5 19.5 8.9 57.2 30.0 22.5 33.3 38.7 22.7 64.1 38.5 52.4 28.3 19.2 44.0 110.4 129.4 30.3 22.8 150.0 115.9 26.6 12.3 71.1 62.3 38.5 97.7 86.4 41.0 23.0 10.9 65.8 25.2 25.9 46.7 45.4 158.0 4.0 0.0 0.0 25.5 24.1 0.1 0.1 0.3 0.2 0.3 0.0 0.0 0.4 0.0 42.3 21.5 3.9 0.0 43.4 0.0 0.3 1.6 27.6 1.2 0.8 1.4 0.0 1.8 0.2 0.0 0.3 0.1 0.0 0.0 21.2 0.0 0.1 0.0 0.0 0.1 2.5 0.3 0.0 0.4 3.3 0.3 41.2 29.6 32.5 0.0 1.4 3.5 0.0 1.4 10.4 0.2 3.7 0.6 2.4 0.1 0.7 0.5 42.1 10.7 8.9 0.0 23.3 0.0 65.8 25.2 35.4 38.3 17.9 28.8 23.0 29.6 34.4 4.1 14.9 21.7 29.7 47.9 25.9 19.8 10.9 46.7 45.4 16.0 18.2 9.1 20.7 14.6 16.6 19.5 8.9 22.7 12.3 345.4 508.3 1064.2 718.5 760.7 31.3 128.4 937.6 317.2 366.3 478.1 5.9 16.7 74.6 2692.4 38.8 1227.5 2851.3 186.9 1168.0 15.8 685.4 823.3 585.8 217.5 1814.8 35.0 917.5 1170.5 1323.9 66.9 652.4 1239.0 602.3 4504.1 1496.2 150.9 1505.1 2283.0 455.0 258.2 20.0 549.7 859.0 132.4 24.5 828.4 26.5 2218.3 1070.6 1059.3 HLF MGC33822 ENSG00000108924 "HLF, PAR bZIP transcription factor" Q16534 17 55265012-55325065 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in all" "liver: 78.8" "Cell type enhanced" "Detected in many" 10 "Bipolar cells: 122.6;Hepatocytes: 152.5;Horizontal cells: 87.4" "Cancer enhanced" "Detected in many" "liver cancer: 13.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 7 "memory CD4 T-cell: 2.4;T-reg: 2.1" "Lineage enriched" "Detected in single" 25 "T-cells: 2.4" "Cell line enriched" "Detected in some" 6 "Hep G2: 60.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA068156, HPA071210" Enhanced Nucleoplasm Yes NA Nucleoplasm "HPA068156: AB_2685963, HPA071210: AB_2686361" "unprognostic (1.24e-1)" "unprognostic (1.19e-3)" "unprognostic (1.27e-1)" "unprognostic (1.35e-1)" "unprognostic (3.30e-1)" "prognostic favorable (1.88e-4)" "unprognostic (5.30e-3)" "prognostic favorable (2.71e-7)" "unprognostic (1.42e-1)" "unprognostic (3.44e-2)" "unprognostic (1.24e-3)" "unprognostic (2.19e-1)" "prognostic favorable (3.55e-6)" "unprognostic (8.47e-2)" "unprognostic (1.64e-1)" "unprognostic (6.85e-2)" "unprognostic (1.60e-2)" 9.5 15.2 13.3 2.0 26.2 1.0 10.8 15.2 38.0 10.5 10.6 6.4 2.4 1.7 10.3 8.5 18.1 9.3 6.1 15.9 12.6 6.9 9.2 78.8 9.5 2.1 6.6 24.5 34.6 2.7 2.8 8.0 1.5 12.3 9.9 3.1 23.7 15.9 9.5 5.3 11.6 3.0 14.3 5.5 5.7 4.7 3.4 6.3 0.0 23.4 7.1 5.6 9.2 5.2 0.0 0.0 0.0 0.0 0.0 2.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.2 0.0 0.0 0.0 0.1 0.0 0.0 10.0 0.2 0.0 0.0 60.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.5 0.0 0.2 0.0 0.2 0.4 0.0 0.0 0.0 0.9 0.0 0.1 0.1 5.0 0.0 4.2 0.2 0.0 2.7 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.2 0.1 1.9 1.7 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.1 13.3 26.2 15.2 38.0 12.6 6.9 6.6 24.5 12.3 6.3 3.0 36.8 0.0 4.7 19.8 122.6 31.9 15.3 1.4 11.4 7.0 9.8 0.1 10.0 1.5 0.9 8.6 0.0 0.0 0.8 0.0 6.0 1.2 0.0 152.5 0.1 87.4 2.9 4.9 4.1 2.7 26.2 1.0 10.1 0.0 0.1 54.5 0.3 0.0 36.7 18.9 13.0 12.9 6.2 0.3 2.7 24.1 1.0 2.2 0.0 0.5 HMGA1 HMGIY ENSG00000137309 "High mobility group AT-hook 1" P17096 6 34236873-34246231 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 107.3" "Cell type enhanced" "Detected in many" 6 "Cytotrophoblasts: 784.6;Pancreatic endocrine cells: 1097.2;Urothelial cells: 1250.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "CAB032200, HPA065612, HPA068442" Enhanced Approved Nucleoplasm,Nucleoli NA NA 18000 Nucleoplasm Nucleoli "CAB032200: AB_2117771, HPA065612: , HPA068442: " "unprognostic (1.81e-1)" "unprognostic (1.25e-1)" "unprognostic (1.08e-1)" "prognostic unfavorable (7.13e-4)" "unprognostic (1.57e-1)" "unprognostic (1.20e-3)" "prognostic unfavorable (1.29e-6)" "prognostic unfavorable (3.36e-4)" "unprognostic (8.54e-2)" "unprognostic (1.84e-2)" "prognostic unfavorable (8.71e-4)" "unprognostic (1.55e-1)" "unprognostic (8.22e-2)" "unprognostic (4.52e-3)" "unprognostic (1.19e-1)" "unprognostic (4.37e-1)" "unprognostic (2.65e-2)" 15.8 3.5 14.8 35.7 13.5 55.4 13.0 13.8 19.0 26.1 22.0 5.9 7.7 42.3 8.6 7.2 79.4 15.1 17.8 13.0 11.7 12.6 14.6 6.9 16.0 46.1 10.7 8.7 3.9 13.0 4.1 5.1 31.8 12.5 8.7 21.2 9.9 22.0 6.9 33.7 38.3 36.0 3.8 8.4 31.6 24.2 32.6 7.2 107.3 12.5 39.6 72.7 13.0 29.6 26.6 33.4 12.8 10.1 7.3 22.4 11.0 121.6 48.2 24.7 17.2 11.5 85.4 108.0 49.2 56.3 38.2 21.3 31.5 85.4 57.4 24.8 20.1 24.0 26.1 29.1 87.7 30.4 12.5 19.5 17.6 16.2 42.1 24.4 62.8 20.3 36.6 9.8 69.1 36.1 98.7 115.2 32.8 70.8 2.9 53.1 12.3 54.4 77.4 120.4 60.7 81.6 80.9 0.5 63.3 25.8 11.2 43.2 18.3 5.2 25.0 45.4 40.8 10.0 67.4 99.8 19.9 62.8 28.9 46.0 23.6 36.5 74.1 42.1 26.2 99.3 6.2 10.1 12.8 10.2 10.1 13.3 26.6 18.7 16.0 30.7 16.4 22.4 17.7 2.6 7.3 9.4 33.4 21.0 11.0 14.8 13.5 13.8 19.0 11.7 12.6 10.7 8.7 12.5 7.2 26.8 23.7 124.5 686.8 384.1 27.4 24.5 38.2 10.7 36.4 38.4 3.9 784.6 39.7 243.5 6.1 27.0 148.7 46.7 242.2 663.0 71.9 750.7 66.8 10.6 337.7 11.1 112.2 16.0 59.4 17.5 5.2 107.5 86.0 66.7 165.5 27.9 1097.2 162.4 2.5 9.0 27.8 0.0 34.9 38.5 398.0 315.9 688.1 51.7 282.8 1250.0 HMGA2 "BABL, HMGIC, LIPO" ENSG00000149948 "High mobility group AT-hook 2" P52926 12 65824131-65966295 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Cell cycle, Cell division, DNA condensation, Growth regulation, Mitosis, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "testis: 25.3" "Cell type enhanced" "Detected in some" 10 "Early spermatids: 15.7;Hofbauer cells: 6.8;Late spermatids: 6.8;Pancreatic endocrine cells: 11.8;Undifferentiated cells: 8.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 63.0;hTERT-RPE1: 46.0;SuSa: 44.3" "Not detected" "Not detected" "CAB017809, HPA039076" Approved Supported "Nucleoplasm,Nucleoli,Nucleoli rim" NA NA "Nucleoplasm, Nucleoli, Nucleoli rim" "CAB017809: , HPA039076: AB_2676335" "unprognostic (2.39e-1)" "unprognostic (6.00e-2)" "unprognostic (2.08e-1)" "unprognostic (3.68e-3)" "unprognostic (5.21e-3)" "prognostic unfavorable (4.79e-4)" "unprognostic (4.05e-3)" "unprognostic (6.17e-3)" "unprognostic (6.71e-2)" "unprognostic (1.16e-1)" "unprognostic (1.54e-6)" "unprognostic (3.33e-2)" "unprognostic (4.55e-5)" "unprognostic (4.22e-2)" "unprognostic (2.53e-1)" "unprognostic (2.53e-2)" "prognostic unfavorable (2.86e-4)" 6.5 0.3 0.5 3.8 0.8 8.1 2.1 0.2 0.6 2.5 7.6 0.4 0.0 2.4 2.7 0.1 1.1 2.4 3.3 0.5 0.3 0.4 1.0 0.4 0.5 0.1 0.3 1.3 2.1 1.7 0.0 1.7 0.3 0.6 0.5 4.6 0.4 0.5 1.8 2.0 0.7 5.1 0.7 1.7 0.8 2.1 25.3 0.0 0.8 1.1 3.0 0.1 0.8 2.8 0.7 0.3 3.8 2.1 1.3 0.7 0.1 9.1 4.0 63.0 9.0 3.0 16.5 0.0 29.1 13.3 5.1 5.1 5.2 3.9 0.0 18.9 1.3 24.0 4.0 10.4 25.1 24.5 0.0 10.9 0.0 0.1 31.5 1.7 0.8 0.1 12.5 1.5 11.0 19.8 46.0 20.1 0.0 0.0 0.1 29.1 0.0 0.0 5.1 36.9 0.8 18.1 2.4 3.1 0.0 13.6 0.0 0.0 0.0 0.0 0.0 16.0 44.3 0.1 0.1 23.5 18.5 5.5 14.1 8.7 0.0 0.0 0.0 22.4 0.0 4.2 3.8 1.0 0.7 0.5 0.6 0.3 0.3 0.4 0.5 0.2 0.7 0.4 0.7 2.5 1.3 2.1 0.3 0.3 0.1 0.5 0.8 0.2 0.6 0.3 0.4 0.3 1.3 0.6 0.0 0.0 1.4 0.0 2.2 0.0 0.0 1.2 0.0 4.0 0.0 0.0 0.0 0.8 0.0 3.0 15.7 0.1 3.3 0.0 0.7 0.3 0.9 0.4 0.0 0.0 6.8 0.0 0.0 0.6 0.0 6.8 0.3 0.0 0.0 0.0 4.7 0.0 11.8 3.5 0.0 0.0 0.0 0.0 0.8 0.5 0.2 0.1 0.7 0.0 8.5 0.9 HNF1A "HNF1, LFB1, MODY3, TCF1" ENSG00000135100 "HNF1 homeobox A" 12 120978543-121002512 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 24.2;kidney: 17.2;liver: 15.6" "Cell type enhanced" "Detected in some" 8 "Enterocytes: 16.0;Hepatocytes: 13.9;Paneth cells: 14.4;Proximal tubular cells: 13.2;Undifferentiated cells: 8.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in some" 6 "A549: 6.2;CACO-2: 20.5;Hep G2: 22.4;OE19: 10.7" "Not detected" "Not detected" "Not detected" "Not detected" "CAB010430, HPA035231" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "CAB010430: AB_2116746, HPA035231: AB_2674528" "unprognostic (5.92e-3)" "unprognostic (8.47e-2)" "unprognostic (4.12e-3)" "unprognostic (6.18e-3)" "unprognostic (3.72e-1)" "unprognostic (1.27e-2)" "unprognostic (9.18e-2)" "unprognostic (9.18e-2)" "unprognostic (2.99e-1)" "unprognostic (2.01e-1)" "unprognostic (9.77e-3)" "unprognostic (5.21e-2)" "unprognostic (6.25e-3)" "unprognostic (5.55e-2)" "unprognostic (2.48e-1)" "unprognostic (6.93e-3)" 0.1 0.0 0.1 0.8 0.1 0.0 0.1 0.1 0.1 0.1 17.3 0.1 0.1 13.7 0.1 1.5 0.1 0.8 5.1 0.1 0.1 0.0 17.2 15.6 0.1 0.1 0.1 0.1 0.2 6.3 0.0 0.1 0.1 0.1 0.1 2.1 0.1 0.1 0.1 0.1 0.0 24.2 0.5 0.1 0.1 3.6 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 0.5 1.8 0.3 0.3 0.4 0.2 0.0 6.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 20.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.7 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.3 0.2 0.2 0.3 0.2 0.3 0.4 0.4 0.1 0.5 0.4 0.4 1.6 0.3 0.3 0.5 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.5 0.1 0.6 0.8 2.5 0.0 0.0 1.8 0.0 0.0 0.0 2.3 0.0 0.0 16.0 0.0 4.6 0.1 0.0 0.4 0.0 13.9 0.1 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 1.0 6.7 0.5 3.2 14.4 0.0 13.2 0.2 0.0 0.1 0.1 0.0 0.3 0.0 0.0 8.9 0.2 HNRNPA2B1 HNRPA2B1 ENSG00000122566 "Heterogeneous nuclear ribonucleoprotein A2/B1" P22626 7 26189927-26201529 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA processing, mRNA splicing, mRNA transport, Transport" "Ribonucleoprotein, RNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001666, HPA005812, CAB012403, HPA065537" Supported Enhanced Nucleoplasm "Intracellular and membrane" NA NA 11000000 Nucleoplasm "CAB012403: , HPA001666: AB_1850836, HPA005812: AB_2667441, HPA065537: AB_2685507" "unprognostic (1.19e-1)" "unprognostic (4.45e-1)" "unprognostic (2.33e-1)" "unprognostic (6.39e-2)" "unprognostic (5.64e-2)" "unprognostic (8.04e-3)" "prognostic unfavorable (1.03e-6)" "unprognostic (1.25e-2)" "unprognostic (9.12e-3)" "unprognostic (4.35e-3)" "unprognostic (1.31e-1)" "prognostic unfavorable (5.12e-4)" "prognostic unfavorable (8.01e-5)" "unprognostic (6.74e-2)" "unprognostic (3.36e-2)" "unprognostic (2.02e-1)" "unprognostic (1.56e-2)" 82.2 97.4 85.1 105.3 106.3 90.9 74.4 123.3 87.4 77.1 85.7 89.4 68.7 87.5 92.6 71.9 90.4 75.1 51.7 87.9 82.4 71.8 113.4 103.7 76.2 127.7 118.6 57.0 121.0 75.7 107.2 121.2 100.7 96.3 75.5 98.6 64.4 71.4 66.5 167.2 58.7 94.8 73.7 139.7 116.5 74.1 73.1 135.4 180.3 81.9 104.4 140.7 74.2 128.8 33.7 46.5 35.1 52.4 32.1 42.5 36.0 124.0 105.9 154.2 115.6 39.7 36.3 71.4 79.6 62.1 88.0 79.7 97.8 90.4 226.9 76.1 73.8 105.0 86.6 164.9 104.0 124.0 70.5 100.5 137.5 127.8 116.9 33.3 148.0 94.2 34.3 54.5 83.7 76.4 46.4 90.8 104.9 161.7 74.2 88.8 100.4 158.3 173.1 136.6 95.1 81.7 147.2 125.3 95.0 101.6 108.6 90.1 110.5 95.7 94.3 58.1 98.3 105.7 128.9 78.4 49.5 102.5 67.0 135.8 98.6 195.4 215.9 63.8 168.7 93.2 17.4 38.7 35.1 42.5 52.4 38.6 33.7 35.5 36.6 46.5 29.2 35.6 35.6 13.0 32.1 48.4 43.6 36.1 36.0 85.1 106.3 123.3 87.4 82.4 71.8 118.6 57.0 96.3 135.4 452.6 512.0 456.4 620.8 656.0 459.5 635.5 267.5 721.4 702.9 326.2 280.8 790.3 391.3 484.7 96.5 561.1 396.4 280.4 392.8 789.3 528.7 417.7 617.9 353.4 530.6 295.6 471.8 332.7 355.7 124.0 380.5 569.8 372.8 501.4 392.2 570.4 369.1 357.7 366.7 366.6 518.1 433.4 564.3 596.8 448.9 524.9 905.5 489.7 465.4 566.2 HOOK3 HK3 ENSG00000168172 "Hook microtubule tethering protein 3" Q86VS8 8 42896932-43030539 "Cancer-related genes, Predicted intracellular proteins" "Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024756 Approved Supported "Golgi apparatus,Centriolar satellite,Cytosol" NA NA "Centriolar satellite" "Golgi apparatus, Cytosol" "HPA024756: AB_1850913" "unprognostic (1.84e-2)" "unprognostic (1.61e-1)" "unprognostic (2.73e-1)" "unprognostic (8.61e-3)" "unprognostic (6.05e-2)" "unprognostic (1.77e-3)" "unprognostic (2.36e-1)" "unprognostic (2.23e-1)" "unprognostic (1.78e-1)" "unprognostic (3.97e-2)" "unprognostic (1.13e-1)" "unprognostic (4.13e-1)" "prognostic unfavorable (1.32e-4)" "unprognostic (1.63e-1)" "unprognostic (3.78e-1)" "unprognostic (2.55e-1)" "unprognostic (7.12e-2)" 15.5 9.3 11.3 10.1 15.1 13.1 16.3 16.0 19.2 13.5 11.3 10.3 14.1 10.2 13.7 12.0 14.8 11.7 20.0 9.5 11.2 11.3 9.9 10.7 14.6 10.3 14.7 11.7 13.4 13.9 13.4 14.4 12.0 13.1 17.7 10.9 6.8 17.1 15.2 24.1 11.0 11.9 19.3 17.5 11.6 12.8 14.5 14.3 7.4 37.5 8.9 10.1 19.2 17.6 1.8 3.8 10.2 3.2 2.0 2.0 1.8 7.4 7.4 18.1 9.8 13.5 12.0 6.9 9.5 8.0 8.0 7.5 9.8 8.7 9.3 9.7 12.7 7.6 4.2 15.0 6.4 13.0 6.3 4.3 17.5 6.1 6.8 7.5 1.8 10.3 9.7 4.7 10.7 9.2 11.1 11.4 6.6 9.6 11.0 9.6 1.8 14.2 3.4 6.5 5.9 2.2 8.3 18.9 2.3 5.9 11.1 4.6 7.4 10.8 4.6 5.0 8.3 8.4 6.3 20.4 12.0 9.3 14.4 6.0 10.8 11.8 12.3 10.1 6.7 17.6 10.2 3.2 3.1 2.0 3.2 0.8 1.6 1.9 1.5 3.8 1.8 1.1 1.5 3.8 2.0 3.1 2.4 1.4 1.8 11.3 15.1 16.0 13.1 11.2 11.3 14.7 11.7 13.1 14.3 86.4 55.8 23.3 27.0 60.8 36.4 44.2 38.2 33.5 45.5 24.4 31.4 32.3 23.2 37.4 88.6 54.3 28.4 23.3 28.8 21.7 50.3 38.0 52.0 28.4 34.2 71.5 62.8 57.7 83.3 26.1 41.4 65.4 52.3 104.6 20.1 29.9 47.3 25.9 50.5 18.0 31.0 64.7 55.1 30.2 18.9 65.4 95.1 27.4 13.5 63.4 HOXA11 "HOX1, HOX1I" ENSG00000005073 "Homeobox A11" P31270 7 27181510-27185223 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 35.7;endometrium 1: 60.9;smooth muscle: 27.3" "Cell type enhanced" "Detected in some" 10 "Distal tubular cells: 5.0;Fibroblasts: 4.3;Intestinal endocrine cells: 5.1;Smooth muscle cells: 2.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 14.7;BJ hTERT+: 17.8;HEK 293: 25.0;THP-1: 17.9;U-937: 23.4" "Not detected" "Not detected" "Not detected" "Not detected" "HPA006770, HPA035623" Enhanced Supported Nucleoplasm NA NA Nucleoplasm "HPA006770: AB_2667672, HPA035623: AB_10601576" "unprognostic (5.95e-2)" "unprognostic (9.23e-2)" "unprognostic (3.07e-2)" "unprognostic (2.70e-2)" "unprognostic (6.29e-2)" "unprognostic (9.78e-2)" "unprognostic (2.82e-3)" "unprognostic (4.36e-2)" "unprognostic (1.61e-2)" "unprognostic (3.05e-2)" "unprognostic (2.08e-3)" "unprognostic (1.73e-2)" "prognostic unfavorable (2.57e-5)" "unprognostic (2.17e-2)" "unprognostic (6.90e-2)" "unprognostic (2.03e-2)" "unprognostic (2.56e-1)" 1.5 0.4 0.0 1.7 0.0 0.0 2.0 0.0 0.0 35.7 9.3 0.0 5.7 0.0 60.9 8.8 0.0 0.7 0.0 0.2 0.0 0.0 3.6 0.1 0.0 0.1 0.0 0.0 1.8 0.0 0.0 0.0 9.0 0.0 16.5 2.4 0.0 0.1 6.3 4.9 0.7 0.2 27.3 0.0 0.0 0.1 3.1 0.0 0.0 0.0 0.0 0.0 20.1 6.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 2.3 0.1 0.0 6.8 8.4 5.9 0.0 14.7 17.8 10.5 7.5 0.1 0.8 0.0 3.4 12.5 0.0 1.6 8.7 0.0 7.7 0.8 25.0 3.1 6.1 0.3 0.5 6.2 0.9 3.7 0.3 0.0 0.0 0.0 7.6 0.6 0.2 0.0 1.1 0.1 0.0 4.8 0.0 2.1 7.4 0.4 0.0 0.1 5.0 4.3 3.2 0.0 3.6 0.0 1.0 2.1 0.6 17.9 0.0 0.1 7.2 1.6 0.7 0.0 0.0 0.0 0.1 23.4 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.2 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 5.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 4.3 2.0 0.0 0.0 0.3 0.0 5.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.0 1.4 0.0 0.0 0.0 0.0 2.3 0.0 0.1 0.0 0.0 0.0 0.6 0.7 HOXA13 "HOX1, HOX1J" ENSG00000106031 "Homeobox A13" P31271 7 27193503-27200106 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 48.5;prostate: 25.1" "Group enriched" "Detected in some" 15 "Basal glandular cells: 2.9;Enterocytes: 7.7;Fibroblasts: 3.5;Glandular cells: 4.8;Intestinal endocrine cells: 8.1;Mucus-secreting cells: 9.8;Paneth cells: 5.8;Undifferentiated cells: 9.7;Urothelial cells: 2.8" "Cancer enhanced" "Detected in many" "prostate cancer: 10.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HAP1: 15.5;HEK 293: 21.6;PC-3: 10.7;RT4: 23.9;THP-1: 10.2;U-937: 11.4" "Not detected" "Not detected" "Not detected" "Not detected" "HPA046098, HPA069061" Supported "Nucleoplasm,Mitotic chromosome,Intermediate filaments" NA NA Nucleoplasm "Mitotic chromosome, Intermediate filaments" "HPA046098: AB_2679536, HPA069061: " "unprognostic (7.20e-2)" "unprognostic (1.89e-1)" "unprognostic (1.02e-1)" "unprognostic (8.04e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-2)" "unprognostic (1.79e-1)" "unprognostic (1.40e-2)" "unprognostic (9.22e-3)" "unprognostic (7.30e-3)" "unprognostic (8.39e-3)" "unprognostic (1.54e-1)" "unprognostic (1.42e-11)" "unprognostic (2.58e-3)" "unprognostic (1.38e-1)" "unprognostic (1.72e-1)" "unprognostic (1.36e-2)" 0.6 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 48.5 6.9 0.0 7.1 0.0 5.5 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 16.5 0.0 25.1 8.6 0.0 0.1 17.9 1.2 0.4 0.1 15.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 12.1 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.9 0.0 1.4 0.1 0.0 0.0 7.6 8.3 3.0 1.9 1.5 0.1 0.0 0.9 3.5 0.4 0.0 15.5 0.0 2.5 0.0 21.6 1.0 4.1 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 4.9 0.0 6.6 10.7 1.5 0.4 0.0 0.0 23.9 0.4 0.0 1.9 0.0 0.1 1.2 0.0 10.2 0.0 0.3 2.7 0.1 0.1 0.0 0.0 0.0 0.0 11.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 7.7 0.0 0.0 0.1 3.5 4.8 0.0 0.0 0.1 0.0 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.0 9.7 2.8 HOXA9 "HOX1, HOX1G" ENSG00000078399 "Homeobox A9" P31269 7 27162435-27175180 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 35.1" "Cell type enhanced" "Detected in many" 9 "Distal tubular cells: 46.4;Intestinal endocrine cells: 37.7;Proximal tubular cells: 60.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "basophil: 5.4;myeloid DC: 6.0;NK-cell: 11.7" "Group enriched" "Detected in many" 5 "dendritic cells: 6.0;granulocytes: 5.4;NK-cells: 11.7" "Cell line enhanced" "Detected in some" "HEK 293: 43.6;PC-3: 15.2;RPTEC TERT1: 15.0;SCLC-21H: 40.5;U-937: 14.5" "HPA061982, HPA076200" Uncertain Enhanced Nucleoplasm NA NA Nucleoplasm "HPA061982: AB_2684651, HPA076200: " "unprognostic (4.72e-1)" "unprognostic (1.23e-2)" "unprognostic (2.86e-1)" "unprognostic (5.24e-3)" "unprognostic (2.36e-1)" "unprognostic (2.02e-1)" "unprognostic (8.35e-2)" "unprognostic (8.44e-3)" "unprognostic (5.50e-2)" "unprognostic (5.71e-2)" "unprognostic (9.87e-3)" "unprognostic (4.42e-2)" "unprognostic (2.80e-3)" "unprognostic (6.45e-2)" "unprognostic (7.58e-2)" "unprognostic (1.92e-2)" "unprognostic (1.35e-1)" 3.2 3.4 0.2 8.8 0.1 2.4 8.7 0.1 0.2 15.5 12.8 0.2 4.1 0.0 10.4 16.8 1.4 12.2 0.3 0.1 0.1 0.0 35.1 0.1 0.8 0.7 0.1 0.1 2.0 0.1 0.0 0.1 1.4 0.4 16.6 4.5 0.2 0.5 5.6 21.0 13.3 8.2 13.1 0.7 1.0 0.0 2.4 0.1 2.6 0.3 0.3 0.3 16.2 11.4 0.5 6.0 5.4 1.0 11.7 1.5 0.5 12.7 0.0 0.0 6.4 2.1 1.6 0.0 5.1 4.1 0.4 0.4 0.8 0.5 0.1 0.5 2.7 0.0 11.9 8.2 0.0 0.4 0.0 43.6 0.1 0.3 0.0 0.2 0.0 0.1 2.2 0.0 0.0 0.0 0.0 10.8 0.0 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 15.2 2.7 0.0 0.0 15.0 0.2 40.5 0.0 5.4 0.0 0.1 0.2 0.0 10.7 0.4 0.0 4.0 4.9 0.0 0.0 0.0 0.0 0.0 14.5 0.0 5.4 1.0 0.0 1.5 0.2 0.2 0.2 0.0 0.1 6.0 0.5 0.3 0.1 0.9 11.7 0.4 1.9 0.2 0.5 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.4 0.1 0.0 0.0 0.8 10.6 22.2 0.0 0.6 0.0 0.0 0.0 17.4 0.0 0.3 46.4 0.0 0.0 0.2 7.9 0.0 0.0 0.3 10.8 14.2 0.0 0.0 0.3 0.0 37.7 0.0 4.8 0.0 0.0 1.6 5.0 0.0 19.1 0.0 0.0 18.4 0.0 60.8 0.0 0.0 3.6 0.0 0.6 24.1 0.2 4.4 19.4 11.5 HOXC11 HOX3H ENSG00000123388 "Homeobox C11" O43248 12 53973126-53977643 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 7.0;skin 1: 9.2" "Group enriched" "Detected in some" 5 "Basal keratinocytes: 6.6;Distal tubular cells: 1.7;Fibroblasts: 2.3;Melanocytes: 3.3;Spermatocytes: 3.8;Suprabasal keratinocytes: 3.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AN3-CA: 23.3;BJ hTERT+: 11.7;HaCaT: 10.3;T-47d: 18.4" "Not detected" "Not detected" "Not detected" "Not detected" HPA038291 Uncertain Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA038291: AB_10674552" "unprognostic (1.50e-3)" "unprognostic (1.93e-2)" "unprognostic (1.14e-2)" "unprognostic (1.51e-1)" "unprognostic (1.93e-3)" "unprognostic (1.17e-2)" "unprognostic (6.90e-3)" "unprognostic (1.32e-2)" "unprognostic (7.41e-3)" "unprognostic (4.46e-3)" "unprognostic (2.25e-1)" "unprognostic (3.26e-3)" "unprognostic (3.99e-2)" "unprognostic (1.06e-1)" "unprognostic (1.82e-1)" 4.8 0.0 0.1 0.1 0.1 0.0 1.2 0.1 0.1 2.5 0.1 0.1 0.1 0.8 2.0 1.0 0.1 0.7 0.1 0.1 0.1 0.0 2.0 0.1 0.1 0.7 0.1 0.1 0.5 0.1 0.0 0.1 0.6 0.3 0.5 0.0 0.1 0.1 2.0 7.0 9.2 2.7 0.4 0.1 0.1 0.0 1.6 0.1 0.5 0.1 0.1 0.1 1.2 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 0.7 0.0 23.3 2.2 3.4 0.0 3.4 11.7 5.0 3.7 0.2 0.9 0.0 0.2 3.2 0.0 10.3 4.4 0.0 2.3 0.6 0.1 0.1 7.6 0.0 0.0 0.1 0.1 0.6 0.9 0.0 0.3 0.0 0.0 0.2 1.0 0.0 3.2 1.4 0.0 0.0 0.0 6.6 0.0 0.0 0.4 0.0 0.4 0.8 0.0 0.1 2.1 5.3 2.0 0.2 18.4 0.0 0.0 0.0 4.0 0.3 0.2 0.0 0.0 0.0 0.0 0.4 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.0 6.6 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.5 3.8 0.2 3.3 0.0 0.0 0.0 0.0 HOXC13 "HOX3, HOX3G" ENSG00000123364 "Homeobox C13" P31276 12 53938765-53946544 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "breast: 4.4;skin 1: 13.5;tongue: 4.1" "Group enriched" "Detected in some" 6 "Basal keratinocytes: 1.4;Spermatogonia: 1.5;Suprabasal keratinocytes: 2.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AN3-CA: 15.7;HaCaT: 33.1;SK-BR-3: 18.3;T-47d: 14.1" "Not detected" "Not detected" "Not detected" "Not detected" HPA051634 Enhanced NA NA "HPA051634: AB_2616459" "unprognostic (5.16e-3)" "unprognostic (1.46e-1)" "unprognostic (1.29e-1)" "unprognostic (2.27e-3)" "unprognostic (2.78e-2)" "unprognostic (1.20e-1)" "unprognostic (2.20e-1)" "unprognostic (4.04e-2)" "unprognostic (1.53e-1)" "unprognostic (9.77e-2)" "unprognostic (9.74e-9)" "unprognostic (2.41e-1)" "unprognostic (1.41e-1)" "unprognostic (1.68e-1)" 2.6 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.3 0.4 0.5 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.9 0.0 0.0 2.5 0.0 0.6 13.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 4.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.6 5.2 0.0 15.7 0.2 0.0 9.4 1.0 2.2 1.4 0.8 1.3 0.2 0.0 0.2 0.0 1.0 33.1 4.0 1.0 0.8 0.0 3.2 0.0 4.3 0.0 0.0 0.0 3.3 0.0 7.8 0.0 3.1 0.0 0.0 0.0 5.6 0.0 5.8 9.7 0.0 0.0 0.1 3.2 1.3 0.0 0.2 0.0 0.0 2.9 0.0 0.0 5.2 18.3 2.4 3.9 14.1 0.0 0.0 0.0 6.8 0.1 2.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 2.0 0.1 0.0 0.0 0.0 HOXD11 "HOX4, HOX4F" ENSG00000128713 "Homeobox D11" P31277 2 176104216-176109754 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "endometrium 1: 15.8" "Group enriched" "Detected in some" 4 "Basal glandular cells: 21.0;Collecting duct cells: 21.0;Distal tubular cells: 8.3;Glandular cells: 6.3;Intestinal endocrine cells: 19.9;Mucus-secreting cells: 8.7;Undifferentiated cells: 6.0;Urothelial cells: 11.2" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEK 293: 20.8;RPTEC TERT1: 2.6;SCLC-21H: 6.3;SiHa: 2.5;U-251 MG: 4.7" "Not detected" "Not detected" "Not detected" "Not detected" HPA055155 Supported Nucleoplasm NA NA Nucleoplasm "HPA055155: AB_2682719" "unprognostic (1.99e-1)" "unprognostic (1.48e-1)" "unprognostic (2.32e-2)" "unprognostic (9.05e-2)" "unprognostic (1.85e-3)" "unprognostic (2.48e-1)" "unprognostic (1.93e-2)" "unprognostic (2.13e-2)" "unprognostic (6.73e-2)" "unprognostic (5.00e-2)" "unprognostic (2.11e-8)" "unprognostic (2.09e-3)" "unprognostic (2.49e-2)" "unprognostic (2.27e-3)" 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 5.4 4.2 0.0 0.0 0.0 15.8 0.4 0.3 0.1 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 1.6 0.3 5.7 0.9 0.0 0.0 2.9 0.0 0.2 0.0 1.7 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 1.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.4 1.3 0.0 0.0 0.1 0.0 20.8 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.3 6.3 0.3 2.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 21.0 0.3 0.0 0.2 0.0 0.0 0.0 21.0 0.0 0.0 8.3 0.0 0.0 0.2 1.0 0.0 0.0 0.1 0.9 6.3 0.0 0.0 0.3 0.0 19.9 0.0 0.0 0.0 0.9 0.0 1.7 0.0 8.7 0.0 0.1 2.9 1.1 0.2 0.0 0.0 0.1 0.0 0.3 0.6 0.0 0.0 6.0 11.2 HOXD13 "HOX4I, SPD" ENSG00000128714 "Homeobox D13" P35453 2 176092891-176095938 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "cervix, uterine: 14.0;intestine: 13.1;prostate: 13.8;seminal vesicle: 19.0;vagina: 15.0" "Cell type enhanced" "Detected in some" 20 "Basal glandular cells: 10.8;Intestinal endocrine cells: 28.0;Mucus-secreting cells: 11.6;Undifferentiated cells: 8.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HAP1: 9.8;HEK 293: 28.1;HL-60: 31.2;JURKAT: 8.8;NB-4: 18.6;SCLC-21H: 8.2" "Not detected" "Not detected" "Not detected" "Not detected" HPA064064 Approved Nucleoplasm NA NA Nucleoplasm "HPA064064: AB_2685186" "unprognostic (2.04e-1)" "unprognostic (1.13e-1)" "prognostic unfavorable (6.95e-5)" "unprognostic (2.52e-3)" "unprognostic (7.25e-2)" "unprognostic (2.08e-2)" "unprognostic (4.62e-2)" "unprognostic (1.77e-1)" "unprognostic (4.66e-1)" "unprognostic (1.01e-2)" "unprognostic (2.82e-4)" "unprognostic (4.95e-2)" "unprognostic (3.70e-2)" "unprognostic (9.98e-3)" 0.4 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 14.0 13.1 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.1 13.8 8.8 0.1 0.1 19.0 0.6 0.0 0.1 3.7 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 3.8 15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 1.2 2.6 0.0 0.0 0.0 0.0 0.0 2.7 0.0 9.8 0.0 1.5 0.0 28.1 4.2 0.0 0.0 0.0 31.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.8 2.0 0.0 0.0 0.0 0.0 18.6 1.0 0.0 1.5 0.0 0.1 0.0 0.0 0.2 8.2 2.0 1.9 0.0 4.5 0.1 0.0 0.0 0.0 1.0 0.0 0.4 2.6 0.0 0.0 0.0 1.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 10.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 28.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 11.6 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 8.3 5.5 HRAS HRAS1 ENSG00000174775 "HRas proto-oncogene, GTPase" P01112 11 532242-537287 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002015, HPA049830, HPA070222" Approved Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB002015: , HPA049830: AB_2680903, HPA070222: " "unprognostic (3.06e-2)" "unprognostic (2.98e-2)" "unprognostic (7.01e-2)" "unprognostic (3.08e-3)" "unprognostic (3.49e-3)" "unprognostic (3.87e-1)" "prognostic unfavorable (2.32e-4)" "unprognostic (1.07e-1)" "unprognostic (2.25e-1)" "unprognostic (1.50e-1)" "unprognostic (2.88e-3)" "unprognostic (9.85e-2)" "unprognostic (2.81e-1)" "unprognostic (1.85e-1)" "unprognostic (1.80e-1)" "unprognostic (1.58e-2)" "unprognostic (1.38e-1)" 12.3 11.4 25.2 9.1 34.5 5.0 16.2 16.1 25.3 7.9 9.5 8.1 10.8 8.9 6.2 9.2 22.3 8.3 10.9 28.7 22.2 22.4 8.2 6.5 8.9 8.0 23.2 12.9 7.7 9.7 11.7 10.3 10.1 15.0 10.0 6.2 8.2 10.1 12.7 51.8 32.0 8.2 8.4 17.0 6.5 7.2 6.1 11.0 5.9 8.1 24.5 9.3 9.9 19.8 2.1 1.1 0.7 4.6 0.1 2.0 0.3 22.1 19.7 9.4 8.4 5.8 4.1 12.2 11.0 5.9 17.4 14.8 9.9 8.8 8.6 3.4 15.0 12.3 17.6 10.0 26.8 4.9 7.0 22.4 4.4 7.9 8.6 8.9 3.5 3.4 6.3 30.0 9.4 10.2 3.6 8.6 7.2 8.9 12.5 9.7 18.2 12.9 12.2 9.6 7.7 19.5 10.3 11.9 7.6 9.7 5.5 36.7 14.6 10.3 18.3 7.9 5.9 15.0 6.8 13.7 15.5 12.2 5.7 14.2 4.6 6.2 6.5 14.6 6.4 14.5 0.0 0.6 0.7 1.4 1.2 1.6 0.8 1.4 1.3 0.7 2.1 2.0 0.6 0.0 0.1 4.6 1.1 2.0 0.3 25.2 34.5 16.1 21.1 22.2 22.4 23.2 12.9 15.0 11.0 11.9 12.5 12.6 82.5 116.5 44.6 21.9 15.3 17.4 4.5 33.2 17.7 72.6 63.0 32.7 1.1 22.2 44.1 0.0 32.3 45.3 34.0 46.2 2.3 13.4 33.9 46.1 28.2 19.0 7.6 5.2 15.8 17.6 60.8 16.2 22.1 28.3 35.8 21.0 21.5 42.9 29.1 32.3 38.7 4.7 23.4 127.5 65.3 12.2 21.3 96.6 HSP90AA1 "FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA" ENSG00000080824 "Heat shock protein 90 alpha family class A member 1" P07900 14 102080738-102139699 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "vagina: 519.3" "Cell type enhanced" "Detected in all" 5 "Basal glandular cells: 6915.7;Urothelial cells: 5558.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002058 Approved Supported Cytosol NA NA 94000000 Cytosol "CAB002058: " "prognostic unfavorable (5.59e-4)" "unprognostic (3.77e-2)" "unprognostic (1.78e-2)" "unprognostic (9.25e-2)" "unprognostic (2.53e-1)" "unprognostic (1.05e-3)" "prognostic unfavorable (3.09e-5)" "unprognostic (7.79e-3)" "unprognostic (5.71e-2)" "unprognostic (7.81e-3)" "unprognostic (3.68e-2)" "unprognostic (1.65e-2)" "prognostic favorable (1.18e-5)" "unprognostic (1.04e-1)" "unprognostic (2.54e-1)" "unprognostic (1.43e-1)" "unprognostic (1.12e-1)" 50.8 75.3 96.1 46.7 106.8 64.1 118.6 81.3 113.4 51.0 47.3 50.7 43.0 31.0 40.7 55.5 40.9 94.7 61.0 70.9 99.6 113.3 75.6 62.5 51.7 48.1 134.4 58.6 53.4 40.1 94.9 121.6 67.2 143.6 63.2 53.3 23.4 57.0 57.0 65.2 35.6 38.9 51.0 139.7 35.7 41.3 84.6 132.7 53.5 91.5 34.3 59.5 54.2 519.3 30.7 46.9 31.8 29.9 57.7 63.1 21.9 86.8 118.8 75.9 52.3 46.1 39.0 100.8 96.7 46.5 118.6 66.9 72.1 81.6 106.8 91.1 62.1 77.8 96.5 217.7 94.5 216.3 80.8 71.7 82.4 67.9 92.0 22.8 122.7 63.6 36.6 40.2 75.8 27.9 74.2 65.4 115.4 113.8 54.9 107.3 117.4 131.1 56.4 78.8 160.2 112.4 126.5 103.1 46.1 68.8 112.3 100.0 72.2 122.2 92.0 53.9 132.9 118.3 49.0 46.2 83.0 53.7 123.3 183.5 52.0 162.1 158.0 78.5 75.9 99.9 31.8 19.9 24.0 47.8 29.9 63.1 29.6 40.5 49.0 23.9 30.7 30.1 43.5 13.5 57.7 27.5 46.9 39.2 21.9 96.1 106.8 81.3 102.7 99.6 113.3 134.4 58.6 143.6 132.7 1057.1 642.7 718.4 6915.7 1191.0 1040.4 2043.0 677.7 2973.9 1019.1 486.8 1981.1 1152.8 290.1 998.3 319.6 818.5 645.6 934.5 749.7 1610.0 1217.1 2796.5 903.1 527.2 1188.6 683.3 908.6 338.8 568.8 289.5 677.7 1578.9 1233.2 998.3 507.2 1211.6 739.1 659.3 679.6 610.3 3287.9 608.0 1393.6 3574.3 1881.8 973.5 1714.6 761.4 693.9 5558.4 HSP90AB1 "HSPC2, HSPCB" ENSG00000096384 "Heat shock protein 90 alpha family class B member 1" P08238 6 44246166-44253888 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Stress response" Chaperone "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Basal glandular cells: 3438.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005230, HPA055729, HPA072606, HPA074351" Enhanced Supported Cytosol "Intracellular and membrane" NA Yes 62000000 Cytosol "CAB005230: AB_2121392, HPA055729: AB_2682899, HPA072606: AB_2732203, HPA074351: AB_2732252" "unprognostic (6.12e-3)" "unprognostic (2.96e-3)" "unprognostic (4.72e-2)" "unprognostic (9.24e-2)" "unprognostic (4.20e-1)" "unprognostic (1.15e-3)" "unprognostic (1.76e-3)" "unprognostic (2.74e-1)" "unprognostic (7.97e-2)" "prognostic favorable (4.03e-4)" "unprognostic (1.31e-1)" "unprognostic (1.60e-1)" "prognostic unfavorable (9.94e-4)" "unprognostic (3.02e-1)" "unprognostic (9.53e-2)" "unprognostic (2.63e-1)" "unprognostic (1.06e-1)" 79.9 116.1 88.0 65.9 105.0 74.6 107.8 92.1 118.2 92.3 60.4 61.7 80.9 40.6 113.3 107.6 71.6 138.4 63.8 115.0 89.0 110.5 72.0 70.7 76.2 73.8 109.7 94.4 238.4 113.9 151.6 95.3 83.6 133.7 93.5 76.4 52.7 64.8 100.3 197.1 67.9 49.0 102.1 93.9 57.5 77.3 45.9 100.2 58.3 133.8 89.8 102.5 86.2 223.4 75.9 50.5 7.2 45.7 55.7 82.5 74.9 135.6 87.0 77.3 95.0 53.1 55.6 81.0 61.3 60.1 113.6 80.0 130.1 41.6 173.8 66.5 63.8 115.6 79.1 188.1 91.3 140.6 57.5 76.1 135.2 49.3 170.0 38.5 135.0 93.7 51.4 61.8 89.2 77.1 99.7 108.6 89.9 180.5 64.9 77.2 137.0 112.4 81.4 90.2 251.8 66.7 108.5 79.1 95.4 76.8 82.5 113.3 69.2 47.6 69.1 86.0 109.7 89.8 67.6 68.1 67.8 113.5 55.4 140.0 75.2 117.8 313.9 73.7 99.3 77.2 7.2 30.2 6.8 49.3 45.7 82.5 75.9 55.2 56.4 50.5 63.2 75.2 71.3 3.7 55.7 43.3 31.4 42.6 74.9 88.0 105.0 92.1 118.2 89.0 110.5 109.7 94.4 133.7 100.2 833.7 606.4 539.1 3438.1 940.9 289.3 1217.7 456.0 1493.6 1074.9 347.2 214.0 960.1 618.4 836.0 145.7 761.3 375.2 163.5 596.7 897.4 930.6 1319.6 967.8 307.7 711.8 321.0 544.1 275.6 256.9 156.5 635.1 727.9 698.5 738.6 374.5 296.6 721.4 313.4 574.6 560.9 223.5 342.8 894.3 197.9 740.6 807.2 939.3 460.3 567.6 2341.3 IDH1 ENSG00000138413 "Isocitrate dehydrogenase (NADP(+)) 1, cytosolic" O75874 2 208236227-208266074 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cytotrophoblasts: 277.8;Hepatocytes: 306.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 107.6;RT4: 75.1" "Low region specificity" "Detected in all" "CAB033218, HPA035248, HPA057936, CAB062556" Enhanced Approved "Nuclear bodies,Cytosol" NA NA 16000000 "Nuclear bodies, Cytosol" "CAB033218: AB_2123166, CAB062556: AB_2665593, HPA035248: AB_10600714, HPA057936: AB_2683559" "unprognostic (2.79e-1)" "unprognostic (1.00e-1)" "unprognostic (1.02e-1)" "unprognostic (2.47e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "prognostic unfavorable (6.93e-5)" "unprognostic (3.32e-1)" "unprognostic (2.20e-3)" "unprognostic (8.03e-2)" "unprognostic (5.54e-2)" "unprognostic (4.18e-3)" "prognostic unfavorable (2.45e-5)" "unprognostic (2.09e-1)" "unprognostic (1.77e-1)" "unprognostic (1.13e-1)" "unprognostic (2.69e-2)" 41.3 82.3 6.2 8.8 7.0 1.3 20.9 6.5 8.3 12.6 35.2 8.7 38.0 30.6 8.0 29.9 30.3 8.8 18.7 10.8 6.3 6.2 20.5 91.0 19.8 14.3 8.1 4.7 19.4 21.5 4.8 6.2 24.1 8.7 38.5 23.1 15.4 18.7 39.0 4.7 7.4 54.1 10.1 9.3 21.3 20.4 15.6 8.4 3.5 7.9 11.0 11.9 43.4 12.1 4.9 22.8 6.4 31.6 7.4 6.6 12.0 9.5 16.1 23.0 9.3 41.8 29.9 13.1 4.0 18.3 6.7 16.4 25.4 23.4 1.9 25.4 12.4 28.6 14.8 16.5 19.3 6.5 1.3 6.2 8.2 13.2 107.6 55.7 5.3 8.2 25.7 41.0 15.4 11.2 10.7 18.5 5.6 8.2 6.6 10.3 6.1 3.8 9.2 42.0 68.5 6.6 3.6 8.4 5.4 30.4 75.1 3.9 6.9 15.2 14.7 49.7 25.4 5.6 15.7 12.2 6.9 6.9 9.7 4.3 3.2 5.0 2.5 22.2 32.5 5.5 5.7 31.6 4.8 4.5 14.5 5.1 4.9 4.0 5.3 22.8 4.9 3.3 3.9 6.4 7.4 6.5 8.4 6.6 12.0 6.2 7.0 6.5 8.3 6.3 6.2 8.1 4.7 8.7 8.4 11.9 38.0 25.9 15.5 11.0 19.3 16.8 58.6 14.7 27.3 27.9 23.6 277.8 18.3 23.8 6.9 15.5 112.0 0.0 76.5 152.3 23.7 78.5 13.9 306.5 146.5 11.1 56.1 41.1 109.5 7.7 22.7 46.5 25.3 53.3 85.9 26.7 42.8 52.6 27.6 74.2 45.5 12.9 12.2 7.7 30.8 13.0 80.0 16.0 106.9 38.2 IDH2 ENSG00000182054 "Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial" P48735 15 90083045-90102504 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 126.2;skeletal muscle: 190.7" "Cell type enhanced" "Detected in many" 8 "Cytotrophoblasts: 682.3;Distal tubular cells: 989.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MOLT-4: 69.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007831 Enhanced Supported Mitochondria NA NA 53000000 Mitochondria "HPA007831: AB_1851397" "unprognostic (2.45e-2)" "prognostic favorable (5.15e-5)" "unprognostic (2.92e-1)" "unprognostic (1.53e-1)" "unprognostic (3.53e-1)" "unprognostic (8.46e-2)" "unprognostic (3.83e-2)" "unprognostic (2.55e-3)" "unprognostic (1.86e-2)" "unprognostic (1.89e-2)" "unprognostic (2.76e-1)" "unprognostic (4.90e-2)" "unprognostic (2.19e-3)" "unprognostic (3.92e-3)" "unprognostic (4.46e-1)" "unprognostic (1.30e-2)" "unprognostic (2.58e-2)" 5.4 2.0 14.9 10.1 16.6 22.6 8.8 4.9 19.1 6.4 16.2 13.8 12.4 16.1 5.9 15.3 23.7 6.0 9.4 126.2 10.2 9.3 25.0 93.2 6.9 15.8 14.4 12.0 3.0 25.1 8.4 3.3 15.1 11.9 13.3 14.5 6.0 28.0 21.9 190.7 11.0 13.9 15.8 11.0 7.5 27.9 1.2 7.6 28.2 3.4 69.0 13.6 11.0 8.6 16.8 32.8 17.2 56.3 22.2 29.5 31.2 10.3 5.9 30.6 30.3 4.3 5.2 26.0 13.0 19.8 12.3 13.2 2.8 9.0 12.3 3.7 10.7 11.7 3.6 4.4 3.9 5.8 24.2 2.9 21.0 2.2 20.6 5.2 14.4 21.3 11.0 2.2 2.9 2.3 14.9 25.1 43.6 3.1 10.6 9.4 30.2 69.1 22.4 9.1 14.2 2.4 58.6 21.9 36.7 18.9 12.5 44.1 22.4 16.1 64.4 5.2 17.8 51.9 44.5 6.0 21.9 3.2 2.8 6.0 17.5 3.2 1.4 7.0 30.3 12.6 9.0 26.4 17.2 26.1 48.0 12.4 16.8 18.7 29.5 32.8 9.8 10.2 18.2 5.1 22.2 56.3 17.8 15.9 31.2 14.9 16.6 4.9 19.1 10.2 9.3 14.4 12.0 11.9 7.6 6.0 21.8 67.0 66.5 35.4 5.3 402.1 104.4 56.2 21.6 71.5 9.8 682.3 989.8 188.2 4.7 25.3 53.5 23.3 255.6 386.0 36.6 189.5 30.1 240.4 229.9 9.5 59.3 41.1 60.4 2.5 13.0 70.5 55.6 96.4 122.1 17.5 127.7 132.1 33.2 128.5 5.1 12.9 38.3 0.5 4.5 58.6 479.2 123.2 268.2 90.1 IKBKB "IKK-beta, IKK2, IKKB, NFKBIKB" ENSG00000104365 "Inhibitor of nuclear factor kappa B kinase subunit beta" O14920 8 42271302-42332653 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Cone photoreceptor cells: 127.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001249, CAB004447" Enhanced Supported Cytosol NA NA Cytosol "CAB004447: AB_627785, HPA001249: AB_1079126" "unprognostic (1.04e-1)" "unprognostic (2.30e-2)" "unprognostic (1.31e-1)" "unprognostic (1.73e-3)" "unprognostic (1.26e-1)" "unprognostic (1.27e-3)" "unprognostic (1.95e-1)" "unprognostic (1.25e-3)" "unprognostic (1.75e-1)" "unprognostic (1.55e-1)" "unprognostic (3.27e-1)" "unprognostic (1.73e-1)" "unprognostic (1.20e-2)" "unprognostic (1.89e-2)" "unprognostic (9.20e-2)" "unprognostic (3.02e-1)" "prognostic favorable (1.46e-6)" 9.1 10.8 10.9 17.0 16.7 9.3 10.0 26.1 16.9 10.3 10.3 12.4 11.4 4.7 15.3 13.2 17.9 16.4 14.9 7.9 13.1 6.9 12.4 9.9 14.9 12.2 20.3 7.9 9.6 13.3 18.0 13.6 11.2 11.9 14.0 10.9 10.5 11.4 9.7 17.6 22.2 9.8 16.4 10.5 18.7 10.8 8.3 18.6 12.9 14.3 8.4 17.1 18.1 12.8 12.6 14.8 14.1 9.6 11.9 11.2 5.8 3.6 12.9 3.7 6.3 14.3 12.4 4.7 3.2 11.3 9.5 8.4 2.9 6.7 7.1 5.5 8.8 9.0 4.1 5.0 12.7 12.3 6.9 5.7 9.9 6.0 2.3 10.9 1.9 10.4 8.2 9.7 9.1 14.2 18.7 14.0 4.7 8.4 3.5 20.8 4.1 6.9 3.1 3.6 11.8 4.1 7.1 6.3 4.1 10.7 3.3 1.1 2.1 2.0 3.6 5.2 6.9 4.8 8.3 7.2 6.7 3.5 5.2 2.3 2.1 2.1 5.0 7.9 4.7 7.6 14.1 9.6 10.4 10.1 7.6 10.3 9.4 10.5 11.2 8.9 12.6 10.2 10.4 11.4 11.9 9.0 14.8 9.9 5.8 10.9 16.7 26.1 16.9 13.1 6.9 20.3 7.9 11.9 18.6 11.9 24.0 17.7 29.3 21.6 11.3 4.5 15.3 14.7 13.6 15.7 127.6 8.6 1.7 11.4 2.0 27.7 11.8 0.0 11.8 4.6 9.8 23.2 36.9 10.2 15.8 17.5 10.9 15.4 26.9 3.0 15.3 17.7 18.6 13.6 15.1 11.6 13.3 14.4 12.0 4.8 52.3 6.5 6.4 2.6 6.4 25.5 12.7 20.3 13.6 25.7 IKZF1 "hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1" ENSG00000185811 "IKAROS family zinc finger 1" Q13422 7 50304068-50405101 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Cell cycle, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 28.7;bone marrow: 55.2;lymphoid tissue: 86.7" "Cell type enhanced" "Detected in many" 11 "B-cells: 46.7;Kupffer cells: 47.2;Macrophages: 43.8;monocytes: 70.3;T-cells: 103.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 26.9;HDLM-2: 45.8;HMC-1: 42.9;JURKAT: 26.3;MOLT-4: 33.5;REH: 36.3;U-698: 68.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB009247, HPA035221, HPA035222" Enhanced Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB009247: AB_2124699, HPA035221: AB_2674524, HPA035222: AB_2674525" "prognostic favorable (4.28e-4)" "prognostic favorable (2.02e-4)" "unprognostic (2.49e-3)" "unprognostic (2.41e-3)" "unprognostic (5.59e-1)" "prognostic favorable (8.63e-4)" "unprognostic (1.45e-2)" "unprognostic (1.37e-2)" "unprognostic (1.15e-2)" "unprognostic (2.43e-1)" "unprognostic (6.63e-2)" "unprognostic (2.95e-1)" "unprognostic (1.69e-3)" "unprognostic (1.71e-1)" "unprognostic (2.84e-2)" "unprognostic (6.77e-2)" "unprognostic (4.67e-2)" 3.5 1.5 2.9 25.5 3.8 55.2 2.3 0.7 1.8 1.6 3.6 2.8 0.8 2.4 1.6 2.1 2.2 2.4 2.9 1.6 3.4 1.8 2.5 2.3 8.3 44.4 5.9 1.1 1.1 1.3 0.2 1.2 1.2 3.4 2.2 2.5 1.5 5.2 0.7 0.9 1.9 14.5 1.4 5.1 31.0 3.7 1.1 4.1 86.7 2.4 1.2 26.3 4.5 2.9 24.0 12.6 12.8 23.6 12.8 28.7 12.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 45.8 0.0 9.2 0.0 0.0 0.0 16.3 42.9 0.0 0.0 0.0 0.0 0.0 0.0 26.3 11.9 3.2 0.0 0.0 33.5 16.2 0.4 0.0 0.0 36.3 0.0 7.6 0.0 0.0 0.3 0.3 0.1 0.2 0.1 0.0 0.0 22.5 0.0 0.0 0.3 0.0 0.0 14.6 7.5 68.8 0.1 17.7 0.1 10.2 7.7 12.8 20.4 23.6 17.0 24.0 21.2 19.9 8.2 21.3 28.7 20.7 11.2 12.8 22.3 12.6 17.1 12.7 2.9 3.8 0.7 1.8 3.4 1.8 5.9 1.1 3.4 4.1 3.0 16.4 46.7 0.1 2.5 0.0 1.1 5.1 2.7 3.4 1.8 0.0 0.3 0.0 0.1 3.0 2.9 0.0 23.3 0.0 0.2 3.4 0.1 22.0 1.0 27.1 0.0 0.0 4.3 47.2 4.5 0.0 43.8 18.6 70.3 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 2.1 0.0 0.7 2.4 0.6 103.3 0.0 0.1 IL2 "IL-2, TCGF" ENSG00000109471 "Interleukin 2" P60568 4 122451470-122456725 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" "Cytokine, Growth factor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 1.9;intestine: 2.4;lymphoid tissue: 1.9" "Group enriched" "Detected in some" 6 "Melanocytes: 3.3;T-cells: 3.8" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "memory CD4 T-cell: 1.9" "Lineage enriched" "Detected in single" 19 "T-cells: 1.9" "Group enriched" "Detected in some" 19 "JURKAT: 1.7;MOLT-4: 2.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB010310 Uncertain "Secreted to blood" NA NA 20300 "CAB010310: AB_649346" "unprognostic (8.87e-5)" "unprognostic (6.13e-3)" "unprognostic (1.38e-3)" "unprognostic (9.79e-3)" "unprognostic (2.56e-2)" "unprognostic (7.32e-2)" "unprognostic (2.06e-5)" "unprognostic (5.21e-3)" "unprognostic (8.01e-2)" 0.6 0.0 0.0 0.6 0.0 0.4 0.5 0.0 0.0 0.9 0.3 0.5 0.1 0.0 0.8 0.6 0.5 0.0 0.0 0.0 0.2 0.3 0.7 1.1 0.0 0.1 0.0 0.0 0.0 0.0 0.4 1.9 0.1 0.0 0.0 0.4 2.4 0.0 0.2 0.8 0.3 0.0 0.4 1.9 0.8 0.4 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 3.8 0.0 0.0 IL21R CD360 ENSG00000103522 "Interleukin 21 receptor" Q9HBE5 16 27402162-27452042 "Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "blood: 17.9;lymphoid tissue: 47.8" "Cell type enhanced" "Detected in some" 10 "B-cells: 11.8;Early spermatids: 5.2;Hofbauer cells: 7.0;T-cells: 8.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "Daudi: 10.3;HDLM-2: 43.9;Karpas-707: 20.4;RH-30: 15.4;RPMI-8226: 24.5;U-266/70: 10.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA042296 Uncertain Uncertain "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "HPA042296: AB_10806236" "unprognostic (2.91e-2)" "unprognostic (2.65e-3)" "unprognostic (6.64e-4)" "unprognostic (1.58e-3)" "unprognostic (2.14e-1)" "prognostic favorable (7.29e-4)" "unprognostic (8.33e-2)" "unprognostic (2.06e-1)" "unprognostic (8.50e-6)" "unprognostic (2.26e-2)" "unprognostic (1.13e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-10)" "unprognostic (8.79e-2)" "unprognostic (4.42e-2)" "unprognostic (1.50e-1)" "unprognostic (9.58e-2)" 0.8 0.6 0.6 33.6 3.7 5.7 0.6 0.5 1.6 0.5 0.9 0.3 0.0 0.5 0.5 1.3 1.0 0.8 1.1 1.8 0.6 2.3 1.6 1.3 5.6 20.9 1.3 0.0 0.5 0.5 0.0 0.9 0.9 1.9 0.9 0.9 1.8 3.7 0.3 0.7 0.7 4.0 0.6 1.7 11.2 1.3 1.0 1.4 47.8 1.3 0.8 31.7 2.7 0.8 11.5 1.6 0.7 17.9 6.3 10.3 4.2 0.0 0.0 0.1 0.1 0.0 0.5 0.3 0.3 0.0 0.0 0.9 0.0 0.0 10.3 0.1 0.8 0.5 0.0 0.0 0.0 0.0 43.9 0.0 2.1 0.0 0.3 1.4 0.0 0.6 1.6 0.0 2.8 0.0 0.3 0.0 0.2 0.1 20.4 1.5 0.0 0.0 0.2 0.3 0.0 0.0 0.1 15.4 24.5 0.0 0.0 0.1 0.0 0.0 0.0 1.1 0.1 0.0 0.5 1.1 0.8 0.3 0.2 0.0 10.3 3.6 2.3 2.1 0.5 0.0 0.2 0.3 0.0 9.8 5.8 3.6 1.0 6.3 10.3 1.6 11.5 6.9 6.7 0.7 6.3 17.9 0.7 7.6 4.2 0.6 3.7 0.5 1.6 0.6 2.3 1.3 0.0 1.9 1.4 0.0 2.2 11.8 0.1 0.3 1.5 2.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.0 5.2 0.6 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 7.0 0.0 0.0 1.3 4.5 4.0 0.0 2.2 1.7 1.0 0.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.9 0.1 0.0 0.6 0.1 8.2 0.0 0.0 IL6ST "CD130, GP130" ENSG00000134352 "Interleukin 6 signal transducer" P40189 5 55935095-55994993 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Host-virus interaction" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 10 "Ito cells: 851.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 21.0" "Lineage enriched" "Detected in many" 5 "T-cells: 21.0" "Cell line enhanced" "Detected in many" "ASC TERT1: 57.7;BJ hTERT+: 58.7;HHSteC: 65.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010558, CAB025784" Approved Supported "Golgi apparatus,Plasma membrane" "Secreted to blood" NA NA 100000000 "Plasma membrane" "Golgi apparatus" "CAB025784: , HPA010558: AB_1078439" "unprognostic (1.81e-2)" "unprognostic (1.25e-1)" "unprognostic (7.61e-2)" "unprognostic (3.95e-2)" "unprognostic (8.93e-2)" "unprognostic (3.99e-2)" "unprognostic (5.18e-2)" "unprognostic (9.53e-3)" "unprognostic (1.89e-2)" "unprognostic (2.29e-1)" "unprognostic (4.78e-2)" "unprognostic (1.59e-1)" "prognostic unfavorable (5.05e-4)" "unprognostic (3.69e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (1.25e-1)" 44.8 34.2 24.7 25.5 23.4 8.8 76.9 15.9 22.9 38.1 23.9 15.0 29.0 8.7 26.1 24.9 22.7 23.1 31.1 31.9 21.9 19.7 37.2 71.2 36.3 70.0 25.8 14.7 42.1 16.4 35.8 36.2 97.0 22.5 31.9 17.1 20.0 26.3 33.0 27.1 12.5 20.6 36.6 33.8 35.5 19.7 13.7 20.3 19.4 37.6 12.5 18.7 33.7 51.1 0.7 2.1 0.9 3.8 0.8 21.0 4.0 9.5 11.9 3.9 9.2 27.6 57.7 15.9 28.5 58.7 15.4 22.9 16.7 9.2 0.3 21.4 17.6 35.0 4.1 3.0 8.5 31.6 0.8 3.1 2.2 9.8 13.7 65.6 0.2 4.6 50.5 4.6 33.4 16.3 22.9 35.1 0.8 1.6 40.2 17.7 1.6 0.4 0.4 0.6 1.2 3.9 0.5 10.8 5.5 8.4 5.6 2.1 3.4 11.5 3.8 11.7 10.7 19.2 1.5 56.4 5.9 6.7 24.1 15.0 9.9 4.2 0.3 15.9 0.4 15.5 0.2 3.8 0.1 0.8 3.5 0.4 0.7 4.9 0.8 2.1 0.6 21.0 5.9 0.9 0.8 0.6 1.8 3.4 4.0 24.7 23.4 15.9 22.9 21.9 19.7 25.8 14.7 22.5 20.3 125.0 112.6 23.8 82.7 92.3 54.8 67.9 140.1 99.0 149.0 64.6 33.4 63.8 6.6 64.2 9.5 210.0 31.1 23.3 53.6 60.1 240.2 110.2 31.3 186.2 46.3 15.9 19.0 851.3 103.7 11.5 98.1 51.0 75.9 21.6 29.0 179.7 66.2 30.6 122.7 46.2 33.9 97.0 142.0 37.1 34.3 73.0 85.1 35.0 13.3 89.2 IL7R CD127 ENSG00000168685 "Interleukin 7 receptor" P16871 5 35852695-35879603 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1" "Group enriched" "Detected in many" 5 "monocytes: 441.0;T-cells: 326.6" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1" "Group enriched" "Detected in many" 33 "NK-cells: 19.1;T-cells: 70.3" "Cell line enhanced" "Detected in many" "BJ: 22.2;BJ hTERT+ SV40 Large T+: 20.1;fHDF/TERT166: 41.6;HBF TERT88: 38.3;REH: 86.5" "Low region specificity" "Detected in single" "Not detected" "Not detected" "CAB010215, HPA067550" Supported "Plasma membrane" "Intracellular and membrane" NA NA 180000 "Plasma membrane" "CAB010215: AB_673727, HPA067550: " "unprognostic (2.93e-3)" "unprognostic (3.38e-2)" "unprognostic (3.82e-3)" "unprognostic (5.58e-3)" "unprognostic (3.06e-2)" "unprognostic (1.74e-1)" "unprognostic (2.51e-3)" "unprognostic (5.53e-2)" "unprognostic (1.12e-1)" "unprognostic (9.29e-3)" "unprognostic (1.43e-1)" "unprognostic (2.69e-1)" "unprognostic (1.76e-2)" "unprognostic (5.64e-2)" "unprognostic (3.27e-3)" "unprognostic (2.22e-1)" "unprognostic (1.78e-1)" 6.7 3.6 0.7 34.0 0.7 3.1 4.8 0.5 0.6 4.8 20.6 0.3 0.9 3.5 1.8 2.9 6.6 3.7 8.5 1.9 0.7 0.7 7.0 2.7 52.6 133.1 0.8 0.1 2.5 1.7 0.0 1.5 1.2 0.8 3.3 5.4 1.7 13.2 1.8 0.9 1.8 34.0 1.2 1.5 32.3 7.8 3.0 0.4 130.9 5.1 5.3 42.9 12.6 4.6 0.4 0.3 1.3 0.2 19.1 70.3 12.7 0.1 0.0 0.1 0.1 0.1 0.1 0.2 22.2 11.2 20.1 11.9 0.1 0.1 2.1 0.0 41.6 3.7 3.5 0.0 1.3 38.3 1.8 0.2 0.6 2.4 0.0 0.3 0.2 1.6 0.3 0.0 4.3 0.9 0.5 0.5 0.1 0.1 0.3 15.7 0.0 0.5 0.2 0.1 0.0 1.0 86.5 1.2 0.1 0.0 1.2 0.0 0.0 3.7 0.3 0.0 0.1 0.1 0.0 1.5 7.9 13.4 3.4 2.9 0.2 0.0 2.5 4.0 2.1 6.1 0.5 0.2 0.1 19.2 0.2 70.3 0.2 39.9 28.0 0.1 0.4 34.5 22.5 1.3 19.1 0.2 0.3 6.7 12.7 0.7 0.7 0.5 0.6 0.7 0.7 0.8 0.1 0.8 0.4 14.9 19.4 10.9 1.9 10.3 0.0 3.2 0.0 10.7 4.5 0.0 0.0 0.1 0.0 0.9 0.1 3.6 0.0 23.3 1.6 0.1 7.1 1.1 18.5 4.5 10.4 0.0 0.0 17.8 12.7 0.0 0.0 79.7 20.3 441.0 0.0 0.0 0.2 0.9 0.0 0.6 0.0 0.0 9.0 0.0 0.0 9.2 0.2 326.6 0.0 3.8 IRF4 "LSIRF, MUM1" ENSG00000137265 "Interferon regulatory factor 4" Q15306 6 391739-411447 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 48.7" "Group enriched" "Detected in some" 6 "Melanocytes: 42.2;monocytes: 92.8" "Cancer enriched" "Detected in many" 9 "melanoma: 27.0" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "memory B-cell: 9.5;myeloid DC: 9.0;naive B-cell: 9.7;plasmacytoid DC: 10.4;T-reg: 4.8" "Group enriched" "Detected in many" 5 "B-cells: 9.7;dendritic cells: 10.4;T-cells: 4.8" "Cell line enhanced" "Detected in some" "HDLM-2: 50.2;Karpas-707: 46.7;RPMI-8226: 45.1;U-266/70: 42.2;U-266/84: 31.4;WM-115: 25.6" "Not detected" "Not detected" "Not detected" "Not detected" "HPA002038, HPA002698, CAB013508" Enhanced Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB013508: , HPA002038: AB_1079148, HPA002698: AB_1851893" "prognostic favorable (6.44e-4)" "unprognostic (1.88e-3)" "unprognostic (1.00e-3)" "unprognostic (1.72e-4)" "unprognostic (2.74e-1)" "prognostic favorable (1.64e-6)" "unprognostic (4.72e-2)" "unprognostic (1.05e-1)" "unprognostic (1.89e-2)" "unprognostic (5.74e-4)" "unprognostic (8.51e-2)" "unprognostic (1.12e-1)" "unprognostic (9.18e-7)" "unprognostic (2.38e-1)" "unprognostic (6.24e-2)" "unprognostic (2.90e-1)" "unprognostic (3.65e-2)" 7.1 0.5 0.4 36.6 0.4 18.4 4.0 0.4 0.4 17.4 13.9 0.1 0.4 5.0 2.2 0.7 6.4 1.2 4.1 1.6 0.4 0.5 1.4 5.6 4.2 31.5 0.5 0.0 1.9 0.7 0.0 0.7 0.5 0.1 1.5 4.8 15.8 21.3 1.9 0.7 4.5 11.1 0.3 0.6 33.8 4.6 1.7 0.1 15.2 1.3 2.4 48.7 8.4 4.2 9.7 10.4 0.0 1.6 0.2 4.8 1.3 0.1 0.0 0.0 0.0 5.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 50.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 5.9 0.0 45.1 0.0 0.0 0.1 0.0 0.0 0.0 7.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 42.2 31.4 13.7 0.0 0.0 25.6 0.0 1.6 0.0 0.6 1.2 0.0 9.5 0.9 0.9 9.0 9.7 1.6 0.7 0.0 0.2 1.2 10.4 4.8 1.3 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.0 0.1 0.1 0.0 4.0 12.0 0.1 7.3 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.6 0.0 0.6 0.2 0.0 0.2 0.2 0.0 0.0 1.8 0.0 0.0 3.1 6.9 42.2 92.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 1.1 3.8 0.1 6.2 0.0 0.0 IRS4 "IRS-4, PY160" ENSG00000133124 "Insulin receptor substrate 4" O14654 X 108732482-108736409 "Cancer-related genes, Predicted intracellular proteins" Transducer "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "pituitary gland: 56.0" "Not detected" "Not detected" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 7 "hypothalamus: 4.6" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEK 293: 14.0;NTERA-2: 1.7;RT4: 4.1;WM-115: 3.1" "Group enriched" "Detected in some" 5 "basal ganglia: 12.8;hypothalamus: 52.4" "Group enriched" "Detected in many" 6 "basal ganglia: 21.5;hypothalamus: 55.3" HPA017372 Uncertain NA NA "HPA017372: AB_2669600" "unprognostic (3.74e-3)" "unprognostic (3.27e-2)" "unprognostic (1.32e-2)" "unprognostic (2.52e-1)" "unprognostic (1.89e-1)" "unprognostic (2.12e-1)" "unprognostic (1.65e-1)" "unprognostic (1.05e-2)" "unprognostic (1.77e-1)" "unprognostic (9.28e-4)" "unprognostic (8.71e-2)" 0.0 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.6 1.9 0.0 0.1 0.3 0.1 2.6 0.3 0.3 0.5 0.0 0.0 0.3 4.6 0.0 0.0 0.1 0.0 0.5 0.1 9.5 0.0 0.0 56.0 0.1 0.6 0.2 0.0 2.7 0.0 0.5 0.0 0.6 0.0 1.0 0.2 0.1 0.5 0.1 0.5 5.1 3.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.3 0.3 4.6 0.5 0.1 0.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ITK "EMT, LYK, PSCTK2" ENSG00000113263 "IL2 inducible T cell kinase" Q08881 5 157142933-157255191 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "blood: 28.0;lymphoid tissue: 60.5" "Cell type enhanced" "Detected in some" 20 "Alveolar cells type 2: 10.4;granulocytes: 32.2;T-cells: 47.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 28 "gdT-cell: 13.8;MAIT T-cell: 9.1;memory CD4 T-cell: 19.5;memory CD8 T-cell: 18.9;naive CD4 T-cell: 28.0;naive CD8 T-cell: 22.8;NK-cell: 9.2;T-reg: 23.1" "Group enriched" "Detected in many" 29 "NK-cells: 9.2;T-cells: 28.0" "Group enriched" "Detected in some" 9 "JURKAT: 36.5;MOLT-4: 13.3" "Low region specificity" "Detected in some" "Not detected" "Not detected" HPA043670 Uncertain "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "HPA043670: " "unprognostic (2.08e-3)" "unprognostic (6.57e-4)" "unprognostic (5.06e-3)" "unprognostic (4.96e-5)" "unprognostic (1.52e-2)" "unprognostic (1.12e-4)" "unprognostic (8.45e-4)" "unprognostic (1.56e-2)" "unprognostic (1.87e-2)" "unprognostic (5.99e-3)" "unprognostic (1.76e-1)" "unprognostic (2.52e-1)" "unprognostic (4.52e-6)" "unprognostic (3.64e-1)" "unprognostic (4.42e-2)" "unprognostic (1.46e-1)" "unprognostic (3.26e-2)" 2.3 0.7 0.5 12.2 0.6 2.5 1.3 1.9 0.5 1.4 3.3 0.0 0.0 0.5 1.2 1.1 1.8 1.4 4.3 0.9 0.5 0.5 1.4 1.2 6.6 60.5 0.9 0.0 0.7 0.7 0.0 0.9 0.1 0.3 1.1 1.3 1.5 3.5 1.1 0.5 1.0 8.9 0.4 1.2 10.7 2.3 1.4 0.0 60.3 1.6 2.7 24.3 4.1 1.3 0.0 0.0 0.4 0.6 9.2 28.0 13.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 2.2 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 36.5 0.0 0.0 0.0 0.0 13.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 13.8 0.0 9.1 0.0 19.5 18.9 0.0 0.0 28.0 22.8 0.4 9.2 0.6 0.0 23.1 13.6 0.5 0.6 1.9 0.5 0.5 0.5 0.9 0.0 0.3 0.0 0.0 10.4 0.0 0.6 2.4 0.0 0.8 0.0 0.0 1.2 1.8 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.0 0.0 0.0 0.5 0.2 32.2 0.6 0.0 0.0 0.0 1.8 0.6 5.5 0.0 1.5 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.1 0.0 0.0 3.0 0.1 47.3 0.0 0.4 JAK1 "JAK1A, JAK1B, JTK3" ENSG00000162434 "Janus kinase 1" P23458 1 64833229-64966504 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 70.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013088 Approved NA NA "CAB013088: " "prognostic favorable (9.63e-4)" "unprognostic (1.24e-1)" "prognostic favorable (2.81e-4)" "unprognostic (5.10e-2)" "unprognostic (1.16e-1)" "unprognostic (4.21e-2)" "unprognostic (1.53e-1)" "unprognostic (7.00e-3)" "unprognostic (8.40e-2)" "unprognostic (7.88e-3)" "unprognostic (1.66e-2)" "unprognostic (8.84e-2)" "prognostic favorable (2.67e-4)" "unprognostic (2.35e-1)" "unprognostic (2.04e-1)" "unprognostic (7.30e-2)" "unprognostic (3.51e-1)" 46.7 20.4 15.5 31.1 16.5 21.2 56.6 24.3 20.4 27.3 27.1 16.3 16.5 13.8 28.2 22.0 27.0 20.7 27.7 27.3 15.3 16.5 31.4 38.3 36.5 61.4 15.6 14.1 33.3 29.1 28.3 39.8 22.9 25.1 26.0 22.2 18.1 19.8 21.3 45.1 29.7 29.3 30.7 16.3 52.7 20.9 17.3 15.0 62.7 29.0 17.9 42.5 37.2 29.3 20.2 15.4 34.9 17.1 68.1 27.5 25.8 11.2 14.6 6.1 0.6 70.7 40.1 7.9 17.5 25.9 14.6 17.2 4.8 6.2 17.1 13.6 31.1 27.2 6.3 4.1 13.5 20.8 22.5 6.6 23.1 7.7 10.4 26.1 8.8 16.1 35.1 18.8 22.0 23.0 17.4 45.4 8.5 8.4 18.3 16.1 6.4 4.8 5.9 4.2 12.9 8.8 6.9 17.6 6.3 37.6 19.8 4.3 12.9 24.0 11.3 10.3 12.7 24.0 5.5 41.2 17.5 7.8 39.6 9.3 11.5 5.2 13.5 16.3 11.7 7.9 31.2 10.9 31.5 22.8 15.2 27.5 20.2 22.0 25.7 15.4 16.1 24.3 20.7 34.9 68.1 17.1 10.5 26.5 25.8 15.5 16.5 24.3 20.4 15.3 16.5 15.6 14.1 25.1 15.0 47.6 79.3 120.3 114.0 103.6 35.7 98.8 79.0 41.5 63.7 106.4 21.6 5.5 36.5 152.3 100.2 130.9 49.5 23.3 184.7 94.8 76.6 173.3 55.4 77.3 52.1 20.6 63.8 178.0 138.0 72.8 88.9 109.3 47.2 252.5 54.9 54.4 180.7 49.2 79.5 61.6 35.1 161.7 144.2 30.5 50.9 145.2 10.2 159.2 38.1 188.3 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5128183 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Kupffer cells: 36.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 40.8" "Lineage enriched" "Detected in all" 4 "granulocytes: 40.8" "Group enriched" "Detected in many" 5 "ASC diff: 19.4;HDLM-2: 27.4;HEL: 56.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" No No Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708" "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 19.8 8.8 11.5 19.0 10.5 19.0 17.7 14.7 14.4 17.8 10.6 7.0 10.3 7.2 14.8 13.6 12.4 13.4 14.6 27.6 10.3 6.7 7.7 5.6 16.1 19.4 7.0 10.5 15.9 6.7 10.1 7.5 12.0 10.0 12.0 7.4 9.4 7.2 7.4 14.4 19.0 12.3 10.4 11.7 21.5 14.1 10.1 9.0 13.6 8.6 6.5 13.5 13.9 15.6 2.1 9.6 40.8 7.5 3.4 2.1 2.5 2.5 1.5 1.5 2.5 19.4 5.0 0.4 3.5 3.0 2.7 1.8 0.1 0.8 0.1 0.8 2.1 2.2 0.9 1.6 2.1 2.0 27.4 0.5 56.1 3.0 0.7 4.0 3.8 2.9 4.1 0.9 1.1 1.8 3.3 2.5 2.0 4.0 6.5 4.8 0.9 0.9 5.4 1.3 1.3 1.7 1.9 2.8 0.8 2.0 1.3 1.7 0.9 1.0 1.5 1.1 1.6 0.8 6.7 5.1 4.1 1.4 4.2 2.4 1.2 2.3 0.5 5.3 1.9 2.0 40.8 7.5 13.4 2.1 7.3 1.7 2.1 1.6 1.2 9.6 1.9 0.9 1.1 7.1 3.4 5.8 3.6 1.6 2.5 11.5 10.5 14.7 14.4 10.3 6.7 7.0 10.5 10.0 9.0 14.9 6.4 6.9 2.8 8.7 7.4 22.0 0.0 5.3 7.9 7.0 7.9 1.8 1.7 3.0 7.4 8.7 3.9 23.3 3.4 0.8 7.0 1.7 13.9 1.6 11.9 7.9 2.9 4.9 36.0 5.3 21.9 27.7 5.0 16.2 4.2 12.2 5.4 14.4 31.5 2.5 11.1 0.0 5.0 14.9 5.7 7.3 2.9 5.0 3.3 4.1 JAK3 "JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK" ENSG00000105639 "Janus kinase 3" P52333 19 17824780-17848071 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "lymphoid tissue: 68.3" "Cell type enhanced" "Detected in many" 7 "B-cells: 18.2;Ito cells: 14.1;Peritubular cells: 13.8;T-cells: 24.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HDLM-2: 20.6;HEL: 9.2;HMC-1: 9.4;Karpas-707: 24.0;U-266/70: 9.3;U-266/84: 13.8;U-937: 14.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA070314 Enhanced Approved "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "HPA070314: AB_2686251" "unprognostic (5.59e-3)" "prognostic favorable (6.42e-5)" "unprognostic (5.71e-2)" "unprognostic (2.34e-1)" "unprognostic (6.13e-3)" "unprognostic (1.11e-3)" "unprognostic (4.21e-2)" "unprognostic (2.60e-1)" "unprognostic (2.38e-2)" "unprognostic (2.36e-1)" "unprognostic (3.58e-2)" "unprognostic (1.94e-1)" "prognostic unfavorable (2.89e-14)" "unprognostic (2.28e-1)" "unprognostic (2.21e-2)" "unprognostic (4.43e-2)" "unprognostic (7.61e-2)" 6.8 1.7 4.0 24.5 8.5 12.0 2.7 2.4 3.1 1.9 2.3 1.0 0.0 2.2 1.7 2.0 2.5 3.5 3.6 4.3 2.7 2.8 3.8 2.0 8.4 68.3 7.5 0.0 11.0 2.0 0.4 2.3 4.1 5.3 3.0 2.4 1.6 6.1 1.5 0.7 1.3 9.5 2.5 8.4 36.1 3.2 1.8 5.8 20.9 3.4 1.7 28.8 5.3 2.4 7.4 4.5 16.9 9.6 8.4 15.0 6.8 0.1 0.3 0.3 1.1 0.4 1.5 0.2 0.5 0.0 0.0 0.1 0.0 0.9 0.4 2.0 0.4 0.3 0.1 0.0 0.2 0.0 20.6 0.0 9.2 0.0 0.8 0.7 0.0 9.4 5.1 0.2 0.0 0.0 0.0 0.2 2.1 0.0 24.0 0.0 0.4 3.6 0.0 0.2 0.5 0.7 4.7 0.0 0.4 0.5 0.0 0.0 0.3 0.1 0.2 0.0 0.1 2.0 1.4 0.4 0.0 0.4 0.0 0.0 9.3 13.8 2.5 0.1 14.0 0.2 1.2 4.9 0.2 12.6 9.6 14.5 6.5 15.0 13.1 4.5 7.4 14.9 13.0 16.9 8.4 8.8 3.7 11.8 6.8 4.0 8.5 2.4 3.1 2.7 2.8 7.5 0.0 5.3 5.8 0.0 5.8 18.2 0.5 0.7 0.3 1.4 0.0 0.0 1.2 1.8 0.0 0.9 0.0 0.6 1.0 5.8 0.0 0.0 0.3 0.7 2.3 0.2 4.7 0.0 11.5 0.0 0.0 14.1 10.8 0.9 11.5 3.5 3.3 12.6 0.0 0.8 0.4 0.0 13.8 0.1 0.5 6.5 2.1 0.3 0.7 0.9 1.1 24.5 0.0 0.5 JUN "AP-1, c-Jun" ENSG00000177606 "Jun proto-oncogene, AP-1 transcription factor subunit" P05412 1 58780788-58784327 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RH-30: 71.6" "Low region specificity" "Detected in all" "CAB003801, CAB007780, HPA031174, HPA059474" Enhanced Enhanced Nucleoplasm Yes No Nucleoplasm "CAB003801: AB_365485, CAB007780: AB_562268, HPA031174: , HPA059474: AB_2684030" "unprognostic (2.06e-2)" "unprognostic (1.76e-2)" "unprognostic (1.34e-1)" "unprognostic (7.85e-2)" "unprognostic (1.60e-1)" "unprognostic (1.70e-1)" "unprognostic (4.11e-2)" "unprognostic (5.21e-2)" "unprognostic (1.24e-1)" "unprognostic (5.00e-2)" "unprognostic (2.14e-1)" "unprognostic (2.82e-1)" "unprognostic (5.15e-2)" "unprognostic (1.45e-1)" "unprognostic (2.83e-1)" "unprognostic (2.37e-1)" "unprognostic (2.81e-3)" 64.5 29.4 26.7 33.7 17.2 68.4 61.7 19.5 20.6 60.0 32.7 30.8 28.4 13.3 40.5 21.8 34.1 72.6 48.5 31.3 20.2 12.4 21.2 39.3 55.1 14.3 15.3 12.0 49.8 48.7 15.0 16.7 21.6 24.1 48.6 16.7 40.5 59.4 39.3 32.2 51.3 28.6 40.7 17.6 22.9 47.0 18.2 18.1 9.0 61.0 35.2 23.3 41.5 33.1 7.4 1.3 4.0 5.1 3.2 2.5 1.2 16.1 2.3 5.2 1.0 8.3 9.5 0.1 20.6 7.5 14.6 8.9 4.2 1.2 0.6 9.9 12.8 31.6 5.6 0.4 6.7 9.3 12.8 37.5 0.2 0.9 4.7 6.9 1.1 3.7 10.2 17.3 18.8 7.9 6.6 10.9 0.7 5.7 9.4 5.6 3.0 1.0 9.0 4.2 7.8 14.7 0.4 71.6 3.2 13.7 1.5 14.5 4.2 14.3 15.0 6.0 5.9 5.3 0.6 19.1 33.3 15.1 12.0 25.8 20.9 3.3 1.2 34.8 2.1 9.5 1.2 5.1 2.0 2.4 1.1 1.3 4.1 1.2 2.5 1.3 7.4 0.3 1.7 4.0 3.2 0.4 0.2 0.9 1.2 26.7 17.2 19.5 20.6 20.2 12.4 15.3 12.0 24.1 18.1 500.2 627.8 505.0 717.3 1097.5 107.5 1349.5 494.3 76.3 282.1 99.5 247.4 529.1 43.1 569.2 40.2 960.8 1411.6 46.7 449.9 86.5 867.7 1920.0 529.9 118.4 560.4 82.6 1440.1 352.4 430.2 18.1 1136.5 481.3 718.7 237.2 1907.1 688.6 543.7 1520.1 243.3 25.0 400.6 1513.4 1714.3 15.6 13.8 843.0 347.6 518.9 938.7 449.9 KAT6A "MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220" ENSG00000083168 "Lysine acetyltransferase 6A" Q92794 8 41929479-42051990 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase" "Cancer-related genes, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017023, HPA063266, HPA065052" Supported Approved "Nucleoli,Nuclear speckles,Cytosol" NA NA "Nuclear speckles" "Nucleoli, Cytosol" "CAB017023: , HPA063266: AB_2684973, HPA065052: AB_2685414" "unprognostic (3.51e-2)" "unprognostic (1.14e-1)" "unprognostic (2.04e-1)" "unprognostic (3.23e-2)" "unprognostic (2.28e-1)" "unprognostic (9.27e-3)" "unprognostic (3.61e-1)" "unprognostic (2.29e-1)" "unprognostic (2.95e-1)" "unprognostic (2.45e-2)" "unprognostic (1.50e-1)" "unprognostic (4.45e-2)" "unprognostic (4.20e-3)" "unprognostic (1.18e-1)" "unprognostic (2.24e-1)" "unprognostic (8.58e-2)" "unprognostic (2.95e-2)" 20.8 10.9 15.3 19.8 20.3 36.8 22.6 29.9 18.7 19.7 14.6 19.4 14.4 10.7 20.6 12.1 16.9 16.5 14.3 13.0 15.5 11.5 12.3 13.6 26.9 28.2 23.2 10.3 27.2 13.1 26.8 22.3 20.9 15.7 14.1 12.0 12.8 15.1 17.0 21.0 25.5 18.0 25.0 22.9 20.4 14.0 14.1 21.7 30.4 17.9 14.3 20.1 16.9 24.2 4.7 1.8 10.9 1.6 3.1 3.9 1.4 13.1 10.8 17.8 11.3 10.0 11.4 6.0 8.8 11.5 10.9 8.5 6.8 6.3 19.5 8.9 8.7 10.6 8.5 13.8 8.4 13.0 10.0 8.1 28.1 6.7 5.1 7.5 14.8 12.9 9.5 9.6 10.1 12.6 8.0 10.5 17.3 23.5 12.4 10.0 5.8 30.0 4.7 6.8 9.9 4.3 24.0 19.9 6.2 5.4 15.1 11.1 9.5 10.3 6.9 7.1 8.4 15.9 6.5 12.2 13.5 9.6 12.0 9.4 10.1 16.4 21.2 7.3 6.7 11.6 3.5 1.6 2.8 3.5 1.2 3.9 2.4 2.6 3.3 1.0 4.7 3.6 2.9 10.9 3.1 1.2 1.8 3.5 1.4 15.3 20.3 29.9 18.7 15.5 11.5 23.2 10.3 15.7 21.7 32.8 30.4 27.2 23.8 44.8 44.6 22.6 25.5 21.4 30.7 12.2 51.1 12.1 3.3 11.8 1.8 50.4 18.7 46.7 10.4 13.1 28.5 21.6 33.6 22.2 14.6 55.6 23.7 43.0 37.4 3.5 26.2 31.3 21.9 8.2 25.7 32.4 13.2 17.5 21.5 9.3 45.4 19.4 33.9 41.9 36.2 53.4 17.6 45.8 18.9 26.1 KAT6B "Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B" ENSG00000156650 "Lysine acetyltransferase 6B" Q8WYB5 10 74825582-75032622 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "PC-3: 22.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006104 Supported Approved "Nucleoplasm,Nuclear bodies" NA NA "Nucleoplasm, Nuclear bodies" "HPA006104: AB_1079445" "unprognostic (4.17e-1)" "unprognostic (1.98e-1)" "unprognostic (1.82e-1)" "unprognostic (2.32e-2)" "unprognostic (7.83e-2)" "unprognostic (2.85e-2)" "unprognostic (3.56e-1)" "unprognostic (2.62e-1)" "unprognostic (2.54e-1)" "unprognostic (1.09e-1)" "unprognostic (9.47e-2)" "unprognostic (8.78e-2)" "prognostic favorable (4.82e-4)" "unprognostic (2.52e-1)" "unprognostic (3.70e-1)" "unprognostic (2.59e-2)" "unprognostic (3.15e-1)" 11.6 9.5 11.1 13.2 11.9 15.1 12.4 19.0 11.6 16.7 12.2 13.3 15.3 7.2 25.1 13.0 12.0 13.2 12.0 10.0 10.6 9.5 9.0 7.3 9.2 9.0 9.0 9.9 24.6 13.3 24.8 31.1 9.4 8.9 13.5 9.6 10.1 17.9 12.0 15.3 10.6 11.3 16.2 9.3 10.4 13.0 12.8 12.1 26.6 13.0 8.9 12.5 14.3 12.7 3.2 1.9 1.6 1.1 5.3 3.7 1.5 3.9 4.1 7.4 6.3 5.9 8.7 3.6 3.5 7.0 3.0 3.4 2.7 4.6 8.5 1.9 6.4 3.2 3.1 3.9 3.1 5.0 3.6 5.7 3.1 3.3 3.9 4.4 7.4 2.1 5.6 5.0 4.2 6.7 9.9 3.5 6.7 3.3 7.3 3.8 4.3 7.1 3.4 4.1 4.3 22.9 11.1 3.8 1.8 2.2 2.0 3.7 6.2 3.6 6.6 3.2 2.8 3.7 2.9 4.2 4.3 5.1 2.8 3.3 5.4 6.3 5.7 4.6 7.8 0.9 0.7 1.1 1.6 3.2 0.9 3.4 2.4 2.4 2.7 1.2 3.2 3.7 3.4 0.9 5.3 0.8 1.9 2.4 1.5 11.1 11.9 19.0 11.6 10.6 9.5 9.0 9.9 8.9 12.1 41.7 50.1 23.2 20.4 17.6 50.8 43.1 10.2 38.8 35.2 8.7 64.8 8.7 8.3 8.6 4.4 18.6 17.3 23.3 15.8 8.8 28.2 22.8 39.4 14.4 9.7 41.3 22.8 13.5 11.0 6.7 39.1 13.9 13.5 4.6 18.3 49.8 10.2 14.4 37.8 8.0 53.6 25.8 24.0 25.6 21.2 15.3 19.0 34.6 15.5 17.1 KCNJ5 "CIR, GIRK4, KATP1, Kir3.4, LQT13" ENSG00000120457 "Potassium voltage-gated channel subfamily J member 5" P48544 11 128891356-128921035 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Cancer-related genes, Disease mutation, Long QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 40.7;ductus deferens: 54.6;pituitary gland: 23.4" "Group enriched" "Detected in many" 4 "Alveolar cells type 2: 10.6;Hofbauer cells: 37.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "neutrophil: 2.9" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 13 "HBEC3-KT: 17.5" "Group enriched" "Detected in many" 6 "basal ganglia: 3.1;hypothalamus: 8.0;midbrain: 2.2;thalamus: 4.0" "Low region specificity" "Detected in all" "HPA014722, HPA017353, CAB022569" Approved NA NA "CAB022569: , HPA014722: AB_1852133, HPA017353: AB_1852135" "unprognostic (2.01e-1)" "unprognostic (2.43e-3)" "unprognostic (2.56e-3)" "unprognostic (5.81e-2)" "unprognostic (4.24e-2)" "unprognostic (3.60e-2)" "unprognostic (2.90e-1)" "unprognostic (3.54e-2)" "unprognostic (6.83e-2)" "unprognostic (1.96e-1)" "unprognostic (3.17e-1)" "unprognostic (9.29e-2)" "unprognostic (1.81e-2)" "unprognostic (6.82e-2)" "unprognostic (9.49e-2)" "unprognostic (1.88e-2)" "unprognostic (2.23e-2)" 1.8 40.7 0.8 0.3 1.9 0.2 0.9 0.3 1.2 0.8 0.8 1.9 54.6 0.4 0.3 1.1 0.6 0.6 1.3 8.7 1.6 2.5 2.0 0.3 3.4 0.8 3.7 0.8 0.8 16.6 0.7 23.4 4.3 3.4 0.8 0.4 3.3 0.9 21.7 0.3 0.4 0.5 0.7 4.5 7.7 1.5 0.7 0.9 2.3 0.7 0.4 0.3 1.1 0.5 0.9 0.4 2.9 0.7 0.6 0.4 0.4 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.3 0.1 0.1 0.0 0.3 0.1 0.4 17.5 0.0 0.2 0.1 0.1 0.6 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.4 0.3 0.0 0.2 0.0 0.4 0.3 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.2 0.0 0.1 0.0 0.2 0.2 0.1 0.0 0.5 0.2 0.1 0.1 1.3 0.0 2.2 0.7 0.6 0.4 0.3 0.3 0.3 0.2 0.3 0.3 0.9 0.3 0.4 2.9 0.6 0.4 0.4 0.2 0.4 0.8 1.9 0.3 1.2 1.6 2.5 3.7 0.8 3.4 0.9 0.0 10.6 0.0 2.3 1.3 1.7 5.8 0.0 0.0 0.0 1.8 0.0 0.7 0.0 0.0 2.1 0.6 0.0 0.0 3.2 0.6 2.1 0.4 0.0 0.0 37.1 1.6 0.0 0.6 1.8 4.5 0.9 1.9 3.3 1.8 0.0 0.3 1.3 0.0 0.7 0.0 1.4 0.0 0.1 0.2 0.7 1.5 1.0 0.0 0.0 0.5 KDM5A "JARID1A, RBBP2" ENSG00000073614 "Lysine demethylase 5A" P29375 12 280129-389454 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, Dioxygenase, Oxidoreductase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006201 Supported "Nuclear bodies,Cytosol" NA NA "Nuclear bodies" Cytosol "HPA006201: AB_1079160" "unprognostic (2.75e-1)" "unprognostic (1.68e-1)" "unprognostic (1.83e-1)" "unprognostic (1.12e-1)" "unprognostic (4.46e-2)" "unprognostic (1.60e-1)" "unprognostic (3.53e-3)" "unprognostic (1.81e-2)" "unprognostic (5.81e-2)" "unprognostic (3.19e-1)" "unprognostic (1.77e-3)" "unprognostic (6.11e-2)" "unprognostic (1.79e-2)" "unprognostic (1.10e-1)" "unprognostic (1.52e-1)" "unprognostic (2.60e-2)" "unprognostic (7.69e-2)" 13.6 14.4 10.6 13.7 13.0 41.6 13.1 21.8 13.2 11.8 10.3 14.8 11.3 7.8 14.2 8.1 13.6 11.2 10.0 10.1 11.5 5.7 9.0 10.7 13.1 14.9 15.1 9.1 15.2 11.5 16.8 13.8 12.4 11.3 10.6 10.9 10.6 12.9 8.6 9.7 20.3 13.0 10.4 10.1 15.5 10.6 21.2 14.8 28.8 11.4 7.1 16.1 13.1 18.8 17.2 16.8 33.7 14.1 18.6 18.1 10.1 7.7 14.0 10.3 7.9 9.3 8.8 11.5 6.9 9.2 10.4 11.3 8.3 9.4 13.0 2.2 11.5 9.1 7.4 10.7 7.8 12.5 20.5 8.9 15.9 14.6 4.9 7.5 20.7 12.6 9.6 7.4 12.8 17.1 10.7 10.5 11.7 9.5 18.3 8.8 5.2 14.8 5.9 16.0 6.7 4.4 13.9 26.9 6.1 5.0 17.9 4.0 11.6 13.6 6.2 7.3 14.9 6.7 13.1 14.3 6.9 9.9 7.6 11.5 6.5 7.1 29.9 8.8 9.1 10.1 30.2 11.3 22.2 17.7 13.1 18.1 14.1 13.8 14.2 11.8 17.2 15.1 12.9 33.7 18.6 14.1 16.8 10.5 10.1 10.6 13.0 21.8 13.2 11.5 5.7 15.1 9.1 11.3 14.8 59.6 53.6 57.8 19.7 29.3 64.2 35.8 35.7 40.2 39.8 33.2 110.0 38.1 3.3 31.6 79.2 46.6 34.3 0.0 27.4 28.3 35.7 25.6 52.1 23.6 26.7 82.6 66.8 42.4 53.2 21.3 44.8 47.2 25.3 60.5 35.6 48.0 31.1 37.9 52.3 10.5 68.8 58.2 30.9 105.6 111.6 41.7 59.5 62.5 36.0 33.9 KDM5C "DXS1272E, JARID1C, MRX13, SMCX, XE169" ENSG00000126012 "Lysine demethylase 5C" P41229 X 53191321-53225422 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Dioxygenase, Oxidoreductase, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038244, HPA046147" Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA038244: AB_2675911, HPA046147: AB_2679555" "unprognostic (1.19e-1)" "unprognostic (1.13e-1)" "unprognostic (1.56e-2)" "unprognostic (7.10e-2)" "unprognostic (9.75e-2)" "unprognostic (2.19e-1)" "prognostic unfavorable (2.11e-4)" "unprognostic (2.08e-2)" "unprognostic (2.11e-1)" "unprognostic (1.24e-1)" "unprognostic (5.45e-2)" "unprognostic (1.58e-2)" "unprognostic (5.05e-3)" "unprognostic (1.96e-2)" "unprognostic (6.91e-2)" "unprognostic (1.30e-1)" "unprognostic (1.00e-1)" 19.5 22.9 22.4 22.6 24.7 26.3 17.9 43.0 31.7 25.9 19.5 23.4 16.7 22.2 29.2 13.3 26.9 24.8 15.2 17.6 21.6 15.3 17.0 18.8 20.6 25.8 24.6 21.8 33.1 22.5 37.7 31.8 34.0 22.8 18.7 13.5 17.0 25.6 17.1 36.6 28.4 22.2 23.6 16.0 25.0 19.4 10.6 26.2 29.0 22.2 11.3 24.5 21.5 26.4 4.5 4.3 4.8 4.0 2.8 6.1 3.8 16.9 23.1 24.8 19.0 17.2 15.7 17.6 10.6 12.4 14.4 13.4 15.6 11.1 15.8 13.8 13.9 40.6 15.2 28.0 22.7 11.0 11.8 41.4 15.3 24.7 11.0 21.2 18.1 30.6 12.4 16.7 28.1 34.7 20.6 21.2 13.2 29.7 10.5 10.5 21.7 13.2 20.4 21.0 8.8 21.7 15.0 14.8 17.1 9.1 16.3 18.7 24.1 32.2 29.9 12.1 23.8 20.9 16.0 14.5 16.1 13.9 14.4 10.3 15.3 12.4 12.0 20.9 21.5 11.9 3.0 3.8 2.7 6.1 3.6 5.1 4.5 3.7 5.7 3.1 3.2 4.5 2.9 4.8 2.8 4.0 4.3 4.3 3.8 22.4 24.7 43.0 31.7 21.6 15.3 24.6 21.8 22.8 26.2 11.9 12.2 11.9 9.7 10.8 25.0 7.7 17.8 12.0 12.5 7.0 23.6 10.6 3.3 13.4 0.6 14.3 21.7 0.0 18.7 11.4 11.3 12.4 12.7 19.8 12.4 23.8 30.0 18.4 14.6 1.7 13.6 9.4 13.5 10.0 27.8 10.9 20.8 24.6 14.9 4.2 16.1 0.0 10.3 7.0 14.6 13.9 17.4 10.2 15.6 15.9 KDM6A UTX ENSG00000147050 "Lysine demethylase 6A" O15550 X 44873177-45112602 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Chromatin regulator, Dioxygenase, Oxidoreductase" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000568, HPA001165, HPA002111" Enhanced Approved "Nucleoplasm,Nucleoli,Nucleoli rim" "Intracellular and membrane" NA NA "Nucleoli, Nucleoli rim" Nucleoplasm "HPA000568: AB_1858705, HPA001165: AB_1080541, HPA002111: AB_1858704" "unprognostic (1.73e-3)" "unprognostic (6.86e-3)" "unprognostic (1.45e-2)" "unprognostic (1.36e-1)" "unprognostic (1.72e-1)" "unprognostic (2.65e-2)" "unprognostic (2.58e-3)" "unprognostic (8.22e-3)" "unprognostic (3.23e-1)" "unprognostic (2.44e-1)" "unprognostic (2.56e-1)" "unprognostic (1.07e-1)" "unprognostic (2.73e-1)" "unprognostic (2.24e-2)" "unprognostic (5.18e-2)" "unprognostic (1.26e-1)" "unprognostic (3.16e-2)" 12.3 12.1 16.5 17.6 24.5 47.9 21.4 26.1 22.0 16.9 11.8 16.7 12.0 13.1 22.6 11.3 15.4 16.9 15.2 9.1 18.2 6.5 11.6 13.5 19.7 15.1 28.8 11.3 23.8 14.9 21.3 20.2 13.3 18.3 10.3 11.3 10.3 16.1 12.6 15.1 21.3 17.6 13.5 14.9 18.1 15.0 17.7 26.1 19.1 14.5 6.9 13.6 14.9 22.8 5.5 7.1 15.7 7.5 6.2 7.9 3.5 8.7 7.6 11.3 11.4 8.1 8.4 24.2 6.8 4.8 8.2 8.6 17.9 7.5 5.7 3.7 6.3 17.0 18.8 14.5 12.0 7.6 8.3 15.5 7.1 9.6 6.7 5.7 3.8 20.2 4.5 9.9 13.5 14.1 8.8 6.3 7.0 9.8 14.2 5.1 5.7 7.8 11.2 9.4 6.7 8.8 8.7 10.9 1.0 4.7 16.3 9.7 5.2 21.7 10.9 9.2 24.8 10.6 0.1 5.3 7.8 6.0 7.8 3.5 9.0 10.8 8.6 5.4 4.0 4.5 15.7 3.8 3.5 5.3 7.5 6.0 5.5 7.2 7.9 7.1 3.8 7.0 6.3 7.3 6.2 7.2 3.8 5.6 3.5 16.5 24.5 26.1 22.0 18.2 6.5 28.8 11.3 18.3 26.1 6.0 8.8 5.2 11.3 23.2 6.5 11.4 10.2 5.3 7.9 7.0 13.7 3.8 0.0 6.5 1.0 9.4 18.8 0.0 6.6 4.9 8.9 11.4 2.3 13.9 6.1 23.8 12.6 6.2 8.9 1.1 6.1 9.7 10.1 7.2 14.2 7.4 7.7 14.4 6.7 3.3 8.4 6.5 10.3 5.6 11.7 23.1 9.2 10.1 11.0 16.3 KDR "CD309, FLK1, VEGFR, VEGFR2" ENSG00000128052 "Kinase insert domain receptor" P35968 4 55078259-55125595 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 6 "Endothelial cells: 100.3;Ito cells: 200.7;Muller glia cells: 229.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 32.5;TIME: 36.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" CAB004028 Enhanced Supported "Plasma membrane" "Intracellular and membrane" NA NA 7400000 "Plasma membrane" "CAB004028: AB_2212507" "unprognostic (1.61e-1)" "unprognostic (2.03e-1)" "unprognostic (9.65e-2)" "unprognostic (1.97e-1)" "unprognostic (9.63e-2)" "unprognostic (1.22e-2)" "unprognostic (1.78e-3)" "unprognostic (2.59e-2)" "unprognostic (1.19e-2)" "unprognostic (1.10e-1)" "unprognostic (8.79e-3)" "unprognostic (1.34e-1)" "prognostic unfavorable (7.26e-4)" "unprognostic (4.00e-2)" "unprognostic (2.30e-1)" "unprognostic (3.22e-1)" "unprognostic (1.86e-1)" 19.7 6.2 1.8 4.4 3.1 0.4 20.5 1.1 2.2 11.4 6.0 1.8 11.5 2.3 28.8 10.2 5.2 9.5 6.2 12.1 2.3 1.7 7.8 10.4 13.2 14.1 3.1 2.9 6.0 8.1 8.0 6.8 34.5 3.9 9.5 1.4 27.6 7.1 10.3 5.3 3.0 3.8 7.7 2.6 4.4 4.2 5.3 1.2 0.5 20.0 5.3 3.0 4.4 12.0 0.1 0.1 0.7 0.0 0.2 0.2 0.1 0.0 0.0 1.7 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 3.8 0.0 0.0 0.3 0.0 0.0 0.2 0.2 32.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.7 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.4 0.0 0.1 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.1 1.8 3.1 1.1 2.2 2.3 1.7 3.1 2.9 3.9 1.2 0.0 8.2 7.5 0.4 2.3 7.4 4.8 0.0 6.7 30.7 0.0 0.0 0.1 0.0 0.5 0.8 100.3 0.0 0.0 0.0 0.1 1.9 0.4 2.3 1.3 0.4 0.0 0.0 200.7 14.5 0.6 0.0 1.0 6.8 0.0 0.0 229.2 0.3 0.0 0.4 0.0 6.0 0.0 1.4 0.2 0.2 2.4 0.1 0.0 0.0 0.4 KDSR "DHSR, FVT1, SDR35C1" ENSG00000119537 "3-ketodihydrosphingosine reductase" Q06136 18 63327726-63367510 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Sphingolipid metabolism" Oxidoreductase "Cancer-related genes, Disease mutation, Palmoplantar keratoderma, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "U-266/70: 38.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003673, HPA044884" Approved NA NA "CAB003673: AB_425440, HPA044884: AB_2679131" "unprognostic (4.44e-2)" "unprognostic (8.57e-2)" "unprognostic (2.52e-2)" "unprognostic (4.56e-2)" "unprognostic (5.88e-3)" "unprognostic (7.50e-3)" "unprognostic (1.80e-2)" "unprognostic (2.66e-1)" "unprognostic (2.97e-1)" "unprognostic (1.97e-1)" "unprognostic (2.70e-2)" "unprognostic (6.81e-2)" "prognostic favorable (9.53e-6)" "unprognostic (3.32e-2)" "unprognostic (5.77e-2)" "unprognostic (2.22e-1)" "unprognostic (2.16e-3)" 21.1 19.4 19.0 11.1 22.4 6.4 29.7 12.5 17.2 18.2 17.3 23.9 14.2 10.0 19.4 30.0 17.8 14.3 17.7 15.8 19.7 16.9 21.3 52.6 15.3 11.5 32.1 14.6 29.1 14.3 19.6 10.5 24.9 19.5 18.0 11.0 15.9 16.1 17.4 12.4 28.8 13.1 18.9 39.0 9.1 11.8 10.4 23.3 8.8 21.2 12.3 9.9 19.9 22.8 4.0 5.6 0.9 5.6 9.8 19.5 3.7 5.9 2.7 2.8 3.1 22.4 16.8 5.5 19.8 12.2 4.4 5.9 1.1 4.1 6.1 8.5 7.7 7.3 26.5 3.5 11.1 5.4 11.4 5.9 4.7 3.6 1.3 17.1 8.5 3.3 16.0 21.2 7.0 20.1 8.1 4.3 4.1 3.7 8.7 11.6 2.4 9.4 3.9 3.3 1.5 10.0 6.4 8.3 8.6 12.1 3.9 3.6 6.9 9.6 4.7 8.5 3.8 2.5 4.9 10.1 18.6 4.5 6.2 8.6 38.2 17.4 3.5 14.0 5.3 5.5 0.0 3.7 0.3 4.8 5.6 19.5 4.0 10.2 7.6 5.6 3.6 7.3 4.6 0.9 9.8 2.6 2.8 12.9 3.7 19.0 22.4 12.5 15.9 19.7 16.9 32.1 14.6 19.5 23.3 32.8 41.4 40.4 112.3 140.9 36.2 21.8 68.8 46.8 48.9 36.6 25.5 53.1 13.3 45.0 0.7 35.9 29.0 0.0 32.1 57.8 53.6 62.1 25.4 77.0 31.7 38.1 19.7 44.8 25.0 3.6 65.9 36.3 54.0 30.7 30.6 57.7 41.5 46.0 66.4 36.6 40.8 32.3 42.2 0.9 5.3 125.1 76.4 20.3 40.8 94.6 KEAP1 "INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454" ENSG00000079999 "Kelch like ECH associated protein 1" Q14145 19 10486120-10503741 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005558, CAB025337" Approved Supported "Nucleoplasm,Centriolar satellite,Cytosol" NA NA "Nucleoplasm, Centriolar satellite" Cytosol "CAB025337: , HPA005558: AB_1079175" "unprognostic (1.98e-1)" "prognostic favorable (3.28e-4)" "unprognostic (1.61e-1)" "unprognostic (1.02e-1)" "unprognostic (1.42e-1)" "unprognostic (1.63e-2)" "unprognostic (2.64e-2)" "unprognostic (1.46e-1)" "unprognostic (1.48e-1)" "unprognostic (5.22e-3)" "unprognostic (2.04e-1)" "unprognostic (9.99e-2)" "unprognostic (1.29e-1)" "unprognostic (7.71e-3)" "unprognostic (5.06e-1)" "unprognostic (8.18e-2)" "unprognostic (1.60e-2)" 16.0 13.7 13.5 10.4 14.3 9.1 12.4 13.2 15.1 13.1 15.7 15.4 13.8 13.6 11.0 12.7 26.3 15.1 12.7 19.7 13.9 13.7 13.2 22.0 10.8 15.5 16.7 7.4 11.8 14.3 11.1 10.2 11.5 14.3 13.9 8.8 11.8 11.3 13.9 63.9 16.8 13.8 11.6 16.5 11.3 10.6 12.2 13.8 13.1 14.5 29.1 16.1 14.5 11.2 14.6 23.7 21.3 19.8 21.0 30.8 19.6 17.3 31.8 8.8 11.7 18.2 15.5 9.4 14.8 11.0 15.2 13.6 22.6 17.5 24.7 39.0 16.4 11.3 15.6 17.5 11.5 7.5 23.9 19.2 37.3 9.5 26.7 17.6 19.5 20.3 16.0 15.6 17.1 8.0 12.7 14.4 7.4 22.8 45.8 13.2 24.0 14.1 53.6 25.7 16.6 26.8 25.7 11.0 28.9 9.8 20.8 24.3 12.7 20.6 13.8 12.8 8.1 11.9 26.1 17.7 24.5 13.2 27.4 17.9 26.7 33.4 24.2 18.9 23.3 17.9 16.1 19.8 21.3 30.8 17.0 29.3 14.6 21.5 28.3 23.7 5.7 13.5 19.1 10.9 21.0 16.6 16.3 25.4 19.6 13.5 14.3 13.2 12.8 13.9 13.7 16.7 7.4 14.3 13.8 26.8 17.3 19.6 22.6 19.5 21.5 20.3 20.4 13.4 17.0 10.4 7.9 22.5 11.6 29.0 22.3 24.1 31.5 0.0 31.3 21.0 19.7 21.7 11.5 28.8 25.7 25.4 25.8 27.0 14.8 34.6 27.0 14.9 10.1 57.7 20.6 39.6 26.7 21.0 24.4 19.1 11.1 12.9 15.6 19.5 17.3 19.3 22.4 22.4 27.9 21.7 KIF5B "KNS, KNS1" ENSG00000170759 "Kinesin family member 5B" P33176 10 32009010-32056431 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Motor protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009846, HPA037589, HPA037590" Approved Enhanced "Centriolar satellite,Cytosol" NA Yes 260000 "Centriolar satellite, Cytosol" "CAB009846: AB_2280915, HPA037589: AB_2675563, HPA037590: AB_2675564" "unprognostic (4.94e-3)" "unprognostic (1.70e-1)" "unprognostic (1.06e-1)" "unprognostic (1.84e-1)" "unprognostic (4.00e-2)" "unprognostic (6.21e-2)" "unprognostic (1.06e-2)" "unprognostic (1.84e-1)" "unprognostic (2.70e-1)" "unprognostic (6.37e-3)" "unprognostic (2.03e-1)" "unprognostic (2.60e-1)" "unprognostic (1.81e-1)" "unprognostic (2.43e-2)" "unprognostic (2.39e-1)" "unprognostic (8.06e-2)" "unprognostic (1.76e-1)" 26.3 19.9 55.7 20.2 55.5 34.1 23.0 22.2 42.4 23.8 34.2 21.7 20.9 23.5 25.7 17.8 28.0 20.3 28.0 48.4 51.5 39.3 21.1 15.3 23.8 16.5 62.9 26.1 18.2 18.9 56.8 22.4 27.7 38.3 31.8 30.0 8.9 20.1 25.6 34.3 17.6 28.6 37.2 80.4 21.1 23.1 27.7 43.7 25.0 23.5 21.5 16.1 33.8 28.1 13.8 27.6 30.0 18.9 13.4 16.5 9.2 30.0 25.6 34.6 24.3 24.8 27.5 14.8 41.5 19.7 32.1 27.5 28.1 33.3 20.6 18.0 49.2 18.3 25.0 31.6 26.5 43.1 17.7 17.2 26.2 23.9 27.3 28.6 18.2 28.9 22.2 37.7 37.0 25.9 25.6 41.0 18.3 31.5 21.8 44.3 18.1 18.9 10.3 5.6 28.9 11.7 24.9 64.6 8.5 24.7 21.1 33.7 24.6 32.1 12.8 30.9 25.2 15.5 26.1 34.1 32.7 30.7 37.8 30.7 6.6 7.5 24.3 31.1 37.7 30.7 20.8 15.2 24.2 11.8 18.9 11.4 13.6 14.9 12.5 14.2 13.8 13.3 13.0 30.0 13.4 18.9 27.6 16.5 9.2 55.7 55.5 22.2 42.4 51.5 39.3 62.9 26.1 38.3 43.7 169.7 163.3 57.7 133.6 189.3 172.7 357.9 96.8 192.7 126.3 99.5 94.2 100.8 38.1 183.2 92.5 169.2 111.4 46.7 153.7 110.6 139.0 208.1 87.9 41.0 117.4 143.0 127.0 87.2 110.1 28.3 54.7 125.3 96.2 194.8 188.9 82.6 173.1 143.2 123.1 50.5 125.5 84.1 199.1 513.7 177.6 206.9 277.6 86.3 159.0 207.4 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 65.5" "Group enriched" "Detected in many" 10 "granulocytes: 496.5;Melanocytes: 200.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7" "Group enriched" "Detected in many" 6 "granulocytes: 12.7;NK-cells: 9.7" "Group enriched" "Detected in some" 13 "HEL: 48.8;HMC-1: 102.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" NA NA 48000000 "Plasma membrane" "CAB003288: AB_2335702, CAB068253: AB_2665717, CAB072867: AB_2665718, HPA004471: AB_1078431, HPA073252: AB_2686589" "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favorable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 8.1 1.6 9.5 6.6 11.8 3.7 65.5 18.3 12.0 12.1 10.3 6.5 10.2 5.8 8.9 4.2 9.9 2.5 15.5 2.4 36.0 4.4 9.4 1.1 13.8 3.8 3.6 6.0 28.5 2.1 1.3 2.3 6.2 5.7 9.6 10.4 20.7 12.9 6.9 1.3 14.6 8.9 10.2 3.9 3.2 12.8 4.0 4.5 0.4 28.9 4.3 4.9 9.8 12.5 0.0 1.8 12.7 0.9 9.7 1.9 0.1 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.6 0.9 2.6 3.2 0.0 0.0 0.0 0.0 1.4 0.1 0.0 0.5 0.0 2.2 0.0 1.2 48.8 0.0 0.0 0.0 0.0 102.6 0.0 0.0 0.0 0.0 0.0 5.7 0.8 0.6 0.1 0.0 0.0 0.2 0.4 1.4 0.0 0.0 0.1 0.0 0.0 0.0 4.8 1.2 0.4 0.0 0.0 0.0 3.0 0.0 0.5 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 12.7 0.0 10.0 0.1 0.0 1.9 0.0 0.3 0.7 1.8 0.0 0.0 0.0 0.8 9.7 0.9 0.0 0.0 0.1 9.5 11.8 18.3 12.0 36.0 4.4 3.6 6.0 5.7 4.5 6.0 34.8 1.4 1.1 12.7 0.0 0.4 5.1 0.0 5.7 3.5 0.0 0.0 3.3 0.8 0.0 2.4 0.0 0.0 0.0 0.1 1.3 0.5 496.5 0.0 0.3 0.0 5.2 1.8 0.3 0.0 1.1 3.1 200.8 0.0 0.3 2.4 0.0 0.0 0.0 0.6 0.3 0.0 0.5 0.0 8.2 3.3 0.2 2.2 0.3 0.3 KLF4 "EZF, GKLF" ENSG00000136826 "Kruppel like factor 4" O43474 9 107484852-107490482 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 92.1" "Cell type enhanced" "Detected in many" 6 "Mucus-secreting cells: 685.3;Suprabasal keratinocytes: 589.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 10 "classical monocyte: 5.2;intermediate monocyte: 7.4;myeloid DC: 4.4;non-classical monocyte: 2.9" "Group enriched" "Detected in many" 12 "dendritic cells: 4.4;monocytes: 7.4" "Cell line enhanced" "Detected in many" "hTCEpi: 32.8;hTERT-HME1: 20.3;OE19: 17.5;U-2197: 49.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA002926 Enhanced Supported Nucleoplasm NA NA Nucleoplasm "HPA002926: AB_1852541" "unprognostic (2.06e-1)" "unprognostic (1.42e-2)" "unprognostic (1.14e-2)" "unprognostic (2.45e-1)" "unprognostic (1.55e-1)" "unprognostic (6.58e-3)" "unprognostic (3.44e-2)" "unprognostic (6.49e-2)" "unprognostic (3.45e-1)" "unprognostic (1.29e-2)" "unprognostic (1.18e-2)" "unprognostic (1.08e-1)" "prognostic favorable (3.93e-5)" "unprognostic (2.55e-1)" "unprognostic (1.67e-1)" "unprognostic (8.13e-2)" "unprognostic (8.32e-2)" 29.2 8.5 2.7 23.8 3.9 14.4 23.7 1.8 3.5 39.1 28.9 5.6 5.5 10.2 17.8 18.6 34.9 22.0 32.4 18.6 2.4 2.2 4.8 5.1 35.6 4.4 2.7 2.2 18.6 2.3 2.7 2.8 41.0 6.2 11.3 29.6 11.7 11.9 6.5 13.6 92.1 39.4 16.0 3.3 21.8 22.2 11.2 2.0 1.9 7.8 81.1 30.7 16.8 24.1 0.0 4.4 0.4 7.4 0.1 0.0 1.3 5.7 2.3 0.2 0.0 6.0 15.5 2.2 2.0 10.6 2.7 3.2 0.8 7.3 0.0 0.3 2.6 9.4 4.2 2.6 1.5 1.0 0.0 1.1 0.0 4.0 0.1 9.0 0.0 0.0 2.0 32.8 5.5 20.3 0.6 0.2 0.1 0.2 0.0 1.5 3.7 0.0 0.7 1.8 17.5 11.5 0.1 0.6 0.1 0.8 1.6 0.1 0.1 1.6 4.8 6.0 4.8 0.7 2.5 1.2 1.6 0.0 49.8 0.8 0.0 0.0 0.0 1.6 1.0 2.8 0.0 5.2 0.0 0.0 7.4 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.4 0.1 2.9 0.4 0.0 1.3 2.7 3.9 1.8 3.5 2.4 2.2 2.7 2.2 6.2 2.0 11.9 47.4 12.3 228.3 387.3 0.4 56.5 17.8 18.7 29.6 1.8 7.9 33.0 1.7 21.1 201.9 242.7 430.0 0.0 34.8 55.7 240.7 170.1 55.2 3.9 80.6 0.0 118.8 142.4 148.1 123.4 133.2 214.3 195.7 12.6 685.3 1.7 32.1 447.5 57.0 1.2 1.8 38.8 108.2 4.1 15.1 589.1 90.3 5.3 253.4 169.8 KLF6 "BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9" ENSG00000067082 "Kruppel like factor 6" Q99612 10 3775996-3785281 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Basal glandular cells: 1442.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013529, HPA069585" Supported Supported Nucleoplasm,Nucleoli,Vesicles,Cytosol No No Nucleoplasm "Nucleoli, Vesicles, Cytosol" "CAB013529: AB_2533431, HPA069585: AB_2686157" "unprognostic (1.23e-1)" "unprognostic (1.53e-2)" "unprognostic (1.47e-3)" "unprognostic (4.53e-2)" "unprognostic (1.47e-1)" "unprognostic (7.55e-2)" "unprognostic (2.00e-1)" "unprognostic (1.08e-3)" "unprognostic (1.61e-1)" "unprognostic (2.83e-2)" "unprognostic (1.36e-2)" "unprognostic (2.35e-2)" "prognostic favorable (2.28e-4)" "unprognostic (8.07e-3)" "unprognostic (4.85e-2)" "unprognostic (6.87e-2)" "unprognostic (1.37e-2)" 69.8 10.0 8.4 26.3 10.6 80.6 101.1 7.4 10.1 28.6 31.7 10.3 9.7 11.0 24.9 28.8 38.6 28.0 38.6 18.6 7.8 5.1 32.2 32.5 46.0 35.8 13.8 4.2 20.2 23.8 7.5 4.7 26.1 11.2 20.1 21.0 13.2 26.9 16.5 57.8 60.2 44.8 42.8 17.0 20.3 26.7 14.3 10.0 12.5 41.0 28.8 21.5 44.7 30.7 15.6 29.8 77.8 18.7 13.0 30.8 23.2 13.2 3.6 6.9 2.2 40.3 40.4 4.3 22.8 11.7 24.4 16.6 9.3 17.9 3.8 5.3 24.7 19.0 8.1 4.2 21.1 20.5 18.6 2.5 0.5 4.1 8.7 17.3 2.5 13.1 13.3 40.3 17.4 33.2 8.7 24.9 2.5 4.1 29.7 31.0 0.9 4.6 3.8 2.6 7.1 6.5 3.0 7.1 13.4 24.0 13.2 3.0 2.9 5.6 16.3 34.2 19.6 8.0 2.1 32.4 33.1 4.6 19.5 10.4 5.7 18.5 7.0 8.9 3.3 10.2 50.9 17.0 43.7 27.1 14.2 23.9 15.6 30.8 26.8 13.1 12.5 9.6 14.8 77.8 13.0 18.7 29.8 22.2 23.2 8.4 10.6 7.4 10.1 7.8 5.1 13.8 4.2 11.2 10.0 1158.3 540.6 237.0 1442.7 520.2 42.2 53.1 293.0 254.3 251.4 130.9 31.4 113.5 18.3 616.6 54.4 455.0 961.8 70.0 474.3 369.8 410.0 832.0 597.5 234.2 510.8 35.0 381.0 212.4 420.1 42.4 120.8 593.9 458.9 839.6 556.8 32.1 706.5 466.4 125.9 61.9 78.0 135.8 372.0 6.2 13.6 549.2 163.8 409.2 300.8 382.6 KLK2 ENSG00000167751 "Kallikrein related peptidase 2" P20151 19 50861568-50880567 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 29 "prostate: 163.5" "Cell type enriched" "Detected in some" 36 "Glandular cells: 729.8" "Cancer enriched" "Detected in some" 1666 "prostate cancer: 989.9" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BEWO: 5.0;NB-4: 10.2" HPA000764 Supported "Secreted in male reproductive system" NA NA "HPA000764: AB_1079700" "unprognostic (3.05e-2)" "unprognostic (2.40e-1)" "unprognostic (1.69e-1)" "unprognostic (8.53e-2)" "unprognostic (1.15e-1)" "unprognostic (8.97e-2)" "unprognostic (3.22e-1)" "unprognostic (6.44e-2)" "unprognostic (8.06e-2)" "unprognostic (3.61e-1)" "unprognostic (2.11e-3)" "unprognostic (7.56e-2)" "unprognostic (8.10e-2)" "unprognostic (1.68e-1)" "unprognostic (2.04e-1)" 0.0 0.1 0.0 0.1 0.0 1.1 0.2 0.0 0.6 0.0 0.0 0.0 0.6 0.1 0.1 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 163.5 0.0 0.1 2.3 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.0 0.6 0.0 0.0 1.1 0.0 0.0 0.2 0.0 2.2 1.9 5.7 2.2 1.6 1.3 0.5 1.7 1.1 0.6 1.6 0.0 0.9 5.0 0.5 0.3 0.2 0.2 0.6 0.8 1.8 0.2 0.0 0.8 2.0 0.2 0.0 0.3 1.7 1.1 0.0 1.3 0.4 0.0 0.3 3.1 0.5 0.3 0.3 0.4 0.5 0.0 1.1 1.5 2.0 0.3 1.8 1.2 10.2 1.1 1.7 0.0 0.9 0.0 2.9 0.0 1.7 0.9 1.6 0.3 1.4 1.3 0.2 1.3 0.4 0.8 1.3 1.9 4.9 1.7 1.8 3.2 0.8 1.9 1.7 1.4 0.9 2.2 1.6 1.2 1.0 1.0 1.0 0.8 1.0 0.5 2.2 0.8 1.3 5.7 1.6 0.8 1.9 0.4 0.5 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 13.7 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.1 0.0 729.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.4 5.0 0.6 0.0 0.0 0.0 9.2 KMT2A "ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1" ENSG00000118058 "Lysine methyltransferase 2A" Q03164 11 118436490-118526832 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Apoptosis, Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017794, CAB024270, HPA044910" Enhanced Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB017794: , CAB024270: , HPA044910: AB_2679141" "unprognostic (6.80e-2)" "unprognostic (8.93e-2)" "unprognostic (1.83e-1)" "unprognostic (4.56e-1)" "unprognostic (4.96e-2)" "unprognostic (1.72e-3)" "unprognostic (4.52e-3)" "unprognostic (6.07e-2)" "unprognostic (1.61e-1)" "unprognostic (8.46e-2)" "unprognostic (3.21e-1)" "unprognostic (1.16e-1)" "unprognostic (5.91e-3)" "unprognostic (7.90e-2)" "unprognostic (3.73e-1)" "unprognostic (1.67e-1)" "unprognostic (1.02e-1)" 14.4 11.3 17.7 17.0 19.2 28.6 16.8 43.8 21.2 17.3 14.6 19.8 18.1 8.5 21.8 17.1 10.6 15.7 14.1 10.2 17.3 13.4 13.1 9.3 15.3 19.6 16.6 18.7 35.6 16.8 28.9 21.8 10.2 15.4 15.6 12.4 14.4 14.2 19.2 11.1 16.8 14.2 15.2 12.1 15.7 12.3 7.9 23.4 16.6 16.6 7.8 19.4 18.8 24.6 6.7 3.5 8.3 2.0 6.5 5.3 0.8 12.1 5.6 15.2 11.4 9.3 11.1 4.5 5.5 8.0 5.8 6.7 11.3 8.8 15.0 11.3 8.0 10.3 10.6 16.1 6.1 11.6 16.5 6.2 29.4 5.2 6.1 5.2 17.5 5.7 5.3 6.2 12.7 17.0 7.3 9.0 9.8 19.1 12.8 7.3 9.5 11.6 10.3 9.2 5.0 8.4 8.8 14.6 5.0 8.5 9.2 12.5 8.1 13.8 4.5 2.9 8.3 7.8 5.9 13.2 9.9 9.0 7.2 9.8 3.7 2.9 10.1 3.7 12.9 5.9 8.3 2.0 4.6 5.3 1.3 4.3 6.2 4.8 4.6 0.8 6.7 4.9 4.8 1.3 6.5 1.4 3.5 3.9 0.8 17.7 19.2 43.8 21.2 17.3 13.4 16.6 18.7 15.4 23.4 65.5 59.8 31.5 64.8 77.2 147.8 34.4 38.2 53.5 35.2 36.6 143.3 12.2 3.3 26.8 6.6 70.1 19.7 0.0 22.3 8.1 43.5 71.4 26.7 23.1 14.2 184.3 63.8 45.4 32.6 4.7 61.9 26.1 40.5 33.3 29.3 117.0 23.2 14.4 73.9 6.9 144.6 64.7 59.7 11.1 14.9 70.4 5.0 50.7 27.3 49.9 KMT2C "HALR, KIAA1506, MLL3" ENSG00000055609 "Lysine methyltransferase 2C" Q8NEZ4 7 152134922-152436005 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Acyltransferase, Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074736 Approved Nucleoplasm NA NA Nucleoplasm "HPA074736: AB_2686709" "unprognostic (7.75e-2)" "unprognostic (3.10e-1)" "unprognostic (2.83e-1)" "unprognostic (1.33e-2)" "unprognostic (1.31e-1)" "unprognostic (5.23e-3)" "unprognostic (1.09e-1)" "unprognostic (1.59e-2)" "unprognostic (1.01e-1)" "unprognostic (1.17e-1)" "unprognostic (3.45e-1)" "unprognostic (1.06e-1)" "prognostic favorable (8.01e-6)" "unprognostic (1.78e-1)" "unprognostic (3.83e-1)" "unprognostic (3.04e-2)" "unprognostic (2.64e-1)" 13.9 12.6 11.7 16.7 18.6 29.7 14.5 24.8 14.1 18.4 12.6 15.5 21.4 9.7 20.2 20.6 14.4 12.8 12.7 10.8 13.4 9.5 10.3 11.4 13.0 12.1 17.7 9.4 18.8 18.4 18.8 18.9 38.0 12.6 14.0 11.8 12.6 15.8 22.9 30.3 25.2 13.1 13.6 16.0 14.6 14.9 13.6 19.6 22.6 16.9 9.3 16.8 17.8 31.6 5.6 3.5 16.1 3.9 5.5 2.9 0.6 9.7 4.9 9.1 9.7 16.5 10.0 10.7 5.1 3.9 4.1 5.0 9.3 5.9 15.5 7.4 9.2 5.6 5.6 9.8 7.4 6.9 9.8 5.0 9.2 7.4 6.4 8.0 15.5 11.3 8.4 10.3 5.8 7.8 6.6 5.8 8.1 14.8 13.4 8.9 13.6 11.2 14.1 5.5 7.6 4.9 7.6 8.3 8.1 7.0 10.0 13.3 10.5 8.4 15.0 5.5 9.9 4.9 12.8 7.3 6.8 3.6 7.3 7.2 14.1 6.9 16.7 8.9 12.8 7.0 8.8 3.5 4.3 2.1 2.2 2.9 5.6 1.7 1.7 1.7 3.8 2.7 1.8 16.1 5.5 3.9 3.5 1.3 0.6 11.7 18.6 24.8 14.1 13.4 9.5 17.7 9.4 12.6 19.6 71.5 66.6 54.7 36.1 79.1 82.8 58.2 45.9 44.2 92.1 43.6 163.0 29.7 5.0 30.2 18.6 49.2 41.0 23.3 28.7 45.7 47.0 48.1 62.5 36.6 29.6 76.3 65.1 41.7 48.8 11.0 62.5 61.0 40.5 25.2 44.5 62.2 33.0 43.8 56.6 15.7 75.2 25.8 50.1 33.5 31.5 84.2 106.4 50.4 30.3 55.0 KMT2D "ALR, CAGL114, MLL2, MLL4, TNRC21" ENSG00000167548 "Lysine methyltransferase 2D" O14686 12 49018975-49059774 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cone photoreceptor cells: 49.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 5.9" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035977 Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" Yes No "Plasma membrane, Cytosol" Nucleoplasm "HPA035977: AB_10670673" "unprognostic (8.33e-2)" "unprognostic (1.49e-1)" "unprognostic (9.14e-2)" "unprognostic (2.52e-1)" "unprognostic (8.07e-2)" "unprognostic (6.91e-3)" "unprognostic (7.35e-2)" "unprognostic (2.29e-1)" "unprognostic (3.57e-1)" "unprognostic (5.14e-2)" "unprognostic (7.23e-2)" "unprognostic (3.07e-1)" "unprognostic (1.68e-2)" "unprognostic (7.10e-2)" "unprognostic (1.87e-1)" "unprognostic (3.20e-2)" "unprognostic (7.60e-2)" 12.1 7.6 4.9 6.7 10.8 26.1 6.8 11.7 10.5 9.5 6.5 5.8 13.0 5.5 15.7 7.4 8.8 8.9 5.8 9.1 6.1 3.5 6.2 6.5 22.9 9.6 6.7 3.3 9.7 11.6 13.3 9.2 12.9 13.7 6.7 6.6 9.8 7.6 8.0 16.1 13.6 9.4 7.1 9.1 13.6 8.3 7.3 5.7 6.2 11.0 6.1 7.6 7.0 6.3 2.0 2.2 5.9 0.5 1.5 0.8 0.6 17.1 16.3 16.5 13.3 17.1 11.5 17.7 9.1 9.5 11.8 6.3 28.6 7.3 17.8 11.8 12.7 8.5 11.6 21.7 10.0 9.8 10.4 17.4 22.6 17.1 15.3 11.7 26.8 22.7 9.7 14.4 16.5 17.1 14.1 17.5 18.5 28.3 9.9 13.3 18.9 13.3 25.0 15.6 23.7 14.1 20.0 10.2 6.4 9.9 19.0 13.8 11.7 14.0 13.8 9.5 15.0 13.7 23.5 23.3 9.3 16.6 8.1 15.2 14.1 9.1 17.3 10.7 13.9 6.9 0.6 0.5 3.0 0.8 0.2 0.4 0.3 0.3 0.5 0.3 2.0 0.3 0.8 5.9 1.5 0.1 2.2 0.0 0.6 4.9 10.8 11.7 10.5 6.1 3.5 6.7 3.3 13.7 5.7 8.9 18.4 11.1 6.5 12.5 25.2 4.7 12.7 5.3 9.1 17.4 49.1 6.6 1.7 5.8 2.5 12.6 11.1 0.0 5.2 4.6 8.5 8.3 8.1 12.3 8.3 20.6 12.6 17.2 19.7 1.1 8.9 9.6 10.1 4.6 10.5 5.2 7.2 8.6 10.3 4.3 38.9 6.5 3.3 3.7 3.2 15.4 9.5 10.4 10.1 8.4 KNL1 "AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7" ENSG00000137812 "Kinetochore scaffold 1" Q8NG31 15 40594020-40664342 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "lymphoid tissue: 54.7;testis: 35.6" "Cell type enhanced" "Detected in some" 12 "Club cells: 3.4;Extravillous trophoblasts: 9.3;Hofbauer cells: 5.6;Proximal tubular cells: 8.4;Syncytiotrophoblasts: 3.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "HPA026624, HPA049647" Enhanced Enhanced "Nucleoplasm,Nuclear bodies" Yes Yes Nucleoplasm "Nuclear bodies" "HPA026624: AB_10601696, HPA049647: AB_2680840" "unprognostic (5.35e-2)" "unprognostic (1.01e-1)" "unprognostic (5.59e-3)" "unprognostic (4.22e-2)" "unprognostic (1.59e-2)" "unprognostic (5.66e-2)" "unprognostic (1.41e-1)" "prognostic unfavorable (2.11e-4)" "unprognostic (2.06e-2)" "unprognostic (1.43e-1)" "unprognostic (3.20e-4)" "unprognostic (2.22e-2)" "unprognostic (1.93e-12)" "unprognostic (3.07e-2)" "unprognostic (3.08e-1)" "unprognostic (8.45e-2)" "unprognostic (7.36e-2)" 0.7 0.5 0.3 7.1 0.4 5.4 0.7 0.3 0.3 0.6 4.0 0.1 0.0 1.5 0.4 0.8 3.9 0.4 0.9 0.5 0.4 0.4 0.9 1.0 1.3 4.7 0.3 0.0 0.5 0.5 0.0 0.4 2.8 0.1 0.5 1.5 0.0 0.8 0.0 0.4 0.8 3.9 0.5 0.4 3.3 0.8 35.6 0.0 54.7 0.5 4.1 3.7 0.7 0.9 2.9 1.2 0.7 0.5 0.7 2.5 0.0 10.9 5.6 11.5 8.3 0.3 1.7 5.1 12.8 5.2 10.0 8.5 6.9 4.4 7.3 4.1 5.5 7.6 13.7 10.8 6.0 10.6 12.6 3.0 21.4 9.6 2.0 0.0 16.3 10.8 0.3 0.2 6.7 4.2 1.3 8.5 13.0 13.7 12.2 11.7 3.7 13.9 3.3 5.6 6.6 6.0 12.7 16.5 3.6 1.5 9.7 9.9 4.6 11.1 6.3 1.3 3.8 6.8 5.0 7.9 11.7 10.4 13.4 7.1 4.7 15.9 14.2 4.7 11.1 11.1 0.4 0.2 0.1 0.1 0.1 0.0 2.9 1.1 0.1 1.2 2.2 0.0 0.7 0.7 0.7 0.5 0.1 2.5 0.0 0.3 0.4 0.3 0.3 0.4 0.4 0.3 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.4 3.4 1.8 0.0 2.4 1.7 0.2 0.0 0.0 0.0 0.0 0.5 9.3 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 8.4 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 KRAS "KRAS1, KRAS2" ENSG00000133703 "KRAS proto-oncogene, GTPase" P01116 12 25204789-25250936 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049830 Approved NA NA 5800000 "HPA049830: AB_2680903" "unprognostic (2.24e-2)" "unprognostic (2.16e-2)" "unprognostic (4.86e-3)" "unprognostic (1.08e-2)" "unprognostic (7.39e-2)" "unprognostic (1.51e-1)" "unprognostic (1.47e-2)" "unprognostic (3.74e-2)" "unprognostic (1.79e-1)" "unprognostic (2.39e-1)" "prognostic unfavorable (3.59e-4)" "unprognostic (6.42e-2)" "prognostic favorable (2.75e-5)" "unprognostic (1.95e-2)" "unprognostic (2.37e-1)" "unprognostic (2.81e-2)" "unprognostic (9.97e-2)" 11.7 9.9 14.4 15.5 19.5 24.1 10.6 21.1 25.6 10.3 26.2 7.3 7.9 16.1 11.3 7.7 25.1 10.1 13.9 9.3 13.6 16.6 14.0 17.9 14.9 15.1 11.6 15.8 13.1 13.6 12.7 9.8 15.7 21.1 12.1 28.1 9.8 16.2 9.8 10.0 14.0 23.7 17.2 11.3 15.7 23.6 7.8 9.5 18.5 11.1 10.6 16.3 16.8 14.3 10.0 7.1 20.8 18.9 9.4 13.8 5.0 6.8 6.9 15.5 8.7 5.8 7.9 31.2 7.0 8.8 7.3 8.7 24.0 15.7 15.7 4.2 12.1 9.8 7.5 18.1 7.6 13.8 10.7 6.3 14.8 7.4 5.9 6.1 13.8 11.3 7.3 10.4 8.8 7.9 13.4 10.6 11.5 10.5 7.5 10.7 5.8 19.0 21.1 34.1 11.2 2.8 16.5 16.4 22.6 10.8 12.1 4.7 13.3 8.3 11.0 8.3 42.6 12.2 10.0 12.2 8.2 10.9 15.4 8.6 6.6 11.0 17.0 6.3 8.1 5.9 20.8 7.8 12.4 11.9 14.4 7.5 10.0 10.4 13.0 7.1 8.6 13.8 12.1 19.0 9.4 18.9 7.1 6.7 5.0 14.4 19.5 21.1 25.6 13.6 16.6 11.6 15.8 21.1 9.5 44.7 28.0 47.9 74.6 89.6 61.8 13.7 71.4 22.7 23.9 36.6 68.7 77.0 49.7 64.2 2.8 58.3 123.1 46.7 79.4 16.4 50.1 116.8 23.1 52.1 45.9 87.4 75.6 73.6 60.9 2.5 37.7 60.3 59.1 92.0 88.6 31.5 107.1 78.0 48.4 38.6 62.1 25.8 43.4 57.5 37.0 136.1 116.4 56.8 58.1 134.2 KTN1 "CG1, KIAA0004, KNT" ENSG00000126777 "Kinectin 1" Q86UP2 14 55559072-55701526 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003178, CAB015331, HPA017876" Enhanced Enhanced "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "CAB015331: , HPA003178: AB_1079218, HPA017876: AB_1852652" "unprognostic (7.00e-3)" "unprognostic (2.99e-2)" "unprognostic (8.60e-2)" "unprognostic (5.50e-2)" "unprognostic (2.49e-1)" "prognostic unfavorable (6.83e-5)" "prognostic unfavorable (3.76e-4)" "unprognostic (1.75e-1)" "unprognostic (1.21e-2)" "unprognostic (1.01e-1)" "unprognostic (9.08e-2)" "unprognostic (8.72e-2)" "prognostic favorable (1.01e-6)" "unprognostic (1.27e-1)" "unprognostic (2.75e-1)" "unprognostic (1.30e-1)" "unprognostic (1.04e-1)" 26.5 27.5 30.8 18.9 37.3 9.5 44.2 30.8 35.2 22.7 28.8 15.8 23.4 13.0 18.8 30.8 26.1 16.8 18.1 36.1 32.2 25.3 33.1 31.8 21.2 16.9 39.3 24.5 23.1 22.8 48.3 54.7 21.3 49.5 26.9 28.7 13.1 21.4 24.0 101.9 41.4 20.1 40.5 51.9 22.1 18.9 40.9 42.0 14.5 33.3 37.9 17.9 32.7 39.7 35.6 58.3 27.0 15.5 19.6 24.0 4.8 40.7 28.2 21.1 23.0 29.2 28.0 30.6 33.3 26.8 20.9 18.6 18.8 50.7 31.4 47.7 34.2 22.3 76.3 25.8 29.0 35.4 52.8 14.1 22.2 46.7 35.6 27.6 32.5 18.0 26.0 26.6 25.8 44.8 45.0 34.3 25.1 21.6 18.4 40.1 31.8 27.9 19.3 16.2 18.9 42.1 22.3 55.5 14.9 52.5 64.1 26.0 21.7 52.7 24.2 29.2 45.0 25.1 20.9 48.3 42.8 54.8 21.9 31.2 8.3 11.2 23.4 50.1 19.1 23.7 27.0 14.8 14.6 19.6 13.1 18.7 28.3 23.2 22.1 14.2 35.6 24.0 20.6 9.4 19.6 15.5 58.3 14.8 4.8 30.8 37.3 30.8 35.2 32.2 25.3 39.3 24.5 49.5 42.0 285.9 218.9 134.1 191.3 581.3 188.0 751.3 254.8 254.3 215.0 406.5 339.7 116.7 26.6 214.2 480.1 300.8 208.9 46.7 262.9 169.7 168.2 247.6 130.6 360.3 102.3 308.3 215.0 264.6 155.1 281.2 230.1 161.1 163.6 161.5 208.3 454.2 307.7 252.8 415.1 100.9 370.8 329.8 235.9 615.9 350.9 632.0 137.8 123.1 224.4 298.6 LASP1 "Lasp-1, MLN50" ENSG00000002834 "LIM and SH3 protein 1" Q14847 17 38869859-38921770 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Ion transport, Transport" Actin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 124.5" "Cell type enhanced" "Detected in many" 8 "Late spermatids: 467.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA012072, CAB022049" Enhanced Supported "Plasma membrane,Focal adhesion sites,Cytosol" NA NA 26000000 "Plasma membrane, Cytosol" "Focal adhesion sites" "CAB022049: , HPA012072: AB_1852714" "unprognostic (1.23e-1)" "unprognostic (2.09e-2)" "unprognostic (1.77e-1)" "prognostic unfavorable (4.57e-4)" "unprognostic (1.47e-1)" "unprognostic (3.03e-2)" "prognostic unfavorable (2.41e-4)" "unprognostic (1.06e-3)" "unprognostic (2.24e-1)" "unprognostic (9.60e-2)" "unprognostic (9.87e-3)" "unprognostic (1.01e-1)" "unprognostic (9.65e-3)" "unprognostic (1.29e-3)" "unprognostic (3.95e-2)" "unprognostic (1.60e-3)" "unprognostic (4.53e-2)" 51.2 20.0 23.8 40.3 22.4 45.4 35.5 15.5 25.7 23.6 57.4 16.3 18.7 54.4 23.4 24.1 22.4 20.8 48.3 15.2 18.4 23.3 33.1 47.5 33.3 44.2 20.0 14.3 28.4 30.1 10.1 17.6 40.0 16.1 18.9 38.6 24.2 22.4 24.1 10.7 18.3 124.5 21.3 12.2 43.1 39.5 13.9 12.9 40.5 18.3 18.7 33.7 22.0 28.3 6.4 13.9 34.0 19.9 17.3 16.5 13.1 35.4 73.9 21.6 19.1 31.8 34.5 37.3 44.6 43.6 47.0 34.6 22.0 38.6 16.2 37.3 68.9 26.7 56.5 9.8 33.9 41.2 11.8 5.3 7.7 21.4 38.3 30.2 17.8 23.4 30.6 11.9 39.8 11.3 29.4 31.5 10.0 13.1 5.4 65.4 11.7 21.1 27.5 10.8 31.2 18.5 11.9 11.5 20.4 57.7 31.2 3.2 7.9 26.5 27.9 23.1 41.8 44.0 21.8 55.0 28.2 41.2 33.0 27.0 14.0 18.4 12.6 29.8 16.0 33.9 9.9 14.8 16.8 16.5 17.1 11.3 6.4 8.4 11.0 13.9 6.3 7.2 10.9 34.0 17.3 19.9 10.7 10.7 13.1 23.8 22.4 15.5 25.7 18.4 23.3 20.0 14.3 16.1 12.9 38.7 25.9 38.3 19.5 37.2 55.7 0.8 66.2 32.1 19.4 69.8 9.8 4.3 14.9 58.2 85.5 48.9 225.0 0.0 65.7 33.5 47.6 22.3 51.8 85.9 75.8 25.4 83.1 70.6 116.7 467.6 48.1 58.0 33.7 52.3 91.2 21.1 95.7 106.3 37.4 62.1 22.0 64.7 29.7 2.1 4.1 24.8 5.4 60.9 75.9 23.8 LCK ENSG00000182866 "LCK proto-oncogene, Src family tyrosine kinase" P06239 1 32251239-32286165 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Host-virus interaction" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "blood: 112.2;lymphoid tissue: 153.0" "Cell type enriched" "Detected in many" 10 "T-cells: 207.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 14 "gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2" "Group enriched" "Detected in many" 13 "NK-cells: 42.8;T-cells: 112.2" "Group enriched" "Detected in some" 6 "JURKAT: 66.9;MOLT-4: 93.9;U-698: 54.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA003494, CAB003816" Enhanced Approved "Golgi apparatus" NA NA "Golgi apparatus" "CAB003816: AB_562158, HPA003494: AB_1852751" "unprognostic (6.38e-3)" "unprognostic (5.45e-3)" "unprognostic (8.39e-2)" "prognostic favorable (2.96e-6)" "unprognostic (2.20e-2)" "prognostic favorable (2.91e-4)" "unprognostic (4.78e-3)" "unprognostic (1.33e-2)" "prognostic favorable (5.65e-5)" "unprognostic (3.07e-2)" "unprognostic (3.80e-2)" "unprognostic (2.83e-1)" "prognostic unfavorable (2.60e-5)" "unprognostic (8.15e-2)" "unprognostic (4.05e-2)" "unprognostic (7.39e-2)" "unprognostic (1.17e-2)" 2.6 0.7 0.4 28.2 0.5 3.8 1.3 0.3 0.5 1.7 3.9 0.5 0.9 2.2 1.1 4.5 2.3 1.6 3.8 1.0 0.4 0.4 3.0 2.3 6.6 34.9 0.9 0.5 1.2 0.8 0.0 0.8 0.7 0.6 2.2 1.9 1.3 8.4 1.3 0.9 1.0 16.5 0.7 1.0 28.9 3.5 0.7 0.5 153.0 2.9 1.5 27.1 5.8 2.1 6.1 0.5 2.5 0.3 42.8 112.2 109.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 11.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 66.9 0.0 0.0 0.0 0.0 93.9 0.0 1.0 0.8 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 54.1 0.0 0.0 0.0 0.6 0.3 0.4 83.4 0.3 77.5 4.0 86.1 90.2 0.3 6.1 97.0 91.3 2.5 42.8 0.3 0.5 112.2 109.3 0.4 0.5 0.3 0.5 0.4 0.4 0.9 0.5 0.6 0.5 0.0 16.0 20.4 0.9 4.0 0.0 1.1 2.5 2.7 2.3 3.5 0.0 0.2 0.0 0.3 0.1 1.6 0.0 0.0 0.4 0.1 2.0 0.8 4.7 1.0 0.3 0.0 2.4 3.7 4.9 0.0 0.0 0.6 3.3 0.0 0.0 0.0 2.7 0.0 0.4 1.1 0.0 0.0 0.9 3.7 1.9 2.8 0.3 207.5 0.4 1.0 LEF1 "TCF10, TCF1ALPHA, TCF7L3" ENSG00000138795 "Lymphoid enhancer binding factor 1" Q9UJU2 4 108047545-108168956 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 231.5" "Cell type enhanced" "Detected in many" 12 "Distal tubular cells: 11.6;Melanocytes: 32.1;Spermatocytes: 21.3;T-cells: 13.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 42.2" "Lineage enriched" "Detected in many" 5 "T-cells: 42.2" "Group enriched" "Detected in many" 5 "JURKAT: 98.3;MOLT-4: 93.3;REH: 72.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002087, CAB019405" Enhanced Approved Nucleoplasm NA NA Nucleoplasm "CAB019405: AB_823558, HPA002087: AB_1079245" "unprognostic (1.03e-3)" "unprognostic (7.36e-3)" "unprognostic (2.97e-2)" "prognostic favorable (1.37e-5)" "unprognostic (9.08e-2)" "unprognostic (5.24e-2)" "unprognostic (3.81e-2)" "unprognostic (1.10e-2)" "unprognostic (1.77e-1)" "unprognostic (5.21e-2)" "unprognostic (9.99e-2)" "unprognostic (1.37e-1)" "prognostic unfavorable (2.47e-6)" "unprognostic (1.12e-1)" "unprognostic (5.22e-2)" "unprognostic (7.88e-2)" "unprognostic (8.91e-2)" 0.9 13.5 3.5 9.3 5.4 7.6 2.0 1.6 3.4 3.6 1.0 2.9 0.8 0.4 6.0 3.5 3.4 5.0 2.8 0.5 4.7 5.2 2.7 0.3 2.4 25.3 4.9 1.9 1.8 0.8 0.0 1.1 7.8 3.1 2.8 1.0 1.6 3.1 0.7 0.5 2.4 3.9 2.9 4.4 7.0 0.9 8.2 2.3 231.5 2.7 1.3 20.6 4.8 3.2 0.3 0.1 0.5 0.0 8.9 42.2 9.5 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 1.2 0.3 0.7 4.1 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.5 0.0 2.9 1.0 0.0 0.0 0.0 3.6 0.5 0.0 0.1 0.0 0.1 0.6 0.0 98.3 2.1 0.0 0.4 0.1 93.3 0.0 0.2 1.0 0.2 72.0 1.4 0.0 0.3 0.2 0.4 0.8 0.0 0.0 13.8 1.1 0.3 0.0 0.0 1.9 1.6 0.0 2.4 6.0 2.5 16.5 1.2 0.0 7.9 0.0 0.0 0.0 2.6 0.0 0.5 0.1 19.7 8.8 0.0 0.3 42.2 29.2 0.5 8.9 0.0 0.1 25.7 9.5 3.5 5.4 1.6 3.4 4.7 5.2 4.9 1.9 3.1 2.3 3.0 3.4 0.0 1.1 3.0 0.0 1.2 0.0 4.0 1.2 0.0 0.0 0.1 11.6 0.0 3.1 3.6 0.0 0.0 0.0 0.1 1.8 1.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 6.9 0.6 0.8 32.1 0.0 0.0 0.4 0.2 0.0 0.0 0.3 0.0 0.0 5.9 21.3 9.6 1.1 0.3 13.1 0.1 0.3 LIFR CD118 ENSG00000113594 "LIF receptor alpha" P42702 5 38474963-38608354 "Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enriched" "Detected in many" 6 "Ito cells: 765.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 40.6;HHSteC: 17.3;SCLC-21H: 26.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "Intracellular and membrane" NA NA 74000 "unprognostic (6.00e-3)" "unprognostic (2.53e-1)" "unprognostic (1.05e-1)" "unprognostic (2.81e-3)" "unprognostic (8.80e-2)" "unprognostic (7.13e-2)" "unprognostic (1.11e-1)" "prognostic favorable (1.92e-4)" "unprognostic (1.78e-1)" "unprognostic (9.80e-2)" "unprognostic (2.73e-3)" "unprognostic (1.06e-1)" "prognostic favorable (1.40e-7)" "unprognostic (3.69e-2)" "unprognostic (1.15e-1)" "unprognostic (2.03e-2)" "unprognostic (1.65e-1)" 35.3 14.7 15.8 8.2 19.2 0.5 33.9 10.1 21.3 27.7 10.4 25.3 22.8 4.9 34.8 14.8 10.4 26.0 10.2 16.3 19.1 11.0 20.3 23.9 21.7 20.2 24.3 11.8 17.9 17.8 13.5 12.5 41.5 23.4 23.6 7.5 17.1 24.9 24.7 24.0 10.5 11.7 26.9 21.4 22.5 18.8 9.3 25.3 4.7 31.4 7.3 8.1 13.6 15.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 2.3 40.6 3.0 11.4 12.7 0.3 3.4 1.9 2.7 1.7 0.4 2.2 0.0 0.5 4.8 6.9 0.3 2.6 0.9 4.7 0.0 3.7 0.0 4.3 1.6 17.3 0.0 0.2 10.6 0.7 6.6 0.7 2.6 3.8 0.4 1.1 6.5 3.4 0.5 0.0 0.1 1.0 0.0 7.2 0.0 8.6 0.0 2.6 1.0 26.6 3.3 14.0 0.7 0.0 5.3 0.9 0.0 0.8 4.4 8.7 10.3 2.0 0.0 0.0 0.0 7.2 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 19.2 10.1 21.3 19.1 11.0 24.3 11.8 23.4 25.3 11.9 34.9 9.3 5.9 20.6 5.8 24.6 10.2 10.7 10.3 14.0 7.9 7.7 5.0 1.9 12.6 122.5 0.0 0.0 7.8 22.5 46.1 21.1 1.1 6.8 3.2 1.6 0.0 765.5 62.0 21.6 105.3 2.6 16.9 0.0 0.0 5.1 6.9 0.0 18.7 13.5 35.3 38.8 42.2 8.9 6.1 15.8 23.9 7.5 0.0 4.7 LMNA "CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1" ENSG00000160789 "Lamin A/C" P02545 1 156082573-156140089 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cardiomyopathy, Charcot-Marie-Tooth disease, Congenital muscular dystrophy, Disease mutation, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "granulocytes: 1139.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "basophil: 10.4;memory CD4 T-cell: 8.9;myeloid DC: 34.8;T-reg: 35.4" "Group enriched" "Detected in all" 8 "dendritic cells: 34.8;granulocytes: 10.4;T-cells: 35.4" "Cell line enhanced" "Detected in many" "WM-115: 137.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004022, HPA006523, HPA006660, HPA012078" Supported Supported "Nucleoplasm,Nuclear speckles" NA NA 3200000 "Nucleoplasm, Nuclear speckles" "CAB004022: AB_2136278, HPA006523: , HPA006660: AB_1079231, HPA012078: " "unprognostic (2.22e-2)" "unprognostic (1.89e-1)" "unprognostic (1.04e-2)" "unprognostic (5.75e-2)" "unprognostic (7.43e-3)" "unprognostic (1.47e-1)" "unprognostic (5.23e-3)" "unprognostic (3.27e-2)" "unprognostic (8.33e-2)" "unprognostic (5.90e-2)" "unprognostic (5.10e-2)" "unprognostic (6.34e-2)" "unprognostic (1.41e-2)" "unprognostic (1.24e-1)" "unprognostic (2.89e-1)" "unprognostic (3.08e-2)" "unprognostic (1.44e-2)" 64.0 37.3 7.4 51.4 11.8 21.3 88.6 9.0 10.8 62.8 32.6 21.9 27.2 28.6 69.1 52.3 62.2 40.1 77.7 62.5 8.8 7.5 25.9 26.6 51.8 39.6 15.7 11.2 60.3 30.9 15.2 17.4 73.3 18.1 34.0 15.2 32.7 37.5 26.4 36.3 68.7 29.9 63.0 10.3 22.4 36.7 30.2 12.9 9.4 31.5 140.0 35.6 46.4 51.2 1.1 34.8 10.4 3.5 1.7 35.4 6.4 59.1 58.7 6.5 17.4 32.9 57.1 20.0 64.0 81.5 48.3 33.4 14.8 58.6 0.5 38.0 98.4 24.9 69.3 9.5 49.6 12.6 20.1 5.6 18.7 47.2 34.3 29.7 3.2 55.2 34.1 21.6 39.2 27.0 25.0 43.1 0.0 10.0 4.5 52.9 46.7 0.1 10.3 4.8 68.6 74.8 0.2 22.7 17.3 47.8 28.4 6.6 13.3 43.2 46.9 59.4 10.0 39.6 15.4 76.8 46.1 29.3 56.9 51.6 4.4 1.2 1.2 75.3 3.1 137.4 10.4 3.5 0.1 1.2 0.8 1.0 1.1 8.9 3.4 34.8 0.0 0.1 0.3 0.8 1.7 0.1 0.3 35.4 6.4 7.4 11.8 9.0 10.8 8.8 7.5 15.7 11.2 18.1 12.9 244.2 393.4 23.4 924.2 542.3 8.1 85.2 119.8 93.7 315.1 153.5 45.2 422.7 92.9 335.7 28.0 269.0 358.5 46.7 313.5 336.4 599.3 268.8 1139.0 91.5 324.9 12.7 414.0 194.0 35.3 30.8 267.2 305.5 814.9 19.0 337.1 35.8 392.9 289.2 270.1 93.5 18.0 200.5 784.5 74.2 30.2 526.5 569.5 18.5 345.1 767.5 LMO1 "RBTN1, RHOM1, TTG1" ENSG00000166407 "LIM domain only 1" P25800 11 8224304-8268716 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "retina: 29.4;skeletal muscle: 29.1" "Group enriched" "Detected in some" 6 "Basal keratinocytes: 16.5;Distal tubular cells: 23.2;Early spermatids: 35.8;Horizontal cells: 38.1" "Cancer enriched" "Detected in many" 6 "glioma: 6.4" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HeLa: 21.7;SCLC-21H: 8.5;SH-SY5Y: 26.0;SiHa: 5.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (3.74e-3)" "unprognostic (1.45e-1)" "unprognostic (4.75e-6)" "unprognostic (9.34e-2)" "unprognostic (2.37e-1)" "unprognostic (1.98e-1)" "unprognostic (7.06e-3)" "unprognostic (8.09e-2)" "unprognostic (2.24e-1)" "unprognostic (9.05e-2)" "unprognostic (4.36e-12)" "unprognostic (1.76e-2)" "unprognostic (8.88e-2)" "unprognostic (2.58e-2)" "unprognostic (3.13e-2)" 0.3 1.7 2.5 0.3 2.1 0.2 0.6 0.4 3.0 0.2 0.2 1.5 0.1 0.4 0.3 2.1 0.6 0.3 0.2 0.5 2.3 5.9 1.0 0.2 0.2 0.2 3.5 0.6 0.2 1.6 0.2 2.1 0.3 2.1 0.3 0.2 29.4 0.2 0.2 29.1 6.4 0.3 0.5 1.2 0.6 0.6 1.6 2.0 0.1 0.2 0.1 0.2 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.6 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.4 0.1 0.3 0.0 0.0 0.0 0.9 0.0 21.7 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.0 0.2 0.0 3.1 0.0 0.0 0.0 0.4 0.9 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 8.5 26.0 5.2 2.9 0.1 1.1 0.0 0.0 0.0 0.0 0.6 0.0 0.2 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 2.1 0.4 3.0 2.3 5.9 3.5 0.6 2.1 2.0 0.0 0.0 0.0 0.0 16.5 1.1 1.0 0.0 4.0 0.0 0.0 0.0 0.1 23.2 0.2 35.8 0.1 0.0 0.0 1.1 4.9 0.2 0.0 1.1 0.0 0.2 38.1 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.5 3.1 0.0 0.4 0.0 3.7 0.0 0.0 0.5 1.2 3.0 0.2 0.0 0.0 0.0 LMO2 "RBTN2, RBTNL1, RHOM2, TTG2" ENSG00000135363 "LIM domain only 2" P25791 11 33858576-33892289 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 11 "Endothelial cells: 121.0;Erythroid cells: 46.7;Ito cells: 110.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basophil: 1.5;classical monocyte: 1.1;eosinophil: 3.0;intermediate monocyte: 3.1;myeloid DC: 4.3;neutrophil: 1.6;non-classical monocyte: 3.6" "Group enriched" "Detected in many" 7 "dendritic cells: 4.3;granulocytes: 3.0;monocytes: 3.6" "Cell line enhanced" "Detected in some" "HEL: 23.3;HL-60: 23.2;K-562: 23.6;NB-4: 9.9;THP-1: 30.8;U-937: 10.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016258, HPA029285, HPA070901, HPA070910" Approved Enhanced Nucleoplasm NA NA Nucleoplasm "CAB016258: AB_2136572, HPA029285: AB_2672978, HPA070901: , HPA070910: " "unprognostic (1.60e-1)" "unprognostic (1.47e-2)" "unprognostic (6.03e-2)" "unprognostic (1.71e-3)" "unprognostic (1.89e-1)" "unprognostic (1.14e-3)" "prognostic favorable (3.12e-4)" "unprognostic (1.73e-3)" "unprognostic (8.95e-2)" "unprognostic (5.76e-2)" "unprognostic (7.86e-3)" "unprognostic (3.69e-1)" "unprognostic (7.10e-2)" "unprognostic (9.65e-2)" "unprognostic (3.90e-1)" "unprognostic (1.45e-1)" "unprognostic (4.46e-2)" 18.2 6.1 13.8 13.6 15.6 28.8 14.5 5.2 18.4 9.4 5.5 10.3 6.4 6.2 9.7 9.9 6.9 8.6 9.1 6.4 15.8 12.2 12.9 5.5 15.9 22.2 14.2 7.2 5.1 3.9 4.2 8.3 8.5 11.9 8.3 2.7 14.6 4.5 4.0 25.0 4.2 5.5 6.6 13.9 22.0 4.4 3.6 11.1 1.0 10.7 8.1 13.3 11.1 14.8 0.5 4.3 3.0 3.6 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.9 0.5 5.7 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.1 23.3 0.0 0.0 0.1 23.2 8.1 0.0 0.0 0.0 0.0 0.0 4.5 0.0 23.6 0.0 0.0 0.1 2.1 9.9 0.4 0.0 0.0 6.6 0.3 0.0 0.0 0.3 1.9 0.0 0.1 0.2 0.0 0.1 0.0 30.8 0.3 0.0 0.1 0.7 0.0 0.0 0.1 0.2 2.1 10.9 0.1 1.5 1.1 3.0 0.0 3.1 0.1 0.5 0.0 0.0 4.3 0.0 0.0 0.0 1.6 0.0 3.6 0.3 0.0 0.5 13.8 15.6 5.2 9.5 15.8 12.2 14.2 7.2 11.9 11.1 3.0 10.3 7.6 7.8 7.4 1.4 1.7 7.6 5.3 0.0 5.2 2.0 0.3 0.0 2.9 0.2 121.0 0.0 46.7 1.7 1.7 8.4 4.1 7.0 1.0 33.2 0.0 0.0 110.5 41.7 0.7 3.7 42.5 10.1 0.0 0.0 1.0 0.9 0.0 0.0 5.6 1.9 0.0 2.8 0.2 2.7 5.3 18.0 0.5 0.4 19.5 LPP ENSG00000145012 "LIM domain containing preferred translocation partner in lipoma" Q93052 3 188153284-188890671 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "smooth muscle: 127.8;urinary bladder: 105.1" "Cell type enhanced" "Detected in all" 11 "Early spermatids: 514.4;Late spermatids: 1329.9;Smooth muscle cells: 529.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 18.0" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 29.5;EFO-21: 36.6;U-698: 61.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA011133, HPA017342" Enhanced Enhanced "Focal adhesion sites,Cytosol" NA NA 520000 "Focal adhesion sites, Cytosol" "HPA011133: AB_1853247, HPA017342: AB_1853249" "unprognostic (1.50e-1)" "unprognostic (4.97e-3)" "unprognostic (1.41e-1)" "unprognostic (2.18e-1)" "unprognostic (1.86e-1)" "unprognostic (4.05e-1)" "unprognostic (2.43e-3)" "unprognostic (7.97e-2)" "unprognostic (2.17e-1)" "unprognostic (5.56e-2)" "unprognostic (3.44e-3)" "unprognostic (2.10e-1)" "unprognostic (2.57e-3)" "unprognostic (2.25e-2)" "unprognostic (6.86e-2)" "unprognostic (2.82e-3)" "unprognostic (1.48e-1)" 19.6 4.2 2.7 29.5 2.8 3.1 12.5 3.0 2.7 42.2 29.9 2.1 19.6 5.0 68.6 14.9 59.7 10.0 37.9 9.3 2.6 2.8 10.9 5.3 11.4 6.0 2.8 1.6 26.1 4.4 4.7 3.2 5.2 3.0 37.7 12.8 8.5 7.0 28.4 11.6 5.9 17.2 127.8 3.2 9.5 12.1 30.7 1.5 5.1 5.4 4.2 7.8 105.1 38.3 5.9 4.9 18.0 4.5 4.3 5.0 1.4 7.7 7.1 5.2 3.5 11.3 11.7 5.6 5.1 6.5 3.7 2.5 12.9 3.7 29.5 36.6 11.4 4.6 3.3 1.5 3.4 9.4 3.2 1.7 1.4 5.5 3.4 4.8 0.6 1.7 8.3 4.8 8.3 7.2 5.4 6.2 1.6 0.0 0.6 6.5 2.4 1.5 0.6 2.1 4.9 2.3 1.9 3.9 0.1 4.1 8.2 0.3 0.0 10.9 3.6 6.1 9.0 2.8 2.4 13.4 8.6 6.6 6.1 12.5 0.0 1.1 61.0 4.3 1.3 7.7 0.8 4.5 1.9 5.0 4.2 3.2 2.9 4.3 3.6 2.4 5.9 2.3 2.9 18.0 4.3 4.0 4.9 1.6 1.4 2.7 2.8 3.0 2.7 2.6 2.8 2.8 1.6 3.0 1.5 83.4 55.0 41.3 72.1 69.3 7.7 101.6 99.3 40.2 83.0 66.3 13.7 35.7 24.9 114.3 514.4 83.0 142.7 23.3 78.6 20.6 102.9 124.2 17.4 84.7 36.8 4.8 74.4 114.2 61.5 1329.9 208.5 76.2 75.9 36.1 86.3 27.1 104.6 158.4 448.3 61.0 7.4 329.8 529.6 8.1 6.6 59.6 15.6 39.5 123.5 109.3 LRIG3 "FLJ90440, KIAA3016" ENSG00000139263 "Leucine rich repeats and immunoglobulin like domains 3" Q6UXM1 12 58872149-58920522 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 4 "Cholangiocytes: 33.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "hTCEpi: 27.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010773 Approved Approved Cytosol NA NA Cytosol "HPA010773: AB_1853275" "unprognostic (1.79e-1)" "unprognostic (2.71e-1)" "unprognostic (1.01e-2)" "unprognostic (3.88e-2)" "unprognostic (2.53e-1)" "unprognostic (3.46e-2)" "unprognostic (1.83e-2)" "unprognostic (1.34e-3)" "unprognostic (1.21e-1)" "unprognostic (1.92e-1)" "unprognostic (3.04e-2)" "unprognostic (4.25e-2)" "unprognostic (2.74e-3)" "unprognostic (2.47e-2)" "unprognostic (1.10e-1)" "unprognostic (1.28e-2)" "unprognostic (1.46e-2)" 15.8 1.7 3.6 11.8 4.1 0.0 16.4 1.0 3.7 18.7 14.8 7.8 12.1 8.4 14.2 13.8 17.1 9.9 17.8 4.7 4.6 1.8 6.5 6.1 9.6 5.0 3.6 2.6 14.7 15.3 4.8 10.3 6.8 5.8 15.5 16.0 13.5 24.9 11.6 5.0 25.9 10.0 21.6 3.0 7.2 13.5 6.4 6.6 5.4 37.6 15.0 12.8 15.7 20.7 0.0 0.0 0.0 0.0 0.0 0.4 0.1 2.0 1.9 7.4 0.5 13.6 15.9 1.7 4.9 14.3 4.8 5.1 5.8 2.7 1.9 10.0 5.4 5.8 9.6 2.7 12.6 3.5 14.6 9.6 0.5 3.3 2.8 2.6 0.8 0.2 15.7 27.4 5.1 11.0 9.4 13.1 2.2 0.1 2.4 3.2 0.9 2.3 0.0 7.9 2.4 2.9 0.0 6.3 4.8 3.7 10.6 7.5 0.0 4.3 2.7 4.5 11.0 5.0 0.1 5.6 6.5 4.5 3.9 6.4 1.0 0.0 0.0 1.3 0.0 3.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.6 4.1 1.0 3.7 4.6 1.8 3.6 2.6 5.8 6.6 14.9 17.4 0.0 7.5 19.9 2.6 4.1 33.1 13.4 23.9 1.8 0.0 0.7 0.0 9.0 0.3 11.4 10.7 0.0 15.8 0.4 8.2 2.6 0.0 6.8 1.9 3.2 11.1 4.3 0.3 0.0 25.0 0.2 3.3 0.0 11.8 2.8 7.5 14.0 27.3 4.2 0.1 6.5 11.3 0.4 1.5 19.6 0.2 0.0 25.9 2.7 LRP1B "LRP-DIT, LRPDIT" ENSG00000168702 "LDL receptor related protein 1B" Q9NZR2 2 140231423-142131701 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 25.7;thyroid gland: 14.9" "Group enriched" "Detected in some" 5 "Bipolar cells: 15.8;Early spermatids: 4.6;Late spermatids: 4.3" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 13 "myeloid DC: 1.4;plasmacytoid DC: 1.2" "Lineage enriched" "Detected in single" 14 "dendritic cells: 1.4" "Cell line enhanced" "Detected in some" "ASC diff: 4.2;HEK 293: 4.5;HeLa: 2.3;HSkMC: 2.2;U-138 MG: 4.9;U-87 MG: 2.6" "Low region specificity" "Detected in all" "HPA069094, HPA074788" Approved Approved Vesicles NA NA 63000 Vesicles "HPA069094: AB_2686082, HPA074788: AB_2797273" "unprognostic (5.31e-4)" "unprognostic (3.68e-2)" "unprognostic (2.61e-1)" "unprognostic (7.36e-4)" "unprognostic (5.19e-2)" "unprognostic (1.26e-1)" "unprognostic (2.00e-2)" "unprognostic (3.49e-1)" "unprognostic (3.75e-1)" "unprognostic (7.02e-3)" "unprognostic (1.64e-3)" "unprognostic (1.05e-1)" "unprognostic (2.94e-3)" "unprognostic (4.85e-3)" "unprognostic (1.52e-1)" "unprognostic (1.66e-2)" "unprognostic (1.36e-1)" 4.8 4.5 17.6 1.3 14.1 1.2 2.6 23.2 25.7 1.4 1.3 6.5 0.0 1.2 1.3 6.8 1.3 1.9 1.4 1.6 18.3 9.3 2.2 1.6 1.4 1.2 10.8 16.7 3.0 1.2 1.1 12.7 1.2 12.8 3.5 1.3 0.1 2.5 3.8 10.5 1.7 1.3 1.3 8.2 1.2 1.5 1.9 10.6 0.0 14.9 0.0 1.3 1.2 1.4 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 4.2 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 1.0 0.2 0.2 0.6 4.5 0.0 2.3 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.4 1.7 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.9 0.2 0.0 0.0 0.4 0.0 0.0 0.0 4.9 0.1 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 17.6 14.1 23.2 21.3 18.3 9.3 10.8 16.7 12.8 10.6 0.0 0.0 0.0 0.3 0.2 15.8 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 1.1 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.7 0.0 0.8 0.0 0.3 0.1 0.1 0.3 0.0 0.0 0.0 0.6 LYL1 bHLHa18 ENSG00000104903 "LYL1, basic helix-loop-helix family member" P12980 19 13099033-13103161 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 37.4;lymphoid tissue: 25.4" "Group enriched" "Detected in many" 4 "Early spermatids: 274.5;Late spermatids: 496.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "eosinophil: 8.8" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HEL: 33.0;HL-60: 23.1;HMC-1: 55.7;K-562: 25.9;NB-4: 33.8;REH: 24.8;THP-1: 22.4;U-937: 22.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA075004 Approved "Golgi apparatus" NA NA "Golgi apparatus" "HPA075004: AB_2686728" "unprognostic (8.62e-2)" "unprognostic (1.58e-1)" "unprognostic (1.27e-2)" "unprognostic (3.29e-3)" "unprognostic (2.76e-1)" "unprognostic (3.64e-3)" "unprognostic (2.46e-1)" "unprognostic (1.05e-2)" "unprognostic (1.90e-2)" "unprognostic (5.87e-2)" "unprognostic (1.78e-3)" "unprognostic (1.36e-1)" "prognostic unfavorable (3.89e-4)" "unprognostic (1.18e-1)" "unprognostic (6.54e-2)" "unprognostic (1.33e-1)" "unprognostic (4.28e-1)" 6.3 3.0 3.4 19.9 5.8 37.4 8.0 1.1 3.8 4.0 3.7 5.5 1.3 3.0 5.3 3.9 5.9 3.8 3.5 4.9 4.5 2.9 3.9 2.0 8.1 24.0 7.1 1.6 3.2 1.6 0.8 1.7 8.0 5.1 6.2 1.4 4.4 6.4 2.4 3.5 2.0 8.8 3.3 6.0 25.4 4.2 11.9 4.1 3.6 3.5 1.4 18.9 3.3 7.0 4.6 1.4 8.8 3.6 0.0 0.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 6.4 2.2 0.0 0.0 0.0 0.1 0.0 0.0 3.7 0.0 33.0 0.0 0.3 0.3 23.1 55.7 0.1 0.0 0.0 0.0 0.0 8.5 0.0 25.9 1.1 0.0 0.0 0.1 33.8 0.0 0.1 0.8 24.8 0.0 2.8 0.0 0.0 0.0 2.4 0.7 0.0 1.5 0.0 0.0 22.4 13.6 0.0 0.0 0.9 0.0 0.0 0.0 5.2 0.0 22.3 0.0 2.5 2.3 8.8 0.1 2.9 0.2 2.8 0.3 0.2 1.4 4.6 0.2 0.2 3.6 0.0 3.6 0.4 0.5 0.6 3.4 5.8 1.1 3.7 4.5 2.9 7.1 1.6 5.1 4.1 0.0 0.3 46.4 0.5 2.3 0.0 2.0 2.5 1.4 0.0 1.8 0.0 0.6 0.0 0.2 274.5 27.4 1.1 70.0 0.0 0.8 4.7 0.2 44.9 0.8 92.6 0.0 1.7 20.9 52.2 496.4 7.5 33.5 6.8 2.8 1.1 1.4 1.2 1.5 11.3 0.2 0.1 12.9 1.8 39.2 5.5 1.6 1.3 2.2 0.8 0.4 LZTR1 "BTBD29, LZTR-1" ENSG00000099949 "Leucine zipper like transcription regulator 1" Q8N653 22 20982013-20999038 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA067852, HPA068772, HPA071248" Approved Approved Nucleoplasm,Centrosome,Cytosol No No Nucleoplasm "Centrosome, Cytosol" "HPA067852: , HPA068772: AB_2686031, HPA071248: AB_2686372" "unprognostic (1.88e-2)" "unprognostic (1.01e-1)" "unprognostic (1.90e-1)" "unprognostic (1.08e-1)" "unprognostic (1.06e-1)" "unprognostic (2.44e-2)" "prognostic unfavorable (5.15e-4)" "unprognostic (9.81e-2)" "unprognostic (3.55e-1)" "unprognostic (3.78e-2)" "unprognostic (1.01e-2)" "unprognostic (2.64e-1)" "unprognostic (1.16e-3)" "unprognostic (4.29e-2)" "unprognostic (1.65e-1)" "unprognostic (6.25e-2)" "unprognostic (1.25e-2)" 21.2 16.9 17.3 15.6 17.4 10.3 17.9 20.7 24.7 18.5 18.3 25.3 20.6 18.9 24.9 14.0 16.5 18.3 21.2 15.8 15.4 10.9 17.2 13.1 16.2 12.8 19.6 16.5 21.7 16.2 24.9 26.0 18.8 19.0 16.9 12.9 18.9 17.5 18.0 17.2 15.0 15.7 21.9 14.0 19.3 14.5 10.8 19.2 10.8 19.6 12.6 12.5 18.5 16.4 1.6 2.2 0.2 3.4 1.8 3.0 1.5 6.3 5.2 7.8 9.4 17.9 12.4 6.3 13.0 9.1 7.4 10.2 3.0 2.6 6.7 4.8 14.5 6.9 8.6 5.8 10.6 3.0 12.5 13.6 7.2 6.8 4.5 9.6 3.9 9.6 11.4 5.4 9.4 6.8 11.8 14.4 6.3 30.0 11.7 8.4 3.8 6.9 3.7 2.4 7.7 5.7 8.2 11.3 2.6 5.9 8.6 7.7 11.4 7.1 12.3 7.6 4.9 5.7 7.2 12.8 17.4 8.9 7.8 7.0 5.1 4.4 2.0 7.8 3.8 8.4 0.0 2.5 0.2 3.0 3.1 1.6 1.6 1.5 2.8 2.2 1.0 2.1 1.5 0.1 1.8 3.4 1.2 0.5 1.5 17.3 17.4 20.7 24.7 15.4 10.9 19.6 16.5 19.0 19.2 11.9 10.4 9.7 1.4 1.9 8.1 11.2 2.5 6.7 5.7 8.7 5.9 3.6 1.7 6.6 0.8 9.5 7.8 0.0 4.3 3.2 5.4 2.0 5.7 6.2 6.9 3.2 8.7 12.3 11.6 1.3 8.1 4.9 6.8 4.6 9.1 6.6 5.7 5.9 9.2 6.1 9.3 0.0 7.2 2.6 1.7 3.1 3.0 6.9 5.8 0.9 MAF c-MAF ENSG00000178573 "MAF bZIP transcription factor" O75444 16 79585843-79600714 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Mental retardation, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 12 "Hofbauer cells: 210.4;Ito cells: 532.8;Kupffer cells: 333.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "basophil: 20.7;MAIT T-cell: 6.3" "Group enriched" "Detected in many" 16 "granulocytes: 20.7;T-cells: 6.3" "Group enriched" "Detected in some" 12 "Karpas-707: 50.3;RPMI-8226: 81.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010296, HPA028289" Approved NA NA "CAB010296: AB_638562, HPA028289: AB_10602024" "unprognostic (6.76e-2)" "unprognostic (1.74e-2)" "unprognostic (6.45e-2)" "unprognostic (7.65e-2)" "unprognostic (7.89e-3)" "unprognostic (1.07e-2)" "unprognostic (1.63e-2)" "unprognostic (2.33e-1)" "unprognostic (8.76e-2)" "unprognostic (3.16e-2)" "unprognostic (9.46e-2)" "unprognostic (1.28e-1)" "prognostic unfavorable (3.74e-4)" "unprognostic (4.54e-2)" "unprognostic (7.83e-2)" "unprognostic (1.09e-2)" "unprognostic (4.56e-3)" 19.0 10.2 15.4 17.3 13.5 2.5 28.5 9.3 11.2 25.6 31.8 10.7 9.1 41.7 18.8 15.6 16.7 15.1 12.4 19.0 14.3 5.8 28.7 18.0 16.8 38.1 20.5 9.9 31.4 3.1 59.1 4.8 21.7 13.9 15.8 7.2 14.1 9.7 10.4 26.3 37.2 57.7 15.8 18.7 19.8 9.5 12.4 14.0 10.2 18.4 16.7 14.3 14.6 23.4 0.0 0.0 20.7 0.8 0.6 6.3 0.4 0.0 0.0 5.3 0.0 0.2 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 1.6 2.0 0.0 0.0 0.0 0.2 0.0 3.5 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.5 50.3 0.3 0.0 0.0 0.1 3.3 0.0 0.0 0.0 1.5 81.9 0.0 0.4 0.1 0.0 0.2 0.0 0.1 2.2 0.0 0.0 1.0 0.0 1.7 0.1 0.2 0.0 0.0 0.0 0.2 0.0 0.3 20.7 0.2 0.0 0.8 0.8 6.3 0.0 2.4 1.9 0.0 0.0 0.2 0.3 0.0 0.6 0.2 0.0 3.1 0.4 15.4 13.5 9.3 11.2 14.3 5.8 20.5 9.9 13.9 14.0 8.9 20.0 10.0 3.4 78.5 3.6 6.5 50.9 0.0 5.7 3.5 0.0 1.5 10.0 1.5 0.9 17.7 9.3 0.0 0.7 2.2 63.5 45.2 20.9 52.3 210.4 0.0 2.9 532.8 333.1 4.8 138.7 42.5 42.2 0.0 2.8 71.1 2.6 3.6 108.2 90.5 2.3 12.9 23.7 0.3 0.9 123.3 3.5 69.2 1.2 4.8 MAFB KRML ENSG00000204103 "MAF bZIP transcription factor B" Q9Y5Q3 20 40685848-40689240 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 87.6;parathyroid gland: 154.1" "Cell type enhanced" "Detected in many" 12 "Hofbauer cells: 322.7;Kupffer cells: 488.8;Macrophages: 252.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "intermediate monocyte: 27.4;non-classical monocyte: 36.7" "Lineage enriched" "Detected in many" 14 "monocytes: 36.7" "Cell line enhanced" "Detected in some" "HSkMC: 16.2;hTCEpi: 34.0;SCLC-21H: 9.3;SiHa: 8.4;U-138 MG: 9.2;U-2197: 13.4;U-87 MG: 8.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA005653 Approved Approved "Nucleoplasm,Nucleoli,Golgi apparatus,Cytosol" Yes NA Nucleoplasm "Nucleoli, Golgi apparatus, Cytosol" "HPA005653: AB_1079293" "unprognostic (1.55e-1)" "unprognostic (1.17e-2)" "unprognostic (1.16e-3)" "prognostic unfavorable (5.64e-4)" "unprognostic (9.16e-2)" "unprognostic (3.92e-2)" "unprognostic (1.10e-1)" "unprognostic (2.10e-1)" "unprognostic (2.57e-2)" "unprognostic (6.09e-2)" "unprognostic (5.45e-3)" "unprognostic (9.92e-2)" "unprognostic (3.95e-2)" "unprognostic (1.05e-1)" "unprognostic (3.21e-3)" "unprognostic (3.49e-2)" "unprognostic (2.30e-2)" 38.3 7.9 3.2 13.0 4.0 17.0 19.5 1.0 9.7 10.6 6.9 3.0 1.2 3.3 5.6 8.9 16.8 7.0 9.2 12.4 3.6 2.3 10.9 14.0 21.9 28.9 4.7 3.4 7.0 6.1 154.1 2.3 9.4 5.0 7.6 3.3 5.6 10.4 2.7 11.0 41.6 7.6 5.5 7.7 87.6 4.7 7.5 3.8 6.9 18.2 20.5 11.4 8.2 10.9 0.0 2.5 0.7 36.7 0.0 0.0 2.5 0.0 0.0 0.0 1.4 0.8 0.1 0.2 0.2 0.0 0.1 0.0 0.2 0.1 0.0 1.1 0.2 0.0 2.0 0.0 0.0 0.0 0.0 0.7 0.0 0.6 0.1 0.5 0.0 0.1 16.2 34.0 0.1 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.1 3.9 1.4 3.3 0.0 0.0 0.0 0.0 0.3 0.2 9.3 0.7 8.4 0.8 2.0 3.1 0.8 0.1 0.2 9.2 0.1 13.4 0.0 0.0 0.0 0.0 8.9 0.3 0.0 0.1 7.3 0.0 0.0 27.4 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.7 0.0 36.7 0.0 0.0 2.5 3.2 4.0 1.0 9.7 3.6 2.3 4.7 3.4 5.0 3.8 20.8 32.3 6.7 25.3 60.9 14.6 153.6 7.6 0.0 13.6 48.8 23.6 7.5 1.7 2.0 0.6 19.9 50.9 0.0 3.0 2.1 61.9 37.1 10.4 32.6 322.7 3.2 55.5 34.4 488.8 0.7 27.3 252.1 20.3 0.0 13.7 25.8 5.4 24.6 23.0 0.8 8.2 12.9 44.3 0.5 0.9 77.0 10.4 4.4 8.1 17.7 MALT1 "MLT, PCASP1" ENSG00000172175 "MALT1 paracaspase" Q9UDY8 18 58671386-58754477 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Hydrolase, Protease" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 80.5;monocytes: 107.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RPTEC TERT1: 51.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004494, HPA048432" Enhanced Approved "Nucleoli fibrillar center,Cytosol" No No "Nucleoli fibrillar center" Cytosol "CAB004494: AB_627909, HPA048432: AB_2680389" "unprognostic (3.25e-1)" "unprognostic (2.31e-1)" "unprognostic (3.64e-2)" "unprognostic (3.25e-2)" "unprognostic (1.65e-3)" "unprognostic (4.67e-2)" "unprognostic (6.46e-2)" "unprognostic (4.50e-2)" "unprognostic (3.33e-2)" "unprognostic (4.16e-3)" "unprognostic (3.74e-1)" "unprognostic (2.07e-1)" "unprognostic (2.53e-2)" "unprognostic (2.34e-1)" "unprognostic (2.97e-1)" "unprognostic (1.03e-1)" "unprognostic (6.00e-2)" 11.2 3.9 4.1 21.7 5.6 10.2 10.6 9.1 6.8 11.0 10.7 3.9 10.9 5.5 8.1 10.5 16.4 6.6 8.1 8.7 4.0 4.3 14.9 10.5 14.3 29.0 4.1 1.8 8.1 6.2 10.0 9.3 8.8 4.9 18.1 7.9 7.5 10.7 8.4 10.7 12.6 12.2 6.6 6.2 19.9 6.2 11.8 4.8 22.4 7.9 12.4 24.0 9.6 12.3 6.3 3.6 1.2 1.7 1.6 4.8 1.1 7.5 10.8 13.2 3.3 2.6 5.9 6.0 13.6 9.6 11.8 10.1 8.8 9.8 12.0 6.1 16.8 8.5 7.4 5.7 5.6 14.6 8.1 3.1 4.2 7.7 14.1 4.3 8.6 5.8 3.7 11.9 9.3 9.4 6.2 2.5 3.4 7.0 21.0 6.4 2.4 1.9 3.7 3.3 3.1 3.7 6.5 7.8 8.5 51.8 3.1 1.4 3.0 7.5 3.8 5.1 9.8 3.8 5.0 3.5 15.3 6.7 4.5 12.5 18.8 22.2 10.5 6.1 6.5 6.0 0.8 1.5 1.0 2.7 1.7 2.1 3.6 4.8 2.9 2.2 6.3 4.3 2.8 1.2 1.6 1.6 3.6 2.9 1.1 4.1 5.6 9.1 6.8 4.0 4.3 4.1 1.8 4.9 4.8 20.8 19.2 15.7 28.7 29.3 12.4 13.1 10.2 6.7 7.9 10.4 80.5 5.2 3.3 14.7 9.8 21.6 6.8 0.0 7.2 5.0 8.0 52.3 31.1 8.9 10.4 52.4 6.4 9.8 16.4 5.3 9.5 23.0 11.8 107.4 8.2 29.6 11.9 20.1 6.7 17.3 17.2 19.4 12.0 33.4 32.5 21.7 7.6 22.4 9.1 29.1 MAML2 "KIAA1819, MAM3" ENSG00000184384 "Mastermind like transcriptional coactivator 2" Q8IZL2 11 95976598-96343180 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Notch signaling pathway, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cone photoreceptor cells: 86.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 27.9" "Low region specificity" "Detected in all" HPA035223 Approved Supported "Nucleoplasm,Nuclear bodies,Cytosol" No No "Nuclear bodies" "Nucleoplasm, Cytosol" "HPA035223: AB_10671101" "unprognostic (8.11e-2)" "unprognostic (2.51e-1)" "unprognostic (7.08e-2)" "unprognostic (9.07e-2)" "unprognostic (3.57e-3)" "unprognostic (3.32e-2)" "unprognostic (3.66e-2)" "unprognostic (2.33e-1)" "unprognostic (3.99e-2)" "unprognostic (8.05e-2)" "prognostic unfavorable (3.89e-4)" "unprognostic (9.11e-2)" "prognostic favorable (1.90e-4)" "unprognostic (9.76e-2)" "unprognostic (1.73e-2)" "unprognostic (1.99e-1)" "unprognostic (7.19e-2)" 26.3 5.5 10.2 16.1 8.1 4.2 19.7 27.8 13.4 15.8 9.2 10.4 8.4 4.3 11.2 8.5 9.3 11.7 10.8 8.9 10.5 6.9 13.8 3.5 15.0 10.9 6.9 3.4 11.7 8.2 13.3 15.2 18.8 9.3 12.3 8.9 10.8 16.6 12.3 4.4 14.2 8.9 10.2 14.4 16.8 6.5 4.3 10.6 21.2 11.8 4.8 13.6 16.0 15.3 2.1 1.2 4.7 1.1 4.2 6.4 2.0 5.6 1.1 9.8 2.6 10.2 11.8 2.1 6.5 9.8 4.3 4.5 0.7 12.0 1.2 15.5 15.1 2.3 5.2 2.0 6.3 6.0 27.9 0.7 0.7 2.0 2.1 6.0 0.0 0.0 17.2 0.6 7.7 4.5 8.0 2.4 0.1 3.1 1.8 7.6 0.4 0.1 1.5 1.0 2.9 1.8 1.9 1.8 6.5 6.4 8.0 0.1 0.9 2.4 1.0 2.7 3.3 0.9 0.3 10.6 7.6 1.8 2.6 4.1 1.2 0.2 1.8 3.6 1.1 13.9 0.1 1.1 0.0 1.5 0.6 2.6 1.9 3.2 4.1 1.2 2.1 6.4 4.3 4.7 4.2 0.7 0.9 1.2 2.0 10.2 8.1 27.8 7.0 10.5 6.9 6.9 3.4 9.3 10.6 14.9 7.5 12.1 17.3 17.3 40.8 4.1 12.7 18.7 19.4 12.2 86.4 10.3 10.0 14.8 1.1 20.5 18.4 0.0 0.4 20.6 19.5 17.4 1.1 0.2 16.3 0.0 6.4 6.7 12.6 1.4 8.1 15.7 11.8 16.2 6.2 24.7 9.5 14.4 8.1 11.8 21.9 32.3 17.3 0.5 0.6 11.8 10.9 16.0 11.8 13.1 MAP2K1 "MAPKK1, MEK1, PRKMK1" ENSG00000169032 "Mitogen-activated protein kinase kinase 1" Q02750 15 66386817-66492312 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003834, HPA026430" Approved Enhanced "Plasma membrane,Cytosol" NA NA 62000 "Plasma membrane, Cytosol" "CAB003834: AB_562310, HPA026430: AB_1853742" "unprognostic (4.05e-2)" "unprognostic (1.23e-2)" "unprognostic (2.07e-1)" "unprognostic (4.92e-2)" "prognostic unfavorable (1.95e-4)" "unprognostic (1.81e-3)" "unprognostic (5.78e-2)" "unprognostic (9.91e-3)" "unprognostic (1.11e-1)" "unprognostic (1.77e-1)" "unprognostic (1.45e-1)" "unprognostic (7.62e-3)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (1.96e-1)" "unprognostic (1.15e-1)" "unprognostic (9.40e-3)" 28.6 16.9 33.9 19.1 54.1 29.0 23.6 32.5 48.4 12.5 12.1 8.4 10.2 10.0 11.8 16.5 22.0 10.6 14.4 19.1 49.2 26.4 15.3 53.1 16.4 23.3 17.6 31.2 13.5 11.7 23.4 12.0 15.4 17.2 14.4 12.9 9.1 13.2 12.4 39.5 12.3 10.9 16.9 17.4 14.5 10.8 7.8 12.6 12.6 12.3 9.7 27.9 13.6 18.7 4.6 16.2 5.5 8.2 8.4 7.9 2.7 33.6 15.9 31.9 13.3 19.3 14.5 18.5 24.4 20.9 26.5 23.7 23.8 27.7 30.9 30.3 20.1 20.2 30.0 29.8 35.7 31.3 24.9 17.8 9.9 16.6 12.9 15.6 13.0 14.8 11.2 22.1 19.2 28.5 28.3 20.7 15.8 17.5 39.6 38.7 13.0 10.5 17.1 16.3 31.2 13.9 11.9 19.7 27.5 25.7 14.5 19.7 11.0 19.8 15.5 20.5 26.9 14.0 11.2 28.5 34.6 21.2 24.4 36.2 24.5 43.6 19.7 36.5 23.1 16.1 3.2 8.2 5.5 7.4 8.2 6.7 3.0 6.6 6.9 8.3 4.6 7.9 4.9 3.9 8.4 7.3 16.2 4.9 2.7 33.9 54.1 32.5 46.9 49.2 26.4 17.6 31.2 17.2 12.6 26.8 21.9 30.2 40.5 73.6 8.5 16.9 38.2 6.7 13.6 24.4 13.7 40.9 39.7 65.3 10.2 19.0 20.0 46.7 20.4 39.4 31.3 59.4 9.2 116.5 44.9 9.5 20.8 17.2 91.3 18.3 20.8 67.7 50.6 88.4 17.0 33.9 70.1 21.0 20.5 28.5 5.6 6.5 53.6 16.3 44.5 58.8 43.3 40.5 16.8 65.5 MAP2K2 "MEK2, PRKMK2" ENSG00000126934 "Mitogen-activated protein kinase kinase 2" P36507 19 4090321-4124129 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Late spermatids: 596.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB003835, HPA051993" Supported Supported Cytosol NA NA Cytosol "CAB003835: AB_562312, HPA051993: AB_2681685" "unprognostic (4.39e-1)" "prognostic favorable (3.72e-4)" "unprognostic (4.24e-1)" "unprognostic (1.26e-3)" "unprognostic (2.58e-1)" "prognostic favorable (7.98e-4)" "unprognostic (2.08e-3)" "unprognostic (2.11e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (7.45e-3)" "unprognostic (4.95e-2)" "unprognostic (1.32e-1)" "prognostic favorable (5.43e-5)" "unprognostic (2.91e-2)" "unprognostic (2.25e-1)" "unprognostic (4.90e-2)" 23.9 33.0 35.6 27.6 36.1 46.7 30.2 31.2 43.4 22.6 38.8 24.6 27.0 70.9 21.8 23.2 32.8 21.7 27.9 41.4 33.1 31.0 22.7 42.0 24.1 44.5 34.4 29.2 30.8 46.0 18.9 29.7 21.3 26.1 25.7 24.3 21.7 41.5 24.0 134.9 27.4 56.7 19.0 25.2 25.9 28.3 42.0 20.9 44.1 26.2 42.2 29.1 20.0 26.9 11.4 10.7 28.3 10.6 11.3 12.1 4.5 36.8 40.7 22.3 31.3 30.9 37.3 22.3 24.3 32.6 33.3 30.2 35.2 20.0 31.6 23.0 27.7 26.8 26.6 17.4 26.0 25.8 26.8 21.2 11.5 22.2 38.9 47.3 21.1 24.3 41.1 25.3 23.4 31.2 44.6 29.4 28.8 22.0 62.4 28.0 46.3 41.8 29.7 25.5 27.2 29.6 32.0 14.7 36.1 29.1 23.7 30.3 30.2 22.3 30.9 75.8 26.9 23.8 36.4 25.9 27.3 23.8 69.8 37.4 62.8 38.0 22.1 42.4 38.2 46.8 15.2 9.1 28.3 11.9 10.6 9.7 8.9 9.7 12.1 10.7 11.4 8.9 11.6 14.4 11.3 8.7 6.0 9.2 4.5 35.6 36.1 31.2 43.4 33.1 31.0 34.4 29.2 26.1 20.9 8.9 38.8 57.0 73.8 31.5 79.0 54.9 17.8 10.7 19.4 38.4 39.3 23.7 124.3 17.7 223.1 33.7 242.0 0.0 38.5 28.5 33.0 88.2 19.6 43.1 46.2 114.4 60.6 34.4 35.6 596.7 33.1 29.7 40.5 12.6 77.6 82.3 41.7 90.9 21.5 75.0 82.4 25.8 32.5 25.9 14.5 55.8 29.7 45.4 69.4 97.8 MAP2K4 "JNKK1, MEK4, MKK4, PRKMK4, SERK1" ENSG00000065559 "Mitogen-activated protein kinase kinase 4" P45985 17 12020824-12143830 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Stress response" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 13.2" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in all" 5 "SuSa: 67.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007751, HPA060074" Enhanced Approved "Nucleoplasm,Cell Junctions" NA NA Nucleoplasm "Cell Junctions" "CAB007751: , HPA060074: AB_2684197" "unprognostic (1.55e-1)" "unprognostic (1.85e-1)" "unprognostic (4.47e-2)" "unprognostic (1.02e-2)" "unprognostic (1.04e-1)" "unprognostic (2.70e-1)" "unprognostic (2.89e-1)" "unprognostic (2.16e-1)" "unprognostic (1.93e-3)" "unprognostic (2.53e-1)" "unprognostic (2.76e-3)" "unprognostic (4.82e-2)" "unprognostic (5.32e-3)" "unprognostic (3.13e-1)" "unprognostic (2.30e-1)" "unprognostic (7.00e-2)" "unprognostic (1.79e-1)" 10.7 13.2 23.7 9.4 21.0 3.1 14.4 25.0 42.7 12.5 11.5 7.9 8.5 9.6 12.1 17.8 18.5 11.5 10.7 14.9 31.7 29.3 15.8 20.6 11.4 14.6 24.5 27.1 13.0 11.1 19.6 16.7 15.1 23.4 14.5 13.1 6.5 9.8 13.2 20.6 14.4 9.9 13.5 16.3 10.7 10.7 10.3 9.8 10.3 16.5 11.6 13.4 11.1 11.2 2.8 1.8 13.2 4.3 3.5 3.3 2.3 10.6 9.2 12.1 6.2 6.7 8.7 7.7 7.3 9.6 8.3 8.0 5.4 3.7 4.4 5.9 11.3 5.4 7.1 10.5 10.1 12.5 7.8 12.3 4.9 5.4 10.2 7.9 4.7 7.4 7.2 10.0 9.7 10.2 8.6 7.5 6.3 5.2 2.6 10.4 3.9 5.6 4.4 7.0 11.5 4.5 7.0 13.6 3.0 11.4 6.9 2.4 7.2 8.4 4.5 7.0 67.1 5.7 3.4 6.8 4.1 6.3 5.6 8.6 5.1 5.7 3.5 7.7 3.7 5.9 0.6 2.7 2.0 3.0 1.5 2.7 2.8 2.4 2.4 1.8 2.7 2.0 3.3 13.2 3.5 4.3 1.8 2.6 2.3 23.7 21.0 25.0 42.7 31.7 29.3 24.5 27.1 23.4 9.8 8.9 14.2 10.8 26.3 36.9 14.2 21.2 10.2 2.7 21.6 14.0 7.9 10.7 21.6 11.2 6.3 8.7 11.8 0.0 12.4 8.6 12.9 32.3 1.1 16.3 10.2 17.5 11.5 10.4 17.7 5.8 10.9 11.7 11.8 19.0 13.8 10.3 14.7 11.5 12.0 17.7 9.7 12.9 12.0 7.9 8.1 34.4 21.2 9.5 10.6 40.3 MAP3K1 "MAPKKK1, MEKK, MEKK1" ENSG00000095015 "Mitogen-activated protein kinase kinase kinase 1" Q13233 5 56815574-56896152 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Kupffer cells: 81.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SH-SY5Y: 27.5;THP-1: 25.7" "Region enriched" "Detected in many" 6 "olfactory region: 22.5" "Low region specificity" "Detected in all" "CAB004500, HPA046509" Approved Approved Cytosol NA NA Cytosol "CAB004500: AB_627926, HPA046509: AB_2679678" "unprognostic (1.77e-1)" "unprognostic (1.71e-2)" "unprognostic (4.09e-1)" "unprognostic (2.18e-1)" "unprognostic (3.48e-2)" "unprognostic (5.39e-3)" "unprognostic (5.20e-3)" "unprognostic (2.52e-2)" "unprognostic (1.35e-1)" "unprognostic (1.41e-1)" "unprognostic (1.05e-2)" "unprognostic (6.73e-2)" "unprognostic (1.97e-3)" "unprognostic (2.18e-2)" "unprognostic (1.58e-1)" "unprognostic (9.92e-3)" "unprognostic (1.11e-1)" 6.7 4.9 5.4 14.6 4.8 15.2 14.9 8.0 4.5 7.6 6.7 5.4 7.3 4.3 7.1 9.4 12.7 7.2 5.9 4.3 3.7 3.2 9.5 4.4 8.8 21.4 6.4 3.1 8.4 9.2 6.3 7.9 8.1 4.5 8.3 4.5 12.6 15.4 9.7 3.5 21.8 11.2 4.0 3.8 21.3 5.5 8.5 5.1 11.7 19.2 6.6 18.2 6.0 11.7 6.6 2.8 6.7 7.2 2.7 5.8 2.3 6.6 4.0 6.3 4.2 1.0 0.8 10.6 1.3 1.7 4.0 5.6 18.7 5.0 5.9 0.4 1.5 3.4 3.4 5.2 2.3 5.6 2.0 2.3 3.3 1.8 8.8 2.5 5.2 9.2 1.0 2.5 1.2 2.0 1.1 1.7 2.0 2.8 10.7 1.0 2.9 3.6 7.1 2.9 3.4 0.5 5.7 4.4 20.3 7.0 6.9 2.6 27.5 3.9 4.9 11.2 5.8 13.4 25.7 5.0 0.4 3.4 1.5 2.4 7.8 4.0 11.3 0.6 3.1 6.8 6.7 4.5 1.0 1.2 6.8 1.2 6.6 3.8 1.8 2.8 5.1 2.5 0.9 2.6 2.7 7.2 1.5 5.8 2.3 5.4 4.8 8.0 4.5 3.7 3.2 6.4 3.1 4.5 5.1 6.0 9.8 47.7 14.5 46.5 15.2 2.7 50.9 4.0 12.5 34.9 45.2 12.9 6.6 14.2 1.6 13.5 6.6 0.0 12.8 7.7 11.3 11.9 7.0 12.1 26.3 27.0 9.8 17.2 81.7 1.9 4.9 40.3 35.4 45.9 10.1 10.6 13.0 7.0 1.8 20.1 34.7 6.5 5.2 10.0 15.0 47.8 5.6 16.6 8.9 10.0 MAP3K13 "LZK, MEKK13" ENSG00000073803 "Mitogen-activated protein kinase kinase kinase 13" O43283 3 185282941-185489097 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "monocytes: 456.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016497, HPA036691, HPA036692" Uncertain Approved "Nucleoplasm,Centriolar satellite,Cytosol" NA NA "Centriolar satellite" "Nucleoplasm, Cytosol" "HPA016497: AB_10670027, HPA036691: AB_10673661, HPA036692: AB_10670845" "unprognostic (8.95e-2)" "unprognostic (6.72e-3)" "unprognostic (9.46e-2)" "prognostic unfavorable (1.28e-5)" "unprognostic (5.16e-2)" "unprognostic (2.81e-1)" "unprognostic (2.61e-1)" "unprognostic (1.23e-2)" "unprognostic (9.04e-2)" "prognostic favorable (1.11e-4)" "prognostic unfavorable (7.27e-5)" "unprognostic (2.70e-3)" "unprognostic (1.54e-2)" "unprognostic (2.94e-2)" "unprognostic (2.82e-1)" "unprognostic (6.64e-2)" "unprognostic (9.31e-3)" 9.8 24.8 21.7 8.7 22.2 9.5 15.1 16.4 26.1 12.9 16.9 18.4 10.5 16.8 12.9 42.1 15.2 14.6 13.1 8.1 19.2 18.6 21.9 20.7 15.2 7.4 23.2 17.1 16.5 24.9 20.9 24.5 9.1 21.8 14.5 18.9 18.6 26.2 11.4 3.3 9.8 23.4 12.1 26.4 8.7 16.4 12.9 15.8 4.4 18.6 8.3 10.3 12.5 11.5 23.7 21.5 21.1 13.2 11.5 17.4 7.8 29.1 5.8 11.3 0.3 10.3 12.7 6.7 6.7 4.6 10.9 13.2 11.2 11.0 0.2 23.0 12.2 18.2 16.7 0.3 15.5 19.4 32.5 15.0 0.1 7.9 9.2 11.2 15.3 8.4 11.5 13.6 9.3 11.7 11.3 12.1 0.3 0.3 23.7 9.7 9.1 1.8 7.2 13.0 22.5 13.7 0.2 13.5 16.0 19.2 7.6 18.6 12.4 11.3 17.1 23.2 12.9 25.8 8.6 8.0 9.0 11.7 16.2 14.5 12.1 15.6 9.6 13.2 7.8 14.7 6.4 13.2 5.1 10.3 12.2 15.8 23.7 12.4 12.8 21.5 19.0 17.4 16.8 21.1 11.5 8.6 9.4 4.8 7.8 21.7 22.2 16.4 26.1 19.2 18.6 23.2 17.1 21.8 15.8 50.6 76.2 44.7 172.9 125.7 111.5 22.1 104.4 64.3 84.2 75.0 86.4 120.9 243.7 92.5 109.7 52.6 82.0 0.0 111.2 29.4 48.3 249.1 28.9 83.1 55.4 42.9 102.2 83.4 50.4 168.4 40.0 59.4 81.0 456.3 109.9 93.7 112.0 96.2 50.9 224.8 81.3 45.3 74.0 119.3 28.8 127.2 170.1 31.2 98.7 249.0 MAPK1 "ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2" ENSG00000100030 "Mitogen-activated protein kinase 1" P28482 22 21754500-21867680 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 80.3" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "K-562: 81.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003995, CAB004229, HPA005700, HPA030069" Approved NA NA 250000 "CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (9.41e-3)" "unprognostic (2.68e-1)" "unprognostic (2.50e-3)" "unprognostic (4.17e-1)" "unprognostic (4.44e-3)" "unprognostic (1.72e-1)" "prognostic unfavorable (4.95e-4)" "unprognostic (2.29e-1)" "unprognostic (1.67e-1)" "unprognostic (1.58e-1)" "unprognostic (8.43e-3)" "unprognostic (1.04e-1)" "unprognostic (1.35e-2)" "unprognostic (2.08e-1)" "unprognostic (1.94e-1)" "unprognostic (1.41e-1)" "unprognostic (6.49e-2)" 16.1 21.1 32.9 18.3 80.3 20.2 13.6 31.0 54.5 18.6 18.5 23.2 9.6 13.7 17.4 10.6 25.7 16.9 14.9 22.8 32.4 23.4 21.7 16.4 19.9 16.6 18.4 23.6 16.0 19.8 27.4 10.9 17.2 27.6 16.4 19.9 14.2 15.8 17.8 28.2 17.5 15.1 22.8 20.4 19.8 17.2 24.2 21.5 19.5 23.0 11.1 21.4 17.7 15.3 2.5 3.2 13.5 4.9 7.0 13.7 2.5 19.7 12.5 16.1 9.2 19.1 19.2 6.1 21.8 20.4 19.6 19.0 9.9 10.5 10.9 10.9 29.2 18.0 18.8 18.9 17.4 25.6 44.0 17.7 19.8 11.7 11.6 15.7 27.8 20.6 14.3 14.0 23.7 21.9 15.4 26.7 11.9 81.1 12.5 23.9 8.1 18.0 6.1 6.1 26.8 12.3 19.8 39.7 2.9 11.2 16.2 13.1 7.3 23.6 14.2 12.7 16.7 10.7 9.4 23.3 16.4 21.4 18.8 13.8 12.0 14.6 17.0 15.5 13.6 17.7 1.0 4.0 5.8 13.7 4.6 3.9 2.0 2.9 4.9 3.2 2.5 2.8 5.1 13.5 7.0 4.9 3.2 2.7 2.5 32.9 80.3 31.0 54.5 32.4 23.4 18.4 23.6 27.6 21.5 44.7 30.2 28.0 22.1 53.3 23.8 34.6 63.7 21.4 33.0 48.8 51.1 18.0 16.6 24.0 33.2 31.2 46.6 23.3 33.6 18.2 31.5 37.5 93.2 59.4 47.7 27.0 57.3 57.7 88.6 9.9 30.2 59.7 38.8 15.4 44.2 32.3 39.5 28.8 41.8 37.6 21.0 32.3 32.2 70.0 47.7 54.1 16.0 95.8 30.7 34.8 MAX "bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8" ENSG00000125952 "MYC associated factor X" P61244 14 65006174-65102695 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 94.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000328, HPA003474" Supported Supported "Nucleoplasm,Golgi apparatus,Vesicles" NA NA Nucleoplasm "Golgi apparatus, Vesicles" "CAB000328: AB_2281783, HPA003474: AB_1079317" "unprognostic (4.50e-3)" "unprognostic (1.51e-3)" "unprognostic (4.08e-2)" "unprognostic (2.87e-1)" "unprognostic (8.37e-2)" "unprognostic (2.42e-2)" "unprognostic (1.13e-3)" "unprognostic (1.30e-3)" "unprognostic (1.53e-2)" "unprognostic (7.36e-3)" "unprognostic (7.19e-2)" "unprognostic (1.66e-2)" "prognostic unfavorable (5.57e-4)" "unprognostic (2.99e-1)" "unprognostic (4.68e-2)" "prognostic favorable (2.12e-4)" "unprognostic (6.03e-2)" 33.4 25.5 31.3 31.5 38.6 68.7 25.8 59.0 38.2 34.6 29.4 37.2 26.3 31.5 34.3 24.0 47.6 38.2 27.9 30.1 29.9 28.4 26.3 21.8 31.4 43.4 37.1 21.6 39.7 20.0 17.4 23.7 30.2 32.7 31.9 25.0 26.8 33.6 37.7 27.8 32.1 40.2 30.7 34.8 42.9 24.8 15.7 40.9 41.3 30.2 22.5 40.7 35.1 40.7 18.7 19.1 87.5 23.6 19.2 30.0 44.8 28.9 11.3 7.0 11.3 18.4 14.4 9.1 10.2 15.6 12.7 15.7 7.2 20.4 24.1 8.6 12.2 11.3 14.5 17.5 14.2 9.6 24.3 10.6 37.5 7.5 7.9 21.6 14.1 94.4 17.2 10.1 11.7 13.0 16.6 14.1 16.3 17.6 9.8 12.9 16.0 32.6 48.6 9.3 17.1 18.6 18.5 11.0 10.8 11.8 9.7 15.1 9.8 13.4 14.3 13.1 6.5 14.0 18.0 17.6 11.7 14.2 10.8 8.1 12.1 10.2 15.3 14.6 13.6 11.7 87.5 23.6 80.6 21.7 20.1 23.7 18.7 25.4 22.1 19.1 17.6 26.6 22.3 49.5 19.2 17.4 18.3 30.0 44.8 31.3 38.6 59.0 38.2 29.9 28.4 37.1 21.6 32.7 40.9 26.8 27.2 50.6 55.5 151.2 22.4 25.5 22.9 21.4 27.3 17.4 19.6 34.8 44.7 33.9 34.8 46.7 63.2 0.0 27.8 36.5 43.0 52.7 62.2 19.1 53.4 44.5 42.5 68.2 78.5 71.7 72.2 46.3 54.0 34.3 40.5 43.3 45.6 87.7 56.6 49.1 15.0 135.8 55.6 40.5 26.6 157.8 45.2 59.0 24.2 65.0 MDM2 "HDM2, MGC5370" ENSG00000135679 "MDM2 proto-oncogene" Q00987 12 68808176-68850686 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" Transferase "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HBEC3-KT: 95.6;U-698: 91.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000086, CAB016303" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB000086: AB_563872, CAB016303: AB_627920" "unprognostic (1.16e-1)" "prognostic favorable (3.23e-4)" "unprognostic (6.16e-2)" "prognostic favorable (4.51e-7)" "unprognostic (7.25e-2)" "unprognostic (6.91e-2)" "unprognostic (3.77e-2)" "unprognostic (1.72e-1)" "unprognostic (2.45e-2)" "unprognostic (3.23e-1)" "unprognostic (1.80e-3)" "unprognostic (2.36e-1)" "unprognostic (4.22e-2)" "unprognostic (4.59e-2)" "unprognostic (1.81e-1)" "unprognostic (2.68e-1)" "unprognostic (8.95e-2)" 16.6 15.3 11.1 12.5 10.8 23.1 12.5 12.0 11.3 13.1 16.6 13.6 11.9 5.2 8.8 9.4 14.2 12.6 12.3 9.0 8.8 8.6 11.2 25.7 15.9 13.3 14.2 7.1 11.0 21.4 11.4 10.4 24.5 11.9 12.6 21.5 7.8 10.5 11.1 19.5 9.8 7.2 10.8 10.8 15.3 9.8 6.5 11.5 29.5 13.6 10.8 14.1 13.5 12.6 4.9 4.0 19.3 6.4 3.6 4.4 3.0 3.1 7.5 7.9 3.9 10.2 9.5 40.2 8.9 8.9 4.7 7.6 4.5 1.4 33.3 2.5 5.8 1.3 1.9 5.4 95.6 7.6 8.8 3.7 6.1 6.3 20.2 10.0 5.4 5.6 14.6 8.2 18.7 12.8 4.7 13.2 5.8 6.2 8.1 9.0 5.1 7.1 1.8 6.6 1.6 1.4 25.3 5.4 2.7 2.9 26.6 6.0 3.5 5.6 4.4 1.9 16.7 10.4 3.6 14.1 3.6 6.8 2.9 3.1 12.3 7.8 91.9 5.5 2.1 14.7 5.3 5.4 4.8 4.4 4.0 3.9 4.7 3.7 4.1 2.8 4.9 4.0 3.7 19.3 3.6 6.4 4.0 3.8 3.0 11.1 10.8 12.0 11.3 8.8 8.6 14.2 7.1 11.9 11.5 29.8 48.8 22.9 24.5 13.9 27.9 17.8 25.5 97.7 62.6 24.4 31.4 43.9 11.6 18.1 1.1 20.2 16.6 0.0 20.8 23.6 22.4 34.7 31.3 38.4 16.5 28.6 24.1 22.1 44.9 1.8 17.8 21.8 11.8 31.5 23.5 26.4 19.8 20.1 14.2 15.3 34.5 19.4 21.7 13.9 20.6 19.3 78.8 25.4 19.7 74.5 MDM4 "HDMX, MDMX" ENSG00000198625 "MDM4, p53 regulator" O15151 1 204516379-204558120 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BEWO: 34.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018919, HPA048821" Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA018919: AB_1853694, HPA048821: AB_2680531" "unprognostic (4.63e-2)" "unprognostic (3.73e-1)" "unprognostic (6.38e-2)" "unprognostic (1.50e-1)" "unprognostic (3.84e-2)" "unprognostic (1.68e-3)" "unprognostic (2.33e-1)" "unprognostic (1.29e-1)" "unprognostic (1.51e-2)" "unprognostic (2.34e-2)" "unprognostic (1.17e-2)" "prognostic unfavorable (9.87e-4)" "prognostic unfavorable (7.06e-6)" "unprognostic (1.20e-1)" "unprognostic (1.73e-1)" "unprognostic (2.49e-2)" "prognostic favorable (2.49e-4)" 12.7 8.8 14.4 21.1 18.0 59.1 14.6 19.7 16.4 12.2 10.6 20.4 15.8 7.6 12.5 23.6 10.4 12.3 10.3 11.3 13.7 8.0 11.1 12.3 15.4 21.0 20.5 9.5 19.0 16.7 11.1 19.0 12.4 13.4 13.1 12.4 14.2 11.3 15.4 12.0 23.7 15.2 18.5 13.5 19.9 11.9 19.6 19.4 55.8 15.1 9.5 21.0 13.9 12.7 15.1 9.0 8.1 4.8 4.9 7.8 2.4 3.6 7.1 7.2 9.9 5.0 5.6 34.0 2.7 2.8 3.5 5.2 3.7 4.9 12.4 2.6 3.8 2.9 3.9 4.8 4.0 4.7 3.7 3.4 9.8 15.8 4.3 3.8 7.7 9.8 5.7 2.6 5.7 10.2 3.7 3.4 8.0 5.6 18.1 3.0 12.0 4.7 6.8 9.9 1.3 3.0 5.6 5.9 4.1 3.4 17.5 3.2 7.2 2.7 5.4 5.1 7.5 10.2 4.5 3.4 4.0 7.1 2.6 4.4 9.1 3.2 10.3 2.8 3.3 5.7 8.1 4.7 6.2 7.2 4.8 6.0 9.0 5.4 5.0 4.1 15.1 7.8 6.5 7.8 4.9 4.3 9.0 3.0 2.4 14.4 18.0 19.7 16.4 13.7 8.0 20.5 9.5 13.4 19.4 26.8 49.9 72.9 46.9 54.7 91.7 33.5 40.8 20.1 61.4 66.3 159.0 39.1 11.6 25.4 65.9 50.6 37.1 93.5 23.0 23.0 48.1 52.9 63.6 48.4 30.6 39.7 62.4 94.5 85.6 124.4 74.2 75.3 40.5 23.4 44.0 44.1 23.4 40.8 50.9 12.8 196.4 51.8 36.2 60.6 71.3 59.7 50.9 73.9 39.6 40.0 MECOM "EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3" ENSG00000085276 "MDS1 and EVI1 complex locus" Q03112 3 169083499-169663618 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 9 "Alveolar cells type 2: 169.5;Club cells: 93.3;Collecting duct cells: 118.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 1.8" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "EFO-21: 15.6;HUVEC TERT2: 22.0;RPTEC TERT1: 28.2;RT4: 44.4;TIME: 20.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA046537 Supported Supported "Nuclear speckles" NA NA "Nuclear speckles" "HPA046537: AB_2679689" "unprognostic (4.09e-2)" "unprognostic (1.96e-1)" "unprognostic (3.24e-3)" "unprognostic (7.29e-2)" "unprognostic (2.87e-2)" "unprognostic (2.53e-1)" "unprognostic (1.83e-2)" "unprognostic (4.77e-3)" "unprognostic (1.53e-2)" "unprognostic (3.27e-3)" "prognostic unfavorable (2.59e-4)" "unprognostic (1.87e-1)" "unprognostic (2.60e-3)" "unprognostic (6.54e-2)" "unprognostic (1.03e-1)" "unprognostic (2.81e-2)" "unprognostic (3.37e-3)" 25.9 0.7 3.3 5.7 5.6 0.3 9.1 3.4 5.3 13.5 13.9 1.6 22.1 11.2 15.4 5.7 10.4 14.3 8.1 8.2 3.3 2.9 32.2 2.6 30.0 1.5 4.6 1.4 6.2 27.8 1.1 5.3 10.0 4.7 9.3 17.5 4.2 5.9 25.3 16.0 2.3 5.9 5.6 5.8 6.4 39.4 2.7 3.5 0.2 4.7 3.3 3.5 18.1 18.5 0.3 0.0 0.6 1.5 1.8 1.0 0.0 9.8 0.1 0.2 0.0 1.3 1.0 0.1 1.3 1.6 0.5 0.9 3.9 10.1 0.0 15.6 0.2 2.2 5.2 4.1 6.1 1.1 0.5 6.4 6.2 1.7 0.1 0.1 0.0 1.9 2.1 0.8 0.3 4.6 4.8 22.0 0.5 4.7 0.7 3.9 1.0 0.0 0.0 0.2 5.1 2.5 3.7 5.1 0.2 28.2 44.4 0.3 1.2 0.4 2.6 0.1 0.3 3.0 0.0 20.9 3.9 2.5 1.0 6.5 0.5 0.1 0.3 1.9 0.0 0.6 0.3 0.0 0.6 0.4 0.2 1.0 0.1 0.1 0.0 0.0 0.3 0.2 0.0 0.3 1.8 1.5 0.0 0.1 0.0 3.3 5.6 3.4 5.3 3.3 2.9 4.6 1.4 4.7 3.5 56.6 169.5 0.0 27.4 1.9 0.0 6.7 5.1 64.3 93.3 118.7 0.0 0.9 44.7 0.8 4.6 40.2 10.5 0.0 65.4 0.1 1.5 9.9 9.2 0.0 0.0 0.0 19.1 34.4 0.6 1.7 0.3 1.0 1.7 1.8 23.3 0.0 42.3 3.5 0.0 0.3 0.0 0.0 0.7 2.1 0.4 1.3 0.3 0.5 49.4 38.8 MED12 "CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230" ENSG00000184634 "Mediator complex subunit 12" Q93074 X 71118556-71142454 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003184, HPA003185" Enhanced Approved Nucleoplasm NA NA Nucleoplasm "HPA003184: AB_1079349, HPA003185: AB_1079350" "unprognostic (1.39e-1)" "unprognostic (2.23e-1)" "unprognostic (5.42e-2)" "unprognostic (2.07e-1)" "unprognostic (6.89e-3)" "unprognostic (7.14e-2)" "unprognostic (1.68e-2)" "unprognostic (1.15e-2)" "unprognostic (2.10e-1)" "unprognostic (1.53e-1)" "unprognostic (2.45e-1)" "unprognostic (2.50e-1)" "unprognostic (1.22e-3)" "unprognostic (1.28e-1)" "unprognostic (1.02e-1)" "unprognostic (3.67e-1)" "unprognostic (5.16e-2)" 18.2 31.3 12.3 15.3 14.7 16.6 18.1 18.0 15.1 16.8 12.8 19.8 21.3 10.2 21.7 16.5 13.1 17.7 14.2 12.9 12.9 8.5 13.3 9.8 14.0 15.3 15.7 10.7 28.8 14.2 20.1 17.9 23.0 11.6 16.5 11.8 18.6 14.6 20.3 14.9 17.6 14.8 16.4 11.2 27.3 14.2 15.3 12.9 33.1 17.8 12.6 15.9 15.4 16.4 4.0 5.1 9.7 3.7 5.0 7.4 3.6 8.7 10.3 16.3 9.7 12.0 10.7 24.1 6.2 8.9 9.9 7.1 12.4 8.3 11.5 8.2 10.7 6.8 8.7 19.0 7.8 7.9 12.1 14.7 19.1 23.2 16.7 9.4 17.5 16.9 12.4 8.5 12.9 15.0 12.7 15.2 14.7 17.7 20.2 9.7 14.7 18.4 10.0 9.3 11.2 13.5 17.3 18.2 8.7 7.5 17.4 9.1 11.0 14.3 7.3 8.1 17.5 8.8 8.7 13.2 10.8 12.8 9.9 4.3 10.0 5.5 8.4 6.3 9.8 7.2 9.7 3.7 7.2 5.9 3.6 5.0 4.0 4.1 5.4 3.9 4.0 4.6 3.9 7.7 5.0 2.4 5.1 7.4 3.6 12.3 14.7 18.0 15.1 12.9 8.5 15.7 10.7 11.6 12.9 8.9 3.4 5.2 5.2 5.4 7.1 8.1 15.3 2.7 6.8 8.7 5.9 17.0 1.7 5.4 0.2 8.7 6.8 0.0 5.4 6.2 7.8 5.7 9.2 3.4 8.0 12.7 7.5 14.1 6.7 0.9 13.0 9.2 5.0 6.4 7.8 5.8 8.6 8.4 12.7 2.2 4.5 0.0 5.0 6.4 7.4 5.0 22.8 6.4 6.4 6.8 MEN1 ENSG00000133895 "Menin 1" O00255 11 64803510-64811294 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030342 Uncertain Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA030342: AB_10610138" "unprognostic (2.06e-1)" "unprognostic (1.76e-1)" "unprognostic (3.78e-2)" "unprognostic (2.31e-2)" "unprognostic (1.05e-1)" "unprognostic (8.41e-2)" "prognostic unfavorable (1.08e-4)" "unprognostic (2.66e-1)" "unprognostic (2.59e-1)" "unprognostic (1.42e-2)" "unprognostic (4.96e-2)" "unprognostic (1.36e-1)" "unprognostic (7.39e-2)" "prognostic favorable (6.31e-5)" "unprognostic (1.40e-1)" "unprognostic (3.03e-1)" "unprognostic (3.76e-1)" 12.1 20.6 13.2 15.6 17.7 11.8 12.5 25.8 26.9 15.5 14.9 16.4 22.2 16.9 14.8 18.4 18.9 17.6 14.7 9.0 12.4 11.5 15.9 23.0 12.8 22.1 12.5 15.6 19.7 25.9 16.8 18.0 16.1 16.0 15.9 11.6 16.6 23.3 19.9 8.4 21.6 15.8 11.0 9.8 20.6 15.3 21.2 12.3 33.2 23.9 6.2 20.3 13.7 15.5 5.2 2.9 3.4 1.5 1.8 4.8 1.0 16.3 22.0 14.1 22.1 15.8 10.2 16.6 11.8 11.7 18.4 12.4 12.7 16.2 23.3 19.3 9.1 15.4 23.4 19.1 16.3 11.1 19.9 28.2 19.3 17.7 16.9 14.0 12.4 13.1 11.7 12.3 15.5 12.8 11.1 17.0 30.0 28.0 8.9 10.2 30.6 31.3 25.1 18.4 13.8 33.1 24.3 16.0 22.3 11.9 15.2 19.9 17.5 13.9 19.7 14.3 10.5 29.3 13.8 10.7 17.4 16.7 20.8 9.9 14.0 16.2 11.8 13.8 9.7 11.0 0.9 1.3 3.4 3.7 1.5 4.8 3.7 2.6 4.6 1.3 5.2 4.5 2.6 0.2 1.8 0.5 2.9 1.9 1.0 13.2 17.7 25.8 26.9 12.4 11.5 12.5 15.6 16.0 12.3 3.0 4.8 19.3 3.8 5.0 8.3 3.7 2.5 1.4 1.2 3.5 5.9 15.7 3.3 7.3 0.9 4.4 8.4 0.0 6.2 18.5 4.6 4.9 1.1 9.4 7.9 3.2 4.1 8.0 0.3 0.6 11.2 2.6 8.5 6.4 8.7 8.4 7.1 10.1 3.5 6.2 5.7 12.9 2.7 16.6 15.5 6.0 13.6 6.7 9.5 3.0 MET "DFNB97, HGFR, RCCP2" ENSG00000105976 "MET proto-oncogene, receptor tyrosine kinase" P08581 7 116672390-116798386 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 6 "Alveolar cells type 2: 78.1;Club cells: 116.0;Urothelial cells: 88.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "A-431: 45.3;CAPAN-2: 49.5" "Group enriched" "Detected in many" 5 "amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1" "Low region specificity" "Detected in many" "CAB005282, CAB018577, HPA055607" Approved Approved "Plasma membrane,Cytosol" "Secreted to blood" NA NA 179000000 70000000 "Plasma membrane, Cytosol" "CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: AB_2682860" "unprognostic (1.60e-2)" "unprognostic (7.71e-2)" "unprognostic (2.53e-2)" "unprognostic (1.58e-1)" "unprognostic (3.57e-3)" "prognostic unfavorable (6.75e-4)" "unprognostic (1.68e-1)" "unprognostic (3.22e-2)" "unprognostic (3.81e-2)" "unprognostic (2.52e-2)" "prognostic unfavorable (1.21e-7)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (5.53e-2)" "unprognostic (8.88e-2)" "unprognostic (2.01e-2)" "unprognostic (2.20e-1)" 16.2 1.1 1.8 4.5 2.3 4.3 11.2 0.9 15.2 9.9 6.5 2.4 2.4 4.4 7.5 5.2 5.1 4.6 12.3 5.4 5.7 1.8 20.1 30.2 15.6 1.4 3.6 2.1 2.0 9.3 0.7 8.1 24.4 2.6 8.0 6.6 34.1 12.2 8.4 12.8 7.2 8.6 4.0 2.3 5.7 10.6 2.7 2.4 0.5 21.4 7.0 2.1 10.1 15.0 0.2 0.3 1.2 0.2 0.3 0.4 0.0 45.3 26.1 0.0 0.1 2.0 2.0 1.8 25.9 10.5 14.0 11.8 5.4 49.5 2.0 43.2 16.2 37.7 12.0 4.4 24.7 28.6 0.1 5.6 0.0 27.1 4.7 0.3 0.0 0.0 2.6 9.8 9.1 30.0 25.3 9.6 0.0 0.9 0.2 25.9 1.0 0.0 0.0 3.9 7.2 26.6 0.0 22.0 0.0 24.5 5.2 3.8 0.0 10.6 3.4 10.1 4.7 0.0 0.2 17.6 20.9 7.4 11.0 20.0 0.5 4.0 0.2 22.9 0.0 2.9 1.1 0.2 0.4 0.4 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 1.2 0.3 0.1 0.3 0.1 0.0 1.8 2.3 0.9 15.2 5.7 1.8 3.6 2.1 2.6 2.4 26.8 78.1 2.4 56.1 34.7 0.9 10.0 15.3 22.7 116.0 29.6 0.0 57.9 0.0 28.0 0.0 11.7 11.2 0.0 39.8 5.0 4.0 55.8 0.0 26.0 6.1 0.0 6.9 1.3 1.0 0.0 0.6 2.0 3.3 1.8 19.7 7.4 69.4 7.0 0.0 13.5 0.3 0.0 2.3 0.0 0.6 15.6 18.2 0.0 12.7 88.5 MITF "bHLHe32, MI, WS2, WS2A" ENSG00000187098 "Melanogenesis associated transcription factor" O75030 3 69739435-69968337 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Albinism, Cancer-related genes, Deafness, Disease mutation, Microphthalmia, Osteopetrosis, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enriched" "Detected in many" 5 "Melanocytes: 555.0" "Group enriched" "Detected in all" 8 "melanoma: 39.2;renal cancer: 9.1" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "basophil: 4.5;classical monocyte: 10.9;intermediate monocyte: 3.6;myeloid DC: 6.8;non-classical monocyte: 5.7" "Group enriched" "Detected in many" 5 "dendritic cells: 6.8;granulocytes: 4.5;monocytes: 10.9" "Cell line enhanced" "Detected in many" "HMC-1: 27.1;SK-MEL-30: 72.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002578, HPA003259" Enhanced NA NA "CAB002578: AB_564111, HPA003259: AB_1079381" "unprognostic (3.29e-1)" "unprognostic (4.26e-2)" "unprognostic (2.98e-2)" "unprognostic (6.04e-2)" "unprognostic (1.03e-1)" "unprognostic (3.25e-1)" "unprognostic (1.04e-2)" "unprognostic (1.09e-1)" "unprognostic (2.75e-1)" "unprognostic (5.31e-3)" "unprognostic (3.87e-3)" "unprognostic (1.94e-1)" "prognostic favorable (8.35e-10)" "unprognostic (6.37e-2)" "unprognostic (1.08e-1)" "unprognostic (2.04e-1)" "unprognostic (1.73e-1)" 12.8 3.8 2.6 2.6 3.9 0.8 17.8 1.7 3.0 30.6 10.1 5.9 6.4 1.5 37.9 6.2 8.3 6.4 9.9 23.4 3.1 2.4 12.8 1.8 7.1 1.7 4.2 1.1 11.1 2.4 9.7 6.2 1.8 4.0 9.0 2.5 40.1 4.0 8.2 39.1 5.8 4.1 26.2 5.0 1.8 5.1 4.7 5.1 0.1 4.4 8.1 1.0 12.1 10.3 0.0 6.8 4.5 10.9 1.4 0.1 3.4 4.9 3.4 0.4 1.5 5.7 0.1 0.6 5.0 2.9 2.3 1.4 1.8 0.2 0.0 1.2 0.0 6.4 2.7 1.0 2.7 2.6 0.0 0.6 10.9 7.3 0.1 1.4 0.2 27.1 4.7 1.1 0.6 2.6 8.7 0.7 0.0 3.6 1.5 1.6 0.2 0.2 0.3 0.2 0.2 2.4 0.0 0.5 2.3 13.7 2.5 0.2 0.6 2.6 0.9 72.8 0.6 0.2 0.6 0.0 1.1 4.1 1.6 1.0 0.1 0.3 0.0 2.3 0.8 2.9 4.5 10.9 0.0 0.0 3.6 0.0 0.0 0.0 0.1 6.8 0.0 0.0 0.0 0.7 1.4 5.7 0.5 0.0 3.4 2.6 3.9 1.7 3.0 3.1 2.4 4.2 1.1 4.0 5.1 26.8 5.0 0.0 3.1 38.0 0.2 101.2 5.1 12.0 9.1 14.0 0.0 1.2 43.1 11.4 1.1 6.8 0.0 0.0 7.7 1.0 21.0 4.4 100.8 2.4 40.1 6.4 1.2 4.3 23.9 0.6 41.1 24.0 555.0 10.8 0.0 0.8 7.4 0.0 47.4 18.3 0.2 12.9 20.3 3.3 7.3 16.6 0.9 2.5 0.6 4.7 MKL1 "BSAC, KIAA1438, MAL, MKL, MRTF-A" ENSG00000196588 "Megakaryoblastic leukemia (translocation) 1" Q969V6 22 40410281-40636702 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Actin-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Early spermatids: 87.5;Late spermatids: 76.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "eosinophil: 50.9" "Group enriched" "Detected in all" 5 "dendritic cells: 26.4;granulocytes: 50.9;monocytes: 15.0" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030782 Approved Supported Nucleoplasm,Cytosol No No Nucleoplasm Cytosol "HPA030782: AB_10600930" "unprognostic (7.90e-3)" "unprognostic (4.51e-2)" "unprognostic (2.99e-1)" "unprognostic (1.29e-1)" "unprognostic (9.04e-2)" "unprognostic (9.37e-2)" "unprognostic (4.38e-3)" "unprognostic (1.02e-3)" "unprognostic (1.30e-1)" "unprognostic (1.35e-2)" "unprognostic (1.51e-1)" "unprognostic (3.74e-2)" "prognostic unfavorable (1.58e-7)" "unprognostic (9.05e-2)" "unprognostic (8.15e-2)" "unprognostic (1.30e-2)" "unprognostic (3.98e-1)" 18.1 11.1 15.4 25.4 19.1 69.2 15.8 16.2 26.1 17.6 14.2 13.5 10.1 11.3 27.6 12.9 12.3 17.5 13.2 16.3 14.2 11.1 11.3 8.9 17.4 25.6 11.8 16.6 16.9 14.5 10.2 10.5 18.9 12.6 14.2 9.4 13.3 16.9 15.7 14.3 18.0 13.6 15.7 11.0 23.9 14.3 25.4 10.8 28.2 17.3 9.0 25.5 15.5 14.6 4.9 26.4 50.9 15.0 3.8 5.6 7.5 10.9 14.8 6.5 7.7 8.2 6.2 12.7 10.7 7.0 9.9 9.6 7.0 3.3 11.7 4.4 11.3 8.5 14.4 5.4 13.2 6.4 13.0 9.5 19.4 16.6 10.3 8.1 22.4 38.2 6.7 15.9 9.5 6.6 7.3 7.2 6.9 5.4 5.3 4.6 10.7 8.7 25.2 5.1 5.6 5.2 14.2 7.2 5.9 7.8 8.2 3.6 3.8 17.5 8.9 6.5 8.7 6.0 25.4 11.8 6.7 18.1 8.9 9.2 7.1 6.3 16.9 5.5 11.4 13.0 12.0 15.0 50.9 4.4 11.6 4.1 3.2 4.0 3.4 17.8 4.9 5.6 4.7 14.5 3.8 15.0 26.4 5.2 7.5 15.4 19.1 16.2 26.1 14.2 11.1 11.8 16.6 12.6 10.8 6.0 8.3 7.8 6.0 13.9 11.5 7.3 2.5 8.1 2.3 8.7 21.6 7.0 3.3 9.5 87.5 7.1 7.4 0.0 12.0 6.9 9.1 8.9 16.1 3.9 10.9 3.2 6.4 6.7 17.0 76.0 10.3 13.9 6.8 16.2 6.5 3.7 14.1 2.9 7.4 2.6 12.0 25.8 12.1 9.2 9.5 11.2 6.5 10.1 3.7 8.0 MLF1 ENSG00000178053 "Myeloid leukemia factor 1" P58340 3 158571163-158607252 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cell cycle, Differentiation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 41.4;skeletal muscle: 53.6;testis: 101.1" "Group enriched" "Detected in many" 15 "Early spermatids: 4250.8;Late spermatids: 9284.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "T-reg: 10.4" "Lineage enriched" "Detected in single" 12 "T-cells: 10.4" "Cell line enhanced" "Detected in many" "A-431: 33.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA069479, HPA079339" Enhanced Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "HPA069479: AB_2686140, HPA079339: " "unprognostic (6.49e-2)" "unprognostic (1.98e-3)" "unprognostic (1.98e-1)" "prognostic unfavorable (2.15e-5)" "unprognostic (1.72e-2)" "unprognostic (2.65e-2)" "unprognostic (8.55e-2)" "unprognostic (4.11e-2)" "unprognostic (2.01e-1)" "unprognostic (2.07e-1)" "unprognostic (7.21e-2)" "unprognostic (1.07e-1)" "unprognostic (7.82e-2)" "prognostic unfavorable (5.54e-4)" "unprognostic (9.34e-3)" "unprognostic (2.47e-3)" "unprognostic (3.36e-2)" 3.5 2.6 6.0 1.8 11.9 0.9 5.3 3.4 7.1 3.1 2.7 6.5 0.5 0.8 4.9 5.6 3.5 18.3 4.9 41.4 6.3 6.3 5.7 1.2 5.2 1.0 4.9 6.3 6.2 3.1 5.2 10.4 1.0 20.1 2.0 1.7 2.8 2.2 1.6 53.6 1.8 1.3 4.5 4.7 1.2 1.9 101.1 5.7 0.0 5.3 18.9 1.4 4.2 1.5 0.6 0.3 0.4 0.3 0.8 10.4 2.3 33.7 4.4 11.4 0.0 6.0 7.1 3.4 3.5 3.3 12.8 11.7 0.0 19.2 0.0 13.4 6.0 18.7 6.6 0.1 5.9 17.1 0.0 7.4 2.0 3.3 0.3 4.1 0.0 2.5 4.4 8.7 6.1 3.4 13.4 3.0 0.0 2.5 0.0 8.4 4.9 0.0 0.1 2.7 18.0 9.9 0.0 6.4 0.4 9.8 2.4 14.7 8.7 15.9 5.6 16.7 11.7 16.2 3.4 1.1 12.0 12.2 14.1 13.6 6.1 3.8 0.0 8.7 0.0 8.6 0.0 0.0 0.0 3.6 0.0 1.6 0.6 8.3 8.7 0.3 0.3 2.1 4.4 0.4 0.8 0.3 0.2 10.4 2.3 6.0 11.9 3.4 7.1 6.3 6.3 4.9 6.3 20.1 5.7 23.8 26.2 2.2 109.9 39.8 12.6 168.2 0.0 238.3 60.3 19.2 31.4 0.6 61.3 22.4 4250.8 23.3 4.2 0.0 6.9 3.5 36.8 26.1 43.8 0.0 6.4 9.5 32.5 8.0 2.7 9284.2 64.7 13.2 21.9 1.8 14.3 25.9 7.6 14.4 47.4 27.5 58.5 19.4 36.9 440.7 150.0 29.9 1.4 8.9 10.3 65.9 MLH1 "COCA2, FCC2, HNPCC, HNPCC2" ENSG00000076242 "MutL homolog 1" P40692 3 36993332-37050918 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, DNA damage, DNA repair" "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013294, HPA052707, HPA060714, CAB070868" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB013294: AB_2533406, CAB070868: , HPA052707: AB_2681923, HPA060714: AB_2684348" "unprognostic (1.26e-2)" "unprognostic (3.88e-3)" "unprognostic (2.36e-2)" "unprognostic (1.82e-1)" "unprognostic (3.33e-2)" "unprognostic (1.05e-1)" "prognostic unfavorable (8.24e-5)" "unprognostic (3.36e-2)" "unprognostic (2.18e-1)" "unprognostic (1.32e-1)" "unprognostic (8.54e-2)" "unprognostic (8.63e-3)" "unprognostic (2.10e-3)" "unprognostic (4.37e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (8.86e-2)" 16.3 20.7 18.2 19.4 21.4 24.4 18.7 19.7 19.6 15.3 17.3 28.8 19.6 12.4 18.7 23.6 15.1 16.2 14.4 32.0 17.3 17.7 18.8 20.5 17.8 22.8 19.9 16.0 17.6 18.1 26.0 29.4 17.3 19.2 18.5 17.7 16.7 15.6 18.1 46.4 14.2 14.1 21.1 21.6 20.7 16.5 27.6 21.5 29.0 22.2 19.5 24.5 16.9 21.4 12.0 12.9 13.2 23.2 6.7 13.4 9.0 14.2 22.5 28.1 0.0 12.5 15.7 12.6 21.3 17.0 24.8 26.4 17.0 15.9 35.3 10.6 17.3 14.0 9.8 24.2 18.0 26.6 16.0 12.5 24.7 20.8 23.8 13.9 30.3 17.2 11.7 12.7 23.1 28.8 9.8 15.3 23.9 31.6 16.9 25.1 11.5 31.6 12.4 20.6 14.5 12.4 3.1 34.4 14.9 15.7 15.5 6.0 14.2 21.6 23.0 14.2 16.4 33.2 21.6 12.1 19.5 21.0 19.1 25.0 13.4 36.6 33.1 15.1 28.7 17.5 10.9 11.7 13.2 13.4 19.5 9.7 12.0 8.4 10.7 12.9 10.3 9.6 9.7 3.4 6.7 23.2 6.1 12.5 9.0 18.2 21.4 19.7 19.6 17.3 17.7 19.9 16.0 19.2 21.5 23.8 12.0 16.0 10.7 6.4 19.2 37.1 15.3 16.0 13.6 10.4 9.8 27.1 16.6 12.5 20.3 11.2 5.3 0.0 13.0 23.0 13.4 8.0 7.0 14.5 17.5 3.2 5.2 12.3 14.3 9.5 10.3 11.4 8.5 19.8 7.2 14.3 8.6 7.0 13.1 9.2 17.9 12.9 9.5 37.0 25.4 4.8 16.7 13.1 7.6 3.4 MLLT1 "ENL, LTG19, YEATS1" ENSG00000130382 "MLLT1, super elongation complex subunit" Q03111 19 6210379-6279948 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 13 "Cytotrophoblasts: 494.9;Syncytiotrophoblasts: 951.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031166 Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA031166: AB_10601874" "unprognostic (3.21e-1)" "unprognostic (2.75e-3)" "unprognostic (4.84e-2)" "unprognostic (3.36e-2)" "unprognostic (2.47e-1)" "prognostic favorable (6.03e-5)" "unprognostic (1.30e-3)" "unprognostic (1.44e-2)" "unprognostic (1.56e-1)" "unprognostic (1.98e-1)" "unprognostic (3.93e-3)" "unprognostic (4.76e-2)" "unprognostic (3.65e-3)" "unprognostic (1.14e-2)" "unprognostic (2.01e-1)" "unprognostic (1.66e-2)" "unprognostic (7.99e-3)" 20.1 13.7 21.8 17.1 23.4 8.8 12.9 32.7 28.6 17.7 16.8 16.8 17.7 13.4 22.1 15.5 13.1 25.5 19.3 18.2 16.9 14.3 10.7 12.8 16.7 10.9 13.0 18.5 29.8 22.4 26.2 10.7 45.2 14.6 17.2 6.8 18.7 21.7 18.8 23.5 18.8 13.1 15.0 10.6 13.9 15.1 10.7 13.7 10.8 18.9 12.1 10.2 20.6 23.6 1.5 5.2 4.9 3.5 1.9 2.5 1.6 24.6 12.1 15.0 17.7 11.7 10.2 17.5 15.3 10.0 12.9 13.3 20.0 8.3 17.9 20.1 20.1 14.5 15.4 11.9 15.0 7.8 15.1 18.6 22.3 32.9 15.0 22.7 14.4 20.5 16.5 13.2 12.3 10.1 14.3 14.6 16.2 21.5 21.0 8.5 13.6 24.6 13.9 18.2 12.4 25.6 21.2 11.2 14.3 7.0 15.3 26.1 23.7 15.8 17.6 19.0 7.8 15.8 17.1 15.2 18.1 14.1 28.0 21.1 25.8 19.9 14.1 21.0 24.8 25.7 0.2 1.9 0.4 1.8 3.0 2.5 1.5 1.3 1.7 1.4 1.4 1.1 1.5 4.9 1.9 3.5 5.2 0.5 1.6 21.8 23.4 32.7 28.6 16.9 14.3 13.0 18.5 14.6 13.7 20.8 37.8 0.0 10.7 0.1 27.3 17.8 5.1 8.1 15.9 12.2 17.7 494.9 6.6 11.4 24.3 22.4 5.5 0.0 14.2 17.8 8.9 15.8 9.3 16.8 52.2 55.6 4.7 18.4 16.7 43.4 17.5 7.0 0.0 5.4 11.7 31.9 12.0 0.0 17.3 5.6 14.4 25.8 7.3 8.2 5.5 0.1 951.9 4.3 11.7 11.9 MLLT10 AF10 ENSG00000078403 "MLLT10, histone lysine methyltransferase DOT1L cofactor" P55197 10 21524675-21743630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 71.2" "Cell type enhanced" "Detected in many" 5 "Spermatocytes: 158.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005747 Enhanced Supported Nucleoplasm NA NA Nucleoplasm "HPA005747: AB_1079393" "unprognostic (6.58e-2)" "unprognostic (1.57e-1)" "unprognostic (7.32e-2)" "unprognostic (1.47e-2)" "unprognostic (1.31e-2)" "prognostic favorable (8.75e-4)" "unprognostic (1.03e-3)" "unprognostic (9.56e-3)" "unprognostic (9.29e-2)" "unprognostic (1.78e-1)" "unprognostic (2.69e-2)" "unprognostic (7.85e-2)" "unprognostic (6.57e-2)" "unprognostic (1.26e-1)" "unprognostic (1.50e-1)" "unprognostic (1.07e-1)" "unprognostic (1.67e-1)" 16.3 12.1 11.7 18.4 14.3 21.9 12.8 25.4 13.6 19.0 17.0 12.0 13.6 8.5 26.3 12.8 14.7 14.5 13.7 15.8 10.2 8.5 12.3 13.5 12.3 11.6 10.5 9.9 21.4 12.3 16.6 23.2 20.3 11.8 12.6 11.3 14.6 13.2 16.3 13.4 18.7 12.1 18.7 11.2 10.6 11.4 71.2 14.3 14.6 18.1 9.7 15.2 18.5 19.6 5.5 6.9 12.0 6.8 5.3 7.2 2.8 14.5 12.4 19.1 13.2 12.1 15.3 21.0 9.2 5.8 11.6 11.3 13.1 15.5 17.4 5.1 10.2 10.0 13.7 21.0 12.4 11.6 12.0 12.2 27.0 10.8 18.9 15.0 0.6 17.4 11.4 14.8 9.6 11.1 11.8 15.3 18.3 28.8 13.6 9.1 11.3 20.9 12.6 7.8 8.1 3.9 18.3 10.2 14.6 11.1 6.9 6.7 18.6 12.2 14.7 20.7 17.7 6.9 18.7 13.8 7.3 12.7 14.5 9.1 11.8 13.6 19.5 8.4 10.4 5.6 10.6 6.8 12.0 5.3 4.6 5.2 5.0 6.2 5.7 5.6 5.5 7.2 6.7 5.8 5.3 5.2 6.9 4.6 2.8 11.7 14.3 25.4 13.6 10.2 8.5 10.5 9.9 11.8 14.3 26.8 36.0 13.7 13.7 33.5 31.4 23.5 20.4 17.4 20.5 17.4 41.2 28.7 11.6 12.4 52.7 20.3 15.5 0.0 11.2 48.3 23.9 18.2 23.3 17.8 25.1 28.6 3.4 27.0 30.5 78.0 36.5 23.5 45.5 20.8 15.6 19.7 11.6 14.0 45.3 17.5 50.9 38.8 19.4 158.1 57.1 38.3 42.0 23.5 18.3 10.1 MLLT11 AF1Q ENSG00000213190 "MLLT11, transcription factor 7 cofactor" Q13015 1 151057758-151068497 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 42.1" "Cell type enhanced" "Detected in many" 14 "Early spermatids: 72.1;Late spermatids: 161.6;monocytes: 56.9" "Cancer enhanced" "Detected in all" "glioma: 29.9" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 38.6;EFO-21: 29.3;SH-SY5Y: 42.4;U-698: 36.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA000540 Uncertain Supported Nucleoplasm,Cytosol No No "Nucleoplasm, Cytosol" "HPA000540: AB_2666024" "unprognostic (2.96e-2)" "unprognostic (1.98e-2)" "unprognostic (1.08e-2)" "prognostic unfavorable (4.26e-5)" "unprognostic (1.69e-1)" "unprognostic (1.96e-2)" "unprognostic (5.80e-2)" "unprognostic (1.17e-1)" "unprognostic (1.01e-2)" "unprognostic (2.49e-2)" "unprognostic (1.44e-1)" "unprognostic (1.01e-1)" "prognostic unfavorable (4.25e-12)" "unprognostic (5.66e-3)" "unprognostic (1.42e-1)" "unprognostic (1.29e-1)" "unprognostic (3.94e-3)" 1.9 7.5 13.6 3.4 9.1 1.1 1.2 16.3 42.1 1.9 2.1 5.1 1.2 0.8 3.7 1.2 1.3 0.8 11.1 11.8 11.3 16.4 1.2 1.2 5.3 2.3 10.3 1.2 4.2 1.3 8.4 1.8 1.2 3.2 1.3 1.1 1.2 1.5 1.2 2.6 1.0 2.0 4.2 5.8 2.1 0.9 1.2 1.2 2.0 1.2 1.2 2.6 3.2 1.2 2.4 1.0 6.5 1.0 4.2 9.2 2.8 1.2 5.3 38.6 6.1 0.6 1.0 0.6 2.4 2.6 2.3 4.2 0.5 2.5 1.9 29.3 1.8 6.5 1.5 9.3 2.2 1.3 11.3 2.6 5.0 3.8 0.1 1.2 0.3 0.8 1.7 0.3 12.7 0.5 8.0 17.0 7.6 5.3 0.9 7.4 0.4 17.7 3.3 16.8 0.1 0.8 16.9 5.1 0.1 4.4 1.1 23.3 42.4 0.2 0.4 1.2 26.5 1.4 0.6 11.8 5.0 5.5 1.8 4.4 0.9 0.8 36.0 12.5 0.3 9.4 1.6 0.6 1.6 5.9 0.7 2.7 2.4 3.9 6.0 0.8 2.1 5.3 9.2 6.5 4.2 1.0 1.0 3.6 2.8 13.6 9.1 16.3 21.0 11.3 16.4 10.3 1.2 3.2 1.2 0.0 0.6 1.5 4.0 3.2 38.5 10.1 0.0 0.0 0.0 3.5 7.9 2.0 14.9 2.6 72.1 3.6 0.0 0.0 1.1 2.1 12.7 1.7 4.6 0.0 5.6 35.0 10.3 5.5 4.8 161.6 2.0 7.6 5.0 56.9 0.0 12.4 2.9 0.0 3.5 1.1 18.5 0.0 35.9 4.7 8.8 3.0 6.2 7.5 0.1 4.1 MLLT3 "AF-9, AF9, YEATS3" ENSG00000171843 "MLLT3, super elongation complex subunit" P42568 9 20341665-20622543 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Mucus-secreting cells: 101.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive CD4 T-cell: 14.4" "Group enriched" "Detected in many" 5 "NK-cells: 3.8;T-cells: 14.4" "Cell line enhanced" "Detected in many" "HEL: 73.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001824 Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA001824: AB_1079394" "unprognostic (3.31e-1)" "unprognostic (2.22e-1)" "unprognostic (1.23e-3)" "unprognostic (1.27e-2)" "unprognostic (1.99e-1)" "unprognostic (7.57e-2)" "unprognostic (3.83e-2)" "unprognostic (1.01e-3)" "unprognostic (2.12e-1)" "unprognostic (3.92e-3)" "unprognostic (1.05e-1)" "unprognostic (2.03e-2)" "prognostic favorable (1.84e-4)" "unprognostic (1.85e-1)" "unprognostic (4.81e-2)" "unprognostic (1.40e-2)" "unprognostic (1.68e-1)" 8.6 17.3 18.0 10.4 25.8 19.7 11.4 34.6 20.3 12.3 20.9 7.2 10.6 7.2 13.6 7.9 10.2 11.5 12.7 8.6 18.0 12.8 10.1 2.1 10.7 9.1 14.8 13.8 10.5 4.6 18.3 24.7 10.3 13.2 11.7 22.8 7.4 21.3 12.1 9.1 7.9 12.3 13.5 12.0 5.9 15.3 3.6 21.4 22.1 22.5 6.1 6.5 12.9 10.4 1.4 0.7 1.6 0.3 3.8 14.4 2.8 2.6 7.2 2.6 2.9 6.0 3.7 1.6 6.8 11.5 3.1 3.5 7.0 2.5 10.0 3.7 3.2 0.9 1.3 2.4 11.8 2.8 20.6 6.3 73.6 22.3 3.3 4.3 1.3 6.2 2.8 4.5 1.1 7.4 10.4 3.0 4.2 0.0 12.9 6.4 2.0 7.2 4.3 1.6 14.4 2.1 0.0 4.7 2.7 14.1 3.9 8.3 2.9 5.5 2.8 3.0 2.6 2.9 1.9 2.0 0.0 1.7 1.7 2.4 5.8 5.3 4.1 0.0 3.2 1.4 1.6 0.3 0.5 3.9 0.2 3.6 0.5 7.0 5.3 0.7 1.4 14.4 8.3 0.1 3.8 0.3 0.4 7.3 2.8 18.0 25.8 34.6 20.3 18.0 12.8 14.8 13.8 13.2 21.4 26.8 23.0 7.3 15.3 7.3 5.5 12.1 7.6 9.4 38.7 21.0 31.4 0.9 11.6 23.0 2.7 8.6 13.6 0.0 7.3 5.3 16.7 15.6 11.5 1.7 2.0 4.8 31.7 6.7 2.6 4.2 12.7 3.2 21.9 1.0 101.9 37.2 18.7 17.3 8.9 7.0 1.0 0.0 16.5 0.1 5.6 7.3 1.4 25.4 28.6 13.2 MLLT6 "AF17, FLJ23480" ENSG00000275023 "MLLT6, PHD finger containing" 17 38705542-38729803 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at transcript level" "Evidence at transcript level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Bipolar cells: 244.7;Cone photoreceptor cells: 192.4;Rod photoreceptor cells: 215.1" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004021 Approved Approved Nucleoplasm NA NA Nucleoplasm "HPA004021: AB_1853995" "prognostic favorable (4.18e-4)" "unprognostic (1.50e-1)" "unprognostic (2.53e-1)" "unprognostic (1.44e-2)" "unprognostic (1.29e-1)" "prognostic favorable (3.98e-4)" "unprognostic (4.98e-2)" "unprognostic (1.79e-2)" "unprognostic (1.77e-1)" "unprognostic (7.12e-3)" "prognostic favorable (7.41e-4)" "unprognostic (1.78e-1)" "unprognostic (1.84e-2)" "unprognostic (9.12e-2)" "unprognostic (1.12e-1)" "unprognostic (2.05e-1)" "unprognostic (2.46e-3)" 6.5 7.6 10.0 10.3 10.6 7.3 6.3 14.1 16.9 6.2 6.8 7.2 11.1 7.2 9.2 8.6 5.5 10.3 9.2 7.5 9.7 5.8 1.2 8.5 11.8 8.5 9.6 13.0 9.0 12.8 10.1 4.8 7.2 7.3 5.7 10.0 10.3 12.5 22.3 8.5 8.9 8.2 8.1 11.7 6.7 4.1 9.2 6.3 7.2 4.8 10.1 5.5 11.5 1.4 0.9 2.0 0.8 2.8 6.0 1.7 5.8 6.5 6.6 14.4 7.3 6.6 3.4 3.6 6.7 4.5 5.4 2.4 11.5 16.6 5.3 4.3 6.4 15.2 4.2 7.5 4.0 17.7 11.5 6.1 10.8 10.6 3.5 9.3 8.3 6.7 7.7 3.9 8.9 10.9 7.3 12.6 10.1 14.0 3.8 4.9 18.2 9.0 0.8 5.0 3.4 10.8 9.0 15.3 5.2 13.5 14.8 16.4 3.8 12.6 10.7 4.3 12.4 6.8 9.6 5.2 7.8 7.3 6.6 23.9 7.8 11.2 7.7 8.6 5.5 1.7 0.8 0.4 6.0 0.5 4.6 1.4 3.2 4.2 0.4 1.4 3.1 4.1 2.0 2.8 0.3 0.9 1.7 1.7 44.7 51.0 32.0 22.5 27.1 244.7 23.4 30.6 14.7 36.4 31.4 192.4 15.0 10.0 20.0 2.7 38.7 26.1 0.0 35.9 4.1 20.2 29.7 35.9 9.4 12.0 112.8 47.7 31.9 18.3 3.1 43.4 18.1 18.6 23.4 30.0 32.6 28.3 21.0 39.6 13.5 215.1 32.3 25.4 16.1 23.5 25.5 32.0 48.9 37.7 23.0 MN1 "MGCR, MGCR1, MGCR1-PEN" ENSG00000169184 "MN1 proto-oncogene, transcriptional regulator" Q10571 22 27748277-27801498 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Developmental protein" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 62.7" "Cell type enhanced" "Detected in many" 11 "Bipolar cells: 9.8;Early spermatids: 22.6;Fibroblasts: 10.0;Late spermatids: 12.6;Peritubular cells: 9.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 6 "non-classical monocyte: 1.7" "Lineage enriched" "Detected in single" 8 "monocytes: 1.7" "Cell line enhanced" "Detected in some" "AF22: 22.1;HeLa: 8.9;hTERT-RPE1: 9.9;RH-30: 8.9;TIME: 14.0;U-2 OS: 12.1;U-2197: 12.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA003072 Approved Approved Nucleoplasm NA NA Nucleoplasm "HPA003072: AB_1079399" "unprognostic (5.64e-2)" "unprognostic (2.48e-2)" "unprognostic (1.09e-2)" "unprognostic (1.26e-1)" "unprognostic (2.88e-2)" "unprognostic (2.52e-2)" "unprognostic (7.01e-2)" "unprognostic (3.03e-2)" "unprognostic (4.17e-2)" "unprognostic (1.64e-1)" "unprognostic (4.00e-2)" "unprognostic (7.33e-2)" "unprognostic (5.13e-7)" "unprognostic (3.84e-2)" "unprognostic (2.00e-1)" "unprognostic (5.28e-3)" "unprognostic (2.21e-4)" 3.7 2.0 3.4 4.2 17.3 2.4 1.9 1.3 5.6 5.9 4.2 2.6 2.5 2.1 3.0 9.0 7.0 3.4 11.1 5.1 2.5 2.7 1.6 1.4 4.3 1.3 3.3 3.5 12.4 1.5 1.3 2.3 2.6 4.5 3.1 2.2 10.8 2.1 2.7 62.7 2.9 2.1 5.8 1.0 1.5 3.5 2.0 5.4 0.0 1.8 14.8 2.1 5.0 4.7 0.0 0.2 0.0 1.7 0.0 0.1 0.0 0.0 1.0 22.1 0.6 0.4 0.9 0.0 0.5 0.8 0.0 0.0 0.0 0.0 0.0 2.2 3.9 0.9 1.8 1.1 1.3 0.0 0.0 0.6 0.0 8.9 0.0 0.5 0.0 0.2 0.0 2.5 0.5 2.2 9.9 0.2 0.0 0.0 0.1 0.7 0.0 0.0 0.2 2.9 0.0 2.0 3.6 8.9 0.0 0.3 0.0 0.0 0.3 1.9 0.0 0.0 5.6 0.2 0.0 14.0 0.7 12.1 12.7 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.2 0.0 0.0 3.4 17.3 1.3 4.2 2.5 2.7 3.3 3.5 4.5 5.4 3.0 2.9 0.5 0.1 3.8 9.8 3.9 2.5 0.0 0.0 0.0 0.0 0.0 0.0 1.1 22.6 4.1 0.0 0.0 0.9 0.1 10.0 0.1 0.0 0.4 0.2 0.0 0.0 0.6 0.3 12.6 4.6 0.7 0.0 0.0 0.0 4.3 1.7 0.0 9.6 0.0 0.6 0.0 2.1 0.5 0.9 2.4 0.0 0.0 0.0 0.1 MPL "CD110, TPOR" ENSG00000117400 "MPL proto-oncogene, thrombopoietin receptor" P40238 1 43337849-43352772 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 8.6" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Cell type enriched" "Detected in single" 5 "neutrophil: 1.6" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.6" "Cell line enriched" "Detected in single" 78 "HEL: 41.7" "Region enhanced" "Detected in single" "cerebral cortex: 1.4" "Low region specificity" "Detected in all" HPA007619 Supported "Nuclear membrane,Plasma membrane" NA NA "Plasma membrane" "Nuclear membrane" "HPA007619: AB_1854080" "unprognostic (2.74e-1)" "unprognostic (6.56e-2)" "unprognostic (2.95e-1)" "unprognostic (8.71e-2)" "unprognostic (1.37e-2)" "unprognostic (1.06e-3)" "unprognostic (1.19e-1)" "unprognostic (1.22e-2)" "unprognostic (5.83e-2)" "unprognostic (1.03e-1)" "unprognostic (5.94e-4)" "unprognostic (1.51e-1)" "unprognostic (1.19e-4)" "unprognostic (2.39e-1)" "unprognostic (3.26e-1)" "unprognostic (1.03e-4)" "unprognostic (1.42e-1)" 1.1 0.3 0.9 0.5 0.8 2.0 0.9 0.5 2.2 0.6 0.6 0.5 0.5 0.3 0.9 1.7 0.9 2.1 0.5 3.9 0.8 0.6 0.5 0.5 2.0 0.5 0.9 0.5 6.6 1.1 0.6 0.6 2.2 0.5 1.5 0.7 0.5 0.5 0.7 0.6 0.4 1.2 2.1 2.5 8.6 0.5 2.1 0.5 0.5 2.2 2.4 0.5 0.9 0.5 0.0 0.0 1.6 0.3 0.0 0.0 4.0 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 41.7 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.4 0.2 0.2 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 4.0 0.9 0.8 0.5 2.2 0.8 0.6 0.9 0.5 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MSH2 "COCA1, HNPCC, HNPCC1" ENSG00000095002 "MutS homolog 2" P43246 2 47402969-47663146 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair" DNA-binding "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Spermatogonia: 59.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009572, HPA066845, CAB070867" Approved Supported Nucleoplasm,Vesicles NA Yes Nucleoplasm Vesicles "CAB009572: AB_2144828, CAB070867: , HPA066845: AB_2732752" "unprognostic (2.35e-1)" "unprognostic (1.54e-2)" "unprognostic (2.89e-3)" "prognostic unfavorable (4.44e-4)" "unprognostic (2.23e-1)" "unprognostic (6.31e-3)" "prognostic unfavorable (1.72e-9)" "unprognostic (1.77e-1)" "unprognostic (7.09e-3)" "unprognostic (8.57e-2)" "prognostic unfavorable (4.63e-4)" "unprognostic (5.38e-2)" "unprognostic (3.29e-3)" "unprognostic (1.20e-3)" "unprognostic (5.74e-1)" "unprognostic (8.46e-2)" "unprognostic (1.48e-1)" 7.3 9.8 14.2 12.2 25.5 11.4 14.1 22.6 18.1 9.4 11.6 7.6 5.6 6.5 10.5 13.3 10.8 11.1 4.9 8.4 13.0 14.0 7.3 5.5 7.1 19.7 12.5 17.0 7.9 8.4 15.3 9.1 9.9 18.5 7.9 13.8 12.3 9.4 7.3 6.7 10.3 8.0 7.8 13.8 9.4 6.7 13.4 13.5 37.0 13.9 6.6 21.4 8.5 7.6 7.4 2.9 3.9 4.2 12.2 12.6 6.2 28.3 9.7 26.5 14.3 2.0 5.6 16.1 16.9 8.4 21.0 20.3 18.2 12.3 34.9 22.8 5.9 14.8 12.1 19.8 9.6 31.7 18.0 14.8 25.1 11.2 16.5 2.0 24.5 8.8 3.1 2.8 17.8 4.8 4.7 11.5 0.8 41.8 8.1 16.0 11.3 28.4 18.5 49.9 17.2 11.5 38.1 47.4 20.4 9.1 15.0 22.0 23.9 14.9 11.6 11.9 22.3 11.6 9.6 4.6 13.9 18.3 14.4 18.8 5.2 18.5 48.9 8.5 18.1 8.6 2.8 1.0 3.9 7.9 4.2 8.6 6.3 7.4 9.5 2.3 7.4 12.6 11.9 0.7 12.2 3.2 2.9 10.1 6.2 14.2 25.5 22.6 18.1 13.0 14.0 12.5 17.0 18.5 13.5 8.9 11.5 13.7 5.7 7.3 16.8 13.8 5.1 25.4 13.6 8.7 43.2 14.2 3.3 9.6 13.1 11.7 4.6 23.3 7.3 16.3 8.7 3.4 11.5 1.0 9.6 11.1 3.4 3.7 4.0 17.6 4.9 4.0 8.5 6.4 9.1 20.0 6.0 5.8 6.0 3.5 38.3 0.0 5.5 34.2 59.5 5.6 4.2 8.7 9.8 2.7 MSH6 GTBP ENSG00000116062 "MutS homolog 6" P52701 2 47695530-47810101 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction" DNA-binding "Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009091, HPA028376, HPA028446, CAB070870" Enhanced Supported "Nucleoplasm,Golgi apparatus,Vesicles" NA Yes Nucleoplasm "Golgi apparatus, Vesicles" "CAB009091: AB_670083, CAB070870: AB_2144959, HPA028376: AB_10598909, HPA028446: AB_10602182" "unprognostic (5.10e-2)" "unprognostic (5.87e-3)" "unprognostic (3.29e-2)" "prognostic unfavorable (1.34e-4)" "unprognostic (1.98e-1)" "unprognostic (3.09e-2)" "prognostic unfavorable (7.86e-4)" "unprognostic (1.79e-1)" "unprognostic (2.35e-3)" "unprognostic (1.01e-1)" "unprognostic (1.74e-3)" "unprognostic (8.99e-2)" "prognostic unfavorable (1.06e-7)" "unprognostic (1.22e-1)" "unprognostic (2.31e-1)" "unprognostic (9.68e-2)" "unprognostic (3.48e-2)" 13.0 20.5 9.7 13.1 18.8 13.6 13.0 20.5 13.1 17.9 13.3 17.6 10.7 6.1 28.2 11.0 12.4 18.3 8.4 8.6 11.4 8.8 9.5 14.6 11.0 21.7 23.9 9.6 43.2 27.6 16.2 17.3 14.9 15.0 14.6 10.3 8.7 12.0 13.2 10.4 10.3 10.5 22.1 14.9 11.6 11.1 25.1 22.0 40.4 13.4 10.4 25.8 14.2 16.4 8.4 8.4 7.6 9.8 9.7 15.1 5.7 27.5 20.6 38.3 9.1 11.6 12.2 17.3 15.3 13.5 15.9 16.7 15.1 9.6 45.5 23.0 16.6 21.9 11.6 34.5 19.5 20.8 19.8 17.2 29.1 16.3 15.3 7.1 29.2 10.7 9.9 6.2 16.2 10.8 14.9 9.9 1.1 25.3 16.7 15.5 19.9 31.1 13.8 33.6 18.6 9.5 73.8 50.2 20.5 9.7 17.9 21.5 23.3 21.3 10.2 9.3 35.1 12.2 10.3 6.0 18.5 22.6 14.0 19.8 15.7 21.2 76.2 15.6 18.7 11.3 7.6 5.8 4.9 8.4 9.8 10.4 8.4 9.5 8.3 8.4 8.1 15.1 7.6 3.9 9.7 9.3 4.2 9.5 5.7 9.7 18.8 20.5 13.1 11.4 8.8 23.9 9.6 15.0 22.0 26.8 18.4 9.7 20.1 22.3 26.4 6.9 0.0 28.1 31.8 7.0 33.4 24.9 3.3 12.8 25.7 15.3 2.6 0.0 8.4 16.9 17.4 11.4 17.3 8.5 11.1 14.3 4.6 12.3 5.1 11.5 23.6 12.1 3.3 7.2 7.9 27.0 8.8 3.5 21.2 5.3 29.7 6.5 17.2 40.0 40.2 15.3 8.0 13.3 9.3 10.7 MSI2 ENSG00000153944 "Musashi RNA binding protein 2" Q96DH6 17 57255851-57684685 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 10 "Cone photoreceptor cells: 710.8;Rod photoreceptor cells: 517.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "REH: 48.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022300, HPA068990" Approved Supported Cytosol NA NA Cytosol "CAB022300: , HPA068990: " "unprognostic (4.73e-2)" "unprognostic (2.28e-1)" "unprognostic (3.42e-2)" "unprognostic (1.26e-1)" "unprognostic (1.12e-1)" "unprognostic (1.08e-1)" "unprognostic (4.20e-2)" "unprognostic (2.20e-2)" "unprognostic (4.89e-2)" "unprognostic (2.96e-1)" "unprognostic (4.17e-2)" "unprognostic (1.18e-1)" "prognostic favorable (9.22e-8)" "prognostic favorable (2.00e-4)" "unprognostic (4.87e-2)" "unprognostic (1.57e-1)" "unprognostic (2.72e-3)" 3.4 34.7 20.0 22.4 21.5 8.4 8.8 18.0 25.3 9.7 14.4 7.7 14.2 5.0 6.7 36.3 4.6 11.1 23.5 28.5 13.9 16.9 18.0 3.6 6.9 9.6 21.0 6.4 22.8 6.1 41.4 23.1 10.7 19.7 10.5 7.4 14.6 9.8 48.5 25.6 3.6 5.4 4.6 14.8 8.7 7.7 7.5 9.5 23.7 12.4 8.4 8.6 11.6 5.0 1.9 3.0 4.8 1.5 1.9 4.1 0.5 3.4 5.9 20.4 7.9 2.3 2.2 16.1 3.9 4.5 5.1 3.1 7.0 5.9 16.1 13.7 2.4 4.1 3.4 13.0 5.2 9.5 22.4 9.1 7.0 13.1 16.1 5.1 7.7 7.2 2.8 6.8 0.6 8.3 6.4 5.2 12.9 15.3 12.1 17.9 8.1 34.8 2.1 7.4 17.5 9.5 48.9 30.6 12.7 12.4 22.6 22.7 42.3 6.3 6.0 18.1 9.8 10.8 6.0 6.6 3.2 8.5 2.8 6.6 16.9 14.2 19.6 8.5 4.7 19.6 4.4 0.4 4.8 2.0 0.3 1.5 1.9 1.9 1.8 0.6 1.1 1.8 1.7 0.4 1.9 1.5 3.0 4.1 0.5 20.0 21.5 18.0 25.3 13.9 16.9 21.0 6.4 19.7 9.5 6.0 26.6 60.1 59.4 21.3 190.2 86.4 56.0 93.7 29.6 71.5 710.8 98.4 104.5 41.8 12.8 24.4 15.3 23.3 12.7 17.2 28.6 73.1 40.5 25.1 17.3 278.1 94.3 28.8 11.1 19.3 59.8 13.2 37.1 1.8 48.0 265.7 11.1 17.5 72.9 43.4 517.0 12.9 27.8 3.9 4.5 14.1 124.8 44.8 33.3 79.0 MSN ENSG00000147065 Moesin P26038 X 65588377-65741931 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047337, CAB047338" Enhanced Enhanced "Plasma membrane" NA NA 340000000 "Plasma membrane" "CAB010898: AB_260635, CAB047336: , CAB047337: , CAB047338: , HPA000263: AB_1856043, HPA011135: AB_1854053, HPA011227: AB_1854054" "unprognostic (1.03e-1)" "unprognostic (7.89e-2)" "unprognostic (7.64e-2)" "unprognostic (5.38e-2)" "unprognostic (4.08e-3)" "unprognostic (3.51e-2)" "unprognostic (1.11e-2)" "unprognostic (1.44e-2)" "unprognostic (3.35e-2)" "unprognostic (1.70e-2)" "unprognostic (9.04e-3)" "unprognostic (1.32e-1)" "prognostic unfavorable (1.60e-5)" "unprognostic (5.68e-3)" "unprognostic (7.75e-2)" "unprognostic (7.21e-2)" "unprognostic (6.81e-2)" 36.3 17.6 10.2 40.7 14.4 38.5 98.2 8.6 18.6 25.1 21.3 19.2 7.6 6.5 33.4 14.2 15.7 21.8 20.2 53.8 11.5 10.4 25.6 29.5 102.8 85.0 17.5 5.4 28.8 19.4 5.7 10.2 24.2 30.0 23.1 13.0 16.6 16.3 21.9 13.6 19.5 18.3 41.4 21.8 31.6 17.3 9.0 12.9 18.7 26.2 17.6 38.1 22.7 28.9 16.0 36.4 54.1 69.0 28.0 37.1 81.8 28.3 21.7 21.3 17.6 25.6 33.9 0.1 71.8 46.5 39.8 30.9 0.0 5.0 23.7 64.2 63.5 21.1 19.5 22.5 51.2 52.0 44.0 6.2 65.9 37.7 0.0 24.2 80.0 106.7 25.3 11.0 73.2 64.8 38.6 87.9 33.2 31.9 74.1 63.0 0.0 47.3 60.0 26.4 0.0 41.4 24.8 38.3 18.1 42.6 0.0 0.1 0.0 57.7 0.4 22.8 25.1 0.2 43.6 139.1 45.4 28.8 61.0 47.5 26.9 40.7 25.8 33.2 101.6 50.5 30.8 44.4 30.0 37.1 58.9 27.9 16.0 20.4 29.1 36.4 13.9 14.0 21.3 54.1 28.0 69.0 5.2 15.5 81.8 10.2 14.4 8.6 18.6 11.5 10.4 17.5 5.4 30.0 12.9 166.7 148.6 101.2 51.9 182.5 0.5 23.6 10.2 32.1 70.5 64.6 3.9 5.0 24.9 169.4 1.1 154.5 2.6 23.3 146.5 11.7 88.8 25.9 158.4 46.9 150.1 4.8 0.0 91.4 236.8 3.0 68.1 215.1 65.8 158.7 2.3 38.6 229.7 3.1 102.9 81.2 1.8 71.1 127.7 1.9 3.6 130.7 3.5 174.0 1.8 47.2 MTCP1 "P13MTCP1, p8MTCP1" ENSG00000214827 "Mature T cell proliferation 1" P56278 X 155061622-155147937 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in some" 9 "Ciliated cells: 4.0;Club cells: 2.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "HeLa: 14.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA032040 Approved "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "HPA032040: AB_2674122" "unprognostic (2.42e-2)" "unprognostic (2.07e-2)" "unprognostic (1.14e-1)" "unprognostic (6.29e-3)" "unprognostic (8.30e-2)" "unprognostic (4.10e-1)" "unprognostic (2.40e-5)" "unprognostic (9.30e-2)" "unprognostic (1.17e-1)" "unprognostic (4.94e-2)" "unprognostic (5.72e-2)" "unprognostic (1.15e-2)" "prognostic unfavorable (4.52e-8)" "unprognostic (1.55e-3)" "unprognostic (1.06e-2)" "unprognostic (1.39e-2)" "unprognostic (1.75e-2)" 6.4 7.1 4.1 5.3 5.3 7.2 15.8 4.4 4.8 6.0 6.2 3.4 7.7 5.7 6.0 8.2 7.0 6.1 4.4 30.1 4.7 2.9 6.7 12.8 8.5 15.5 4.5 2.7 9.1 20.7 3.9 6.5 3.5 6.4 5.8 6.1 3.9 7.3 7.0 11.4 12.0 6.7 8.7 7.2 6.7 6.2 16.1 3.8 2.5 8.2 5.4 7.2 6.9 4.0 0.2 0.0 0.8 0.7 0.5 2.0 0.1 1.4 4.9 2.4 3.9 1.6 1.3 2.7 3.0 1.5 1.9 4.8 4.3 7.5 2.7 3.1 0.6 3.0 4.8 3.2 3.5 2.4 1.8 3.2 1.2 14.3 2.3 1.4 2.9 3.3 2.4 1.7 3.2 3.0 2.3 1.8 4.7 1.1 4.9 1.3 2.0 3.7 6.1 1.1 1.8 0.8 4.0 2.6 6.1 2.4 2.1 1.2 1.8 2.2 1.2 2.1 1.7 2.2 1.3 1.8 2.2 3.9 2.1 2.2 10.7 4.6 5.2 4.3 3.5 3.1 0.0 0.6 0.8 1.1 0.0 2.0 0.2 1.2 0.4 0.0 0.1 0.2 1.4 0.0 0.5 0.7 0.0 0.0 0.1 4.1 5.3 4.4 4.8 4.7 2.9 4.5 2.7 6.4 3.8 0.0 1.0 0.0 0.2 0.2 0.0 0.6 0.0 4.0 2.3 0.0 0.0 0.1 0.0 0.5 0.0 0.3 0.0 0.0 1.1 0.2 0.3 0.3 0.0 1.0 0.4 0.0 1.7 0.0 1.0 0.2 1.1 0.5 1.7 1.0 0.0 0.0 1.1 0.0 0.4 0.2 0.0 0.0 0.3 0.5 0.2 0.6 0.2 0.0 0.5 0.0 MTOR "FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1" ENSG00000198793 "Mechanistic target of rapamycin kinase" P42345 1 11106535-11262507 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Sertoli cells: 38.8;Spermatocytes: 48.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB069425, HPA071227" Approved Approved Vesicles,Cytosol NA NA "Vesicles, Cytosol" "CAB069425: , HPA071227: AB_2686367" "unprognostic (3.18e-1)" "unprognostic (1.50e-1)" "unprognostic (1.20e-1)" "unprognostic (2.45e-3)" "unprognostic (5.50e-2)" "unprognostic (2.55e-2)" "unprognostic (1.39e-1)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "unprognostic (8.24e-3)" "unprognostic (3.48e-2)" "unprognostic (1.88e-1)" "prognostic favorable (1.49e-5)" "unprognostic (1.27e-1)" "unprognostic (2.45e-1)" "unprognostic (6.60e-2)" "unprognostic (7.55e-2)" 11.3 13.9 18.7 13.0 22.5 12.3 14.9 25.2 25.2 11.3 14.5 18.2 10.4 11.2 13.8 23.6 13.1 10.5 15.7 14.2 14.5 13.6 15.8 19.4 10.8 14.3 14.0 14.4 10.7 16.6 26.5 16.0 12.5 15.5 15.2 17.1 14.4 14.2 15.2 24.6 16.5 13.6 15.2 10.4 15.4 13.1 38.6 13.1 16.6 13.2 9.9 15.7 11.7 10.2 3.9 4.0 3.0 6.4 2.6 5.6 2.3 15.2 13.9 18.7 14.2 22.7 10.8 9.4 12.9 12.4 17.3 17.0 14.2 14.1 17.0 11.1 15.2 10.7 18.2 25.3 19.8 22.4 13.5 18.5 22.6 28.7 17.9 14.2 21.9 16.8 13.8 15.1 24.7 25.1 8.2 21.8 16.4 25.2 14.6 12.0 17.4 15.1 16.8 14.2 16.0 13.1 15.2 22.1 11.4 15.3 13.9 18.9 13.9 27.6 15.0 16.9 21.5 12.2 13.0 23.3 15.1 13.7 11.5 17.3 14.4 13.4 33.4 10.9 23.8 15.9 0.7 2.9 3.0 5.2 6.4 4.3 3.9 3.0 2.7 4.0 3.4 3.6 3.1 2.0 2.6 3.3 3.1 5.6 2.3 18.7 22.5 25.2 25.2 14.5 13.6 14.0 14.4 15.5 13.1 14.9 10.2 5.2 4.5 3.1 0.0 25.7 2.5 2.7 10.3 8.7 0.0 6.5 1.7 6.3 31.2 7.8 7.9 0.0 5.4 5.9 5.1 7.5 12.7 13.0 6.1 0.0 9.9 5.5 7.3 29.3 7.2 6.0 8.5 5.4 6.8 0.0 8.6 3.5 7.8 4.3 0.0 38.8 6.9 48.4 31.3 5.0 8.2 6.5 9.5 5.5 MUC1 "ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM" ENSG00000185499 "Mucin 1, cell surface associated" P15941 1 155185824-155192916 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 168.1;kidney: 158.5;lung: 143.5" "Cell type enhanced" "Detected in many" 11 "Alveolar cells type 2: 1308.2;Collecting duct cells: 465.9;Exocrine glandular cells: 994.6;Pancreatic endocrine cells: 807.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Cell type enhanced" "Detected in some" "T-reg: 4.0" "Group enriched" "Detected in many" 10 "granulocytes: 1.3;T-cells: 4.0" "Group enriched" "Detected in many" 6 "CAPAN-2: 139.4;OE19: 65.3;RPTEC TERT1: 107.0;T-47d: 47.0" "CAB000036, CAB001986, HPA004179, HPA007235, HPA008855" Enhanced Supported "Plasma membrane" "Secreted in other tissues" NA NA 4900000 "Plasma membrane" "CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283" "unprognostic (4.74e-2)" "unprognostic (2.84e-2)" "unprognostic (2.19e-1)" "unprognostic (8.01e-2)" "unprognostic (1.32e-2)" "unprognostic (1.70e-1)" "unprognostic (2.61e-3)" "unprognostic (6.34e-2)" "unprognostic (1.43e-1)" "unprognostic (3.23e-1)" "prognostic unfavorable (4.60e-4)" "unprognostic (4.75e-1)" "unprognostic (2.05e-2)" "unprognostic (1.13e-1)" "unprognostic (8.12e-2)" "unprognostic (1.42e-1)" "unprognostic (1.21e-1)" 1.5 0.7 0.8 12.6 1.2 0.9 12.6 0.4 0.7 31.6 15.9 1.2 2.4 2.9 10.5 9.8 51.8 18.7 168.1 0.8 0.5 0.3 158.5 2.0 143.5 0.3 0.5 0.3 14.9 74.2 0.0 4.7 15.5 2.1 6.1 16.1 0.8 17.0 5.9 0.8 1.8 3.6 2.8 0.7 0.6 105.0 4.3 0.5 0.7 15.7 10.5 47.8 12.3 5.2 0.0 0.2 1.3 0.1 0.0 4.0 0.2 1.8 0.9 0.6 0.5 0.4 0.5 0.2 0.6 1.4 0.7 1.9 0.0 139.4 0.0 10.1 1.1 0.3 2.8 0.1 0.0 0.2 1.2 0.1 0.2 11.8 0.0 0.3 0.0 4.4 1.2 0.2 0.3 0.2 1.5 0.2 0.2 1.0 1.9 0.5 14.2 0.1 0.1 0.4 65.3 0.2 0.2 0.0 3.4 107.0 0.1 0.6 0.2 3.3 5.9 0.1 0.5 47.0 0.6 0.2 0.4 0.8 1.3 0.1 2.1 1.1 0.0 0.7 0.1 0.1 1.3 0.1 0.0 0.0 0.0 0.8 0.0 2.3 0.4 0.2 0.0 0.3 0.7 0.0 0.0 0.0 0.0 4.0 0.2 0.8 1.2 0.4 0.7 0.5 0.3 0.5 0.3 2.1 0.5 402.0 1308.2 0.9 16.1 0.6 1.0 0.4 384.7 92.3 252.5 465.9 3.9 0.1 29.9 144.7 27.3 3.5 49.2 0.0 994.6 1.2 3.1 11.6 45.2 0.5 0.2 1.6 29.4 1.3 3.4 68.9 2.3 2.6 5.0 42.3 249.7 1.1 807.2 66.2 1.4 0.9 0.2 0.0 1.9 6.2 0.8 1.0 0.2 0.0 132.5 164.3 MYB c-myb ENSG00000118513 "MYB proto-oncogene, transcription factor" P10242 6 135181315-135219173 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "lymphoid tissue: 104.9" "Cell type enhanced" "Detected in many" 11 "Ciliated cells: 44.2;granulocytes: 25.4;Intestinal endocrine cells: 16.9;Mucus-secreting cells: 26.5;Undifferentiated cells: 37.5" "Cancer enhanced" "Detected in many" "breast cancer: 17.7" "Region enhanced" "Detected in some" "basal ganglia: 4.7" "Group enriched" "Detected in some" 4 "basophil: 5.6;eosinophil: 10.0" "Lineage enriched" "Detected in many" 6 "granulocytes: 10.0" "Cell line enhanced" "Detected in many" "HL-60: 39.5;MOLT-4: 72.0;NB-4: 37.5;REH: 44.5;THP-1: 62.8;U-937: 34.2" "Low region specificity" "Detected in some" "Not detected" "Not detected" "CAB017704, HPA071605" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB017704: , HPA071605: " "unprognostic (1.69e-1)" "unprognostic (5.82e-2)" "unprognostic (1.82e-3)" "unprognostic (1.37e-2)" "unprognostic (4.06e-1)" "unprognostic (8.35e-3)" "unprognostic (1.13e-3)" "unprognostic (2.48e-2)" "unprognostic (6.44e-2)" "unprognostic (1.00e-1)" "unprognostic (3.71e-2)" "prognostic favorable (9.65e-4)" "unprognostic (2.41e-11)" "prognostic favorable (9.87e-4)" "unprognostic (8.35e-2)" "unprognostic (3.04e-2)" "unprognostic (9.40e-2)" 0.5 0.7 1.3 9.1 4.7 18.9 13.2 0.3 0.6 1.4 15.4 0.5 0.3 6.5 0.9 1.0 3.7 5.0 1.7 0.6 0.7 0.7 0.4 0.5 1.8 3.3 0.3 0.5 1.0 0.3 0.4 0.3 0.6 0.5 1.6 16.7 0.5 0.8 1.5 1.0 3.5 5.9 0.7 0.4 1.4 0.9 2.0 0.6 104.9 0.4 2.0 4.7 0.7 1.5 0.1 1.7 10.0 0.8 0.0 0.5 0.1 0.3 0.0 0.3 0.5 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.0 0.2 1.8 0.0 0.0 0.0 0.1 1.0 0.0 0.1 3.1 0.4 25.2 0.1 0.0 0.0 39.5 20.0 0.0 0.0 0.1 0.0 0.0 0.0 24.8 20.4 3.8 0.2 2.0 72.0 37.5 0.2 3.5 0.3 44.5 1.0 6.1 0.0 0.2 1.9 1.2 0.0 2.0 0.0 0.1 1.5 62.8 0.0 0.0 0.3 1.5 0.4 4.8 1.2 12.2 0.0 34.2 0.4 5.6 0.8 10.0 0.0 0.1 0.2 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.0 0.0 0.0 1.7 0.5 0.1 1.3 4.7 0.3 0.6 0.7 0.7 0.3 0.5 0.5 0.6 0.0 2.2 2.9 1.1 2.4 0.6 0.4 2.5 44.2 10.3 0.0 0.0 0.7 0.0 0.0 0.1 0.0 2.9 0.0 0.7 0.6 0.4 2.7 25.4 0.0 0.9 0.0 16.9 0.0 1.2 0.0 0.0 1.5 8.5 0.0 26.5 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.5 6.0 0.2 1.9 37.5 2.0 MYC "bHLHe39, c-Myc, MYCC" ENSG00000136997 "MYC proto-oncogene, bHLH transcription factor" P01106 8 127735434-127741434 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Basal glandular cells: 812.6;Basal keratinocytes: 900.0;Smooth muscle cells: 529.5;Suprabasal keratinocytes: 935.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RPMI-8226: 132.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000084, CAB010307, HPA055893, HPA066556" Approved Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000084: , CAB010307: AB_631274, HPA055893: AB_2682960, HPA066556: AB_2685691" "unprognostic (1.45e-2)" "unprognostic (4.00e-3)" "unprognostic (3.94e-3)" "unprognostic (2.41e-3)" "unprognostic (8.14e-2)" "unprognostic (3.36e-3)" "unprognostic (5.80e-2)" "unprognostic (4.94e-3)" "unprognostic (1.59e-1)" "prognostic unfavorable (7.52e-4)" "unprognostic (5.19e-3)" "unprognostic (9.86e-3)" "prognostic unfavorable (5.49e-8)" "unprognostic (7.85e-2)" "unprognostic (4.66e-2)" "unprognostic (2.48e-1)" "prognostic unfavorable (4.96e-5)" 67.4 20.8 3.2 46.6 7.1 16.3 36.0 1.2 5.0 23.9 23.3 3.8 11.8 11.1 23.8 14.4 47.6 59.5 32.4 23.7 5.8 2.2 11.2 36.6 16.0 40.5 5.8 1.2 38.7 64.6 2.1 7.4 14.9 9.8 20.6 11.3 6.1 14.4 21.8 69.6 78.5 17.2 21.3 12.0 38.3 24.7 16.3 3.8 40.2 9.0 48.4 27.1 28.9 37.3 25.5 8.8 1.0 10.3 20.9 55.2 22.0 7.2 14.0 1.2 12.5 20.4 24.1 3.7 8.7 3.8 10.9 9.1 19.2 19.1 74.3 12.3 5.2 10.7 15.8 65.1 28.3 7.2 17.5 22.7 44.7 23.8 25.0 18.8 31.2 7.2 16.8 62.6 7.3 58.0 8.8 12.5 26.2 66.0 39.3 5.4 20.8 51.0 68.1 3.5 31.3 28.1 28.4 5.3 132.1 9.1 7.5 86.4 8.2 4.0 34.1 22.6 2.1 13.9 20.5 15.2 8.2 9.8 6.3 10.9 0.7 1.2 35.9 7.2 35.0 4.1 0.7 10.3 0.1 8.6 9.1 43.4 25.5 31.1 18.6 8.8 20.6 55.2 34.8 1.0 20.9 6.1 0.3 24.8 22.0 3.2 7.1 1.2 3.6 5.8 2.2 5.8 1.2 9.8 3.8 53.6 68.5 50.1 812.6 900.0 0.0 10.2 28.1 18.7 83.0 12.2 0.0 20.0 1.7 71.3 0.9 89.5 6.3 0.0 37.0 51.5 149.4 176.0 54.4 27.1 25.9 0.0 12.0 96.3 42.9 1.1 91.5 19.1 160.3 3.6 66.1 1.0 60.5 11.5 63.3 5.3 0.2 45.3 529.5 0.5 0.7 935.3 4.9 39.5 82.4 301.8 MYCL "bHLHe38, LMYC, MYCL1" ENSG00000116990 "MYCL proto-oncogene, bHLH transcription factor" P12524 1 39895426-39902256 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pancreas: 46.4;skin 1: 26.0" "Cell type enhanced" "Detected in many" 5 "Cytotrophoblasts: 21.7;Hepatocytes: 21.9;Mucus-secreting cells: 22.7;Urothelial cells: 22.1" "Cancer enhanced" "Detected in all" "urothelial cancer: 28.9" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "classical monocyte: 11.5;intermediate monocyte: 5.5;myeloid DC: 12.9;plasmacytoid DC: 15.4" "Group enriched" "Detected in many" 75 "dendritic cells: 15.4;monocytes: 11.5" "Group enriched" "Detected in some" 7 "U-266/70: 96.4;U-266/84: 70.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA063132, HPA074515" Enhanced "Nucleoplasm,Mitotic chromosome" NA NA Nucleoplasm "Mitotic chromosome" "HPA063132: AB_2684946, HPA074515: " "unprognostic (7.45e-2)" "unprognostic (6.91e-2)" "unprognostic (7.36e-2)" "unprognostic (1.83e-3)" "unprognostic (1.61e-2)" "unprognostic (2.92e-3)" "unprognostic (6.72e-3)" "prognostic favorable (4.49e-4)" "unprognostic (1.24e-1)" "unprognostic (1.77e-2)" "unprognostic (5.44e-2)" "unprognostic (1.12e-1)" "unprognostic (5.01e-3)" "unprognostic (2.75e-2)" "unprognostic (5.21e-2)" "unprognostic (1.53e-2)" "unprognostic (5.80e-2)" 0.3 0.3 1.2 4.4 2.1 0.1 1.7 0.8 1.7 3.6 7.5 1.8 8.5 2.6 1.0 4.0 17.8 1.6 2.3 0.7 1.1 0.9 0.8 6.4 1.9 2.9 0.6 1.4 0.5 46.4 0.0 2.1 11.2 1.8 5.3 3.6 1.8 4.6 16.6 0.6 26.0 7.3 1.2 1.1 4.0 3.3 1.5 0.6 6.4 4.2 3.1 6.0 18.4 7.3 0.0 15.4 0.1 11.5 0.0 0.1 3.8 0.2 0.0 2.9 0.7 0.0 0.0 7.1 0.1 0.0 0.2 0.1 0.1 0.1 0.4 0.3 0.0 0.0 0.7 2.0 0.5 0.1 0.4 1.1 0.1 0.0 0.1 0.0 0.0 1.7 0.2 2.4 0.0 0.2 0.0 0.2 1.1 0.7 0.0 0.1 0.2 0.0 0.0 2.8 0.4 0.1 0.2 3.4 0.6 0.2 11.6 0.5 0.7 0.2 0.4 0.1 1.1 0.7 3.7 0.0 0.0 1.1 1.3 0.1 96.4 70.7 0.2 0.0 0.4 0.0 0.0 11.5 0.0 0.0 5.5 0.0 0.0 0.0 0.1 12.9 0.0 0.0 0.0 0.1 0.0 2.3 15.4 0.0 3.8 1.2 2.1 0.8 1.7 1.1 0.9 0.6 1.4 1.8 0.6 0.0 0.6 0.0 9.0 6.0 0.2 3.3 0.0 1.4 4.5 8.7 0.0 21.7 0.0 1.1 0.1 0.5 9.5 0.0 5.1 11.3 0.7 4.8 0.0 21.9 4.9 0.0 16.6 2.5 6.9 0.2 0.0 9.6 1.7 0.0 22.7 1.1 2.4 8.5 0.0 0.0 0.0 0.0 0.3 0.0 0.7 10.3 14.6 0.0 10.5 22.1 MYCN "bHLHe37, MYCNOT, N-myc, NMYC" ENSG00000134323 "MYCN proto-oncogene, bHLH transcription factor" P04198 2 15940564-15947007 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 16.8" "Cell type enriched" "Detected in some" 8 "Extravillous trophoblasts: 75.4" "Cancer enhanced" "Detected in many" "testis cancer: 45.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 12.9;BEWO: 70.2;HMC-1: 16.9;NTERA-2: 26.6;RH-30: 18.6;SuSa: 12.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA057420 Approved Nucleoplasm,Nucleoli NA NA Nucleoli Nucleoplasm "HPA057420: AB_2683434" "unprognostic (8.04e-2)" "unprognostic (1.96e-1)" "unprognostic (1.29e-1)" "unprognostic (2.07e-2)" "unprognostic (4.11e-1)" "unprognostic (2.46e-2)" "unprognostic (1.23e-2)" "unprognostic (3.03e-2)" "unprognostic (1.81e-1)" "unprognostic (3.35e-3)" "unprognostic (3.09e-2)" "unprognostic (2.09e-1)" "unprognostic (1.12e-3)" "unprognostic (8.89e-2)" "unprognostic (2.47e-1)" "unprognostic (4.90e-2)" "unprognostic (1.23e-1)" 0.9 1.9 5.1 1.8 5.5 1.6 1.2 1.4 8.4 3.1 1.2 12.1 0.0 3.0 1.9 0.8 1.3 1.4 2.6 2.3 7.0 4.7 6.0 1.5 1.6 2.9 6.0 2.2 10.3 0.7 0.4 0.7 16.8 6.8 0.6 1.3 1.1 6.6 0.7 1.0 2.4 1.7 0.9 8.9 0.9 8.5 6.5 4.0 5.7 5.1 2.3 3.5 2.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.9 0.0 0.0 0.0 70.2 0.0 0.0 0.0 0.0 1.0 0.0 0.0 1.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 16.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.1 0.0 26.6 0.6 0.0 0.0 18.6 3.5 0.0 0.9 0.2 4.7 0.0 0.0 0.0 12.6 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 5.5 1.4 7.0 7.0 4.7 6.0 2.2 6.8 4.0 0.0 0.0 0.0 0.1 0.5 2.6 0.7 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 1.2 0.2 0.0 0.0 0.0 75.4 0.6 0.0 0.0 0.5 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.8 0.2 0.0 0.4 2.1 0.1 0.0 0.0 0.5 3.6 0.0 9.6 0.0 0.2 0.0 MYD88 ENSG00000172936 "Myeloid differentiation primary response 88" Q99836 3 38138478-38143022 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Immunity, Inflammatory response, Innate immunity" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 68.0" "Cell type enhanced" "Detected in many" 5 "Kupffer cells: 75.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SK-BR-3: 55.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009104 Approved Supported Vesicles,Mitochondria,Cytosol NA NA Cytosol "Vesicles, Mitochondria" "CAB009104: AB_2146724" "prognostic favorable (8.45e-4)" "unprognostic (1.19e-1)" "unprognostic (4.31e-2)" "unprognostic (2.51e-2)" "unprognostic (4.77e-2)" "unprognostic (4.38e-3)" "unprognostic (4.37e-2)" "unprognostic (3.63e-1)" "unprognostic (1.67e-1)" "unprognostic (7.28e-2)" "unprognostic (1.01e-2)" "unprognostic (7.30e-2)" "unprognostic (2.11e-2)" "unprognostic (4.41e-1)" "unprognostic (4.17e-2)" "unprognostic (1.65e-1)" "unprognostic (2.08e-2)" 25.0 11.3 5.9 19.5 6.9 18.1 14.7 5.2 4.6 10.0 13.4 5.8 5.0 15.1 9.5 12.3 25.5 9.8 12.4 10.4 5.3 3.2 15.1 47.9 25.6 40.1 6.2 3.5 13.3 10.3 5.4 10.4 17.8 6.7 11.3 14.3 8.8 13.9 5.4 3.9 12.5 30.4 10.7 7.0 39.0 12.5 5.8 5.1 28.5 10.4 17.5 30.8 13.9 13.7 7.8 34.7 49.0 68.0 8.3 14.3 34.6 8.1 12.2 1.8 10.8 8.6 11.2 3.8 8.1 13.2 22.8 24.3 7.6 10.0 17.6 4.8 14.5 5.2 10.3 14.4 8.1 7.6 13.6 3.0 9.5 6.2 11.5 7.1 12.1 24.8 12.9 8.6 12.9 4.8 4.3 13.0 13.5 4.1 7.2 12.0 8.3 19.8 3.9 7.7 17.2 12.1 8.5 2.3 7.5 11.7 19.3 0.8 4.0 11.5 55.1 7.1 1.5 8.6 13.7 12.0 4.5 2.7 20.7 7.7 10.7 11.8 13.1 8.7 21.1 9.7 38.3 37.6 48.1 12.2 56.5 10.4 7.8 11.0 12.2 34.7 6.7 7.7 10.9 49.0 8.3 68.0 16.6 14.3 34.6 5.9 6.9 5.2 4.6 5.3 3.2 6.2 3.5 6.7 5.1 6.0 14.6 17.4 10.4 12.8 0.9 1.5 7.6 10.7 11.4 5.2 0.0 12.2 6.6 22.7 0.7 10.5 25.9 0.0 24.0 20.1 9.1 11.9 24.2 27.6 30.3 0.0 9.2 9.8 75.0 0.6 12.7 48.3 3.3 18.0 16.3 3.5 43.6 34.5 9.9 9.2 0.0 12.9 7.0 2.1 0.4 15.1 10.1 20.3 13.1 37.7 MYH11 "SMHC, SMMHC" ENSG00000133392 "Myosin heavy chain 11" P35749 16 15703172-15857033 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin" "Aortic aneurysm, Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 507.4;urinary bladder: 394.5" "Group enriched" "Detected in many" 29 "Peritubular cells: 1569.5;Sertoli cells: 614.4;Smooth muscle cells: 1327.8" "Cancer enhanced" "Detected in many" "prostate cancer: 173.2" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "BEWO: 3.6;NB-4: 3.9;U-698: 9.9" "Low region specificity" "Detected in many" "Region enhanced" "Detected in single" "midbrain: 54.5" "CAB002302, HPA014539, HPA015310" Enhanced Enhanced "Plasma membrane,Cytosol" NA NA 130000000 "Plasma membrane, Cytosol" "CAB002302: AB_563902, HPA014539: AB_1234906, HPA015310: AB_1854261" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (4.18e-2)" "unprognostic (9.21e-3)" "unprognostic (6.70e-2)" "unprognostic (2.75e-2)" "prognostic favorable (1.10e-5)" "unprognostic (1.41e-2)" "unprognostic (1.87e-1)" "unprognostic (3.44e-2)" "unprognostic (1.28e-1)" "unprognostic (1.14e-1)" "unprognostic (1.19e-3)" "unprognostic (4.06e-2)" "unprognostic (9.53e-2)" "unprognostic (5.00e-2)" "unprognostic (5.45e-3)" 13.2 3.0 0.6 31.5 1.2 0.0 5.9 0.5 1.7 90.3 227.5 1.3 100.0 11.6 102.0 38.4 233.0 43.8 94.3 6.2 0.6 0.7 4.7 0.7 8.5 1.5 1.4 2.6 45.5 1.3 0.0 1.0 5.3 3.6 164.7 22.2 37.0 8.8 127.2 6.4 5.0 50.6 507.4 1.4 3.7 77.7 22.3 0.2 0.1 3.7 6.2 3.0 394.5 57.5 1.5 0.9 6.0 0.9 1.1 1.5 0.4 0.1 0.4 0.2 0.1 0.0 0.0 3.6 0.1 0.0 0.0 0.0 0.0 0.4 0.1 0.2 0.0 0.2 0.6 0.0 0.0 0.0 0.4 0.4 0.2 0.1 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.1 1.5 0.0 0.3 0.3 3.9 0.4 0.1 0.1 0.4 0.2 1.9 0.0 0.2 0.7 1.4 0.2 0.5 1.2 0.2 0.5 0.0 0.3 0.1 0.3 2.0 0.1 0.5 0.4 9.9 0.4 0.4 0.4 3.1 0.9 2.7 1.2 0.6 1.2 1.5 1.5 1.4 0.5 1.2 1.4 1.4 6.0 1.1 0.6 0.9 1.4 0.4 0.6 1.2 0.5 1.7 0.6 0.7 1.4 2.6 3.6 0.2 0.0 2.6 4.5 1.6 11.7 1.5 38.7 0.0 1.4 2.3 0.0 7.9 0.2 0.0 0.0 36.6 5.7 0.0 0.0 0.3 0.2 8.0 5.1 0.0 0.0 1.1 0.0 1.2 4.3 0.0 30.8 39.7 3.8 11.8 2.8 0.3 0.3 0.2 0.0 1569.5 0.0 1.6 614.4 1327.8 3.2 7.5 16.3 0.0 4.9 0.4 2.5 MYH9 "DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA" ENSG00000100345 "Myosin heavy chain 9" P35579 22 36281277-36388067 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Cell shape" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001644, CAB015386, HPA064783" Enhanced Supported "Plasma membrane,Actin filaments,Cytosol" No No 3100000000 "Plasma membrane, Actin filaments" Cytosol "CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721" "unprognostic (1.38e-1)" "unprognostic (9.12e-2)" "unprognostic (4.21e-2)" "unprognostic (6.34e-2)" "unprognostic (1.49e-1)" "unprognostic (3.90e-2)" "unprognostic (9.56e-2)" "unprognostic (8.28e-2)" "unprognostic (5.50e-2)" "unprognostic (6.38e-2)" "unprognostic (1.93e-2)" "unprognostic (1.61e-1)" "unprognostic (7.98e-2)" "unprognostic (9.48e-2)" "unprognostic (1.64e-1)" "unprognostic (1.62e-1)" "unprognostic (2.59e-2)" 115.5 26.1 11.9 43.7 12.9 55.6 59.0 9.3 16.8 67.1 44.6 18.0 26.4 26.9 120.8 39.7 48.3 45.6 66.9 39.2 11.0 8.1 45.0 42.8 74.4 57.7 15.1 9.2 56.4 43.9 19.0 15.4 65.7 17.9 47.6 23.6 32.4 66.2 27.2 36.9 40.3 49.8 46.7 13.5 91.5 37.1 25.8 11.9 76.0 42.5 38.4 65.0 56.0 53.7 6.9 8.2 28.5 11.5 4.2 16.6 19.3 61.6 28.6 9.1 7.8 17.0 21.4 46.4 41.4 53.6 59.1 44.4 30.9 17.7 16.0 24.6 69.2 28.2 42.8 13.3 80.9 60.9 36.0 12.6 30.8 30.7 26.3 52.3 34.9 49.4 25.3 24.9 79.9 67.9 58.0 48.7 11.8 6.7 21.7 47.2 16.4 12.4 20.6 5.4 17.4 17.7 23.6 28.3 14.8 33.4 60.0 13.8 5.6 58.1 22.9 26.7 24.6 17.0 18.1 139.1 131.2 39.8 25.1 74.7 14.3 11.3 13.5 49.6 17.7 38.0 26.8 10.4 28.5 16.6 9.6 14.7 6.9 12.0 13.2 8.2 6.4 9.6 10.1 19.7 4.2 11.5 3.8 12.6 19.3 11.9 12.9 9.3 16.8 11.0 8.1 15.1 9.2 17.9 11.9 110.2 86.9 60.5 130.0 128.0 2.3 53.2 81.5 28.1 77.3 87.2 2.0 72.9 6.6 289.4 34.4 187.8 163.7 0.0 209.5 151.1 61.7 129.5 90.2 89.4 89.7 77.9 70.9 122.8 115.2 27.9 63.0 105.6 81.0 160.5 123.0 11.0 299.7 150.8 198.7 19.2 4.7 200.5 251.3 3.0 6.8 118.2 38.8 112.2 120.6 111.1 MYO5A "GS1, MYH12, MYO5, MYR12" ENSG00000197535 "Myosin VA" Q9Y4I1 15 52307283-52529050 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Protein transport, Transport" "Actin-binding, Calmodulin-binding, Motor protein, Myosin" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.5;parathyroid gland: 47.6" "Cell type enhanced" "Detected in many" 7 "Bipolar cells: 82.8;Melanocytes: 92.8" "Cancer enhanced" "Detected in all" "melanoma: 25.2" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Karpas-707: 60.0;RPMI-8226: 40.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001356 Enhanced Approved "Focal adhesion sites,Centriolar satellite" NA NA "Focal adhesion sites, Centriolar satellite" "HPA001356: AB_1079441" "unprognostic (1.54e-1)" "unprognostic (1.78e-1)" "unprognostic (6.95e-2)" "unprognostic (2.29e-2)" "unprognostic (1.97e-2)" "unprognostic (3.91e-2)" "unprognostic (2.30e-2)" "unprognostic (6.65e-2)" "unprognostic (7.89e-2)" "unprognostic (4.74e-2)" "unprognostic (9.36e-3)" "unprognostic (1.71e-1)" "unprognostic (5.63e-3)" "unprognostic (3.79e-3)" "unprognostic (1.24e-1)" "unprognostic (7.16e-2)" "prognostic unfavorable (4.22e-4)" 8.4 7.1 16.6 9.5 27.5 15.7 5.5 27.4 34.5 6.2 4.4 7.8 0.4 3.3 4.2 3.2 5.0 3.6 7.3 4.6 15.9 15.4 4.6 2.7 7.3 11.2 15.6 17.6 5.4 4.3 47.6 10.5 5.2 29.3 4.5 5.2 9.9 4.0 3.4 4.1 10.4 3.9 7.7 10.1 7.3 4.1 4.6 7.1 3.1 6.8 2.7 10.3 7.3 4.2 2.3 5.2 6.3 4.4 0.7 4.5 1.9 5.5 9.8 5.2 6.3 5.3 6.5 5.6 10.1 9.1 5.4 4.2 0.9 2.2 5.3 2.6 12.0 7.9 4.6 12.0 10.4 6.7 30.0 2.8 4.9 2.5 1.2 2.7 2.6 4.8 4.3 6.5 7.9 15.8 5.3 31.4 3.5 0.1 60.0 10.4 9.8 2.3 0.3 2.4 0.1 7.8 4.2 8.4 40.7 4.4 4.0 3.8 2.3 9.4 7.8 18.3 4.0 4.1 2.9 15.0 10.9 4.7 5.1 9.8 6.2 13.8 6.4 11.9 7.5 15.7 0.9 4.4 5.4 2.9 3.6 4.5 2.3 2.9 1.9 5.2 1.6 0.5 1.0 6.3 0.7 2.6 3.1 4.1 1.9 16.6 27.5 27.4 34.5 15.9 15.4 15.6 17.6 29.3 7.1 11.9 10.7 12.3 8.4 18.4 82.8 8.7 5.1 9.4 29.6 14.0 37.3 0.5 0.0 4.8 16.0 9.0 0.0 0.0 5.4 0.4 6.0 6.8 22.0 1.0 21.3 25.4 1.2 1.8 24.4 6.4 3.4 39.4 92.8 27.9 0.0 4.5 5.0 0.8 1.8 2.2 27.1 6.5 4.7 8.7 7.0 10.2 0.9 12.9 0.0 7.4 MYOD1 "bHLHc1, MYF3, MYOD, PUM" ENSG00000129152 "Myogenic differentiation 1" P15172 11 17719568-17722131 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Myogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "skeletal muscle: 31.8" "Cell type enriched" "Detected in single" 7 "Spermatogonia: 3.0" "Cancer enhanced" "Detected in single" "ovarian cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 15 "RH-30: 103.7" "Not detected" "Not detected" "Not detected" "Not detected" "HPA055436, HPA078647" Enhanced Nucleoplasm NA NA Nucleoplasm "HPA055436: , HPA078647: " "unprognostic (1.07e-3)" "unprognostic (2.10e-1)" "unprognostic (1.01e-1)" 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.0 0.5 0.0 31.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 4.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 103.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.0 0.0 0.0 0.0 0.0 0.0 NAB2 MADER ENSG00000166886 "NGFI-A binding protein 2" Q15742 12 57088894-57095476 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" Repressor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Syncytiotrophoblasts: 47.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004510, HPA027464" Approved Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB004510: AB_627982, HPA027464: AB_10601138" "prognostic favorable (7.41e-4)" "unprognostic (4.04e-2)" "unprognostic (2.20e-3)" "unprognostic (2.43e-2)" "unprognostic (4.74e-2)" "unprognostic (2.10e-1)" "unprognostic (1.88e-3)" "unprognostic (1.80e-1)" "unprognostic (5.85e-2)" "unprognostic (1.19e-1)" "unprognostic (2.13e-1)" "unprognostic (6.98e-2)" "prognostic unfavorable (9.38e-6)" "unprognostic (1.95e-1)" "unprognostic (9.76e-2)" "unprognostic (5.67e-3)" "unprognostic (6.19e-3)" 9.5 12.6 11.7 9.9 14.2 4.8 7.9 33.3 20.4 18.7 13.7 5.3 9.6 8.2 22.8 18.9 10.5 15.6 14.5 9.6 8.6 6.8 8.4 18.7 12.8 9.1 4.4 14.6 29.2 8.5 14.5 17.0 13.4 6.8 15.0 4.4 8.5 5.6 14.5 7.1 18.6 7.1 14.5 4.1 8.0 8.2 11.8 7.0 12.4 9.8 7.7 8.6 14.5 26.5 4.2 1.2 0.9 5.4 0.9 2.5 1.2 5.5 3.6 18.9 17.3 17.0 22.3 2.0 16.8 15.2 10.6 8.9 5.8 3.3 3.5 6.9 16.5 3.2 10.1 6.5 12.4 5.7 1.5 1.7 4.2 2.8 5.9 12.9 3.4 10.1 24.7 13.7 12.6 4.3 16.9 2.8 2.6 9.5 3.7 12.3 26.0 5.1 16.3 3.8 4.8 6.3 3.8 24.9 1.8 4.5 2.2 2.1 5.0 8.1 4.7 35.2 5.1 10.6 7.4 3.2 15.7 13.1 11.1 4.9 8.7 2.1 1.8 15.3 2.2 9.4 0.0 2.3 0.3 1.2 5.3 1.4 2.1 2.0 1.5 1.2 4.2 2.5 2.5 0.9 0.9 5.4 0.0 1.9 1.2 11.7 14.2 33.3 20.4 8.6 6.8 4.4 14.6 6.8 7.0 11.9 15.4 9.0 20.1 26.3 18.7 2.4 0.0 1.4 13.6 8.7 2.0 2.7 6.6 7.2 0.4 10.5 2.6 0.0 1.2 8.8 23.4 12.6 16.2 13.0 10.6 9.5 6.3 16.5 13.7 2.1 18.1 18.0 20.3 0.0 0.5 7.5 3.3 0.0 17.7 4.4 3.8 19.4 16.0 1.6 15.0 28.4 47.0 5.1 1.3 8.4 NCOA1 "bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1" ENSG00000084676 "Nuclear receptor coactivator 1" Q15788 2 24491914-24770702 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Acyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RH-30: 41.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019402, HPA070213, HPA070520" Supported Enhanced "Nucleoplasm,Plasma membrane,Cytosol" No No Nucleoplasm "Plasma membrane, Cytosol" "CAB019402: AB_2196189, HPA070213: AB_2686235, HPA070520: AB_2686276" "unprognostic (2.73e-1)" "unprognostic (5.82e-2)" "unprognostic (2.46e-2)" "unprognostic (9.89e-3)" "unprognostic (7.60e-2)" "unprognostic (2.36e-2)" "unprognostic (7.06e-3)" "unprognostic (1.45e-1)" "unprognostic (1.43e-1)" "unprognostic (1.72e-1)" "unprognostic (2.93e-3)" "unprognostic (1.16e-1)" "unprognostic (2.10e-2)" "unprognostic (7.15e-2)" "unprognostic (3.08e-1)" "unprognostic (1.29e-1)" "unprognostic (2.92e-2)" 9.8 10.0 15.3 7.3 18.0 8.9 10.5 15.9 17.1 13.7 8.9 13.5 4.9 12.5 13.0 11.5 10.8 10.0 8.3 8.8 20.8 12.2 11.9 8.8 9.4 8.2 10.8 9.9 17.2 10.3 23.9 16.0 10.1 14.2 9.6 10.1 19.9 10.6 13.0 42.5 9.3 10.9 11.6 9.7 9.6 7.6 11.4 10.7 8.5 7.0 12.2 9.3 9.7 10.8 2.5 5.5 14.2 3.5 3.4 4.1 1.8 6.7 5.0 8.9 4.6 9.8 9.0 13.6 3.6 7.3 4.6 4.1 4.7 2.9 4.9 1.5 6.6 8.8 1.6 5.3 3.1 5.0 23.3 7.7 17.6 2.0 1.9 6.2 8.0 14.7 14.3 4.7 4.4 3.6 5.7 4.6 6.4 10.7 8.2 6.9 4.5 7.1 2.9 4.2 4.0 3.4 5.7 41.0 2.5 5.0 9.2 8.1 6.4 8.4 5.1 3.7 4.9 6.1 4.1 5.0 7.7 6.1 5.2 3.6 9.5 8.2 8.6 4.4 5.1 3.8 11.0 3.5 6.9 3.8 2.7 4.1 1.8 3.4 4.1 2.6 2.5 3.3 4.0 14.2 3.4 2.8 5.5 3.7 1.8 15.3 18.0 15.9 17.1 20.8 12.2 10.8 9.9 14.2 10.7 35.7 29.8 13.6 10.7 27.1 97.2 33.1 15.3 20.1 31.8 14.0 49.1 11.2 6.6 12.0 13.1 29.2 24.6 23.3 23.0 14.9 31.2 14.1 18.6 20.3 15.3 58.8 24.2 33.2 25.2 3.8 43.7 26.2 18.6 10.0 22.7 63.8 17.7 35.1 40.7 11.4 67.4 38.8 35.4 32.1 36.8 27.0 4.5 25.4 23.0 14.6 NCOA2 "bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2" ENSG00000140396 "Nuclear receptor coactivator 2" Q15596 8 70109762-70403805 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" Activator "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA060243 Supported "Nucleoplasm,Nuclear bodies" NA NA "Nucleoplasm, Nuclear bodies" "HPA060243: AB_2684229" "unprognostic (9.79e-3)" "unprognostic (1.40e-1)" "unprognostic (2.72e-1)" "unprognostic (4.94e-3)" "unprognostic (1.91e-2)" "unprognostic (2.18e-3)" "unprognostic (1.30e-1)" "unprognostic (6.77e-2)" "unprognostic (2.06e-1)" "unprognostic (7.00e-2)" "unprognostic (2.20e-2)" "unprognostic (2.63e-2)" "prognostic favorable (5.08e-4)" "unprognostic (2.52e-1)" "unprognostic (3.35e-1)" "unprognostic (1.07e-1)" "unprognostic (1.76e-1)" 13.6 13.2 16.9 13.1 14.0 22.5 14.9 19.2 14.0 13.9 17.3 10.1 49.7 12.4 16.6 33.6 20.0 12.5 12.6 15.8 13.9 13.0 16.4 25.5 15.5 16.9 10.8 11.4 18.5 9.7 23.4 17.1 16.2 10.0 14.8 11.8 15.3 14.8 21.7 13.2 14.9 28.8 19.2 9.6 14.5 11.7 15.5 12.9 15.3 13.4 10.3 13.8 18.9 17.2 3.8 2.5 9.4 7.8 2.1 3.8 1.6 8.8 11.0 12.2 6.9 11.1 11.4 12.5 5.1 5.1 3.9 3.8 5.6 10.3 10.5 2.1 9.3 6.5 5.2 14.9 7.0 4.4 24.8 11.8 18.3 5.6 8.9 5.8 3.7 4.9 9.9 7.9 5.3 7.6 6.2 2.7 7.7 5.8 16.0 4.5 8.8 9.1 3.7 6.4 10.1 5.2 9.0 5.1 6.5 6.3 14.7 9.3 6.8 8.8 4.7 7.2 8.9 11.1 6.8 3.5 5.7 7.3 7.2 2.7 21.1 10.8 10.2 5.8 4.9 8.3 4.5 2.5 3.5 3.8 3.9 2.8 2.2 2.3 3.3 2.5 3.8 2.8 2.7 9.4 2.1 7.8 1.1 3.2 1.6 16.9 14.0 19.2 13.5 13.9 13.0 10.8 11.4 10.0 12.9 11.9 24.3 16.7 7.9 14.3 23.6 31.3 33.1 9.4 34.2 24.4 49.1 16.2 10.0 6.0 4.0 14.5 20.6 23.3 10.7 10.2 16.2 17.2 21.9 57.7 14.7 69.9 24.2 22.7 43.2 5.7 18.4 19.9 20.3 4.6 17.5 14.7 10.9 11.5 20.8 15.7 29.6 25.8 15.6 11.2 15.4 18.7 26.5 25.4 16.0 12.2 NCOA4 "ARA70, DKFZp762E1112, ELE1, PTC3, RFG" ENSG00000266412 "Nuclear receptor coactivator 4" Q13772 10 46005088-46030714 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 100.1" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Group enriched" "Detected in all" 4 "dendritic cells: 30.2;granulocytes: 100.1;monocytes: 40.4" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA051260, HPA065208" Uncertain Approved "Nucleoli,Golgi apparatus,Cytosol" NA NA Nucleoli "Golgi apparatus, Cytosol" "HPA051260: AB_2681412, HPA065208: AB_2685432" "unprognostic (4.23e-2)" "unprognostic (1.50e-1)" "unprognostic (2.44e-2)" "unprognostic (1.82e-1)" "prognostic favorable (3.26e-4)" "unprognostic (1.34e-1)" "unprognostic (1.80e-1)" "unprognostic (9.34e-2)" "unprognostic (4.67e-2)" "unprognostic (5.22e-2)" "unprognostic (9.16e-2)" "unprognostic (2.04e-2)" "prognostic favorable (8.04e-6)" "unprognostic (1.35e-1)" "unprognostic (4.71e-3)" "unprognostic (1.14e-1)" "unprognostic (2.78e-1)" 18.5 6.9 5.5 9.5 10.0 17.4 10.0 5.5 11.3 10.8 22.5 13.6 5.9 27.0 9.9 9.4 17.0 6.3 9.0 16.6 5.7 20.8 40.9 11.6 11.6 8.7 7.1 11.0 9.1 9.3 9.6 28.4 13.5 14.7 12.4 9.9 12.6 8.5 15.5 6.8 36.4 11.2 9.7 23.8 8.9 6.4 8.1 26.8 13.2 13.9 16.3 13.0 6.4 7.3 30.2 100.1 40.4 13.4 10.9 53.9 31.8 13.5 15.9 16.3 42.1 38.2 39.8 29.3 47.4 28.9 28.4 20.8 23.6 36.0 35.3 47.8 16.2 32.6 16.6 32.3 32.3 25.4 17.1 24.3 18.6 59.4 29.5 61.8 54.3 37.1 32.4 24.6 41.4 30.9 42.5 18.2 26.4 21.7 39.4 14.2 30.0 23.2 9.6 24.6 8.0 17.8 23.1 21.5 34.6 27.1 16.0 10.8 29.6 33.8 29.3 32.9 24.4 30.4 39.1 17.9 21.5 18.9 19.7 16.2 17.3 35.8 22.4 52.1 9.5 69.1 40.4 70.7 10.0 26.8 10.9 7.3 9.4 9.5 30.2 6.6 10.2 8.6 100.1 13.4 30.4 9.3 10.8 53.9 47.6 78.0 32.8 33.2 44.0 13.3 136.0 38.2 50.9 59.1 41.8 27.5 85.3 68.0 41.7 72.4 47.2 113.4 186.9 45.2 92.9 44.2 51.5 191.6 148.1 148.2 19.1 25.8 53.4 209.6 51.8 34.5 96.2 49.0 73.1 41.3 37.9 41.1 57.5 44.6 100.4 11.3 12.9 47.2 22.7 15.1 49.4 132.3 41.5 50.4 45.0 NCOR1 "hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1" ENSG00000141027 "Nuclear receptor corepressor 1" O75376 17 16029157-16218185 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043246, HPA050288, HPA051168, CAB072830" Supported Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB072830: , HPA043246: AB_2678386, HPA050288: AB_2681073, HPA051168: AB_2681370" "unprognostic (1.83e-1)" "unprognostic (3.05e-1)" "unprognostic (9.17e-2)" "unprognostic (1.10e-1)" "unprognostic (7.38e-2)" "unprognostic (3.59e-2)" "unprognostic (2.55e-2)" "unprognostic (4.27e-2)" "unprognostic (4.87e-2)" "unprognostic (4.06e-2)" "unprognostic (7.07e-2)" "unprognostic (1.52e-2)" "prognostic favorable (7.92e-5)" "unprognostic (4.40e-2)" "unprognostic (2.52e-1)" "unprognostic (1.33e-1)" "unprognostic (5.42e-2)" 19.6 21.2 25.4 24.0 30.8 27.0 25.0 41.8 31.5 24.0 30.6 19.6 18.6 33.2 29.0 19.5 25.0 20.5 21.9 17.8 22.4 17.8 25.6 33.8 20.1 19.5 25.1 19.1 25.9 24.3 39.9 39.8 19.8 21.6 20.8 29.7 17.1 20.9 29.1 43.0 23.8 36.9 29.7 26.4 23.7 29.8 22.1 26.4 38.8 25.3 15.7 23.8 29.6 27.0 43.4 29.9 78.2 24.8 30.4 35.5 19.7 20.4 34.2 24.4 20.3 20.1 15.3 12.2 15.1 17.1 16.6 15.1 18.3 9.4 21.5 10.7 26.3 12.4 15.6 30.0 18.3 24.7 28.6 22.2 21.4 29.6 21.4 19.7 13.4 25.6 15.7 19.2 25.7 30.1 14.2 23.0 30.4 18.6 8.9 16.3 13.3 23.6 8.6 12.1 36.0 9.3 23.6 24.8 10.0 17.2 23.2 8.3 13.9 24.9 10.9 11.8 65.5 10.5 15.3 20.0 17.1 10.1 12.5 20.8 6.1 7.1 12.5 16.3 16.0 14.6 78.2 24.8 52.2 31.3 19.5 25.9 40.7 35.5 34.1 17.5 43.4 34.7 34.8 48.5 30.4 24.0 29.9 31.7 19.7 25.4 30.8 41.8 31.5 22.4 17.8 25.1 19.1 21.6 26.4 74.5 98.7 86.4 91.4 60.2 144.1 78.9 66.2 61.6 72.8 50.6 149.2 79.2 29.9 80.2 53.7 68.9 164.0 93.5 85.1 85.7 74.0 70.9 83.3 105.0 67.5 122.3 84.4 59.5 70.8 35.4 94.0 84.8 35.4 184.0 101.0 81.4 89.5 133.5 114.2 37.3 152.7 90.5 89.5 82.3 75.1 59.6 73.2 110.7 125.6 110.0 NCOR2 "CTG26, SMRT, SMRTE, TNRC14, TRAC-1" ENSG00000196498 "Nuclear receptor corepressor 2" Q9Y618 12 124324415-124567589 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Horizontal cells: 114.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 8.1" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001928 Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA001928: AB_1079454" "unprognostic (9.51e-3)" "unprognostic (7.37e-3)" "unprognostic (4.66e-2)" "unprognostic (2.55e-3)" "unprognostic (2.14e-1)" "unprognostic (7.37e-2)" "unprognostic (3.19e-2)" "unprognostic (8.86e-2)" "unprognostic (2.21e-2)" "unprognostic (2.90e-3)" "unprognostic (6.42e-3)" "unprognostic (1.96e-1)" "unprognostic (9.86e-2)" "unprognostic (6.26e-2)" "unprognostic (1.59e-1)" "unprognostic (7.56e-2)" "unprognostic (8.90e-2)" 24.0 22.0 21.3 21.3 19.0 16.8 18.3 33.8 33.5 24.5 17.2 24.3 17.7 16.4 21.3 19.0 15.7 16.3 21.5 18.2 22.0 14.8 16.0 11.2 23.4 11.9 19.0 15.6 28.6 30.0 13.8 39.5 13.2 28.3 21.3 7.6 32.7 29.2 24.5 62.4 22.8 22.2 17.4 12.2 17.4 24.0 10.8 22.0 9.3 16.7 25.0 7.6 16.3 14.7 0.6 1.7 8.1 4.0 0.2 1.9 0.4 19.7 37.2 10.6 10.1 6.2 8.4 31.8 20.5 10.2 12.0 5.3 19.7 14.6 20.0 15.2 16.7 10.7 18.8 4.2 21.8 4.9 21.1 8.2 16.1 35.1 12.0 12.4 12.1 20.5 13.5 8.2 14.9 8.9 18.4 11.4 9.2 20.6 6.0 10.7 17.0 43.4 14.0 14.8 7.5 36.2 14.1 17.7 10.1 5.7 23.1 28.1 20.5 25.2 21.3 12.9 8.3 17.3 15.3 54.6 27.9 48.3 27.5 43.4 11.5 11.5 12.2 15.9 9.0 26.1 8.1 0.7 1.6 1.9 0.4 0.5 0.6 0.5 1.5 0.3 0.4 0.6 0.5 1.6 0.2 4.0 1.7 0.0 0.4 21.3 19.0 33.8 28.4 22.0 14.8 19.0 15.6 28.3 22.0 107.2 54.1 4.5 21.5 29.7 63.3 27.7 20.4 18.7 56.9 17.4 37.3 6.7 3.3 19.2 1.6 21.0 23.6 0.0 24.0 33.5 32.5 20.3 39.5 16.3 25.4 114.4 18.0 14.7 40.3 4.8 57.5 32.4 15.1 18.0 18.7 30.6 26.9 17.3 61.2 7.0 57.9 6.5 30.6 1.7 10.3 21.3 10.5 13.1 20.4 17.9 NDRG1 "CAP43, DRG1, NDR1, RTP, TDD5" ENSG00000104419 "N-myc downstream regulated 1" Q92597 8 133237171-133302022 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Charcot-Marie-Tooth disease, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Basal keratinocytes: 508.1;Horizontal cells: 556.2;Suprabasal keratinocytes: 583.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 70.6;hTERT-HME1: 142.3;U-87 MG: 95.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006881 Approved Supported Microtubules,Cytosol NA NA Cytosol Microtubules "HPA006881: AB_1078392" "unprognostic (6.96e-3)" "unprognostic (3.31e-3)" "unprognostic (8.53e-2)" "unprognostic (1.41e-3)" "unprognostic (1.54e-3)" "unprognostic (2.60e-2)" "prognostic unfavorable (1.47e-4)" "unprognostic (3.04e-3)" "unprognostic (5.33e-2)" "unprognostic (4.29e-2)" "unprognostic (9.09e-2)" "unprognostic (2.46e-1)" "prognostic unfavorable (4.13e-4)" "unprognostic (7.27e-2)" "unprognostic (1.91e-1)" "unprognostic (2.47e-3)" "unprognostic (4.28e-2)" 43.9 23.6 42.0 17.0 80.9 18.0 29.8 6.4 36.2 33.1 47.7 73.2 24.2 74.2 20.9 20.6 83.0 24.7 26.8 22.2 48.7 32.9 62.6 12.1 31.0 11.4 96.3 19.8 37.5 16.7 17.8 18.6 32.5 50.0 115.0 22.4 16.2 29.0 26.4 13.2 56.9 78.2 19.2 102.0 11.5 45.7 15.0 74.3 10.3 21.4 40.0 34.9 58.7 64.9 1.9 12.2 8.9 4.1 1.3 9.3 2.9 22.0 2.7 0.2 0.1 14.0 9.8 3.0 1.6 12.1 1.1 6.2 1.4 3.1 0.1 15.8 6.6 2.6 7.1 0.2 34.8 2.4 1.4 26.1 0.2 5.6 1.6 5.3 0.7 0.5 9.1 70.6 5.9 142.3 13.4 5.2 2.9 0.2 15.4 2.0 1.3 2.0 2.1 0.4 8.1 18.3 0.2 2.4 10.2 3.6 3.2 1.6 1.6 3.4 36.5 8.8 6.1 0.1 2.4 6.8 9.9 5.1 4.3 1.2 11.5 30.3 0.1 95.8 8.3 19.5 8.9 4.1 0.0 6.3 3.7 9.3 1.7 5.9 7.5 6.1 1.9 4.6 3.1 4.2 1.3 4.0 12.2 8.0 2.9 42.0 80.9 6.4 36.2 48.7 32.9 96.3 19.8 50.0 74.3 134.0 42.5 17.1 123.5 508.1 21.1 16.5 73.9 9.4 26.1 177.9 2.0 8.9 28.2 21.1 5.4 137.1 330.3 0.0 11.8 79.9 76.6 236.9 21.9 52.2 15.9 556.2 21.2 77.3 31.9 4.3 45.5 36.0 96.2 19.0 134.0 72.1 84.1 91.2 41.4 59.7 33.2 45.3 59.4 0.9 6.4 583.4 36.3 25.4 80.8 209.3 NF1 ENSG00000196712 "Neurofibromin 1" P21359 17 31094927-31382116 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "GTPase activation" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Early spermatids: 149.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Group enriched" "Detected in many" 6 "B-cells: 2.3;granulocytes: 6.5;T-cells: 8.4" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045502 Uncertain Approved Mitochondria No No Mitochondria "HPA045502: AB_2679352" "unprognostic (6.69e-2)" "unprognostic (8.73e-2)" "unprognostic (8.26e-2)" "unprognostic (1.76e-2)" "unprognostic (2.06e-2)" "unprognostic (2.79e-2)" "unprognostic (1.38e-1)" "unprognostic (1.07e-1)" "unprognostic (1.11e-1)" "unprognostic (1.30e-2)" "unprognostic (3.14e-2)" "unprognostic (3.88e-2)" "unprognostic (1.00e-2)" "unprognostic (2.19e-1)" "unprognostic (1.53e-1)" "unprognostic (1.40e-1)" "unprognostic (3.70e-1)" 12.9 15.9 22.6 13.3 25.9 5.5 18.5 30.2 26.0 17.6 13.6 19.8 12.2 11.0 16.9 17.0 10.5 15.2 13.1 17.3 21.6 19.6 20.0 15.1 12.7 11.5 19.4 25.6 22.9 16.5 34.1 19.0 19.4 20.9 16.1 14.7 12.1 14.4 20.5 14.8 12.0 12.1 14.5 21.4 11.9 13.0 15.4 21.5 11.6 31.1 7.6 12.4 15.3 19.5 2.3 0.7 6.5 0.4 0.9 8.4 1.0 9.8 12.9 15.7 8.4 13.4 17.5 7.9 8.6 15.5 12.7 14.4 11.6 6.7 9.5 2.5 16.0 15.0 17.3 14.2 12.0 21.5 4.6 8.9 8.4 12.1 5.9 9.5 15.0 7.0 13.8 7.7 13.5 16.5 14.4 6.1 10.1 12.0 9.5 12.1 7.8 12.5 5.5 4.6 6.1 4.3 9.8 24.0 7.6 9.6 14.2 6.5 9.8 15.9 5.3 8.8 11.6 16.2 9.6 8.9 10.2 14.2 12.0 3.2 8.7 4.2 10.5 8.3 6.3 10.5 6.5 0.4 0.9 2.3 0.2 1.6 2.3 4.4 3.9 0.5 2.1 3.3 3.2 1.0 0.9 0.4 0.7 8.4 1.0 22.6 25.9 30.2 23.5 21.6 19.6 19.4 25.6 20.9 21.5 29.8 23.6 12.7 38.9 34.3 61.1 39.2 40.8 29.4 20.5 38.4 129.6 44.8 19.9 23.9 149.0 31.8 28.2 0.0 19.3 22.1 28.2 47.4 10.4 31.7 18.9 66.7 19.0 31.9 24.3 70.0 34.5 21.8 20.3 16.2 26.8 49.7 28.6 35.4 47.4 23.7 66.0 45.3 36.7 28.2 25.6 29.6 41.2 18.5 22.6 60.1 NF2 "ACN, BANF, merlin, SCH" ENSG00000186575 "Neurofibromin 2" P35240 22 29603556-29698598 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Deafness, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Early spermatids: 61.9;Late spermatids: 86.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003097, CAB005385" Supported Enhanced "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane" "Nucleoplasm, Cytosol" "CAB005385: AB_2298548, HPA003097: AB_1079473" "unprognostic (3.27e-1)" "unprognostic (1.34e-2)" "unprognostic (1.34e-1)" "unprognostic (1.76e-2)" "unprognostic (3.14e-1)" "unprognostic (1.62e-1)" "unprognostic (5.76e-3)" "unprognostic (1.61e-1)" "unprognostic (3.67e-2)" "unprognostic (2.16e-2)" "unprognostic (2.01e-3)" "unprognostic (4.66e-1)" "prognostic favorable (2.89e-5)" "unprognostic (7.73e-3)" "unprognostic (1.31e-1)" "unprognostic (2.24e-1)" "unprognostic (9.62e-2)" 11.8 12.4 23.6 11.1 20.1 10.0 15.4 20.8 28.1 10.8 9.7 9.0 11.8 7.8 10.5 11.3 14.2 11.3 8.0 19.7 26.6 16.4 13.5 11.1 11.9 24.1 18.0 13.5 11.0 12.9 46.8 8.6 6.9 11.4 10.2 8.7 9.5 9.3 15.4 25.7 12.1 8.5 11.9 10.7 10.4 8.8 21.6 10.1 14.9 15.6 11.5 9.9 10.6 10.2 8.5 13.6 6.6 17.3 11.6 15.0 9.8 26.6 10.8 3.8 24.6 7.4 7.4 3.6 21.7 12.2 23.8 20.6 10.6 6.6 7.1 18.0 22.3 16.5 9.5 7.8 12.6 21.3 10.3 6.1 8.4 8.1 7.6 7.9 12.0 10.0 6.8 5.7 16.9 20.6 8.1 16.7 4.6 4.1 6.6 23.1 11.2 7.3 4.8 2.8 6.3 10.2 7.6 20.3 6.8 24.2 12.5 5.8 4.0 12.4 8.4 4.9 4.0 5.4 4.8 31.0 35.5 40.5 15.4 36.6 10.3 8.2 8.5 9.4 4.7 22.6 6.6 9.5 3.6 15.0 13.5 12.8 8.2 11.3 10.1 13.6 8.5 9.8 9.2 2.3 11.6 17.3 9.3 9.4 9.8 23.6 20.1 20.8 28.1 26.6 16.4 18.0 13.5 11.4 10.1 6.0 16.1 9.0 9.6 12.6 16.5 19.9 17.8 6.7 7.9 14.0 9.8 9.9 18.3 42.9 61.9 9.8 8.4 0.0 21.5 6.3 12.6 9.5 23.0 12.5 12.4 28.6 12.6 10.4 10.0 86.8 6.6 7.2 8.5 6.4 7.5 17.3 28.7 15.6 11.7 16.2 8.5 6.5 14.9 21.4 7.2 12.5 3.2 10.9 9.8 8.6 NFATC2 "NF-ATP, NFAT1, NFATp" ENSG00000101096 "Nuclear factor of activated T cells 2" Q13469 20 51386957-51562831 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 44.6" "Cell type enhanced" "Detected in many" 8 "Melanocytes: 59.1;T-cells: 40.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HDLM-2: 14.4;HMC-1: 16.6;WM-115: 25.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA008789, CAB018567, HPA024369" Enhanced Supported Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB018567: AB_628012, HPA008789: AB_1079474, HPA024369: AB_1854413" "unprognostic (2.69e-3)" "unprognostic (2.92e-2)" "unprognostic (2.31e-1)" "unprognostic (1.58e-2)" "unprognostic (1.15e-1)" "unprognostic (1.26e-2)" "unprognostic (3.94e-2)" "unprognostic (4.05e-2)" "unprognostic (9.26e-2)" "unprognostic (3.74e-3)" "unprognostic (2.17e-2)" "unprognostic (4.86e-2)" "prognostic unfavorable (1.57e-4)" "unprognostic (9.25e-2)" "unprognostic (1.02e-1)" "unprognostic (1.05e-2)" "unprognostic (6.59e-2)" 8.6 2.4 4.1 44.6 8.2 4.4 9.8 1.1 5.1 8.4 7.8 6.8 3.9 8.4 7.0 7.6 4.0 5.6 19.4 8.5 4.1 3.3 3.4 6.7 6.1 25.2 8.4 0.7 5.0 8.7 3.9 3.7 8.1 10.4 5.4 4.1 6.2 7.9 7.2 5.4 7.0 11.7 5.9 6.5 16.0 11.0 4.5 6.5 8.6 7.0 13.2 18.7 4.5 4.9 1.6 1.7 3.8 0.7 7.6 7.7 1.6 1.6 1.7 0.0 2.2 0.0 0.0 4.6 0.2 1.1 0.7 0.3 8.3 1.5 11.1 1.3 0.5 1.6 0.0 0.5 0.0 0.6 14.4 0.2 4.7 1.2 2.1 0.0 1.3 16.6 0.0 0.0 0.6 0.0 0.1 5.1 3.9 4.6 7.4 0.0 1.8 1.9 7.8 0.1 1.0 4.0 0.8 0.0 4.9 0.3 0.0 0.1 0.0 5.2 1.3 12.1 1.1 2.0 3.1 0.5 1.0 1.9 2.5 0.1 6.3 4.1 11.5 1.1 5.2 25.0 0.3 0.0 3.8 7.7 0.7 3.2 1.6 4.3 6.1 1.7 1.6 2.4 4.4 0.2 7.6 0.2 0.6 2.3 1.6 4.1 8.2 1.1 5.1 4.1 3.3 8.4 0.7 10.4 6.5 6.0 4.8 3.9 10.4 12.8 0.0 2.8 5.1 10.7 9.1 0.0 0.0 2.4 1.7 3.6 1.5 16.9 1.1 0.0 4.9 0.5 28.2 7.4 15.0 6.0 28.1 0.0 7.5 9.2 21.2 0.4 2.0 16.7 59.1 3.6 6.2 0.0 8.0 0.0 0.4 0.2 0.0 0.0 12.2 0.5 0.9 11.3 0.8 40.6 7.1 5.6 NFE2L2 NRF2 ENSG00000116044 "Nuclear factor, erythroid 2 like 2" Q16236 2 177227595-177392697 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002990, CAB020317, HPA043438" Supported Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Nucleoplasm, Plasma membrane" Cytosol "CAB020317: , HPA002990: AB_1079476, HPA043438: AB_2678482" "unprognostic (2.11e-1)" "unprognostic (3.12e-2)" "unprognostic (5.22e-2)" "unprognostic (1.41e-1)" "unprognostic (5.95e-2)" "unprognostic (3.90e-1)" "unprognostic (5.27e-2)" "unprognostic (9.58e-2)" "unprognostic (3.48e-2)" "unprognostic (9.86e-2)" "unprognostic (4.86e-2)" "unprognostic (1.83e-1)" "prognostic favorable (2.26e-4)" "unprognostic (1.97e-2)" "unprognostic (1.61e-1)" "unprognostic (1.26e-1)" "unprognostic (9.77e-3)" 30.9 24.4 25.4 19.3 34.7 15.0 24.6 36.4 29.7 31.7 28.3 25.8 22.2 28.1 27.7 30.9 82.5 27.0 28.9 32.3 28.0 16.9 44.8 49.3 29.0 19.7 49.0 18.7 53.1 16.3 21.7 52.5 29.4 33.5 39.0 25.4 21.7 34.7 28.1 25.9 48.1 29.2 42.1 42.7 26.8 45.9 21.9 41.6 21.1 49.5 35.8 25.5 43.7 47.1 23.5 41.1 42.4 35.6 25.8 43.2 22.6 10.6 12.3 11.2 12.0 37.8 40.8 12.8 18.2 25.3 16.6 18.8 16.2 20.4 10.5 19.8 20.6 31.6 19.8 13.1 27.7 23.3 8.1 8.0 13.5 21.6 31.6 48.4 8.0 12.8 28.1 65.2 23.6 35.1 39.4 16.4 8.3 14.0 20.6 22.8 10.6 8.1 21.1 12.2 55.2 11.6 6.7 9.8 10.6 25.4 40.1 14.6 9.5 41.2 13.3 43.1 33.7 10.3 21.6 24.7 17.2 11.5 19.1 11.1 14.5 8.7 8.8 17.2 8.9 33.0 42.4 35.6 21.4 23.0 34.1 26.6 23.5 26.9 23.6 41.1 19.9 43.2 28.2 39.9 25.8 31.9 15.5 25.0 22.6 25.4 34.7 36.4 29.7 28.0 16.9 49.0 18.7 33.5 41.6 145.9 85.8 49.5 216.1 262.7 59.6 57.4 96.8 143.2 127.4 146.5 15.7 88.4 333.2 126.2 58.6 116.1 96.6 0.0 147.7 27.7 204.6 118.5 212.0 76.9 78.0 54.0 72.6 97.6 100.1 19.8 266.3 164.9 91.1 213.8 57.7 176.6 122.9 89.2 201.2 56.4 47.1 38.8 169.0 50.5 33.8 275.8 155.7 62.3 90.2 201.5 NFIB "NFI-RED, NFIB2, NFIB3" ENSG00000147862 "Nuclear factor I B" O00712 9 14081843-14398983 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "DNA replication, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 2.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AN3-CA: 55.0;HBEC3-KT: 22.3;HUVEC TERT2: 22.2;TIME: 21.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003956 Supported Supported "Nucleoplasm,Nucleoli fibrillar center" NA NA "Nucleoplasm, Nucleoli fibrillar center" "HPA003956: AB_1854424" "unprognostic (1.93e-1)" "unprognostic (3.18e-2)" "unprognostic (4.00e-1)" "unprognostic (2.16e-3)" "unprognostic (1.12e-1)" "unprognostic (2.55e-2)" "unprognostic (1.32e-1)" "unprognostic (4.72e-3)" "unprognostic (7.46e-2)" "unprognostic (9.35e-2)" "unprognostic (3.68e-1)" "unprognostic (1.12e-1)" "prognostic favorable (3.53e-4)" "unprognostic (4.69e-1)" "unprognostic (2.39e-1)" "unprognostic (1.87e-2)" "unprognostic (1.62e-1)" 29.3 9.5 22.6 9.2 12.9 1.0 39.7 30.0 22.9 14.8 17.0 13.6 34.1 11.3 16.8 22.3 11.5 17.0 18.0 24.1 22.0 9.3 18.8 22.3 16.3 9.8 10.8 15.5 18.7 17.5 8.2 6.0 14.7 13.7 21.3 10.4 9.2 40.0 41.3 20.8 23.6 16.8 24.2 14.9 10.4 14.2 7.6 15.6 2.7 18.8 13.9 7.7 27.4 23.4 0.3 0.3 2.4 0.4 0.5 1.0 1.3 6.4 4.6 2.9 55.0 13.9 8.1 0.1 0.1 0.0 1.3 4.8 0.0 2.6 0.1 4.3 0.4 4.2 1.4 2.7 22.3 2.4 0.9 2.6 19.8 10.4 0.6 4.6 0.5 0.1 7.0 3.1 5.0 18.5 5.2 22.2 0.0 0.6 0.1 1.8 3.0 0.0 0.1 1.0 2.9 5.4 0.0 2.6 0.0 4.1 2.4 4.6 17.2 4.7 5.8 1.9 0.1 11.7 0.0 21.7 4.3 6.4 3.3 4.0 0.5 0.4 1.6 3.8 0.1 5.4 1.3 0.1 0.2 0.3 0.2 1.0 0.2 0.2 0.2 0.1 0.3 0.2 0.1 2.4 0.5 0.4 0.3 0.5 1.3 22.6 12.9 30.0 18.8 22.0 9.3 10.8 15.5 13.7 15.6 47.6 31.8 8.5 155.7 238.9 30.8 173.3 203.8 49.5 63.7 43.6 0.0 4.1 33.2 58.5 2.9 193.3 44.6 0.0 108.3 1.6 65.3 158.3 3.5 91.3 1.9 0.0 21.9 176.8 10.2 2.3 124.0 9.2 89.4 2.8 28.6 261.1 66.5 55.8 45.6 159.0 8.8 84.1 186.4 0.7 0.9 147.9 1.4 2.2 68.3 55.3 NFKB2 "LYT-10, NF-kB2, p105, p49/p100, p52" ENSG00000077150 "Nuclear factor kappa B subunit 2" Q00653 10 102394110-102402529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "monocytes: 115.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 50.5;Karpas-707: 55.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008422, CAB022098, HPA023900" Enhanced Approved Nucleoplasm,Cytosol NA NA Cytosol Nucleoplasm "CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435" "unprognostic (1.10e-2)" "unprognostic (1.43e-1)" "prognostic unfavorable (3.86e-4)" "unprognostic (1.53e-2)" "unprognostic (8.08e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-3)" "unprognostic (3.98e-2)" "prognostic favorable (8.45e-5)" "unprognostic (4.04e-1)" "unprognostic (8.34e-2)" "unprognostic (4.14e-2)" "prognostic unfavorable (6.69e-12)" "unprognostic (2.37e-3)" "unprognostic (1.63e-1)" "unprognostic (4.90e-2)" "unprognostic (1.56e-1)" 14.9 10.8 5.6 43.6 7.1 40.6 18.7 2.0 4.9 12.5 20.1 4.2 9.4 11.3 18.8 11.0 12.9 10.8 20.4 10.9 4.6 2.5 15.5 14.5 20.6 34.2 6.6 2.5 15.1 17.4 5.2 6.3 12.8 7.9 19.6 5.2 7.3 16.7 15.1 13.6 10.4 14.1 24.0 7.7 28.0 13.1 6.6 5.8 19.5 11.5 14.8 39.2 21.9 24.4 5.2 1.4 7.5 3.4 1.3 2.0 0.9 21.4 13.4 2.7 10.7 3.3 5.1 6.4 6.1 19.6 6.2 9.0 8.0 17.6 9.9 15.3 3.7 15.5 13.0 6.1 8.4 2.5 50.5 3.6 2.5 3.2 4.6 9.4 1.6 14.4 7.0 4.1 10.4 10.3 8.6 2.2 5.2 2.3 55.2 2.4 7.3 2.5 6.7 3.4 4.7 4.8 5.4 7.4 7.8 10.5 6.3 0.5 3.0 5.0 12.2 8.6 2.9 9.4 4.8 6.4 6.5 9.5 9.1 16.3 36.5 33.8 10.4 10.6 4.2 3.4 0.3 2.4 0.1 1.4 1.5 1.4 5.2 1.7 1.5 1.4 4.5 1.8 1.5 7.5 1.3 3.4 0.9 2.0 0.9 5.6 7.1 2.0 4.9 4.6 2.5 6.6 2.5 7.9 5.8 8.9 9.1 51.9 51.4 38.6 1.9 2.2 17.8 1.4 18.2 17.4 15.7 4.7 5.0 29.4 1.1 15.8 40.4 0.0 18.1 14.3 9.4 46.1 72.5 3.4 19.0 0.0 15.6 9.8 13.8 0.9 6.9 24.3 28.7 115.4 13.1 4.9 35.6 14.0 4.6 9.2 5.1 0.0 25.6 1.7 10.2 39.0 19.3 24.9 10.6 38.3 NFKBIE IKBE ENSG00000146232 "NFKB inhibitor epsilon" O00221 6 44258166-44265788 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "monocytes: 85.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA002692, HPA005941, CAB010272" Supported Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" NA NA "Nucleoli fibrillar center" "Nucleoplasm, Cytosol" "CAB010272: AB_2235977, HPA002692: AB_1079479, HPA005941: AB_1079478" "prognostic favorable (1.72e-5)" "unprognostic (1.43e-1)" "unprognostic (1.39e-2)" "unprognostic (2.37e-2)" "unprognostic (6.32e-3)" "unprognostic (1.28e-1)" "prognostic unfavorable (3.50e-4)" "unprognostic (4.88e-2)" "unprognostic (1.09e-1)" "unprognostic (3.43e-2)" "unprognostic (3.36e-1)" "unprognostic (2.60e-1)" "prognostic unfavorable (1.37e-6)" "unprognostic (2.61e-2)" "unprognostic (8.83e-2)" "unprognostic (1.37e-2)" "prognostic favorable (8.07e-4)" 5.8 5.2 7.6 24.6 5.4 24.0 5.2 9.4 7.8 3.7 8.0 4.2 3.2 6.7 4.7 5.5 6.9 3.0 9.8 4.6 7.9 5.5 11.5 8.7 15.9 17.1 6.0 4.1 6.1 7.1 3.5 4.1 6.0 4.8 7.1 5.9 3.6 7.7 4.1 3.7 7.4 9.5 3.6 5.0 29.6 6.3 7.9 3.7 14.5 5.5 4.6 22.7 6.7 6.7 8.1 8.2 7.1 10.2 0.8 3.5 1.6 13.9 3.5 4.9 7.7 1.9 1.4 2.6 2.5 12.2 7.7 8.1 7.5 6.6 7.5 8.9 2.5 20.7 3.0 5.2 7.8 8.7 12.9 2.9 3.9 1.5 8.4 6.0 12.8 11.8 3.7 3.4 7.1 4.4 6.5 5.2 3.6 3.6 20.2 1.9 7.1 2.5 26.1 2.6 22.0 1.9 4.7 4.4 6.9 17.7 15.2 3.1 4.0 1.7 6.4 10.1 4.3 4.4 15.0 9.1 4.4 5.1 2.7 7.7 12.9 5.4 13.9 3.9 14.2 8.2 7.1 8.1 3.8 1.8 9.4 3.5 8.1 2.4 1.6 6.8 7.3 1.1 1.7 3.2 0.8 10.2 8.2 3.0 1.6 7.6 5.4 9.4 7.8 7.9 5.5 6.0 4.1 4.8 3.7 0.0 11.9 25.1 19.3 34.0 3.3 3.4 15.3 0.0 3.4 3.5 2.0 4.3 14.9 42.8 13.7 8.7 11.0 0.0 18.4 6.2 6.8 25.5 33.3 1.6 52.3 3.2 14.3 4.9 17.8 25.0 1.7 66.3 45.5 85.6 7.0 2.6 39.6 24.6 2.5 10.3 4.0 6.5 16.9 21.4 8.7 34.4 4.5 9.6 6.6 32.1 NIN ENSG00000100503 Ninein Q8N4C6 14 50719763-50831121 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Dwarfism, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Muller glia cells: 87.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA005939, HPA070691" Approved Enhanced "Nucleoplasm,Nucleoli,Nucleoli rim,Centrosome" NA NA Centrosome "Nucleoplasm, Nucleoli, Nucleoli rim" "HPA005939: AB_2667474, HPA070691: AB_2686296" "unprognostic (1.98e-1)" "unprognostic (1.06e-1)" "unprognostic (3.54e-2)" "unprognostic (3.96e-1)" "unprognostic (1.52e-1)" "unprognostic (1.43e-2)" "unprognostic (3.41e-2)" "unprognostic (3.31e-1)" "unprognostic (5.81e-3)" "unprognostic (1.78e-2)" "unprognostic (2.07e-1)" "unprognostic (4.06e-1)" "unprognostic (2.46e-2)" "unprognostic (2.67e-1)" "unprognostic (1.28e-1)" "unprognostic (2.58e-2)" "unprognostic (7.66e-3)" 13.0 6.1 15.1 24.9 10.3 34.8 9.7 12.6 14.0 8.0 9.2 7.6 4.5 5.0 11.8 6.1 11.8 8.2 7.6 16.4 11.7 4.9 6.7 5.2 10.7 30.2 7.6 10.0 11.0 5.4 9.1 12.3 20.2 7.1 6.5 7.7 6.2 8.2 5.1 16.9 10.9 8.3 12.0 7.1 18.2 9.3 4.6 9.0 16.4 7.8 5.1 25.8 11.7 10.3 6.8 6.3 18.4 2.3 1.5 6.0 1.3 12.3 8.7 18.3 15.5 7.0 11.4 7.6 10.6 9.1 8.9 7.5 5.6 6.6 29.1 7.3 14.3 8.5 13.0 14.7 6.7 18.9 14.0 4.5 10.7 5.4 5.3 4.1 18.6 30.9 7.8 5.4 15.7 6.4 5.3 14.2 15.1 2.6 11.9 13.5 13.5 14.1 7.5 2.5 3.9 9.7 16.0 33.8 2.1 8.0 14.0 8.5 9.6 13.3 4.0 11.4 4.2 7.6 16.6 20.7 22.8 31.7 8.7 11.7 9.6 4.8 20.1 5.9 15.2 12.3 12.6 2.3 18.4 3.3 1.7 3.5 6.8 2.2 6.0 1.5 5.5 4.4 3.8 8.3 1.5 1.5 6.3 1.9 1.3 15.1 10.3 12.6 14.0 11.7 4.9 7.6 10.0 7.1 9.0 6.0 7.7 41.0 7.0 16.4 7.5 37.9 12.7 26.8 36.4 10.4 58.9 9.2 3.3 6.9 22.3 24.1 4.1 0.0 3.5 8.9 27.9 13.0 30.1 3.9 20.1 6.4 12.1 27.0 40.6 7.8 7.8 47.2 21.9 12.6 3.9 87.7 4.7 5.8 8.9 5.1 18.0 32.3 20.8 0.0 0.4 18.3 8.1 37.4 4.6 14.5 NKX2-1 "BCH, NKX2A, TITF1, TTF-1, TTF1" ENSG00000136352 "NK2 homeobox 1" P43699 14 36516392-36521149 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 18 "lung: 51.5;thyroid gland: 122.8" "Group enriched" "Detected in some" 6 "Alveolar cells type 1: 128.1;Alveolar cells type 2: 108.1;Club cells: 46.6" "Group enriched" "Detected in some" 39 "lung cancer: 30.9;thyroid cancer: 103.2" "Group enriched" "Detected in some" 6 "basal ganglia: 2.4;hypothalamus: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 10 "SCLC-21H: 48.7" "Group enriched" "Detected in some" 5 "basal ganglia: 3.4;hypothalamus: 12.0" "Group enriched" "Detected in some" 13 "basal ganglia: 6.4;hypothalamus: 16.1" "CAB000078, CAB053633, HPA074316" Enhanced Uncertain "Golgi apparatus,Vesicles" NA NA "Golgi apparatus, Vesicles" "CAB000078: , CAB053633: AB_442138, HPA074316: " "unprognostic (3.79e-1)" "unprognostic (4.25e-3)" "unprognostic (1.12e-1)" "unprognostic (1.79e-2)" "unprognostic (1.26e-2)" "unprognostic (2.23e-1)" "unprognostic (1.18e-1)" "unprognostic (1.29e-1)" "unprognostic (1.83e-2)" "unprognostic (4.18e-1)" 0.1 0.1 0.0 0.0 2.4 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 2.5 0.0 0.0 51.5 0.1 0.0 0.1 0.0 0.0 0.0 4.9 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.4 0.0 122.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 48.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.4 0.0 0.1 0.2 2.5 0.0 0.1 0.1 0.4 128.1 108.1 0.0 0.0 0.0 0.0 0.6 0.0 14.7 46.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 NONO "NMT55, NRB54, P54, P54NRB, PPP1R114" ENSG00000147140 "Non-POU domain containing octamer binding" Q15233 X 71283192-71301168 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022069, HPA054094, HPA054559" Enhanced Enhanced "Nucleoplasm,Nucleoli fibrillar center,Nuclear speckles" NA NA 150000 Nucleoplasm "Nucleoli fibrillar center, Nuclear speckles" "CAB022069: , HPA054094: AB_2682376, HPA054559: AB_2682522" "unprognostic (2.39e-3)" "unprognostic (2.22e-2)" "unprognostic (2.64e-1)" "prognostic unfavorable (9.29e-4)" "unprognostic (8.87e-2)" "unprognostic (5.54e-2)" "unprognostic (1.02e-3)" "unprognostic (9.34e-2)" "unprognostic (2.32e-2)" "unprognostic (1.41e-2)" "unprognostic (3.12e-1)" "unprognostic (2.07e-1)" "unprognostic (7.29e-3)" "unprognostic (6.79e-2)" "unprognostic (5.73e-3)" "unprognostic (2.76e-2)" "unprognostic (3.04e-2)" 37.2 55.9 30.2 37.7 30.8 51.2 37.2 54.8 38.6 45.4 33.4 36.0 38.4 29.9 52.4 40.5 41.0 40.5 37.2 30.5 27.5 29.0 40.1 43.3 37.3 45.7 28.8 31.7 69.2 61.0 39.4 48.2 42.4 27.5 40.8 37.5 42.5 39.8 41.4 37.2 38.4 35.2 40.5 38.3 45.9 40.3 34.4 29.0 98.4 51.0 39.1 57.4 43.6 36.8 44.1 47.3 35.3 51.8 45.4 51.8 58.9 59.7 66.1 91.5 50.2 37.3 38.6 50.1 49.0 45.6 66.3 58.6 52.4 44.4 68.0 54.6 45.1 45.8 44.7 136.6 42.6 73.1 51.7 91.2 55.8 69.4 52.2 31.7 78.1 49.0 40.8 30.4 67.1 45.0 55.0 54.5 49.3 71.1 71.3 61.2 53.0 101.1 71.2 114.0 60.3 53.7 90.9 96.0 58.3 50.9 52.9 63.5 78.9 63.5 41.5 56.3 55.5 39.0 50.6 50.0 42.9 64.5 60.0 56.7 41.2 77.9 77.4 32.1 90.9 61.4 35.3 44.8 34.9 45.8 47.6 51.8 43.7 46.6 44.9 47.3 44.1 50.8 50.2 20.8 45.4 51.8 41.2 50.1 58.9 30.2 30.8 54.8 38.6 27.5 29.0 28.8 31.7 27.5 29.0 71.5 74.4 79.8 78.6 112.2 63.2 53.3 94.3 53.5 84.2 41.8 39.3 104.8 48.0 113.5 9.9 89.5 55.4 70.0 96.7 148.6 89.4 78.5 84.5 108.5 99.0 50.9 134.1 70.0 136.1 12.1 98.7 83.7 54.0 104.6 95.9 77.6 111.2 84.2 120.2 93.8 45.1 64.7 107.2 22.8 62.3 107.0 108.8 84.7 122.4 84.4 NOTCH1 TAN1 ENSG00000148400 "Notch 1" P46531 9 136494433-136545786 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters" "Angiogenesis, Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Endothelial cells: 41.3;Ito cells: 68.2;Muller glia cells: 50.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 8.8" "Group enriched" "Detected in many" 4 "granulocytes: 8.8;NK-cells: 2.7" "Cell line enhanced" "Detected in many" "HaCaT: 25.0;HMC-1: 21.7;hTCEpi: 24.0;MOLT-4: 38.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008112, CAB022466, HPA067168" Supported Approved Nucleoplasm NA NA 8100000 Nucleoplasm "CAB008112: AB_2153490, CAB022466: , HPA067168: AB_2685795" "unprognostic (1.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.16e-1)" "unprognostic (8.38e-3)" "unprognostic (3.04e-1)" "unprognostic (1.13e-1)" "unprognostic (7.56e-2)" "unprognostic (1.02e-1)" "unprognostic (5.74e-3)" "unprognostic (5.50e-3)" "unprognostic (8.78e-2)" "unprognostic (8.50e-2)" "prognostic unfavorable (5.45e-4)" "unprognostic (2.14e-2)" "unprognostic (1.92e-1)" "unprognostic (5.65e-2)" "unprognostic (8.84e-2)" 20.0 4.0 10.0 14.5 10.4 14.6 12.8 3.8 18.8 12.8 14.2 19.9 8.2 9.8 11.2 5.1 13.3 9.6 13.1 9.6 10.7 5.8 9.4 7.2 17.4 13.7 11.6 7.5 9.2 17.8 3.7 5.6 8.5 9.3 12.1 5.7 10.4 14.2 11.8 8.2 32.3 10.8 7.7 6.6 20.7 8.6 4.1 9.9 34.8 9.4 10.2 10.9 12.3 22.2 0.6 1.1 8.8 1.0 2.7 1.3 0.9 4.4 7.5 6.2 3.1 0.2 0.5 7.8 2.2 0.6 1.3 0.4 1.1 0.5 6.1 4.7 1.7 1.6 25.0 2.0 10.3 0.2 13.8 1.1 3.4 3.0 0.4 3.4 3.6 21.7 0.4 24.0 1.8 3.8 1.5 8.0 2.7 1.5 1.1 0.9 8.1 38.1 5.8 5.2 3.2 3.4 7.9 5.0 11.2 0.9 3.8 0.0 0.4 3.3 3.5 1.4 1.9 2.1 5.8 11.8 3.3 4.8 3.2 2.4 1.3 1.1 2.4 2.2 2.5 16.9 0.7 1.0 2.8 1.3 0.4 0.8 0.4 0.6 1.0 0.6 0.6 0.4 1.1 8.8 2.7 0.4 1.1 0.4 0.9 10.0 10.4 3.8 11.7 10.7 5.8 11.6 7.5 9.3 9.9 8.9 28.2 13.8 10.6 22.0 0.3 7.3 7.6 0.0 6.8 1.8 2.0 0.7 0.0 4.8 0.3 41.3 4.9 0.0 3.4 1.8 4.8 6.6 34.6 6.8 8.0 1.6 2.4 68.2 10.5 0.0 1.1 17.1 6.8 1.0 11.0 50.6 2.2 7.0 0.7 4.1 1.7 6.5 11.5 0.2 3.2 26.1 0.9 12.9 24.7 14.1 NOTCH2 ENSG00000134250 "Notch 2" Q04721 1 119911553-120069626 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, Receptor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Paneth cells: 129.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048743 Approved Supported "Nucleoplasm,Plasma membrane" NA NA 67000000 "Nucleoplasm, Plasma membrane" "HPA048743: AB_2680508" "unprognostic (1.33e-1)" "unprognostic (1.43e-2)" "unprognostic (2.66e-1)" "unprognostic (1.40e-3)" "unprognostic (7.98e-2)" "unprognostic (4.01e-2)" "unprognostic (1.22e-1)" "unprognostic (7.32e-2)" "unprognostic (1.18e-2)" "prognostic unfavorable (5.24e-4)" "prognostic unfavorable (9.48e-4)" "unprognostic (3.86e-2)" "unprognostic (6.12e-3)" "unprognostic (1.55e-2)" "unprognostic (2.65e-2)" "unprognostic (1.12e-2)" "unprognostic (7.35e-3)" 12.0 7.3 6.0 9.4 6.8 4.4 10.6 3.0 5.6 14.5 7.6 4.4 11.3 1.6 12.3 11.8 13.4 11.4 12.8 7.9 6.8 2.3 5.5 11.4 10.6 5.7 5.3 7.6 15.5 27.6 6.1 3.3 10.3 6.5 9.9 5.2 9.4 17.7 10.0 9.3 17.2 6.1 12.4 6.2 11.5 5.8 15.7 4.4 8.0 11.4 8.6 6.6 9.6 13.0 4.2 5.2 7.7 9.6 1.5 1.7 2.0 15.0 5.1 7.9 6.1 33.0 28.3 7.9 11.5 15.9 15.4 16.7 4.7 4.1 0.3 9.7 21.8 13.7 5.7 12.5 10.2 24.6 18.1 8.0 8.7 13.7 0.4 12.3 9.1 2.3 22.7 6.6 46.1 30.7 23.3 7.8 4.1 0.1 19.2 18.5 16.9 3.8 2.6 10.2 1.4 5.7 2.5 27.9 9.7 8.1 9.6 0.3 4.0 15.6 14.7 8.3 16.7 8.1 3.1 27.4 20.1 13.9 30.1 18.0 8.0 3.9 4.4 29.5 8.4 19.1 5.6 6.4 6.4 1.5 6.6 1.7 4.2 1.3 1.1 5.2 3.9 1.0 1.7 7.7 1.5 9.6 4.2 0.8 2.0 6.0 6.8 3.0 5.6 6.8 2.3 5.3 7.6 6.5 4.4 32.8 21.6 24.1 40.5 41.1 3.5 11.2 25.5 2.7 13.6 17.4 5.9 1.2 0.0 37.1 15.7 3.7 3.0 0.0 11.3 6.7 53.5 36.6 15.1 35.0 29.9 3.2 5.8 5.5 68.6 9.3 50.9 36.3 37.1 13.6 7.5 46.7 22.9 129.8 80.2 4.3 10.2 19.4 32.3 4.8 3.6 77.8 1.4 13.6 13.8 52.7 NPM1 "B23, NPM" ENSG00000181163 "Nucleophosmin 1" P06748 5 171387116-171411137 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011384, CAB012983" Supported Enhanced "Nucleoplasm,Nucleoli rim" Yes No 810000 "Nucleoli rim" Nucleoplasm "CAB012983: AB_2533084, HPA011384: AB_1854692" "unprognostic (1.84e-3)" "unprognostic (2.59e-1)" "unprognostic (2.23e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-1)" "prognostic unfavorable (7.48e-4)" "prognostic unfavorable (4.82e-6)" "unprognostic (1.86e-2)" "unprognostic (5.25e-3)" "unprognostic (1.39e-1)" "unprognostic (2.26e-3)" "unprognostic (1.27e-1)" "prognostic unfavorable (2.89e-6)" "unprognostic (2.19e-1)" "unprognostic (1.17e-1)" "unprognostic (1.52e-1)" "unprognostic (1.24e-2)" 56.8 44.7 29.9 61.1 33.6 76.0 67.0 37.7 34.6 113.5 57.8 24.8 39.3 36.7 78.2 50.5 81.6 65.0 44.0 48.5 28.8 31.6 64.9 78.8 59.5 128.1 36.1 27.9 177.4 102.0 27.1 57.9 65.2 36.1 87.2 49.3 29.5 47.3 48.2 67.9 42.7 52.8 92.4 43.2 85.9 54.0 56.7 31.3 111.3 112.6 66.5 82.1 116.8 65.7 85.3 54.1 12.3 29.1 59.0 126.6 91.4 119.9 81.3 98.8 139.9 60.4 110.3 147.3 109.2 99.8 148.0 133.3 193.9 84.8 321.2 86.8 63.1 99.7 70.4 137.0 248.2 192.8 100.0 108.7 113.3 79.7 142.8 89.5 228.2 94.0 97.3 87.5 100.4 198.1 116.7 110.3 74.8 137.8 73.9 107.4 149.0 148.9 162.3 123.6 64.0 99.9 133.7 109.0 164.6 126.2 84.6 77.9 62.6 65.2 106.8 197.6 72.0 131.0 101.3 68.9 49.5 109.2 56.9 183.8 59.2 107.6 193.2 74.9 185.8 98.7 12.3 26.9 8.4 45.7 29.1 84.6 85.3 85.1 66.2 54.1 62.8 126.6 99.0 4.0 59.0 23.1 48.7 73.2 91.4 29.9 33.6 37.7 34.6 28.8 31.6 36.1 27.9 36.1 31.3 321.6 347.3 775.5 994.0 1243.7 166.1 228.8 387.3 346.6 597.1 307.1 41.2 1400.5 630.0 839.1 64.3 646.8 150.8 116.8 796.2 1641.6 855.4 473.8 427.8 235.7 952.5 120.8 347.6 298.3 500.7 53.0 902.7 605.7 578.6 960.4 654.2 214.7 840.7 333.1 610.9 657.5 112.2 426.9 861.0 695.1 635.2 890.7 1286.9 674.9 783.2 797.7 NR4A3 "CHN, CSMF, MINOR, NOR1" ENSG00000119508 "Nuclear receptor subfamily 4 group A member 3" Q92570 9 99821855-99866891 "Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 80.6" "Cell type enhanced" "Detected in many" 11 "Cardiomyocytes: 218.8;granulocytes: 120.9;Melanocytes: 84.4;Smooth muscle cells: 116.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 1.3;NK-cell: 1.3" "Group enriched" "Detected in many" 6 "granulocytes: 1.3;NK-cells: 1.3" "Group enriched" "Detected in some" 5 "BJ hTERT+: 21.5;HeLa: 7.4;SK-MEL-30: 14.8;U-266/70: 8.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA043360 Uncertain NA NA "HPA043360: AB_10961186" "prognostic favorable (5.97e-4)" "unprognostic (6.92e-3)" "unprognostic (5.34e-2)" "unprognostic (2.78e-3)" "unprognostic (1.40e-1)" "unprognostic (9.46e-2)" "unprognostic (2.89e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-3)" "unprognostic (1.40e-2)" "unprognostic (2.28e-1)" "unprognostic (3.30e-1)" "unprognostic (2.25e-1)" "unprognostic (1.29e-3)" "unprognostic (6.11e-2)" "unprognostic (2.80e-2)" "unprognostic (1.69e-1)" 19.9 46.5 3.5 10.2 4.5 22.1 5.9 1.6 5.0 9.7 4.8 9.5 6.3 0.8 10.7 6.1 3.1 15.7 16.6 37.3 4.1 2.5 3.8 7.1 12.4 1.2 1.6 3.1 37.2 4.0 4.0 12.2 4.7 5.0 12.0 3.2 7.0 1.6 80.6 28.5 1.5 4.2 23.0 5.1 2.6 9.0 1.3 3.4 7.6 4.2 15.5 1.9 23.5 7.5 0.0 0.2 1.3 0.0 1.3 0.0 0.0 0.1 0.1 0.6 0.1 1.2 0.4 1.0 1.3 21.5 0.2 0.3 0.2 0.1 0.1 0.3 0.5 0.4 0.1 0.4 0.0 0.1 1.8 0.3 0.1 7.4 0.0 0.1 0.1 2.1 0.3 0.0 0.5 0.1 0.1 0.0 0.0 0.0 0.5 0.1 0.6 0.0 0.2 0.0 0.1 0.6 0.0 1.0 0.0 0.0 0.1 0.4 0.4 2.4 1.7 14.8 0.2 0.0 0.0 0.1 1.4 0.4 1.7 0.1 8.8 0.1 0.0 0.9 0.0 0.8 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.3 0.0 0.0 0.0 0.0 3.5 4.5 1.6 5.0 4.1 2.5 1.6 3.1 5.0 3.4 11.9 22.4 0.9 7.4 70.6 0.7 218.8 2.5 18.7 14.8 15.7 9.8 1.8 0.0 0.1 1.3 7.3 0.6 0.0 1.4 1.2 43.7 5.1 120.9 0.5 10.3 0.0 26.1 8.6 16.8 1.2 1.4 35.2 84.4 74.9 2.2 1.0 0.2 0.3 1.1 0.0 0.8 0.0 116.4 0.3 1.4 51.9 4.7 5.0 0.9 2.3 NRAS N-ras ENSG00000213281 "NRAS proto-oncogene, GTPase" P01111 1 114704469-114716894 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010157, HPA049830, CAB079912" Uncertain Supported "Plasma membrane" NA NA 4800000 "Plasma membrane" "CAB010157: AB_632073, CAB079912: AB_2784586, HPA049830: AB_2680903" "unprognostic (4.75e-2)" "unprognostic (2.81e-1)" "unprognostic (1.09e-3)" "unprognostic (2.11e-2)" "unprognostic (8.59e-3)" "unprognostic (1.14e-1)" "prognostic unfavorable (3.03e-7)" "unprognostic (7.76e-3)" "unprognostic (1.57e-2)" "unprognostic (1.01e-3)" "prognostic unfavorable (1.36e-4)" "unprognostic (6.60e-3)" "prognostic unfavorable (7.87e-4)" "unprognostic (2.68e-1)" "unprognostic (1.30e-1)" "unprognostic (1.16e-1)" "unprognostic (3.33e-2)" 18.0 9.7 13.1 16.5 14.4 33.5 12.4 9.7 16.6 10.0 18.4 15.8 3.8 14.4 9.8 6.2 19.7 8.7 11.8 7.1 11.7 13.8 24.0 23.9 13.4 18.7 15.3 9.6 10.3 14.2 8.3 7.6 27.4 19.0 9.2 18.5 8.4 12.4 5.2 7.9 16.1 23.4 9.6 20.9 19.5 14.4 9.8 9.7 45.0 11.1 14.0 19.6 13.2 10.5 11.0 9.9 23.7 15.0 12.1 11.1 10.1 24.7 6.7 18.1 6.8 7.5 16.1 12.9 11.8 13.2 22.2 25.0 13.5 9.3 18.8 15.7 15.9 15.5 7.1 24.1 19.2 31.9 25.6 9.4 12.7 10.2 16.0 14.9 31.6 19.8 14.5 15.6 25.4 18.6 7.0 28.2 14.9 20.2 21.7 19.5 66.1 21.8 12.3 30.7 8.1 4.9 16.7 32.2 11.7 19.6 13.4 11.0 16.5 12.1 10.0 28.4 22.0 8.8 25.7 21.5 12.1 23.2 22.6 24.2 38.4 26.4 22.1 24.2 17.3 43.6 23.7 10.0 9.6 9.8 15.0 8.9 11.0 8.0 9.7 9.9 8.8 8.7 11.1 2.7 12.1 12.7 7.7 10.4 10.1 13.1 14.4 9.7 16.6 11.7 13.8 15.3 9.6 19.0 9.7 14.9 13.9 22.5 24.9 27.2 4.4 4.0 25.5 18.7 12.5 21.0 7.9 18.9 11.6 31.0 2.9 23.3 32.2 0.0 27.3 39.9 16.8 25.2 31.1 24.5 43.1 4.8 23.6 40.5 41.2 4.4 7.5 27.8 21.9 41.5 29.5 7.1 39.8 29.4 6.0 27.8 2.2 6.5 10.8 6.5 14.1 31.7 26.1 20.3 24.7 34.0 NRG1 "GGF, HGL, HRG, NDF, NRG1-IT2" ENSG00000157168 "Neuregulin 1" Q02297 8 31639386-32767959 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Growth factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 28.3" "Cell type enhanced" "Detected in many" 6 "Alveolar cells type 1: 35.7;Basal glandular cells: 36.6;Early spermatids: 31.2;Horizontal cells: 27.0" "Cancer enhanced" "Detected in many" "head and neck cancer: 4.4" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in some" 5 "classical monocyte: 22.8" "Lineage enriched" "Detected in many" 5 "monocytes: 22.8" "Cell line enhanced" "Detected in many" "A549: 38.0;BJ: 26.0;fHDF/TERT166: 29.1;GAMG: 40.0;HBF TERT88: 25.6;hTEC/SVTERT24-B: 27.3;hTERT-HME1: 28.6" "Low region specificity" "Detected in all" HPA010964 Uncertain Approved Nucleoplasm "Secreted to blood" NA NA Nucleoplasm "HPA010964: AB_1854641" "unprognostic (5.76e-3)" "unprognostic (8.60e-2)" "unprognostic (1.96e-4)" "unprognostic (2.67e-1)" "unprognostic (1.94e-4)" "unprognostic (4.99e-2)" "unprognostic (6.69e-2)" "unprognostic (7.72e-2)" "unprognostic (2.98e-1)" "unprognostic (5.65e-2)" "unprognostic (7.99e-2)" "unprognostic (8.49e-2)" "unprognostic (4.47e-2)" "unprognostic (1.31e-1)" "unprognostic (2.88e-1)" "unprognostic (5.40e-2)" "unprognostic (7.83e-2)" 0.7 2.1 4.6 5.0 3.3 1.2 8.8 14.8 8.1 10.6 4.2 0.3 2.1 3.5 2.5 1.1 3.7 2.0 4.8 2.2 4.7 15.4 11.5 23.6 5.7 0.6 6.2 3.5 2.9 0.9 0.8 23.9 0.2 28.3 3.2 5.4 3.6 2.5 1.6 0.2 4.3 5.7 1.1 2.5 1.7 3.1 6.4 0.8 0.2 13.8 7.2 2.2 7.2 3.5 0.0 4.9 0.8 22.8 0.0 0.0 4.6 0.1 38.0 0.6 0.0 0.3 0.7 0.0 26.0 18.4 21.6 16.6 0.0 0.8 0.0 4.8 29.1 40.0 20.5 0.1 10.4 25.6 0.0 0.2 0.5 0.5 0.5 0.1 0.0 0.0 0.3 1.1 27.3 28.6 1.9 12.4 0.0 0.0 0.1 7.7 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 16.0 1.1 1.1 1.3 1.9 0.0 0.0 2.1 0.0 0.0 9.0 15.0 4.6 23.9 14.5 0.0 0.0 0.2 7.7 0.0 1.8 0.0 22.8 0.2 0.0 2.1 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 4.6 4.6 3.3 14.8 8.1 4.7 15.4 6.2 3.5 28.3 0.8 35.7 2.4 0.5 36.6 23.1 11.2 1.7 10.2 4.0 13.6 3.5 7.9 0.0 8.3 1.8 31.2 1.4 0.0 0.0 0.2 0.0 0.7 14.3 1.1 6.6 0.5 27.0 0.0 6.7 16.0 14.6 0.3 1.8 1.7 0.0 0.0 4.8 0.8 0.0 0.4 14.6 3.0 0.0 0.9 1.4 1.0 5.4 0.0 0.0 0.0 5.6 NSD1 "ARA267, FLJ22263, KMT3B, STO" ENSG00000165671 "Nuclear receptor binding SET domain protein 1" Q96L73 5 177133025-177300215 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cone photoreceptor cells: 141.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048431, HPA070333, HPA073705" Supported Supported "Nucleoplasm,Plasma membrane" NA NA "Nucleoplasm, Plasma membrane" "HPA048431: AB_2680388, HPA070333: AB_2686255, HPA073705: AB_2732239" "unprognostic (3.48e-2)" "unprognostic (7.46e-2)" "unprognostic (7.14e-3)" "unprognostic (2.64e-3)" "unprognostic (1.38e-1)" "unprognostic (9.67e-2)" "unprognostic (2.29e-2)" "unprognostic (7.08e-2)" "unprognostic (1.68e-3)" "unprognostic (8.04e-2)" "unprognostic (1.48e-1)" "unprognostic (2.09e-1)" "unprognostic (7.77e-3)" "unprognostic (3.53e-2)" "unprognostic (1.01e-1)" "unprognostic (7.51e-2)" "unprognostic (7.32e-2)" 11.8 13.2 11.9 25.4 15.7 23.9 14.0 28.9 16.7 15.6 14.2 18.5 17.0 10.6 19.0 13.9 17.8 13.6 15.8 11.7 12.8 11.5 14.4 10.5 12.3 19.4 12.9 11.7 16.6 27.1 24.6 19.3 16.0 13.4 14.2 14.3 13.8 13.5 18.7 20.6 16.1 14.5 15.6 13.2 16.1 13.1 28.1 16.1 27.3 20.1 10.6 22.7 13.4 20.2 10.2 8.9 18.7 10.8 10.9 7.8 2.9 9.9 12.8 13.3 11.5 6.6 8.5 0.4 9.0 9.0 12.7 11.8 2.8 8.3 20.5 10.2 12.4 11.7 8.5 21.2 20.0 15.4 34.7 12.8 9.1 14.5 0.1 10.9 19.6 10.8 8.0 12.1 15.0 14.1 9.0 18.4 13.0 12.4 7.2 12.7 20.8 13.6 6.3 14.5 6.7 11.3 15.1 1.7 6.3 8.2 12.1 16.3 11.2 23.4 10.2 7.0 12.9 10.2 16.3 13.5 8.8 12.9 5.6 11.1 8.5 7.4 14.7 5.1 9.6 9.4 10.7 9.1 9.4 7.5 6.1 6.3 8.5 6.3 5.0 6.7 10.2 7.8 6.3 18.7 10.9 10.8 8.9 5.7 2.9 11.9 15.7 28.9 16.7 12.8 11.5 12.9 11.7 13.4 16.1 20.8 26.1 42.4 26.2 15.0 91.7 37.5 33.1 13.4 36.4 52.4 141.4 34.8 14.9 22.8 25.5 31.5 21.9 0.0 18.5 20.4 23.3 24.0 39.4 16.3 24.2 84.2 40.3 31.3 29.2 33.9 47.2 39.1 15.1 50.5 19.4 35.7 20.1 24.6 31.1 13.9 100.0 51.8 19.6 63.2 47.7 18.1 29.6 51.1 21.5 23.5 NSD2 "KMT3G, MMSET, WHSC1" ENSG00000109685 "Nuclear receptor binding SET domain protein 2" O96028 4 1871424-1982207 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Alveolar cells type 1: 11.9;Alveolar cells type 2: 17.3;Ciliated cells: 13.4;Club cells: 14.8;Collecting duct cells: 12.2;Hofbauer cells: 11.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015801, CAB068246, CAB068247" Enhanced Supported Nucleoplasm No No Nucleoplasm "CAB068246: AB_2665690, CAB068247: AB_2665689, HPA015801: AB_1858830" "unprognostic (3.70e-1)" "unprognostic (9.80e-2)" "unprognostic (3.33e-2)" "unprognostic (1.77e-1)" "unprognostic (4.01e-1)" "unprognostic (1.31e-2)" "prognostic unfavorable (2.61e-4)" "unprognostic (3.24e-2)" "unprognostic (6.22e-2)" "unprognostic (7.66e-2)" "unprognostic (2.09e-1)" "unprognostic (9.25e-3)" "prognostic unfavorable (7.19e-4)" "unprognostic (3.89e-2)" "unprognostic (2.95e-1)" "unprognostic (1.31e-1)" "unprognostic (6.15e-2)" 8.7 7.6 17.6 11.5 16.2 35.1 8.5 20.6 18.2 7.0 14.8 12.4 6.3 14.0 9.5 7.4 12.7 6.8 6.9 11.9 15.1 10.9 8.4 7.5 11.1 18.8 14.7 16.1 7.0 11.7 10.7 11.8 9.8 14.6 8.7 17.7 9.4 10.2 7.4 11.8 12.1 14.6 10.5 15.3 13.5 11.0 26.3 13.4 46.7 13.8 5.5 17.7 8.6 9.4 4.9 3.9 4.1 1.8 2.7 4.3 0.6 27.7 14.0 42.3 18.5 4.6 6.8 12.3 22.4 19.9 27.5 30.8 12.4 33.0 29.9 7.7 18.5 36.0 12.1 27.3 18.5 47.3 14.3 11.3 35.6 19.4 7.3 5.8 21.8 18.7 2.6 4.7 24.1 23.2 15.2 21.6 30.2 19.3 31.4 22.5 10.9 58.1 22.9 17.8 14.1 16.2 33.2 27.6 10.3 11.3 13.2 26.3 21.0 18.4 6.9 8.4 19.2 16.3 14.6 16.7 27.5 20.5 17.4 45.1 14.7 15.5 27.1 16.5 21.6 25.5 2.1 1.7 1.7 2.9 1.8 3.2 1.8 3.2 3.2 1.5 4.9 2.8 2.3 4.1 2.7 1.4 3.9 4.3 0.6 17.6 16.2 20.6 18.2 15.1 10.9 14.7 16.1 14.6 13.4 11.9 17.3 0.0 0.0 0.0 0.0 0.0 0.0 13.4 14.8 12.2 0.0 10.0 3.3 10.2 0.0 0.0 0.0 0.0 6.1 7.3 0.0 0.0 2.3 0.0 11.6 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 10.0 0.0 0.0 10.2 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 NSD3 "FLJ20353, KMT3F, WHISTLE, WHSC1L1" ENSG00000147548 "Nuclear receptor binding SET domain protein 3" Q9BZ95 8 38269697-38382272 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Cytotrophoblasts: 85.7;Extravillous trophoblasts: 142.9;monocytes: 86.6;Syncytiotrophoblasts: 109.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005659, CAB013721, HPA018893" Uncertain Approved Nucleoplasm,Mitochondria NA NA Mitochondria Nucleoplasm "CAB013721: , HPA005659: AB_1080596, HPA018893: AB_1858833" "unprognostic (6.21e-2)" "unprognostic (3.73e-2)" "unprognostic (2.18e-2)" "unprognostic (4.12e-1)" "unprognostic (2.25e-1)" "unprognostic (1.53e-2)" "unprognostic (4.35e-2)" "unprognostic (1.97e-2)" "unprognostic (2.49e-1)" "unprognostic (5.72e-2)" "prognostic unfavorable (7.48e-4)" "unprognostic (5.06e-2)" "unprognostic (5.60e-3)" "unprognostic (6.69e-2)" "unprognostic (4.04e-1)" "unprognostic (1.05e-2)" "unprognostic (1.60e-2)" 19.2 11.3 31.1 15.8 31.4 36.3 20.1 51.5 37.7 18.5 15.5 16.7 14.0 16.2 16.0 12.5 17.0 16.8 17.0 12.7 24.4 16.6 14.2 11.2 17.9 22.3 25.0 26.8 26.5 16.3 21.0 24.2 22.5 21.9 16.4 18.7 12.3 18.3 17.9 12.3 16.2 17.7 16.0 15.3 17.2 19.7 9.3 25.6 16.7 19.2 6.9 20.4 19.6 23.3 26.7 5.6 26.2 5.1 8.6 18.0 2.9 24.1 13.9 23.9 16.1 16.8 19.3 17.7 20.3 22.4 17.6 20.5 7.4 13.4 28.8 18.7 13.8 17.1 14.6 18.9 16.2 25.2 11.4 11.1 36.7 11.2 8.6 17.2 16.1 13.3 10.3 16.5 15.9 32.4 16.5 20.1 31.9 26.0 19.2 16.7 8.7 47.1 13.7 16.2 18.8 6.6 21.6 26.1 9.1 12.5 18.7 13.5 18.2 16.5 14.5 14.1 16.0 18.2 12.3 19.2 18.3 19.0 27.2 11.9 17.1 20.4 27.8 15.5 16.3 13.2 13.9 5.1 9.1 8.0 2.4 5.3 16.5 12.0 7.1 4.1 26.7 15.0 6.3 26.2 8.6 1.5 5.6 18.0 2.9 31.1 31.4 51.5 37.7 24.4 16.6 25.0 26.8 21.9 25.6 62.5 52.3 0.0 0.0 0.0 0.0 0.0 0.0 62.9 55.7 48.8 0.0 85.7 19.9 60.6 0.0 0.0 0.0 0.0 53.3 142.9 0.0 0.0 8.1 0.0 39.1 0.0 0.0 0.0 0.0 0.0 0.0 12.5 0.0 86.6 0.0 0.0 50.3 0.0 0.0 28.5 0.0 0.0 0.0 0.0 0.0 0.0 109.4 0.0 0.0 0.0 NT5C2 "cN-II, GMP, NT5B, PNT5, SPG65" ENSG00000076685 "5'-nucleotidase, cytosolic II" P49902 10 103088017-103193306 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Nucleotide metabolism" "Allosteric enzyme, Hydrolase" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003751 Approved NA NA "HPA003751: AB_1854664" "unprognostic (8.18e-2)" "unprognostic (1.98e-1)" "unprognostic (2.55e-2)" "unprognostic (2.46e-1)" "unprognostic (5.54e-2)" "unprognostic (4.87e-3)" "unprognostic (2.24e-2)" "unprognostic (1.72e-1)" "unprognostic (6.41e-2)" "unprognostic (9.59e-2)" "unprognostic (2.93e-3)" "unprognostic (6.20e-2)" "unprognostic (3.26e-2)" "unprognostic (3.70e-2)" "unprognostic (6.40e-2)" "unprognostic (3.43e-1)" "unprognostic (1.50e-1)" 15.0 17.0 17.6 18.2 21.2 31.6 19.7 22.5 19.6 17.5 20.7 25.4 24.5 10.9 24.6 19.6 38.6 14.8 17.0 16.5 16.7 20.7 19.6 15.5 18.8 16.8 21.8 17.3 24.8 19.4 18.7 29.5 16.9 29.1 22.9 17.0 26.2 67.2 21.6 41.6 11.7 13.9 20.4 19.1 20.5 15.9 21.7 14.5 29.7 39.2 16.3 31.5 21.1 31.1 6.7 9.7 23.8 14.5 10.5 8.7 7.1 50.7 20.7 14.4 32.3 12.7 14.1 8.3 25.5 24.8 12.4 12.9 15.0 40.7 24.3 19.8 17.6 10.8 26.0 9.5 13.1 14.6 14.6 8.9 17.5 8.8 14.5 22.7 25.3 8.7 21.7 14.6 10.8 17.5 30.2 11.4 11.8 11.3 17.0 21.5 30.0 22.6 32.8 13.6 15.5 25.6 36.9 12.4 7.0 17.8 29.0 4.3 10.8 13.4 10.6 20.0 20.4 16.1 19.7 11.6 9.9 10.0 14.1 18.6 14.9 24.7 32.6 10.0 29.3 2.8 19.8 11.7 23.8 8.1 11.9 8.7 6.7 7.0 6.5 9.7 4.2 6.0 6.2 21.4 10.5 14.5 7.3 6.5 7.1 17.6 21.2 22.5 18.0 16.7 20.7 21.8 17.3 29.1 14.5 77.4 27.5 10.4 26.3 6.5 19.9 2.4 20.4 32.1 67.1 26.2 43.2 16.3 10.0 27.7 82.0 15.7 21.6 0.0 22.4 10.0 11.0 32.1 8.1 14.9 17.8 44.5 11.1 12.3 30.0 49.8 23.0 20.7 25.3 13.6 16.7 78.8 41.7 14.2 12.7 13.9 53.0 32.3 12.6 23.0 21.5 6.6 29.3 16.6 13.3 73.2 NTRK1 "MTC, TRK, TRKA" ENSG00000198400 "Neurotrophic receptor tyrosine kinase 1" P04629 1 156815640-156881850 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "adrenal gland: 15.8;blood: 32.3;brain: 28.3" "Group enriched" "Detected in some" 8 "granulocytes: 56.4;Horizontal cells: 54.0" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Region enriched" "Detected in many" 5 "pons and medulla: 28.3" "Cell type enriched" "Detected in single" 127 "basophil: 32.3" "Lineage enriched" "Detected in single" 323 "granulocytes: 32.3" "Cell line enriched" "Detected in some" 4 "HMC-1: 42.1" "Region enhanced" "Detected in some" "basal ganglia: 8.2" "Low region specificity" "Detected in all" "CAB004606, HPA035799, HPA076570" Approved Approved Vesicles,Cytosol NA NA 140000 "Vesicles, Cytosol" "CAB004606: AB_628397, HPA035799: AB_2674788, HPA076570: " "unprognostic (5.89e-3)" "unprognostic (7.56e-2)" "unprognostic (2.74e-2)" "unprognostic (5.99e-3)" "unprognostic (7.26e-2)" "unprognostic (1.43e-3)" "unprognostic (1.56e-1)" "unprognostic (7.42e-3)" "unprognostic (7.63e-2)" "unprognostic (1.35e-1)" "unprognostic (6.73e-2)" "unprognostic (2.29e-2)" "unprognostic (3.18e-11)" "unprognostic (2.18e-3)" "unprognostic (3.79e-2)" "unprognostic (1.07e-1)" "unprognostic (4.89e-1)" 1.0 15.8 0.5 0.8 6.0 0.9 0.4 0.0 0.7 0.9 1.1 0.1 0.0 0.8 1.6 2.0 0.7 0.6 2.1 1.5 0.0 1.2 2.9 0.2 1.9 0.3 2.1 0.6 0.3 0.3 0.3 1.1 0.5 28.3 2.2 0.2 3.1 1.2 0.5 0.7 0.2 0.4 1.1 1.2 0.2 1.0 2.4 1.5 0.4 0.3 0.0 0.4 0.7 0.8 0.0 0.0 32.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 6.8 0.0 0.0 0.0 0.0 42.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.8 0.0 0.0 0.0 1.2 0.0 0.0 0.6 1.2 0.0 0.1 0.0 0.0 0.8 9.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.6 0.0 0.0 1.6 0.2 0.0 0.0 0.0 0.0 32.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 6.0 0.0 0.6 0.0 1.2 2.1 0.6 28.3 1.5 0.0 2.2 0.0 0.0 0.0 6.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 56.4 0.0 0.1 54.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.2 2.5 0.1 0.0 0.0 0.0 0.0 NTRK3 TRKC ENSG00000140538 "Neurotrophic receptor tyrosine kinase 3" Q16288 15 87859751-88256768 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 41.8" "Cell type enhanced" "Detected in many" 13 "Bipolar cells: 58.9;Early spermatids: 85.5;Late spermatids: 103.3;Sertoli cells: 51.8;Smooth muscle cells: 37.7" "Cancer enhanced" "Detected in some" "glioma: 2.5" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 8 "U-138 MG: 48.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009233, HPA027484, HPA048065" Approved Supported "Nuclear membrane,Nucleoli,Nucleoli rim" NA NA 11000000 "Nucleoli, Nucleoli rim" "Nuclear membrane" "CAB009233: AB_632555, HPA027484: AB_2672297, HPA048065: AB_2680245" "unprognostic (1.27e-3)" "unprognostic (1.24e-2)" "unprognostic (1.98e-2)" "unprognostic (2.04e-2)" "unprognostic (1.65e-1)" "unprognostic (3.34e-1)" "unprognostic (3.18e-2)" "unprognostic (2.23e-2)" "unprognostic (2.34e-1)" "unprognostic (3.91e-1)" "unprognostic (2.88e-1)" "unprognostic (1.09e-1)" "unprognostic (5.78e-3)" "unprognostic (6.45e-3)" "unprognostic (1.06e-2)" "unprognostic (1.26e-2)" "unprognostic (2.49e-3)" 20.8 7.4 22.0 2.5 28.1 1.5 6.2 30.4 41.8 7.0 4.0 8.4 1.3 2.0 12.4 6.7 3.4 9.5 3.9 5.5 22.0 11.1 5.1 2.0 5.7 3.1 11.2 18.7 5.1 2.9 1.6 7.9 2.8 14.7 6.8 4.7 8.0 11.5 8.7 1.9 2.9 2.5 7.7 13.7 4.1 3.0 13.8 13.7 0.0 2.5 0.7 4.3 7.1 4.8 0.7 0.4 1.3 0.5 0.5 0.8 0.0 0.0 6.1 1.3 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 48.6 0.9 0.0 0.6 0.0 0.0 0.0 1.4 0.0 0.1 1.2 0.5 0.4 0.3 0.1 0.2 0.4 0.3 0.3 0.1 0.7 0.4 0.4 1.3 0.5 0.1 0.4 0.8 0.0 22.0 28.1 30.4 28.9 22.0 11.1 11.2 18.7 14.7 13.7 0.0 0.0 0.0 5.9 0.5 58.9 5.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 85.5 0.7 0.0 0.0 0.0 0.0 1.7 0.6 0.0 0.0 0.9 1.6 0.0 1.8 0.0 103.3 3.1 0.2 0.0 0.0 0.0 8.9 0.0 0.0 25.8 0.0 2.7 51.8 37.7 8.8 1.9 0.1 0.1 0.0 0.0 0.1 NUMA1 ENSG00000137497 "Nuclear mitotic apparatus protein 1" Q14980 11 72002864-72080693 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Mitosis" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019841, HPA019859, HPA029912" Enhanced Supported Nucleoplasm,Cytosol NA Yes Nucleoplasm Cytosol "HPA019841: AB_1854708, HPA019859: AB_1854709, HPA029912: AB_10602811" "unprognostic (1.60e-2)" "unprognostic (3.31e-1)" "unprognostic (2.06e-2)" "unprognostic (2.84e-1)" "unprognostic (1.14e-1)" "unprognostic (6.47e-2)" "unprognostic (5.75e-2)" "unprognostic (8.74e-3)" "unprognostic (5.91e-2)" "unprognostic (9.45e-2)" "unprognostic (1.60e-2)" "unprognostic (2.51e-2)" "prognostic favorable (7.92e-4)" "unprognostic (1.28e-1)" "unprognostic (1.37e-1)" "unprognostic (1.49e-1)" "unprognostic (1.39e-1)" 29.7 33.5 23.6 20.6 28.1 26.8 33.1 38.4 31.8 51.9 37.7 55.6 40.1 25.5 58.3 30.9 34.1 37.8 31.2 21.2 21.6 19.4 23.0 13.1 28.3 23.3 37.6 24.8 51.4 30.0 70.7 29.5 26.0 28.3 50.3 24.2 41.2 35.3 40.1 43.7 41.9 30.2 45.3 29.5 23.0 31.2 25.9 39.5 39.4 32.6 22.5 31.8 50.5 37.2 10.3 12.9 4.9 5.7 7.0 9.7 6.6 18.5 23.6 29.6 19.9 26.4 27.5 15.1 25.1 29.1 26.2 22.9 24.5 34.4 25.3 22.0 30.7 18.8 39.9 27.0 25.4 24.0 26.0 12.7 31.0 37.1 18.6 21.2 23.4 22.6 29.0 16.8 25.6 25.9 40.7 22.1 22.9 18.2 30.6 17.9 35.8 30.2 13.1 18.4 35.6 17.1 37.1 51.7 19.5 19.6 29.1 35.8 50.8 40.1 37.1 37.3 13.4 49.9 13.7 30.5 27.8 21.7 39.3 16.6 19.9 19.6 35.6 18.6 11.1 15.8 4.9 5.6 2.5 9.7 3.5 7.4 5.2 6.0 7.5 4.9 10.3 7.5 5.2 4.6 7.0 5.7 12.9 7.2 6.6 23.6 28.1 38.4 31.8 21.6 19.4 37.6 24.8 28.3 39.5 38.7 32.9 12.4 27.2 23.0 61.9 5.2 35.7 32.1 30.7 50.6 68.7 24.3 14.9 24.4 28.1 29.2 50.4 0.0 27.8 11.2 25.5 31.2 30.1 20.3 24.6 49.3 45.5 31.3 31.9 14.3 63.9 23.2 18.6 20.8 58.2 49.2 27.3 31.6 47.7 22.6 57.0 38.8 21.7 11.9 20.4 24.6 37.6 28.4 48.3 21.6 NUP214 "CAIN, CAN, D9S46E, N214" ENSG00000126883 "Nucleoporin 214" P35658 9 131125561-131234670 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "blood: 131.5" "Cell type enhanced" "Detected in many" 9 "Early spermatids: 225.7;Kupffer cells: 255.0;Late spermatids: 282.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 43.7;neutrophil: 131.5" "Group enriched" "Detected in many" 5 "granulocytes: 131.5;monocytes: 43.7" "Cell line enhanced" "Detected in all" "K-562: 73.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048789 Approved "Nucleoplasm,Vesicles,Focal adhesion sites" NA NA 100000 Nucleoplasm "Vesicles, Focal adhesion sites" "HPA048789: AB_2680521" "unprognostic (1.30e-1)" "unprognostic (9.51e-3)" "unprognostic (9.92e-3)" "unprognostic (1.15e-1)" "unprognostic (7.42e-2)" "unprognostic (8.31e-2)" "unprognostic (1.07e-3)" "unprognostic (2.10e-2)" "unprognostic (3.35e-1)" "unprognostic (4.95e-1)" "unprognostic (6.60e-3)" "unprognostic (1.08e-1)" "prognostic favorable (2.39e-5)" "unprognostic (5.49e-2)" "unprognostic (6.84e-2)" "unprognostic (1.82e-1)" "unprognostic (1.53e-1)" 16.9 10.3 11.5 13.8 13.9 29.4 12.9 13.0 14.4 10.2 11.4 19.8 10.4 9.0 15.0 13.7 16.1 12.1 10.2 9.7 9.5 8.1 19.0 15.1 11.7 13.3 13.2 8.8 14.2 17.0 16.7 16.9 13.0 11.3 11.1 10.8 15.3 13.0 11.1 15.5 17.5 11.7 11.1 14.3 35.8 12.3 63.7 13.3 27.4 11.8 7.6 16.8 10.7 11.2 1.2 16.8 131.5 43.7 1.2 0.8 17.9 6.8 9.8 8.4 5.0 6.8 6.6 8.8 6.1 6.3 8.0 6.5 8.0 5.0 11.1 4.9 8.4 8.3 15.7 11.3 8.0 7.8 8.0 5.5 6.9 14.0 15.6 6.0 10.8 7.5 7.1 7.4 10.2 8.3 5.1 8.1 7.4 73.0 6.4 8.2 12.8 14.2 16.4 9.1 9.9 8.6 5.0 10.6 11.1 9.2 6.3 7.1 7.4 10.2 9.4 5.3 6.3 12.4 27.0 7.0 14.1 7.9 9.2 9.9 5.6 10.9 10.8 6.9 6.5 8.5 3.5 43.7 17.3 0.7 18.4 0.8 1.2 0.7 0.6 16.8 1.1 0.7 0.7 131.5 1.2 15.0 1.5 0.4 17.9 11.5 13.9 13.0 14.4 9.5 8.1 13.2 8.8 11.3 13.3 17.9 19.9 15.2 9.5 7.7 29.6 24.0 15.3 16.0 15.9 22.7 43.2 10.9 8.3 9.1 225.7 14.6 13.6 0.0 13.1 9.3 11.4 11.4 8.1 11.9 75.5 15.9 19.5 18.4 255.0 282.5 21.6 77.0 10.1 15.4 14.3 14.8 12.0 5.8 19.1 6.7 31.6 6.5 8.1 90.1 44.5 9.5 9.2 11.8 16.3 9.3 NUP98 NUP96 ENSG00000110713 "Nucleoporin 98" P52948 11 3671083-3797792 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Early spermatids: 93.4;Late spermatids: 116.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074810 Supported Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "HPA074810: AB_2686714" "unprognostic (1.11e-1)" "unprognostic (1.49e-1)" "unprognostic (7.41e-2)" "unprognostic (2.13e-1)" "unprognostic (7.71e-3)" "unprognostic (3.40e-1)" "unprognostic (4.08e-3)" "unprognostic (6.47e-2)" "unprognostic (1.04e-2)" "unprognostic (1.83e-2)" "unprognostic (7.76e-3)" "unprognostic (1.02e-1)" "unprognostic (1.23e-1)" "unprognostic (5.09e-1)" "unprognostic (1.91e-1)" "unprognostic (2.46e-1)" "unprognostic (1.21e-1)" 20.2 13.5 8.7 23.5 11.7 40.8 23.5 14.2 13.2 18.0 15.3 14.6 17.8 11.2 19.2 17.5 18.6 17.3 17.1 18.2 7.8 8.0 12.8 20.1 20.7 17.4 11.4 8.7 25.5 19.0 25.7 23.6 20.7 12.7 18.6 15.2 17.8 17.4 25.0 35.2 18.5 15.7 20.8 10.4 18.3 16.0 57.0 10.6 27.5 20.9 15.0 26.6 22.6 19.3 8.9 9.9 24.9 10.0 6.1 13.2 8.7 29.8 23.4 19.3 21.3 21.4 17.6 17.0 21.3 24.9 29.3 26.4 25.7 37.1 29.2 10.1 25.5 29.6 32.2 33.9 21.0 40.0 20.7 24.5 31.3 19.2 17.6 18.0 39.9 26.4 20.0 14.5 16.1 29.4 13.0 22.7 33.4 38.9 23.5 31.1 12.2 40.1 13.0 24.4 32.8 18.0 24.5 23.5 14.0 16.7 23.6 17.8 11.9 30.9 25.1 14.2 21.0 15.4 15.7 16.6 23.5 20.4 25.5 19.4 14.2 24.2 31.0 15.9 17.2 24.7 19.1 7.9 15.5 11.0 10.0 11.0 8.9 10.7 9.7 9.9 7.8 12.2 10.5 24.9 6.1 6.3 2.7 13.2 8.7 8.7 11.7 14.2 13.2 7.8 8.0 11.4 8.7 12.7 10.6 26.8 25.1 21.4 28.7 44.3 14.4 14.3 25.5 13.4 22.7 7.0 15.7 18.8 3.3 11.1 93.4 20.3 12.8 23.3 10.3 14.1 19.3 22.7 17.4 20.2 15.1 14.3 20.6 16.5 15.1 116.3 15.8 20.9 15.1 27.9 14.0 12.4 10.6 12.7 13.4 7.4 14.9 32.3 23.7 48.2 32.6 44.2 38.9 20.2 16.2 23.9 NUTM1 "C15orf55, DKFZp434O192, FAM22H, NUT" ENSG00000184507 "NUT midline carcinoma family member 1" Q86Y26 15 34343315-34357737 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 127 "testis: 48.9" "Group enriched" "Detected in some" 5 "Early spermatids: 35.9;Spermatogonia: 9.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 1.1;NTERA-2: 2.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA040421 Enhanced NA NA "HPA040421: AB_10793965" "unprognostic (4.14e-2)" "unprognostic (3.61e-1)" "unprognostic (2.11e-1)" "unprognostic (7.38e-2)" "unprognostic (1.99e-1)" "unprognostic (8.37e-2)" "unprognostic (8.66e-2)" "unprognostic (2.76e-1)" "unprognostic (1.34e-1)" "unprognostic (5.55e-2)" "unprognostic (1.34e-2)" "unprognostic (5.97e-3)" "unprognostic (1.61e-1)" "unprognostic (2.77e-1)" "unprognostic (4.27e-2)" "unprognostic (4.79e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.1 48.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.4 0.4 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.6 0.1 0.1 0.1 0.0 0.3 0.5 0.3 0.0 0.0 0.4 0.5 0.1 0.2 0.1 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.1 0.3 0.1 2.2 0.6 0.3 0.2 0.2 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.6 0.2 0.6 0.2 0.0 0.7 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 35.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 9.2 0.0 0.0 0.0 0.0 0.0 NUTM2A FAM22A ENSG00000184923 "NUT family member 2A" Q8IVF1 10 87225448-87236908 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Low tissue specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 1.3" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "HMC-1: 14.5" HPA064635 Approved "Nuclear bodies" NA NA "Nuclear bodies" "HPA064635: " "unprognostic (1.75e-2)" "unprognostic (1.33e-2)" "unprognostic (1.03e-1)" "unprognostic (8.29e-2)" "unprognostic (5.67e-2)" "unprognostic (8.08e-2)" "unprognostic (1.75e-2)" "unprognostic (6.84e-2)" "unprognostic (2.46e-3)" "unprognostic (1.75e-2)" "unprognostic (7.24e-2)" "unprognostic (1.40e-1)" "unprognostic (4.24e-3)" "unprognostic (1.35e-1)" "unprognostic (1.11e-1)" "unprognostic (1.96e-2)" "unprognostic (2.65e-1)" 3.5 1.8 2.8 0.4 2.5 1.7 1.1 1.5 2.9 1.1 1.8 1.3 1.7 2.1 0.9 1.9 0.8 3.0 3.4 2.2 1.5 1.3 1.6 0.9 2.9 3.0 2.4 2.9 2.0 1.3 2.5 1.0 5.9 0.8 2.3 4.4 2.0 0.7 3.6 1.7 1.8 2.4 2.6 0.2 1.4 1.2 0.4 0.0 1.3 0.2 0.0 0.2 0.2 1.4 0.2 0.7 0.0 1.9 0.9 0.9 0.7 1.8 0.8 0.5 0.2 0.8 1.4 0.1 0.0 0.2 1.4 0.0 1.0 0.1 0.3 1.5 1.7 0.4 0.2 0.7 0.6 14.5 0.5 4.2 1.0 1.2 1.1 0.0 2.5 1.8 0.4 0.2 0.7 1.2 2.5 3.2 0.0 0.5 1.7 0.2 0.0 0.5 0.1 1.8 2.8 0.7 0.6 0.6 0.0 0.3 0.9 1.5 0.0 0.2 0.8 0.1 0.0 0.1 0.7 0.9 1.5 0.0 0.0 0.2 1.3 0.1 0.2 0.0 0.4 0.0 0.1 0.0 0.0 0.1 0.2 0.4 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 NUTM2B "bA119F19.1, FAM22B" ENSG00000188199 "NUT family member 2B" A6NNL0 10 79703227-79714681 "Cancer-related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "No human protein/transcript evidence" "Low tissue specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "eosinophil: 1.0" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "HMC-1: 6.2" HPA064635 Approved "Nuclear bodies" NA NA "Nuclear bodies" "HPA064635: " "unprognostic (9.51e-2)" "unprognostic (6.09e-2)" "unprognostic (1.21e-2)" "unprognostic (1.10e-1)" "unprognostic (3.63e-1)" "unprognostic (6.60e-2)" "unprognostic (2.47e-2)" "unprognostic (7.66e-2)" "unprognostic (1.33e-2)" "unprognostic (1.95e-1)" "unprognostic (7.79e-3)" "unprognostic (1.15e-1)" "unprognostic (9.70e-2)" "unprognostic (9.97e-2)" "unprognostic (5.72e-2)" "unprognostic (5.37e-2)" "unprognostic (2.32e-2)" 0.9 1.8 2.8 1.6 2.6 3.6 0.6 2.2 3.0 1.1 1.0 0.6 0.9 1.6 0.4 2.3 0.3 2.1 2.8 1.9 1.6 1.1 1.9 1.6 1.7 2.0 2.1 2.2 2.7 0.7 1.6 0.4 3.0 0.7 2.3 2.2 1.2 0.2 1.9 2.0 0.9 4.6 1.1 1.6 0.4 0.7 0.5 0.4 1.0 0.8 0.1 0.1 0.1 1.4 1.4 2.9 2.3 1.0 0.9 1.5 0.6 1.1 0.9 0.9 0.2 3.2 3.2 0.5 0.5 1.3 1.4 0.2 1.4 0.5 2.0 1.2 2.3 0.5 0.8 1.2 1.7 6.2 2.0 1.0 0.4 0.7 2.7 0.0 4.8 3.3 1.8 0.6 2.7 0.4 4.7 3.4 0.0 1.8 0.7 0.5 0.4 1.2 0.4 1.6 3.9 2.1 2.6 3.6 1.1 0.5 3.0 1.7 0.3 0.6 0.5 1.0 0.7 0.2 0.8 0.0 0.3 0.0 0.0 0.0 1.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.5 0.1 0.0 0.4 0.1 0.8 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 OLIG2 "BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17" ENSG00000205927 "Oligodendrocyte transcription factor 2" Q13516 21 33025845-33029196 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 66.2" "Not detected" "Not detected" "Cancer enriched" "Detected in some" 52 "glioma: 46.9" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 8 "eosinophil: 15.4" "Lineage enriched" "Detected in single" 154 "granulocytes: 15.4" "Cell line enhanced" "Detected in some" "HMC-1: 30.0;NB-4: 21.7;THP-1: 18.8;WM-115: 6.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003254, CAB019381" Enhanced Uncertain "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "CAB019381: , HPA003254: AB_1854795" "unprognostic (5.14e-1)" "unprognostic (4.56e-1)" "unprognostic (1.44e-2)" "unprognostic (8.27e-2)" "unprognostic (3.24e-2)" "unprognostic (4.34e-2)" "unprognostic (4.81e-2)" "unprognostic (5.41e-2)" "unprognostic (1.39e-1)" "unprognostic (5.78e-5)" "unprognostic (2.76e-1)" 1.3 1.3 24.1 1.4 19.1 1.4 1.3 4.2 66.2 1.3 1.3 41.4 0.0 1.7 1.3 1.3 1.3 1.3 1.3 1.3 23.6 15.6 1.3 1.3 1.3 1.3 20.9 15.5 1.3 1.3 1.3 0.0 1.3 17.1 1.3 1.3 0.0 1.3 1.3 1.3 1.3 1.5 1.3 16.8 1.3 1.4 1.3 16.6 0.0 1.3 0.0 1.3 1.4 0.0 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 3.5 0.0 0.0 0.0 0.6 4.3 0.0 0.0 0.0 0.8 30.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 21.7 1.9 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 18.8 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.8 0.0 6.1 1.8 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 19.1 4.2 27.6 23.6 15.6 20.9 15.5 17.1 16.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 P2RY8 P2Y8 ENSG00000182162 "P2Y receptor family member 8" Q86VZ1 X 1462572-1537107 "Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.7;lymphoid tissue: 19.0" "Group enriched" "Detected in some" 5 "B-cells: 29.8;Kupffer cells: 10.2;monocytes: 20.8;T-cells: 20.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 33.9;MOLT-4: 16.7;NB-4: 16.7;RPMI-8226: 20.8;THP-1: 20.8;U-266/70: 28.5;U-698: 55.5;U-937: 17.2" "Not detected" "Not detected" HPA003631 Enhanced NA NA "HPA003631: AB_1079543" "unprognostic (4.32e-2)" "unprognostic (3.22e-5)" "unprognostic (6.31e-2)" "unprognostic (2.51e-2)" "unprognostic (1.17e-1)" "prognostic favorable (7.80e-5)" "prognostic favorable (1.73e-4)" "unprognostic (5.27e-3)" "unprognostic (5.76e-3)" "unprognostic (5.52e-3)" "prognostic favorable (6.54e-4)" "unprognostic (4.29e-2)" "unprognostic (8.45e-3)" "unprognostic (2.90e-1)" "unprognostic (4.00e-2)" "unprognostic (3.55e-1)" "unprognostic (2.80e-1)" 2.9 4.8 0.5 8.9 2.2 13.9 8.2 0.9 1.8 4.7 1.6 0.5 0.5 1.3 7.1 0.5 0.8 0.8 1.6 11.8 0.9 0.2 13.5 0.8 2.1 19.0 3.6 1.7 5.8 1.1 1.0 6.9 3.4 2.7 1.6 1.3 0.5 1.6 0.5 1.1 0.4 7.8 0.5 3.9 16.6 2.0 0.5 2.0 0.5 8.1 0.5 16.7 2.7 2.8 18.5 5.8 17.8 7.3 15.6 26.7 18.3 0.1 0.1 0.1 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.2 33.9 0.1 0.0 0.1 0.1 0.0 0.0 0.0 1.3 0.1 0.3 0.3 1.7 0.0 14.8 3.6 0.0 0.0 0.0 0.0 0.3 0.0 10.1 0.3 14.3 0.0 0.0 16.7 16.7 0.2 0.0 0.3 15.1 0.1 20.8 0.0 0.2 0.0 0.2 0.1 0.3 0.1 0.3 0.1 20.8 0.0 0.3 0.3 0.1 0.0 28.5 5.3 55.5 0.0 17.2 0.0 17.8 7.3 12.4 26.7 5.5 24.6 15.4 20.2 25.1 5.8 18.5 16.1 16.5 4.7 15.6 2.2 1.5 15.9 18.3 0.5 2.2 0.9 1.8 0.9 0.2 3.6 1.7 2.7 2.0 0.0 2.6 29.8 0.0 0.3 0.0 0.8 0.0 0.0 1.2 1.8 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.2 0.0 0.4 0.1 1.1 0.0 1.9 0.0 0.0 4.3 10.2 0.0 0.0 1.6 1.7 20.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.0 20.1 0.0 0.0 PAFAH1B2 ENSG00000168092 "Platelet activating factor acetylhydrolase 1b catalytic subunit 2" P68402 11 117144267-117176894 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051836 Approved Supported "Nucleoli,Plasma membrane,Cytosol" NA NA 1600000 Cytosol "Nucleoli, Plasma membrane" "HPA051836: AB_2681630" "unprognostic (1.08e-2)" "unprognostic (3.14e-2)" "unprognostic (2.07e-2)" "unprognostic (3.88e-2)" "unprognostic (9.94e-2)" "unprognostic (1.21e-3)" "prognostic unfavorable (9.44e-4)" "prognostic unfavorable (3.07e-4)" "unprognostic (1.01e-1)" "prognostic favorable (4.25e-4)" "prognostic unfavorable (7.79e-5)" "unprognostic (8.18e-2)" "unprognostic (1.11e-2)" "unprognostic (9.97e-2)" "unprognostic (3.25e-1)" "unprognostic (2.46e-1)" "unprognostic (1.34e-1)" 21.5 34.1 30.6 19.2 29.7 33.5 32.3 43.5 41.3 21.6 20.2 33.3 12.7 21.1 23.4 22.8 23.3 20.8 19.3 26.2 31.9 36.8 24.6 22.5 20.5 17.7 39.3 31.6 23.6 23.0 23.1 24.2 26.9 39.6 22.2 19.6 17.3 19.3 17.4 14.1 20.8 18.0 19.9 51.6 18.3 21.4 29.9 26.3 15.1 30.9 10.8 20.4 25.9 20.3 26.8 21.6 36.8 35.7 18.9 31.4 26.9 15.0 17.2 19.9 28.7 22.2 15.6 15.5 25.3 22.1 14.1 12.9 31.4 33.2 16.2 36.3 30.3 14.1 24.1 28.9 32.7 18.6 14.5 11.1 41.8 15.7 20.1 19.9 14.4 16.0 17.2 25.9 28.1 35.5 15.4 23.0 9.1 22.1 12.4 21.5 9.6 13.9 21.2 18.2 20.9 13.6 15.6 22.5 17.8 21.5 23.5 22.2 29.4 29.2 22.1 9.6 17.6 24.6 12.4 36.8 25.8 17.1 12.6 17.9 3.9 6.0 21.8 10.4 27.7 21.6 32.1 30.8 26.7 24.2 33.3 28.2 26.8 28.0 25.3 21.6 25.4 29.3 31.4 36.8 18.9 35.7 15.8 19.5 26.9 30.6 29.7 43.5 37.8 31.9 36.8 39.3 31.6 39.6 26.3 26.8 33.3 41.0 38.7 108.6 36.9 31.1 68.8 17.4 26.1 62.8 45.2 36.3 39.7 52.6 7.3 54.4 31.6 0.0 34.5 77.2 42.9 53.9 18.5 39.2 38.5 44.5 79.3 57.7 59.6 8.9 42.0 55.7 47.2 49.5 37.2 33.5 72.8 46.7 32.2 44.8 33.5 12.9 46.4 45.1 75.6 101.4 45.7 38.5 39.1 38.8 PATZ1 "dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG" ENSG00000100105 "POZ/BTB and AT hook containing zinc finger 1" Q9HBE1 22 31325804-31346232 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047893, HPA048315" Approved Supported Nucleoplasm No No Nucleoplasm "HPA047893: AB_2680201, HPA048315: AB_2680353" "unprognostic (3.25e-1)" "unprognostic (8.72e-2)" "unprognostic (1.77e-1)" "unprognostic (2.88e-3)" "prognostic favorable (1.06e-4)" "unprognostic (1.77e-1)" "unprognostic (8.34e-3)" "prognostic favorable (8.71e-5)" "unprognostic (1.14e-1)" "unprognostic (1.41e-2)" "unprognostic (1.99e-3)" "unprognostic (1.76e-1)" "prognostic favorable (8.54e-8)" "unprognostic (9.22e-2)" "unprognostic (2.15e-1)" "unprognostic (1.51e-1)" "prognostic favorable (7.79e-6)" 9.6 11.2 13.0 12.7 12.9 12.9 12.1 16.8 16.0 14.2 13.0 21.7 21.8 9.4 19.6 14.4 7.3 22.2 14.1 10.4 14.0 11.8 11.4 11.0 17.4 30.3 15.3 13.4 27.7 16.6 25.4 11.0 8.9 13.6 14.0 6.8 17.5 17.5 17.8 9.1 7.5 11.9 15.6 12.5 14.3 10.5 13.0 15.5 38.5 18.9 8.2 13.8 17.4 14.2 4.7 7.1 4.8 1.8 3.5 5.7 2.0 8.4 10.6 21.8 12.8 5.8 5.3 11.4 2.6 6.6 10.6 9.7 7.4 8.2 18.1 9.4 4.8 3.7 6.6 14.7 7.9 5.4 10.5 13.5 7.6 7.4 15.1 9.5 25.5 10.3 8.3 9.6 6.7 7.5 8.4 8.3 8.9 3.2 7.3 6.7 25.8 16.3 17.5 14.6 15.5 12.6 27.6 9.3 5.9 7.1 18.0 28.5 22.9 6.5 7.9 14.2 7.5 15.7 16.3 5.8 7.1 13.4 4.4 8.7 9.5 6.2 16.5 3.0 3.3 12.1 0.0 1.8 4.8 3.4 1.1 3.5 4.7 2.6 4.4 2.5 3.8 5.7 4.1 0.8 3.5 0.6 7.1 3.7 2.0 13.0 12.9 16.8 16.0 14.0 11.8 15.3 13.4 13.6 15.5 3.0 12.2 2.9 5.4 1.4 15.6 12.2 10.2 10.7 10.3 19.2 7.9 4.3 16.6 11.3 0.4 4.5 2.9 0.0 5.2 1.4 4.9 8.2 5.8 11.3 7.6 20.6 19.7 9.2 6.4 1.3 8.9 5.0 3.3 3.6 9.1 13.3 7.4 3.5 8.1 6.8 14.2 6.5 3.3 0.7 7.2 1.4 0.7 7.4 10.8 5.6 PAX3 "HUP2, WS1" ENSG00000135903 "Paired box 3" P23760 2 222199888-222298996 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Myogenesis, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Deafness, Disease mutation, Proto-oncogene, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 19.1;retina: 39.6" "Group enriched" "Detected in some" 8 "Early spermatids: 10.9;Late spermatids: 19.5;Melanocytes: 32.1" "Cancer enriched" "Detected in some" 24 "melanoma: 20.3" "Group enriched" "Detected in some" 6 "cerebellum: 19.1;pons and medulla: 7.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+: 7.6;BJ hTERT+ SV40 Large T+ RasG12V: 9.1;HBF TERT88: 6.7;RH-30: 13.1;SK-MEL-30: 23.1" "Group enriched" "Detected in some" 7 "cerebellum: 3.9;midbrain: 1.6;pons and medulla: 1.4" "Group enriched" "Detected in many" 5 "cerebellum: 10.0;midbrain: 11.7;pons and medulla: 3.5" "HPA063659, HPA069000" Enhanced Nucleoplasm NA NA Nucleoplasm "HPA063659: AB_2685080, HPA069000: AB_2686067" "unprognostic (2.57e-2)" "unprognostic (1.48e-2)" "unprognostic (1.27e-2)" "unprognostic (1.65e-1)" "unprognostic (2.61e-2)" "unprognostic (3.70e-1)" "unprognostic (6.18e-2)" "unprognostic (1.41e-1)" "unprognostic (2.26e-1)" "unprognostic (9.70e-2)" 0.8 0.1 0.0 0.1 0.8 0.1 2.9 19.1 0.2 0.3 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.0 0.2 0.1 0.1 0.1 0.2 2.2 0.0 0.1 0.2 0.1 0.0 0.1 7.8 0.4 0.1 39.6 7.9 0.2 8.6 7.9 0.1 0.1 4.2 0.1 0.2 2.9 0.8 0.0 0.1 3.9 0.5 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 5.2 5.1 7.6 9.1 0.0 0.5 0.0 0.0 3.5 0.1 0.0 0.0 0.0 6.7 0.0 5.9 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 5.4 0.1 0.0 0.0 0.0 13.1 0.0 0.0 0.0 1.3 0.0 0.0 0.0 23.1 5.9 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 2.9 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.8 19.1 0.1 0.0 0.2 2.2 0.0 7.8 0.8 0.0 0.0 0.0 0.0 2.6 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.5 0.9 0.0 32.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.3 0.4 0.0 0.0 0.0 0.0 PAX5 BSAP ENSG00000196092 "Paired box 5" Q02548 9 36833275-37034185 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "blood: 21.6;lymphoid tissue: 33.4" "Cell type enriched" "Detected in some" 27 "B-cells: 57.6" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in single" 5 "midbrain: 1.6" "Group enriched" "Detected in some" 209 "memory B-cell: 20.1;naive B-cell: 21.6" "Lineage enriched" "Detected in single" 216 "B-cells: 21.6" "Group enriched" "Detected in some" 8 "Daudi: 21.5;REH: 62.5;U-698: 28.2" "Region enriched" "Detected in single" 11 "midbrain: 4.7" "Group enriched" "Detected in some" 6 "hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2" "CAB026269, CAB026869, HPA056394, HPA068498" Enhanced Supported Supported Nucleoplasm,Vesicles,Cytosol NA NA Nucleoplasm "Vesicles, Cytosol" "CAB026269: , CAB026869: , HPA056394: AB_2683116, HPA068498: AB_2685997" "unprognostic (4.69e-4)" "unprognostic (3.83e-1)" "unprognostic (9.13e-2)" "unprognostic (1.42e-1)" "unprognostic (2.65e-2)" "unprognostic (1.15e-1)" "unprognostic (2.09e-2)" "unprognostic (2.95e-2)" "unprognostic (2.48e-1)" "unprognostic (2.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.46e-2)" "unprognostic (1.11e-3)" "unprognostic (3.15e-1)" "unprognostic (8.96e-2)" "unprognostic (6.03e-2)" "unprognostic (1.01e-1)" 0.4 0.2 0.2 33.4 0.2 5.5 0.2 0.2 0.2 0.2 0.7 0.1 0.0 0.0 0.2 0.0 0.7 0.2 0.4 0.2 0.2 0.3 0.5 0.3 0.3 23.2 1.6 0.0 0.2 0.2 0.0 0.5 0.1 0.2 0.3 0.3 0.4 2.5 0.0 0.6 0.2 8.7 0.0 0.3 16.5 0.7 0.9 0.0 2.3 0.4 0.2 30.1 1.3 0.2 21.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.6 0.1 0.1 62.5 0.1 0.1 0.0 0.0 4.4 1.0 0.0 0.2 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.1 0.0 0.0 0.0 21.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.2 0.2 0.2 0.3 1.6 0.0 0.2 0.0 0.0 0.0 57.6 0.2 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.1 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 PAX7 Hup1 ENSG00000009709 "Paired box 7" P23759 1 18631006-18748866 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Myogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "skeletal muscle: 12.9;tongue: 12.0" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "breast cancer: 0.5;cervical cancer: 1.5;lung cancer: 1.2" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "A549: 3.4;CAPAN-2: 3.8;U-2 OS: 8.2" "Region enriched" "Detected in single" 17 "midbrain: 5.5" "Low region specificity" "Detected in many" NA NA "unprognostic (8.41e-4)" "unprognostic (2.07e-1)" "unprognostic (5.35e-2)" "unprognostic (3.96e-2)" "unprognostic (4.21e-1)" "unprognostic (1.96e-1)" "unprognostic (1.34e-1)" 0.4 0.1 0.6 0.0 0.6 0.0 0.0 0.0 3.4 0.1 0.0 0.0 0.0 0.1 0.0 2.3 0.5 0.1 0.0 0.0 0.8 0.8 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 2.4 0.0 3.4 0.3 0.0 0.0 0.1 0.1 12.9 0.0 0.1 0.0 1.0 0.0 0.0 0.3 0.0 0.0 0.0 12.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.6 0.0 3.4 0.8 0.8 2.4 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PAX8 ENSG00000125618 "Paired box 8" Q06710 2 113215997-113278950 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Congenital hypothyroidism, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "kidney: 69.3;thyroid gland: 120.5" "Group enriched" "Detected in many" 4 "Collecting duct cells: 233.8;Proximal tubular cells: 100.4" "Group enriched" "Detected in many" 12 "endometrial cancer: 60.6;ovarian cancer: 63.5;renal cancer: 33.2;thyroid cancer: 122.2" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in some" 8 "EFO-21: 27.1;GAMG: 16.8;RPTEC TERT1: 63.8" "Region enriched" "Detected in some" 4 "pons and medulla: 5.8" "HPA030062, CAB055097, CAB061888, HPA064554" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB055097: AB_2236705, CAB061888: AB_10895719, HPA030062: AB_10603982, HPA064554: AB_2685283" "unprognostic (2.63e-3)" "unprognostic (3.80e-1)" "unprognostic (1.17e-1)" "prognostic unfavorable (1.75e-5)" "unprognostic (7.24e-2)" "unprognostic (5.16e-5)" "unprognostic (1.56e-2)" "unprognostic (3.29e-2)" "unprognostic (1.03e-1)" "unprognostic (2.16e-1)" "unprognostic (4.13e-2)" "unprognostic (4.00e-2)" "unprognostic (3.37e-2)" "unprognostic (3.27e-1)" "unprognostic (2.37e-1)" "unprognostic (8.93e-3)" "unprognostic (1.02e-1)" 0.9 1.4 1.1 0.5 0.4 0.0 0.6 0.2 0.8 3.8 0.4 0.2 11.7 0.1 2.2 15.2 0.6 9.6 0.8 0.6 0.5 0.5 69.3 0.4 0.5 0.7 0.4 0.3 3.8 0.6 0.1 0.7 0.8 1.5 1.1 0.1 0.5 0.5 10.0 0.3 0.5 0.6 0.4 0.8 0.3 0.4 1.9 0.2 0.4 120.5 0.0 0.2 0.8 1.9 4.4 2.8 1.5 3.4 1.9 2.5 1.1 2.9 0.2 0.1 0.0 0.1 0.0 1.0 0.8 2.7 0.2 0.4 1.8 0.5 0.5 27.1 0.2 16.8 0.0 0.5 0.8 0.2 1.2 0.0 0.4 0.2 1.0 0.3 0.0 0.0 0.7 0.1 0.2 0.6 3.3 0.0 0.0 0.4 2.0 0.8 0.6 0.3 1.2 0.1 0.7 1.8 0.0 0.2 0.6 63.8 4.7 0.5 0.0 3.4 0.0 1.8 0.0 0.0 1.1 0.9 4.6 0.1 0.8 2.3 0.4 1.4 0.1 4.0 0.6 0.0 1.5 3.4 0.0 0.6 1.8 1.5 4.4 1.5 1.1 2.8 1.9 2.5 1.5 0.5 1.9 1.3 1.1 0.8 1.1 1.1 0.4 0.2 0.8 0.5 0.5 0.4 0.3 1.5 0.2 3.0 1.3 0.8 1.7 0.6 0.6 0.8 2.5 0.0 4.5 233.8 0.0 2.1 39.7 9.6 1.5 0.5 5.8 0.0 2.6 2.0 1.9 1.0 0.0 0.0 4.5 0.0 4.6 1.3 1.3 3.1 4.6 2.6 0.0 2.8 2.3 3.3 17.3 7.0 0.4 100.4 0.7 6.5 0.1 4.2 5.8 0.6 0.7 1.0 3.7 1.7 PBRM1 "BAF180, PB1" ENSG00000163939 "Polybromo 1" Q86U86 3 52545352-52685917 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Chromatin regulator, DNA-binding" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015629, HPA059373" Uncertain Enhanced Nucleoplasm NA NA Nucleoplasm "HPA015629: AB_1855012, HPA059373: AB_2683994" "unprognostic (1.87e-1)" "unprognostic (1.73e-1)" "unprognostic (1.91e-2)" "unprognostic (2.00e-1)" "unprognostic (6.15e-2)" "unprognostic (1.34e-2)" "unprognostic (1.02e-2)" "unprognostic (9.54e-2)" "unprognostic (1.87e-2)" "unprognostic (1.43e-1)" "unprognostic (1.99e-2)" "unprognostic (4.32e-2)" "unprognostic (2.89e-3)" "unprognostic (3.06e-1)" "unprognostic (1.96e-1)" "unprognostic (1.53e-2)" "unprognostic (1.06e-1)" 24.3 14.8 13.8 20.6 15.9 17.2 24.4 19.1 13.8 18.9 18.5 14.0 22.9 12.2 25.9 13.9 19.9 18.9 13.7 15.9 11.1 10.0 11.7 14.5 14.9 16.5 16.5 8.2 25.1 15.4 14.4 30.6 28.0 14.7 16.1 15.3 12.7 17.5 16.2 21.8 17.2 14.3 21.1 15.6 19.1 14.8 13.1 13.7 51.0 22.0 10.5 17.1 22.4 23.0 6.6 10.7 11.1 8.7 4.6 7.4 1.9 12.5 8.1 29.0 14.2 14.3 14.6 20.3 17.3 11.9 20.0 17.6 9.1 8.5 30.4 2.4 20.3 16.6 8.6 25.1 13.1 24.4 32.5 13.5 28.8 15.3 7.0 20.5 24.0 21.9 13.6 15.2 22.4 14.5 15.8 19.3 24.1 16.4 16.7 20.1 4.2 39.5 7.2 17.6 8.5 13.3 20.7 18.2 15.5 8.3 24.5 19.7 21.8 20.8 5.0 16.5 18.4 9.4 13.9 22.2 18.8 14.3 16.2 21.1 12.1 19.0 28.9 11.6 19.5 18.7 10.1 5.0 11.1 4.8 3.2 4.9 3.6 4.8 5.3 4.8 6.6 7.4 4.7 2.7 4.6 8.7 10.7 4.5 1.9 13.8 15.9 19.1 13.8 11.1 10.0 16.5 8.2 14.7 13.7 38.7 54.1 19.5 31.0 35.9 42.0 48.4 28.1 53.5 38.7 22.7 45.2 31.3 16.6 31.4 28.7 40.3 25.3 23.3 40.4 28.9 31.5 35.3 27.8 37.0 45.9 28.6 33.8 35.0 63.3 14.7 31.7 46.6 45.5 50.5 30.6 28.5 42.9 28.1 54.8 13.9 43.3 25.8 45.3 41.9 32.8 45.0 42.6 34.1 34.5 33.3 PBX1 ENSG00000185630 "PBX homeobox 1" P40424 1 164555584-164899296 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Sexual differentiation, Steroidogenesis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "basophil: 2.9" "Lineage enriched" "Detected in single" 9 "granulocytes: 2.9" "Cell line enhanced" "Detected in many" "HEL: 30.9;NTERA-2: 30.3;SK-BR-3: 62.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003505, HPA003881, CAB018768" Supported Enhanced "Nucleoplasm,Nuclear bodies,Cytosol" NA NA Nucleoplasm "Nuclear bodies, Cytosol" "CAB018768: AB_675783, HPA003505: AB_1855019, HPA003881: AB_1855020" "unprognostic (2.26e-2)" "unprognostic (1.95e-1)" "unprognostic (9.09e-2)" "unprognostic (2.14e-2)" "unprognostic (5.21e-3)" "unprognostic (6.94e-3)" "unprognostic (5.95e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "unprognostic (2.24e-3)" "unprognostic (2.30e-1)" "unprognostic (8.81e-2)" "unprognostic (1.34e-2)" "unprognostic (2.13e-1)" "unprognostic (5.07e-2)" "unprognostic (1.11e-1)" "unprognostic (1.25e-1)" 13.2 17.3 14.9 8.3 15.0 1.4 16.4 14.1 17.4 73.4 26.3 11.2 15.9 13.6 67.2 15.3 20.8 35.1 25.8 12.6 10.9 9.7 15.4 4.2 10.4 2.3 11.6 14.6 35.2 29.4 21.3 12.4 9.6 8.1 27.6 9.3 10.2 19.6 25.1 16.8 6.0 14.6 56.8 8.0 5.1 13.9 9.7 8.7 2.7 17.4 8.5 6.6 32.2 24.7 0.0 0.1 2.9 0.0 0.3 0.2 2.5 1.1 22.6 22.3 6.0 15.1 7.3 1.3 9.5 6.1 2.6 1.8 4.3 4.0 0.0 2.0 12.9 1.4 7.9 8.8 2.5 1.0 1.1 9.4 30.9 18.2 0.0 10.0 0.0 7.9 7.2 0.0 1.6 0.7 5.6 0.1 0.0 0.0 0.0 0.7 14.9 0.0 0.1 30.3 1.3 1.1 0.0 7.4 9.0 1.8 13.5 0.8 13.2 10.9 62.4 0.0 21.3 23.7 0.0 0.1 1.3 3.1 8.8 2.7 2.8 21.3 0.0 0.1 0.0 0.1 2.9 0.0 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.7 0.3 0.0 0.1 0.0 2.5 14.9 15.0 14.1 17.4 10.9 9.7 11.6 14.6 8.1 8.7 20.8 15.2 0.9 91.3 20.3 27.6 44.2 91.7 25.4 21.6 31.4 104.1 89.0 28.2 41.5 72.1 39.2 28.0 0.0 58.9 4.5 75.2 44.0 71.4 17.3 8.6 4.8 87.2 60.8 1.6 78.2 59.0 6.8 15.1 1.8 35.4 34.9 31.8 59.6 97.6 49.4 28.8 38.8 62.7 0.9 11.5 24.6 87.5 3.2 39.4 82.1 PCM1 PTC4 ENSG00000078674 "Pericentriolar material 1" Q15154 8 17922840-18029944 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Spermatocytes: 451.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023370, HPA023374, CAB058695" Enhanced Enhanced "Nuclear membrane,Centrosome,Cytosol" NA NA Centrosome "Nuclear membrane, Cytosol" "CAB058695: AB_2665588, HPA023370: AB_1855072, HPA023374: AB_1855073" "unprognostic (1.52e-2)" "unprognostic (1.77e-2)" "unprognostic (6.54e-3)" "unprognostic (3.35e-2)" "unprognostic (9.52e-2)" "unprognostic (1.62e-2)" "unprognostic (1.40e-1)" "unprognostic (7.74e-3)" "unprognostic (1.09e-1)" "unprognostic (2.26e-1)" "unprognostic (2.84e-1)" "unprognostic (2.83e-1)" "unprognostic (1.76e-2)" "unprognostic (2.16e-1)" "unprognostic (4.60e-1)" "unprognostic (1.34e-1)" "unprognostic (2.45e-1)" 19.6 19.0 26.2 26.7 40.4 25.1 25.1 29.2 29.0 25.0 21.1 21.6 22.8 12.4 23.3 27.3 16.4 26.4 17.8 23.0 22.9 18.4 18.8 22.0 19.1 21.1 24.5 24.9 29.1 27.0 42.0 35.8 19.8 26.4 20.2 16.3 16.2 19.4 25.3 63.1 17.6 18.3 26.7 27.2 20.8 17.9 80.0 28.0 40.2 28.2 19.1 20.4 27.0 22.6 11.5 14.9 19.9 7.5 11.2 13.0 4.3 20.6 22.1 34.0 45.0 19.2 20.0 17.6 17.5 21.5 18.7 21.1 14.9 12.4 27.1 12.1 17.4 16.1 15.0 21.7 16.1 31.9 8.9 8.4 46.6 15.6 30.3 21.4 20.4 12.0 17.4 17.2 21.7 24.1 16.4 21.4 28.4 31.4 21.1 22.8 10.3 43.6 33.7 28.0 17.3 6.4 26.3 30.4 9.7 15.5 28.8 26.0 19.6 18.7 10.3 26.8 15.2 16.2 29.7 19.1 17.1 14.0 20.8 14.7 9.0 19.9 24.3 14.4 22.5 17.4 19.9 6.0 14.4 11.5 3.8 12.0 11.1 10.4 13.0 5.9 11.5 11.6 11.6 6.4 11.2 7.5 14.9 10.3 4.3 26.2 40.4 29.2 29.0 22.9 18.4 24.5 24.9 26.4 28.0 119.1 118.7 34.0 55.5 30.0 182.6 220.7 38.2 392.1 177.5 82.0 329.9 42.5 24.9 61.5 377.1 62.9 27.3 70.0 51.3 30.8 46.8 39.6 133.4 45.3 37.2 122.3 68.3 61.4 51.5 176.2 85.4 63.1 52.3 59.5 45.1 137.5 50.9 39.3 91.9 20.6 207.3 122.9 58.7 451.7 165.6 33.4 50.6 87.1 43.7 42.1 PDCD1LG2 "B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2" ENSG00000197646 "Programmed cell death 1 ligand 2" Q9BQ51 9 5510570-5571254 "Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 5 "Extravillous trophoblasts: 15.1;monocytes: 45.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BJ: 25.9;BJ hTERT+: 40.8;HDLM-2: 31.1;TIME: 18.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA013411 Approved Uncertain Cytosol "Secreted - unknown location" NA NA 34000000 Cytosol "HPA013411: AB_1855102" "unprognostic (3.93e-2)" "unprognostic (1.90e-1)" "unprognostic (3.51e-3)" "unprognostic (6.68e-3)" "unprognostic (7.66e-2)" "unprognostic (6.77e-2)" "unprognostic (5.72e-2)" "unprognostic (2.91e-1)" "unprognostic (1.68e-1)" "unprognostic (4.37e-3)" "unprognostic (5.79e-2)" "unprognostic (5.29e-2)" "prognostic unfavorable (1.15e-4)" "unprognostic (5.00e-2)" "unprognostic (4.66e-2)" "unprognostic (2.01e-1)" "unprognostic (7.51e-3)" 15.2 1.8 1.2 7.7 1.4 0.2 9.5 0.7 1.2 7.0 1.9 2.3 0.0 0.8 2.9 7.2 3.9 3.8 4.0 5.8 1.2 1.3 2.5 6.4 13.3 10.8 1.6 0.5 4.1 1.8 0.5 1.1 12.9 1.9 5.0 2.5 2.4 2.9 1.7 5.5 3.6 2.5 4.6 3.7 19.5 1.9 4.2 1.2 8.1 3.5 3.5 8.1 6.0 5.4 0.5 0.9 4.1 3.6 0.0 3.0 0.7 2.1 0.0 0.0 0.0 1.8 2.1 0.0 25.9 40.8 12.5 15.2 0.0 0.1 0.0 0.1 10.5 1.8 0.2 0.0 3.5 12.5 31.1 0.0 0.0 0.0 0.0 10.1 0.0 0.0 1.9 0.0 5.8 6.9 3.6 8.2 0.0 0.0 3.1 15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.5 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 18.0 9.0 0.5 4.3 7.1 0.4 0.0 0.0 5.1 0.0 1.1 4.1 0.9 0.0 1.4 3.6 1.9 0.5 2.2 0.9 0.9 0.3 0.0 1.0 2.0 0.0 0.5 0.0 3.0 0.7 1.2 1.4 0.7 1.2 1.2 1.3 1.6 0.5 1.9 1.2 6.0 0.3 0.8 0.0 0.9 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.1 0.0 0.1 0.0 1.9 0.0 0.0 0.2 15.1 2.1 0.1 3.5 0.0 2.8 0.0 0.0 6.7 4.3 0.0 5.5 2.2 1.7 45.9 0.0 0.0 2.1 0.0 2.1 0.0 0.0 0.0 1.4 0.0 0.0 0.9 0.7 0.0 0.0 0.0 PDE4DIP "CMYA2, KIAA0454, KIAA0477, MMGL" ENSG00000178104 "Phosphodiesterase 4D interacting protein" Q5VU43 1 148808181-149048286 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 10 "heart muscle: 106.0;skeletal muscle: 276.2" "Cell type enhanced" "Detected in many" 11 "Cardiomyocytes: 631.5;Rod photoreceptor cells: 241.6;Syncytiotrophoblasts: 258.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 63.3;ASC TERT1: 51.5;K-562: 51.7" "Low region specificity" "Detected in all" HPA012678 Supported "Golgi apparatus" NA NA "Golgi apparatus" "HPA012678: AB_1855123" "unprognostic (2.14e-1)" "unprognostic (3.27e-1)" "unprognostic (5.31e-2)" "unprognostic (6.73e-2)" "unprognostic (7.82e-2)" "unprognostic (1.16e-2)" "unprognostic (2.17e-1)" "unprognostic (9.72e-2)" "unprognostic (7.65e-2)" "unprognostic (1.67e-1)" "unprognostic (2.23e-2)" "unprognostic (5.08e-2)" "unprognostic (1.70e-3)" "unprognostic (1.82e-1)" "unprognostic (4.14e-2)" "unprognostic (9.13e-2)" "unprognostic (2.28e-1)" 4.8 2.9 9.2 4.3 8.3 2.3 9.0 12.1 15.1 4.8 6.2 8.3 5.6 3.8 3.1 11.8 6.1 3.3 5.0 106.0 9.7 7.8 6.6 9.3 5.5 3.8 15.6 8.1 2.3 3.4 13.6 7.7 10.2 9.3 4.6 4.1 7.2 5.4 4.5 276.2 4.1 7.7 3.1 18.5 2.9 4.4 1.7 11.2 1.5 3.1 18.1 3.8 3.6 6.1 12.0 6.7 7.4 5.9 4.7 13.2 4.3 7.9 1.5 2.2 2.4 63.3 51.5 13.2 9.3 8.9 9.1 12.0 7.3 5.0 4.0 2.9 13.4 26.1 4.1 5.4 6.6 15.5 3.0 7.7 2.0 3.3 2.9 16.7 1.8 2.2 36.6 13.2 38.8 21.1 20.9 3.5 3.4 51.7 9.5 16.2 13.5 1.3 1.1 7.9 6.6 3.3 2.9 5.7 1.5 5.4 8.2 10.9 1.0 9.1 26.7 7.3 10.0 7.9 2.3 4.7 10.6 2.4 26.5 20.7 4.2 5.9 6.0 43.3 1.6 6.5 7.4 5.3 4.1 5.4 5.9 5.5 12.0 10.9 7.2 6.7 11.7 8.4 4.6 1.2 4.7 1.9 2.9 13.2 4.3 9.2 8.3 12.1 10.2 9.7 7.8 15.6 8.1 9.3 11.2 47.6 46.3 21.7 9.6 25.5 78.0 631.5 35.7 121.8 61.4 66.3 108.0 166.9 53.0 10.9 30.1 5.7 27.3 0.0 6.1 103.0 37.0 5.3 12.8 70.6 41.3 31.8 41.5 6.2 35.7 38.7 9.8 70.6 52.3 22.6 33.0 44.3 4.9 20.7 9.2 14.7 241.6 32.3 42.4 6.7 16.8 14.3 258.6 12.8 17.8 3.8 PDGFB "SIS, SSV" ENSG00000100311 "Platelet derived growth factor subunit B" P01127 22 39223359-39244751 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Developmental protein, Growth factor, Mitogen" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 11 "Endothelial cells: 22.4;Ito cells: 20.9;Pancreatic endocrine cells: 35.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 10.8" "Lineage enriched" "Detected in single" 12 "T-cells: 10.8" "Cell line enhanced" "Detected in many" "A-431: 13.6;EFO-21: 29.7;HUVEC TERT2: 22.9;SK-BR-3: 22.7;TIME: 28.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011604, HPA011972, CAB018341" Supported Approved Vesicles "Secreted to blood" NA NA 4390000 98000 Vesicles "CAB011604: AB_2162180, CAB018341: AB_2162187, HPA011972: AB_1855134" "unprognostic (4.96e-2)" "unprognostic (8.94e-3)" "unprognostic (8.41e-2)" "unprognostic (2.66e-1)" "unprognostic (9.84e-2)" "unprognostic (4.46e-3)" "unprognostic (4.34e-1)" "prognostic unfavorable (3.67e-5)" "unprognostic (3.22e-2)" "unprognostic (2.07e-1)" "unprognostic (1.05e-1)" "unprognostic (8.68e-2)" "unprognostic (1.84e-3)" "unprognostic (5.12e-3)" "unprognostic (7.47e-2)" "unprognostic (6.50e-2)" "unprognostic (1.03e-1)" 23.5 6.4 10.4 6.4 9.3 0.6 22.5 5.7 13.0 8.3 14.3 12.4 4.2 4.7 10.8 6.5 6.5 5.6 10.8 13.8 9.7 6.1 10.9 3.8 20.8 6.1 14.7 7.3 4.0 8.3 9.2 3.5 37.3 9.6 5.8 3.7 12.1 7.9 8.6 15.2 7.5 6.7 8.9 11.4 5.6 6.2 5.2 10.3 0.8 12.6 8.6 2.3 6.9 5.0 0.0 0.9 0.1 0.4 0.0 10.8 2.3 13.6 1.1 3.6 0.0 0.0 0.0 4.2 0.0 0.1 0.0 0.0 5.4 4.3 0.0 29.7 0.0 1.3 5.1 0.2 1.2 0.0 0.0 0.1 0.3 0.4 1.9 2.0 0.0 7.7 0.0 0.1 0.0 0.2 0.4 22.9 0.0 0.5 2.6 0.8 5.6 0.0 0.0 1.3 3.4 1.4 0.0 0.1 9.2 12.4 0.0 0.1 0.0 0.2 22.7 0.1 2.8 10.3 0.0 28.4 0.0 2.8 0.0 3.1 0.0 0.1 0.1 0.0 0.6 13.1 0.0 0.0 0.0 8.1 0.1 10.8 0.0 4.7 6.1 0.0 0.0 4.1 2.2 0.1 0.0 0.4 0.9 2.4 2.3 10.4 9.3 5.7 13.0 9.7 6.1 14.7 7.3 9.6 10.3 0.0 1.4 0.0 1.1 2.5 0.8 2.8 0.0 1.4 0.0 7.0 0.0 5.6 0.0 12.5 1.1 22.4 0.0 0.0 3.1 5.3 1.3 1.4 0.0 0.8 6.1 0.0 1.7 20.9 1.9 0.0 0.6 8.7 1.7 1.8 0.5 0.3 35.1 0.0 0.0 1.3 0.0 6.5 2.0 0.0 0.2 1.3 3.8 1.3 0.0 0.1 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229097-54298247 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 81.5" "Group enriched" "Detected in many" 9 "Fibroblasts: 171.4;Leydig cells: 416.6;Peritubular cells: 384.4" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "ASC diff: 82.8;ASC TERT1: 38.8;BJ hTERT+: 48.0;fHDF/TERT166: 33.4;HHSteC: 28.0;HSkMC: 70.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" NA NA 150000 "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: AB_2732399" "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favorable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavorable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 35.0 12.4 12.6 16.1 7.6 0.9 17.2 2.4 20.1 33.2 19.1 9.2 6.4 9.6 27.6 14.6 21.9 22.5 16.2 15.3 8.9 7.4 22.8 8.4 24.1 26.9 9.2 4.0 81.5 6.8 1.6 2.1 25.1 7.2 18.6 15.2 19.2 8.5 8.3 11.9 7.0 17.4 19.7 8.8 51.6 13.6 19.0 9.3 0.5 11.3 12.8 4.3 35.9 24.6 0.9 0.4 2.5 0.4 0.3 0.8 0.3 0.0 0.0 0.2 0.1 82.8 38.8 0.1 4.3 48.0 0.0 0.1 11.5 0.0 0.1 0.1 33.4 0.1 0.1 3.3 0.0 0.0 0.4 0.1 0.1 0.1 0.2 28.0 0.0 0.0 70.4 0.0 5.5 0.0 0.9 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.1 6.7 0.0 0.1 0.0 0.3 0.1 0.0 0.1 15.2 0.5 16.6 0.0 0.0 0.0 0.1 0.4 0.0 0.3 2.5 0.4 0.2 0.5 0.2 0.2 0.6 0.8 0.4 0.0 0.9 0.7 0.4 2.3 0.3 0.3 0.4 0.2 0.3 12.6 7.6 2.4 7.3 8.9 7.4 9.2 4.0 7.2 9.3 0.0 0.3 0.9 0.3 15.1 0.7 4.0 0.0 0.0 0.0 0.0 0.0 1.3 1.7 2.9 1.6 3.3 0.0 0.0 5.8 1.2 171.4 0.4 0.0 0.8 2.8 0.0 0.0 38.1 0.6 3.7 416.6 1.6 21.9 8.2 0.0 18.3 12.2 0.0 384.4 0.0 0.4 0.0 13.2 1.1 3.5 13.8 1.1 0.0 0.0 0.8 PDGFRB "CD140b, JTK12, PDGFR, PDGFR1" ENSG00000113721 "Platelet derived growth factor receptor beta" P09619 5 150113837-150155872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Chemotaxis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enriched" "Detected in many" 5 "Sertoli cells: 1267.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.9;non-classical monocyte: 4.1" "Group enriched" "Detected in many" 8 "monocytes: 4.1;T-cells: 2.9" "Group enriched" "Detected in some" 4 "ASC diff: 173.0;ASC TERT1: 59.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003842, CAB018144, HPA028499" Enhanced Supported "Golgi apparatus,Vesicles" NA NA 35000000 Vesicles "Golgi apparatus" "CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018" "unprognostic (4.75e-2)" "unprognostic (2.48e-1)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (3.27e-1)" "unprognostic (5.61e-2)" "unprognostic (1.02e-1)" "unprognostic (3.36e-2)" "unprognostic (2.12e-2)" "unprognostic (2.57e-3)" "unprognostic (6.72e-2)" "unprognostic (1.25e-1)" "prognostic unfavorable (5.87e-8)" "unprognostic (3.13e-3)" "unprognostic (1.25e-2)" "unprognostic (5.47e-2)" "prognostic unfavorable (8.11e-4)" 61.8 10.4 8.3 11.0 9.1 0.5 66.1 4.6 10.4 73.1 15.7 6.7 6.9 5.1 44.3 17.3 21.7 26.1 51.7 24.2 8.2 3.9 17.0 4.6 28.9 21.5 7.9 8.1 46.5 7.5 10.4 7.7 46.4 7.7 24.2 6.3 22.9 11.2 19.3 29.8 20.3 11.2 29.8 5.0 19.6 9.2 21.5 6.7 1.4 21.4 16.0 7.3 23.6 35.1 0.4 0.1 0.0 4.1 0.0 2.9 0.6 0.0 0.0 1.0 0.0 173.0 59.9 0.4 6.0 25.1 4.2 7.1 0.6 0.0 0.0 0.8 17.3 2.4 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.4 0.4 24.5 0.0 0.0 27.0 0.0 5.8 0.0 13.5 0.0 0.0 0.0 0.6 0.6 0.0 0.0 0.0 1.1 0.0 0.0 0.4 0.3 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 5.0 0.0 0.0 0.0 6.8 2.2 2.9 0.3 0.0 0.0 0.0 4.2 0.0 0.1 0.0 0.0 0.0 2.9 0.6 0.0 0.4 0.1 0.8 0.1 0.1 0.0 1.3 0.0 0.0 4.1 0.0 0.0 0.6 8.3 9.1 4.6 10.4 8.2 3.9 7.9 8.1 7.7 6.7 0.0 0.6 0.0 0.5 21.3 5.0 13.4 0.0 1.4 0.0 1.8 3.9 0.6 0.0 0.0 0.8 16.2 0.0 0.0 0.0 1.0 68.8 0.6 0.0 1.5 1.4 0.0 0.0 6.7 0.0 4.7 153.1 2.2 23.6 1.0 0.0 74.9 0.1 0.0 191.6 0.0 1.1 1267.6 273.4 1.1 1.5 13.4 0.7 1.0 0.4 0.9 PER1 "PER, RIGUI" ENSG00000179094 "Period circadian regulator 1" O15534 17 8140472-8156506 "Cancer-related genes, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HBEC3-KT: 23.7;hTCEpi: 27.6;hTERT-HME1: 27.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047947, HPA067064" Supported Nucleoplasm,Cytosol NA NA Cytosol Nucleoplasm "HPA047947: AB_2680219, HPA067064: AB_2685774" "unprognostic (7.64e-2)" "prognostic favorable (3.89e-4)" "unprognostic (5.54e-2)" "unprognostic (1.20e-1)" "unprognostic (2.59e-1)" "unprognostic (9.44e-2)" "prognostic favorable (2.56e-4)" "unprognostic (5.28e-2)" "unprognostic (6.67e-2)" "unprognostic (6.21e-3)" "unprognostic (6.87e-2)" "unprognostic (4.68e-2)" "unprognostic (7.09e-3)" "prognostic unfavorable (1.94e-4)" "unprognostic (2.08e-1)" "unprognostic (1.37e-1)" "unprognostic (3.34e-2)" 39.4 33.4 13.2 21.6 15.0 27.3 31.3 19.5 23.9 27.8 24.6 20.9 27.8 6.9 19.5 17.2 31.6 25.2 36.9 24.0 13.3 6.3 14.2 18.6 25.8 10.8 15.6 11.3 50.1 61.8 19.3 29.8 12.7 20.1 23.1 8.1 36.6 23.3 43.5 70.3 47.9 16.9 29.3 17.5 16.7 23.6 13.8 17.1 4.6 28.5 33.1 12.1 30.2 25.0 1.6 4.9 3.3 3.6 0.5 2.1 1.2 1.0 3.9 4.5 6.5 14.8 10.9 2.5 1.5 2.8 2.0 2.4 3.9 2.5 7.3 1.2 2.2 2.2 3.1 4.5 23.7 1.4 2.3 5.6 3.8 8.5 1.1 20.4 1.5 5.8 16.3 27.6 3.4 27.0 2.6 4.3 5.6 4.7 10.1 3.6 3.5 4.4 3.0 3.8 1.2 2.6 6.1 2.5 3.8 4.7 0.8 1.9 4.8 3.3 3.8 3.1 1.9 2.8 1.1 7.3 2.3 4.3 0.8 1.3 6.0 2.2 2.5 3.1 1.9 1.6 0.0 3.6 1.7 1.9 2.5 2.1 1.0 1.7 1.2 4.9 1.6 1.6 1.1 3.3 0.5 1.2 0.7 1.1 1.2 13.2 15.0 19.5 23.9 13.3 6.3 15.6 11.3 20.1 17.1 50.6 66.2 20.2 37.2 47.3 37.1 20.0 33.1 30.8 42.1 26.2 92.3 5.0 5.0 4.0 27.7 50.9 21.9 23.3 3.5 3.3 40.1 42.6 67.1 35.2 17.4 19.1 48.1 36.2 45.9 38.0 38.0 57.8 45.5 7.2 12.9 31.6 7.5 14.4 31.8 3.3 48.6 32.3 42.8 5.2 7.8 52.2 11.3 20.8 9.3 9.3 PHF6 "BFLS, BORJ, CENP-31, KIAA1823, MGC14797" ENSG00000156531 "PHD finger protein 6" Q8IWS0 X 134373253-134428791 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Epilepsy, Hypotrichosis, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001023 Enhanced Supported Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA001023: AB_1079606" "unprognostic (2.38e-3)" "unprognostic (8.21e-2)" "unprognostic (1.99e-1)" "unprognostic (3.04e-3)" "unprognostic (6.03e-3)" "unprognostic (5.20e-3)" "prognostic unfavorable (3.38e-4)" "unprognostic (1.81e-1)" "unprognostic (4.85e-2)" "unprognostic (1.08e-1)" "prognostic unfavorable (9.96e-4)" "unprognostic (1.09e-1)" "unprognostic (5.96e-2)" "unprognostic (4.84e-2)" "unprognostic (7.45e-2)" "unprognostic (1.28e-1)" "unprognostic (1.29e-2)" 7.4 19.3 10.2 14.1 12.2 6.5 9.7 18.2 13.5 8.7 8.0 11.6 20.3 7.8 9.0 30.1 11.5 7.3 6.1 7.2 11.0 11.1 9.9 7.5 8.4 20.4 12.5 9.3 30.7 10.4 24.1 18.1 8.2 13.3 8.6 9.5 5.4 11.3 16.8 6.2 7.4 10.2 8.1 17.1 17.8 8.1 8.3 14.4 30.2 11.8 6.0 25.0 8.9 9.8 18.4 11.0 5.3 7.4 9.6 9.9 5.0 11.5 9.6 42.3 17.3 7.9 10.1 8.0 11.6 9.3 12.5 15.5 5.7 12.0 18.6 26.7 7.0 12.2 10.4 29.5 13.1 21.1 15.1 13.7 18.0 16.5 6.6 8.4 17.9 10.0 6.7 10.0 13.6 17.0 12.6 17.4 18.2 13.2 9.2 15.3 7.6 28.9 8.9 12.9 15.8 13.0 28.5 15.4 14.1 13.3 14.0 14.7 17.2 8.9 8.2 12.2 13.1 7.7 9.9 13.2 11.7 8.4 14.6 17.8 4.7 10.9 25.1 7.6 21.4 14.5 5.3 6.1 3.7 7.9 6.0 8.5 18.4 8.2 7.1 8.8 12.8 9.9 8.2 2.5 9.6 7.4 11.0 8.3 5.0 10.2 12.2 18.2 13.5 11.0 11.1 12.5 9.3 13.3 14.4 20.8 17.3 24.1 12.5 11.6 21.9 13.7 7.6 16.0 13.6 15.7 17.7 9.9 19.9 12.5 2.6 14.3 7.9 0.0 11.8 6.8 11.3 10.2 23.2 12.7 13.2 17.5 10.9 19.6 12.6 2.1 19.2 15.3 6.8 19.0 13.4 25.6 12.4 15.0 14.5 16.5 18.2 25.8 9.2 4.6 17.9 10.0 3.9 22.0 16.6 11.0 PHOX2B "NBPhox, Phox2b, PMX2B" ENSG00000109132 "Paired like homeobox 2b" Q99453 4 41744082-41748970 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "adrenal gland: 14.5;brain: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 99 "pons and medulla: 24.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 91 "SH-SY5Y: 53.6" "Region enriched" "Detected in single" 17 "pons and medulla: 5.9" "Region enriched" "Detected in single" 27 "pons and medulla: 2.0" "HPA074325, HPA074941" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "HPA074325: AB_2686678, HPA074941: AB_2732272" "unprognostic (1.01e-1)" "unprognostic (2.47e-1)" "unprognostic (5.27e-2)" 0.0 14.5 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.2 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 24.8 0.2 1.4 0.8 0.0 0.0 0.0 0.0 3.2 0.5 0.4 0.0 0.9 0.1 0.0 0.1 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 53.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 24.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PICALM "CALM, CLTH" ENSG00000073921 "Phosphatidylinositol binding clathrin assembly protein" Q13492 11 85957684-86069882 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Endocytosis "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 25.8" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019053, HPA019061" Enhanced Enhanced Vesicles NA NA 28000 Vesicles "HPA019053: AB_1855361, HPA019061: AB_1855362" "unprognostic (9.27e-3)" "unprognostic (7.29e-2)" "unprognostic (3.51e-1)" "unprognostic (6.83e-2)" "unprognostic (5.13e-2)" "unprognostic (1.93e-1)" "unprognostic (5.36e-3)" "unprognostic (9.02e-3)" "unprognostic (9.80e-2)" "unprognostic (6.27e-3)" "prognostic unfavorable (6.61e-4)" "unprognostic (4.31e-1)" "prognostic favorable (2.02e-6)" "unprognostic (1.26e-2)" "unprognostic (5.21e-3)" "unprognostic (2.52e-1)" "unprognostic (1.02e-1)" 72.9 24.2 35.6 43.1 51.4 37.1 51.3 30.2 39.7 38.7 35.9 60.0 27.7 39.6 41.6 26.0 41.3 31.5 48.1 41.4 43.7 34.2 63.9 53.8 45.1 35.2 52.0 33.5 38.2 29.7 70.6 23.8 76.7 50.7 29.9 32.0 26.7 31.8 37.0 35.5 35.0 45.3 49.9 70.7 49.5 30.7 22.9 55.1 31.0 30.8 28.5 34.8 44.0 49.2 2.1 7.1 25.8 8.5 3.9 5.3 3.1 29.2 13.9 22.1 15.5 33.9 35.7 41.7 37.7 48.9 29.8 26.3 54.9 39.9 22.8 38.9 60.3 31.2 24.2 23.1 27.5 43.1 6.7 8.3 64.7 19.0 17.4 34.6 15.2 29.2 30.9 29.8 55.8 46.5 50.6 32.2 15.4 41.4 18.8 56.0 17.2 17.7 14.0 12.1 47.2 7.9 12.3 33.4 16.2 57.8 24.7 13.4 10.9 46.2 15.6 12.4 29.0 21.2 12.3 34.9 55.1 19.2 64.9 30.0 6.7 17.7 20.9 13.0 12.0 37.1 3.6 8.5 4.2 3.9 7.2 3.3 2.1 2.9 5.3 7.1 1.4 3.0 2.7 25.8 3.9 7.2 2.5 3.8 3.1 35.6 51.4 30.2 39.7 43.7 34.2 52.0 33.5 50.7 55.1 32.8 63.6 25.0 34.9 103.0 19.5 39.7 33.1 32.1 25.0 68.0 11.8 37.0 26.6 54.1 51.3 74.2 54.8 70.0 32.6 99.4 46.2 37.9 47.3 49.9 74.3 38.1 24.1 74.3 121.6 73.1 33.1 105.1 57.3 46.9 31.2 20.9 64.7 45.6 41.1 65.4 16.5 77.6 77.5 17.1 12.0 84.3 34.6 40.6 25.2 76.6 PIK3CA PI3K ENSG00000121879 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha" P42336 3 179148114-179240093 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Phagocytosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009985, CAB017804" Approved Supported Mitochondria,Cytosol NA NA Cytosol Mitochondria "CAB017804: , HPA009985: AB_1079610" "unprognostic (1.81e-1)" "unprognostic (2.77e-1)" "unprognostic (2.18e-1)" "unprognostic (2.69e-3)" "unprognostic (6.49e-3)" "unprognostic (1.43e-1)" "unprognostic (2.65e-2)" "unprognostic (1.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.37e-1)" "unprognostic (2.57e-3)" "unprognostic (5.21e-2)" "unprognostic (4.50e-2)" "unprognostic (1.16e-2)" "unprognostic (2.48e-1)" "unprognostic (9.74e-2)" "unprognostic (3.82e-2)" 20.1 12.3 13.7 11.5 13.4 25.7 22.4 17.1 24.5 12.9 14.0 5.2 5.7 6.5 15.3 7.9 11.6 11.1 13.2 14.2 18.4 9.7 11.7 10.8 13.2 13.8 9.8 15.7 15.4 9.2 24.7 11.6 16.5 16.3 10.7 8.9 7.2 10.9 10.9 15.2 12.0 10.5 12.8 14.4 16.2 10.6 9.3 9.8 29.6 11.0 7.3 13.9 15.1 15.7 6.2 2.6 7.8 3.8 2.4 5.0 1.1 14.6 5.0 8.0 7.4 19.0 22.2 5.9 9.4 12.7 9.3 14.7 4.3 10.9 13.4 16.1 11.2 13.2 6.0 6.6 8.1 13.5 22.4 5.8 18.4 5.5 3.8 9.1 10.3 10.5 14.0 8.6 10.2 11.7 10.4 13.3 9.7 9.1 15.0 13.3 5.8 7.9 9.3 6.4 7.3 6.8 12.0 8.1 16.1 7.3 9.0 4.5 7.7 10.2 9.1 12.2 7.3 15.2 8.9 14.0 8.7 5.7 13.7 9.3 7.3 10.3 24.1 7.9 7.8 5.1 2.1 3.8 1.6 5.0 2.9 3.9 5.8 4.2 2.8 2.2 6.2 4.6 3.8 7.8 2.4 3.0 2.6 4.1 1.1 13.7 13.4 17.1 24.5 18.4 9.7 9.8 15.7 16.3 9.8 29.8 23.2 13.7 15.2 13.1 26.3 15.4 7.6 18.7 17.0 7.0 29.5 8.1 1.7 9.8 1.7 21.4 4.9 0.0 11.9 5.0 18.3 27.3 30.1 17.4 9.5 36.5 2.4 29.4 21.2 1.6 30.2 16.4 13.5 16.2 9.6 15.6 13.1 12.7 37.1 11.2 26.2 25.8 22.1 9.6 7.6 13.0 7.3 14.0 9.2 27.6 PIK3CB PIK3C1 ENSG00000051382 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" P42338 3 138652699-138834938 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Autophagy, Cell adhesion, Endocytosis" "Kinase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HEL: 42.0;HMC-1: 66.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB031938, HPA042288, HPA064207" Approved Supported Nucleoplasm,Nucleoli,Vesicles,Midbody Yes No Nucleoplasm "Nucleoli, Vesicles, Midbody" "CAB031938: AB_2165408, HPA042288: , HPA064207: AB_2685212" "unprognostic (4.89e-2)" "unprognostic (1.42e-2)" "unprognostic (5.97e-2)" "unprognostic (7.85e-2)" "unprognostic (4.89e-2)" "unprognostic (6.01e-2)" "prognostic unfavorable (6.42e-4)" "unprognostic (3.98e-2)" "unprognostic (1.35e-1)" "unprognostic (2.28e-1)" "prognostic unfavorable (3.99e-5)" "unprognostic (2.15e-1)" "unprognostic (6.18e-3)" "unprognostic (9.33e-2)" "unprognostic (7.82e-2)" "unprognostic (2.79e-1)" "unprognostic (4.59e-2)" 12.5 9.9 10.6 9.7 20.6 17.4 11.5 29.9 25.0 12.4 14.6 11.9 11.7 13.7 9.6 6.9 15.2 10.9 8.7 12.7 12.2 14.2 22.6 9.3 9.5 9.1 11.9 15.2 8.8 20.3 20.2 10.9 18.1 24.1 13.4 15.7 12.2 14.9 15.9 33.4 19.6 16.4 8.3 12.5 9.9 11.0 6.4 10.7 14.4 37.4 7.1 11.9 13.4 11.0 4.6 9.1 11.3 7.8 1.3 6.5 2.6 23.0 10.0 4.3 3.6 3.9 5.3 29.3 5.4 5.2 5.5 5.9 10.7 8.8 9.3 14.8 5.3 10.6 9.9 5.6 8.6 9.9 11.8 6.3 42.0 6.8 6.4 4.0 10.2 66.6 4.5 6.6 3.8 7.8 9.8 8.3 4.5 16.0 6.9 6.9 10.6 5.9 7.2 6.2 17.0 9.4 4.3 4.5 6.6 8.5 12.8 3.7 2.7 15.0 6.5 19.3 13.2 16.3 24.4 8.7 3.5 4.5 7.7 7.6 11.7 7.6 8.5 8.6 9.9 4.9 7.0 7.8 11.3 4.0 4.5 2.7 4.6 5.2 3.0 9.1 4.1 6.5 4.4 10.0 1.3 4.3 1.4 2.2 2.6 10.6 20.6 29.9 25.0 12.2 14.2 11.9 15.2 24.1 10.7 8.9 14.7 4.7 12.9 16.9 15.4 30.2 12.7 14.7 21.6 17.4 23.6 29.1 5.0 9.4 0.9 8.5 21.3 0.0 16.5 46.3 6.5 23.0 13.9 15.8 13.4 20.6 15.6 11.6 28.8 1.1 3.4 19.7 6.8 14.4 14.9 8.2 15.2 21.8 6.3 18.9 17.9 6.5 6.1 10.7 14.9 20.5 40.0 6.1 12.7 15.3 PIK3R1 "GRB1, p85, p85-ALPHA" ENSG00000145675 "Phosphoinositide-3-kinase regulatory subunit 1" P27986 5 68215720-68301821 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction, Protein transport, Stress response, Transport" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cardiomyocytes: 241.2;Leydig cells: 159.3;Muller glia cells: 180.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 73.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001216, CAB004268" Approved Supported Cytosol NA NA Cytosol "CAB004268: AB_628126, HPA001216: AB_1079612" "unprognostic (5.74e-2)" "unprognostic (6.58e-2)" "unprognostic (2.01e-1)" "unprognostic (1.31e-2)" "unprognostic (1.18e-1)" "unprognostic (1.33e-2)" "prognostic favorable (8.09e-4)" "unprognostic (3.78e-3)" "unprognostic (1.78e-1)" "unprognostic (2.71e-1)" "unprognostic (6.10e-2)" "unprognostic (1.32e-1)" "unprognostic (4.59e-3)" "unprognostic (5.66e-3)" "unprognostic (1.27e-1)" "unprognostic (5.92e-2)" "unprognostic (1.54e-1)" 26.2 13.4 26.0 13.0 24.3 51.6 42.3 15.3 50.3 27.1 20.3 12.8 12.8 8.1 41.3 22.1 20.8 33.0 18.1 33.9 24.0 13.4 17.9 46.5 16.3 12.0 22.0 40.8 25.8 6.8 22.3 9.4 15.0 18.2 15.2 10.8 8.7 54.6 16.2 48.9 19.1 16.1 36.3 17.6 18.8 13.1 7.6 23.6 16.2 12.8 8.5 10.8 25.2 24.4 2.2 2.1 10.6 4.1 8.2 14.8 4.0 1.1 2.1 6.4 19.1 73.1 21.4 2.8 6.1 2.8 2.3 2.5 5.3 1.9 5.6 10.5 8.4 1.1 2.6 1.8 12.4 3.0 23.5 2.3 6.7 1.8 4.3 24.6 6.9 5.4 22.6 28.2 4.3 22.9 1.1 3.1 6.6 1.0 4.3 2.1 2.9 16.7 2.7 1.8 3.8 1.1 15.8 3.0 4.4 3.1 12.6 1.2 5.8 1.0 1.6 4.0 3.9 9.2 4.9 3.7 2.8 2.8 4.6 3.8 4.8 7.1 6.5 3.0 8.6 2.0 10.6 1.2 5.9 9.2 1.7 12.7 1.2 11.5 8.4 2.1 2.2 14.8 10.8 1.5 8.2 4.1 0.9 8.5 4.0 26.0 24.3 15.3 50.3 24.0 13.4 22.0 40.8 18.2 23.6 47.6 25.6 14.3 14.9 12.8 45.1 241.2 28.1 12.0 27.3 5.2 23.6 12.3 61.3 13.7 9.4 23.1 20.0 0.0 8.1 13.0 36.6 8.2 66.0 142.1 25.9 46.1 9.2 39.9 52.0 6.8 159.3 29.5 32.1 21.6 24.8 180.6 9.7 19.3 114.9 31.6 85.9 19.4 26.7 0.9 2.6 8.9 8.4 132.3 21.7 6.0 PIM1 PIM ENSG00000137193 "Pim-1 proto-oncogene, serine/threonine kinase" P11309 6 37170203-37175426 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Suprabasal keratinocytes: 199.7;Urothelial cells: 399.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 64.6" "Group enriched" "Detected in all" 5 "granulocytes: 64.6;T-cells: 19.0" "Cell line enhanced" "Detected in many" "HEL: 35.7;HMC-1: 66.4;K-562: 30.6;U-698: 119.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003941, CAB017040" Uncertain Supported Nucleoli,Cytosol NA NA Cytosol Nucleoli "CAB017040: , HPA003941: AB_1079618" "unprognostic (1.25e-2)" "unprognostic (4.77e-1)" "unprognostic (3.61e-2)" "prognostic unfavorable (9.73e-4)" "unprognostic (1.91e-2)" "unprognostic (1.06e-1)" "unprognostic (3.75e-1)" "unprognostic (4.64e-2)" "unprognostic (2.36e-1)" "unprognostic (1.10e-1)" "unprognostic (2.65e-2)" "unprognostic (7.32e-2)" "unprognostic (2.14e-3)" "unprognostic (8.16e-3)" "unprognostic (1.04e-1)" "unprognostic (5.26e-3)" "unprognostic (2.90e-1)" 39.3 5.4 7.4 18.5 8.9 80.9 20.1 8.1 9.9 23.0 17.9 4.7 4.2 17.9 15.4 9.8 56.3 21.6 24.7 20.8 8.2 3.7 7.5 24.5 14.5 35.7 7.4 2.2 20.0 9.6 2.0 5.6 28.7 12.7 15.6 8.8 6.9 12.8 4.5 26.5 31.3 26.1 31.6 10.7 21.4 12.1 6.8 7.6 15.0 7.2 20.1 28.8 32.6 31.2 1.7 1.4 64.6 1.7 8.4 19.0 8.5 3.0 1.3 2.0 1.1 4.7 2.5 24.0 1.1 3.4 2.3 3.6 4.6 4.3 6.2 1.7 1.3 5.1 3.6 2.1 3.3 2.1 28.1 1.4 35.7 1.3 5.9 4.8 0.6 66.4 8.5 4.1 2.1 1.4 2.5 0.6 1.5 30.6 10.0 0.3 0.8 1.9 3.2 3.8 5.7 2.0 4.8 3.7 7.3 0.6 18.8 10.0 2.0 2.4 0.3 0.6 4.9 0.5 1.0 1.2 1.3 4.0 6.0 1.3 4.7 2.5 119.4 0.5 9.0 1.3 64.6 1.7 24.4 14.7 1.6 19.0 1.7 13.1 12.9 1.4 1.3 11.9 9.0 14.1 8.4 0.9 0.4 9.4 8.5 7.4 8.9 8.1 9.9 8.2 3.7 7.4 2.2 12.7 7.6 20.8 23.1 27.2 134.9 113.6 4.2 17.3 12.7 4.0 22.7 8.7 0.0 27.3 5.0 30.7 3.8 14.3 33.2 46.7 15.5 92.9 73.9 69.5 46.4 27.1 44.8 14.3 35.6 9.2 40.0 10.4 7.5 45.8 42.2 101.0 11.9 4.3 37.7 17.5 2.8 13.0 0.9 0.0 57.5 3.3 34.5 199.7 67.5 126.4 6.6 399.5 PLAG1 ZNF912 ENSG00000181690 "PLAG1 zinc finger" Q6DJT9 8 56160904-56211324 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Bipolar cells: 24.0;Horizontal cells: 30.2;Rod photoreceptor cells: 28.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 13.1;ASC TERT1: 17.5;HSkMC: 12.3;hTERT-HME1: 12.8" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" HPA072290 Supported "Nucleoplasm,Nuclear speckles,Centrosome,Cytosol" NA NA "Nucleoplasm, Nuclear speckles" "Centrosome, Cytosol" "HPA072290: AB_2686508" "unprognostic (1.89e-2)" "unprognostic (1.93e-2)" "unprognostic (1.22e-3)" "unprognostic (1.63e-4)" "unprognostic (6.81e-2)" "unprognostic (1.07e-1)" "unprognostic (5.63e-3)" "unprognostic (8.56e-2)" "unprognostic (1.18e-1)" "unprognostic (7.99e-2)" "unprognostic (3.42e-2)" "unprognostic (1.97e-1)" "unprognostic (1.32e-3)" "unprognostic (2.83e-2)" "unprognostic (3.94e-1)" "unprognostic (1.21e-2)" "unprognostic (6.14e-2)" 1.9 3.6 2.4 3.5 2.9 2.1 2.5 11.0 2.7 7.6 3.8 4.1 9.0 3.4 3.4 9.8 2.0 7.5 2.1 6.8 1.9 1.8 3.7 1.2 4.6 6.7 4.8 2.1 11.6 2.2 2.1 17.8 8.0 4.6 5.1 1.6 7.9 7.5 9.2 1.4 3.4 5.5 2.5 6.3 6.2 3.0 5.2 4.5 11.7 3.5 1.5 5.2 4.8 7.0 3.5 0.2 1.1 0.5 0.7 4.6 1.0 1.5 0.0 9.6 0.1 13.1 17.5 3.0 4.3 5.5 2.0 0.9 0.6 5.0 0.2 4.2 2.3 0.5 0.3 2.7 5.7 2.1 0.1 5.9 6.1 0.5 1.4 2.8 2.0 1.9 12.3 3.2 1.1 12.8 5.6 3.8 4.3 2.6 0.1 4.2 0.0 0.5 3.6 2.8 0.4 1.4 4.7 0.7 3.7 2.6 0.5 0.1 0.0 0.1 0.0 0.3 6.8 0.1 1.9 5.7 3.0 3.8 4.8 1.0 1.5 1.1 2.3 3.4 0.7 0.8 1.1 0.1 1.1 0.3 0.1 0.2 3.5 1.0 0.6 0.1 2.0 4.6 4.3 1.0 0.7 0.5 0.2 0.2 1.0 2.4 2.9 11.0 2.7 1.9 1.8 4.8 2.1 4.6 4.5 6.0 2.7 6.2 2.3 0.9 24.0 9.4 2.5 1.4 2.3 5.2 23.6 6.8 0.0 0.6 4.6 3.3 2.1 0.0 1.2 3.6 3.7 2.8 1.1 0.5 4.5 30.2 5.2 19.6 1.3 4.5 14.1 1.9 15.1 0.0 3.0 18.4 1.2 0.9 9.6 0.5 28.0 0.0 0.7 4.3 6.8 0.6 5.9 1.0 1.6 5.3 PLCG1 "NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1" ENSG00000124181 "Phospholipase C gamma 1" P19174 20 41136960-41196801 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction, Lipid degradation, Lipid metabolism" "Hydrolase, Transducer" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "gdT-cell: 5.9;MAIT T-cell: 8.0;memory CD4 T-cell: 5.2;memory CD8 T-cell: 4.9;naive CD4 T-cell: 5.7;naive CD8 T-cell: 5.4;NK-cell: 4.0;T-reg: 4.4" "Group enriched" "Detected in many" 8 "NK-cells: 4.0;T-cells: 8.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004277, HPA036681, HPA036682" Approved Enhanced Cytosol NA NA Cytosol "CAB004277: AB_628119, HPA036681: AB_2675245, HPA036682: AB_2675246" "unprognostic (2.77e-1)" "unprognostic (1.35e-1)" "unprognostic (1.65e-1)" "unprognostic (4.31e-2)" "unprognostic (5.82e-2)" "unprognostic (2.09e-2)" "unprognostic (4.45e-3)" "unprognostic (1.25e-2)" "unprognostic (2.29e-2)" "unprognostic (1.16e-1)" "prognostic favorable (4.72e-4)" "unprognostic (3.32e-1)" "unprognostic (2.73e-3)" "unprognostic (1.82e-1)" "unprognostic (2.65e-1)" "unprognostic (9.27e-2)" "unprognostic (2.79e-2)" 20.2 15.1 25.1 20.9 22.1 8.3 34.9 52.6 26.8 19.9 13.9 23.4 12.5 16.5 27.6 13.9 13.5 17.0 18.7 20.9 25.4 13.6 15.3 6.8 19.3 30.7 18.5 20.5 28.7 9.1 16.9 14.2 22.2 18.7 18.4 13.2 20.0 13.2 20.6 13.4 22.3 17.1 22.2 15.4 20.1 12.4 19.9 23.9 48.1 28.5 11.9 21.9 17.1 21.1 0.7 0.0 0.0 0.0 4.0 8.0 3.3 5.4 6.9 33.2 24.3 13.3 9.3 10.6 8.9 11.5 18.0 15.3 16.6 1.8 12.1 11.0 9.7 18.9 10.1 14.4 16.0 10.5 3.4 7.7 0.8 11.5 19.5 10.1 4.7 3.3 11.9 9.0 13.3 10.4 16.3 20.0 26.0 9.0 8.0 16.2 40.4 29.2 3.7 12.3 7.0 12.7 23.3 24.2 5.9 9.9 10.0 11.8 22.5 16.0 7.5 16.0 19.4 8.7 5.6 21.6 43.1 14.0 13.7 10.8 8.9 3.9 10.0 10.2 5.2 17.8 0.0 0.0 0.0 5.9 0.0 8.0 0.3 5.2 4.9 0.0 0.7 5.7 5.4 0.0 4.0 0.0 0.0 4.4 3.3 25.1 22.1 52.6 26.8 25.4 13.6 18.5 20.5 18.7 23.9 14.9 6.5 0.8 1.8 4.9 3.7 9.2 0.0 1.4 3.4 3.5 9.8 1.3 0.0 2.7 5.1 15.8 6.4 0.0 1.4 1.6 6.1 1.9 1.1 2.5 3.2 3.2 1.7 13.5 2.2 5.3 14.1 1.7 3.3 1.0 9.8 7.2 2.8 3.7 17.3 2.4 4.6 12.9 5.1 11.6 11.5 6.0 0.7 6.9 5.1 0.9 PML "MYL, RNF71, TRIM19" ENSG00000140464 "Promyelocytic leukemia" P29590 15 73994673-74047812 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Antiviral defense, Apoptosis, Biological rhythms, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008312, CAB010194, CAB016304" Supported Enhanced "Nuclear bodies" NA NA "Nuclear bodies" "CAB010194: AB_2166848, CAB016304: AB_628162, HPA008312: AB_1079643" "prognostic favorable (3.24e-4)" "unprognostic (4.83e-2)" "unprognostic (5.76e-2)" "unprognostic (1.58e-3)" "unprognostic (7.53e-3)" "unprognostic (1.58e-1)" "unprognostic (2.35e-2)" "unprognostic (5.30e-3)" "unprognostic (4.54e-3)" "unprognostic (1.15e-1)" "prognostic unfavorable (3.29e-4)" "unprognostic (2.67e-2)" "prognostic unfavorable (6.27e-8)" "unprognostic (1.58e-2)" "unprognostic (4.17e-2)" "unprognostic (1.02e-1)" "unprognostic (8.99e-2)" 46.2 15.4 13.5 29.9 13.0 30.0 50.0 11.4 17.2 24.7 21.9 8.3 22.1 16.9 29.4 22.1 19.3 23.0 25.6 17.6 10.7 7.5 20.5 12.9 37.2 27.3 11.9 12.4 21.2 11.0 9.6 15.0 22.4 16.1 21.2 8.7 14.6 38.0 27.7 18.7 24.2 19.6 20.1 14.3 25.9 21.4 8.7 13.1 25.3 25.9 23.3 23.0 20.7 35.6 11.8 12.9 19.1 18.2 12.7 13.2 7.8 13.8 5.3 4.6 4.5 13.3 18.8 16.0 7.2 12.9 22.4 26.0 5.5 25.2 6.2 25.5 12.9 21.5 25.7 6.3 14.5 3.2 21.8 9.7 13.5 8.3 6.0 15.4 12.8 12.4 35.3 10.5 15.1 7.9 16.6 15.6 10.3 11.3 11.2 13.2 6.5 10.4 20.0 5.0 2.9 9.6 8.1 5.6 11.6 25.1 23.2 4.0 4.4 11.5 6.4 17.2 4.3 5.0 10.7 25.9 22.7 6.2 11.3 14.4 11.7 7.3 3.0 15.7 16.3 7.3 5.4 12.7 19.1 12.4 18.0 9.6 11.8 9.9 13.2 12.9 9.8 8.1 8.2 11.0 12.7 18.2 8.3 12.9 7.8 13.5 13.0 11.4 17.2 10.7 7.5 11.9 12.4 16.1 13.1 14.9 13.5 14.1 13.0 20.4 7.6 8.9 7.6 8.1 5.7 5.2 2.0 7.9 6.6 21.2 3.3 33.9 11.5 0.0 16.4 12.5 16.8 16.3 11.5 8.9 25.8 7.9 13.7 28.3 18.0 3.6 25.6 16.2 6.8 25.2 12.1 10.3 42.2 9.3 22.6 11.4 5.2 38.8 18.4 1.1 3.6 17.1 4.1 15.7 10.8 22.2 POLD1 "CDC2, POLD" ENSG00000062822 "DNA polymerase delta 1, catalytic subunit" P28340 19 50384204-50418016 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA excision, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Exonuclease, Hydrolase, Nuclease, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 8 "Paneth cells: 38.7;Spermatogonia: 26.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004375, HPA046524" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB004375: AB_675487, HPA046524: AB_2679684" "unprognostic (2.45e-1)" "unprognostic (7.02e-3)" "unprognostic (1.59e-1)" "unprognostic (4.35e-2)" "unprognostic (2.55e-1)" "unprognostic (1.85e-2)" "prognostic unfavorable (2.87e-6)" "unprognostic (4.12e-2)" "unprognostic (1.16e-2)" "unprognostic (2.83e-1)" "unprognostic (5.08e-1)" "unprognostic (3.92e-3)" "unprognostic (4.01e-3)" "unprognostic (1.28e-2)" "unprognostic (1.61e-1)" "unprognostic (2.89e-1)" "unprognostic (3.70e-2)" 7.9 5.7 5.4 18.3 9.9 31.6 6.6 9.4 5.4 8.2 10.0 6.1 5.9 6.8 9.5 7.2 11.3 6.9 5.2 5.5 4.4 3.2 7.6 9.3 10.9 15.7 7.0 3.6 8.2 8.4 5.2 5.1 10.9 6.7 6.3 5.2 4.9 8.1 5.4 7.2 13.1 9.9 6.2 7.7 14.1 6.5 13.2 6.5 27.4 12.1 8.1 14.2 5.9 7.8 9.3 10.5 2.1 8.5 5.4 7.3 5.6 18.2 25.2 13.8 7.9 1.8 1.5 14.2 11.4 5.0 14.1 17.9 13.7 14.5 26.2 6.4 3.4 6.3 15.0 16.3 12.4 4.8 22.1 43.8 22.8 24.4 18.0 1.6 21.7 20.1 2.9 3.8 12.7 3.8 3.0 7.2 22.0 24.5 20.4 5.8 12.3 33.5 33.9 16.3 11.8 18.3 33.3 23.2 23.0 4.5 17.5 14.4 13.0 11.3 13.9 2.6 5.2 7.6 20.6 5.6 7.1 23.2 7.7 20.0 19.2 31.6 28.0 7.8 24.5 7.0 1.6 6.2 2.1 7.3 7.8 6.2 7.8 6.5 5.9 5.7 9.3 6.5 5.9 1.1 5.4 8.5 10.5 4.5 5.6 5.4 9.9 9.4 5.4 4.4 3.2 7.0 3.6 6.7 6.5 3.0 3.8 3.7 1.7 5.7 3.3 2.8 2.5 2.7 3.4 3.5 5.9 12.2 0.0 4.4 1.7 2.6 4.6 0.0 3.4 11.7 4.1 1.3 0.0 2.1 13.6 0.0 6.9 1.8 6.3 1.1 2.8 5.0 5.0 3.6 5.3 1.2 3.9 38.7 4.9 2.2 4.1 0.0 2.1 10.9 26.7 4.5 6.4 4.3 10.0 0.6 POLE POLE1 ENSG00000177084 "DNA polymerase epsilon, catalytic subunit" Q07864 12 132623753-132687365 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Sertoli cells: 25.8;Spermatocytes: 25.4" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebellum: 34.8" "Cell type enhanced" "Detected in some" "NK-cell: 4.8" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected" "Not detected" "HPA058210, HPA067385" Supported "Nucleoplasm,Plasma membrane" NA NA Nucleoplasm "Plasma membrane" "HPA058210: AB_2683639, HPA067385: AB_2685830" "unprognostic (1.60e-1)" "unprognostic (1.77e-3)" "unprognostic (2.00e-1)" "unprognostic (9.17e-2)" "unprognostic (1.68e-1)" "unprognostic (2.01e-2)" "unprognostic (3.96e-3)" "unprognostic (2.23e-1)" "prognostic unfavorable (1.44e-4)" "unprognostic (7.12e-2)" "unprognostic (2.21e-1)" "unprognostic (1.67e-1)" "prognostic unfavorable (3.19e-8)" "unprognostic (8.60e-2)" "unprognostic (3.18e-1)" "unprognostic (1.28e-1)" "unprognostic (9.95e-2)" 6.1 3.4 6.7 10.2 4.4 29.3 6.2 34.8 14.4 7.0 6.6 2.0 7.6 7.3 6.1 4.4 7.5 6.2 6.5 4.7 5.6 1.6 3.8 8.6 5.4 8.2 3.3 4.3 8.7 6.8 3.6 3.1 6.5 5.1 6.8 7.7 4.3 8.7 7.4 8.9 17.9 8.5 6.8 3.7 16.7 7.8 25.6 4.4 29.8 5.1 6.0 10.3 6.7 8.7 0.5 1.7 0.8 0.8 4.8 0.7 0.5 11.2 15.0 22.3 10.6 4.7 3.7 19.9 11.5 5.2 13.8 10.1 18.2 6.7 12.9 4.9 6.2 5.3 15.7 15.5 7.8 8.4 6.0 19.6 20.4 19.4 8.9 0.9 15.9 11.7 2.8 3.1 14.4 4.7 3.8 4.8 16.6 22.8 7.3 6.8 18.2 26.1 29.2 17.3 5.3 9.0 21.7 12.6 5.8 4.4 18.4 18.6 10.7 13.4 11.0 2.5 11.2 16.2 9.9 4.4 12.6 12.9 9.5 11.6 9.7 6.5 20.3 6.9 22.0 8.9 0.0 0.3 0.8 0.5 0.1 0.7 0.5 0.3 0.4 0.7 0.3 0.5 0.3 0.1 4.8 0.8 1.7 0.6 0.5 6.7 4.4 34.8 14.4 5.6 1.6 3.3 4.3 5.1 4.4 0.0 7.9 4.5 3.5 5.0 8.1 5.6 0.0 2.7 0.0 1.8 0.0 6.2 0.0 2.1 6.5 3.0 4.7 0.0 2.7 9.0 4.7 3.7 2.3 8.9 10.4 0.0 6.9 12.9 7.9 7.0 6.4 3.2 5.0 1.0 6.7 3.7 2.4 5.8 3.2 0.8 5.0 25.8 3.3 25.4 7.9 6.8 3.3 5.7 9.8 2.5 POLQ POLH ENSG00000051341 "DNA polymerase theta" O75417 3 121431427-121546641 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 9.5;lymphoid tissue: 21.4" "Cell type enhanced" "Detected in some" 10 "Club cells: 3.4;Extravillous trophoblasts: 2.8;Spermatocytes: 7.0;Spermatogonia: 3.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.6" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 5.2" HPA053359 Supported "Nucleoplasm,Golgi apparatus,Cytosol" NA Yes Nucleoplasm "Golgi apparatus, Cytosol" "HPA053359: " "unprognostic (1.59e-1)" "unprognostic (4.18e-2)" "unprognostic (2.66e-2)" "prognostic unfavorable (5.46e-5)" "unprognostic (2.70e-1)" "unprognostic (6.23e-3)" "unprognostic (3.09e-5)" "unprognostic (8.55e-3)" "unprognostic (1.09e-4)" "unprognostic (2.86e-1)" "unprognostic (5.59e-5)" "unprognostic (2.06e-3)" "unprognostic (0.00e+0)" "prognostic favorable (1.04e-4)" "unprognostic (1.76e-1)" "unprognostic (6.01e-2)" "unprognostic (5.76e-2)" 0.5 0.8 0.2 8.2 0.7 9.5 0.6 0.6 0.4 0.9 3.5 0.2 0.8 2.0 0.9 0.6 6.0 0.3 0.4 0.8 0.3 0.2 0.4 0.6 0.9 4.7 0.3 0.0 0.4 0.4 0.0 0.2 2.8 0.3 0.4 3.7 0.1 1.1 0.8 1.2 2.4 3.9 0.5 0.4 2.6 1.1 5.8 0.6 21.4 0.3 5.6 7.5 0.6 1.7 0.5 1.1 1.6 0.4 0.0 0.4 0.0 13.5 9.2 7.9 5.6 0.7 0.9 7.2 6.4 2.5 7.6 10.2 7.3 5.0 16.1 2.9 3.5 9.2 10.7 9.3 4.1 12.9 4.7 5.1 10.3 5.7 4.5 0.0 11.1 9.5 0.1 0.3 6.9 4.3 1.3 3.7 6.0 6.8 12.3 7.9 5.2 10.0 6.5 7.5 4.1 4.5 8.5 9.5 5.7 2.4 7.8 4.3 3.9 7.4 4.0 2.6 7.2 3.7 11.1 2.9 6.7 8.8 2.6 8.3 6.2 5.0 16.7 3.2 8.3 4.9 1.6 0.2 0.0 0.3 0.2 0.0 0.3 0.4 0.3 0.4 0.5 0.0 0.2 0.0 0.0 0.4 1.1 0.1 0.0 0.2 0.7 0.6 0.4 0.3 0.2 0.3 0.0 0.3 0.6 0.0 0.3 0.0 0.4 0.8 0.3 1.4 0.0 1.4 3.4 0.0 0.0 0.9 0.0 0.1 0.3 0.0 0.4 0.0 0.0 2.8 0.7 0.3 0.0 0.0 1.9 0.0 0.0 0.0 0.6 0.2 0.3 1.5 0.0 1.0 0.4 0.5 0.3 0.3 0.0 0.1 0.1 0.0 0.5 7.0 3.3 0.1 0.2 0.9 0.9 0.9 POT1 "DKFZp586D211, hPot1" ENSG00000128513 "Protection of telomeres 1" Q9NUX5 7 124822386-124929983 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Spermatocytes: 27.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" HPA068538 Supported Nucleoplasm NA NA Nucleoplasm "HPA068538: AB_2686001" "unprognostic (1.39e-3)" "unprognostic (1.34e-1)" "unprognostic (2.04e-1)" "unprognostic (5.71e-2)" "unprognostic (1.69e-1)" "unprognostic (1.49e-1)" "unprognostic (1.38e-3)" "unprognostic (7.88e-2)" "unprognostic (2.26e-2)" "unprognostic (1.51e-1)" "unprognostic (2.48e-2)" "unprognostic (9.89e-2)" "unprognostic (1.42e-1)" "unprognostic (2.92e-1)" "unprognostic (1.75e-2)" "unprognostic (4.77e-3)" "unprognostic (7.42e-2)" 12.0 13.2 11.1 8.3 14.3 6.2 15.8 13.0 16.6 13.4 10.1 16.0 12.0 7.8 17.0 13.4 10.1 12.6 11.3 11.2 15.5 11.3 16.6 14.7 9.9 14.0 15.0 12.4 15.7 9.4 15.5 29.6 11.1 16.4 12.0 9.7 12.2 8.7 10.1 9.5 8.0 8.8 13.1 16.4 13.6 9.5 15.8 14.8 17.9 21.5 9.3 12.9 13.6 9.8 4.8 3.6 2.7 3.3 5.2 7.4 2.7 12.9 5.5 8.2 6.3 5.5 10.3 5.8 7.3 8.6 8.3 12.6 4.5 13.1 11.7 5.9 5.5 11.6 5.1 9.0 7.4 13.2 15.1 13.1 11.4 5.5 4.8 12.4 11.0 6.8 7.3 8.9 7.7 12.1 9.6 10.5 4.8 20.2 28.1 9.3 2.5 14.6 11.6 9.3 8.4 9.1 8.7 8.6 16.7 7.2 7.2 8.8 11.7 7.4 9.9 10.3 13.2 4.4 10.6 3.4 10.0 4.4 12.1 9.6 15.6 15.9 16.6 10.1 12.6 12.4 0.9 3.1 2.7 4.3 3.3 6.3 4.8 4.5 5.0 3.1 3.4 7.4 5.5 0.7 5.2 3.0 3.6 4.4 2.7 11.1 14.3 13.0 16.6 15.5 11.3 15.0 12.4 16.4 14.8 6.0 5.5 4.2 5.9 4.0 7.0 8.2 7.6 2.7 2.3 12.2 9.8 5.8 16.6 4.2 13.5 4.3 0.8 0.0 3.9 6.8 6.0 3.8 3.5 10.4 5.6 7.9 8.6 6.2 10.0 6.8 8.1 6.1 15.1 4.6 3.2 12.6 3.0 0.0 4.2 8.6 9.3 0.0 8.2 27.5 12.0 2.3 3.8 6.2 4.0 1.8 POU2AF1 "BOB1, OBF1" ENSG00000110777 "POU class 2 associating factor 1" Q16633 11 111352252-111455630 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 21.2;lymphoid tissue: 84.0" "Cell type enhanced" "Detected in many" 13 "B-cells: 67.0;Ciliated cells: 73.6;Erythroid cells: 46.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 11 "memory B-cell: 19.9;naive B-cell: 14.2" "Lineage enriched" "Detected in many" 13 "B-cells: 19.9" "Cell line enhanced" "Detected in some" "Daudi: 46.5;Karpas-707: 53.2;U-266/70: 51.9;U-266/84: 23.4;U-698: 95.5" "Not detected" "Not detected" "Not detected" "Not detected" CAB011193 Enhanced NA NA "CAB011193: AB_532299" "prognostic favorable (1.68e-4)" "prognostic favorable (1.63e-4)" "unprognostic (1.04e-2)" "unprognostic (5.50e-3)" "unprognostic (1.88e-1)" "prognostic favorable (3.59e-4)" "unprognostic (2.09e-1)" "unprognostic (3.63e-3)" "unprognostic (7.15e-2)" "unprognostic (2.52e-2)" "unprognostic (1.34e-1)" "unprognostic (4.81e-2)" "unprognostic (8.51e-8)" "unprognostic (2.35e-1)" "unprognostic (3.90e-1)" "unprognostic (7.14e-3)" "unprognostic (1.23e-1)" 0.9 0.5 0.6 62.7 0.7 2.0 1.4 0.4 0.6 1.9 7.8 1.8 0.0 6.7 0.7 0.3 8.7 1.1 1.4 0.5 0.8 0.7 2.1 1.0 2.6 42.6 1.0 0.5 1.2 0.5 0.0 0.4 0.5 1.2 1.3 4.1 1.2 8.4 0.9 0.4 0.4 21.2 0.0 1.4 74.2 12.2 1.0 0.9 5.0 1.7 1.4 84.0 5.0 1.4 19.9 0.1 1.5 0.2 0.3 0.7 0.6 0.1 0.1 0.0 0.0 0.8 0.8 0.1 0.0 0.0 0.0 0.0 0.1 0.0 46.5 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.5 1.7 53.2 0.0 0.1 0.2 0.2 0.0 0.0 0.0 9.9 0.1 12.5 0.0 0.1 0.1 0.9 0.1 0.0 0.0 0.4 0.2 0.1 0.4 0.0 0.4 0.0 0.0 51.9 23.4 95.5 0.0 0.1 0.0 1.5 0.1 0.3 0.1 0.1 0.1 19.9 0.2 0.1 0.0 14.2 0.2 0.1 0.9 0.3 0.2 0.1 0.7 0.6 0.6 0.7 0.4 0.6 0.8 0.7 1.0 0.5 1.2 0.9 0.0 5.1 67.0 6.0 0.2 0.0 1.6 12.7 73.6 18.2 0.0 0.0 0.0 0.0 0.0 6.0 0.0 0.0 46.7 5.0 0.0 0.6 1.1 0.0 0.0 0.1 0.0 2.9 1.3 0.3 7.9 0.3 0.2 8.5 0.0 0.1 0.0 0.4 0.2 0.4 0.3 0.0 0.0 0.0 5.9 0.7 0.0 0.0 0.5 0.0 7.3 POU5F1 "MGC22487, OCT3, Oct4, OTF3" ENSG00000204531 "POU class 5 homeobox 1" Q01860 6 31164337-31180731 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Cholangiocytes: 15.3;Collecting duct cells: 8.7;Enterocytes: 8.4;Pancreatic endocrine cells: 8.5" "Cancer enriched" "Detected in many" 34 "testis cancer: 355.9" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 12 "HAP1: 49.8;NTERA-2: 132.5;SuSa: 87.3" "CAB025600, CAB026380, HPA058267, CAB079773" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB025600: , CAB026380: , CAB079773: AB_2687916, HPA058267: AB_2683659" "unprognostic (3.25e-2)" "unprognostic (3.12e-1)" "unprognostic (2.87e-1)" "unprognostic (1.06e-2)" "unprognostic (3.02e-2)" "unprognostic (2.11e-2)" "unprognostic (2.62e-2)" "unprognostic (2.27e-1)" "unprognostic (2.59e-1)" "unprognostic (9.27e-2)" "unprognostic (2.27e-2)" "unprognostic (4.79e-2)" "unprognostic (1.19e-3)" "unprognostic (1.38e-1)" "unprognostic (1.35e-1)" "unprognostic (3.86e-2)" "prognostic favorable (2.04e-5)" 1.2 0.0 1.2 1.2 1.2 1.2 1.2 1.2 1.2 2.3 2.3 1.2 1.2 4.9 3.1 5.7 1.2 5.2 4.3 1.2 1.2 0.0 11.1 5.0 2.0 1.2 1.2 1.2 1.2 8.8 0.0 1.2 1.2 1.2 4.7 1.0 1.2 1.2 3.0 1.2 1.8 5.9 1.2 1.2 1.2 6.3 2.2 1.2 1.2 1.2 1.2 1.2 11.2 1.2 3.0 1.8 1.8 1.0 1.1 0.9 0.3 0.5 0.2 7.7 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.2 0.0 0.0 0.6 49.8 0.6 0.0 0.0 0.2 0.0 0.4 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 132.5 0.2 0.0 0.1 0.1 0.1 1.0 1.0 0.0 0.0 0.2 0.0 0.0 87.3 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.1 0.1 0.0 0.1 0.0 1.4 1.0 0.5 0.8 0.7 0.5 1.0 0.4 0.4 0.2 3.0 0.9 0.6 1.8 1.1 0.5 1.8 0.3 0.3 1.2 1.2 1.2 1.2 1.2 0.0 1.2 1.2 1.2 1.2 0.0 1.4 0.5 2.4 4.6 0.7 0.4 15.3 1.4 1.2 8.7 2.0 0.0 0.0 4.8 0.0 0.7 8.4 0.0 5.8 0.1 0.5 3.6 0.0 1.5 0.1 0.0 1.2 0.6 0.0 0.0 0.0 0.8 1.7 1.0 3.1 0.0 8.5 3.7 0.7 2.1 0.9 0.0 1.2 0.0 0.4 3.3 0.1 0.0 2.9 3.8 PPARG "NR1C3, PPARG1, PPARG2, PPARgamma" ENSG00000132170 "Peroxisome proliferator activated receptor gamma" P37231 3 12287368-12434356 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 97.6;breast: 102.1" "Cell type enhanced" "Detected in many" 11 "Cytotrophoblasts: 90.9;Extravillous trophoblasts: 187.1;Urothelial cells: 210.8" "Cancer enhanced" "Detected in all" "urothelial cancer: 33.5" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 1.8;intermediate monocyte: 2.3" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "ASC diff: 47.9;ASC TERT1: 27.3;BEWO: 56.5;CAPAN-2: 25.2;HSkMC: 28.1;RT4: 34.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB004282, HPA051239, HPA063663" Approved Enhanced Nucleoplasm,Vesicles NA NA "Nucleoplasm, Vesicles" "CAB004282: AB_628115, HPA051239: AB_2681400, HPA063663: AB_2685081" "unprognostic (7.35e-3)" "unprognostic (3.27e-2)" "unprognostic (4.05e-2)" "unprognostic (8.37e-2)" "unprognostic (2.41e-2)" "unprognostic (5.27e-3)" "prognostic unfavorable (3.41e-5)" "unprognostic (9.13e-2)" "unprognostic (2.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (2.77e-1)" "prognostic favorable (1.59e-8)" "unprognostic (1.51e-2)" "unprognostic (1.46e-1)" "unprognostic (9.68e-3)" "prognostic favorable (5.52e-5)" 97.6 1.6 1.9 17.1 1.2 0.7 102.1 1.5 1.3 3.1 24.9 0.8 2.1 7.5 3.5 2.2 2.8 2.4 8.7 12.5 1.4 0.9 6.7 5.9 24.8 11.4 1.1 0.9 6.7 1.2 2.8 0.3 26.8 0.9 10.4 13.9 1.1 5.8 1.5 5.0 2.7 9.6 7.4 1.2 7.0 11.9 3.5 0.6 0.9 6.2 4.3 2.1 30.2 14.1 0.0 0.4 0.0 2.3 0.0 0.7 0.3 9.7 8.7 0.0 0.0 47.9 27.3 56.5 0.9 10.5 1.3 0.5 1.8 25.2 0.0 0.0 0.9 17.1 4.0 3.5 0.1 0.2 23.5 4.9 0.0 1.9 2.3 12.8 0.0 0.0 28.1 2.3 2.4 9.1 5.0 0.1 0.2 0.0 0.0 2.0 2.5 0.0 0.1 0.1 22.7 25.2 0.0 0.0 0.0 7.2 34.5 0.0 0.2 4.1 1.5 0.5 1.7 0.0 7.8 7.9 1.8 2.6 1.0 0.0 0.0 0.0 0.0 0.8 0.1 0.2 0.0 1.8 0.0 0.0 2.3 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.3 1.9 1.2 1.5 1.3 1.4 0.9 1.1 0.9 0.9 0.6 3.0 7.4 0.0 33.7 0.9 0.5 5.2 2.5 2.7 3.4 5.2 0.0 90.9 1.7 0.1 2.6 17.7 47.1 0.0 0.6 187.1 4.3 35.2 9.2 3.8 46.3 0.0 8.1 19.6 14.5 0.8 3.7 8.6 3.3 2.8 20.5 0.5 10.2 42.1 0.0 11.3 0.0 12.9 5.7 7.9 21.8 1.0 74.4 1.3 16.6 210.8 PPFIBP1 "hSGT2, hSgt2p, L2, SGT2" ENSG00000110841 "PPFIA binding protein 1" Q86W92 12 27523431-27695564 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Cardiomyocytes: 154.9;Endothelial cells: 139.6;Ito cells: 144.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "naive B-cell: 7.0" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "SuSa: 53.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA001924 Uncertain Approved "Plasma membrane,Cytosol" NA NA "Plasma membrane, Cytosol" "HPA001924: AB_1079665" "unprognostic (5.27e-2)" "unprognostic (5.71e-2)" "unprognostic (3.10e-2)" "prognostic unfavorable (6.29e-4)" "unprognostic (4.73e-2)" "unprognostic (6.94e-2)" "unprognostic (1.47e-1)" "prognostic unfavorable (5.11e-4)" "unprognostic (7.33e-2)" "unprognostic (3.84e-2)" "prognostic unfavorable (2.56e-4)" "unprognostic (1.92e-2)" "prognostic favorable (5.11e-7)" "unprognostic (8.54e-2)" "unprognostic (7.54e-2)" "unprognostic (2.64e-1)" "unprognostic (4.09e-2)" 21.3 17.1 15.5 8.0 16.8 2.2 22.6 4.9 25.0 18.3 15.4 13.3 13.0 7.1 28.1 9.3 17.1 16.5 12.2 43.3 17.1 9.0 23.8 15.7 25.0 7.8 13.1 16.4 53.1 13.7 12.7 22.2 34.5 15.3 15.3 11.1 8.1 14.2 18.4 13.7 17.8 10.0 20.5 11.2 16.6 15.1 7.1 13.3 6.2 23.9 14.9 6.2 17.2 18.4 7.0 2.0 1.5 0.6 0.3 1.8 0.6 4.4 8.9 7.3 6.2 12.1 33.8 13.0 16.1 18.1 9.5 13.7 23.4 13.5 3.3 18.8 32.6 12.7 11.1 3.9 14.7 17.1 7.6 2.2 7.4 6.8 3.4 5.3 2.2 4.1 26.2 10.3 27.6 28.4 18.6 32.4 4.5 3.8 3.4 33.7 3.4 2.1 0.6 13.0 6.3 6.9 3.4 18.1 1.2 14.1 9.8 0.6 3.0 8.0 4.3 22.4 53.2 5.5 3.4 31.5 26.8 9.0 14.6 16.4 0.0 0.0 0.2 29.8 3.2 42.2 1.5 0.6 0.3 0.7 0.2 1.4 0.7 1.3 0.7 0.6 7.0 1.3 1.3 1.5 0.3 0.2 2.0 1.8 0.6 15.5 16.8 4.9 25.0 17.1 9.0 13.1 16.4 15.3 13.3 92.3 20.3 24.3 55.3 36.5 2.3 154.9 2.5 9.4 14.8 76.8 3.9 28.5 10.0 37.2 2.6 139.6 7.0 0.0 21.6 18.9 41.3 34.7 3.5 12.7 8.3 42.9 17.9 144.9 21.5 3.1 19.5 6.4 59.1 3.6 14.6 7.5 26.9 14.4 39.6 16.6 1.7 19.4 44.8 1.7 9.1 24.1 76.9 5.9 11.5 75.3 PPM1D "PP2C-DELTA, Wip1" ENSG00000170836 "Protein phosphatase, Mg2+/Mn2+ dependent 1D" O15297 17 60600183-60666280 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Cell cycle" "Hydrolase, Protein phosphatase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 51.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 26.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA022277, HPA061848" Approved Supported Nucleoplasm,Nucleoli NA NA Nucleoplasm Nucleoli "HPA022277: AB_1858839, HPA061848: " "unprognostic (1.48e-1)" "unprognostic (1.36e-2)" "prognostic favorable (3.52e-4)" "unprognostic (1.76e-1)" "unprognostic (1.02e-1)" "unprognostic (5.12e-2)" "prognostic unfavorable (4.27e-4)" "unprognostic (5.50e-2)" "unprognostic (1.70e-2)" "unprognostic (6.07e-2)" "unprognostic (2.52e-3)" "unprognostic (3.46e-2)" "unprognostic (1.95e-3)" "unprognostic (7.33e-2)" "unprognostic (1.58e-1)" "unprognostic (1.71e-2)" "unprognostic (1.98e-1)" 12.2 7.0 6.1 5.7 9.2 13.6 11.9 30.8 6.6 11.1 10.0 10.6 7.8 7.6 12.0 8.3 8.6 11.1 8.3 5.8 7.7 4.4 7.4 7.4 9.2 7.9 10.3 4.6 17.3 12.3 8.1 8.9 18.5 8.8 9.3 9.4 8.2 8.1 6.8 9.7 8.1 8.1 8.2 7.3 9.2 7.3 16.2 12.5 15.5 8.7 6.9 7.0 7.8 11.3 7.3 13.1 20.5 13.2 6.8 8.3 6.8 2.7 5.5 6.2 5.3 4.2 2.6 8.0 4.3 2.9 2.8 4.0 5.6 1.6 7.9 3.6 3.0 1.1 3.0 4.0 1.8 3.8 1.4 8.8 5.7 5.4 6.5 3.5 2.3 4.4 2.3 2.9 4.2 2.5 2.3 6.4 3.4 4.1 3.3 3.0 26.9 6.2 3.4 2.7 2.6 4.3 7.6 7.9 4.7 2.5 3.4 8.5 6.2 5.7 1.9 1.3 6.9 2.3 3.1 4.7 3.7 10.1 2.8 2.3 5.4 5.7 6.0 1.5 2.3 2.8 8.2 13.2 14.1 6.7 10.2 5.9 7.3 5.6 6.1 13.1 5.9 6.1 6.2 20.5 6.8 6.1 5.8 8.3 6.8 6.1 9.2 30.8 6.6 7.7 4.4 10.3 4.6 8.8 12.5 29.8 7.7 13.7 4.0 18.7 12.0 5.6 5.1 2.7 4.5 5.2 3.9 13.6 3.3 6.0 51.4 15.8 10.1 0.0 6.0 5.1 11.2 6.9 1.1 2.8 7.5 3.2 13.8 20.3 23.0 8.1 12.7 9.8 3.3 6.4 9.0 6.4 5.1 8.6 7.1 4.2 10.1 0.0 12.0 24.5 13.9 15.7 32.3 7.5 10.5 5.5 PPP2R1A "PP2A-Aalpha, PP2AA, PR65A" ENSG00000105568 "Protein phosphatase 2 scaffold subunit Aalpha" P30153 19 52190039-52229533 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Chromosome partition" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB018599 Approved Cytosol NA NA 3400000 Cytosol "CAB018599: AB_628178" "unprognostic (1.78e-1)" "unprognostic (2.31e-2)" "unprognostic (4.52e-2)" "unprognostic (2.87e-1)" "unprognostic (6.67e-2)" "unprognostic (7.82e-2)" "prognostic unfavorable (1.76e-4)" "prognostic unfavorable (2.50e-4)" "unprognostic (4.30e-2)" "unprognostic (3.06e-1)" "unprognostic (6.48e-3)" "unprognostic (8.28e-2)" "prognostic favorable (1.20e-4)" "unprognostic (1.97e-1)" "unprognostic (3.57e-2)" "unprognostic (1.70e-2)" "unprognostic (9.19e-2)" 25.3 57.3 60.7 20.5 71.0 18.0 21.4 47.5 82.1 29.6 31.2 26.6 21.5 33.4 26.4 37.9 37.7 47.0 39.9 74.7 70.2 44.8 31.0 29.3 20.0 27.5 44.0 50.9 45.8 24.3 37.8 29.5 24.6 51.0 31.0 29.8 31.0 24.3 35.6 50.6 33.5 25.3 34.5 25.2 20.5 19.8 21.7 18.1 29.0 28.9 35.9 30.6 27.3 23.1 52.8 62.8 51.9 67.2 69.8 56.3 67.8 30.9 52.6 42.0 37.3 34.2 35.8 22.1 26.1 34.2 34.9 30.6 26.4 24.5 27.1 18.8 41.5 19.2 22.4 45.0 39.4 20.3 20.0 121.9 19.9 29.0 29.7 31.3 21.5 19.0 48.0 32.6 32.7 30.1 32.8 33.1 18.2 23.1 19.1 38.7 35.8 30.0 41.0 41.5 31.2 46.5 29.5 24.4 30.3 56.1 51.0 31.7 33.9 32.0 32.0 19.5 28.6 28.9 38.0 31.4 27.7 25.1 13.5 29.8 19.8 29.0 31.8 29.8 21.8 34.9 45.0 55.3 51.9 50.4 67.2 45.8 48.4 45.1 47.1 62.8 52.8 37.7 43.0 33.7 69.8 59.8 39.0 56.3 67.8 60.7 71.0 47.5 82.1 70.2 44.8 44.0 50.9 51.0 18.1 41.7 30.7 69.2 78.9 62.5 111.3 81.8 68.8 52.2 36.4 113.4 23.6 183.6 99.5 195.0 3.8 51.7 133.3 0.0 136.1 214.1 70.0 78.9 68.0 44.8 127.2 136.7 102.6 66.9 55.1 6.8 67.0 47.0 50.6 131.7 108.9 97.9 137.7 175.6 80.2 103.3 48.5 77.6 81.4 14.8 54.1 55.3 152.2 70.3 147.4 93.1 PPP6C PP6 ENSG00000119414 "Protein phosphatase 6 catalytic subunit" O00743 9 125146573-125189939 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Cell cycle, Immunity, Innate immunity" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050940 Uncertain NA NA "HPA050940: AB_2681283" "unprognostic (6.45e-2)" "unprognostic (4.01e-3)" "unprognostic (7.12e-2)" "unprognostic (5.36e-2)" "unprognostic (2.78e-2)" "unprognostic (2.92e-2)" "unprognostic (2.57e-3)" "unprognostic (1.53e-1)" "unprognostic (2.14e-1)" "unprognostic (2.44e-1)" "unprognostic (1.71e-2)" "unprognostic (2.28e-2)" "prognostic favorable (4.50e-6)" "unprognostic (1.54e-2)" "unprognostic (3.51e-1)" "unprognostic (1.12e-2)" "unprognostic (1.12e-1)" 21.7 20.1 20.1 15.7 24.5 24.8 21.2 20.8 26.2 17.0 19.1 25.9 15.1 13.9 15.6 17.2 21.2 14.0 12.9 15.3 19.8 16.6 22.8 17.8 16.3 21.5 20.1 16.1 17.5 27.7 21.3 17.3 17.6 17.8 14.5 21.8 16.8 26.9 14.6 50.5 19.3 17.3 16.3 22.6 19.4 16.5 22.8 23.7 34.1 22.2 20.5 24.0 13.8 15.6 17.3 14.8 32.2 19.5 13.9 23.3 13.8 14.1 10.3 18.8 17.8 20.2 16.9 19.0 15.0 16.3 22.2 18.6 16.5 15.0 20.4 11.7 20.1 18.9 28.9 25.4 16.3 25.8 18.2 12.3 16.7 16.2 14.6 16.6 29.1 23.2 13.9 22.4 18.2 17.4 17.1 20.7 23.4 19.5 23.7 23.9 21.0 27.4 18.4 17.5 39.6 19.2 22.4 28.5 27.2 18.8 14.3 19.5 19.3 26.8 21.6 17.4 16.7 33.4 18.4 20.0 13.7 13.1 26.5 19.9 26.2 47.2 27.0 18.4 19.1 22.2 27.2 13.2 21.4 14.7 17.4 18.0 17.3 18.9 16.6 14.8 13.3 18.9 17.5 32.2 13.9 19.5 10.7 23.3 13.8 20.1 24.5 20.8 26.2 19.8 16.6 20.1 16.1 17.8 23.7 38.7 27.8 41.7 45.6 68.7 15.2 30.8 35.7 21.4 23.9 26.2 7.9 40.2 48.0 40.6 102.7 41.4 34.6 23.3 47.6 45.3 30.1 41.0 43.9 36.1 46.7 14.3 46.0 46.6 52.3 56.7 27.6 48.9 42.2 46.9 41.6 28.7 41.6 38.6 33.9 54.9 12.9 51.8 44.8 93.3 43.0 76.5 72.9 49.0 37.9 48.2 PRCC RCCP1 ENSG00000143294 "Papillary renal cell carcinoma (translocation-associated)" Q92733 1 156750610-156800817 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017151, HPA019463, HPA019481" Supported Enhanced "Nuclear speckles" NA NA "Nuclear speckles" "CAB017151: , HPA019463: AB_1855672, HPA019481: AB_1855673" "unprognostic (6.12e-2)" "unprognostic (2.68e-1)" "unprognostic (2.68e-3)" "prognostic unfavorable (5.55e-4)" "unprognostic (3.19e-1)" "unprognostic (1.72e-1)" "prognostic unfavorable (8.63e-4)" "unprognostic (3.03e-1)" "unprognostic (9.16e-2)" "unprognostic (3.27e-3)" "unprognostic (1.14e-1)" "unprognostic (6.80e-2)" "prognostic unfavorable (8.99e-15)" "unprognostic (1.72e-1)" "unprognostic (2.74e-1)" "prognostic unfavorable (3.72e-4)" "unprognostic (1.02e-2)" 31.3 24.9 28.5 25.8 29.7 33.7 23.7 33.2 43.5 29.8 30.0 35.9 21.8 24.6 35.1 22.8 30.3 25.6 28.7 23.8 28.0 24.5 26.1 33.1 22.0 30.1 22.1 25.2 30.1 23.7 31.0 22.7 38.8 22.6 25.6 21.5 25.6 37.2 24.0 47.4 33.6 30.1 25.7 20.4 29.7 24.1 26.2 19.2 51.9 27.5 29.8 30.7 25.4 23.8 21.4 27.1 36.9 23.1 19.3 22.1 16.9 20.1 17.4 13.8 15.8 11.6 9.2 24.0 14.1 13.8 15.7 13.6 27.3 17.0 20.7 24.4 11.1 9.1 21.0 19.6 14.8 12.3 25.8 25.6 15.1 12.9 17.6 14.3 20.8 17.9 13.0 17.2 13.7 12.5 12.3 14.4 13.7 24.9 19.3 11.0 35.9 23.7 24.4 33.3 28.1 21.7 20.8 12.2 27.8 16.5 19.4 24.5 43.8 14.9 37.6 23.3 23.7 27.0 33.5 13.2 16.0 16.8 17.6 23.1 49.7 74.3 32.0 15.8 13.5 14.8 26.9 20.0 36.9 20.5 20.6 19.6 18.0 18.5 22.1 22.4 21.4 18.4 18.9 19.3 19.3 23.1 27.1 18.5 16.9 28.5 29.7 33.2 43.5 28.0 24.5 22.1 25.2 22.6 19.2 8.9 16.0 27.9 32.9 46.5 17.3 10.6 20.4 12.0 15.9 19.2 21.6 54.4 18.3 35.7 5.8 27.0 25.1 0.0 28.1 52.6 29.2 25.0 16.2 15.3 37.9 27.0 33.0 23.4 18.7 7.1 28.1 25.4 20.3 51.3 23.1 16.5 29.8 27.4 26.9 23.7 16.8 32.3 32.5 33.6 48.1 44.8 84.6 34.1 27.7 31.8 PRDM1 "BLIMP1, PRDI-BF1" ENSG00000057657 "PR/SET domain 1" O75626 6 106086320-106109939 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Immunity, Innate immunity, Transcription, Transcription regulation" "DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 49.9" "Cell type enhanced" "Detected in many" 8 "Cone photoreceptor cells: 49.1;T-cells: 100.2;Urothelial cells: 77.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 4 "eosinophil: 5.6;gdT-cell: 12.6;MAIT T-cell: 19.3;memory CD4 T-cell: 12.0;memory CD8 T-cell: 11.6;naive CD8 T-cell: 6.8;neutrophil: 6.8;T-reg: 15.4" "Group enriched" "Detected in many" 5 "granulocytes: 6.8;T-cells: 19.3" "Cell line enhanced" "Detected in some" "Karpas-707: 68.5;RPMI-8226: 12.8;U-266/70: 25.7;U-266/84: 16.6" "Region enriched" "Detected in single" 6 "olfactory region: 4.4" "Low region specificity" "Detected in all" "HPA030033, HPA075427" Approved Approved Nucleoplasm,Nucleoli NA NA Nucleoli Nucleoplasm "HPA030033: AB_10601050, HPA075427: " "unprognostic (9.60e-2)" "unprognostic (3.28e-2)" "unprognostic (1.71e-1)" "unprognostic (1.98e-2)" "unprognostic (4.03e-1)" "unprognostic (3.77e-2)" "unprognostic (1.04e-1)" "unprognostic (1.49e-1)" "unprognostic (2.42e-1)" "unprognostic (1.81e-1)" "unprognostic (3.50e-2)" "unprognostic (7.56e-2)" "prognostic unfavorable (9.81e-5)" "unprognostic (1.52e-1)" "unprognostic (3.51e-1)" "unprognostic (2.45e-3)" "unprognostic (7.90e-2)" 11.6 1.5 1.6 26.3 3.2 10.4 7.0 5.3 1.6 14.0 16.5 1.9 1.4 5.4 11.6 2.2 33.4 3.8 8.1 2.3 1.9 2.0 3.1 2.4 18.8 33.3 2.1 0.5 4.2 1.8 1.2 2.1 9.0 4.9 3.6 11.0 4.3 10.6 3.0 2.0 8.9 18.2 3.4 7.4 24.2 8.6 3.0 1.5 3.1 7.7 35.7 49.9 12.8 18.0 1.5 0.2 6.8 0.6 2.5 19.3 1.3 0.4 0.1 0.3 0.0 0.5 0.7 0.0 2.3 7.2 0.7 1.3 0.4 2.8 0.6 0.1 4.6 0.1 0.1 0.0 1.1 0.8 6.4 0.0 0.1 1.4 0.0 1.1 0.2 0.5 0.7 3.6 1.0 3.0 0.2 0.9 0.3 0.4 68.5 0.1 0.0 0.0 0.1 0.2 0.4 0.0 0.1 0.0 12.8 0.6 0.1 0.0 0.0 0.3 0.3 0.0 0.5 0.3 0.7 0.4 1.1 0.6 0.6 2.1 25.7 16.6 1.5 1.6 0.4 0.6 1.2 0.4 5.6 12.6 0.6 19.3 1.5 12.0 11.6 0.2 0.5 1.1 6.8 6.8 2.5 0.1 0.2 15.4 1.3 1.6 3.2 5.3 1.6 1.9 2.0 2.1 0.5 4.9 1.5 0.0 9.0 19.7 8.0 17.3 0.8 1.4 0.0 2.7 7.9 3.5 49.1 0.4 0.0 0.3 0.8 20.4 7.3 23.3 0.2 0.5 5.1 3.1 3.5 1.5 19.3 0.0 1.7 8.0 24.7 0.0 0.0 38.5 35.4 47.7 3.1 0.5 4.8 4.3 1.1 0.1 0.4 0.0 16.4 0.3 1.3 36.3 0.6 100.2 2.5 77.0 PRDM16 "KIAA1675, KMT8F, MEL1, MGC166915, PFM13" ENSG00000142611 "PR/SET domain 16" Q9HAZ2 1 3069168-3438621 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Cardiomyopathy, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 13 "Alveolar cells type 1: 32.8;Cholangiocytes: 17.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 13 "NK-cell: 5.4" "Lineage enriched" "Detected in single" 13 "NK-cells: 5.4" "Cell line enhanced" "Detected in some" "AN3-CA: 2.5;HEK 293: 2.9;HHSteC: 3.4;hTERT-RPE1: 11.5;MCF7: 2.6;OE19: 5.7" "Region enriched" "Detected in many" 5 "basal ganglia: 16.1" "Low region specificity" "Detected in many" "HPA050343, HPA060467" Supported Nucleoplasm NA NA Nucleoplasm "HPA050343: AB_2681099, HPA060467: AB_2684287" "unprognostic (2.44e-1)" "unprognostic (1.44e-1)" "unprognostic (5.31e-4)" "unprognostic (1.27e-1)" "unprognostic (1.14e-1)" "unprognostic (3.95e-2)" "unprognostic (9.15e-3)" "unprognostic (5.68e-4)" "unprognostic (2.58e-1)" "unprognostic (2.07e-2)" "unprognostic (5.21e-2)" "unprognostic (1.71e-1)" "unprognostic (7.80e-6)" "unprognostic (2.14e-1)" "unprognostic (1.73e-1)" "prognostic unfavorable (4.70e-5)" "unprognostic (4.06e-2)" 2.7 0.7 5.3 1.4 5.6 0.5 1.6 0.5 4.7 2.1 6.2 3.3 12.8 14.1 1.5 4.5 1.1 2.0 11.7 5.1 5.2 1.9 7.0 0.6 4.2 1.4 2.9 3.1 3.6 12.7 1.2 1.1 0.6 3.3 1.1 0.9 16.1 1.3 15.0 1.2 0.9 8.0 1.5 2.5 4.2 14.8 1.4 4.8 0.0 10.7 0.0 0.9 1.1 1.5 0.3 0.1 0.0 0.0 5.4 0.4 0.0 0.0 0.0 0.9 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.4 0.5 0.0 0.4 0.0 0.4 0.0 2.2 0.0 0.0 0.2 2.9 0.0 0.0 0.5 3.4 0.0 1.2 0.0 0.0 0.0 0.0 11.5 0.0 0.2 0.0 0.0 0.0 2.6 0.2 0.0 0.3 5.7 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.6 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.4 0.0 5.4 0.0 0.0 0.0 0.0 5.3 5.6 0.5 4.7 5.2 1.9 2.9 3.1 3.3 4.8 32.8 8.0 0.0 0.2 0.6 0.0 4.8 17.8 2.7 9.1 7.0 0.0 0.0 5.0 7.6 0.0 0.7 0.0 0.0 4.3 2.9 0.0 0.3 0.0 0.0 0.0 1.6 5.2 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.3 1.3 5.3 0.0 1.8 0.2 0.0 0.0 5.3 0.2 1.1 0.0 0.0 0.0 1.2 0.1 PREX2 "DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129" ENSG00000046889 "Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2" Q70Z35 8 67952118-68237030 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Guanine-nucleotide releasing factor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 11 "Early spermatids: 31.5;Endothelial cells: 35.0;Ito cells: 52.8;Muller glia cells: 74.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "AF22: 12.8;HUVEC TERT2: 17.4;JURKAT: 7.5;NTERA-2: 11.1;RH-30: 5.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015234, HPA075956" Enhanced Approved "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "HPA015234: AB_1847604, HPA075956: AB_2686769" "unprognostic (2.25e-1)" "unprognostic (3.32e-2)" "unprognostic (1.30e-2)" "unprognostic (3.39e-2)" "unprognostic (1.79e-1)" "unprognostic (2.37e-2)" "unprognostic (4.19e-1)" "unprognostic (8.27e-2)" "unprognostic (2.00e-1)" "unprognostic (1.98e-2)" "unprognostic (2.53e-2)" "unprognostic (8.77e-2)" "prognostic unfavorable (1.61e-7)" "unprognostic (8.30e-3)" "unprognostic (2.79e-1)" "unprognostic (3.67e-2)" "unprognostic (6.64e-2)" 18.8 3.0 14.1 3.3 17.9 1.0 8.5 11.4 16.4 10.8 4.4 13.1 3.0 4.3 6.2 4.5 4.4 12.4 7.6 7.6 15.5 8.1 4.1 3.2 9.1 2.4 12.4 10.0 5.2 3.1 3.7 4.4 17.5 17.2 6.3 4.4 2.6 3.0 5.7 4.9 4.4 4.0 6.1 12.7 3.5 4.1 2.7 16.2 0.0 12.1 3.9 2.9 5.9 15.8 1.1 0.3 0.8 0.1 0.2 0.4 0.0 0.0 0.0 12.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.4 7.5 0.0 0.0 0.0 0.0 2.6 0.0 11.1 0.0 0.0 0.0 5.0 0.0 0.6 0.0 3.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 1.2 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.1 0.1 0.4 0.1 0.2 0.5 0.2 0.2 0.0 1.1 0.2 0.3 0.5 0.2 0.1 0.3 0.0 0.0 14.1 17.9 11.4 13.6 15.5 8.1 12.4 10.0 17.2 16.2 3.0 5.3 0.0 3.2 3.5 24.6 4.4 0.0 1.4 5.7 1.8 2.0 0.0 0.0 0.0 31.5 35.0 0.0 0.0 0.0 0.0 5.5 0.5 1.1 0.4 0.1 4.8 0.0 52.8 3.1 4.9 10.3 0.2 8.5 0.0 0.0 74.9 0.0 0.0 9.9 0.0 3.0 25.8 3.4 0.7 0.7 2.3 0.0 0.0 0.0 1.4 PRKACA PKACa ENSG00000072062 "Protein kinase cAMP-activated catalytic subunit alpha" P17612 19 14091688-14118084 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Cardiomyocytes: 110.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010361, HPA071185" Approved Approved "Cytokinetic bridge,Cytosol" NA NA 1300000 Cytosol "Cytokinetic bridge" "CAB010361: AB_2268772, HPA071185: AB_2686356" "unprognostic (1.08e-1)" "prognostic favorable (6.28e-6)" "unprognostic (2.09e-2)" "prognostic unfavorable (6.26e-5)" "unprognostic (1.38e-2)" "unprognostic (2.95e-1)" "unprognostic (1.64e-1)" "unprognostic (9.36e-3)" "unprognostic (7.01e-2)" "unprognostic (3.41e-1)" "prognostic favorable (6.47e-4)" "unprognostic (2.86e-1)" "unprognostic (1.17e-1)" "unprognostic (4.68e-2)" "unprognostic (1.87e-1)" "unprognostic (3.66e-2)" "unprognostic (6.14e-3)" 25.6 43.4 19.6 17.8 22.7 9.1 34.1 29.1 39.6 20.6 17.5 16.0 16.2 13.4 19.8 15.6 20.9 18.8 16.4 91.6 20.7 29.4 14.7 34.5 16.5 28.2 21.6 27.5 47.0 15.6 20.8 24.6 15.4 26.9 16.6 16.2 18.4 15.5 24.9 92.4 13.4 14.4 29.0 16.2 28.1 13.9 24.4 11.1 15.2 15.7 26.2 14.8 21.1 17.3 1.7 2.4 8.6 5.3 0.7 1.7 1.2 26.2 15.3 34.7 41.3 30.7 32.7 6.3 28.0 25.9 39.8 36.5 18.6 9.4 11.4 22.7 44.3 19.4 17.2 24.4 26.5 37.8 20.7 12.3 20.9 28.9 18.0 26.3 12.9 22.2 31.1 12.8 31.6 11.0 24.6 33.5 18.7 19.6 29.8 40.6 38.9 29.0 9.7 12.4 26.6 34.1 26.2 32.0 26.3 19.4 16.7 27.4 17.5 25.3 15.5 11.5 17.5 22.1 12.5 25.9 47.0 13.1 62.9 26.1 20.6 21.1 16.8 31.5 19.6 17.6 0.3 3.4 0.4 1.7 5.3 0.8 1.7 0.9 1.1 2.4 1.3 1.2 1.7 8.6 0.7 4.6 1.6 0.8 1.2 19.6 22.7 29.1 39.6 20.7 29.4 21.6 27.5 26.9 11.1 6.0 4.3 11.5 6.1 7.8 40.4 110.4 28.1 4.0 2.3 14.0 25.5 5.8 6.6 10.7 25.7 21.6 16.0 0.0 16.2 4.8 14.3 7.3 0.0 30.1 29.0 3.2 16.8 31.9 44.8 12.8 45.5 32.4 13.5 7.2 14.3 24.1 13.5 7.0 48.8 9.6 23.0 19.4 17.3 25.7 6.4 9.8 6.8 7.2 11.4 6.4 PRKAR1A "CNC1, PRKAR1, TSE1" ENSG00000108946 "Protein kinase cAMP-dependent type I regulatory subunit alpha" P10644 17 68511780-68551319 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Cardiomyocytes: 608.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019378, HPA049979" Approved Approved Cytosol NA NA 11000000 Cytosol "CAB019378: , HPA049979: AB_2680980" "unprognostic (8.69e-2)" "unprognostic (6.97e-2)" "unprognostic (5.34e-2)" "unprognostic (2.04e-1)" "unprognostic (1.68e-1)" "unprognostic (4.39e-2)" "unprognostic (2.61e-1)" "unprognostic (6.42e-2)" "unprognostic (2.27e-1)" "unprognostic (2.30e-1)" "unprognostic (1.19e-2)" "unprognostic (5.55e-2)" "unprognostic (8.56e-3)" "unprognostic (6.26e-2)" "unprognostic (6.92e-2)" "unprognostic (3.29e-2)" "unprognostic (1.11e-1)" 47.1 48.0 41.7 34.5 54.8 14.6 38.7 40.4 57.4 48.2 23.8 44.9 31.4 15.1 43.6 37.7 29.6 43.2 37.4 122.7 42.5 52.3 49.2 43.4 47.3 29.5 50.1 43.6 62.5 19.1 107.8 41.9 47.3 57.7 35.6 24.2 32.2 47.5 43.6 99.8 22.8 19.3 39.4 52.8 35.3 25.1 36.9 40.1 28.2 51.8 23.6 29.2 33.8 33.4 11.3 26.9 52.6 28.7 18.5 13.0 22.9 16.6 32.1 41.2 24.6 55.0 62.5 6.2 22.5 46.5 35.2 31.2 12.5 22.5 16.9 15.5 49.1 36.1 13.8 30.4 36.5 50.6 11.4 10.9 26.2 27.9 40.8 39.9 20.0 29.4 44.6 38.0 40.6 34.3 39.6 58.4 14.5 11.8 26.7 42.6 31.6 22.0 10.7 15.2 17.2 21.9 15.4 68.2 18.7 53.4 36.3 15.0 20.3 20.6 37.7 86.7 40.0 29.5 28.3 41.4 49.7 23.7 22.4 20.9 22.3 15.8 25.2 30.1 19.1 30.9 31.1 26.1 46.3 13.0 25.5 13.0 11.3 9.8 11.6 26.9 8.5 8.9 9.8 52.6 18.5 28.7 8.8 12.3 22.9 41.7 54.8 40.4 57.4 42.5 52.3 50.1 43.6 57.7 40.1 137.0 210.8 75.1 77.8 126.8 93.4 608.0 89.2 258.3 168.4 239.0 62.8 66.4 150.9 74.2 287.1 138.4 34.9 23.3 45.5 74.3 135.4 82.7 180.2 101.7 123.8 131.9 131.3 160.2 157.1 53.4 123.7 102.2 182.2 93.8 51.5 115.8 62.1 52.9 179.3 150.9 56.6 84.1 208.1 100.7 40.5 115.2 69.0 106.6 36.6 95.0 PRRX1 "PHOX1, PMX1" ENSG00000116132 "Paired related homeobox 1" P54821 1 170662728-170739419 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 4 "Early spermatids: 327.5;Late spermatids: 303.2;Leydig cells: 237.3;Peritubular cells: 98.3;Smooth muscle cells: 139.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 73.9;ASC TERT1: 59.0;BJ: 20.9;BJ hTERT+: 41.3;HSkMC: 30.1;U-138 MG: 29.0;U-2197: 27.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA051084, HPA063566" Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA051084: AB_2681338, HPA063566: AB_2732702" "unprognostic (2.03e-1)" "unprognostic (2.00e-1)" "unprognostic (1.09e-1)" "unprognostic (7.00e-2)" "unprognostic (1.24e-1)" "unprognostic (4.97e-2)" "unprognostic (2.52e-2)" "unprognostic (1.88e-2)" "unprognostic (2.94e-3)" "unprognostic (1.13e-1)" "unprognostic (1.98e-2)" "unprognostic (3.29e-1)" "prognostic unfavorable (6.60e-10)" "unprognostic (4.23e-3)" "unprognostic (4.48e-2)" "unprognostic (2.68e-3)" "unprognostic (1.69e-3)" 44.8 4.4 5.2 7.2 6.3 0.0 21.0 4.0 9.2 58.5 4.1 6.7 10.6 0.4 31.4 19.4 10.8 17.9 14.5 19.5 6.8 4.5 1.8 0.7 10.4 13.0 6.1 5.3 27.6 1.9 3.4 3.1 2.7 7.7 17.3 2.5 17.4 18.4 34.1 58.6 11.9 2.2 23.0 6.6 1.0 2.3 17.6 6.8 5.0 21.7 28.7 14.9 19.4 31.2 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 73.9 59.0 0.0 20.9 41.3 2.9 2.9 0.0 0.0 0.0 0.0 17.2 0.0 0.0 3.6 0.0 0.9 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 30.1 0.0 14.4 0.0 5.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 29.0 0.5 27.6 3.2 0.0 0.0 0.0 15.2 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 5.2 6.3 4.0 3.9 6.8 4.5 6.1 5.3 7.7 6.8 0.0 0.3 0.0 0.4 14.4 0.0 29.7 0.0 0.0 1.2 0.0 0.0 0.1 0.0 0.9 327.5 6.4 0.0 0.0 0.2 0.2 42.1 1.3 0.0 0.0 0.7 0.0 0.0 0.0 0.0 303.2 237.3 3.9 13.5 0.0 0.0 0.3 0.9 0.0 98.3 0.0 0.1 51.8 139.5 6.0 1.4 10.3 0.1 0.0 0.0 1.3 PSIP1 "DFS70, LEDGF, p52, p75, PSIP2" ENSG00000164985 "PC4 and SFRS1 interacting protein 1" O75475 9 15464066-15511019 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Spermatocytes: 273.8;Spermatogonia: 282.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 132.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013718, HPA019697" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB013718: , HPA019697: AB_1852779" "unprognostic (8.54e-2)" "unprognostic (3.70e-2)" "unprognostic (1.31e-1)" "unprognostic (3.29e-2)" "unprognostic (1.22e-1)" "unprognostic (2.23e-1)" "unprognostic (2.89e-3)" "unprognostic (5.10e-2)" "unprognostic (5.93e-2)" "unprognostic (2.53e-2)" "unprognostic (6.49e-3)" "unprognostic (5.49e-2)" "unprognostic (6.98e-2)" "unprognostic (2.04e-1)" "unprognostic (2.99e-1)" "unprognostic (7.14e-2)" "unprognostic (1.39e-1)" 15.1 20.3 42.7 20.8 48.8 24.9 12.2 65.3 49.4 22.6 16.1 19.0 11.5 10.8 27.9 18.2 12.9 20.0 14.9 16.0 38.7 42.7 16.1 10.5 15.6 35.4 34.1 30.2 43.6 8.1 18.8 24.9 18.7 32.4 18.3 15.3 12.3 9.0 21.1 16.3 12.3 14.2 21.3 37.7 24.6 12.5 37.2 29.3 70.4 18.1 6.5 31.9 17.0 16.1 11.4 2.6 8.5 4.3 8.0 16.4 1.9 17.9 11.9 40.7 29.8 8.8 10.7 9.1 21.7 15.5 19.5 23.3 5.0 9.3 38.3 5.0 11.4 10.9 5.0 25.3 11.7 28.3 25.1 15.3 132.4 31.3 9.3 10.7 15.4 14.7 8.9 3.4 16.3 12.0 19.5 17.0 18.1 21.8 21.3 12.6 6.5 31.9 38.4 63.1 0.4 18.6 29.8 22.2 7.7 10.9 6.3 25.9 28.5 19.4 8.6 10.1 26.5 8.6 20.8 12.0 14.2 14.4 10.6 20.5 9.1 12.8 34.5 11.4 15.6 8.1 8.5 2.1 4.2 5.5 1.6 6.7 8.4 11.0 7.6 2.4 11.4 16.4 10.1 7.2 8.0 4.3 2.6 9.8 1.9 42.7 48.8 65.3 46.6 38.7 42.7 34.1 30.2 32.4 29.3 50.6 32.2 51.9 42.9 28.3 223.7 37.1 20.4 58.9 36.4 45.4 62.8 99.5 53.0 8.4 62.0 69.9 10.7 46.7 7.5 66.4 50.7 20.2 15.0 16.3 26.7 130.3 36.5 55.3 27.7 44.5 116.5 31.1 38.8 43.3 27.2 149.7 3.6 23.2 126.2 41.8 252.4 122.9 61.2 273.8 282.5 18.4 34.6 73.4 41.7 15.4 PTCH1 "BCNS, NBCCS, PTCH" ENSG00000185920 "Patched 1" Q13635 9 95442980-95517057 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Receptor "Cancer-related genes, Disease mutation, Holoprosencephaly, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 17 "Late spermatids: 165.3;Leydig cells: 176.9;Peritubular cells: 417.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 8.9" "Lineage enriched" "Detected in many" 8 "T-cells: 8.9" "Cell line enhanced" "Detected in many" "NTERA-2: 15.8;WM-115: 37.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013717, HPA075072" Uncertain Approved "Golgi apparatus" NA NA "Golgi apparatus" "CAB013717: , HPA075072: AB_2686733" "unprognostic (1.46e-1)" "unprognostic (1.06e-1)" "unprognostic (3.16e-1)" "unprognostic (1.79e-2)" "unprognostic (3.22e-2)" "unprognostic (9.01e-2)" "unprognostic (2.13e-1)" "unprognostic (3.54e-3)" "unprognostic (2.63e-1)" "unprognostic (8.66e-3)" "unprognostic (1.52e-2)" "unprognostic (2.82e-1)" "unprognostic (1.13e-6)" "unprognostic (8.63e-2)" "unprognostic (4.40e-2)" "unprognostic (2.76e-1)" "unprognostic (2.82e-1)" 4.1 3.8 6.7 6.0 9.5 0.7 7.9 21.0 6.4 28.5 12.5 6.1 8.0 7.8 16.2 4.2 3.0 7.4 13.2 2.8 7.0 6.6 4.9 2.2 7.1 4.5 9.5 3.2 5.2 10.8 3.4 4.0 3.7 6.9 6.9 12.3 11.2 6.9 9.5 2.7 4.3 10.9 8.5 5.1 3.8 12.1 14.3 7.9 1.0 6.3 1.9 3.2 11.3 6.9 1.0 0.0 0.0 0.0 0.3 8.9 1.8 5.1 2.5 10.9 6.8 1.6 2.7 6.2 1.0 0.9 1.2 0.7 2.5 2.5 4.1 1.8 1.9 2.3 11.8 6.2 0.8 0.7 4.0 4.1 0.0 2.5 1.1 1.5 0.1 2.3 2.5 1.3 1.1 0.8 2.3 2.2 1.8 3.6 4.8 0.5 1.0 0.0 1.6 15.8 3.7 1.0 0.0 8.3 2.1 0.8 0.7 7.5 3.7 3.7 3.6 1.6 10.6 0.9 1.1 0.5 1.4 7.2 7.3 0.7 9.7 8.4 2.7 2.0 2.0 37.6 0.0 0.0 0.0 8.9 0.0 5.3 1.0 1.7 3.8 0.0 0.3 2.8 3.2 0.0 0.3 0.0 0.0 1.4 1.8 6.7 9.5 21.0 6.4 7.0 6.6 9.5 3.2 6.9 7.9 0.0 5.4 0.9 2.8 3.5 17.4 5.1 10.2 1.4 2.3 0.0 39.3 2.0 5.0 2.5 80.9 3.7 1.3 0.0 3.5 1.6 6.9 5.8 1.1 1.0 0.7 19.1 20.8 3.1 0.8 165.3 176.9 0.8 11.8 0.0 11.2 71.0 2.6 3.5 417.9 1.1 13.5 38.8 4.2 3.3 33.2 3.9 1.1 4.3 5.0 1.1 PTEN "BZS, MHAM, MMAC1, PTEN1, TEP1" ENSG00000171862 "Phosphatase and tensin homolog" P60484 10 87863113-87971930 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Lipid metabolism, Neurogenesis" "Hydrolase, Protein phosphatase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 29.6" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB004076, HPA031335" Approved Supported Nucleoplasm,Cytosol "Secreted - unknown location" NA NA Nucleoplasm Cytosol "CAB004076: AB_390810, HPA031335: AB_2797221" "unprognostic (8.72e-2)" "unprognostic (2.45e-1)" "unprognostic (5.43e-1)" "unprognostic (1.50e-2)" "unprognostic (3.71e-2)" "unprognostic (1.30e-1)" "unprognostic (2.18e-1)" "unprognostic (2.08e-1)" "unprognostic (2.07e-1)" "unprognostic (6.87e-2)" "unprognostic (9.77e-2)" "unprognostic (2.71e-1)" "prognostic unfavorable (7.35e-4)" "unprognostic (1.57e-1)" "unprognostic (2.73e-1)" "unprognostic (6.54e-3)" "unprognostic (2.41e-1)" 42.4 24.1 17.7 20.9 17.7 13.5 32.8 39.9 19.7 43.1 26.7 9.9 19.0 15.1 29.8 22.8 26.8 30.3 21.0 19.1 16.0 17.4 19.6 32.4 27.2 30.4 15.7 19.5 29.1 21.3 16.4 23.6 36.4 14.2 35.3 17.7 21.6 16.8 20.8 16.8 20.4 25.4 26.0 11.7 40.9 17.8 18.7 12.5 49.7 25.2 13.3 18.6 29.6 30.9 4.3 5.1 29.6 11.0 4.3 4.7 2.0 10.2 4.8 5.5 5.0 12.8 8.8 5.0 5.5 12.2 6.5 9.1 4.9 12.6 12.1 3.7 9.0 3.8 6.2 7.4 6.3 10.3 6.0 2.1 4.0 12.5 6.0 13.7 13.5 6.9 6.0 17.6 8.2 10.6 27.6 9.1 7.7 3.0 32.9 5.9 7.8 7.6 24.6 2.0 8.9 0.0 11.8 2.9 8.9 10.1 5.8 2.0 9.0 7.3 3.5 9.2 4.6 9.7 19.6 7.9 21.4 5.0 8.3 4.4 10.8 14.0 13.8 6.6 12.8 1.2 8.3 7.9 12.2 3.6 11.0 3.9 4.3 4.0 3.5 5.1 3.7 4.7 4.5 29.6 4.3 7.2 4.2 3.5 2.0 17.7 17.7 39.9 19.7 16.0 17.4 15.7 19.5 14.2 12.5 32.8 55.3 40.2 50.0 49.8 113.3 39.2 40.8 25.4 28.4 27.9 37.3 22.6 28.2 23.2 57.0 44.4 33.9 0.0 25.8 44.5 52.3 36.9 25.3 58.6 31.3 42.9 30.0 47.9 167.4 70.7 52.6 69.1 59.1 27.9 44.1 54.1 30.2 24.6 51.2 30.8 55.8 90.5 118.8 24.9 24.0 52.6 47.9 35.7 39.2 51.2 PTK6 BRK ENSG00000101213 "Protein tyrosine kinase 6" Q13882 20 63528001-63537370 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 44.0;intestine: 24.2;skin 1: 24.2" "Cell type enhanced" "Detected in many" 12 "Alveolar cells type 2: 34.1;Enterocytes: 90.1;Mucus-secreting cells: 39.1;Paneth cells: 65.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "A-431: 10.6;CAPAN-2: 20.4;HaCaT: 16.6;hTCEpi: 22.5;OE19: 27.4;RT4: 13.0;T-47d: 12.5" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB032952, HPA036070, HPA036071" Approved Supported "Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol" NA NA Nucleoplasm "Nuclear bodies, Plasma membrane, Cytosol" "CAB032952: AB_634461, HPA036070: AB_10602292, HPA036071: AB_10669982" "unprognostic (2.32e-2)" "unprognostic (1.36e-1)" "unprognostic (1.05e-1)" "unprognostic (2.42e-2)" "unprognostic (1.41e-1)" "unprognostic (1.35e-1)" "unprognostic (1.04e-1)" "unprognostic (2.29e-1)" "unprognostic (3.03e-1)" "unprognostic (3.72e-2)" "prognostic unfavorable (1.96e-4)" "unprognostic (1.28e-1)" "prognostic unfavorable (1.26e-9)" "unprognostic (4.19e-2)" "unprognostic (1.74e-1)" "unprognostic (1.73e-1)" "unprognostic (4.24e-2)" 0.7 0.0 0.4 5.3 0.4 0.0 1.7 0.4 0.4 7.6 18.1 0.5 0.8 13.6 0.6 0.5 44.0 0.0 11.7 0.4 0.4 0.0 0.8 1.7 1.1 0.4 0.4 0.4 0.4 1.4 0.0 0.4 0.6 0.4 2.2 7.4 0.4 7.6 0.4 0.4 24.2 24.2 0.9 0.4 0.4 12.5 0.4 0.4 0.4 0.4 18.9 17.2 6.5 15.0 1.3 4.5 1.2 2.4 0.3 1.9 0.9 10.6 1.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 20.4 0.0 3.6 0.0 0.0 16.6 0.0 0.0 0.0 2.6 0.2 0.0 4.3 0.0 0.0 0.0 3.4 0.0 22.5 0.0 0.1 0.1 0.0 0.0 0.1 1.2 0.1 5.9 0.0 0.1 0.1 27.4 7.7 0.0 0.6 0.2 0.0 13.0 0.1 1.1 1.2 4.0 0.0 0.0 12.5 0.8 0.1 0.1 0.2 0.4 0.1 0.2 0.0 0.0 0.2 0.2 0.5 1.2 2.4 0.4 0.5 1.7 1.9 1.2 0.4 0.1 4.5 1.3 0.4 0.6 1.2 0.3 1.3 0.3 0.5 0.9 0.4 0.4 0.4 0.4 0.4 0.0 0.4 0.4 0.4 0.4 11.9 34.1 0.0 2.8 5.3 2.0 0.4 12.7 9.4 17.0 0.0 2.0 0.2 0.0 1.4 0.0 0.3 90.1 0.0 1.4 0.1 0.4 1.3 9.2 1.5 0.7 0.0 5.2 0.6 4.1 0.0 0.3 2.8 0.0 0.0 39.1 2.4 10.3 65.1 0.0 0.1 3.9 0.0 0.4 0.2 0.2 13.6 0.1 0.0 18.8 13.8 PTPN11 "BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2" ENSG00000179295 "Protein tyrosine phosphatase, non-receptor type 11" Q06124 12 112418351-112509913 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes, Deafness, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cardiomyocytes: 136.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005377 Approved Supported "Nucleoplasm,Nucleoli rim,Actin filaments,Cytosol" NA NA 160000 "Nucleoli rim" "Nucleoplasm, Actin filaments, Cytosol" "CAB005377: AB_632401" "unprognostic (2.18e-3)" "unprognostic (1.73e-3)" "unprognostic (5.62e-2)" "unprognostic (1.19e-1)" "unprognostic (1.63e-2)" "unprognostic (2.27e-1)" "unprognostic (6.05e-2)" "unprognostic (4.25e-2)" "unprognostic (3.55e-2)" "unprognostic (1.88e-1)" "unprognostic (2.22e-2)" "unprognostic (8.85e-2)" "unprognostic (3.75e-3)" "unprognostic (1.66e-1)" "unprognostic (2.46e-1)" "unprognostic (3.62e-2)" "unprognostic (1.80e-2)" 25.4 16.8 38.6 14.4 39.0 17.7 30.8 17.5 39.5 18.3 14.7 26.9 9.9 11.9 19.1 13.3 17.6 11.1 13.1 30.1 38.0 32.2 18.0 23.1 15.1 14.5 45.3 22.5 13.1 14.0 29.3 12.9 16.6 26.2 16.2 13.9 9.4 12.0 20.0 34.0 14.1 11.1 28.0 45.7 10.9 12.8 7.6 32.1 10.9 21.2 8.2 13.7 17.4 15.4 17.3 17.1 22.0 11.8 11.3 15.4 6.3 35.4 33.8 24.7 23.4 36.0 35.2 29.2 43.1 47.0 34.0 25.6 33.7 13.7 37.5 22.5 39.8 21.5 21.2 31.7 38.2 56.5 28.4 26.1 54.5 31.5 18.4 35.9 43.7 34.8 28.4 38.5 36.5 51.9 32.8 28.0 29.0 41.4 13.2 32.8 25.6 30.7 21.3 29.9 34.7 22.2 31.6 36.4 21.5 31.3 39.9 17.2 21.1 41.5 31.8 26.5 26.1 36.6 30.3 34.1 40.0 35.9 23.7 37.6 25.6 42.2 37.5 33.3 30.7 37.3 22.0 11.0 15.0 14.8 9.5 14.1 15.5 13.4 12.1 12.6 17.3 15.4 11.8 10.3 11.3 11.8 17.1 9.8 6.3 38.6 39.0 17.5 39.5 38.0 32.2 45.3 22.5 26.2 32.1 56.6 53.2 13.4 22.8 22.8 27.6 136.3 30.6 20.1 50.0 34.9 15.7 20.0 28.2 34.0 65.9 35.8 17.2 0.0 36.7 21.0 25.9 57.9 26.7 93.6 22.8 12.7 12.6 27.0 32.4 19.0 47.8 23.7 13.5 16.2 19.6 59.0 45.4 20.4 75.0 29.8 21.4 32.3 31.9 7.7 5.3 24.0 29.4 19.8 18.7 65.6 PTPN13 "PTP-BAS, PTP-BL, PTP1E, PTPL1" ENSG00000163629 "Protein tyrosine phosphatase, non-receptor type 13" Q12923 4 86594315-86815171 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 7 "Alveolar cells type 2: 152.9;Basal keratinocytes: 97.1;Rod photoreceptor cells: 171.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "intermediate monocyte: 3.0;MAIT T-cell: 2.3;memory CD4 T-cell: 2.2;non-classical monocyte: 4.9" "Group enriched" "Detected in many" 7 "monocytes: 4.9;T-cells: 2.3" "Cell line enhanced" "Detected in many" "AF22: 45.2;RT4: 21.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002213, HPA063119" Approved Supported "Nucleoplasm,Nucleoli fibrillar center,Cytosol" NA NA Nucleoplasm "Nucleoli fibrillar center, Cytosol" "CAB002213: AB_564089, HPA063119: " "unprognostic (5.36e-2)" "unprognostic (4.46e-1)" "unprognostic (1.11e-1)" "unprognostic (2.54e-3)" "unprognostic (4.02e-1)" "unprognostic (9.03e-3)" "unprognostic (4.43e-2)" "unprognostic (4.38e-2)" "unprognostic (2.46e-1)" "unprognostic (7.05e-2)" "unprognostic (3.69e-2)" "unprognostic (1.46e-1)" "unprognostic (1.28e-3)" "unprognostic (3.95e-3)" "unprognostic (2.26e-1)" "unprognostic (2.66e-1)" "unprognostic (2.85e-2)" 10.3 5.9 10.8 2.7 16.9 0.7 9.9 5.7 11.6 15.9 4.1 13.0 7.6 1.2 10.8 21.2 18.7 11.4 6.5 5.3 10.4 5.7 22.1 1.6 18.0 4.3 16.9 7.9 24.1 4.3 26.6 38.3 3.0 14.2 12.0 2.4 39.0 5.9 9.4 1.0 43.0 2.3 8.7 10.3 3.5 3.6 12.2 17.6 1.9 16.9 12.4 11.8 15.7 17.6 0.0 0.5 0.1 4.9 0.1 2.3 0.1 5.1 2.6 45.2 4.4 19.1 16.7 0.0 9.5 19.4 3.6 4.6 0.0 2.6 0.0 2.1 10.5 1.3 17.0 7.8 14.3 7.0 0.1 5.8 4.3 5.6 0.0 2.3 7.5 0.0 10.7 4.6 2.6 8.7 7.6 0.0 0.0 0.0 7.4 0.0 2.3 0.6 2.7 10.3 0.0 1.9 1.5 0.0 0.0 13.8 21.5 2.6 3.8 2.8 6.3 5.2 7.6 3.7 0.2 0.0 3.5 2.7 0.0 1.2 7.7 0.0 0.0 3.7 0.0 1.5 0.0 0.2 0.0 0.2 3.0 2.3 0.0 2.2 0.3 0.5 0.0 0.0 0.0 0.1 0.1 4.9 0.0 0.1 0.1 10.8 16.9 5.7 11.6 10.4 5.7 16.9 7.9 14.2 17.6 44.7 152.9 0.0 21.0 97.1 9.8 1.7 10.2 32.1 75.1 45.4 86.4 0.2 3.3 4.3 20.2 2.2 0.0 0.0 3.0 0.1 20.2 12.1 4.7 0.0 0.2 1.6 4.6 1.8 2.2 14.8 42.3 5.7 18.6 0.0 0.5 14.1 4.3 3.5 30.8 9.2 171.6 12.9 12.5 24.4 21.6 86.9 0.2 4.4 0.2 45.5 PTPRB PTPB ENSG00000127329 "Protein tyrosine phosphatase, receptor type B" P23467 12 70515866-70637440 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Angiogenesis "Hydrolase, Protein phosphatase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 6 "Endothelial cells: 113.4;Ito cells: 448.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 7 "memory B-cell: 3.5" "Lineage enriched" "Detected in single" 7 "B-cells: 3.5" "Cell line enhanced" "Detected in some" "EFO-21: 11.3;hTERT-RPE1: 9.1;HUVEC TERT2: 28.0;TIME: 40.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004782, HPA067868" Uncertain Approved "Vesicles,Plasma membrane,Cell Junctions" NA NA 6700000 "Plasma membrane" "Vesicles, Cell Junctions" "CAB004782: , HPA067868: AB_2685911" "unprognostic (3.18e-1)" "unprognostic (2.99e-6)" "unprognostic (1.56e-1)" "unprognostic (1.80e-1)" "unprognostic (3.55e-2)" "unprognostic (1.77e-2)" "prognostic favorable (6.05e-4)" "unprognostic (4.59e-1)" "unprognostic (2.22e-2)" "unprognostic (1.85e-1)" "unprognostic (2.28e-2)" "unprognostic (1.40e-1)" "prognostic favorable (1.02e-4)" "unprognostic (2.91e-2)" "unprognostic (7.18e-2)" "unprognostic (1.31e-1)" "unprognostic (1.38e-1)" 23.5 7.0 4.5 5.5 7.0 0.1 22.9 3.6 6.1 11.3 8.0 4.3 7.1 5.3 17.1 8.5 5.8 8.2 11.4 17.6 6.2 5.1 18.7 12.0 39.9 3.3 6.9 4.6 5.5 4.4 4.9 5.7 23.3 7.8 6.1 8.2 16.0 3.6 7.1 11.8 4.7 7.4 13.3 7.3 22.9 5.2 3.7 4.3 0.7 14.0 12.2 2.6 6.5 14.7 3.5 0.1 0.2 0.0 0.4 0.3 0.2 1.9 0.1 0.8 0.1 0.0 0.0 0.4 0.4 1.9 1.0 2.4 0.0 1.5 0.7 11.3 0.3 0.1 6.9 0.1 0.3 3.6 0.6 0.3 0.1 0.8 0.5 0.1 0.3 0.0 0.0 0.3 2.8 0.0 9.1 28.0 0.0 1.5 0.5 0.6 0.0 0.0 0.0 1.0 1.9 0.4 0.0 0.7 0.4 5.2 0.8 0.0 0.4 0.7 0.0 1.6 0.2 0.0 0.6 40.9 0.4 0.4 0.1 2.4 0.5 0.4 0.3 0.2 0.5 0.0 0.2 0.0 0.0 0.2 0.0 0.0 3.5 0.0 0.3 0.0 0.3 0.1 0.0 0.1 0.4 0.0 0.1 0.0 0.2 4.5 7.0 3.6 6.1 6.2 5.1 6.9 4.6 7.8 4.3 0.0 19.9 13.7 0.8 3.3 5.4 9.2 17.8 0.0 1.2 3.5 0.0 0.0 0.0 1.4 4.3 113.4 4.3 46.7 0.8 0.0 1.9 0.6 23.3 2.0 0.3 4.8 0.0 448.7 26.3 2.5 1.1 2.0 5.0 0.0 4.8 0.3 7.2 14.4 0.0 0.0 0.8 0.0 0.9 0.7 0.5 1.4 0.0 1.7 5.2 0.6 PTPRC "CD45, GP180, LCA, T200" ENSG00000081237 "Protein tyrosine phosphatase, receptor type C" 1 198638457-198757476 "Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "blood: 116.9;lymphoid tissue: 172.5" "Cell type enhanced" "Detected in many" 12 "B-cells: 266.4;granulocytes: 232.9;Kupffer cells: 338.8;Macrophages: 290.3;T-cells: 539.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 47.1;HEL: 26.6;HL-60: 24.0;JURKAT: 61.5;MOLT-4: 35.5;THP-1: 19.7;U-266/70: 22.0;U-266/84: 20.0;U-698: 28.2;U-937: 21.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000052, HPA000440, CAB002800, CAB056154, CAB068221" Enhanced Uncertain Nucleoplasm,Vesicles "Intracellular and membrane" NA NA "Nucleoplasm, Vesicles" "CAB000052: AB_2314143, CAB002800: AB_2237910, CAB056154: AB_2665572, CAB068221: AB_2665571, HPA000440: AB_611377" "unprognostic (1.51e-2)" "unprognostic (1.24e-2)" "unprognostic (5.10e-3)" "unprognostic (2.33e-3)" "unprognostic (1.30e-1)" "unprognostic (2.40e-3)" "unprognostic (1.62e-1)" "unprognostic (3.17e-2)" "unprognostic (1.25e-1)" "unprognostic (3.18e-2)" "unprognostic (8.08e-2)" "unprognostic (3.95e-1)" "prognostic unfavorable (2.42e-4)" "unprognostic (2.31e-1)" "unprognostic (3.43e-2)" "unprognostic (6.41e-2)" "unprognostic (7.06e-2)" 9.8 2.9 3.4 48.0 6.2 36.1 4.3 1.3 3.5 3.1 5.6 2.8 0.5 4.9 2.9 3.9 4.8 5.6 8.8 4.9 3.9 4.5 4.4 5.2 27.5 93.2 7.9 1.3 2.9 2.1 0.3 2.5 4.5 5.3 4.2 5.8 3.3 10.7 1.0 1.7 2.5 22.2 4.5 13.2 89.3 6.5 2.3 5.3 172.5 4.6 3.9 53.2 13.1 3.7 28.5 42.8 94.7 103.8 53.7 76.1 116.9 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 47.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 26.6 0.0 0.0 0.0 24.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 61.5 0.5 0.7 0.0 0.0 35.5 14.5 0.1 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.3 0.4 0.0 0.1 0.1 0.0 0.0 19.7 0.3 0.0 0.2 0.1 0.1 22.0 20.0 28.2 0.0 21.5 0.1 20.8 52.0 56.3 76.1 99.7 64.5 28.5 52.9 72.7 42.8 26.8 60.2 60.3 94.7 53.7 103.8 6.4 54.6 116.9 3.4 6.2 1.3 3.5 3.9 4.5 7.9 1.3 5.3 5.3 41.7 86.9 266.4 0.7 14.1 0.0 4.1 7.6 21.4 26.1 1.8 0.0 0.4 0.0 0.0 2.0 11.9 0.1 23.3 0.0 0.5 8.9 0.9 232.9 3.0 90.3 0.0 1.2 14.1 338.8 1.5 1.1 290.3 20.3 120.0 0.2 0.0 0.1 0.0 0.0 1.7 0.2 6.5 4.3 0.2 0.2 13.2 0.7 539.1 0.5 0.9 PTPRK R-PTP-kappa ENSG00000152894 "Protein tyrosine phosphatase, receptor type K" Q15262 6 127968779-128520674 "Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "memory B-cell: 2.3;naive B-cell: 4.8;naive CD8 T-cell: 1.6" "Group enriched" "Detected in many" 7 "B-cells: 4.8;T-cells: 1.6" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054056, HPA054822" Uncertain Supported "Vesicles,Plasma membrane,Cell Junctions" NA NA 13000000 "Cell Junctions" "Vesicles, Plasma membrane" "HPA054056: AB_2682359, HPA054822: AB_2682614" "unprognostic (3.15e-2)" "unprognostic (1.07e-2)" "unprognostic (5.79e-3)" "unprognostic (4.95e-3)" "unprognostic (1.89e-2)" "unprognostic (7.26e-2)" "unprognostic (3.27e-1)" "unprognostic (6.06e-2)" "unprognostic (2.04e-1)" "unprognostic (1.08e-1)" "prognostic unfavorable (1.99e-4)" "unprognostic (1.46e-1)" "prognostic favorable (9.33e-5)" "unprognostic (2.10e-1)" "unprognostic (1.55e-1)" "unprognostic (2.59e-1)" "unprognostic (9.32e-2)" 12.0 5.2 18.6 10.7 20.3 1.2 20.9 4.7 24.4 12.2 21.9 25.6 11.2 25.7 12.1 10.3 9.1 13.2 29.6 11.4 17.2 12.6 13.3 23.6 17.4 5.7 20.5 19.3 15.6 25.7 11.4 12.2 17.4 14.9 16.3 23.4 3.9 18.3 17.5 9.1 13.5 27.4 14.6 17.1 6.4 24.6 2.7 23.7 15.3 10.1 6.5 7.6 18.4 15.1 4.8 0.0 0.0 0.0 0.4 1.6 0.2 4.5 4.9 2.9 0.2 6.2 8.3 3.0 12.3 23.8 5.1 4.6 8.1 3.8 0.0 3.7 11.3 14.8 12.9 3.1 9.7 7.2 13.6 4.9 0.1 7.5 11.2 7.6 0.0 0.4 6.1 9.0 10.6 14.5 13.3 13.8 4.4 0.0 0.2 12.4 9.1 6.9 0.0 3.1 8.3 6.3 24.8 6.3 0.8 12.6 9.3 15.5 0.0 12.7 14.2 0.7 3.5 3.9 0.3 23.4 8.0 5.6 15.5 11.1 0.1 1.6 0.0 10.2 0.0 8.4 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.1 0.1 0.0 4.8 0.4 1.6 0.0 0.4 0.0 0.0 0.1 0.2 18.6 20.3 4.7 24.4 17.2 12.6 20.5 19.3 14.9 23.7 23.8 27.4 9.7 78.6 56.3 3.1 19.3 76.5 18.7 33.0 17.4 3.9 21.8 0.0 51.8 3.4 46.7 63.1 0.0 53.2 4.5 30.5 99.0 1.1 36.5 5.1 9.5 42.2 8.0 1.0 2.1 15.8 1.8 16.9 2.8 41.3 7.0 84.8 57.5 17.0 11.2 0.6 58.2 35.8 3.6 5.8 33.2 22.4 1.0 48.9 100.5 PTPRT "KIAA0283, RPTPrho" ENSG00000196090 "Protein tyrosine phosphatase, receptor type T" O14522 20 42072752-43189970 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protein phosphatase, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 23.5;fallopian tube: 17.0" "Cell type enhanced" "Detected in some" 17 "Bipolar cells: 40.8;Ciliated cells: 33.5;Early spermatids: 10.0;Late spermatids: 9.9" "Cancer enhanced" "Detected in many" "breast cancer: 5.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 4.6;RPMI-8226: 1.2;SCLC-21H: 2.9;U-266/70: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA017336, CAB069423" Approved NA NA "CAB069423: AB_1622602, HPA017336: AB_1855943" "unprognostic (7.17e-3)" "unprognostic (1.02e-1)" "unprognostic (5.61e-3)" "unprognostic (1.08e-2)" "unprognostic (5.95e-2)" "unprognostic (3.71e-2)" "unprognostic (1.97e-1)" "unprognostic (1.31e-2)" "unprognostic (6.93e-2)" "unprognostic (2.00e-1)" "unprognostic (1.37e-6)" "unprognostic (3.16e-1)" "unprognostic (1.13e-2)" "unprognostic (1.81e-1)" "unprognostic (3.17e-1)" "unprognostic (1.10e-1)" "unprognostic (1.17e-1)" 0.6 0.8 5.0 0.6 11.1 0.5 4.6 1.6 23.5 1.6 0.7 0.9 0.0 1.2 0.5 1.8 0.5 17.0 0.7 0.8 4.7 6.5 0.6 0.9 2.1 1.0 2.2 12.6 0.5 0.9 0.5 4.1 4.6 5.1 0.8 0.6 0.5 2.0 4.6 0.5 0.8 1.0 0.5 1.4 0.7 1.8 2.8 0.9 4.9 0.5 0.0 1.1 0.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 2.9 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 11.1 1.6 22.6 4.7 6.5 2.2 12.6 5.1 0.9 0.0 0.6 0.0 0.0 0.8 40.8 1.1 0.0 33.5 1.2 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.2 4.8 0.0 7.4 0.3 9.9 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.1 QKI QK3 ENSG00000112531 "QKI, KH domain containing RNA binding" Q96PU8 6 163414000-163578596 "Cancer-related genes, Predicted intracellular proteins" "Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport" "Developmental protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 100.3" "Cell type enhanced" "Detected in many" 5 "Cardiomyocytes: 308.9" "Cancer enriched" "Detected in all" 6 "glioma: 42.0" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "AF22: 64.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019123, CAB022602" Enhanced Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB022602: , HPA019123: AB_1855980" "unprognostic (2.42e-1)" "unprognostic (5.81e-2)" "unprognostic (1.31e-1)" "unprognostic (1.06e-2)" "unprognostic (8.57e-2)" "unprognostic (1.65e-1)" "prognostic unfavorable (1.27e-4)" "unprognostic (1.34e-1)" "unprognostic (7.06e-2)" "unprognostic (1.76e-3)" "unprognostic (1.08e-1)" "unprognostic (5.15e-2)" "prognostic unfavorable (2.31e-5)" "prognostic unfavorable (3.69e-4)" "unprognostic (1.16e-1)" "unprognostic (3.86e-1)" "unprognostic (4.09e-2)" 32.4 12.4 37.5 16.2 63.5 27.1 14.6 15.1 100.3 14.9 12.2 83.9 3.7 4.0 14.7 4.9 16.0 12.3 15.7 64.0 43.7 18.1 11.1 18.4 24.9 11.4 72.5 31.9 18.4 7.6 7.8 4.7 23.4 46.5 7.9 8.4 7.1 10.2 11.1 59.9 12.4 7.1 21.1 68.8 16.9 8.9 20.5 74.3 5.0 10.4 10.8 11.4 15.8 17.7 1.7 7.3 10.8 8.4 7.4 3.8 1.3 4.3 18.2 64.8 21.5 19.6 21.9 15.1 11.8 27.9 19.3 23.4 12.3 4.0 5.2 9.9 29.5 13.2 6.5 34.3 12.2 31.4 10.5 11.1 20.6 10.1 13.8 24.0 11.0 6.3 25.6 5.0 20.7 32.9 18.9 26.6 7.8 30.2 12.4 12.4 8.2 7.3 2.3 8.3 4.3 9.2 11.3 40.4 10.5 10.6 13.7 1.3 7.5 12.6 6.8 5.2 27.5 2.6 18.0 27.0 13.4 11.3 14.4 21.6 7.9 9.6 6.4 11.5 9.7 31.4 3.4 8.4 3.8 2.3 5.4 3.8 1.4 1.6 2.0 4.3 1.7 1.5 2.5 10.8 7.4 5.5 7.3 1.1 1.3 37.5 63.5 15.1 41.4 43.7 18.1 72.5 31.9 46.5 74.3 140.0 54.6 32.8 29.3 136.6 56.8 308.9 40.8 21.4 36.4 19.2 55.0 41.8 18.3 21.6 45.5 100.3 0.0 46.7 10.3 40.7 66.9 33.8 60.0 61.0 75.9 30.2 0.0 146.1 189.4 77.1 80.3 114.7 108.0 31.5 0.0 113.1 17.4 0.0 92.6 25.9 30.1 45.3 91.7 34.4 14.6 118.9 46.1 25.8 0.0 35.3 RABEP1 "neurocrescin, RAB5EP, rabaptin-5, RABPT5" ENSG00000029725 "Rabaptin, RAB GTPase binding effector protein 1" Q15276 17 5282265-5385812 "Cancer-related genes, Predicted intracellular proteins" "Apoptosis, Endocytosis, Protein transport, Transport" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004549, HPA019669, HPA024235, HPA024691" Supported Supported Vesicles NA NA Vesicles "CAB004549: AB_628192, HPA019669: AB_1856019, HPA024235: AB_1856020, HPA024691: AB_1856021" "unprognostic (3.22e-1)" "unprognostic (2.90e-2)" "unprognostic (2.45e-1)" "unprognostic (8.75e-3)" "unprognostic (1.64e-1)" "unprognostic (8.25e-2)" "unprognostic (3.71e-2)" "unprognostic (1.20e-1)" "unprognostic (1.60e-2)" "unprognostic (7.73e-2)" "prognostic favorable (6.43e-4)" "unprognostic (1.14e-1)" "unprognostic (6.09e-3)" "unprognostic (7.67e-2)" "unprognostic (2.60e-1)" "unprognostic (1.00e-1)" "unprognostic (9.00e-3)" 19.2 16.7 29.6 18.8 31.1 10.3 31.8 24.1 32.7 16.3 14.2 19.0 12.5 10.9 18.1 18.3 12.7 12.9 15.0 27.4 29.7 25.9 16.6 21.8 13.1 21.1 36.2 24.4 15.5 12.1 38.4 16.3 20.2 31.3 22.2 14.2 10.0 14.8 16.0 41.2 11.6 13.4 20.8 35.6 17.7 15.7 11.8 29.0 21.4 17.6 13.5 25.5 14.5 13.0 37.6 14.2 12.6 19.3 9.1 11.2 6.4 18.1 22.4 23.6 13.2 24.8 24.9 13.0 23.6 17.6 24.7 23.7 19.9 7.6 38.3 19.8 23.8 13.9 14.3 34.5 19.6 35.0 25.2 31.6 23.4 27.8 15.0 23.4 15.3 15.5 19.2 13.5 23.8 30.9 15.0 21.4 19.5 19.9 18.9 21.4 12.6 25.3 12.6 10.9 9.9 10.9 24.0 28.3 12.7 12.5 16.6 10.2 16.0 20.9 20.8 19.8 21.8 37.8 7.0 18.8 21.3 9.9 21.4 27.6 11.1 12.1 20.6 16.5 25.1 14.5 4.9 9.0 8.7 11.2 9.2 9.8 30.2 8.7 10.6 9.2 37.6 11.1 9.7 12.6 9.1 19.3 14.2 8.0 6.4 29.6 31.1 24.1 32.5 29.7 25.9 36.2 24.4 31.3 29.0 32.8 42.6 30.0 28.5 21.3 46.6 80.2 15.3 24.1 45.5 17.4 37.3 31.8 34.9 26.0 5.7 28.5 14.6 0.0 20.5 27.9 29.4 43.8 11.6 25.1 71.8 33.4 15.6 34.4 30.4 4.6 31.4 35.3 28.7 27.1 14.3 85.2 23.9 31.6 26.5 29.4 49.0 25.8 29.9 70.4 72.8 17.8 21.6 29.6 14.6 29.3 RAC1 "p21-Rac1, Rac-1, TC-25" ENSG00000136238 "Rac family small GTPase 1" P63000 7 6374523-6403977 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" Hydrolase "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB035994, HPA047820" Approved Approved Nucleoplasm,Nucleoli,Cytosol NA NA 44000000 "Nucleoplasm, Cytosol" Nucleoli "CAB035994: , HPA047820: AB_2680167" "unprognostic (8.66e-3)" "unprognostic (2.47e-1)" "unprognostic (4.00e-1)" "unprognostic (2.40e-2)" "unprognostic (1.88e-3)" "unprognostic (4.06e-2)" "prognostic unfavorable (1.74e-5)" "prognostic unfavorable (4.59e-4)" "unprognostic (1.59e-1)" "unprognostic (2.04e-1)" "prognostic unfavorable (4.57e-5)" "unprognostic (3.63e-1)" "prognostic unfavorable (2.11e-4)" "unprognostic (1.95e-1)" "unprognostic (2.11e-2)" "unprognostic (4.13e-2)" "unprognostic (8.72e-3)" 45.2 35.0 71.0 28.4 64.0 24.4 46.5 42.1 93.0 48.7 58.9 75.5 22.5 51.6 48.7 49.5 93.4 47.2 40.0 48.4 73.8 59.8 47.8 42.9 45.6 38.3 76.7 60.9 45.1 29.2 51.0 25.2 55.8 54.9 40.5 64.0 37.2 43.3 48.9 57.4 58.6 49.8 57.3 88.2 35.0 49.7 28.1 47.1 41.3 40.9 42.8 50.7 52.2 54.0 11.0 32.0 49.1 31.9 7.3 11.8 10.7 75.1 34.1 35.3 38.3 41.9 53.5 21.1 42.4 52.1 56.6 57.7 33.5 71.1 21.2 27.5 59.1 58.6 53.6 37.6 51.4 72.5 9.9 31.2 21.3 27.6 24.1 50.4 19.2 17.4 35.6 46.0 40.7 45.7 43.1 49.8 21.0 38.0 16.8 60.9 54.8 10.5 45.2 63.2 38.3 40.9 18.7 35.9 31.1 72.7 47.7 26.8 45.1 29.9 109.6 34.0 42.1 61.8 57.8 52.2 37.2 56.0 45.5 48.9 12.8 14.0 20.0 34.3 36.7 70.4 7.6 31.9 16.4 7.2 22.2 4.5 11.0 8.1 9.2 32.0 11.0 9.8 6.5 49.1 7.3 22.1 18.2 11.8 10.7 71.0 64.0 42.1 93.0 73.8 59.8 76.7 60.9 54.9 47.1 137.0 112.5 192.8 745.4 829.8 84.3 183.1 481.6 92.3 104.6 338.5 23.6 691.3 454.3 121.1 58.5 522.9 706.2 303.7 149.3 914.8 466.9 1152.5 132.3 288.4 738.1 138.2 323.2 535.2 736.9 43.7 441.0 745.3 435.3 408.4 531.5 280.9 231.2 471.0 444.5 611.5 54.4 472.1 495.6 210.1 328.6 1004.1 707.0 194.1 436.1 1582.5 RAD21 "hHR21, KIAA0078, SCC1" ENSG00000164754 "RAD21 cohesin complex component" O60216 8 116845935-116874866 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Apoptosis, Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation" "Activator, Developmental protein, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020044, CAB022065" Supported Enhanced Nucleoplasm NA Yes Nucleoplasm "CAB022065: , HPA020044: AB_1856035" "unprognostic (7.85e-2)" "unprognostic (4.92e-1)" "unprognostic (3.05e-1)" "unprognostic (5.43e-3)" "unprognostic (9.56e-2)" "unprognostic (3.50e-1)" "prognostic unfavorable (1.71e-4)" "unprognostic (1.86e-3)" "unprognostic (8.99e-2)" "unprognostic (8.80e-2)" "unprognostic (5.58e-3)" "unprognostic (3.56e-2)" "unprognostic (4.40e-2)" "unprognostic (2.00e-1)" "unprognostic (1.82e-1)" "unprognostic (1.39e-1)" "unprognostic (1.95e-1)" 31.6 40.9 48.2 30.5 52.2 78.5 37.7 58.8 55.3 24.2 36.3 37.5 21.5 24.8 30.5 25.3 32.1 23.1 22.0 37.8 45.6 44.1 30.5 27.9 29.6 49.2 54.3 35.4 33.5 18.2 29.1 30.0 38.9 45.5 26.5 37.3 19.0 25.3 31.0 37.8 24.0 26.0 33.4 49.7 31.2 31.5 37.6 56.2 58.3 41.9 20.9 50.4 37.1 36.0 8.7 5.4 17.9 7.1 8.0 25.4 6.2 41.6 20.5 40.2 22.5 20.2 17.5 18.0 29.0 27.5 32.2 29.8 16.8 39.3 61.6 16.0 20.6 17.2 23.3 34.2 18.7 37.8 81.7 21.9 62.8 25.2 21.3 12.7 20.1 37.0 14.9 15.4 18.8 22.8 21.3 25.1 89.9 25.2 86.3 27.7 25.1 92.1 11.9 23.6 53.8 25.9 33.8 29.2 30.9 19.2 24.5 50.8 26.2 30.4 82.1 19.6 22.0 34.4 24.9 18.4 22.8 33.4 23.8 30.3 45.7 52.5 55.5 19.5 29.0 27.2 17.2 4.5 15.5 11.0 5.3 11.2 8.7 12.9 13.0 5.4 8.3 13.5 13.0 17.9 8.0 7.1 4.5 25.4 6.2 48.2 52.2 58.8 55.3 45.6 44.1 54.3 35.4 45.5 56.2 238.2 123.7 70.9 67.0 84.9 73.4 149.3 48.4 87.0 138.8 52.4 29.5 106.6 36.5 47.5 247.8 88.8 56.4 70.0 38.8 119.7 73.7 80.6 143.9 61.8 58.9 63.5 81.0 64.4 91.5 303.2 107.9 82.3 65.8 97.4 62.9 99.6 49.1 57.5 100.0 50.1 60.7 71.1 54.7 31.6 81.6 87.8 95.1 93.8 69.2 65.3 RAD51B "hREC2, R51H2, RAD51L1, REC2" ENSG00000182185 "RAD51 paralog B" O15315 14 67819779-68730218 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA recombination, DNA repair" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016191, HPA051869" Enhanced Approved "Nucleoplasm,Nuclear bodies" NA NA "Nuclear bodies" Nucleoplasm "CAB016191: AB_2238209, HPA051869: AB_2681644" "unprognostic (9.10e-3)" "unprognostic (5.45e-2)" "unprognostic (4.92e-1)" "unprognostic (6.65e-2)" "unprognostic (2.38e-2)" "unprognostic (4.85e-2)" "unprognostic (6.42e-3)" "unprognostic (2.54e-2)" "unprognostic (1.06e-1)" "unprognostic (3.08e-1)" "unprognostic (6.80e-3)" "unprognostic (1.47e-1)" "unprognostic (6.25e-2)" "unprognostic (1.77e-1)" "unprognostic (2.49e-2)" "unprognostic (6.79e-2)" "unprognostic (8.13e-3)" 5.1 4.9 4.2 4.6 10.1 9.2 8.2 2.0 5.6 8.2 4.3 11.6 11.2 1.7 10.8 13.8 7.0 6.0 6.4 3.4 5.6 3.2 4.3 3.2 5.0 6.6 9.2 4.0 10.0 5.7 8.0 10.0 8.0 7.5 7.0 4.0 9.4 18.7 3.8 2.4 7.1 5.8 6.7 7.3 6.9 3.7 3.4 7.3 12.6 4.9 4.6 12.1 7.7 8.3 13.6 6.6 14.0 5.9 7.8 10.1 4.8 12.2 4.9 5.4 3.3 5.1 8.7 3.4 6.2 4.8 6.9 8.9 3.4 16.7 15.2 4.1 3.8 8.0 11.1 3.4 10.0 9.5 6.7 3.5 7.2 4.4 2.7 2.7 6.1 7.3 4.4 7.7 7.9 8.4 3.2 6.2 11.3 5.8 7.1 5.6 9.6 11.8 2.1 3.2 11.9 4.9 13.4 6.5 5.5 5.4 3.5 3.7 2.4 5.0 1.8 10.8 6.7 8.4 5.5 1.6 8.5 8.2 6.6 5.1 3.4 3.5 12.0 4.7 10.7 4.8 14.0 5.9 5.4 8.6 4.7 7.1 13.6 8.2 9.2 6.5 11.5 10.1 9.7 0.7 7.8 4.5 6.6 9.1 4.8 4.2 10.1 2.0 5.6 5.6 3.2 9.2 4.0 7.5 7.3 0.0 0.6 3.9 4.8 6.0 1.3 1.5 0.0 1.4 2.3 1.8 7.9 4.8 3.3 1.8 1.5 3.6 1.4 0.0 1.2 5.5 2.5 3.4 4.6 0.6 5.7 1.6 4.6 0.6 4.3 1.3 3.4 3.6 8.5 10.0 2.7 5.1 1.1 0.0 4.2 1.6 5.9 0.0 2.0 3.8 3.2 6.0 3.3 2.5 1.3 3.1 RAF1 "c-Raf, CRAF, Raf-1" ENSG00000132155 "Raf-1 proto-oncogene, serine/threonine kinase" P04049 3 12583601-12664226 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in all" "neutrophil: 53.9" "Lineage enriched" "Detected in all" 5 "granulocytes: 53.9" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002640, CAB019291" Approved Approved "Nuclear speckles" NA NA "Nuclear speckles" "CAB019291: , HPA002640: AB_1856047" "unprognostic (6.33e-2)" "unprognostic (1.29e-1)" "unprognostic (5.92e-2)" "unprognostic (2.17e-3)" "unprognostic (6.51e-3)" "unprognostic (7.66e-3)" "unprognostic (2.66e-3)" "unprognostic (1.53e-2)" "unprognostic (2.72e-1)" "unprognostic (7.66e-2)" "unprognostic (2.92e-2)" "unprognostic (1.29e-2)" "unprognostic (2.79e-2)" "unprognostic (1.79e-1)" "unprognostic (1.27e-1)" "unprognostic (2.64e-2)" "unprognostic (2.36e-2)" 19.5 15.6 15.1 14.7 17.1 32.2 17.5 35.2 18.9 19.9 20.3 21.1 19.6 18.4 24.9 15.7 24.6 18.6 20.2 39.3 15.3 11.0 21.7 36.2 19.7 15.7 16.0 13.4 24.9 31.3 30.7 16.9 24.8 14.3 18.8 19.2 25.0 18.3 18.4 79.7 23.9 29.6 23.7 13.8 22.1 23.7 16.7 17.8 27.7 26.9 27.9 26.1 20.5 20.4 6.6 9.3 53.9 9.9 8.5 8.6 7.7 15.4 17.8 27.1 21.0 23.6 19.1 54.6 23.6 40.0 31.3 35.5 13.9 12.8 16.2 11.3 36.5 16.9 9.9 28.5 20.9 32.6 28.3 22.4 21.8 21.4 12.9 23.9 21.2 20.7 17.6 21.2 32.2 26.1 21.6 22.4 24.9 15.8 42.6 30.1 26.4 27.2 15.7 27.6 19.3 24.2 22.0 23.8 20.4 18.7 23.4 8.5 17.8 19.3 18.7 12.5 22.0 31.0 28.1 16.0 21.5 20.5 18.0 26.2 33.2 52.9 34.9 18.5 24.8 22.8 11.3 9.7 18.4 7.4 9.9 7.5 6.6 7.3 7.2 9.3 6.3 7.5 7.6 53.9 8.5 9.6 4.2 8.6 7.7 15.1 17.1 35.2 18.9 15.3 11.0 16.0 13.4 14.3 17.8 20.8 36.5 39.7 31.1 30.6 51.6 25.8 28.1 25.4 21.6 26.2 62.8 34.3 11.6 22.9 7.1 29.1 32.5 0.0 32.0 39.8 32.9 38.2 33.5 36.5 25.2 41.3 28.2 31.3 36.8 3.4 36.2 34.2 25.3 29.7 29.6 32.1 28.8 34.8 38.9 15.7 84.2 32.3 33.0 17.7 27.4 38.0 52.1 38.3 29.5 36.9 RANBP2 "ADANE, ANE1, NUP358" ENSG00000153201 "RAN binding protein 2" P49792 2 108719481-108785811 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "mRNA transport, Protein transport, Translocation, Transport, Ubl conjugation pathway" "RNA-binding, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564" Supported Supported "Nucleoplasm,Nuclear membrane,Vesicles" NA NA "Nuclear membrane" "Nucleoplasm, Vesicles" "CAB034063: AB_2176784, HPA018437: AB_2620151, HPA023960: AB_2671385, HPA049497: AB_2680794, HPA051675: AB_2681570, HPA067564: AB_2685862" "unprognostic (2.51e-1)" "unprognostic (3.99e-2)" "unprognostic (1.22e-1)" "unprognostic (4.37e-2)" "unprognostic (1.28e-2)" "unprognostic (9.30e-2)" "unprognostic (5.47e-2)" "unprognostic (2.91e-1)" "unprognostic (4.02e-2)" "unprognostic (2.54e-1)" "unprognostic (4.23e-1)" "unprognostic (5.23e-2)" "unprognostic (1.62e-2)" "unprognostic (8.74e-2)" "unprognostic (3.08e-1)" "unprognostic (3.40e-2)" "unprognostic (2.53e-1)" 20.5 24.3 14.4 17.0 18.6 35.5 24.4 23.1 22.2 19.8 17.1 12.8 25.5 13.3 19.9 21.5 17.0 19.1 14.8 20.2 12.9 12.5 18.9 19.5 17.7 19.2 15.1 17.0 32.4 24.1 48.5 37.5 18.8 16.5 21.8 15.8 14.3 20.0 31.6 37.5 17.3 17.4 23.2 17.8 16.3 20.9 20.6 15.9 26.6 28.7 18.0 17.5 20.5 19.7 5.6 5.1 8.3 6.3 4.2 8.7 2.3 18.4 11.3 16.3 14.7 19.0 17.0 15.8 16.6 13.2 13.8 12.1 28.1 8.9 29.1 12.9 17.3 17.0 15.6 27.8 17.3 20.1 17.7 13.5 30.3 14.0 19.8 11.1 35.3 10.2 14.3 13.2 21.5 16.8 13.6 21.0 12.7 32.4 16.1 18.2 10.2 15.6 14.4 20.5 9.3 13.6 14.8 25.0 14.0 12.2 23.1 23.7 10.9 14.7 12.7 16.1 10.2 8.1 16.3 25.0 14.4 19.1 10.1 18.5 13.4 19.8 26.4 11.2 16.0 11.1 8.3 5.3 5.1 7.6 3.4 8.7 5.5 6.3 6.9 4.2 5.6 6.2 6.7 8.3 4.2 6.3 5.1 5.1 2.3 14.4 18.6 23.1 22.2 12.9 12.5 15.1 17.0 16.5 15.9 71.5 71.1 34.9 25.8 49.5 43.3 85.9 33.1 57.6 70.5 55.8 68.7 22.7 1.7 31.3 59.8 43.8 25.7 0.0 44.1 15.0 32.3 38.2 83.1 49.9 41.1 30.2 102.2 27.0 44.0 22.0 35.6 64.2 45.5 49.5 50.9 18.7 36.5 25.9 52.6 15.4 37.7 45.3 62.9 74.1 59.2 59.2 34.0 44.5 31.5 31.5 RAP1GDS1 SmgGDS ENSG00000138698 "Rap1 GTPase-GDP dissociation stimulator 1" P52306 4 98261384-98443861 "Cancer-related genes, Predicted intracellular proteins" "GTPase activation" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 12 "Early spermatids: 332.5;Late spermatids: 174.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019060 Approved Supported Cytosol NA NA 120000 Cytosol "HPA019060: AB_1856068" "unprognostic (8.12e-2)" "unprognostic (1.50e-1)" "unprognostic (2.69e-3)" "unprognostic (1.66e-1)" "unprognostic (9.11e-2)" "unprognostic (1.35e-2)" "unprognostic (1.57e-3)" "unprognostic (3.44e-1)" "unprognostic (6.31e-2)" "unprognostic (1.27e-1)" "unprognostic (3.15e-1)" "unprognostic (4.60e-1)" "prognostic favorable (2.00e-4)" "unprognostic (7.11e-2)" "unprognostic (3.09e-1)" "unprognostic (1.47e-1)" "unprognostic (2.76e-1)" 11.3 9.7 25.8 12.9 28.2 9.0 13.1 28.0 43.6 9.3 12.0 20.0 9.0 7.3 8.9 8.7 13.7 6.1 8.6 6.8 29.7 28.0 12.3 15.2 10.1 15.3 36.9 20.5 7.9 13.8 8.4 15.3 9.6 30.1 8.0 14.0 8.0 8.6 11.9 3.6 10.5 9.0 16.3 37.0 12.5 8.2 15.5 26.2 16.2 13.0 4.8 17.0 12.5 7.6 13.9 31.9 16.0 14.7 19.5 22.7 8.4 17.9 10.5 13.4 11.5 17.3 20.7 5.4 30.6 17.0 18.3 14.4 7.8 23.3 21.3 10.0 22.8 8.9 10.3 16.5 28.0 24.8 21.8 6.8 13.2 13.5 10.2 34.3 21.9 9.2 24.1 17.1 16.1 25.0 15.2 23.9 21.9 8.7 18.3 45.2 9.4 36.2 10.9 4.9 14.7 7.6 15.1 8.0 7.2 18.6 14.1 19.9 12.1 12.8 28.8 16.9 7.7 6.5 14.3 23.5 19.0 13.6 8.7 18.1 6.3 11.0 18.0 15.7 16.5 24.6 16.0 10.6 5.7 14.2 14.6 14.3 13.9 14.5 13.6 16.7 11.0 7.8 11.9 1.6 19.5 14.7 31.9 22.7 8.4 25.8 28.2 28.0 30.5 29.7 28.0 36.9 20.5 30.1 26.2 14.9 9.8 23.0 8.8 12.4 41.4 10.1 20.4 5.3 15.9 15.7 47.1 5.8 19.9 16.8 332.5 13.5 11.1 23.3 18.3 13.9 11.6 11.1 15.0 16.3 22.1 14.3 20.1 16.0 29.4 174.5 8.6 23.3 16.9 29.7 13.9 15.6 19.2 16.7 10.3 15.9 66.0 0.0 11.8 14.6 22.5 14.6 3.8 30.8 17.4 12.8 RARA "NR1B1, RAR" ENSG00000131759 "Retinoic acid receptor alpha" P10276 17 40309192-40357643 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 26.6" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 63.9;SK-BR-3: 40.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058282, HPA071548" Supported "Nucleoplasm,Nucleoli,Actin filaments,Cytosol" NA NA Nucleoplasm "Nucleoli, Actin filaments, Cytosol" "HPA058282: AB_2683666, HPA071548: " "unprognostic (8.05e-3)" "unprognostic (1.89e-1)" "unprognostic (9.48e-3)" "prognostic favorable (2.60e-4)" "unprognostic (8.67e-3)" "unprognostic (4.87e-3)" "unprognostic (2.77e-1)" "unprognostic (5.73e-2)" "unprognostic (1.45e-1)" "unprognostic (3.54e-2)" "unprognostic (1.19e-1)" "unprognostic (1.79e-1)" "unprognostic (2.29e-3)" "unprognostic (1.59e-2)" "unprognostic (5.60e-2)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" 27.6 13.5 5.0 18.6 7.6 32.3 23.7 11.5 15.2 30.2 29.6 5.0 16.8 18.0 23.8 23.9 17.3 23.3 30.2 24.3 5.9 6.1 14.6 24.0 32.0 23.4 4.6 7.8 50.0 9.3 7.4 18.1 16.6 6.5 22.9 8.5 26.8 12.1 32.7 43.1 14.3 31.6 18.6 3.7 31.1 14.3 21.8 2.9 9.7 16.3 15.4 20.2 31.5 20.3 1.0 6.1 26.6 9.3 2.5 2.6 1.9 5.1 12.1 3.6 6.1 7.1 10.9 3.6 4.2 6.4 6.2 4.0 8.3 4.4 2.7 6.6 9.5 5.7 15.0 4.1 10.0 3.6 20.5 6.1 7.8 6.1 8.1 11.4 2.8 24.7 15.3 2.9 6.6 8.4 23.7 9.2 2.4 4.9 6.0 7.0 63.9 1.8 9.5 3.1 4.7 3.8 3.6 21.3 10.3 3.6 4.1 1.5 12.4 9.0 40.6 12.4 3.6 38.2 11.2 10.7 7.8 13.3 13.6 4.6 14.4 4.8 2.3 13.1 5.5 23.0 8.7 4.2 15.7 1.6 6.9 2.6 1.0 1.7 1.7 6.1 0.9 0.8 1.3 26.6 2.5 9.3 1.8 1.4 1.9 5.0 7.6 11.5 15.2 5.9 6.1 4.6 7.8 6.5 2.9 3.0 9.5 5.6 22.6 17.3 24.2 3.2 10.2 4.0 2.3 7.0 5.9 1.9 11.6 14.3 58.0 20.4 52.7 0.0 16.9 5.1 23.8 11.2 34.6 22.8 11.3 3.2 9.2 22.7 35.4 50.8 38.6 37.4 27.0 0.0 14.2 9.3 16.8 24.6 21.5 11.8 8.2 32.3 33.0 2.9 6.9 16.6 4.3 11.5 13.2 19.2 RB1 "OSRC, PPP1R130, RB" ENSG00000139687 "RB transcriptional corepressor 1" P06400 13 48303726-48599436 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "monocytes: 107.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "MOLT-4: 58.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000095, CAB016687, HPA050082" Supported Supported Nucleoplasm NA NA Nucleoplasm "CAB000095: , CAB016687: AB_1622010, HPA050082: AB_2681008" "unprognostic (4.24e-3)" "unprognostic (1.00e-1)" "unprognostic (3.62e-2)" "unprognostic (4.67e-2)" "unprognostic (2.04e-2)" "unprognostic (3.86e-1)" "unprognostic (4.69e-2)" "unprognostic (7.08e-2)" "unprognostic (1.59e-1)" "prognostic unfavorable (6.92e-4)" "unprognostic (4.06e-2)" "unprognostic (9.40e-2)" "unprognostic (4.67e-2)" "unprognostic (1.79e-1)" "unprognostic (9.99e-2)" "unprognostic (2.31e-1)" "unprognostic (1.70e-1)" 19.6 21.5 14.9 23.2 18.4 14.7 28.1 25.6 19.4 18.0 13.2 11.5 19.0 12.3 16.8 19.5 27.9 12.7 15.3 19.5 15.4 15.3 18.1 12.1 25.4 30.1 17.0 11.8 15.2 11.6 12.8 17.2 21.5 16.0 15.5 15.3 11.6 20.0 17.4 27.9 20.3 14.3 16.8 23.6 29.4 13.7 14.4 15.3 39.1 19.9 15.8 25.3 17.4 23.6 20.5 10.3 13.2 12.2 3.6 4.6 4.0 9.1 4.9 13.5 14.5 6.7 7.8 6.1 18.0 15.0 19.0 16.2 4.2 16.2 11.8 4.2 12.0 10.5 12.7 17.5 14.5 29.0 16.5 6.7 21.7 10.2 7.2 7.1 18.6 20.6 4.3 8.9 12.3 15.8 15.9 13.1 29.2 7.2 9.7 21.7 4.3 58.2 9.4 6.6 20.8 5.4 25.0 13.5 13.5 19.7 8.9 0.6 13.8 17.8 8.9 14.7 12.5 9.7 24.3 10.1 11.8 7.7 14.3 16.2 4.3 1.2 0.1 6.2 11.7 15.9 11.0 9.7 5.0 4.6 12.2 3.7 17.4 3.8 4.6 9.3 20.5 3.2 3.8 13.2 3.6 12.1 10.3 4.5 4.0 14.9 18.4 25.6 19.4 15.4 15.3 17.0 11.8 16.0 15.3 3.0 18.7 56.5 18.3 25.2 14.4 15.9 17.8 20.1 14.8 29.6 27.5 5.9 13.3 15.8 20.6 33.6 15.9 0.0 10.4 8.0 15.4 21.4 11.5 14.7 64.6 17.5 16.8 38.6 83.9 10.6 24.2 88.8 25.3 107.4 18.5 21.8 13.3 9.9 26.9 21.1 18.5 19.4 20.6 27.9 14.3 33.4 3.7 20.8 15.0 14.4 RBM10 "DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5" ENSG00000182872 "RNA binding motif protein 10" P98175 X 47144869-47186813 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034972, HPA057372" Approved Enhanced "Nuclear speckles" NA NA "Nuclear speckles" "HPA034972: AB_10602919, HPA057372: AB_2683421" "unprognostic (9.07e-2)" "prognostic favorable (6.71e-4)" "unprognostic (7.83e-2)" "unprognostic (1.61e-2)" "unprognostic (1.86e-1)" "unprognostic (3.04e-2)" "unprognostic (4.47e-3)" "unprognostic (8.11e-2)" "unprognostic (9.86e-3)" "unprognostic (1.76e-1)" "prognostic favorable (2.86e-6)" "unprognostic (1.18e-1)" "unprognostic (6.23e-3)" "unprognostic (3.33e-2)" "unprognostic (1.09e-1)" "unprognostic (4.40e-2)" "unprognostic (1.20e-3)" 18.1 22.2 19.8 38.0 21.9 34.0 17.1 41.2 22.9 19.9 20.5 25.7 22.7 21.8 22.1 17.3 23.7 26.2 29.1 21.7 19.8 18.3 18.4 21.6 17.1 27.2 20.1 19.2 36.4 27.4 20.1 28.3 24.9 17.9 23.5 14.2 18.5 25.1 28.8 20.6 23.8 23.7 18.9 17.2 24.7 20.5 8.7 21.4 32.9 26.8 18.0 22.7 17.6 20.9 15.9 14.6 14.4 19.2 12.3 18.3 11.5 20.9 22.7 21.8 25.8 11.7 9.6 25.3 16.0 9.4 16.5 16.1 19.8 17.2 25.6 9.8 11.0 21.1 20.5 28.4 20.1 9.1 26.0 25.7 19.1 27.6 20.7 17.1 19.3 23.1 12.6 9.7 27.3 22.2 11.9 17.7 24.8 15.9 20.6 10.0 32.0 35.4 32.8 35.9 15.8 25.5 31.3 18.2 26.4 12.2 18.6 25.9 19.7 24.1 18.1 15.3 13.5 22.2 19.3 15.4 19.5 24.8 21.0 16.7 21.7 17.5 21.1 17.3 14.0 27.2 14.0 10.8 14.4 18.3 14.5 17.0 15.9 14.7 15.3 12.3 15.6 14.8 14.1 10.1 12.3 19.2 14.6 16.6 11.5 19.8 21.9 41.2 21.9 19.8 18.3 20.1 19.2 17.9 21.4 38.7 44.1 14.3 20.3 9.8 26.5 30.9 25.5 30.8 36.4 8.7 13.7 27.7 10.0 17.2 0.6 18.8 24.8 0.0 15.2 23.9 18.1 14.5 23.1 19.8 16.9 20.6 34.3 14.7 12.9 1.6 16.7 11.8 15.1 18.0 24.9 14.0 16.8 18.6 24.1 11.5 25.3 0.0 16.9 5.7 6.1 9.3 38.6 17.5 23.4 16.5 RBM15 "OTT, OTT1" ENSG00000162775 "RNA binding motif protein 15" Q96T37 1 110338506-110346681 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" RNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 48.7" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015201, HPA019824, HPA049642" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB015201: , HPA019824: AB_1856113, HPA049642: AB_2680839" "unprognostic (1.70e-1)" "unprognostic (1.63e-1)" "unprognostic (9.39e-2)" "unprognostic (7.57e-3)" "unprognostic (2.43e-1)" "unprognostic (2.11e-2)" "prognostic unfavorable (7.61e-4)" "unprognostic (1.13e-1)" "unprognostic (1.84e-2)" "unprognostic (4.91e-2)" "unprognostic (9.67e-2)" "unprognostic (2.76e-2)" "prognostic unfavorable (1.37e-4)" "prognostic favorable (7.97e-4)" "unprognostic (2.88e-1)" "unprognostic (2.46e-2)" "unprognostic (2.12e-1)" 8.5 7.6 6.3 12.2 7.6 48.7 7.9 18.6 8.3 6.6 8.8 7.6 8.3 7.3 8.5 7.2 8.0 7.3 6.6 8.8 5.2 4.3 6.3 11.0 10.5 13.7 8.3 6.0 8.6 7.5 7.1 8.1 7.1 5.9 5.7 5.7 8.1 7.4 6.4 17.2 7.2 11.3 5.5 5.0 12.5 8.3 14.0 7.9 21.8 7.0 5.3 13.4 6.5 8.6 10.5 4.8 9.8 6.9 5.0 9.9 5.5 7.1 7.8 7.0 7.2 4.5 4.7 11.1 3.8 5.0 6.0 7.9 9.5 6.5 13.5 6.1 4.3 4.9 10.1 11.0 9.5 8.9 14.0 10.1 10.9 11.8 6.9 6.2 11.8 11.6 4.3 6.6 8.3 7.8 3.1 6.3 10.3 15.4 23.7 6.0 7.3 10.6 9.3 15.0 6.3 4.4 12.6 10.6 9.2 4.9 7.2 8.5 4.3 8.3 10.5 8.0 7.9 7.2 14.3 4.4 5.7 10.4 6.2 6.9 18.3 9.2 29.3 8.6 12.0 7.1 8.2 6.9 9.4 7.0 6.0 9.9 10.5 7.7 6.0 4.8 10.0 6.8 8.2 9.8 5.0 6.4 4.7 7.5 5.5 6.3 7.6 18.6 8.3 5.2 4.3 8.3 6.0 5.9 7.9 6.0 3.0 15.3 8.2 29.5 5.4 10.8 7.6 9.4 2.3 3.5 13.7 7.6 0.0 3.4 6.2 9.8 7.5 0.0 3.1 6.2 8.9 8.6 28.8 13.5 5.6 0.0 9.2 10.4 5.7 4.1 3.7 5.5 8.5 1.8 8.4 5.6 4.2 2.9 4.9 3.3 7.1 0.0 13.3 24.4 14.5 29.5 3.9 12.5 7.6 6.7 REL "c-Rel, I-Rel" ENSG00000162924 "REL proto-oncogene, NF-kB subunit" Q04864 2 60881521-60931610 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 6 "Basal keratinocytes: 459.8;monocytes: 666.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 27.2;U-698: 52.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004404 Uncertain NA NA "CAB004404: AB_670194" "unprognostic (2.77e-1)" "unprognostic (2.05e-2)" "unprognostic (8.26e-2)" "unprognostic (1.20e-1)" "unprognostic (2.23e-1)" "unprognostic (4.41e-2)" "unprognostic (1.11e-1)" "unprognostic (7.15e-2)" "unprognostic (2.15e-1)" "unprognostic (5.87e-2)" "unprognostic (4.38e-2)" "unprognostic (4.37e-1)" "unprognostic (2.82e-2)" "unprognostic (2.91e-2)" "unprognostic (3.53e-1)" "unprognostic (3.85e-1)" "unprognostic (3.66e-2)" 11.2 4.7 3.5 25.9 5.4 35.1 7.7 9.8 5.0 9.7 8.4 4.3 6.2 4.8 8.7 6.6 11.9 6.9 10.1 5.7 3.2 3.1 4.5 8.0 20.5 15.3 5.5 1.8 13.3 7.1 10.8 9.1 6.3 4.7 10.8 5.3 6.0 7.9 6.9 5.0 14.2 9.3 7.7 10.6 22.5 6.0 5.0 5.2 15.3 7.2 6.4 23.8 21.3 14.1 20.8 9.5 11.2 12.9 6.5 7.2 5.5 3.0 1.9 1.4 1.9 1.1 1.1 3.1 1.0 1.6 1.0 1.2 1.4 2.7 27.2 2.7 0.9 2.1 3.7 2.5 1.8 2.1 7.4 2.4 2.7 2.9 1.4 0.6 5.4 3.3 1.1 4.8 2.2 3.4 1.3 2.5 3.0 3.6 1.8 0.7 1.6 3.9 2.2 1.8 2.0 0.7 5.5 4.0 1.1 1.1 12.3 1.4 1.5 3.0 3.3 1.0 2.2 1.9 2.4 2.6 2.3 2.6 1.5 1.6 2.3 1.1 52.8 1.3 4.7 1.1 6.5 9.6 6.0 7.2 10.9 5.0 14.4 3.8 5.5 9.5 20.8 2.4 5.4 11.2 6.5 12.9 6.7 4.6 5.5 3.5 5.4 9.8 5.0 3.2 3.1 5.5 1.8 4.7 5.2 297.8 270.0 109.1 108.9 459.8 79.2 3.5 30.6 224.9 226.3 48.8 80.5 23.7 3.3 27.0 2.4 35.8 37.1 23.3 25.4 48.8 168.6 77.4 397.7 17.9 49.4 55.6 40.8 30.1 118.1 1.5 14.4 236.3 128.2 666.4 32.4 20.3 28.9 43.2 22.3 5.5 51.9 12.9 114.0 28.3 27.0 404.9 64.9 103.8 41.6 203.1 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077027-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 63.9" "Cell type enriched" "Detected in some" 44 "Horizontal cells: 74.7" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "non-classical monocyte: 6.7" "Group enriched" "Detected in many" 13 "dendritic cells: 2.1;monocytes: 6.7" "Cell line enhanced" "Detected in some" "MCF7: 18.0;NB-4: 11.8;SH-SY5Y: 91.8;THP-1: 27.4" "Low region specificity" "Detected in many" "Region enriched" "Detected in all" 6 "midbrain: 95.5" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" No NA 260000 "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavorable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 15.2 1.1 1.8 1.3 0.7 1.2 4.1 9.0 1.9 3.1 0.9 1.1 1.5 0.9 0.6 1.2 0.7 1.0 1.2 1.5 5.8 1.0 11.7 0.7 0.8 17.5 1.2 0.8 1.3 63.9 6.3 0.8 16.8 2.2 1.5 2.8 13.6 2.0 4.5 1.1 2.6 1.1 2.8 0.6 2.1 2.0 0.0 0.1 0.8 5.1 0.6 1.9 1.4 0.2 2.1 0.0 6.7 0.0 0.3 0.4 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.0 0.0 11.8 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 91.8 0.0 0.0 0.0 0.1 1.3 27.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 6.7 2.1 0.3 0.4 1.1 1.3 4.1 9.0 1.5 5.8 17.5 1.2 16.8 0.0 0.0 0.3 0.0 0.5 0.2 0.1 1.6 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.0 0.0 0.2 1.7 1.0 1.2 1.1 0.8 0.1 74.7 0.0 0.0 0.0 1.4 0.3 0.0 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.4 0.0 1.4 0.4 1.1 0.5 0.0 0.0 0.0 0.1 RHOA "ARH12, ARHA, Rho12, RhoA, RHOH12" ENSG00000067560 "Ras homolog family member A" P61586 3 49359145-49412998 "Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins" "Cell cycle, Cell division, Host-virus interaction" Hydrolase "Cancer-related genes, Disease mutation, Ectodermal dysplasia, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005052 Approved Supported "Plasma membrane,Cytosol" NA NA 65000000 "Plasma membrane, Cytosol" "CAB005052: AB_562216" "unprognostic (1.50e-1)" "unprognostic (3.38e-1)" "prognostic favorable (3.08e-4)" "unprognostic (8.75e-2)" "unprognostic (1.63e-1)" "unprognostic (1.24e-1)" "prognostic unfavorable (9.15e-4)" "unprognostic (1.39e-1)" "unprognostic (8.83e-2)" "unprognostic (9.44e-3)" "unprognostic (2.21e-2)" "unprognostic (4.29e-2)" "prognostic favorable (3.21e-6)" "unprognostic (5.14e-2)" "unprognostic (7.50e-2)" "unprognostic (1.57e-1)" "unprognostic (4.52e-2)" 141.1 89.5 63.0 79.8 60.6 91.4 93.1 34.3 77.3 80.3 79.1 100.4 48.9 63.6 84.4 66.4 116.7 67.8 74.2 72.5 57.6 54.8 104.0 80.7 104.6 102.4 74.0 43.8 102.7 64.9 45.8 48.2 105.3 68.8 76.0 80.3 81.6 66.5 72.0 86.0 73.9 90.8 88.9 97.3 116.0 73.4 57.3 60.3 127.1 108.1 80.1 99.8 103.4 75.7 42.6 78.4 124.2 125.7 38.3 50.5 151.5 55.7 43.0 54.0 57.9 62.0 94.0 42.2 121.4 77.8 84.9 78.3 36.4 58.5 81.8 34.9 145.8 49.3 31.8 59.3 66.2 87.2 63.1 35.3 78.1 57.9 42.7 66.5 77.0 58.6 73.4 47.1 69.4 55.9 85.8 108.6 43.5 41.6 51.5 100.6 26.6 83.8 75.1 51.6 56.0 54.8 38.8 54.3 64.3 73.4 63.7 19.8 45.1 72.9 52.8 54.7 55.8 34.2 86.8 117.2 68.2 61.8 89.9 87.2 51.2 103.7 93.9 66.4 75.8 77.8 52.5 99.7 106.8 49.1 125.7 41.6 42.6 41.4 47.6 78.4 37.5 32.2 40.1 124.2 38.3 120.4 58.7 50.5 151.5 63.0 60.6 34.3 77.3 57.6 54.8 74.0 43.8 68.8 60.3 360.3 233.2 266.1 228.8 240.6 42.2 113.5 155.4 182.0 182.0 171.0 5.9 328.4 288.5 303.4 30.3 372.7 339.7 93.5 302.0 572.5 345.6 260.3 251.7 153.0 691.2 77.9 225.0 312.5 712.8 42.2 310.4 490.6 310.4 582.5 261.8 172.7 313.0 270.7 383.3 255.4 33.0 271.7 354.1 227.5 221.8 244.4 439.3 304.1 267.8 270.4 RHOH "ARHH, RhoH, TTF" ENSG00000168421 "Ras homolog family member H" Q15669 4 40191053-40246967 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 54.8;lymphoid tissue: 94.7" "Group enriched" "Detected in many" 5 "B-cells: 118.6;granulocytes: 136.5;Melanocytes: 54.0;T-cells: 125.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in single" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "Daudi: 34.9;HMC-1: 26.8;JURKAT: 35.1;MOLT-4: 48.5;U-266/70: 18.8;U-266/84: 15.1;U-698: 32.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA030345, HPA061314" Uncertain Approved "Golgi apparatus,Vesicles" NA NA "Golgi apparatus, Vesicles" "HPA030345: AB_10601607, HPA061314: " "unprognostic (4.00e-2)" "unprognostic (1.83e-4)" "unprognostic (1.24e-2)" "unprognostic (2.22e-5)" "unprognostic (1.35e-1)" "unprognostic (1.32e-3)" "unprognostic (1.16e-1)" "unprognostic (2.73e-2)" "unprognostic (2.30e-2)" "unprognostic (4.30e-2)" "unprognostic (9.07e-2)" "unprognostic (1.38e-1)" "unprognostic (3.31e-6)" "unprognostic (2.96e-1)" "unprognostic (3.91e-2)" "unprognostic (4.46e-2)" "unprognostic (2.44e-2)" 1.8 0.6 0.6 33.8 1.1 21.7 5.2 0.4 0.4 1.3 2.4 0.5 0.4 1.6 2.0 0.9 2.5 1.5 4.1 1.1 0.6 0.7 1.6 1.7 4.8 43.2 0.8 0.2 0.7 0.8 0.0 0.9 0.3 0.8 2.1 2.0 1.0 7.8 0.6 0.5 1.2 15.1 0.7 1.2 33.1 2.7 0.7 0.6 94.7 1.6 1.9 41.0 5.1 1.5 41.2 4.7 32.2 0.2 12.3 54.8 21.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 34.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 5.2 0.0 0.0 0.0 5.7 26.8 0.4 0.0 0.0 0.0 0.0 0.0 35.1 0.4 0.3 0.0 0.0 48.5 3.6 0.6 0.0 0.1 5.2 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.6 0.1 0.1 0.0 0.1 0.0 0.0 18.8 15.1 32.2 0.0 1.2 0.0 32.2 0.2 29.6 21.6 0.1 19.4 30.5 34.6 29.1 0.3 41.2 54.8 43.3 1.6 12.3 0.2 4.7 47.0 21.1 0.6 1.1 0.4 0.4 0.6 0.7 0.8 0.2 0.8 0.6 3.0 16.4 118.6 1.4 6.4 0.0 0.8 2.5 1.4 4.5 0.0 0.0 0.1 0.0 0.0 0.4 0.7 0.0 23.3 0.0 0.1 4.1 1.1 136.5 0.0 2.2 0.0 0.0 1.8 4.6 0.0 0.0 12.1 54.0 10.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.2 0.0 6.0 0.2 125.8 0.0 1.8 RMI2 "BLAP18, C16orf75, MGC24665" ENSG00000175643 "RecQ mediated genome instability 2" Q96E14 16 11249619-11351762 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "DNA replication" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 31.7;testis: 29.6" "Cell type enhanced" "Detected in many" 11 "Cytotrophoblasts: 100.7;Peritubular cells: 40.0;Spermatogonia: 42.9;Syncytiotrophoblasts: 39.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "memory B-cell: 6.5" "Group enriched" "Detected in many" 5 "B-cells: 6.5;T-cells: 3.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" HPA040995 Uncertain Supported "Nuclear speckles,Cytosol" NA Yes "Nuclear speckles" Cytosol "HPA040995: AB_10795531" "unprognostic (2.76e-1)" "prognostic favorable (5.69e-5)" "unprognostic (1.17e-1)" "unprognostic (3.09e-3)" "unprognostic (1.69e-2)" "unprognostic (1.80e-3)" "prognostic unfavorable (2.77e-5)" "unprognostic (3.98e-1)" "unprognostic (1.16e-1)" "unprognostic (1.83e-1)" "unprognostic (3.44e-3)" "unprognostic (3.89e-1)" "unprognostic (2.18e-1)" "unprognostic (5.50e-2)" "unprognostic (3.68e-2)" "unprognostic (3.60e-3)" "unprognostic (1.03e-1)" 1.0 1.8 4.2 18.0 5.1 4.8 2.8 0.7 4.1 2.8 7.3 1.0 0.4 4.3 2.5 3.2 11.8 1.0 2.6 1.9 2.5 1.5 3.1 2.3 2.9 17.9 1.6 5.6 3.6 1.6 0.7 1.1 13.2 1.2 2.6 9.0 0.8 2.9 1.7 1.1 8.7 5.6 1.1 1.4 4.2 4.0 29.6 1.2 31.7 1.4 2.8 20.4 3.6 4.5 6.5 0.6 0.9 0.0 0.3 3.0 0.3 19.2 12.9 25.4 10.8 1.1 5.5 10.6 11.2 8.9 10.6 17.7 4.9 22.9 26.7 9.7 5.2 12.0 11.3 10.8 10.7 17.3 5.2 10.1 14.6 7.6 32.6 0.4 5.6 6.6 1.2 2.1 4.6 4.4 4.2 5.8 11.8 20.1 21.3 5.5 22.2 19.3 26.2 21.3 26.9 5.1 23.5 27.4 28.5 6.3 12.5 14.6 11.6 9.5 15.9 8.3 15.3 27.0 8.4 1.8 8.5 8.0 16.3 1.6 5.8 9.6 31.7 7.9 18.5 15.7 0.0 0.0 0.9 0.6 0.0 0.0 6.5 0.2 0.0 0.4 2.5 1.8 0.7 0.2 0.3 0.0 0.6 3.0 0.3 4.2 5.1 0.7 4.1 2.5 1.5 1.6 5.6 1.2 1.2 0.0 0.3 4.9 6.4 6.1 0.1 0.8 5.1 0.0 2.3 7.0 0.0 100.7 5.0 2.3 2.2 0.7 1.1 23.3 0.4 27.0 2.6 1.6 0.0 0.8 15.8 0.0 2.4 1.3 1.0 4.3 14.7 3.4 3.3 1.8 5.9 0.0 1.1 3.5 40.0 0.0 0.5 32.3 0.9 31.4 42.9 4.6 39.9 0.0 7.0 2.8 RNF213 "C17orf27, KIAA1554, KIAA1618, MYMY2, NET57" ENSG00000173821 "Ring finger protein 213" Q63HN8 17 80260866-80398786 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Angiogenesis, Ubl conjugation pathway" "Hydrolase, Transferase" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 36.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003347, HPA026790" Approved Supported Cytosol NA NA Cytosol "HPA003347: AB_1079204, HPA026790: AB_10602296" "unprognostic (8.98e-2)" "unprognostic (1.60e-1)" "unprognostic (8.97e-3)" "prognostic unfavorable (4.65e-5)" "unprognostic (7.39e-2)" "unprognostic (3.99e-2)" "unprognostic (2.23e-2)" "unprognostic (1.52e-1)" "unprognostic (4.57e-2)" "unprognostic (3.85e-1)" "unprognostic (1.96e-2)" "unprognostic (1.12e-1)" "unprognostic (1.52e-3)" "unprognostic (8.92e-2)" "unprognostic (1.13e-2)" "unprognostic (1.40e-1)" "unprognostic (4.56e-2)" 17.0 15.1 7.4 16.9 10.3 22.4 10.2 4.7 7.5 11.0 12.2 15.6 14.9 8.5 16.6 13.0 13.2 9.7 12.1 8.5 7.8 7.8 17.1 11.6 15.4 17.9 10.9 5.6 11.5 9.0 41.1 11.4 15.1 10.0 11.2 8.0 12.3 11.7 12.5 9.0 8.7 14.8 13.6 14.3 17.0 10.6 5.9 8.7 24.5 15.9 7.5 18.2 13.6 15.4 7.2 13.9 37.9 9.6 11.4 12.1 1.8 16.2 28.9 2.9 2.0 10.6 16.2 2.2 4.1 9.0 18.6 15.9 3.1 7.5 1.0 3.5 8.6 19.9 9.5 3.9 5.3 6.3 36.8 1.8 2.5 11.7 5.4 4.5 2.7 2.6 8.9 3.6 10.4 4.5 5.8 14.3 11.8 4.7 6.1 6.9 3.9 10.6 1.1 2.1 3.0 6.7 7.3 6.7 1.2 5.2 14.1 2.8 3.9 10.0 21.2 7.6 6.8 4.8 3.4 18.5 10.4 8.3 6.1 4.2 2.7 2.5 2.9 7.8 3.2 3.7 6.9 9.6 4.2 12.1 8.0 8.1 6.2 8.6 9.7 2.3 7.2 6.9 8.5 37.9 11.4 6.9 13.9 6.4 1.8 7.4 10.3 4.7 7.5 7.8 7.8 10.9 5.6 10.0 8.7 83.4 56.5 111.7 32.9 31.8 18.0 28.5 79.0 38.8 38.7 96.0 47.1 18.7 11.6 100.5 1.1 68.4 78.6 23.3 139.5 24.8 43.3 49.8 44.1 45.9 84.7 22.3 44.2 79.2 104.8 2.0 56.4 97.6 28.7 162.3 61.5 23.6 181.0 73.7 48.4 56.6 71.2 64.7 34.9 1.4 4.4 30.1 18.2 168.3 34.5 65.7 RNF43 "DKFZp781H0392, FLJ20315, URCC" ENSG00000108375 "Ring finger protein 43" Q68DV7 17 58352500-58417595 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "Ubl conjugation pathway, Wnt signaling pathway" "Developmental protein, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 7 "Enterocytes: 33.4;Mucus-secreting cells: 39.0;Undifferentiated cells: 47.8" "Cancer enhanced" "Detected in many" "colorectal cancer: 41.7" "Region enriched" "Detected in many" 7 "cerebellum: 30.6" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 13.4;Hep G2: 26.2;OE19: 29.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA008079 Uncertain NA NA "HPA008079: AB_1856371" "unprognostic (2.53e-1)" "unprognostic (1.09e-1)" "unprognostic (7.46e-2)" "unprognostic (2.56e-1)" "unprognostic (1.10e-1)" "unprognostic (4.33e-2)" "unprognostic (1.39e-1)" "unprognostic (3.62e-1)" "unprognostic (2.93e-1)" "unprognostic (1.05e-1)" "unprognostic (5.69e-2)" "unprognostic (3.79e-1)" "prognostic favorable (6.04e-9)" "unprognostic (3.61e-3)" "unprognostic (2.56e-1)" "unprognostic (3.58e-1)" "unprognostic (1.04e-2)" 0.4 9.4 2.2 6.2 3.5 1.9 4.5 30.6 4.3 3.4 26.4 0.9 21.3 18.5 1.7 9.1 10.0 3.9 8.1 3.3 1.9 1.3 8.0 7.0 6.1 2.7 0.8 1.1 1.6 13.2 3.0 13.3 8.7 4.1 8.0 16.3 3.8 13.7 19.0 0.5 8.9 29.0 0.9 0.8 0.9 4.9 3.1 0.7 3.0 1.8 5.7 6.6 4.0 4.4 0.9 1.1 1.7 1.8 5.6 3.6 1.2 0.6 9.3 1.7 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 13.4 4.5 3.8 4.8 0.0 1.1 2.6 0.3 3.6 0.0 7.9 6.5 3.0 0.4 26.2 0.0 3.7 2.7 0.0 7.4 0.0 1.1 0.5 0.0 1.2 0.2 3.3 0.0 0.1 2.0 3.5 0.2 29.2 0.6 6.2 0.0 2.0 3.3 5.1 1.0 0.3 0.8 0.4 0.3 3.2 1.1 1.0 0.0 0.1 1.1 0.0 0.0 3.4 1.6 2.9 0.3 0.4 2.2 1.7 0.2 1.6 3.1 0.8 3.2 0.9 2.5 3.6 0.4 0.9 2.3 3.0 0.8 5.6 1.8 1.1 1.2 1.2 2.2 3.5 30.6 4.3 1.9 1.3 0.8 1.1 4.1 0.7 3.0 6.2 0.5 15.7 8.5 2.4 3.5 10.2 4.0 3.4 17.4 2.0 19.4 13.3 5.6 1.2 0.7 33.4 0.0 2.4 2.2 0.6 8.7 0.0 8.7 2.3 4.8 14.9 0.6 0.6 1.3 0.3 0.7 13.5 2.8 39.0 11.7 4.5 24.6 0.4 2.2 2.8 0.0 0.4 1.1 0.5 5.4 4.9 3.9 47.8 5.4 ROS1 "c-ros-1, MCF3, ROS" ENSG00000047936 "ROS proto-oncogene 1, receptor tyrosine kinase" P08922 6 117288300-117425855 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "epididymis: 38.6;lung: 20.2" "Group enriched" "Detected in some" 5 "Alveolar cells type 1: 14.9;Alveolar cells type 2: 56.7" "Cancer enriched" "Detected in some" 13 "lung cancer: 6.9" "Group enriched" "Detected in some" 10 "cerebral cortex: 7.4;olfactory region: 2.5" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "GAMG: 16.3;HSkMC: 8.7;hTCEpi: 18.1;LHCN-M2: 12.5" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049098, HPA072424" Uncertain Approved Vesicles NA NA Vesicles "HPA049098: AB_2680628, HPA072424: AB_2686519" "unprognostic (8.18e-2)" "unprognostic (4.64e-3)" "unprognostic (1.60e-1)" "unprognostic (2.37e-2)" "unprognostic (7.57e-2)" "unprognostic (2.05e-2)" "unprognostic (1.57e-1)" "unprognostic (1.79e-1)" "unprognostic (2.79e-2)" "unprognostic (1.00e-2)" "unprognostic (2.42e-1)" "unprognostic (5.20e-2)" "unprognostic (1.56e-12)" "unprognostic (1.09e-2)" "unprognostic (2.81e-1)" "unprognostic (1.91e-1)" "unprognostic (2.12e-1)" 0.3 0.2 0.2 0.0 0.4 0.0 0.2 0.2 7.4 0.2 0.4 0.0 7.9 0.0 0.2 38.6 0.2 0.2 0.0 0.2 0.2 0.2 0.4 0.2 20.2 0.0 0.2 2.5 0.2 0.2 0.0 0.3 0.7 0.0 0.2 0.3 0.0 0.2 2.3 0.2 0.7 0.3 0.0 0.2 0.2 0.3 0.7 0.0 0.0 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.3 0.2 0.0 0.0 0.1 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 8.7 18.1 0.2 1.6 0.0 0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 1.6 0.0 2.2 1.4 0.1 1.7 0.0 0.0 0.0 1.6 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.2 7.4 0.2 0.2 0.2 2.5 0.0 0.0 14.9 56.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 6.8 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 RPL10 "DXS648, DXS648E, FLJ23544, L10, NOV, QM" ENSG00000147403 "Ribosomal protein L10" P27635 X 154389955-154409168 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Translation regulation" "Developmental protein, Ribonucleoprotein, Ribosomal protein" "Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB010339, HPA011311" Enhanced Enhanced "Endoplasmic reticulum,Cytosol" NA NA 130000 "Endoplasmic reticulum, Cytosol" "CAB010339: AB_2181277, HPA011311: AB_1856431" "unprognostic (2.46e-3)" "unprognostic (3.57e-2)" "unprognostic (1.72e-1)" "unprognostic (2.14e-2)" "unprognostic (1.25e-2)" "unprognostic (2.06e-1)" "unprognostic (6.11e-2)" "unprognostic (9.01e-3)" "unprognostic (1.91e-1)" "unprognostic (2.21e-1)" "unprognostic (5.39e-2)" "unprognostic (3.37e-1)" "prognostic unfavorable (7.67e-6)" "unprognostic (6.84e-2)" "unprognostic (1.86e-1)" "unprognostic (1.65e-2)" "unprognostic (5.68e-2)" 103.6 65.3 41.4 108.0 48.5 103.7 152.6 82.4 70.7 118.2 80.6 44.6 107.8 51.3 100.4 75.5 105.2 122.3 52.6 82.5 38.2 31.9 112.1 155.0 97.6 190.2 48.2 37.4 223.5 242.3 35.0 51.9 87.4 53.1 83.6 77.1 66.7 109.9 101.5 125.9 121.8 108.9 78.7 51.4 93.9 90.5 33.9 47.2 158.9 198.9 137.9 134.4 86.9 119.3 252.9 168.6 64.4 124.1 149.1 304.9 445.3 190.6 88.4 88.6 67.9 201.2 381.1 78.4 73.4 170.1 141.3 179.7 78.4 85.8 378.1 177.6 122.3 139.8 74.1 173.4 175.7 121.4 83.0 137.5 51.0 63.4 85.9 236.7 109.5 75.5 287.6 278.2 84.9 265.3 244.2 221.6 161.8 71.8 120.9 137.9 95.7 119.3 106.6 69.8 188.1 152.9 143.1 84.0 210.1 154.1 68.1 71.1 118.8 17.7 156.2 216.7 89.4 56.8 153.2 106.6 49.4 94.0 111.2 162.3 287.9 207.9 376.0 75.1 158.2 61.7 64.4 124.1 18.1 149.9 107.7 256.2 252.9 251.6 186.2 151.2 243.2 304.9 231.1 13.0 149.1 94.9 168.6 178.0 445.3 41.4 48.5 82.4 70.7 38.2 31.9 48.2 37.4 53.1 47.2 1664.5 2043.1 10322.4 11239.3 10721.6 451.7 309.0 3949.0 1271.5 2545.5 1934.9 233.7 5960.7 5721.4 3854.4 49.9 6113.6 2058.8 1915.6 11641.3 8484.3 6948.0 9869.1 2815.7 3204.1 6194.0 254.3 2785.1 5085.5 7653.2 131.8 7835.9 9465.3 7747.1 9437.5 6244.9 793.3 8332.0 5018.5 3353.3 5769.1 609.3 2942.7 9122.3 99.1 315.1 12724.6 6324.6 8194.7 7230.3 10693.0 RPL22 "EAP, L22" ENSG00000116251 "Ribosomal protein L22" P35268 1 6181269-6209389 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Heparin-binding, Ribonucleoprotein, Ribosomal protein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA068294 Approved Nucleoplasm,Nucleoli NA NA 320000 Nucleoli Nucleoplasm "HPA068294: AB_2732781" "unprognostic (3.16e-3)" "unprognostic (1.28e-1)" "unprognostic (3.13e-1)" "unprognostic (3.62e-2)" "unprognostic (2.27e-2)" "unprognostic (1.09e-1)" "unprognostic (1.29e-3)" "unprognostic (4.40e-2)" "unprognostic (7.06e-2)" "unprognostic (3.26e-1)" "unprognostic (1.48e-1)" "unprognostic (4.24e-2)" "unprognostic (1.46e-3)" "unprognostic (3.83e-1)" "unprognostic (3.88e-2)" "unprognostic (2.46e-1)" "unprognostic (1.98e-1)" 75.5 71.5 54.3 79.7 42.8 124.7 75.0 46.7 39.5 95.8 73.9 39.2 53.9 66.5 133.6 63.9 103.9 59.1 61.8 50.8 47.4 38.6 58.8 90.2 55.3 142.6 50.6 39.7 163.1 154.8 30.4 57.0 49.8 37.4 90.8 46.4 57.0 140.3 66.8 114.0 79.7 62.6 106.6 58.3 79.1 62.0 38.2 35.0 95.3 91.0 112.8 81.1 101.5 91.9 75.6 62.3 11.0 38.9 42.2 98.8 73.9 89.4 25.5 54.4 55.5 38.3 60.3 43.0 78.2 31.5 28.8 24.6 50.6 77.8 138.9 64.4 28.9 19.9 51.8 40.8 40.6 38.0 68.0 66.5 135.0 58.1 62.8 38.0 178.6 54.2 53.1 33.7 25.6 53.1 59.6 35.9 39.0 111.2 84.2 33.0 39.5 78.0 145.7 33.8 59.9 56.7 75.3 112.8 107.6 42.1 31.1 75.2 69.0 63.6 184.4 143.1 49.3 59.3 141.6 87.7 41.1 45.3 54.2 73.4 67.7 92.9 210.2 27.2 184.7 25.4 11.0 38.9 8.8 38.0 34.3 66.9 75.6 71.1 52.3 59.8 72.4 98.8 78.1 2.9 42.2 27.8 62.3 54.0 73.9 54.3 42.8 46.7 39.5 47.4 38.6 50.6 39.7 37.4 35.0 413.9 647.4 2117.2 1742.6 1617.7 195.0 241.8 1080.3 472.4 833.7 554.8 123.7 1561.4 1614.8 1042.5 368.7 1236.7 707.2 537.3 1569.0 2352.9 1052.3 1320.4 878.8 1234.2 1317.3 133.5 877.3 1218.4 1697.8 247.8 1877.2 1676.9 1020.7 1556.4 1647.3 322.2 1580.5 1090.7 1160.1 1724.2 283.7 763.2 1114.2 317.0 420.5 1692.2 1548.7 1448.0 2302.5 1714.3 RPL5 "L5, PPP1R135" ENSG00000122406 "Ribosomal protein L5" P46777 1 92831983-92841924 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding" "Cancer-related genes, Diamond-Blackfan anemia, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA043717, HPA054444" Approved Supported "Nucleoli,Nucleoli rim,Endoplasmic reticulum,Cytosol" NA NA 130000 "Endoplasmic reticulum, Cytosol" "Nucleoli, Nucleoli rim" "HPA043717: AB_10964719, HPA054444: AB_2732584" "unprognostic (5.81e-3)" "unprognostic (3.96e-1)" "unprognostic (1.04e-1)" "unprognostic (1.52e-1)" "unprognostic (9.44e-3)" "unprognostic (1.96e-1)" "unprognostic (1.03e-3)" "unprognostic (9.95e-2)" "unprognostic (8.68e-2)" "unprognostic (1.23e-1)" "unprognostic (3.98e-2)" "unprognostic (3.48e-1)" "prognostic unfavorable (6.81e-5)" "unprognostic (2.26e-2)" "unprognostic (3.12e-2)" "unprognostic (1.09e-1)" "unprognostic (3.97e-1)" 119.4 80.3 50.0 70.0 50.1 113.8 140.5 46.9 46.8 158.6 111.4 45.0 75.1 61.7 135.2 114.6 159.4 100.5 73.1 73.0 43.5 43.1 99.7 114.9 89.9 148.2 54.5 36.2 296.8 306.5 40.8 90.3 90.2 44.3 175.4 78.8 64.3 121.5 73.2 109.1 97.8 95.3 153.4 61.9 130.1 90.0 68.8 45.7 156.6 210.0 97.7 118.9 191.2 146.6 104.5 85.2 12.8 45.9 72.4 143.0 142.1 118.8 51.1 91.0 76.7 118.4 239.2 146.0 71.1 95.2 88.5 63.5 135.2 52.0 224.2 114.2 79.8 84.0 76.0 104.3 133.2 113.2 71.0 142.8 116.3 85.0 124.4 142.0 178.1 49.1 195.6 210.2 78.6 173.1 160.6 122.3 118.5 144.0 118.2 101.4 67.4 141.8 201.9 140.6 90.4 96.5 130.3 176.3 144.8 107.4 99.0 77.6 92.9 46.3 129.2 206.7 78.2 71.2 245.0 74.2 44.7 81.8 84.6 128.1 73.2 69.5 151.7 30.3 153.6 30.3 12.8 45.9 7.2 60.9 44.8 122.1 104.5 111.5 91.6 85.2 88.4 143.0 123.9 4.4 72.4 38.3 71.1 83.2 142.1 50.0 50.1 46.9 46.8 43.5 43.1 54.5 36.2 44.3 45.7 607.4 848.7 2690.4 3540.6 2525.4 316.8 352.2 1200.0 674.6 1189.7 390.8 84.4 2237.8 1689.4 1278.7 1159.8 1643.6 564.1 537.3 2338.5 3530.6 1572.9 2535.7 1002.7 856.3 1297.7 138.2 1189.1 1198.2 1468.3 888.7 2620.2 1565.9 1334.5 1646.5 1585.6 343.0 1936.2 1164.3 2027.0 1766.3 226.7 1034.8 1885.9 531.9 457.4 2528.9 2185.2 1965.9 2487.8 3230.9 RPN1 OST1 ENSG00000163902 "Ribophorin I" P04843 3 128619970-128681075 "Cancer-related genes, Plasma proteins, Predicted membrane proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009748, HPA026828, HPA051520" Enhanced Enhanced "Endoplasmic reticulum,Cytosol" NA NA 8200000 "Endoplasmic reticulum" Cytosol "CAB009748: AB_2182230, HPA026828: AB_10610418, HPA051520: AB_2681521" "unprognostic (4.83e-2)" "unprognostic (5.92e-2)" "unprognostic (1.10e-1)" "unprognostic (7.67e-2)" "unprognostic (2.36e-1)" "unprognostic (2.12e-2)" "prognostic unfavorable (4.80e-4)" "unprognostic (2.71e-1)" "unprognostic (2.43e-1)" "unprognostic (2.28e-2)" "unprognostic (4.58e-3)" "unprognostic (2.87e-1)" "unprognostic (7.68e-2)" "unprognostic (7.86e-2)" "unprognostic (1.52e-2)" "unprognostic (1.44e-1)" "unprognostic (9.74e-2)" 52.3 37.5 22.2 26.6 23.8 24.4 48.2 20.9 31.4 45.8 40.8 31.9 58.8 28.5 38.3 110.2 32.2 38.3 38.8 47.1 23.0 28.0 55.4 174.0 47.4 50.6 26.4 18.3 37.8 62.9 43.5 36.9 58.3 24.3 31.4 41.1 28.6 54.1 55.5 34.4 24.0 37.0 33.5 31.8 48.0 33.7 26.9 23.3 34.3 69.1 27.3 36.5 32.7 39.7 26.7 53.1 64.4 43.5 23.4 45.1 53.3 60.5 33.0 27.6 50.7 74.7 50.1 62.5 52.2 68.7 69.4 80.9 68.4 57.1 37.9 49.3 75.3 64.7 61.0 44.5 46.5 68.0 27.2 28.6 66.8 24.6 56.2 82.4 54.2 35.2 41.5 54.4 45.6 67.5 46.5 54.2 28.7 27.5 50.9 45.5 55.4 30.0 59.6 35.0 81.1 30.3 32.9 37.1 91.2 48.1 36.4 42.5 24.5 42.9 44.5 52.8 36.9 47.6 56.1 35.2 35.9 28.1 52.5 38.7 54.9 43.2 40.5 58.9 40.4 51.8 38.8 43.5 35.7 37.3 40.0 45.1 26.7 30.7 33.8 43.5 18.3 19.1 29.2 64.4 23.4 40.2 53.1 30.5 53.3 22.2 23.8 20.9 31.4 23.0 28.0 26.4 18.3 24.3 23.3 56.6 71.5 37.3 71.3 44.0 11.5 35.3 61.1 66.9 47.8 106.4 7.9 108.3 13.3 99.9 13.7 58.2 107.9 46.7 81.2 161.1 79.3 88.0 42.7 155.3 122.7 19.1 41.6 107.4 134.1 20.7 87.2 73.4 55.6 36.9 102.4 27.5 98.9 83.4 60.5 80.2 11.7 45.3 39.6 49.9 59.8 46.7 131.0 50.0 106.2 66.4 RSPO2 MGC35555 ENSG00000147655 "R-spondin 2" Q6UXX9 8 107899316-108083648 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Sensory transduction, Wnt signaling pathway" "Developmental protein, Heparin-binding" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.0;placenta: 20.1" "Cell type enhanced" "Detected in some" 13 "Early spermatids: 1.4;Late spermatids: 2.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 5 "intermediate monocyte: 1.6" "Lineage enriched" "Detected in single" 17 "monocytes: 1.6" "Cell line enhanced" "Detected in some" "HEK 293: 3.6;HEL: 3.3;NTERA-2: 2.0;U-138 MG: 3.6;U-266/70: 10.7" "Group enriched" "Detected in some" 7 "amygdala: 8.2;cerebral cortex: 18.2;hippocampal formation: 23.2" "Group enriched" "Detected in many" 5 "amygdala: 23.3;cerebral cortex: 18.0;hippocampal formation: 24.1;midbrain: 33.2" "HPA024764, CAB025900, HPA053068" Uncertain "Secreted in other tissues" NA NA "CAB025900: , HPA024764: AB_10603236, HPA053068: AB_2682031" "unprognostic (1.10e-2)" "unprognostic (2.18e-1)" "unprognostic (3.97e-2)" "unprognostic (1.52e-1)" "unprognostic (2.04e-1)" "unprognostic (1.19e-1)" "unprognostic (8.33e-3)" "unprognostic (1.82e-1)" "unprognostic (9.48e-2)" "unprognostic (1.31e-1)" "unprognostic (1.40e-1)" "unprognostic (8.45e-2)" "unprognostic (1.95e-2)" "unprognostic (1.17e-2)" 0.4 0.5 3.9 1.4 6.3 0.5 0.2 1.9 27.0 3.6 12.0 4.2 3.6 5.1 0.3 3.6 8.9 0.2 4.8 0.5 5.8 10.5 0.2 1.1 9.3 0.2 15.7 5.4 1.1 0.2 0.2 2.8 20.1 2.0 11.6 10.1 15.5 0.2 3.4 0.3 0.3 5.8 0.7 1.3 0.2 8.3 2.0 1.7 0.0 0.2 0.0 0.2 2.2 1.2 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 3.3 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.3 0.0 0.2 0.0 3.6 0.2 0.1 0.0 10.7 0.0 0.0 1.1 0.4 0.0 0.0 0.3 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 6.3 1.9 27.0 5.8 10.5 15.7 5.4 2.0 1.7 0.0 0.0 0.0 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.0 0.0 0.8 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.8 0.0 0.0 0.0 RSPO3 "FLJ14440, THSD2" ENSG00000146374 "R-spondin 3" Q9BXY4 6 127118604-127197765 "Cancer-related genes, Predicted secreted proteins" "Sensory transduction, Wnt signaling pathway" Heparin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 5 "Early spermatids: 10.8;Fibroblasts: 10.4;Ito cells: 16.0;Leydig cells: 25.3;Sertoli cells: 6.5" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 5 "cerebellum: 5.7;hippocampal formation: 20.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 23.5;BJ hTERT+: 4.1;hTERT-RPE1: 7.8;U-138 MG: 5.2;U-87 MG: 5.1" "Low region specificity" "Detected in all" "Region enhanced" "Detected in many" "hippocampal formation: 32.5" HPA029957 Uncertain "Secreted to blood" NA NA "HPA029957: AB_10602087" "unprognostic (4.77e-2)" "unprognostic (3.95e-2)" "unprognostic (1.27e-2)" "unprognostic (2.27e-2)" "unprognostic (1.10e-1)" "unprognostic (2.99e-1)" "unprognostic (9.71e-2)" "unprognostic (1.49e-2)" "unprognostic (3.77e-2)" "unprognostic (3.21e-1)" "unprognostic (1.37e-1)" "unprognostic (3.37e-1)" "unprognostic (1.07e-3)" "unprognostic (7.94e-2)" "unprognostic (2.76e-1)" "unprognostic (1.64e-2)" "unprognostic (7.89e-3)" 18.5 10.5 2.8 12.1 0.8 0.0 40.7 5.7 2.3 12.9 8.5 0.0 23.8 1.2 50.3 32.5 23.7 14.9 7.6 4.2 20.5 1.7 3.3 4.2 3.8 10.2 0.8 2.4 13.2 1.5 0.0 2.6 24.1 0.8 10.2 4.7 8.6 3.9 15.3 19.7 2.2 6.7 34.1 0.6 1.4 10.8 12.4 0.0 0.2 2.9 2.1 0.9 9.3 39.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.5 0.0 0.0 1.4 0.0 0.0 0.0 4.1 0.2 0.5 0.0 0.0 0.0 0.5 0.2 0.5 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 7.8 2.6 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.2 0.0 0.0 0.2 0.0 0.0 0.0 5.2 2.0 0.7 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.8 5.7 2.2 20.5 1.7 0.8 2.4 0.8 0.0 0.0 0.0 0.0 0.0 0.8 1.7 0.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 10.8 2.8 0.0 0.0 0.0 1.0 10.4 0.6 0.0 0.0 1.3 0.0 0.0 16.0 0.3 1.1 25.3 0.0 1.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.5 2.7 0.0 0.1 0.1 1.4 0.0 0.0 0.1 RUNX1 "AML1, AMLCR1, CBFA2, PEBP2A2" ENSG00000159216 "Runt related transcription factor 1" Q01196 21 34787801-36004667 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 54.3;lymphoid tissue: 58.6" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "basophil: 17.0" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEL: 61.2;HMC-1: 36.9;JURKAT: 56.6" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA004176, HPA037912" Enhanced Enhanced Nucleoplasm,Vesicles No No Nucleoplasm Vesicles "HPA004176: AB_1078412, HPA037912: AB_2675733" "unprognostic (4.06e-3)" "unprognostic (2.35e-2)" "unprognostic (1.42e-2)" "unprognostic (1.52e-1)" "unprognostic (5.15e-3)" "unprognostic (2.62e-1)" "unprognostic (5.87e-2)" "unprognostic (1.15e-1)" "unprognostic (1.13e-1)" "unprognostic (1.12e-3)" "unprognostic (2.33e-2)" "unprognostic (3.47e-2)" "prognostic unfavorable (3.44e-15)" "unprognostic (1.48e-1)" "unprognostic (1.50e-1)" "unprognostic (6.17e-2)" "unprognostic (5.47e-2)" 11.5 3.2 5.2 14.8 7.3 29.8 54.3 1.0 4.3 12.5 4.7 3.8 4.0 3.8 2.9 7.4 6.5 4.6 12.4 7.6 6.1 2.0 4.2 6.7 17.9 13.9 8.5 1.1 6.5 5.8 1.6 5.5 6.4 6.0 9.9 5.1 3.5 29.8 8.8 14.4 8.3 5.1 6.8 12.3 10.6 12.7 2.9 6.6 58.6 4.6 5.7 14.2 11.0 9.1 3.2 3.4 17.0 3.9 1.3 4.8 2.0 12.2 0.9 0.0 0.0 3.2 4.1 8.1 6.9 7.1 3.9 2.9 0.6 9.4 6.1 0.4 6.1 6.5 11.1 0.7 8.3 5.6 9.3 0.9 61.2 2.4 2.8 5.9 7.0 36.9 8.0 5.0 11.8 11.7 5.4 2.2 56.6 4.1 3.5 8.2 2.6 28.5 11.2 0.5 6.7 3.6 28.9 21.4 3.7 5.2 4.9 0.3 0.0 7.2 1.8 2.5 1.8 3.7 16.6 9.1 6.4 8.3 9.5 10.4 11.8 4.8 5.7 8.0 15.5 9.3 17.0 3.2 6.3 3.4 1.4 3.3 3.2 3.1 3.2 0.9 3.1 4.8 3.8 3.5 1.3 3.9 3.4 4.0 2.0 5.2 7.3 1.0 4.3 6.1 2.0 8.5 1.1 6.0 6.6 50.6 30.7 14.5 44.6 37.0 2.1 2.2 38.2 56.2 39.8 19.2 0.0 0.8 1.7 35.7 16.8 5.8 12.0 0.0 24.4 19.6 25.7 45.4 16.3 4.3 57.2 0.0 5.8 4.9 79.5 21.7 4.4 63.0 27.0 31.5 10.8 0.5 63.1 12.7 4.2 1.2 0.6 0.0 31.5 23.0 24.9 17.7 2.1 37.4 14.4 53.7 RUNX1T1 "AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2" ENSG00000079102 "RUNX1 translocation partner 1" Q06455 8 91954967-92103286 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 57.8" "Cell type enhanced" "Detected in many" 8 "Bipolar cells: 122.4;Ito cells: 87.8;Leydig cells: 89.2;Peritubular cells: 93.0;Sertoli cells: 64.7" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in all" 4 "cerebellum: 57.8" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "Daudi: 13.2;fHDF/TERT166: 11.2;HEL: 24.1;HSkMC: 9.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049852, HPA070951" Approved Supported Nucleoplasm NA NA Nucleoplasm "HPA049852: AB_2680914, HPA070951: AB_2686326" "unprognostic (2.37e-1)" "unprognostic (1.90e-1)" "unprognostic (1.90e-1)" "unprognostic (2.35e-1)" "unprognostic (1.62e-1)" "unprognostic (3.37e-4)" "unprognostic (2.29e-4)" "unprognostic (5.56e-3)" "unprognostic (1.24e-2)" "unprognostic (1.62e-2)" "unprognostic (2.11e-2)" "unprognostic (2.37e-1)" "unprognostic (5.70e-4)" "unprognostic (8.98e-3)" "unprognostic (6.78e-2)" "unprognostic (1.51e-1)" "unprognostic (7.80e-3)" 9.6 4.6 7.7 4.5 11.5 0.4 6.9 57.8 13.0 14.0 7.8 1.1 2.0 2.0 11.8 5.9 4.1 7.7 7.8 12.3 5.8 4.0 2.5 1.3 6.0 2.0 3.6 9.6 7.7 1.8 1.7 8.6 8.7 4.2 4.2 4.0 5.3 4.7 4.1 5.5 3.6 3.6 10.3 3.0 2.9 4.2 5.6 3.7 0.0 5.2 3.3 1.8 5.7 5.9 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.3 1.3 3.5 5.1 0.0 5.2 7.9 3.5 5.4 0.0 0.0 13.2 0.0 11.2 0.0 0.0 2.8 0.3 2.3 0.0 2.2 24.1 0.0 0.0 1.4 0.0 0.0 9.7 0.0 5.8 0.3 0.0 7.4 0.0 0.1 0.0 0.9 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 4.2 0.0 0.0 0.0 5.7 0.0 0.0 0.8 0.3 0.0 0.6 0.0 2.6 0.0 4.2 0.5 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 7.7 11.5 57.8 13.0 5.8 4.0 3.6 9.6 4.2 3.7 0.0 0.6 0.0 0.1 5.6 122.4 43.1 0.0 0.0 1.2 0.0 15.7 1.1 1.7 0.0 2.0 49.6 0.0 0.0 0.2 0.2 62.1 0.3 1.1 0.5 1.7 33.4 45.7 87.8 4.9 4.0 89.2 0.8 10.1 0.0 0.0 3.9 0.3 0.0 93.0 0.0 7.1 64.7 41.5 3.0 13.0 4.3 0.9 0.0 0.0 0.0 SALL4 "dJ1112F19.1, ZNF797" ENSG00000101115 "Spalt like transcription factor 4" Q9UJQ4 20 51782331-51802520 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "parathyroid gland: 8.8;testis: 11.7;thyroid gland: 8.6" "Cell type enriched" "Detected in some" 7 "Horizontal cells: 25.4" "Cancer enriched" "Detected in many" 11 "testis cancer: 22.7" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 9 "NK-cell: 6.3" "Lineage enriched" "Detected in single" 9 "NK-cells: 6.3" "Cell line enhanced" "Detected in some" "AF22: 13.1;AN3-CA: 9.1;BEWO: 17.5;NTERA-2: 31.5;SiHa: 8.0;SuSa: 22.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015291, HPA015791" Enhanced Enhanced Nucleoplasm Yes No Nucleoplasm "HPA015291: AB_1856548, HPA015791: AB_1856547" "unprognostic (1.30e-1)" "unprognostic (2.35e-2)" "unprognostic (1.11e-1)" "unprognostic (1.09e-3)" "unprognostic (3.55e-2)" "unprognostic (7.43e-2)" "unprognostic (3.63e-2)" "unprognostic (1.47e-1)" "unprognostic (1.20e-1)" "unprognostic (9.23e-2)" "unprognostic (2.50e-2)" "unprognostic (2.39e-2)" "unprognostic (2.42e-8)" "unprognostic (5.90e-3)" "unprognostic (1.82e-1)" "unprognostic (5.00e-5)" "unprognostic (7.41e-2)" 0.3 0.4 0.3 0.3 0.9 1.2 0.3 0.8 0.9 0.4 0.7 0.3 2.2 0.1 0.3 0.8 0.3 0.2 0.3 0.3 0.3 0.1 0.5 1.9 0.3 0.3 0.3 0.3 0.3 4.6 8.8 0.6 0.3 0.9 3.1 0.2 4.5 2.2 0.4 0.3 0.3 0.7 0.3 0.3 0.8 0.3 11.7 0.3 0.3 8.6 0.3 0.3 0.9 0.3 0.1 0.1 0.6 0.1 6.3 0.2 0.0 0.0 0.8 13.1 9.1 0.0 0.0 17.5 0.0 0.1 0.0 0.1 4.5 0.1 0.0 0.1 0.1 0.1 2.2 0.1 0.0 0.1 0.2 0.0 0.0 3.0 0.2 0.1 0.0 1.0 0.4 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.9 0.0 0.0 31.5 0.1 0.2 1.2 0.0 0.0 0.0 0.2 3.0 1.6 8.0 0.0 0.7 22.0 0.0 0.5 0.0 0.5 1.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.6 6.3 0.1 0.1 0.0 0.0 0.3 0.9 0.8 0.9 0.3 0.1 0.3 0.3 0.9 0.3 0.0 1.3 0.0 0.7 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.2 0.0 0.4 1.1 0.0 0.0 0.2 25.4 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.5 1.7 0.0 0.0 0.0 0.0 1.0 SDC4 "amphiglycan, ryudocan, SYND4" ENSG00000124145 "Syndecan 4" P31431 20 45325288-45348424 "Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 141.1" "Cell type enhanced" "Detected in many" 4 "Exocrine glandular cells: 450.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HBEC3-KT: 75.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005716, CAB013240" Enhanced Approved "Golgi apparatus,Plasma membrane" "Secreted to blood" NA NA "Golgi apparatus" "Plasma membrane" "CAB013240: AB_2533250, HPA005716: AB_1080160" "unprognostic (1.34e-2)" "unprognostic (1.80e-1)" "unprognostic (1.71e-2)" "unprognostic (2.16e-1)" "unprognostic (5.39e-2)" "unprognostic (6.59e-3)" "unprognostic (1.16e-1)" "unprognostic (5.93e-2)" "unprognostic (2.68e-1)" "unprognostic (2.95e-2)" "prognostic unfavorable (4.20e-4)" "unprognostic (1.97e-1)" "prognostic favorable (2.44e-7)" "unprognostic (3.00e-1)" "unprognostic (2.18e-1)" "prognostic favorable (2.67e-4)" "unprognostic (7.42e-2)" 15.9 26.2 19.9 15.7 24.3 3.5 40.5 6.9 20.1 20.4 24.8 19.2 9.0 13.3 17.6 14.7 42.4 27.4 26.2 19.5 19.8 12.1 56.6 141.1 56.7 4.8 23.5 20.5 14.7 36.6 6.2 12.5 23.0 30.9 19.5 22.3 21.8 47.6 17.5 25.5 45.5 13.8 38.7 23.0 9.0 46.9 33.7 15.7 2.0 26.5 25.2 23.5 34.4 16.4 0.7 2.8 2.0 3.1 1.4 8.1 1.2 23.0 3.0 1.6 0.1 41.2 25.4 71.1 29.5 40.3 33.5 24.0 35.1 58.9 0.0 13.2 37.1 33.8 30.0 1.2 75.0 40.8 6.6 1.1 0.7 2.4 13.7 44.9 0.1 1.2 34.1 50.4 13.8 33.8 18.6 4.4 0.5 1.1 0.0 19.2 22.9 0.0 2.0 3.0 20.1 9.3 0.0 14.9 0.0 55.0 30.8 0.6 2.3 40.6 25.2 7.2 19.6 18.2 1.4 8.2 25.6 21.3 2.5 19.0 1.2 0.9 0.1 40.2 2.3 15.2 2.0 3.1 0.7 1.3 1.1 4.1 0.6 4.1 1.6 2.8 0.7 0.9 1.1 1.6 1.4 1.1 2.5 8.1 1.2 19.9 24.3 6.9 20.1 19.8 12.1 23.5 20.5 30.9 15.7 271.0 364.7 7.8 299.2 332.0 10.3 49.5 201.2 113.8 195.7 179.7 11.8 27.4 54.7 239.6 0.5 9.0 87.8 0.0 450.4 202.4 50.9 254.2 12.8 232.3 18.5 0.0 52.9 14.7 15.1 2.9 3.7 36.5 72.6 56.9 103.4 8.5 443.3 93.4 4.9 128.2 23.3 0.0 42.6 0.9 2.8 413.3 56.3 18.8 79.5 364.0 SDHA "FP, SDH2, SDHF" ENSG00000073578 "Succinate dehydrogenase complex flavoprotein subunit A" P31040 5 218241-256700 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 100.1;skeletal muscle: 114.0" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB034929, HPA041981, HPA064582" Enhanced Supported Nucleoli,Mitochondria No No 780000 Mitochondria Nucleoli "CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293" "prognostic unfavorable (6.00e-4)" "unprognostic (1.93e-1)" "unprognostic (5.97e-2)" "unprognostic (1.36e-1)" "unprognostic (1.89e-1)" "unprognostic (1.62e-1)" "unprognostic (2.80e-1)" "unprognostic (3.14e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-2)" "unprognostic (1.97e-1)" "unprognostic (1.24e-1)" "prognostic favorable (9.53e-8)" "unprognostic (1.11e-2)" "unprognostic (2.62e-1)" "unprognostic (3.57e-1)" "unprognostic (1.79e-1)" 17.6 31.4 15.3 11.5 20.3 10.6 12.8 18.8 29.0 10.2 29.4 17.3 10.0 44.3 11.3 12.1 15.3 12.6 14.8 100.1 15.8 14.5 36.5 55.4 10.7 11.7 19.6 19.3 14.5 14.7 23.2 9.5 9.2 29.7 10.7 24.6 14.5 17.3 12.0 114.0 11.5 39.9 16.5 13.2 13.9 21.2 14.6 14.8 15.7 12.5 39.6 12.5 13.2 11.1 28.3 31.9 29.1 29.2 27.1 48.9 32.4 18.7 30.4 12.5 20.4 21.6 16.2 34.0 14.5 18.4 25.0 25.5 32.9 25.6 23.2 45.8 16.5 18.9 24.3 22.1 29.6 14.8 49.4 20.2 11.8 84.1 42.8 13.4 14.7 15.4 16.1 19.0 18.6 9.9 19.9 27.0 16.6 19.0 19.3 11.7 28.7 19.4 39.7 4.3 20.5 38.6 25.1 18.2 45.0 53.1 24.9 13.8 7.9 68.2 44.1 17.9 8.1 26.7 18.6 19.5 18.5 18.2 11.0 11.9 20.6 8.8 17.1 17.9 21.2 11.7 17.8 24.4 29.1 36.4 29.2 32.1 28.3 34.8 35.1 31.9 24.5 34.5 31.7 5.9 27.1 24.1 20.5 48.9 32.4 15.3 20.3 18.8 29.0 15.8 14.5 19.6 19.3 29.7 14.8 32.8 63.8 52.9 58.0 54.4 45.7 238.2 76.5 58.9 40.9 71.5 96.2 94.1 121.0 78.8 32.8 37.6 207.8 0.0 39.4 87.2 53.2 29.4 42.7 135.6 60.4 95.3 45.6 43.0 39.1 20.2 63.3 43.9 86.0 78.5 75.8 40.3 44.9 92.8 52.3 129.8 77.8 77.6 45.0 66.5 55.1 31.5 129.4 59.9 128.8 78.3 SET "2PP2A, IPP2A2, PHAPII" ENSG00000119335 "SET nuclear proto-oncogene" Q01105 9 128683424-128696400 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Chaperone, DNA-binding" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB005232, HPA063683" Supported Enhanced "Nucleoplasm,Lipid droplets" NA NA 880000 Nucleoplasm "Lipid droplets" "CAB005232: AB_2185634, HPA063683: AB_2685088" "unprognostic (1.92e-1)" "unprognostic (2.22e-1)" "unprognostic (2.31e-1)" "unprognostic (3.77e-1)" "unprognostic (7.15e-2)" "unprognostic (4.37e-3)" "prognostic unfavorable (9.41e-7)" "unprognostic (2.00e-2)" "unprognostic (1.88e-2)" "unprognostic (3.62e-1)" "unprognostic (3.78e-2)" "unprognostic (3.27e-2)" "unprognostic (1.29e-1)" "unprognostic (7.57e-2)" "unprognostic (1.91e-1)" "unprognostic (2.09e-1)" "unprognostic (1.54e-2)" 47.2 49.7 66.5 59.3 65.8 71.8 56.5 64.2 61.2 54.4 51.3 55.3 45.6 40.1 64.8 33.1 71.6 51.6 48.9 81.6 63.6 57.3 51.7 57.8 51.2 91.1 65.4 56.1 76.5 61.3 55.0 38.7 65.4 47.3 59.2 56.4 36.3 52.1 46.9 76.3 53.6 45.7 59.0 73.5 62.8 46.8 34.8 58.6 152.9 69.1 46.2 92.7 74.4 84.1 72.2 66.4 43.2 56.5 78.8 77.9 69.7 51.4 58.8 84.6 66.9 25.2 39.6 78.0 42.5 47.1 61.5 42.4 80.7 63.2 133.1 36.0 43.7 48.1 96.5 124.9 63.9 70.3 60.7 53.2 76.6 91.4 65.6 56.5 139.7 50.2 33.0 50.1 52.3 105.0 49.5 57.5 71.6 148.6 54.0 50.3 86.8 117.0 51.6 141.2 78.7 62.6 107.0 105.1 107.8 47.4 58.1 86.2 54.1 93.6 62.9 50.8 62.8 78.4 43.6 55.0 72.7 54.5 44.8 70.3 42.5 122.1 158.5 34.6 74.5 69.2 34.5 53.9 43.2 58.9 56.5 72.1 72.2 67.9 62.8 52.7 66.3 65.8 77.9 35.4 78.8 45.6 66.4 52.3 69.7 66.5 65.8 64.2 61.2 63.6 57.3 65.4 56.1 47.3 58.6 113.2 124.3 265.7 328.1 598.4 174.9 190.6 209.0 89.7 129.7 186.7 41.2 273.8 330.0 223.2 30.8 200.0 100.9 93.5 188.0 401.9 250.8 373.4 128.3 164.3 210.2 117.6 245.8 160.2 212.7 25.3 151.8 217.3 310.4 235.4 230.5 205.1 229.0 108.7 163.0 257.3 97.8 129.4 279.5 127.7 287.7 613.8 263.1 219.3 275.8 519.4 SETBP1 "KIAA0437, SEB" ENSG00000152217 "SET binding protein 1" Q9Y6X0 18 44680173-45068510 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" DNA-binding "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Leydig cells: 58.1;Peritubular cells: 37.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 4.9;naive B-cell: 7.5" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in many" 4 "AF22: 9.5;Karpas-707: 37.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA049022, HPA057259" Uncertain Supported "Nucleoplasm,Nuclear bodies,Cytosol" NA NA Nucleoplasm "Nuclear bodies, Cytosol" "HPA049022: AB_2680602, HPA057259: AB_2683384" "unprognostic (1.25e-1)" "unprognostic (1.57e-1)" "unprognostic (1.11e-1)" "unprognostic (1.97e-2)" "unprognostic (4.63e-2)" "unprognostic (1.80e-1)" "unprognostic (1.91e-1)" "unprognostic (3.57e-2)" "unprognostic (3.49e-1)" "unprognostic (2.01e-2)" "unprognostic (2.71e-3)" "unprognostic (6.52e-2)" "prognostic favorable (6.34e-8)" "unprognostic (2.18e-2)" "unprognostic (2.29e-1)" "unprognostic (6.06e-2)" "unprognostic (7.81e-5)" 10.6 2.9 3.8 13.2 8.7 2.1 9.8 16.0 12.6 16.9 14.6 4.2 19.9 2.5 14.0 17.5 6.6 11.0 7.9 6.8 3.6 3.5 15.0 7.2 9.8 7.0 2.9 7.4 12.8 8.2 9.1 5.1 10.2 3.2 12.2 5.3 14.0 6.9 21.3 14.5 6.6 6.9 19.9 3.7 5.9 9.1 5.5 1.2 3.4 8.4 8.7 8.8 11.9 13.3 7.5 4.3 0.2 1.6 0.0 0.6 0.2 0.0 1.7 9.5 0.0 2.7 0.7 0.6 0.8 1.7 0.9 0.7 0.1 0.0 0.5 0.3 1.0 0.5 2.8 1.0 3.0 0.6 0.8 0.5 0.0 1.0 0.6 0.0 0.0 0.0 2.3 1.1 0.0 1.8 1.6 0.3 0.0 0.0 37.9 0.2 0.5 0.0 0.0 1.3 0.0 0.6 3.1 0.0 3.3 3.2 2.2 4.8 2.5 0.0 0.0 0.5 4.5 1.3 0.0 0.0 5.6 2.1 0.0 4.4 5.0 0.3 0.0 3.4 0.1 3.2 0.2 0.0 0.0 0.6 1.1 0.0 4.9 0.1 0.5 0.1 7.5 0.0 0.2 0.0 0.0 1.6 4.3 0.0 0.2 3.8 8.7 16.0 12.6 3.6 3.5 2.9 7.4 3.2 1.2 0.0 2.6 26.0 8.5 13.7 11.5 3.6 10.2 2.7 3.4 15.7 17.7 1.3 3.3 4.1 0.9 9.5 0.4 0.0 2.9 1.2 27.4 6.4 0.0 13.5 1.6 3.2 11.5 12.3 1.6 1.8 58.1 2.7 3.3 0.0 2.5 9.1 3.3 8.4 37.4 6.8 19.3 6.5 30.7 0.0 0.1 13.2 0.7 4.9 4.6 1.0 SETD2 "FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A" ENSG00000181555 "SET domain containing 2" Q9BYW2 3 47016429-47163967 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Antiviral defense, Differentiation, DNA damage, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation" "Activator, Chromatin regulator, Developmental protein, Methyltransferase, Transferase" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042451 Approved Approved "Nuclear speckles,Cytosol" NA NA "Nuclear speckles" Cytosol "HPA042451: AB_10806239" "unprognostic (2.78e-1)" "unprognostic (1.01e-1)" "unprognostic (6.08e-2)" "unprognostic (1.01e-1)" "unprognostic (3.37e-2)" "unprognostic (1.37e-2)" "unprognostic (1.40e-2)" "unprognostic (1.01e-2)" "prognostic unfavorable (8.19e-4)" "unprognostic (6.19e-2)" "unprognostic (2.45e-1)" "unprognostic (7.84e-2)" "prognostic favorable (7.99e-6)" "unprognostic (1.03e-1)" "unprognostic (1.91e-1)" "unprognostic (8.79e-2)" "unprognostic (5.43e-2)" 13.2 10.5 12.2 15.2 15.4 20.0 11.7 22.4 16.4 13.4 14.0 9.1 12.9 9.5 15.8 7.5 10.8 11.4 8.7 8.8 10.6 6.8 11.4 10.3 10.4 11.8 11.7 9.5 16.0 13.4 21.4 16.3 10.7 11.3 12.4 10.9 7.7 12.7 14.8 27.6 12.5 11.5 11.9 9.8 13.8 10.4 12.8 12.8 23.2 15.8 5.5 12.8 16.1 15.5 4.8 2.6 6.0 2.3 7.1 3.9 1.0 11.6 9.2 15.4 7.9 9.3 10.7 6.5 10.7 10.4 12.6 11.5 9.7 7.6 25.7 6.7 14.8 12.3 7.1 16.7 10.2 17.1 14.7 6.6 26.4 15.3 7.5 7.0 19.7 15.3 9.2 9.9 12.4 15.4 10.2 11.6 13.3 16.9 9.7 10.3 6.1 14.5 2.6 11.7 5.6 7.7 9.6 15.0 13.3 6.4 15.3 6.7 10.6 18.1 7.1 6.7 11.5 7.5 14.7 14.8 13.9 10.4 11.8 17.1 12.5 13.9 26.0 8.0 11.3 8.1 2.4 2.2 5.2 3.9 2.3 2.4 3.7 2.4 3.0 2.5 4.8 3.5 3.0 6.0 7.1 1.9 2.6 1.0 1.0 12.2 15.4 22.4 16.4 10.6 6.8 11.7 9.5 11.3 12.8 44.7 53.3 20.6 20.5 29.7 33.4 58.5 22.9 66.9 80.8 10.4 39.3 16.3 10.0 17.4 24.0 29.3 26.5 0.0 19.3 10.1 20.8 25.9 55.6 26.7 14.3 25.4 21.2 23.4 27.2 20.8 28.1 21.6 16.9 20.8 27.8 21.7 20.0 17.5 31.1 9.3 37.0 12.9 21.7 78.1 18.9 31.1 15.4 27.7 24.8 34.2 SF3B1 "Hsh155, Prp10, PRPF10, SAP155, SF3b155" ENSG00000115524 "Splicing factor 3b subunit 1" O75533 2 197389784-197435091 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050275 Approved Enhanced "Nuclear speckles" NA NA 840000 "Nuclear speckles" "HPA050275: AB_2681071" "unprognostic (6.86e-2)" "unprognostic (2.78e-1)" "unprognostic (2.14e-1)" "unprognostic (3.51e-1)" "unprognostic (4.42e-2)" "unprognostic (1.25e-3)" "unprognostic (2.44e-3)" "unprognostic (3.31e-3)" "unprognostic (1.25e-2)" "unprognostic (2.20e-1)" "unprognostic (6.79e-2)" "unprognostic (1.78e-2)" "unprognostic (2.57e-2)" "unprognostic (9.15e-2)" "unprognostic (1.16e-1)" "unprognostic (1.79e-1)" "unprognostic (3.41e-2)" 53.9 49.9 36.5 54.5 44.9 88.0 57.9 60.8 47.3 72.3 54.2 44.3 45.6 36.8 64.6 72.0 50.5 53.3 43.1 39.6 34.7 26.0 49.7 50.7 53.1 65.3 56.5 27.7 73.6 60.5 66.2 81.4 64.6 46.7 50.0 51.0 37.0 54.4 45.4 49.3 48.5 67.8 41.2 50.2 88.1 48.8 33.3 53.5 113.0 53.3 38.0 65.7 62.4 56.0 32.7 41.9 41.1 37.8 39.6 45.9 29.4 30.2 27.8 62.7 34.2 48.6 49.7 52.6 42.4 43.4 37.0 45.5 53.0 32.7 57.9 28.6 43.1 38.4 29.4 62.6 34.4 58.0 44.3 38.9 61.2 68.0 62.3 36.7 65.0 44.7 51.9 33.7 38.6 47.5 63.1 43.1 38.6 43.8 40.0 41.0 26.6 59.7 62.6 49.3 34.3 44.0 52.7 53.6 38.4 51.5 77.0 35.2 43.6 40.5 24.8 29.0 81.0 24.5 49.8 43.4 29.1 25.0 29.3 30.1 36.4 59.2 83.1 27.9 39.3 32.1 27.7 33.1 39.1 37.5 37.8 40.6 32.7 32.5 35.3 41.9 30.8 33.9 33.9 41.1 39.6 36.1 23.8 45.9 29.4 36.5 44.9 60.8 47.3 34.7 26.0 56.5 27.7 46.7 53.5 166.7 222.4 88.0 131.1 105.8 96.4 104.9 73.9 257.0 221.8 87.2 68.7 93.6 48.0 91.8 6.7 106.2 77.2 46.7 82.1 86.2 104.2 87.4 231.0 63.5 87.0 89.0 106.0 112.3 145.9 14.9 111.4 119.2 72.6 130.8 98.8 119.0 91.7 60.4 98.3 63.2 88.9 116.4 99.9 81.4 93.6 103.8 119.3 119.3 74.2 125.4 SFPQ "PPP1R140, PSF" ENSG00000116560 "Splicing factor proline and glutamine rich" P23246 1 35176378-35193148 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009886, HPA047513, HPA054689" Enhanced Enhanced Nucleoplasm NA NA 280000 Nucleoplasm "CAB009886: AB_2186937, HPA047513: AB_2680073, HPA054689: AB_2682574" "prognostic favorable (9.56e-5)" "unprognostic (1.01e-1)" "unprognostic (1.02e-3)" "unprognostic (1.99e-1)" "unprognostic (5.53e-2)" "unprognostic (1.86e-2)" "prognostic unfavorable (7.91e-13)" "unprognostic (3.10e-1)" "unprognostic (4.00e-3)" "unprognostic (3.85e-2)" "unprognostic (2.20e-2)" "unprognostic (8.03e-3)" "unprognostic (1.25e-3)" "unprognostic (1.16e-2)" "unprognostic (3.97e-3)" "unprognostic (3.07e-1)" "unprognostic (3.77e-3)" 40.5 35.7 31.5 39.4 31.4 122.5 48.3 53.0 38.5 39.0 31.4 37.8 32.9 30.0 45.3 36.5 45.5 43.0 28.1 34.0 29.1 24.6 36.4 34.2 47.6 48.8 26.3 32.6 59.9 40.2 45.8 46.3 35.5 31.9 35.5 38.0 35.7 39.6 38.0 44.9 42.9 34.1 36.5 32.8 42.4 35.5 37.5 32.9 95.2 35.3 24.1 60.6 35.9 38.6 6.9 11.2 4.4 8.8 4.9 8.9 3.3 36.4 30.5 53.2 30.1 13.1 19.7 49.9 20.0 20.3 34.2 25.0 33.1 26.4 66.6 27.8 23.1 21.4 33.4 57.8 39.1 46.6 35.5 38.4 50.0 32.9 39.3 17.7 52.0 29.8 15.7 15.2 29.6 14.4 15.2 29.7 35.3 56.5 31.8 33.2 31.7 60.8 44.6 63.4 22.0 29.5 61.9 36.1 43.3 33.0 44.3 38.4 42.7 28.8 22.5 28.9 38.9 26.3 37.1 31.6 27.4 40.3 17.9 42.7 36.5 31.0 67.8 19.5 34.5 38.9 2.6 6.5 4.4 7.7 8.8 8.9 6.2 7.6 6.1 5.8 6.9 7.2 7.9 3.4 4.9 6.4 11.2 8.2 3.3 31.5 31.4 53.0 38.5 29.1 24.6 26.3 32.6 31.9 32.9 157.8 233.8 123.2 218.3 317.6 223.2 127.3 68.8 123.1 187.7 104.7 180.6 178.4 69.6 106.2 101.7 173.0 92.7 46.7 119.2 185.7 204.4 133.7 151.3 95.2 121.1 162.1 210.6 114.8 123.3 250.0 132.3 139.5 133.3 108.2 106.4 182.5 126.2 101.2 109.6 66.5 219.0 51.8 200.9 192.3 171.1 286.1 255.5 127.5 133.5 143.0 SFRP4 "FRP-4, frpHE, FRZB-2" ENSG00000106483 "Secreted frizzled related protein 4" Q6FHJ7 7 37905932-38025695 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Differentiation, Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 144.9;endometrium 1: 100.7;retina: 123.0" "Cell type enriched" "Detected in some" 5 "Peritubular cells: 177.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 14.1;HSkMC: 5.5;U-937: 5.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "HPA009712, HPA050585" Enhanced "Secreted in female reproductive system" NA NA 1500000 "HPA009712: AB_1856778, HPA050585: AB_2681183" "unprognostic (5.93e-2)" "unprognostic (5.84e-3)" "unprognostic (2.75e-2)" "unprognostic (1.58e-3)" "unprognostic (2.61e-1)" "unprognostic (2.35e-2)" "unprognostic (4.02e-2)" "unprognostic (2.60e-1)" "unprognostic (1.21e-1)" "unprognostic (3.76e-2)" "unprognostic (2.12e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (1.36e-5)" "unprognostic (7.37e-3)" "unprognostic (1.61e-1)" "unprognostic (4.35e-3)" "unprognostic (1.89e-3)" 4.6 2.3 0.5 0.9 0.9 0.0 12.5 0.3 0.4 144.9 0.8 1.7 5.4 0.0 100.7 11.5 3.2 35.1 2.5 5.5 0.4 0.4 1.2 0.2 3.9 0.8 0.8 0.7 42.7 1.4 0.1 4.0 0.4 1.3 4.9 0.2 123.0 2.3 7.1 1.4 0.3 0.5 14.5 3.3 4.1 0.5 5.8 0.3 0.4 3.3 2.5 0.5 8.8 14.8 0.4 0.8 0.4 0.6 0.1 0.1 0.0 0.0 2.6 2.9 0.0 14.1 0.6 0.1 0.0 0.1 0.0 0.0 0.4 0.0 0.1 0.1 3.0 0.4 0.1 0.0 0.3 0.3 0.0 0.0 0.2 0.2 2.0 0.1 0.4 0.0 5.5 0.7 0.6 0.0 1.0 0.2 0.2 0.0 0.3 0.2 0.4 0.0 1.7 0.1 0.0 0.0 0.2 1.7 0.0 0.1 0.3 0.1 0.3 0.0 0.0 0.3 0.6 0.0 0.0 0.9 0.0 1.2 1.7 0.2 0.5 0.1 0.2 0.3 5.3 0.9 0.0 0.1 0.0 0.0 0.6 0.0 0.4 0.0 0.0 0.1 0.1 0.1 0.0 0.4 0.1 0.0 0.8 0.0 0.0 0.5 0.9 0.3 0.4 0.4 0.4 0.8 0.7 1.3 0.3 0.0 2.6 0.0 1.7 0.9 0.0 0.4 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.8 0.5 0.0 0.0 0.4 0.1 8.6 1.6 0.0 0.0 0.2 0.0 0.0 4.3 0.0 0.9 38.6 0.8 0.0 0.0 0.0 2.7 0.1 0.0 177.1 2.1 0.1 0.0 3.1 0.2 0.5 1.4 0.2 0.0 0.0 0.0 SH2B3 "IDDM20, LNK" ENSG00000111252 "SH2B adaptor protein 3" Q9UQQ2 12 111405948-111451623 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Ito cells: 49.7;Kupffer cells: 110.0;Macrophages: 49.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 32.3;hTEC/SVTERT24-B: 37.0;U-87 MG: 56.2;WM-115: 42.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA005483 Approved Approved Nucleoplasm NA NA Nucleoplasm "HPA005483: AB_1079260" "unprognostic (2.77e-1)" "unprognostic (1.74e-1)" "unprognostic (1.20e-1)" "unprognostic (1.12e-1)" "unprognostic (1.18e-1)" "unprognostic (9.09e-2)" "unprognostic (1.23e-1)" "unprognostic (2.42e-1)" "unprognostic (1.18e-1)" "unprognostic (4.65e-2)" "unprognostic (8.17e-3)" "unprognostic (9.08e-2)" "prognostic unfavorable (6.20e-4)" "unprognostic (2.86e-1)" "unprognostic (3.89e-3)" "unprognostic (1.11e-1)" "unprognostic (2.24e-2)" 17.6 9.0 7.9 13.7 7.9 34.4 19.8 3.8 9.3 8.9 7.5 7.2 3.1 5.3 8.0 7.1 5.6 7.5 12.7 15.3 5.8 5.5 9.2 12.5 17.6 27.8 6.6 4.0 8.2 11.0 4.7 7.6 16.1 5.2 8.4 9.3 8.7 5.0 4.2 10.2 3.6 10.3 9.1 7.8 31.7 5.5 13.3 6.8 9.5 10.2 3.2 11.8 10.0 5.8 1.8 6.1 3.8 10.3 2.3 1.7 1.9 2.3 1.4 1.8 1.9 6.4 9.6 1.2 7.5 20.6 5.7 6.2 2.1 1.3 3.9 5.4 11.4 19.5 0.4 1.4 4.3 9.4 3.3 0.7 13.4 0.6 1.5 6.3 5.8 32.3 5.7 1.0 37.0 3.3 12.8 30.9 3.3 9.6 1.6 20.9 0.8 2.4 11.7 2.8 0.6 5.4 2.4 4.2 2.5 2.7 0.9 1.2 1.3 1.3 0.1 10.7 1.7 0.9 8.4 23.9 5.3 3.0 4.5 12.1 3.6 3.8 4.5 56.2 4.2 42.8 1.1 4.3 1.5 1.6 10.3 1.4 1.8 1.4 1.7 5.9 0.7 1.0 1.3 3.8 2.3 7.6 6.1 0.5 1.9 7.9 7.9 3.8 9.3 5.8 5.5 6.6 4.0 5.2 6.8 3.0 31.9 11.5 1.3 6.1 4.1 14.9 5.1 0.0 2.3 1.8 2.0 0.4 1.7 3.1 9.6 32.1 3.8 0.0 7.5 1.1 9.8 2.4 37.0 9.4 35.5 3.2 3.4 49.7 110.0 4.0 2.6 49.7 15.1 34.3 2.6 0.9 6.9 7.0 3.9 1.4 3.1 0.0 17.6 9.4 4.0 3.6 0.8 11.8 1.7 0.8 SH3GL1 "CNSA1, EEN, MGC111371, SH3D2B, SH3P8" ENSG00000141985 "SH3 domain containing GRB2 like 1, endophilin A2" Q99961 19 4360370-4400547 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" Endocytosis "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Extravillous trophoblasts: 128.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA021485 Approved Enhanced Cytosol NA NA Cytosol "HPA021485: AB_1856816" "unprognostic (1.32e-1)" "prognostic favorable (1.50e-4)" "unprognostic (6.85e-2)" "prognostic favorable (1.86e-4)" "unprognostic (1.84e-1)" "unprognostic (1.02e-1)" "prognostic unfavorable (1.10e-4)" "unprognostic (1.92e-2)" "unprognostic (1.21e-1)" "unprognostic (1.42e-2)" "unprognostic (1.32e-1)" "unprognostic (1.54e-1)" "prognostic unfavorable (9.36e-8)" "unprognostic (5.48e-3)" "unprognostic (2.45e-1)" "unprognostic (1.02e-3)" "unprognostic (4.10e-2)" 20.5 22.4 12.8 17.7 14.5 28.9 17.5 19.1 25.9 21.6 18.7 13.3 11.9 25.4 16.9 12.1 66.0 15.0 16.1 13.2 13.0 8.0 13.8 19.7 14.8 13.0 11.4 13.0 23.5 20.5 5.6 17.3 33.9 9.4 17.1 6.2 14.9 22.1 16.8 8.6 40.4 29.8 18.8 9.0 19.5 16.4 13.7 11.3 10.1 14.2 19.1 33.0 22.2 30.0 6.1 6.5 9.7 5.1 3.8 7.4 3.4 31.7 14.4 15.0 19.8 17.6 27.5 27.7 27.7 24.0 24.8 24.7 22.5 16.8 7.2 11.8 27.5 12.0 26.3 10.6 30.5 6.6 9.5 17.7 8.6 19.9 29.4 25.5 7.7 9.8 23.0 21.3 20.8 12.9 12.3 29.1 7.0 22.3 16.4 19.8 26.6 7.5 8.1 37.6 11.6 16.1 5.9 20.9 12.5 19.5 28.2 14.8 22.8 24.5 24.5 17.4 7.4 16.8 12.3 43.8 23.9 17.4 49.9 28.1 10.5 6.4 7.6 34.3 20.2 32.7 1.0 3.8 4.8 5.0 1.9 4.8 6.1 7.4 6.9 5.0 4.5 4.2 4.5 9.7 3.8 5.1 6.5 6.6 3.4 12.8 14.5 19.1 25.9 13.0 8.0 11.4 13.0 9.4 11.3 8.9 22.1 14.3 32.2 54.0 16.6 3.3 7.6 6.7 9.1 8.7 5.9 32.6 11.6 31.4 5.6 21.5 32.5 23.3 25.4 128.0 43.2 30.1 9.2 18.8 42.1 9.5 9.8 33.7 15.9 4.9 30.2 14.3 21.9 16.2 16.3 12.4 36.0 15.0 22.6 17.9 8.0 12.9 23.1 13.3 12.4 75.0 37.0 13.8 16.4 59.9 SIX1 DFNA23 ENSG00000126778 "SIX homeobox 1" Q15475 14 60643415-60658259 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 39.1;salivary gland: 55.1;skeletal muscle: 59.0" "Cell type enhanced" "Detected in some" 19 "Basal glandular cells: 23.3;Ciliated cells: 65.6;Club cells: 33.0;Glandular cells: 24.0;Urothelial cells: 14.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 5 "olfactory region: 1.2;pons and medulla: 4.5" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 14.3;LHCN-M2: 53.4;RH-30: 29.2" "Not detected" "Not detected" "Not detected" "Not detected" "HPA001893, CAB058690" Enhanced Supported Nucleoplasm,Nucleoli No No Nucleoplasm Nucleoli "CAB058690: AB_2665581, HPA001893: AB_1079991" "unprognostic (3.62e-1)" "unprognostic (5.44e-2)" "unprognostic (5.09e-2)" "prognostic unfavorable (8.92e-6)" "unprognostic (1.33e-2)" "unprognostic (1.44e-2)" "unprognostic (2.04e-3)" "prognostic favorable (3.94e-4)" "unprognostic (1.40e-1)" "unprognostic (9.15e-2)" "unprognostic (6.45e-2)" "unprognostic (1.89e-1)" "unprognostic (3.06e-8)" "unprognostic (8.61e-2)" "unprognostic (2.13e-1)" "unprognostic (1.94e-1)" "unprognostic (3.86e-1)" 7.1 0.4 0.3 0.1 0.5 0.1 4.7 0.3 0.6 7.4 0.2 0.2 0.0 0.1 0.2 2.1 1.3 0.5 0.4 0.4 0.3 0.3 0.3 0.2 1.8 0.3 0.4 1.2 0.3 0.3 16.8 39.1 0.1 4.5 8.7 0.1 2.0 55.1 0.2 59.0 0.4 0.2 0.7 0.5 0.2 0.5 1.6 0.0 6.5 2.4 22.5 3.0 1.4 9.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 8.3 1.9 0.2 11.9 6.9 8.1 0.1 2.0 4.5 2.3 2.0 0.0 3.8 0.0 1.1 0.4 1.1 2.7 3.9 3.6 0.8 0.0 9.5 0.9 0.8 2.7 0.0 0.0 0.1 6.0 1.8 1.6 0.3 14.3 0.1 0.7 2.6 0.0 53.4 1.3 0.0 0.2 0.0 0.0 4.8 0.0 29.2 0.0 2.3 6.5 1.1 0.1 2.3 0.1 2.4 0.2 1.4 0.2 6.8 3.2 3.2 3.7 3.0 0.2 0.0 0.0 0.8 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.5 0.3 0.5 0.3 0.3 0.4 1.2 4.5 0.0 3.0 1.0 0.0 23.3 0.1 0.0 0.8 0.0 65.6 33.0 1.8 0.0 0.0 1.7 0.0 0.2 0.0 0.0 0.0 0.7 0.4 0.8 24.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.8 0.2 0.0 1.1 0.0 0.3 0.0 0.2 0.0 2.5 0.1 0.2 0.0 0.0 14.9 SLC34A2 NAPI-3B ENSG00000157765 "Solute carrier family 34 member 2" O95436 4 25648011-25678748 "Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "lung: 259.9;seminal vesicle: 69.1" "Group enriched" "Detected in many" 4 "Alveolar cells type 1: 443.7;Alveolar cells type 2: 1050.6" "Cancer enhanced" "Detected in many" "thyroid cancer: 585.2" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "basophil: 1.9" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in some" 81 "BEWO: 12.6;EFO-21: 47.7;RPTEC TERT1: 34.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA037989, HPA066474" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Plasma membrane" "Nucleoplasm, Cytosol" "HPA037989: AB_10670536, HPA066474: " "unprognostic (1.60e-2)" "unprognostic (1.12e-1)" "unprognostic (1.38e-1)" "unprognostic (4.25e-2)" "unprognostic (7.33e-2)" "unprognostic (9.83e-2)" "unprognostic (2.37e-2)" "unprognostic (6.60e-3)" "unprognostic (6.27e-2)" "unprognostic (1.89e-2)" "unprognostic (5.77e-2)" "unprognostic (2.24e-1)" "unprognostic (7.08e-3)" "unprognostic (3.25e-1)" "unprognostic (6.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.93e-1)" 0.1 0.1 0.1 0.0 0.1 0.0 3.2 0.2 0.1 13.0 0.1 0.0 24.7 2.9 6.9 2.1 0.5 13.0 3.4 0.1 0.1 0.1 10.8 0.5 259.9 0.0 0.1 0.0 2.9 4.4 0.0 0.6 2.6 0.8 0.3 0.0 1.6 27.4 69.1 0.1 0.7 2.1 0.0 0.1 0.1 0.4 0.5 0.0 0.4 27.9 0.1 1.9 0.0 0.1 0.4 0.2 1.9 0.5 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.6 0.0 0.0 0.0 0.0 0.1 0.0 0.1 47.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 34.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.2 0.1 0.1 0.0 0.0 0.0 1.9 0.5 0.2 0.3 0.3 0.1 0.2 0.1 0.1 0.0 0.4 0.3 0.2 1.5 0.4 0.1 0.2 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.8 0.0 443.7 1050.6 0.0 0.1 0.0 0.0 0.6 40.8 125.8 178.6 19.2 0.0 1.6 5.0 57.7 3.5 0.0 0.0 0.0 7.1 0.0 0.0 3.5 26.7 0.0 0.2 0.0 0.0 0.0 0.0 14.0 1.1 0.0 0.0 0.0 0.0 0.0 14.4 0.0 0.0 2.9 0.0 0.0 0.1 0.5 0.1 0.0 0.2 0.0 0.0 0.1 SLC45A3 "IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein" ENSG00000158715 "Solute carrier family 45 member 3" Q96JT2 1 205657851-205680459 "Cancer-related genes, Predicted membrane proteins, Transporters" Transport "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "prostate: 115.0" "Group enriched" "Detected in many" 11 "Glandular cells: 50.8;granulocytes: 117.6" "Cancer enriched" "Detected in all" 49 "prostate cancer: 539.9" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 226 "basophil: 22.6" "Lineage enriched" "Detected in single" 226 "granulocytes: 22.6" "Cell line enriched" "Detected in some" 30 "HMC-1: 141.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA019073, HPA019075" Enhanced Approved Nucleoplasm,Vesicles NA NA Vesicles Nucleoplasm "HPA019073: AB_1857177, HPA019075: AB_1857179" "unprognostic (1.80e-1)" "unprognostic (1.08e-3)" "unprognostic (3.13e-2)" "prognostic unfavorable (4.04e-5)" "unprognostic (6.93e-2)" "unprognostic (2.36e-2)" "unprognostic (1.15e-1)" "unprognostic (1.50e-1)" "unprognostic (1.84e-1)" "unprognostic (1.10e-1)" "unprognostic (2.90e-2)" "unprognostic (1.18e-1)" "unprognostic (3.03e-2)" "unprognostic (3.16e-1)" "unprognostic (1.55e-1)" "unprognostic (1.96e-1)" "prognostic favorable (7.33e-5)" 0.8 1.5 2.5 1.5 6.2 0.7 0.8 0.4 5.8 1.9 2.1 19.0 0.0 2.1 0.9 0.6 0.9 1.1 1.8 0.7 4.2 2.0 1.1 4.0 1.7 1.6 13.2 1.6 1.0 0.7 0.5 1.9 0.6 7.2 115.0 1.6 0.2 0.9 0.7 2.2 0.9 2.1 0.8 12.4 5.0 6.4 1.4 11.1 0.0 0.5 0.7 0.7 1.5 0.4 0.0 0.0 22.6 0.0 0.0 0.0 0.2 1.5 0.5 0.4 0.4 0.0 0.0 0.3 0.2 0.0 0.5 0.4 1.1 2.9 0.4 0.7 0.0 0.5 0.5 0.2 0.5 0.0 0.6 0.4 4.7 0.1 0.3 0.3 0.8 141.5 0.0 0.1 0.3 0.0 0.3 1.6 0.7 0.7 0.2 0.2 0.3 0.1 1.3 2.0 2.7 1.7 0.1 0.7 0.2 0.6 2.2 0.2 0.5 0.2 3.5 0.6 0.4 0.8 0.2 1.5 0.2 1.6 0.5 1.1 0.0 0.1 0.0 0.3 0.2 1.1 22.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.5 6.2 0.4 5.8 4.2 2.0 13.2 1.6 7.2 11.1 0.0 5.6 1.3 1.1 0.0 0.2 1.7 5.1 2.7 1.2 1.8 0.0 0.4 0.0 1.8 0.1 0.6 3.4 0.0 0.5 0.1 0.6 50.8 117.6 4.9 2.0 0.0 0.0 0.0 0.6 0.0 1.7 0.9 0.0 1.0 7.4 0.2 2.4 7.0 1.4 1.8 0.0 6.5 1.0 0.0 1.5 0.1 0.0 0.0 4.4 0.8 SMAD2 "JV18-1, MADH2, MADR2" ENSG00000175387 "SMAD family member 2" Q15796 18 47808957-47931146 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Cone photoreceptor cells: 200.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB025507, HPA067203, CAB073546" Approved Supported Nucleoplasm,Nucleoli,Cytosol NA NA "Nucleoplasm, Nucleoli, Cytosol" "CAB025507: , CAB073546: , HPA067203: AB_2685803" "unprognostic (1.55e-1)" "unprognostic (2.49e-1)" "unprognostic (1.43e-2)" "unprognostic (9.82e-3)" "unprognostic (9.88e-2)" "unprognostic (1.06e-1)" "prognostic unfavorable (9.44e-5)" "unprognostic (1.91e-2)" "unprognostic (7.59e-2)" "unprognostic (1.41e-3)" "unprognostic (6.46e-2)" "unprognostic (4.91e-2)" "unprognostic (9.20e-3)" "unprognostic (2.68e-1)" "unprognostic (6.13e-2)" "unprognostic (3.20e-2)" "unprognostic (6.28e-2)" 38.5 39.2 29.0 26.2 25.9 19.6 31.4 19.5 28.9 28.8 34.2 29.4 28.9 21.5 26.6 26.3 33.5 28.8 25.7 31.1 26.1 27.1 26.4 20.9 28.3 23.8 30.9 24.3 36.6 28.1 25.7 24.4 34.8 28.6 27.8 29.8 31.7 29.7 28.7 33.9 28.0 26.4 34.6 35.4 34.1 26.3 29.2 26.2 60.7 46.1 23.6 31.5 35.1 35.7 12.0 21.8 28.9 24.7 24.5 25.9 19.7 22.2 32.0 19.5 18.9 31.2 38.2 22.3 24.3 29.2 25.4 29.7 12.2 21.4 34.6 17.5 30.8 35.6 24.6 21.9 27.1 34.1 37.6 11.2 29.4 48.3 19.8 36.4 40.8 30.1 28.2 35.0 21.7 50.3 29.6 28.0 28.2 13.6 29.0 31.2 14.5 28.0 19.6 9.6 1.1 7.6 20.5 28.5 23.6 57.0 38.4 18.1 21.2 29.2 20.1 23.8 19.9 15.2 27.2 31.3 37.7 21.8 10.2 17.6 28.5 27.3 30.2 26.1 27.9 27.5 28.9 22.6 25.0 16.9 24.7 21.2 12.0 23.1 20.9 21.8 9.4 25.8 19.8 22.7 24.5 20.8 15.5 25.9 19.7 29.0 25.9 19.5 28.9 26.1 27.1 30.9 24.3 28.6 26.2 41.7 29.7 22.0 39.2 48.3 44.4 40.0 40.8 30.8 45.5 73.3 200.3 37.8 33.2 31.7 53.8 44.7 32.0 46.7 38.2 33.2 34.3 51.4 20.8 22.6 38.9 33.4 49.0 57.7 52.1 97.0 38.6 38.2 49.0 44.1 42.5 37.9 37.5 24.6 50.2 32.1 82.1 32.3 35.9 26.3 39.6 54.1 58.1 38.1 35.7 55.8 SMAD3 "HsT17436, JV15-2, MADH3" ENSG00000166949 "SMAD family member 3" P84022 15 67063763-67195195 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" DNA-binding "Aortic aneurysm, Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Glandular cells: 111.1;Urothelial cells: 247.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008094, HPA046386, HPA067203, CAB069409" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB008094: AB_2302271, CAB069409: AB_1622941, HPA046386: AB_2679647, HPA067203: AB_2685803" "unprognostic (1.04e-1)" "unprognostic (1.83e-1)" "unprognostic (1.06e-1)" "unprognostic (1.99e-2)" "unprognostic (1.61e-1)" "unprognostic (1.98e-2)" "unprognostic (8.40e-3)" "unprognostic (1.80e-2)" "unprognostic (7.62e-2)" "unprognostic (6.82e-2)" "prognostic unfavorable (2.48e-4)" "unprognostic (2.93e-1)" "unprognostic (2.14e-2)" "unprognostic (3.10e-1)" "unprognostic (1.79e-1)" "unprognostic (1.15e-1)" "unprognostic (5.97e-2)" 25.3 4.6 12.2 18.5 12.4 12.4 21.6 5.0 12.7 20.9 17.9 7.6 9.5 12.7 19.9 16.6 35.3 14.3 27.7 19.7 7.5 4.8 15.6 13.6 13.9 14.0 6.0 7.5 23.0 12.6 7.0 10.8 11.5 8.2 20.5 9.2 30.8 12.5 10.8 37.3 19.6 19.0 23.2 5.5 11.2 15.8 7.0 7.7 10.5 21.8 23.4 29.7 31.4 24.6 4.8 2.5 3.2 1.9 0.4 6.3 1.8 12.2 41.2 7.7 3.7 13.6 31.4 6.1 7.1 29.3 9.9 8.0 8.5 32.9 4.1 9.6 20.2 44.6 29.1 8.0 30.0 9.9 3.2 3.0 0.4 11.6 6.4 10.2 1.6 0.7 28.4 7.0 8.7 7.4 22.0 33.3 1.3 9.9 11.5 12.3 6.3 0.3 6.2 4.5 6.5 12.9 0.4 2.3 1.5 6.6 39.5 0.2 2.6 9.4 5.2 8.1 15.7 1.4 7.6 28.0 13.4 12.6 9.6 8.0 4.4 1.2 5.1 12.1 1.7 12.0 0.0 1.9 3.2 5.5 1.5 5.7 2.1 6.2 6.3 1.8 4.8 2.8 2.4 0.1 0.4 1.5 2.5 3.1 1.8 12.2 12.4 5.0 12.7 7.5 4.8 6.0 7.5 8.2 7.7 44.7 14.5 13.6 67.6 79.0 8.3 9.5 15.3 24.1 30.7 34.9 5.9 0.8 3.3 53.0 0.9 20.1 34.4 0.0 44.0 4.0 34.3 111.1 24.2 11.3 8.4 0.0 3.4 9.8 4.8 3.7 24.7 13.8 20.3 3.6 11.9 9.7 71.0 21.0 19.4 12.2 0.4 25.8 14.6 0.3 0.7 42.8 1.4 12.5 15.7 247.9 SMAD4 "DPC4, MADH4" ENSG00000141646 "SMAD family member 4" Q13485 18 51028394-51085045 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019154 Approved Supported Nucleoplasm,Centrosome,Cytosol NA NA "Nucleoplasm, Cytosol" Centrosome "HPA019154: AB_1853480" "unprognostic (1.58e-1)" "unprognostic (1.75e-1)" "unprognostic (1.25e-2)" "unprognostic (4.83e-2)" "unprognostic (1.17e-2)" "unprognostic (4.05e-1)" "unprognostic (7.29e-3)" "unprognostic (9.00e-2)" "unprognostic (4.01e-2)" "unprognostic (2.51e-2)" "unprognostic (1.03e-3)" "unprognostic (4.40e-2)" "prognostic favorable (1.92e-5)" "unprognostic (2.62e-2)" "unprognostic (4.23e-1)" "unprognostic (1.36e-1)" "unprognostic (1.44e-1)" 25.6 17.5 16.0 14.0 16.7 11.4 24.9 29.7 16.0 27.9 22.6 17.9 21.3 15.1 28.2 18.8 21.7 20.5 17.5 19.6 15.3 11.5 21.0 22.0 20.1 16.0 17.2 13.3 30.5 25.0 30.0 28.9 30.6 14.2 27.8 17.4 18.4 23.1 22.8 39.7 18.2 23.4 27.6 13.9 21.7 19.3 17.6 18.4 38.8 35.0 13.9 18.1 29.0 24.1 3.6 3.6 3.4 1.8 2.9 4.7 1.3 8.5 11.4 30.9 8.9 12.8 19.8 17.4 15.1 16.6 20.3 25.5 7.0 2.0 14.3 4.5 13.0 10.4 14.2 17.3 6.8 21.6 12.4 9.8 9.9 11.4 8.0 12.7 17.2 7.8 8.9 11.5 10.0 14.7 19.6 14.7 7.3 11.1 13.2 12.0 4.5 10.2 5.0 16.1 4.6 7.1 13.3 15.7 14.0 9.7 3.7 19.1 11.3 14.1 2.6 9.4 13.7 7.0 10.0 11.0 17.2 8.0 4.3 10.0 19.9 13.8 12.4 11.2 6.7 11.3 0.8 1.8 1.8 3.2 1.1 3.7 2.2 3.3 2.6 3.6 3.6 4.0 4.7 3.4 2.9 1.3 2.9 4.3 1.3 16.0 16.7 29.7 16.0 15.3 11.5 17.2 13.3 14.2 18.4 20.8 23.2 11.8 18.4 22.8 13.2 33.5 40.8 16.0 19.4 21.0 19.6 15.5 10.0 16.2 7.3 23.2 15.6 0.0 10.8 16.8 23.8 31.7 4.6 40.0 13.2 14.3 38.1 23.9 26.1 11.4 30.8 16.7 27.0 5.4 33.8 18.9 18.1 24.3 28.7 18.5 20.8 25.8 29.2 13.9 16.2 23.8 10.5 13.8 26.2 22.5 SMARCA4 "BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2" ENSG00000127616 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4" P51532 19 10960825-11079426 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Neurogenesis, Transcription, Transcription regulation" "Activator, Chromatin regulator, Helicase, Hydrolase, Repressor, RNA-binding" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Cardiomyocytes: 219.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004208 Supported Supported Nucleoplasm NA NA 260000 Nucleoplasm "CAB004208: AB_626762" "unprognostic (2.68e-1)" "unprognostic (4.85e-2)" "unprognostic (1.71e-1)" "unprognostic (3.43e-3)" "unprognostic (1.40e-1)" "unprognostic (6.33e-3)" "prognostic unfavorable (1.11e-4)" "unprognostic (7.19e-2)" "unprognostic (7.29e-2)" "unprognostic (1.73e-2)" "unprognostic (1.97e-1)" "unprognostic (1.15e-2)" "unprognostic (6.80e-3)" "unprognostic (6.83e-3)" "unprognostic (5.44e-2)" "unprognostic (1.01e-1)" "unprognostic (1.29e-1)" 10.3 12.4 15.5 18.0 21.3 20.5 10.9 29.1 28.0 13.2 12.8 16.6 9.7 14.3 16.6 9.4 24.7 15.7 12.8 11.6 14.4 17.7 13.0 9.9 13.0 18.1 17.1 16.8 13.6 13.4 18.1 11.5 14.6 16.1 13.3 9.4 17.3 18.2 12.5 21.9 20.4 12.0 10.6 16.1 13.2 14.5 22.2 12.4 58.2 15.5 10.1 21.5 15.2 12.6 9.8 11.2 8.6 13.5 11.4 13.7 5.9 20.5 1.1 36.7 34.7 7.2 6.1 16.1 14.3 8.6 17.5 13.0 28.7 0.9 48.3 22.2 12.5 0.7 15.1 28.6 17.7 9.7 19.8 21.4 38.4 18.2 33.3 10.9 27.8 19.2 10.2 8.6 14.7 15.2 7.8 15.6 21.1 34.4 18.2 13.7 41.9 46.2 23.9 37.2 10.0 31.1 49.2 23.2 25.0 11.2 26.1 41.8 37.9 15.2 19.6 16.3 12.3 16.6 20.9 20.6 26.1 13.6 23.8 23.6 37.7 41.8 47.9 14.8 26.7 22.1 8.1 8.3 8.6 13.7 9.5 12.2 7.4 10.4 11.6 8.5 9.8 11.4 11.2 5.2 11.4 13.5 11.2 8.8 5.9 15.5 21.3 29.1 28.0 14.4 17.7 17.1 16.8 16.1 12.4 62.5 67.7 32.7 32.8 32.7 82.3 219.1 43.3 46.8 51.2 41.8 66.8 57.1 34.9 75.0 39.4 30.8 34.6 23.3 53.1 46.8 38.0 38.3 29.0 19.2 36.4 95.3 60.6 22.7 21.0 29.3 24.2 23.3 15.1 57.7 37.3 37.2 60.6 38.6 12.7 19.3 63.8 12.9 30.3 93.0 96.0 45.2 51.0 28.4 50.9 40.7 SMARCB1 "BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1" ENSG00000099956 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1" Q12824 22 23786931-23838008 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding" "Cancer-related genes, Disease mutation, Hypotrichosis, Mental retardation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AF22: 19.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009196, HPA018248, HPA019127" Supported Supported "Nucleoplasm,Nucleoli fibrillar center" NA NA Nucleoplasm "Nucleoli fibrillar center" "CAB009196: AB_2191983, HPA018248: AB_1851162, HPA019127: AB_1851165" "unprognostic (2.15e-1)" "unprognostic (5.62e-2)" "unprognostic (6.60e-3)" "unprognostic (1.63e-2)" "unprognostic (4.01e-3)" "unprognostic (2.14e-1)" "prognostic unfavorable (6.52e-4)" "unprognostic (4.10e-1)" "unprognostic (1.86e-1)" "unprognostic (1.03e-2)" "unprognostic (2.10e-2)" "unprognostic (4.43e-3)" "prognostic favorable (1.14e-6)" "unprognostic (1.24e-1)" "unprognostic (4.58e-2)" "unprognostic (4.57e-2)" "unprognostic (7.04e-2)" 11.0 15.2 14.6 33.2 15.4 16.9 12.1 30.4 21.9 13.4 25.1 16.4 11.4 41.1 17.2 11.0 15.6 12.3 15.0 12.6 13.2 14.2 14.6 11.7 14.0 32.8 13.0 13.8 21.3 16.1 7.9 15.7 20.8 12.8 11.0 9.4 16.7 40.9 13.1 28.1 14.7 27.4 10.6 12.8 19.8 24.1 37.7 12.9 29.4 15.7 12.0 16.0 21.1 12.2 19.5 9.9 4.8 11.6 7.0 7.5 5.9 1.5 1.0 19.2 1.8 1.8 0.5 3.9 6.1 1.8 1.8 2.9 2.2 1.8 15.7 5.3 0.8 2.0 2.9 4.6 3.0 3.0 2.6 6.7 13.0 1.8 1.3 2.1 13.8 3.8 1.1 2.2 2.1 4.7 0.9 0.9 1.9 3.5 8.7 1.1 3.9 11.2 3.2 5.7 4.7 3.8 7.0 15.5 7.0 1.6 3.0 9.1 6.9 1.4 0.4 10.3 10.4 1.5 2.1 1.6 1.6 6.7 2.6 1.7 9.6 8.8 10.4 1.3 7.6 4.6 4.0 10.0 4.8 3.8 10.2 5.2 19.5 4.6 4.6 9.3 6.4 3.8 2.5 0.8 7.0 11.6 9.9 7.5 5.9 14.6 15.4 30.4 21.9 13.2 14.2 13.0 13.8 12.8 12.9 6.0 10.4 102.1 57.3 44.6 51.7 3.7 38.2 18.7 6.8 45.4 19.6 106.2 71.3 80.0 26.9 31.5 31.9 23.3 67.3 185.0 45.7 53.3 33.5 17.7 66.6 63.5 68.9 36.8 19.7 12.4 33.1 35.4 54.0 63.1 50.5 72.3 62.0 51.8 30.1 65.4 36.9 19.4 58.2 125.7 116.1 46.3 133.9 35.0 61.6 56.7 SMARCD1 "BAF60A, CRACD1, Rsc6p" ENSG00000066117 "SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1" Q96GM5 12 50084972-50100712 "Cancer-related genes, Predicted intracellular proteins" Neurogenesis "Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004101 Supported Supported Nucleoplasm,Vesicles NA NA Nucleoplasm Vesicles "HPA004101: AB_1080026" "unprognostic (1.88e-1)" "unprognostic (1.89e-1)" "unprognostic (1.51e-1)" "unprognostic (2.11e-2)" "unprognostic (1.02e-1)" "unprognostic (2.76e-1)" "prognostic unfavorable (2.53e-8)" "unprognostic (3.62e-2)" "unprognostic (1.44e-1)" "unprognostic (4.23e-2)" "unprognostic (1.16e-2)" "unprognostic (2.10e-2)" "unprognostic (1.20e-3)" "unprognostic (2.18e-1)" "unprognostic (3.45e-1)" "unprognostic (1.38e-1)" "unprognostic (5.04e-2)" 21.3 24.5 16.4 22.6 22.7 29.9 21.3 27.8 28.2 19.8 19.9 29.5 17.6 18.8 23.6 23.4 23.3 19.9 18.2 15.6 16.3 13.8 25.1 18.3 19.4 26.1 15.7 20.4 24.7 19.6 44.3 17.8 24.7 18.8 20.4 22.4 20.3 21.4 25.9 16.6 19.7 24.0 23.8 18.5 28.1 17.4 34.4 14.9 64.3 24.3 17.9 36.7 19.3 18.2 6.0 6.7 4.4 3.4 3.1 6.9 2.3 8.1 13.8 40.7 23.5 12.7 12.0 20.2 10.1 18.0 29.9 17.5 37.7 12.8 31.8 15.3 19.4 13.6 10.5 34.3 26.7 25.9 24.6 25.3 31.4 13.9 21.8 15.1 27.7 12.6 12.1 17.9 17.7 32.0 20.1 35.2 34.0 26.5 19.8 15.1 19.1 40.2 14.9 50.8 12.5 22.6 48.3 10.6 27.8 17.0 19.1 21.9 36.6 21.3 10.9 42.5 31.6 24.5 23.3 21.1 15.4 17.3 9.7 20.7 27.9 24.5 28.3 12.5 11.2 17.4 4.4 2.3 4.1 6.1 2.1 5.8 6.0 3.3 3.9 3.6 5.6 2.1 6.9 1.1 3.1 3.4 6.7 5.0 2.3 16.4 22.7 27.8 28.2 16.3 13.8 15.7 20.4 18.8 14.9 0.0 8.1 33.4 17.8 14.7 31.0 5.7 15.3 9.4 25.0 26.2 19.6 17.5 44.7 25.2 3.2 21.0 17.7 0.0 24.9 16.2 12.9 16.7 16.1 12.7 15.1 25.4 29.9 14.1 10.7 6.6 15.3 11.0 16.9 34.3 18.6 26.7 27.6 14.0 15.2 30.4 26.0 32.3 13.3 21.9 31.5 17.1 9.3 16.0 15.7 14.4 SMO "FZD11, SMOH" ENSG00000128602 "Smoothened, frizzled class receptor" Q99835 7 129188872-129213545 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 8 "Collecting duct cells: 10.4;Leydig cells: 19.2;Muller glia cells: 15.1;Peritubular cells: 20.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 20.3;AN3-CA: 37.6;NTERA-2: 28.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011446 Approved NA NA "CAB011446: " "unprognostic (2.48e-2)" "unprognostic (2.69e-2)" "unprognostic (7.09e-2)" "unprognostic (1.10e-1)" "unprognostic (8.16e-2)" "unprognostic (2.02e-1)" "unprognostic (3.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.38e-3)" "unprognostic (1.59e-1)" "unprognostic (1.17e-2)" "unprognostic (8.74e-3)" "unprognostic (1.62e-1)" "unprognostic (5.15e-3)" "unprognostic (2.09e-1)" "unprognostic (2.25e-1)" "unprognostic (2.61e-2)" 4.0 4.1 4.2 3.8 4.8 0.5 7.4 5.3 4.6 18.2 5.8 5.1 9.2 2.5 20.9 18.7 10.3 11.4 10.0 5.2 8.4 3.7 10.6 13.7 2.4 2.0 4.3 4.5 23.0 7.1 14.4 13.5 2.6 9.0 18.4 2.2 17.2 9.4 12.8 3.5 16.6 3.5 9.8 7.0 2.0 4.2 7.9 3.4 5.3 9.2 6.8 4.6 6.3 17.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.6 8.0 20.3 37.6 0.5 0.1 6.4 2.2 2.9 4.5 2.6 6.1 0.1 0.0 6.2 4.5 10.2 12.4 12.2 0.7 1.7 0.0 9.9 3.9 0.0 9.8 2.5 0.1 0.0 7.4 5.0 1.4 0.0 9.0 2.6 11.2 0.6 0.0 1.4 0.0 10.3 0.0 28.8 0.0 2.3 15.0 8.7 0.0 2.3 0.0 0.6 13.6 0.0 0.0 5.3 8.1 4.9 2.6 0.0 0.3 6.5 7.8 4.3 0.4 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 4.8 5.3 4.6 8.4 3.7 4.3 4.5 9.0 3.4 0.0 0.0 0.0 2.3 1.6 0.6 1.2 2.5 0.0 4.5 10.4 0.0 0.3 1.7 3.2 0.3 0.4 0.0 0.0 1.0 0.3 4.4 2.8 0.0 5.1 3.3 0.0 0.0 1.3 1.3 0.9 19.2 0.4 0.0 1.0 0.0 15.1 1.9 0.0 20.5 3.7 0.3 6.5 2.1 0.0 0.4 2.5 0.5 0.0 0.0 0.4 SND1 "p100, TDRD11" ENSG00000197157 "Staphylococcal nuclease and tudor domain containing 1" Q7KZF4 7 127652180-128092609 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Transcription, Transcription regulation" "Endonuclease, Hydrolase, Nuclease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 5 "Cytotrophoblasts: 195.0;Syncytiotrophoblasts: 223.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002529, HPA002632, CAB019323" Enhanced Enhanced Cytosol NA NA 1200000 Cytosol "CAB019323: , HPA002529: AB_1857317, HPA002632: AB_1857316" "unprognostic (2.06e-1)" "unprognostic (8.27e-3)" "unprognostic (2.21e-1)" "prognostic favorable (1.95e-4)" "unprognostic (5.10e-3)" "unprognostic (6.83e-2)" "unprognostic (1.17e-2)" "unprognostic (2.91e-2)" "unprognostic (4.22e-2)" "unprognostic (3.81e-2)" "unprognostic (1.56e-1)" "unprognostic (2.30e-1)" "unprognostic (1.36e-2)" "unprognostic (9.96e-2)" "unprognostic (1.99e-1)" "unprognostic (3.42e-2)" "unprognostic (2.26e-3)" 21.5 29.8 25.3 25.3 19.8 22.5 45.4 28.1 28.1 33.3 20.0 13.0 57.7 21.3 36.1 38.4 24.8 26.7 25.3 28.3 20.9 16.6 17.3 39.6 38.8 64.2 20.2 19.0 39.7 130.3 22.2 30.3 33.7 27.6 24.5 20.2 13.9 37.5 66.7 20.5 21.5 19.2 41.0 40.1 24.9 30.8 37.0 18.0 22.3 26.6 13.5 24.9 26.5 24.2 28.1 34.9 16.1 30.0 21.0 30.9 28.5 28.5 25.9 19.8 35.9 30.1 31.5 27.2 33.6 39.8 30.8 34.6 33.4 24.8 37.9 17.0 41.2 26.0 24.0 27.9 36.4 30.1 20.7 23.6 20.9 30.9 32.0 54.8 32.3 20.6 46.3 40.7 26.3 44.1 35.1 38.2 15.7 23.1 38.1 30.7 21.3 35.1 24.2 22.2 29.0 32.3 24.5 17.7 84.8 24.1 20.1 25.0 27.0 24.3 113.2 38.9 31.1 14.1 23.0 37.9 25.1 16.4 45.5 26.1 47.0 17.6 39.8 50.3 27.9 45.3 16.1 30.0 5.9 26.1 28.1 30.9 28.1 19.8 21.0 32.3 16.2 14.3 15.8 2.2 21.0 22.8 34.9 15.8 28.5 25.3 19.8 28.1 28.1 20.9 16.6 20.2 19.0 27.6 18.0 14.9 43.1 29.8 20.4 17.4 11.2 26.2 38.2 14.7 20.5 27.9 19.6 195.0 14.9 60.6 12.9 28.0 32.8 23.3 83.7 91.7 29.4 34.2 34.6 43.3 73.2 28.6 70.2 26.4 48.3 40.2 42.3 43.7 32.1 80.2 55.0 15.6 63.2 31.6 38.9 25.1 32.0 32.3 19.5 19.2 29.2 24.0 223.8 27.7 53.0 21.3 SOCS1 "Cish1, JAB, SOCS-1, SSI-1, TIP3" ENSG00000185338 "Suppressor of cytokine signaling 1" O15524 16 11254405-11256200 "Cancer-related genes, Predicted intracellular proteins" "Growth regulation, Ubl conjugation pathway" "Signal transduction inhibitor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 42.3;lymphoid tissue: 58.3" "Cell type enhanced" "Detected in many" 5 "T-cells: 63.1" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in many" 6 "cerebellum: 15.2" "Cell type enhanced" "Detected in many" "basophil: 12.9" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 5 "HDLM-2: 48.3" "Not detected" "Not detected" "Not detected" "Not detected" "CAB010355, HPA074108" Approved Supported "Nucleoplasm,Cytoplasmic bodies" NA NA Nucleoplasm "Cytoplasmic bodies" "CAB010355: AB_2193144, HPA074108: AB_2686661" "unprognostic (4.50e-3)" "unprognostic (3.30e-2)" "unprognostic (1.24e-1)" "unprognostic (1.66e-2)" "unprognostic (1.25e-2)" "prognostic favorable (1.10e-4)" "unprognostic (1.71e-2)" "unprognostic (4.09e-3)" "unprognostic (5.31e-3)" "unprognostic (4.82e-2)" "unprognostic (1.17e-1)" "unprognostic (5.39e-2)" "prognostic unfavorable (1.08e-6)" "unprognostic (1.56e-1)" "unprognostic (5.68e-2)" "unprognostic (6.08e-2)" "unprognostic (1.67e-1)" 10.9 2.8 0.7 19.2 1.5 13.9 37.9 15.2 1.1 15.8 6.3 0.3 2.2 3.3 4.9 7.6 5.6 4.2 11.0 3.6 0.6 1.0 11.1 42.3 9.6 25.8 0.8 0.0 9.3 3.8 0.7 16.8 9.3 2.4 5.3 1.8 3.2 3.7 3.9 2.3 6.0 11.0 6.5 1.1 14.7 6.6 7.1 0.4 58.3 5.1 4.8 14.7 5.4 8.3 4.4 1.3 12.9 0.1 5.5 2.7 0.4 1.2 0.2 0.5 0.1 1.6 0.2 1.9 1.0 7.5 0.4 0.6 0.3 0.2 2.9 2.2 0.4 1.4 0.5 0.2 0.1 0.1 48.3 0.3 0.8 0.0 3.9 0.7 0.0 8.9 0.7 0.1 1.0 0.1 0.2 0.1 0.3 6.4 0.8 0.0 1.1 3.2 1.8 5.4 0.0 0.8 0.3 0.3 0.3 0.5 0.2 0.7 0.1 0.2 1.7 0.5 1.5 0.0 0.4 0.0 0.6 3.2 0.4 0.6 0.2 0.2 4.5 1.2 0.3 0.6 12.9 0.1 8.8 2.2 0.0 2.0 1.4 2.5 2.7 0.0 4.4 2.7 2.5 0.3 5.5 0.0 1.3 2.6 0.4 0.7 1.5 15.2 0.6 0.6 1.0 0.8 0.0 2.4 0.4 0.0 4.1 11.5 14.7 10.9 1.9 9.2 5.1 2.7 0.0 48.8 5.9 21.5 19.9 11.3 40.7 3.6 23.6 0.0 7.3 4.3 30.9 5.9 54.0 2.4 4.0 0.0 25.0 10.4 6.5 17.6 6.6 8.4 28.7 24.4 12.9 7.4 6.9 9.1 39.3 7.0 4.2 0.0 16.5 0.9 2.0 5.9 48.3 63.1 6.6 10.8 SOX2 ENSG00000181449 "SRY-box 2" P48431 3 181711924-181714436 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Microphthalmia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 80.1" "Cell type enriched" "Detected in some" 9 "Muller glia cells: 455.6" "Cancer enhanced" "Detected in many" "glioma: 136.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 68.9;HAP1: 29.3;NTERA-2: 56.2;U-251 MG: 12.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA045725, HPA062851, HPA071379, CAB079745" Enhanced Supported Enhanced Nucleoplasm NA NA Nucleoplasm "CAB079745: , HPA045725: AB_2679431, HPA062851: , HPA071379: " "unprognostic (1.80e-2)" "unprognostic (3.18e-3)" "unprognostic (5.69e-2)" "unprognostic (6.96e-2)" "unprognostic (2.74e-3)" "unprognostic (1.60e-1)" "unprognostic (1.79e-2)" "unprognostic (4.48e-3)" "unprognostic (1.71e-1)" "unprognostic (4.38e-3)" "unprognostic (1.83e-1)" "unprognostic (7.68e-2)" "unprognostic (3.81e-9)" "unprognostic (1.12e-1)" "unprognostic (2.12e-1)" "unprognostic (1.26e-1)" "unprognostic (1.12e-2)" 1.8 2.5 30.3 2.0 25.8 1.5 1.6 13.9 80.1 1.8 2.3 24.3 0.0 2.0 1.5 1.8 15.9 5.0 1.8 1.7 36.0 19.2 1.5 1.5 3.4 1.5 19.4 18.5 1.7 1.6 1.5 5.8 1.5 18.6 3.9 2.0 1.0 6.3 1.9 1.6 1.8 2.3 1.7 18.4 1.6 9.7 3.0 22.4 0.0 1.5 2.1 6.9 2.3 1.7 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.2 68.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.1 29.3 0.7 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 56.2 2.9 0.1 0.0 0.1 0.0 7.6 0.1 0.1 0.3 0.0 0.0 0.0 11.9 0.4 0.0 0.0 0.0 1.0 0.0 12.9 0.0 0.0 0.0 0.0 0.0 8.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.3 25.8 13.9 20.0 36.0 19.2 19.4 18.5 18.6 22.4 0.0 5.9 0.0 41.2 0.2 3.5 0.4 0.0 52.2 38.7 3.5 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 4.9 1.1 0.0 0.1 0.0 0.0 1.3 0.0 0.0 0.6 0.2 3.3 0.0 0.0 455.6 0.0 0.0 0.0 0.0 8.2 0.0 0.1 1.5 0.2 0.4 0.2 0.0 0.0 7.0 SPEN "KIAA0929, MINT, RBM15C, SHARP" ENSG00000065526 "Spen family transcriptional repressor" Q96T58 1 15847864-15940460 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Notch signaling pathway, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA015825, HPA050257" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA015825: AB_1856823, HPA050257: AB_2681065" "unprognostic (3.91e-1)" "unprognostic (1.74e-1)" "unprognostic (3.76e-1)" "unprognostic (2.04e-1)" "unprognostic (1.48e-1)" "unprognostic (3.06e-2)" "unprognostic (6.93e-3)" "unprognostic (2.26e-1)" "unprognostic (4.26e-2)" "unprognostic (4.88e-3)" "unprognostic (1.71e-1)" "unprognostic (5.98e-2)" "unprognostic (1.06e-3)" "unprognostic (1.49e-1)" "unprognostic (1.66e-1)" "unprognostic (2.26e-1)" "unprognostic (1.83e-1)" 18.2 11.2 18.2 18.2 22.2 27.2 17.3 38.2 25.9 18.5 13.4 20.7 17.7 11.9 19.0 12.7 16.7 19.4 11.8 13.5 17.6 11.5 14.4 13.2 17.8 16.6 23.4 17.5 31.2 23.9 35.1 17.5 16.2 19.0 14.9 13.3 11.6 16.2 16.2 24.0 22.8 16.0 15.1 22.0 16.5 13.7 13.6 23.3 18.3 20.1 8.7 18.0 17.1 41.9 5.0 2.7 7.7 2.4 1.3 1.7 0.6 12.7 10.8 13.5 10.1 13.6 8.3 7.3 6.6 8.7 7.2 6.1 9.8 10.0 18.0 7.9 13.0 8.5 18.5 12.7 11.8 11.6 16.2 35.2 22.6 9.6 6.2 6.1 18.5 10.8 6.1 8.5 10.7 15.6 6.8 8.2 13.8 23.5 18.6 5.8 7.1 15.3 7.3 6.1 7.4 8.3 14.8 13.2 11.1 4.0 11.5 10.5 10.6 18.6 9.1 7.9 6.4 3.2 9.1 14.7 6.6 8.2 12.8 9.4 11.2 7.3 20.6 6.5 15.0 9.2 7.7 1.5 0.9 1.6 2.4 1.3 1.8 1.7 1.4 0.7 5.0 0.9 1.3 4.2 1.3 1.2 2.7 1.1 0.6 18.2 22.2 38.2 25.9 17.6 11.5 23.4 17.5 19.0 23.3 74.5 74.0 31.3 47.9 93.0 64.6 48.1 20.4 38.8 66.0 5.2 49.1 10.9 3.3 16.9 3.4 55.5 30.7 23.3 15.0 12.0 46.5 43.4 59.1 26.3 13.3 90.6 30.4 13.5 30.8 3.6 25.3 30.1 20.3 25.2 24.4 29.6 18.0 23.2 33.6 6.5 54.5 19.4 54.6 34.9 51.9 88.8 13.2 20.2 18.7 49.2 SPOP "BTBD32, TEF2" ENSG00000121067 "Speckle type BTB/POZ protein" O43791 17 49598884-49678234 "Cancer-related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "unprognostic (1.96e-2)" "unprognostic (1.43e-2)" "unprognostic (8.83e-2)" "unprognostic (3.23e-1)" "unprognostic (2.15e-2)" "unprognostic (4.51e-2)" "prognostic unfavorable (6.88e-4)" "unprognostic (1.89e-2)" "unprognostic (7.20e-2)" "unprognostic (1.17e-2)" "unprognostic (1.51e-2)" "unprognostic (1.24e-3)" "unprognostic (7.67e-2)" "unprognostic (2.81e-1)" "unprognostic (3.45e-2)" "unprognostic (1.10e-2)" "unprognostic (3.29e-1)" 22.0 16.5 22.5 16.9 24.9 7.9 18.6 39.8 26.9 27.5 59.5 25.0 25.1 15.2 36.2 21.2 35.4 25.2 17.2 22.7 22.7 18.8 17.0 20.2 19.1 19.6 20.9 21.4 26.0 18.5 15.1 28.5 18.2 23.2 38.8 23.5 21.8 22.8 49.5 29.2 15.2 24.1 45.1 18.4 18.8 28.4 10.5 26.8 28.6 26.4 14.3 23.3 35.6 22.3 43.2 55.6 59.6 43.1 40.7 58.4 50.8 14.2 16.1 18.6 7.0 20.9 22.3 12.6 18.8 19.4 24.9 25.9 32.8 15.7 23.6 36.0 17.0 17.2 11.5 21.1 13.7 29.8 43.7 23.3 27.4 16.4 18.7 24.0 17.9 22.4 16.7 17.6 19.4 21.1 18.1 25.3 17.6 28.3 24.3 16.7 13.9 32.9 16.5 4.9 33.7 19.7 18.7 27.1 30.5 13.5 8.5 28.0 13.0 11.8 6.0 15.4 10.5 23.2 18.7 22.2 27.0 18.7 21.1 15.4 24.4 20.3 20.6 15.8 16.1 13.5 57.0 41.8 50.6 36.2 37.1 36.1 42.4 40.6 39.2 55.6 43.2 58.4 45.3 59.6 40.7 43.1 37.2 36.0 50.8 22.5 24.9 39.8 26.9 22.7 18.8 20.9 21.4 23.2 26.8 44.7 34.5 45.7 39.5 38.0 59.7 46.4 22.9 33.5 30.7 27.9 41.2 19.1 24.9 30.3 13.7 56.0 23.9 0.0 24.6 19.6 43.7 25.3 30.1 39.9 33.5 71.5 49.4 54.6 50.5 4.5 52.0 43.8 37.1 65.9 43.6 94.4 23.0 36.5 68.9 22.7 54.6 71.1 58.6 30.9 46.6 38.3 30.2 43.7 32.2 18.0 SRC "ASV, c-src, SRC1" ENSG00000197122 "SRC proto-oncogene, non-receptor tyrosine kinase" P12931 20 37344685-37406050 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell adhesion, Cell cycle, Host-virus interaction, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "intermediate monocyte: 5.3;non-classical monocyte: 4.4" "Group enriched" "Detected in many" 6 "dendritic cells: 3.0;monocytes: 5.3" "Cell line enhanced" "Detected in many" "A549: 35.9;HBEC3-KT: 33.4;RT4: 34.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004023, HPA030875" Approved Supported "Nucleoplasm,Plasma membrane,Cell Junctions,Cytosol" NA NA 20000000 "Plasma membrane, Cell Junctions" "Nucleoplasm, Cytosol" "CAB004023: AB_2106059, HPA030875: AB_2673640" "unprognostic (5.58e-2)" "unprognostic (9.83e-2)" "unprognostic (3.56e-1)" "unprognostic (4.54e-3)" "unprognostic (1.52e-1)" "unprognostic (1.54e-2)" "prognostic unfavorable (4.90e-5)" "unprognostic (3.89e-2)" "unprognostic (7.04e-2)" "unprognostic (8.13e-2)" "unprognostic (1.54e-2)" "prognostic unfavorable (1.63e-4)" "prognostic unfavorable (1.22e-4)" "unprognostic (2.33e-2)" "unprognostic (4.72e-2)" "unprognostic (3.65e-2)" "prognostic favorable (5.22e-5)" 6.9 17.5 12.8 11.1 12.0 5.4 9.9 6.4 16.0 16.0 16.4 3.5 15.1 29.5 20.3 9.7 16.2 14.2 42.1 5.8 11.3 6.6 13.4 2.9 10.4 7.0 3.3 9.9 15.8 19.1 6.6 11.3 6.3 5.1 19.9 13.1 13.1 7.5 22.5 3.4 7.7 28.1 27.2 3.6 12.2 29.8 27.3 4.8 4.0 6.6 10.5 10.4 26.4 20.0 0.3 3.0 0.1 5.3 0.6 0.1 1.6 7.7 35.9 8.3 7.4 3.1 5.0 17.2 7.2 6.2 8.8 5.6 13.5 7.0 0.2 4.5 13.0 10.0 14.2 4.9 33.4 3.4 0.0 4.5 2.0 1.3 20.9 7.5 0.1 3.1 5.3 11.4 5.7 7.7 9.8 8.0 4.6 0.2 0.0 1.4 5.3 1.9 0.2 3.9 21.5 32.6 8.4 2.2 0.2 3.7 34.4 7.7 27.9 8.1 11.4 8.9 6.6 10.2 2.8 11.6 10.5 7.1 3.8 6.4 0.1 0.2 0.1 7.4 0.0 7.8 0.0 2.6 0.0 0.0 5.3 0.0 0.3 0.0 0.1 1.1 0.3 0.0 0.0 0.1 0.6 4.4 3.0 0.1 1.6 12.8 12.0 6.4 16.0 11.3 6.6 3.3 9.9 5.1 4.8 3.0 1.7 4.4 10.8 7.2 5.4 1.6 15.3 1.4 0.0 12.2 2.0 1.6 1.7 9.7 1.3 1.4 30.0 0.0 16.2 7.0 8.2 11.2 0.0 0.9 5.8 3.2 16.1 1.3 6.9 1.5 10.0 12.1 1.7 7.2 25.9 4.1 29.0 18.1 16.3 9.5 4.7 12.9 6.4 0.2 0.7 8.0 1.9 0.0 14.9 27.7 SRSF2 "PR264, SC-35, SC35, SFRS2, SFRS2A" ENSG00000161547 "Serine and arginine rich splicing factor 2" Q01130 17 76734115-76737374 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049905 Supported Approved Nucleoplasm,Cytosol NA NA 140000 Nucleoplasm Cytosol "HPA049905: AB_2680945" "unprognostic (2.50e-1)" "unprognostic (2.16e-3)" "unprognostic (2.73e-3)" "prognostic unfavorable (8.73e-4)" "unprognostic (1.75e-2)" "unprognostic (4.19e-2)" "prognostic unfavorable (3.53e-8)" "unprognostic (1.19e-1)" "unprognostic (7.79e-3)" "unprognostic (7.03e-3)" "unprognostic (1.92e-1)" "unprognostic (1.07e-3)" "prognostic unfavorable (1.05e-7)" "unprognostic (3.85e-2)" "unprognostic (8.05e-2)" "unprognostic (1.95e-1)" "prognostic favorable (9.87e-4)" 35.4 40.2 20.6 56.6 30.3 73.1 35.3 33.3 36.2 42.1 37.7 34.0 19.5 41.8 37.0 33.6 51.1 35.1 34.8 32.4 19.9 22.6 36.9 66.7 37.3 64.3 21.6 24.0 47.1 34.2 29.1 33.8 51.2 29.5 31.3 36.5 35.5 35.6 40.5 44.9 41.1 46.6 25.5 23.9 52.5 35.6 29.2 18.9 105.3 41.1 41.3 64.5 30.6 35.7 11.1 30.2 4.2 23.5 15.6 12.7 12.2 48.2 38.9 46.2 32.2 11.3 9.6 48.0 31.2 23.1 36.2 33.6 40.8 33.8 74.4 22.8 29.3 26.1 43.7 45.8 36.0 36.5 31.1 79.8 55.8 37.7 47.4 12.9 61.6 33.4 10.6 8.2 30.0 8.7 14.7 28.2 33.3 56.7 32.9 28.3 38.6 67.6 67.3 54.1 28.1 55.5 68.5 49.7 54.9 24.2 34.8 39.4 56.3 35.6 30.6 16.8 25.4 37.5 45.0 29.5 33.5 43.1 22.2 50.4 43.3 32.5 86.0 30.1 49.0 27.6 1.0 17.5 4.2 12.3 23.5 12.6 11.1 8.5 12.7 30.2 9.8 9.8 9.0 2.1 15.6 14.7 22.4 10.6 12.2 20.6 30.3 33.3 36.2 19.9 22.6 21.6 24.0 29.5 18.9 110.2 104.2 263.7 359.4 409.3 143.7 75.1 117.2 84.3 119.4 83.7 86.4 268.2 132.6 175.8 190.8 186.2 246.5 140.2 136.4 478.7 232.5 241.3 217.7 110.3 220.7 93.8 255.6 111.1 135.5 118.5 147.3 197.1 268.2 218.2 170.4 153.0 146.8 241.8 119.9 87.2 188.9 116.4 279.5 292.6 343.6 387.6 264.3 196.1 264.9 438.8 SRSF3 "SFRS3, SRp20" ENSG00000112081 "Serine and arginine rich splicing factor 3" P84103 6 36594353-36605600 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing, mRNA transport, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012986, HPA056981" Supported Supported Nucleoplasm NA NA 1600000 Nucleoplasm "CAB012986: AB_2533150, HPA056981: AB_2683299" "unprognostic (3.25e-1)" "unprognostic (1.08e-3)" "prognostic favorable (2.56e-4)" "unprognostic (8.19e-2)" "unprognostic (2.06e-2)" "unprognostic (2.77e-2)" "prognostic unfavorable (6.22e-5)" "unprognostic (2.92e-2)" "prognostic unfavorable (1.95e-4)" "prognostic favorable (1.37e-4)" "unprognostic (9.61e-2)" "unprognostic (1.21e-1)" "prognostic unfavorable (2.02e-4)" "unprognostic (9.88e-2)" "unprognostic (3.33e-2)" "unprognostic (8.33e-2)" "unprognostic (1.06e-2)" 45.3 27.4 37.4 42.1 38.3 69.5 43.5 42.6 39.1 36.4 41.7 32.9 34.0 25.5 37.2 31.8 42.9 40.8 27.4 37.5 33.0 28.1 34.3 36.9 32.3 51.8 35.8 27.0 53.9 31.3 22.4 47.2 37.4 38.1 40.1 46.6 30.1 30.2 33.0 29.2 36.2 35.8 43.1 31.9 36.4 35.2 27.2 36.7 67.5 35.9 46.7 67.0 49.6 38.6 28.0 73.9 12.9 38.0 37.6 37.6 53.9 52.3 35.0 61.8 47.2 23.9 18.8 38.2 37.5 31.5 63.3 48.8 41.1 37.7 88.1 27.1 41.0 41.4 41.6 81.1 59.7 67.7 41.1 49.9 52.9 27.8 46.2 29.2 70.9 44.8 16.6 20.3 41.2 46.1 20.2 48.0 53.7 63.7 37.4 45.9 40.9 87.1 67.2 65.1 61.6 36.8 77.8 59.2 52.8 44.8 43.7 47.8 45.2 41.7 41.0 56.7 46.2 41.5 76.3 31.3 32.4 47.3 32.4 56.3 36.9 54.6 120.8 27.8 66.1 44.9 12.9 38.0 11.5 32.9 36.2 37.1 28.0 31.1 34.5 73.9 24.0 31.4 32.3 3.7 37.6 24.4 43.7 37.6 53.9 37.4 38.3 42.6 39.1 33.0 28.1 35.8 27.0 38.1 36.7 187.6 233.6 318.3 350.5 417.2 149.0 207.3 150.3 167.3 258.2 118.7 51.1 416.8 308.4 279.1 130.6 291.5 222.5 70.0 281.9 659.0 372.0 205.6 389.0 176.1 317.5 93.8 319.4 203.1 270.2 235.9 196.2 343.3 317.2 322.0 216.3 322.7 247.9 247.6 161.9 198.3 123.9 200.5 442.5 331.9 315.7 389.7 439.9 330.0 297.7 236.4 SS18 "SSXT, SYT" ENSG00000141380 "SS18, nBAF chromatin remodeling complex subunit" Q15532 18 26016253-26091217 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA055741, HPA059539" Supported Approved Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA055741: AB_2682901, HPA059539: AB_2684055" "unprognostic (2.03e-2)" "unprognostic (1.76e-1)" "unprognostic (1.48e-2)" "unprognostic (1.95e-2)" "unprognostic (3.39e-1)" "unprognostic (8.74e-2)" "unprognostic (4.59e-2)" "unprognostic (1.53e-2)" "unprognostic (1.63e-2)" "unprognostic (1.45e-2)" "unprognostic (1.04e-1)" "unprognostic (2.47e-1)" "prognostic favorable (4.86e-4)" "unprognostic (1.03e-1)" "unprognostic (3.50e-2)" "unprognostic (1.40e-2)" "unprognostic (1.30e-1)" 26.1 40.5 18.7 30.4 26.4 15.5 26.6 17.6 20.2 24.8 21.4 31.8 32.1 14.0 31.7 32.7 29.8 27.2 23.4 22.4 21.6 16.1 30.0 30.9 21.9 25.8 32.6 16.3 39.4 20.6 39.4 41.8 43.2 25.3 28.6 18.7 26.1 26.0 33.5 10.3 31.3 22.6 31.0 23.7 24.7 22.5 28.3 32.6 27.8 35.6 24.7 35.2 25.5 25.9 15.9 13.1 19.9 17.1 20.7 17.6 13.1 19.2 14.0 34.4 16.8 27.4 24.8 17.4 23.7 21.6 21.0 20.1 9.2 16.0 33.7 19.0 27.7 19.0 25.3 18.6 23.0 26.0 21.5 8.9 16.7 20.5 14.8 21.7 25.5 25.9 31.8 27.2 26.3 28.9 21.0 15.7 9.8 12.2 17.3 28.9 19.4 10.4 14.8 6.5 18.1 13.5 12.1 26.7 16.2 22.2 22.8 14.7 22.2 36.2 16.8 10.2 25.8 17.1 15.1 18.0 44.2 8.8 10.2 23.2 31.3 20.8 24.3 20.7 17.8 23.4 19.9 11.7 16.5 15.1 17.1 17.6 15.9 14.6 15.7 13.1 13.0 15.5 17.4 5.6 20.7 16.7 7.4 15.7 13.1 18.7 26.4 17.6 20.2 21.6 16.1 32.6 16.3 25.3 32.6 26.8 21.3 28.3 27.1 7.9 28.5 14.1 17.8 36.1 23.9 22.7 15.7 57.3 18.3 26.4 40.7 25.3 17.2 0.0 22.5 41.2 19.5 22.9 36.8 30.1 23.9 82.6 23.7 24.5 20.0 31.2 30.8 17.1 5.0 12.6 21.1 51.6 26.7 14.0 38.5 23.8 29.7 38.8 27.1 23.4 19.0 11.5 71.2 25.4 14.5 21.7 SS18L1 "CREST, KIAA0693" ENSG00000184402 "SS18L1, nBAF chromatin remodeling complex subunit" O75177 20 62143795-62182484 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Hepatocytes: 33.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011827, HPA059046" Approved Supported Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB011827: AB_778216, HPA059046: AB_2683888" "unprognostic (4.12e-2)" "unprognostic (5.82e-2)" "unprognostic (1.54e-1)" "unprognostic (3.03e-2)" "unprognostic (6.57e-2)" "prognostic favorable (8.00e-5)" "unprognostic (1.39e-1)" "prognostic favorable (3.74e-4)" "unprognostic (1.01e-1)" "unprognostic (1.87e-1)" "unprognostic (2.47e-3)" "unprognostic (6.43e-2)" "unprognostic (2.42e-1)" "unprognostic (1.06e-1)" "unprognostic (2.66e-1)" "unprognostic (1.01e-1)" "unprognostic (9.94e-3)" 6.6 8.9 11.9 7.7 12.7 7.7 8.6 35.9 15.8 7.0 7.0 9.9 12.2 9.5 9.7 10.9 9.3 6.9 7.2 6.4 11.5 10.9 11.5 33.3 8.2 7.4 11.2 14.5 10.0 10.4 8.4 10.7 8.8 13.1 8.7 7.8 7.4 8.6 11.8 19.2 23.7 9.0 7.7 9.9 9.2 8.8 10.7 10.9 6.0 8.3 6.7 7.1 6.8 8.6 3.6 1.3 2.5 2.7 1.6 2.8 0.5 6.5 7.8 10.9 9.9 4.9 5.7 7.9 6.2 2.4 10.4 5.2 26.8 6.1 4.0 8.3 3.5 5.4 17.0 6.7 5.9 9.5 2.7 4.4 17.8 16.4 13.8 3.6 6.5 15.9 3.4 13.0 5.3 4.4 6.1 4.7 6.9 11.9 7.7 5.8 7.8 9.8 10.1 4.4 6.6 9.0 10.9 14.1 4.5 7.8 8.3 20.7 11.5 11.1 13.6 9.3 7.2 12.7 10.4 5.5 19.9 12.0 7.3 8.6 8.6 7.7 3.6 9.9 6.4 6.5 0.3 1.6 0.6 1.7 1.1 1.1 0.7 0.9 1.4 1.3 3.6 2.8 0.9 2.5 1.6 2.7 0.8 0.8 0.5 11.9 12.7 35.9 15.8 11.5 10.9 11.2 14.5 13.1 10.9 8.9 6.5 6.0 4.4 14.5 14.4 7.7 2.5 4.0 11.4 7.0 21.6 4.5 3.3 4.1 8.6 7.4 6.8 0.0 2.3 2.7 10.4 7.3 1.1 33.3 4.2 14.3 13.7 8.0 11.9 16.0 6.9 7.4 11.8 3.6 6.6 4.9 6.3 7.0 3.2 7.3 17.7 6.5 8.9 3.9 10.6 15.3 6.4 5.0 5.3 4.7 SSX1 CT5.1 ENSG00000126752 "SSX family member 1" Q16384 X 48255317-48267444 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 14 "testis: 12.6" "Group enriched" "Detected in some" 12 "Sertoli cells: 6.5;Spermatocytes: 9.8;Spermatogonia: 22.6" "Cancer enhanced" "Detected in many" "liver cancer: 7.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "Daudi: 28.8;Karpas-707: 41.8;U-2197: 9.7" HPA045683 Supported Approved Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA045683: AB_2679418" "unprognostic (2.25e-1)" "unprognostic (3.51e-3)" "unprognostic (2.36e-1)" "unprognostic (4.32e-3)" "unprognostic (3.38e-1)" "unprognostic (5.41e-2)" "unprognostic (6.94e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 12.6 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.2 0.9 0.4 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 28.8 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 41.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 9.7 0.0 0.0 2.0 0.0 2.4 0.0 0.0 0.9 0.4 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.5 0.5 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 9.8 22.6 0.0 0.0 0.0 0.0 0.0 SSX2 "CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX" ENSG00000241476 "SSX family member 2" Q16385 X 52696896-52707189 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 57 "testis: 24.1" "Cell type enriched" "Detected in single" 28 "Spermatogonia: 2.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "PC-3: 3.2;U-2197: 1.9" "HPA045683, CAB046020" Enhanced Approved Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "CAB046020: AB_2194010, HPA045683: AB_2679418" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.5 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.3 0.0 0.0 0.0 0.2 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.9 0.0 0.6 0.1 0.6 1.9 0.0 0.0 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 SSX4 CT5.4 ENSG00000268009 "SSX family member 4" O60224 X 48383516-48393347 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 14 "testis: 6.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 10 "BEWO: 3.6;Karpas-707: 8.8;U-266/70: 5.2;U-266/84: 9.5" HPA045683 Approved Approved Nucleoplasm,Nucleoli NA NA "Nucleoplasm, Nucleoli" "HPA045683: AB_2679418" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.1 0.7 0.3 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 8.8 0.0 0.0 0.0 0.0 0.3 0.2 0.3 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.1 0.0 0.0 0.0 5.2 9.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 STAG2 "SA-2, SA2, SCC3B" ENSG00000101972 "Stromal antigen 2" Q8N3U4 X 123960212-124422664 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Chromosome partition, Meiosis, Mitosis" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA002857 Supported NA NA "HPA002857: AB_1079861" "unprognostic (1.62e-1)" "unprognostic (1.01e-2)" "unprognostic (6.75e-2)" "unprognostic (2.16e-2)" "unprognostic (1.37e-2)" "unprognostic (2.70e-2)" "unprognostic (3.77e-2)" "unprognostic (9.67e-3)" "unprognostic (4.68e-2)" "unprognostic (1.86e-1)" "unprognostic (1.24e-1)" "unprognostic (3.38e-1)" "unprognostic (1.59e-3)" "unprognostic (2.81e-1)" "unprognostic (2.77e-2)" "unprognostic (1.63e-1)" "unprognostic (3.97e-1)" 24.0 18.8 21.5 23.9 23.7 39.7 30.1 35.4 23.5 28.1 25.1 16.4 25.2 14.9 24.3 21.0 24.3 20.0 16.3 15.7 21.4 17.9 22.2 18.1 23.4 26.2 24.9 17.5 31.1 19.7 46.1 27.6 25.5 20.6 25.9 18.3 14.2 20.7 27.8 27.6 18.9 21.9 25.9 30.6 26.7 17.6 9.3 26.4 69.3 32.0 19.7 27.1 37.7 37.8 12.8 12.5 30.3 14.4 12.1 15.5 6.7 17.5 16.5 24.9 15.7 10.7 16.2 16.1 16.6 17.9 17.3 21.8 15.4 18.8 32.4 23.6 14.9 19.4 16.0 50.9 14.1 24.5 23.0 21.7 29.9 33.1 10.1 11.1 39.1 23.6 12.7 14.0 20.5 33.1 15.0 14.5 33.1 29.2 34.6 12.7 19.1 50.0 17.6 13.0 16.1 24.6 35.5 32.9 27.1 13.4 33.5 22.5 17.9 37.5 14.0 19.7 18.6 8.4 18.0 17.6 0.1 9.3 20.3 18.9 14.9 22.5 40.7 10.9 24.1 17.4 16.8 10.2 18.1 10.8 13.1 12.6 10.0 11.2 10.1 12.5 12.8 15.5 12.4 30.3 12.1 14.4 11.2 8.7 6.7 21.5 23.7 35.4 23.5 21.4 17.9 24.9 17.5 20.6 26.4 59.6 44.6 53.3 44.3 49.9 49.3 38.4 28.1 60.2 64.8 41.8 56.9 28.0 18.3 37.3 0.9 53.4 25.6 46.7 33.1 27.7 48.0 69.8 54.5 35.8 31.4 42.9 55.8 46.6 58.6 1.6 60.9 61.9 32.1 38.7 36.8 54.0 42.5 20.1 65.0 27.0 60.0 64.7 43.2 7.0 11.3 49.1 59.7 50.7 37.9 72.3 STAT3 APRF ENSG00000168610 "Signal transducer and activator of transcription 3" P40763 17 42313324-42388568 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Diabetes mellitus, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001671, CAB003859, HPA058603, CAB068241, CAB068242" Supported Supported Nucleoplasm,Cytosol NA NA 220000 "Nucleoplasm, Cytosol" "CAB003859: AB_347629, CAB068241: AB_2665663, CAB068242: AB_2665662, HPA001671: AB_1080102, HPA058603: AB_2683772" "unprognostic (1.83e-2)" "unprognostic (2.42e-1)" "unprognostic (9.23e-3)" "unprognostic (2.91e-1)" "unprognostic (5.59e-3)" "unprognostic (1.78e-2)" "unprognostic (8.26e-2)" "unprognostic (1.51e-1)" "unprognostic (1.32e-1)" "unprognostic (1.77e-1)" "unprognostic (2.21e-1)" "unprognostic (1.26e-1)" "unprognostic (6.47e-3)" "unprognostic (7.75e-3)" "unprognostic (2.21e-2)" "unprognostic (7.63e-2)" "unprognostic (1.61e-1)" 44.6 30.7 23.2 34.4 27.5 35.3 49.3 15.7 23.5 25.1 31.5 18.4 21.7 20.5 33.2 27.4 36.4 32.7 34.0 82.9 20.1 14.7 34.5 90.0 45.7 45.5 26.0 11.1 40.6 32.1 18.6 27.9 24.6 27.6 28.9 21.8 24.3 29.3 22.9 53.4 28.4 28.6 49.7 25.1 41.4 29.4 15.4 25.7 16.8 38.0 31.2 28.8 40.4 53.1 10.8 13.7 69.7 20.2 13.9 21.7 26.7 17.0 32.3 14.3 14.1 30.5 29.2 10.4 20.0 25.4 17.3 16.9 8.5 16.5 5.3 19.8 19.8 26.2 26.0 12.9 20.4 14.2 43.9 8.9 36.9 19.6 17.4 22.6 9.0 24.1 45.5 20.1 13.8 20.0 18.2 23.5 9.8 22.6 17.0 11.4 12.0 33.3 9.0 8.3 17.4 0.0 7.4 38.2 7.8 27.4 22.1 13.1 8.5 23.0 54.6 8.2 17.9 28.7 13.5 19.7 26.9 13.7 15.9 16.3 26.2 20.4 4.5 16.6 9.5 11.9 26.2 19.4 24.9 21.7 20.2 17.3 10.8 16.0 16.8 13.7 10.4 16.6 15.8 69.7 13.9 18.7 7.5 12.0 26.7 23.2 27.5 15.7 23.5 20.1 14.7 26.0 11.1 27.6 25.7 86.4 150.9 56.2 91.3 115.1 87.1 46.2 43.3 85.6 108.1 127.4 265.1 21.1 14.9 68.7 27.3 107.9 156.0 0.0 83.8 34.3 140.9 148.0 138.6 102.5 60.4 23.8 119.1 104.3 64.9 11.1 66.4 84.8 69.2 88.4 68.1 108.0 75.8 94.7 57.3 38.3 352.3 64.7 221.4 32.2 15.1 139.9 26.1 86.3 72.7 78.8 STAT5B ENSG00000173757 "Signal transducer and activator of transcription 5B" P51692 17 42199168-42276707 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 7 "Early spermatids: 85.5;Late spermatids: 113.5;Peritubular cells: 70.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 43.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004298, CAB005418, HPA042128, HPA049883, HPA051156" Approved Approved Cytosol NA NA 170000 Cytosol "CAB004298: AB_2197067, CAB005418: AB_632445, HPA042128: AB_2677864, HPA049883: AB_2680931, HPA051156: AB_2681366" "unprognostic (1.49e-1)" "unprognostic (3.60e-2)" "unprognostic (4.06e-2)" "prognostic favorable (9.37e-4)" "unprognostic (2.68e-1)" "unprognostic (4.29e-1)" "unprognostic (2.23e-1)" "unprognostic (1.03e-1)" "unprognostic (3.06e-2)" "unprognostic (7.98e-2)" "prognostic favorable (1.63e-4)" "unprognostic (1.36e-1)" "prognostic favorable (2.39e-5)" "unprognostic (9.19e-2)" "unprognostic (2.95e-1)" "unprognostic (1.54e-1)" "unprognostic (2.13e-1)" 25.7 24.0 13.5 19.5 16.3 21.8 26.2 32.1 15.9 21.6 21.0 13.7 16.3 8.6 31.9 12.0 11.6 24.5 18.1 12.8 11.9 20.1 12.4 13.5 15.8 24.6 16.0 13.9 34.4 12.1 12.0 22.6 55.4 17.2 20.8 10.3 16.4 12.9 21.7 38.3 12.2 14.8 33.1 10.6 22.1 14.4 13.2 15.7 21.7 15.4 9.6 19.8 21.5 33.1 2.5 2.4 18.8 2.8 3.5 8.3 3.8 5.3 8.4 12.5 3.3 15.6 7.9 6.0 5.5 9.8 7.9 6.9 3.6 4.5 17.4 8.3 6.3 15.7 6.9 7.4 4.8 6.3 43.9 8.6 17.0 15.8 5.6 8.6 7.5 27.5 9.7 7.4 5.9 7.6 6.8 12.5 11.8 30.6 3.8 3.2 5.2 35.1 19.7 3.1 12.4 0.0 15.1 7.8 6.0 5.0 8.6 9.2 5.4 10.1 12.9 7.7 2.9 9.1 8.8 9.5 11.1 3.9 5.7 7.6 7.5 3.4 8.7 4.4 7.9 5.7 8.8 2.8 4.6 5.9 2.5 6.4 2.5 8.3 6.7 2.4 2.5 5.9 5.0 18.8 3.5 2.8 1.8 6.9 3.8 13.5 16.3 32.1 15.9 11.9 20.1 16.0 13.9 17.2 15.7 6.0 17.9 3.7 4.7 7.9 18.0 17.3 10.2 5.3 9.1 3.5 19.6 5.9 5.0 7.2 85.5 23.3 6.2 23.3 10.1 5.7 10.8 8.0 15.1 10.2 8.1 9.5 9.8 16.0 14.2 113.5 43.7 11.1 10.1 10.0 7.2 8.4 10.7 7.8 70.0 8.1 13.8 38.8 22.8 4.2 4.1 8.5 10.6 24.5 7.5 5.4 STAT6 "D12S1644, IL-4-STAT" ENSG00000166888 "Signal transducer and activator of transcription 6" P42226 12 57095408-57132139 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001861 Approved Supported Nucleoplasm,Cytosol NA NA Cytosol Nucleoplasm "HPA001861: AB_1080106" "unprognostic (3.43e-3)" "unprognostic (1.87e-1)" "unprognostic (1.37e-1)" "prognostic favorable (1.69e-4)" "unprognostic (4.14e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" "unprognostic (6.70e-2)" "unprognostic (1.88e-2)" "unprognostic (3.65e-1)" "unprognostic (5.39e-2)" "unprognostic (1.00e-2)" "unprognostic (2.81e-2)" "unprognostic (1.67e-1)" "unprognostic (1.55e-1)" "prognostic favorable (7.76e-4)" "prognostic favorable (1.14e-4)" 33.6 34.9 10.4 35.9 12.8 12.8 27.9 4.6 11.6 37.8 47.3 6.2 28.4 23.9 44.5 26.6 40.8 31.8 33.8 20.9 10.2 3.9 35.0 31.0 34.9 25.2 13.3 12.0 41.9 21.2 18.1 9.2 22.0 9.8 42.3 26.2 23.3 30.1 26.5 11.4 39.1 59.4 43.8 12.2 48.4 32.1 13.3 7.9 29.3 31.1 24.4 42.8 43.1 34.0 6.2 9.6 27.6 13.0 4.7 5.9 14.0 16.7 16.7 4.1 6.8 40.8 39.7 11.9 13.3 29.4 14.9 10.9 7.5 22.8 40.2 20.9 29.6 0.1 23.4 5.1 25.9 11.0 18.0 1.9 9.2 17.8 9.4 24.4 10.7 30.4 55.3 21.5 18.0 16.0 39.3 26.2 13.2 6.5 5.7 19.1 5.7 11.7 12.0 6.3 20.9 3.4 13.6 0.3 13.7 25.7 28.0 0.1 0.4 12.5 10.4 12.6 5.9 15.5 24.6 21.7 0.3 8.7 15.5 0.2 0.1 0.4 10.0 13.4 10.4 17.9 9.8 12.5 6.8 5.9 13.0 5.2 6.2 4.8 4.8 9.6 6.2 4.7 4.3 27.6 4.7 11.0 4.6 4.9 14.0 10.4 12.8 4.6 11.6 10.2 3.9 13.3 12.0 9.8 7.9 44.7 57.5 34.4 35.4 26.6 1.0 12.0 22.9 45.5 46.6 47.1 0.0 1.6 13.3 32.2 6.4 29.9 63.9 0.0 31.0 8.4 26.5 42.7 55.6 33.4 31.9 0.0 31.8 38.6 76.0 8.6 55.0 54.0 20.3 52.3 38.2 3.3 38.1 49.1 47.7 21.9 1.0 25.8 27.8 0.9 1.1 28.7 5.3 29.9 37.3 48.9 STIL "MCPH7, SIL" ENSG00000123473 "STIL, centriolar assembly protein" Q15468 1 47250139-47314147 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 36.0;testis: 23.8" "Cell type enhanced" "Detected in many" 9 "Spermatocytes: 18.6;Spermatogonia: 17.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA046543 Approved "Plasma membrane,Cytosol" NA Yes "Plasma membrane, Cytosol" "HPA046543: AB_2679692" "unprognostic (2.07e-1)" "unprognostic (6.29e-2)" "unprognostic (5.54e-3)" "unprognostic (2.67e-3)" "unprognostic (1.76e-1)" "unprognostic (1.56e-2)" "unprognostic (2.90e-5)" "unprognostic (7.35e-3)" "unprognostic (4.04e-3)" "unprognostic (1.41e-1)" "prognostic unfavorable (1.33e-4)" "unprognostic (5.81e-2)" "unprognostic (3.36e-14)" "unprognostic (5.76e-3)" "unprognostic (2.58e-1)" "unprognostic (1.64e-1)" "unprognostic (2.28e-1)" 1.2 1.4 1.3 10.8 2.4 11.0 2.9 1.4 2.2 1.2 4.1 0.9 2.5 3.6 1.5 2.2 5.8 0.9 1.7 2.0 1.4 1.2 1.5 1.6 1.7 5.0 1.3 1.5 1.2 1.5 0.9 0.9 5.5 1.1 1.7 6.4 0.8 3.6 0.5 0.8 4.2 4.0 1.3 1.2 3.4 2.2 23.8 1.0 36.0 1.1 3.5 7.1 1.3 2.1 1.9 1.6 5.4 0.7 3.3 1.2 0.5 16.9 9.1 13.1 11.7 0.9 2.3 8.4 15.0 7.2 16.8 17.7 9.8 8.4 20.0 7.1 7.5 17.3 11.3 15.3 7.9 18.1 14.9 6.9 22.5 11.3 8.6 0.5 18.2 11.5 0.8 1.3 14.4 9.4 2.1 11.1 15.3 15.9 19.1 12.6 7.7 17.6 5.7 15.9 9.4 7.5 11.5 21.4 9.6 4.7 10.2 11.7 7.0 16.1 11.9 7.8 16.3 7.7 10.4 6.5 15.9 16.1 11.4 20.3 6.3 13.1 19.7 7.4 13.9 14.7 4.3 0.7 1.1 1.1 0.4 0.5 1.7 1.2 1.0 0.5 1.9 0.8 0.8 5.4 3.3 0.3 1.6 1.1 0.5 1.3 2.4 1.4 2.2 1.4 1.2 1.3 1.5 1.1 1.0 3.0 0.3 2.2 0.5 0.8 1.2 0.5 0.0 6.7 2.3 0.0 3.9 1.2 0.0 1.2 0.7 0.9 1.8 0.0 0.4 3.8 0.8 1.2 2.3 0.5 2.3 0.0 1.7 1.8 1.9 1.3 0.3 1.2 0.0 4.6 4.3 0.8 1.8 1.5 0.7 0.3 0.7 0.0 0.0 18.6 17.8 2.0 0.7 0.8 3.4 1.4 STK11 "LKB1, PJS" ENSG00000118046 "Serine/threonine kinase 11" Q15831 19 1177558-1228435 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Autophagy, Cell cycle, Differentiation, DNA damage, Spermatogenesis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 11 "Early spermatids: 124.0;Late spermatids: 234.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 11.7" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016231, HPA017254, CAB022105, HPA067481" Approved Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB016231: AB_627890, CAB022105: , HPA017254: AB_1852924, HPA067481: AB_2685847" "unprognostic (8.60e-2)" "unprognostic (1.68e-1)" "unprognostic (5.00e-2)" "prognostic favorable (3.69e-5)" "unprognostic (2.04e-2)" "prognostic favorable (1.96e-4)" "unprognostic (9.11e-3)" "unprognostic (3.19e-1)" "unprognostic (9.08e-2)" "unprognostic (1.26e-1)" "unprognostic (1.95e-3)" "unprognostic (7.70e-3)" "unprognostic (3.54e-2)" "unprognostic (3.16e-2)" "unprognostic (1.60e-1)" "unprognostic (3.31e-1)" "unprognostic (3.12e-3)" 13.4 13.7 13.5 11.8 12.4 19.3 16.7 17.8 16.0 12.2 16.1 8.3 19.8 18.1 10.8 8.7 15.1 10.0 11.8 15.3 12.6 9.8 10.7 22.1 9.4 12.5 9.7 10.4 11.0 16.8 10.7 11.6 12.2 9.9 12.2 5.3 11.9 16.0 12.2 49.2 16.8 18.0 7.7 7.6 16.9 15.5 59.8 7.5 11.8 12.4 14.5 19.0 11.4 9.8 2.7 1.9 11.7 6.3 1.9 1.8 0.5 21.2 10.3 7.8 14.8 7.4 6.7 16.5 10.4 10.9 9.8 10.4 8.4 14.9 13.9 11.5 10.8 4.4 13.8 7.7 16.0 3.0 26.0 18.8 14.2 0.6 10.5 16.0 14.3 23.9 12.2 11.7 7.5 11.2 8.9 9.8 11.1 26.6 19.2 5.5 15.9 13.7 14.5 15.0 7.3 12.7 21.8 8.4 15.6 8.8 15.6 18.1 13.1 0.0 7.7 11.2 4.7 12.1 23.5 13.2 10.1 11.5 19.8 16.5 37.8 15.9 10.4 10.1 19.1 10.4 2.0 4.2 4.5 0.6 6.0 0.4 2.7 1.0 1.8 1.9 1.0 1.0 0.9 11.7 1.9 6.3 1.0 0.7 0.5 13.5 12.4 17.8 16.0 12.6 9.8 9.7 10.4 9.9 7.5 6.0 13.6 11.1 6.4 14.8 23.6 11.8 17.8 2.7 6.8 22.7 17.7 6.7 6.6 8.1 124.0 14.7 29.5 0.0 11.9 4.5 10.4 14.2 2.3 25.2 12.9 17.5 14.5 16.0 22.2 234.7 22.7 10.4 15.1 17.2 29.2 19.3 13.0 25.9 19.4 8.6 19.8 12.9 20.8 49.9 19.4 13.6 7.3 8.6 33.0 10.9 STRN "PPP2R6A, STRN1" ENSG00000115808 Striatin O43815 2 36843640-36966472 "Cancer-related genes, Predicted intracellular proteins" Calmodulin-binding "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cardiomyocytes: 51.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017286 Approved Approved Nucleoplasm,Cytosol No No 11000 Cytosol Nucleoplasm "HPA017286: AB_1857618" "unprognostic (1.65e-1)" "unprognostic (1.65e-1)" "unprognostic (3.57e-3)" "unprognostic (2.23e-2)" "unprognostic (3.25e-1)" "unprognostic (1.53e-1)" "unprognostic (1.63e-3)" "unprognostic (7.37e-2)" "unprognostic (1.25e-1)" "unprognostic (2.42e-1)" "unprognostic (1.77e-3)" "unprognostic (1.33e-1)" "prognostic favorable (2.27e-4)" "unprognostic (1.13e-1)" "unprognostic (6.43e-2)" "unprognostic (2.11e-1)" "unprognostic (3.43e-2)" 11.8 8.1 11.4 11.0 22.1 17.4 13.3 16.4 14.2 11.2 14.0 10.9 8.9 10.1 8.6 7.1 25.9 6.8 8.4 25.7 16.2 10.2 11.6 10.2 10.3 9.6 16.9 9.4 9.9 7.1 11.3 6.3 12.6 10.5 8.1 13.7 5.6 16.2 6.9 16.0 16.1 13.2 11.1 34.3 10.9 11.4 9.8 14.8 18.6 8.1 15.5 16.7 11.3 14.4 1.5 0.8 3.7 1.5 0.5 2.1 0.4 23.3 11.8 15.8 6.6 8.7 12.2 15.8 9.5 8.9 9.2 8.5 12.0 7.6 15.5 7.6 11.9 13.2 11.1 13.3 10.4 11.4 17.5 10.2 25.1 10.4 6.2 8.3 15.0 14.1 7.3 9.1 14.7 11.6 6.8 11.7 6.2 18.7 12.3 11.3 6.7 14.9 6.6 12.6 9.5 6.0 9.7 25.0 6.7 7.6 19.3 2.9 9.6 14.1 10.9 8.9 9.2 7.8 5.8 15.5 16.5 16.7 10.2 12.4 12.5 18.8 13.7 8.4 15.1 11.4 3.4 0.8 1.4 2.1 1.5 0.7 1.5 1.5 1.3 0.4 0.9 0.8 0.9 3.7 0.5 1.4 0.8 0.3 0.4 11.4 22.1 16.4 13.0 16.2 10.2 16.9 9.4 10.5 14.8 8.9 7.7 5.2 9.0 18.3 11.7 51.7 10.2 1.4 17.0 22.7 19.6 6.9 8.3 8.8 1.7 17.5 17.3 0.0 7.2 7.9 7.9 14.5 4.7 7.3 7.6 17.5 10.9 15.4 22.2 0.9 8.9 11.0 8.5 10.8 16.4 9.3 12.8 10.5 11.7 7.7 15.4 0.0 10.3 10.3 18.1 29.1 13.6 10.2 13.8 29.3 SUFU "PRO1280, SUFUH, SUFUXL" ENSG00000107882 "SUFU negative regulator of hedgehog signaling" Q9UMX1 10 102503987-102633535 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Developmental protein" "Cancer-related genes, Ciliopathy, Disease mutation, Joubert syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 8 "Early spermatids: 126.0;Late spermatids: 78.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008700 Supported Supported Nucleoplasm NA NA Nucleoplasm "HPA008700: AB_1080125" "unprognostic (1.55e-1)" "unprognostic (4.00e-2)" "unprognostic (5.14e-2)" "unprognostic (1.33e-1)" "unprognostic (4.69e-2)" "unprognostic (5.68e-2)" "unprognostic (3.69e-2)" "unprognostic (5.99e-2)" "unprognostic (1.64e-1)" "unprognostic (3.15e-3)" "unprognostic (9.60e-2)" "unprognostic (2.13e-1)" "unprognostic (3.72e-3)" "unprognostic (1.82e-1)" "unprognostic (1.44e-1)" "unprognostic (5.10e-2)" "unprognostic (3.82e-3)" 10.7 12.8 15.0 15.2 12.8 3.9 18.3 23.0 15.3 13.4 10.4 11.3 12.1 7.7 14.4 13.3 14.7 14.2 16.2 11.0 11.8 7.8 10.8 10.0 21.4 20.5 11.9 11.0 18.0 8.9 20.0 7.8 13.9 10.0 15.4 8.8 11.9 12.6 16.7 14.1 23.1 9.4 14.3 10.7 13.1 7.9 21.1 13.1 19.9 6.2 12.7 15.0 15.2 15.0 2.3 4.5 6.2 5.5 2.8 3.1 2.8 6.3 6.7 10.9 15.7 11.3 9.5 5.3 6.6 12.8 9.6 8.7 6.2 4.7 6.5 18.8 7.3 3.9 4.5 13.4 7.3 6.3 4.0 10.4 15.5 3.9 5.9 5.4 5.6 11.2 10.9 5.8 7.1 5.8 17.6 12.3 6.4 3.4 6.0 5.8 5.3 10.6 8.5 3.1 4.1 5.1 11.5 11.8 3.4 6.3 9.5 3.7 5.9 5.2 4.9 5.9 10.5 10.8 3.7 13.5 4.3 6.1 4.5 7.2 4.9 3.2 4.7 5.3 11.0 2.9 4.2 4.5 6.2 2.5 5.5 2.0 2.3 3.1 2.8 4.5 2.1 2.2 2.5 1.1 2.8 5.5 2.5 1.9 2.8 15.0 12.8 23.0 15.3 11.8 7.8 11.9 11.0 10.0 13.1 0.0 3.0 0.9 2.2 2.7 3.4 3.6 0.0 4.0 4.5 3.5 7.9 6.9 1.7 3.9 126.0 4.3 4.0 0.0 2.6 3.1 5.4 1.9 3.5 4.9 10.4 1.6 1.2 12.9 10.2 78.9 4.6 5.6 0.0 7.2 2.2 2.9 3.5 0.0 6.3 4.4 3.9 0.0 3.4 4.2 4.5 5.6 5.8 5.1 2.8 1.1 SUZ12 "CHET9, JJAZ1, KIAA0160" ENSG00000178691 "SUZ12 polycomb repressive complex 2 subunit" Q15022 17 31937018-32001045 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA057436 Approved Supported "Nucleoplasm,Nucleoli,Nucleoli rim,Nuclear bodies" Yes No "Nucleoplasm, Nucleoli, Nucleoli rim, Nuclear bodies" "HPA057436: AB_2683439" "unprognostic (1.23e-1)" "unprognostic (1.11e-1)" "unprognostic (3.65e-3)" "unprognostic (1.23e-1)" "unprognostic (2.49e-1)" "unprognostic (7.31e-2)" "unprognostic (2.66e-3)" "unprognostic (8.05e-2)" "unprognostic (7.27e-2)" "unprognostic (3.06e-2)" "unprognostic (6.29e-2)" "unprognostic (8.70e-2)" "unprognostic (3.28e-2)" "unprognostic (2.25e-1)" "unprognostic (1.28e-1)" "unprognostic (5.91e-2)" "unprognostic (1.31e-1)" 10.1 10.8 13.4 15.4 10.4 25.5 33.5 16.0 13.8 11.2 11.4 7.5 13.6 10.1 12.5 8.1 12.3 9.8 7.7 9.7 9.1 7.6 10.9 11.5 10.6 19.9 9.3 9.9 10.0 10.1 15.5 10.4 15.3 9.5 10.7 10.9 6.9 10.1 9.6 8.7 9.9 12.2 9.6 7.7 15.2 10.7 17.1 12.5 31.8 12.0 6.5 18.9 10.8 19.5 5.5 4.6 4.1 2.6 4.4 5.5 1.2 14.3 12.7 12.0 13.7 6.9 8.9 12.3 14.0 12.4 17.2 20.8 9.6 8.1 31.3 10.8 8.7 14.7 12.7 17.8 8.0 28.0 11.0 17.3 21.7 10.8 6.9 8.2 34.1 22.3 6.2 9.1 17.1 13.2 10.4 10.5 15.0 20.9 43.6 14.7 5.0 40.5 19.8 6.8 10.1 7.8 24.2 30.8 25.4 10.1 14.0 15.4 12.0 22.5 7.3 13.5 8.7 21.1 28.5 7.7 13.7 12.5 16.3 21.5 23.8 29.6 38.8 10.0 21.1 12.3 1.4 1.9 3.8 3.8 2.6 3.0 5.5 4.1 4.0 1.4 4.4 3.9 5.5 4.1 4.4 1.8 4.6 4.2 1.2 13.4 10.4 16.0 13.8 9.1 7.6 9.3 9.9 9.5 12.5 38.7 37.9 23.1 41.1 52.0 74.2 24.8 35.7 28.1 37.5 33.2 102.1 49.4 14.9 23.6 8.9 34.9 15.6 23.3 19.1 45.9 33.8 46.2 15.1 37.5 27.9 58.8 28.3 38.6 41.9 10.7 24.7 37.6 23.6 86.6 31.9 41.7 22.6 10.5 24.1 24.5 76.3 12.9 32.5 100.7 141.1 62.7 58.1 39.9 33.0 48.2 SYK ENSG00000165025 "Spleen associated tyrosine kinase" P43405 9 90801787-90898549 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Host-virus interaction, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 38.5" "Cell type enhanced" "Detected in many" 6 "B-cells: 53.8;Hofbauer cells: 63.0;Kupffer cells: 79.3;Macrophages: 66.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 15 "classical monocyte: 21.4;eosinophil: 23.3;intermediate monocyte: 19.0;memory B-cell: 23.1;myeloid DC: 24.9;naive B-cell: 17.5;neutrophil: 32.8;NK-cell: 8.7;non-classical monocyte: 16.4;plasmacytoid DC: 18.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Daudi: 39.4;HEL: 22.7;HL-60: 31.3;HMC-1: 20.9;REH: 26.2;THP-1: 24.1;U-698: 18.6;U-937: 22.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001384, CAB007773" Enhanced Approved "Vesicles,Plasma membrane,Cytosol" No NA 1000000 "Plasma membrane, Cytosol" Vesicles "CAB007773: AB_562232, HPA001384: AB_1080144" "unprognostic (1.01e-1)" "unprognostic (5.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.69e-2)" "unprognostic (2.31e-1)" "unprognostic (7.92e-2)" "unprognostic (1.06e-1)" "unprognostic (1.34e-1)" "unprognostic (6.41e-2)" "unprognostic (1.78e-2)" "unprognostic (7.20e-2)" "unprognostic (9.93e-2)" "unprognostic (2.55e-3)" "unprognostic (8.77e-2)" "unprognostic (5.36e-3)" "unprognostic (3.41e-2)" "unprognostic (1.06e-2)" 7.2 3.3 6.0 38.1 9.6 18.2 6.7 1.1 4.5 3.7 10.3 6.7 1.5 12.3 2.3 6.7 16.2 6.9 6.6 5.5 7.2 3.2 8.6 2.5 13.7 36.4 9.1 2.5 2.1 8.9 25.9 3.1 5.0 6.1 4.1 8.3 2.8 8.9 1.8 1.4 8.3 22.2 3.5 11.3 38.5 7.4 5.5 7.9 30.5 18.1 7.8 32.2 8.6 7.5 23.1 24.9 32.8 21.4 8.7 0.1 10.2 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 39.4 1.1 0.0 1.3 6.1 0.8 3.2 0.0 0.0 5.4 22.7 0.0 0.0 0.0 31.3 20.9 0.0 4.5 0.0 0.4 0.0 0.0 4.9 0.6 3.2 0.0 4.8 0.0 13.7 0.2 14.8 0.0 26.2 0.0 10.8 0.8 5.9 2.1 1.8 0.0 2.8 0.0 0.1 2.5 24.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 18.6 0.0 22.1 0.0 1.4 21.4 23.3 0.1 19.0 0.1 23.1 0.0 0.0 24.9 17.5 0.0 0.0 32.8 8.7 16.4 18.5 0.0 10.2 6.0 9.6 1.1 4.5 7.2 3.2 9.1 2.5 6.1 7.9 11.9 22.7 53.8 3.7 3.1 0.9 1.6 12.7 12.0 17.0 14.0 0.0 1.2 13.3 12.6 5.5 1.1 18.4 0.0 10.9 1.3 1.1 1.8 40.6 0.9 63.0 0.0 9.9 4.9 79.3 4.7 0.6 66.0 11.8 24.4 23.8 0.0 15.3 28.1 0.0 0.3 0.1 6.5 1.0 0.7 0.7 5.0 1.1 5.3 24.7 6.5 TAF15 "hTAFII68, Npl3, RBP56, TAF2N" ENSG00000270647 "TATA-box binding protein associated factor 15" Q92804 17 35713791-35864615 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "DNA-binding, RNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052059, HPA063647" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA052059: AB_2681711, HPA063647: AB_2685072" "unprognostic (1.26e-1)" "unprognostic (2.66e-3)" "unprognostic (1.10e-1)" "unprognostic (1.63e-2)" "unprognostic (1.82e-1)" "unprognostic (1.27e-1)" "unprognostic (8.48e-3)" "unprognostic (4.75e-2)" "unprognostic (8.06e-3)" "unprognostic (2.08e-2)" "unprognostic (2.33e-1)" "unprognostic (1.44e-2)" "unprognostic (1.79e-2)" "unprognostic (1.39e-2)" "unprognostic (5.41e-2)" "unprognostic (3.35e-2)" "unprognostic (2.99e-1)" 14.0 12.9 12.7 15.3 16.2 13.9 11.0 13.7 14.1 10.5 11.7 15.0 13.2 12.7 10.2 11.0 12.6 8.0 11.5 13.1 11.8 9.8 15.0 8.9 19.4 14.7 8.3 10.7 11.3 14.6 18.1 11.1 11.1 11.4 10.1 9.2 9.8 15.3 26.9 14.7 13.4 17.5 15.9 12.7 11.0 11.3 15.5 21.1 9.4 12.8 15.8 12.0 9.8 3.7 3.2 3.8 3.6 4.7 7.2 2.2 29.2 48.1 25.7 24.9 20.6 11.7 16.9 33.4 11.4 15.3 15.0 32.2 21.2 58.2 24.1 21.6 18.3 31.1 34.1 33.7 22.0 16.4 44.7 33.5 34.9 33.7 20.4 54.0 22.5 18.6 17.7 23.1 36.3 17.7 20.6 36.2 31.4 24.1 17.2 34.9 58.8 13.1 15.9 27.3 13.8 35.1 38.3 21.8 19.3 52.6 19.5 19.2 41.6 12.6 13.2 31.4 29.5 18.6 27.7 11.8 25.8 16.9 40.1 22.8 27.8 42.4 23.3 26.7 19.3 3.8 3.5 3.5 4.9 3.4 7.2 3.0 3.5 3.8 2.5 3.7 3.3 3.7 2.0 4.7 3.6 3.2 3.9 2.2 14.9 50.3 37.4 49.0 32.1 54.1 35.5 43.3 50.9 64.8 57.6 39.3 72.7 3.3 35.9 4.6 49.6 37.7 46.7 25.7 39.3 25.9 36.3 54.3 53.9 37.4 57.2 47.1 33.2 42.9 8.9 28.4 36.7 32.1 34.3 49.4 55.6 28.8 28.1 38.2 26.6 42.8 45.3 31.9 60.1 72.8 32.5 65.2 42.4 50.6 42.6 TAL1 "bHLHa17, SCL, TCL5" ENSG00000162367 "TAL bHLH transcription factor 1, erythroid differentiation factor" P17542 1 47216290-47232220 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 33.1" "Cell type enhanced" "Detected in some" 22 "Endothelial cells: 18.0;Erythroid cells: 93.5;granulocytes: 35.8;Ito cells: 30.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "basophil: 3.2;neutrophil: 1.2" "Lineage enriched" "Detected in single" 7 "granulocytes: 3.2" "Cell line enhanced" "Detected in some" "HEL: 52.8;HMC-1: 25.4;HUVEC TERT2: 11.0;JURKAT: 21.1;K-562: 16.5;TIME: 12.0" "Region enriched" "Detected in some" 5 "midbrain: 17.1" "Low region specificity" "Detected in many" "CAB017805, HPA047866, HPA073983" Approved Enhanced Nucleoplasm Yes NA Nucleoplasm "CAB017805: , HPA047866: AB_2680192, HPA073983: AB_2732246" "unprognostic (2.63e-1)" "unprognostic (2.62e-2)" "unprognostic (1.22e-1)" "unprognostic (2.40e-2)" "unprognostic (1.59e-1)" "unprognostic (8.80e-3)" "unprognostic (3.95e-3)" "unprognostic (1.33e-1)" "unprognostic (4.15e-2)" "unprognostic (1.99e-2)" "unprognostic (5.42e-3)" "unprognostic (3.68e-1)" "unprognostic (1.02e-2)" "unprognostic (2.76e-2)" "unprognostic (2.19e-1)" "unprognostic (1.51e-1)" "unprognostic (1.18e-2)" 9.1 2.7 7.0 1.8 5.7 33.1 7.1 1.6 6.9 3.3 2.4 12.0 2.3 1.6 3.7 3.3 2.5 4.1 4.2 3.9 8.8 3.5 4.5 2.4 14.6 2.2 11.1 4.4 1.5 1.3 2.2 2.1 9.8 7.3 2.4 2.4 2.1 1.4 3.0 3.1 2.0 3.3 4.4 9.4 8.5 2.1 1.8 9.2 0.0 6.7 4.1 1.5 2.5 5.5 0.3 0.1 3.2 0.3 0.4 0.4 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 52.8 0.0 0.0 0.0 0.0 25.4 0.0 0.0 0.0 0.0 0.0 11.0 21.1 16.5 0.0 0.0 0.0 8.8 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 12.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.3 0.4 0.1 1.2 0.4 0.1 0.1 0.1 2.2 7.0 5.7 1.6 6.9 8.8 3.5 11.1 4.4 7.3 9.2 0.0 0.0 0.0 0.0 0.8 0.0 1.7 2.5 0.0 2.3 1.8 0.0 0.1 0.0 0.0 4.8 18.0 0.0 93.5 0.0 0.1 0.9 0.0 35.8 0.0 7.9 0.0 0.0 30.7 2.1 10.2 0.0 0.2 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.2 0.4 0.9 0.0 0.0 0.0 0.0 TAL2 bHLHa19 ENSG00000186051 "TAL bHLH transcription factor 2" Q16559 9 105662457-105663112 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "blood: 8.8;kidney: 4.6;skeletal muscle: 17.3" "Cell type enhanced" "Detected in some" 16 "Cone photoreceptor cells: 3.9;Distal tubular cells: 6.6;Intestinal endocrine cells: 3.4;Muller glia cells: 1.8" "Cancer enhanced" "Detected in some" "renal cancer: 1.6" "Group enriched" "Detected in some" 21 "memory B-cell: 8.8;naive B-cell: 7.9;plasmacytoid DC: 2.2" "Group enriched" "Detected in many" 18 "B-cells: 8.8;dendritic cells: 2.2" "Cell line enhanced" "Detected in some" "CACO-2: 3.4;HAP1: 4.9;K-562: 12.9" "Low region specificity" "Detected in single" "Not detected" "Not detected" HPA030886 Uncertain Approved Cytosol NA NA Cytosol "HPA030886: AB_10601596" "unprognostic (3.89e-2)" "unprognostic (1.45e-1)" "unprognostic (8.51e-2)" "unprognostic (5.54e-2)" "unprognostic (2.24e-1)" "unprognostic (9.06e-2)" "unprognostic (4.98e-2)" "unprognostic (1.03e-1)" "unprognostic (2.70e-3)" "unprognostic (2.63e-1)" "unprognostic (7.00e-4)" "unprognostic (2.84e-2)" "prognostic favorable (2.69e-4)" "unprognostic (2.70e-2)" "unprognostic (1.24e-1)" "unprognostic (1.29e-1)" "unprognostic (7.39e-2)" 0.1 0.3 0.5 0.1 0.7 0.0 0.0 0.3 0.6 0.2 0.0 0.0 0.2 0.9 0.1 0.2 0.0 0.3 0.4 0.5 4.6 0.3 0.0 0.2 0.7 0.3 0.1 0.0 0.8 0.1 0.1 0.1 0.0 0.2 17.3 0.1 0.1 0.0 0.8 0.3 0.0 0.6 0.1 0.4 0.1 0.0 8.8 2.2 0.0 0.0 0.3 0.0 0.1 0.0 0.7 2.5 0.7 0.3 0.0 0.3 0.1 0.3 0.1 0.4 3.4 0.2 0.1 0.3 0.0 0.7 0.1 4.9 0.0 0.2 0.6 0.5 1.1 0.0 0.0 0.2 0.6 1.9 0.3 0.6 0.1 0.2 0.2 0.0 0.8 12.9 0.3 0.4 0.3 0.8 0.7 0.2 0.0 0.2 0.1 0.1 0.0 0.0 0.0 2.9 1.2 0.2 0.3 0.2 0.1 0.2 2.1 0.5 0.3 0.8 0.7 1.1 1.0 2.0 0.1 0.2 2.4 0.8 0.0 0.0 0.0 0.0 0.0 0.0 8.8 0.0 0.0 0.0 7.9 0.0 0.0 0.0 0.3 0.0 2.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 3.9 0.0 6.6 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.2 0.0 0.4 1.1 0.9 0.0 0.0 0.3 1.3 0.0 0.0 0.0 0.0 0.0 TBL1XR1 "C21, DC42, FLJ12894, IRA1, TBLR1" ENSG00000177565 "Transducin beta like 1 X-linked receptor 1" Q9BZK7 3 177019340-177228000 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "Activator, Chromatin regulator, Repressor" "Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "U-698: 71.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA019182 Supported Approved Nucleoplasm NA NA Nucleoplasm "HPA019182: AB_1857800" "unprognostic (4.11e-2)" "unprognostic (3.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.27e-3)" "prognostic favorable (5.16e-5)" "unprognostic (4.44e-2)" "prognostic unfavorable (1.08e-7)" "unprognostic (3.75e-1)" "unprognostic (4.84e-2)" "unprognostic (3.04e-1)" "unprognostic (3.13e-3)" "unprognostic (2.50e-1)" "prognostic unfavorable (4.25e-5)" "unprognostic (5.83e-2)" "unprognostic (1.69e-1)" "unprognostic (1.50e-1)" "unprognostic (1.17e-1)" 20.7 26.0 27.4 24.3 26.8 27.3 20.3 27.5 28.1 28.9 29.9 22.6 15.4 24.0 23.9 20.5 23.8 21.9 22.7 30.3 26.2 20.7 19.9 21.8 30.8 27.8 21.4 25.9 26.5 19.9 30.6 11.3 24.0 19.7 24.4 23.2 24.7 21.3 17.7 21.1 17.8 24.3 21.9 19.6 24.7 21.3 17.4 22.3 28.4 45.6 14.9 32.1 29.1 25.5 7.4 13.3 12.9 4.6 6.8 8.3 4.1 23.9 12.3 16.0 9.0 13.6 14.8 9.6 7.6 11.8 6.6 9.1 14.1 19.9 24.6 35.9 10.9 17.5 14.8 11.9 15.8 13.3 25.8 3.7 13.8 21.0 8.4 11.7 21.9 8.2 21.8 8.2 9.7 24.1 13.0 10.3 17.3 10.3 43.6 8.5 8.6 20.4 3.0 10.1 15.4 8.3 11.7 20.4 26.2 5.9 34.0 5.8 9.2 10.2 8.0 9.5 10.5 29.3 16.8 15.7 10.8 9.1 6.0 16.4 23.8 30.5 71.1 7.3 16.4 12.3 11.4 3.0 3.8 5.8 4.6 5.1 7.3 5.7 6.6 4.0 7.4 5.0 6.4 12.9 6.8 3.9 13.3 8.3 4.1 27.4 26.8 27.5 28.1 26.2 20.7 21.4 25.9 19.7 22.3 68.5 47.1 43.4 46.9 81.4 116.0 84.2 48.4 61.6 62.6 99.5 117.8 22.3 24.9 43.8 5.7 62.9 42.8 23.3 37.3 28.5 65.8 123.0 24.3 58.7 32.8 109.7 81.9 55.9 85.4 5.2 59.2 54.6 62.4 31.5 74.5 41.8 53.4 23.0 68.6 46.2 81.2 45.3 41.5 8.4 53.9 97.7 23.0 49.8 75.7 61.8 TBX3 "TBX3-ISO, UMS, XHL" ENSG00000135111 "T-box 3" O15119 12 114670254-114684164 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 117.7" "Cell type enriched" "Detected in many" 6 "Syncytiotrophoblasts: 513.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 34.0;BJ hTERT+: 32.4;RT4: 42.4" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA005799, HPA075876" Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA005799: AB_1857817, HPA075876: " "unprognostic (3.27e-1)" "unprognostic (2.64e-1)" "unprognostic (2.84e-1)" "unprognostic (1.11e-1)" "unprognostic (3.40e-2)" "unprognostic (5.97e-3)" "unprognostic (1.56e-1)" "unprognostic (2.99e-2)" "unprognostic (9.43e-2)" "unprognostic (1.15e-1)" "unprognostic (3.35e-1)" "unprognostic (3.06e-1)" "unprognostic (3.64e-3)" "unprognostic (1.09e-3)" "unprognostic (1.43e-1)" "unprognostic (1.01e-1)" "prognostic favorable (3.28e-4)" 4.3 60.5 0.9 3.3 1.9 0.0 19.9 0.7 2.3 18.2 12.2 1.7 69.6 14.2 13.1 18.7 1.9 7.5 5.0 6.2 1.2 1.5 4.1 15.1 12.6 0.8 1.2 0.5 15.6 1.1 0.3 5.3 67.8 1.6 32.3 1.5 2.6 7.3 117.7 4.2 4.8 19.4 9.7 1.4 2.6 2.2 3.5 1.2 0.5 36.3 7.3 3.5 24.6 25.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.7 6.0 0.0 0.0 9.0 12.4 13.5 34.0 32.4 13.2 13.1 5.3 1.4 0.0 0.5 5.9 0.8 1.5 2.8 1.2 16.3 0.0 4.1 0.0 1.5 15.5 2.9 0.0 0.0 5.5 0.8 4.4 9.1 0.0 0.1 0.0 1.2 0.0 1.1 0.5 0.0 0.1 0.0 17.2 1.8 0.0 0.0 0.8 0.0 42.4 2.2 6.6 4.8 2.2 1.1 15.8 1.7 0.0 0.0 4.0 2.6 2.3 11.0 0.0 0.0 0.0 8.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.9 0.7 2.3 1.2 1.5 1.2 0.5 1.6 1.2 0.0 3.4 0.9 88.0 8.8 6.3 9.8 0.0 0.0 0.0 33.2 3.9 39.8 0.0 0.4 1.3 26.5 25.4 0.0 0.0 5.9 9.5 74.0 0.0 31.0 5.4 1.6 4.7 0.6 1.6 1.8 4.9 0.8 3.3 0.0 13.8 1.5 0.5 23.0 5.6 0.0 2.0 38.8 34.1 0.1 4.7 8.5 513.4 0.7 4.5 62.6 TCEA1 "GTF2S, SII, TCEA, TF2S, TFIIS" ENSG00000187735 "Transcription elongation factor A1" P23193 8 53966552-54022529 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043786 Approved Supported Nucleoplasm,Nucleoli NA NA Nucleoplasm Nucleoli "HPA043786: AB_10959468" "unprognostic (5.35e-2)" "unprognostic (9.90e-2)" "unprognostic (2.39e-1)" "unprognostic (2.11e-3)" "unprognostic (3.34e-2)" "unprognostic (1.17e-1)" "unprognostic (3.72e-2)" "unprognostic (1.77e-1)" "unprognostic (4.14e-2)" "unprognostic (1.00e-2)" "unprognostic (1.56e-2)" "unprognostic (1.25e-1)" "prognostic unfavorable (3.75e-5)" "unprognostic (3.80e-3)" "unprognostic (1.10e-1)" "unprognostic (1.13e-1)" "unprognostic (3.05e-2)" 26.7 25.3 30.7 40.5 31.5 29.6 31.1 26.1 27.4 26.0 28.3 21.9 26.6 20.3 27.3 20.9 27.5 23.6 24.7 21.4 27.8 24.2 26.5 56.8 22.3 39.2 29.7 17.6 28.5 38.4 32.2 28.7 21.1 27.1 31.3 22.5 20.6 25.4 25.4 21.8 22.8 22.4 38.9 36.8 30.0 26.1 17.3 31.3 39.9 54.6 18.6 46.9 39.6 37.3 60.0 31.9 20.5 17.8 25.2 40.1 17.8 27.3 27.7 24.8 25.5 17.6 21.9 17.8 21.7 25.5 25.7 28.7 15.8 22.9 67.2 24.7 24.9 27.4 21.1 31.3 19.9 37.5 38.4 15.7 50.8 13.5 23.3 55.3 19.9 21.9 15.7 53.8 24.2 106.8 21.3 21.9 23.2 32.2 58.4 23.3 13.0 41.1 13.9 40.3 44.5 8.3 31.9 8.7 12.0 35.4 18.7 23.3 16.9 17.9 15.8 58.3 24.2 22.8 22.3 19.4 18.9 17.4 21.2 19.5 36.1 22.6 45.5 33.3 22.8 26.6 18.1 17.8 20.5 30.1 16.8 28.6 60.0 31.4 27.7 22.1 44.4 28.0 29.1 6.4 25.2 15.6 31.9 40.1 17.8 30.7 31.5 26.1 27.4 27.8 24.2 29.7 17.6 27.1 31.3 83.4 82.6 150.6 116.2 120.3 70.8 20.7 79.0 139.2 124.0 94.2 84.4 99.1 142.6 96.9 85.2 85.7 52.6 93.5 95.8 104.8 89.7 121.1 94.9 140.5 76.9 54.0 83.7 48.5 68.2 129.1 124.8 89.2 111.3 118.2 83.8 139.0 101.0 71.9 124.8 130.8 97.6 77.6 122.7 77.9 84.3 131.6 93.7 107.1 78.7 109.8 TCF12 "bHLHb20, HEB, HsT17266, HTF4" ENSG00000140262 "Transcription factor 12" Q99081 15 56918623-57299281 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" "Developmental protein, DNA-binding" "Cancer-related genes, Craniosynostosis, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 89.4" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004432, HPA065827" Approved Supported "Nucleoplasm,Nuclear speckles" NA NA "Nucleoplasm, Nuclear speckles" "CAB004432: AB_671267, HPA065827: AB_2685564" "unprognostic (1.19e-1)" "unprognostic (1.11e-1)" "unprognostic (8.26e-2)" "unprognostic (1.65e-1)" "unprognostic (2.07e-3)" "unprognostic (1.11e-1)" "unprognostic (6.63e-2)" "unprognostic (1.85e-1)" "prognostic unfavorable (8.89e-4)" "unprognostic (7.83e-2)" "unprognostic (7.26e-3)" "unprognostic (5.57e-3)" "prognostic unfavorable (5.24e-5)" "unprognostic (2.03e-1)" "unprognostic (2.93e-1)" "unprognostic (3.15e-2)" "unprognostic (1.41e-1)" 20.9 14.3 24.9 12.6 37.5 10.9 18.4 32.7 41.8 48.2 16.5 33.6 14.0 16.0 28.1 15.0 14.8 28.2 21.4 15.7 28.4 16.4 17.0 14.4 17.3 13.7 33.9 15.3 26.2 12.5 29.2 15.7 19.1 27.9 26.3 17.9 14.7 20.1 17.5 18.1 16.0 15.8 25.8 25.3 13.6 17.3 14.7 41.3 89.4 17.0 9.6 15.8 23.3 21.2 11.8 15.9 16.0 19.3 12.2 17.6 10.2 6.5 12.3 54.1 17.4 24.7 21.7 9.5 13.5 23.7 12.0 15.9 7.9 5.3 9.0 11.1 20.4 8.6 7.9 21.1 9.7 15.3 11.8 7.9 18.0 13.3 9.5 17.0 11.3 9.5 19.0 17.6 11.0 29.2 16.0 21.4 40.5 20.1 11.3 16.2 2.2 26.7 6.3 14.6 6.8 5.3 36.5 62.8 8.4 16.5 12.2 11.0 32.0 14.5 5.3 13.1 18.0 8.2 22.3 16.4 19.3 14.8 8.2 19.6 6.5 11.6 15.0 10.8 22.1 23.1 16.0 11.2 8.7 15.0 14.3 12.4 10.8 12.2 13.6 15.9 11.8 14.1 12.7 1.3 12.2 19.3 6.6 17.6 10.2 24.9 37.5 32.7 26.9 28.4 16.4 33.9 15.3 27.9 41.3 50.6 15.8 14.2 18.0 23.7 12.8 14.5 20.4 16.0 27.3 15.7 33.4 8.5 11.6 15.2 19.4 27.4 15.8 0.0 10.3 12.7 31.5 19.7 22.0 16.0 23.5 12.7 8.6 22.7 34.0 15.6 23.9 26.0 13.5 10.0 16.5 26.9 13.8 17.5 32.5 13.6 25.1 45.3 20.6 18.9 12.5 29.5 10.9 16.0 16.4 15.6 TCF3 "bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR" ENSG00000071564 "Transcription factor 3" P15923 19 1609290-1652605 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Differentiation, Neurogenesis, Transcription, Transcription regulation" DNA-binding "Cancer-related genes, Disease mutation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Daudi: 76.6;REH: 76.2;U-698: 96.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018351, HPA049808, HPA062476" Approved Enhanced Nucleoplasm No No Nucleoplasm "CAB018351: AB_675504, HPA049808: AB_2680892, HPA062476: AB_2684775" "unprognostic (8.82e-2)" "unprognostic (4.74e-2)" "unprognostic (1.26e-2)" "unprognostic (1.25e-1)" "unprognostic (1.91e-2)" "unprognostic (8.25e-3)" "prognostic unfavorable (2.46e-4)" "unprognostic (2.07e-2)" "unprognostic (7.99e-2)" "unprognostic (2.35e-1)" "unprognostic (2.42e-1)" "unprognostic (9.29e-3)" "prognostic unfavorable (1.53e-4)" "unprognostic (4.87e-3)" "unprognostic (1.88e-1)" "unprognostic (3.07e-1)" "unprognostic (8.05e-2)" 13.0 8.8 12.8 31.6 9.8 33.2 17.4 8.3 11.9 15.5 16.2 11.9 9.4 18.1 16.6 11.3 16.7 12.1 19.0 9.4 11.2 6.2 11.9 8.9 13.2 42.0 10.7 6.0 18.2 13.5 6.3 13.9 10.8 11.0 17.1 9.7 12.4 13.6 6.9 11.2 16.7 23.0 8.8 10.4 33.1 14.9 36.0 11.2 63.2 15.9 11.6 38.0 15.2 13.9 11.3 12.1 2.9 2.8 2.3 4.2 1.6 15.9 8.2 22.6 20.3 3.2 8.6 10.1 9.9 7.8 11.4 10.1 16.2 12.6 76.6 11.3 8.1 2.1 16.6 13.8 10.8 6.7 46.4 9.2 7.2 10.3 17.6 7.4 17.6 10.1 5.5 12.5 8.9 6.9 10.2 13.7 28.5 29.6 26.6 7.2 28.2 48.6 17.1 31.4 9.7 8.6 76.2 10.4 17.3 7.7 14.1 21.6 30.3 9.4 9.3 11.5 8.8 11.8 31.4 16.4 15.0 17.8 18.5 16.9 64.8 31.6 96.6 9.8 22.5 13.4 2.9 1.3 0.9 3.5 1.4 3.7 10.8 2.2 3.2 2.7 11.3 3.2 4.2 0.4 2.3 2.8 12.1 2.1 1.6 12.8 9.8 8.3 11.9 11.2 6.2 10.7 6.0 11.0 11.2 6.0 7.8 26.7 4.5 12.4 10.7 8.9 2.5 0.0 10.3 1.8 25.5 3.4 1.7 9.4 6.7 9.5 13.5 0.0 5.9 7.4 11.5 8.0 6.9 3.9 6.7 4.8 15.5 8.6 7.2 3.9 12.7 6.5 10.1 5.4 13.0 9.0 14.7 14.0 9.6 4.5 13.6 19.4 10.5 3.7 15.8 11.5 2.4 8.6 18.4 6.7 TCF7L2 "TCF-4, TCF4" ENSG00000148737 "Transcription factor 7 like 2" Q9NQB0 10 112950250-113167678 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Wnt signaling pathway" "Activator, DNA-binding, Repressor" "Cancer-related genes, Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 5 "Extravillous trophoblasts: 184.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 9 "intermediate monocyte: 12.1;non-classical monocyte: 33.1" "Lineage enriched" "Detected in many" 13 "monocytes: 33.1" "Low cell line specificity" "Detected in many" "Group enriched" "Detected in many" 8 "midbrain: 84.5;thalamus: 98.3" "Group enriched" "Detected in all" 5 "midbrain: 190.1;pons and medulla: 104.8;thalamus: 169.1" "CAB013535, HPA038800" Supported Approved "Nucleoplasm,Nuclear bodies,Cytosol" Yes No Nucleoplasm "Nuclear bodies, Cytosol" "CAB013535: AB_2533167, HPA038800: " "unprognostic (1.79e-2)" "unprognostic (3.36e-1)" "unprognostic (1.11e-1)" "unprognostic (2.31e-2)" "unprognostic (4.59e-3)" "unprognostic (1.72e-1)" "unprognostic (2.09e-1)" "unprognostic (9.84e-2)" "unprognostic (5.09e-1)" "unprognostic (7.10e-2)" "unprognostic (6.10e-3)" "unprognostic (3.46e-2)" "unprognostic (7.25e-3)" "unprognostic (1.60e-1)" "unprognostic (1.55e-1)" "unprognostic (3.64e-1)" "unprognostic (7.36e-3)" 27.4 10.3 8.7 18.7 10.0 7.3 46.4 5.4 10.3 27.4 34.2 15.4 28.1 21.0 26.6 14.9 12.6 18.2 15.3 13.5 8.1 17.9 10.2 22.9 26.9 13.9 8.5 9.0 25.6 13.9 16.5 17.9 24.0 10.2 14.4 23.7 13.9 14.9 52.8 13.7 17.6 40.4 18.0 13.9 27.3 24.0 10.6 10.1 6.6 14.3 9.3 7.0 21.5 16.3 0.0 1.7 2.5 33.1 0.0 0.6 1.1 7.1 18.6 20.4 19.7 10.7 7.1 24.4 5.1 9.9 3.5 4.3 12.3 21.6 0.0 5.7 9.5 4.8 5.1 6.9 8.8 4.5 0.8 6.4 5.0 12.4 11.3 11.4 1.9 1.8 12.6 3.2 5.5 9.4 15.1 5.9 4.2 5.2 0.3 4.1 13.9 3.2 1.2 14.6 8.0 10.7 9.0 15.0 3.2 7.7 9.9 0.4 6.3 7.7 7.6 8.1 16.5 4.9 1.1 13.7 3.3 9.6 8.5 10.4 1.3 0.1 0.1 3.3 4.2 7.4 0.1 1.8 0.1 0.6 12.1 0.4 0.0 0.1 0.5 1.7 0.0 0.1 0.3 2.5 0.0 33.1 0.0 0.0 1.1 8.7 10.0 5.4 10.3 8.1 17.9 8.5 9.0 10.2 10.1 20.8 21.6 4.7 23.8 37.8 2.4 10.6 35.7 20.1 34.2 38.4 5.9 36.9 10.0 28.5 5.5 37.0 121.0 0.0 38.6 184.2 40.4 33.1 0.0 57.7 15.1 4.8 19.0 55.3 68.7 2.7 54.7 21.0 30.4 1.0 68.2 36.6 41.7 91.2 45.6 13.4 5.7 90.5 44.3 3.0 23.4 34.8 23.8 4.3 42.7 42.0 TCL1A TCL1 ENSG00000100721 "T cell leukemia/lymphoma 1A" P56279 14 95709967-95714196 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 12 "blood: 179.4;lymphoid tissue: 63.7" "Group enriched" "Detected in some" 5 "B-cells: 166.3;Spermatogonia: 48.5" "Cancer enriched" "Detected in many" 18 "testis cancer: 64.4" "Not detected" "Not detected" "Group enriched" "Detected in some" 381 "memory B-cell: 45.6;naive B-cell: 179.4;plasmacytoid DC: 79.8" "Group enriched" "Detected in many" 487 "B-cells: 179.4;dendritic cells: 79.8" "Group enriched" "Detected in some" 157 "Daudi: 71.1;REH: 92.4;U-698: 94.4" "Not detected" "Not detected" "CAB004045, HPA016604" Enhanced Enhanced "Nucleoplasm,Endoplasmic reticulum,Cytosol" NA NA "Endoplasmic reticulum, Cytosol" Nucleoplasm "CAB004045: AB_2179419, HPA016604: AB_1857859" "unprognostic (1.27e-3)" "unprognostic (3.12e-4)" "unprognostic (2.61e-4)" "unprognostic (2.01e-2)" "unprognostic (1.27e-1)" "unprognostic (4.75e-4)" "unprognostic (7.70e-2)" "unprognostic (9.67e-3)" "unprognostic (1.03e-1)" "unprognostic (3.35e-1)" "unprognostic (1.14e-1)" "unprognostic (2.14e-2)" "unprognostic (2.64e-2)" "unprognostic (1.87e-1)" "unprognostic (3.94e-1)" "unprognostic (2.06e-1)" "unprognostic (4.55e-1)" 0.4 0.2 0.2 53.4 0.2 4.8 0.3 0.2 0.2 0.2 0.9 0.0 0.2 0.0 0.3 0.0 0.8 0.3 0.6 0.3 0.2 0.2 1.1 0.4 3.2 63.7 0.2 0.0 0.3 0.2 0.0 0.2 0.6 0.0 0.4 0.2 0.1 2.9 0.0 0.2 0.2 10.4 0.1 0.2 33.5 0.5 5.3 0.0 4.7 0.8 1.2 53.6 3.6 0.3 179.4 79.8 0.2 0.1 0.0 0.1 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 71.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 92.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.4 0.1 0.0 0.0 0.5 94.4 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.1 45.6 0.0 0.0 0.1 179.4 0.1 0.0 0.2 0.0 0.1 79.8 0.0 6.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 2.2 166.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.3 0.0 1.2 0.0 0.0 0.9 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 20.6 48.5 0.0 0.0 0.0 0.0 0.0 TERT "EST2, hEST2, TCS1, TP2, TRT" ENSG00000164362 "Telomerase reverse transcriptase" O14746 5 1253147-1295069 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins" "DNA-binding, Nucleotidyltransferase, Ribonucleoprotein, RNA-directed DNA polymerase, Transferase" "Cancer-related genes, Disease mutation, Dyskeratosis congenita" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "bone marrow: 3.4;lymphoid tissue: 12.0;testis: 5.0" "Cell type enhanced" "Detected in some" 24 "Cardiomyocytes: 1.2;Spermatogonia: 1.9" "Low cancer specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 62.6;fHDF/TERT166: 59.4;HBEC3-KT: 120.8;hTEC/SVTERT24-B: 76.3;LHCN-M2: 34.4;TIME: 98.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" "HPA054641, HPA065897" Supported Supported "Nucleoplasm,Nuclear speckles,Cytosol" NA NA Nucleoplasm "Nuclear speckles, Cytosol" "HPA054641: AB_2682554, HPA065897: AB_2685576" "unprognostic (1.21e-2)" "unprognostic (2.88e-2)" "unprognostic (1.24e-3)" "unprognostic (1.53e-1)" "unprognostic (1.43e-3)" "unprognostic (6.42e-3)" "unprognostic (1.85e-2)" "unprognostic (2.21e-1)" "unprognostic (6.91e-2)" "unprognostic (1.89e-1)" "unprognostic (3.59e-1)" "unprognostic (9.16e-4)" "unprognostic (8.84e-11)" "unprognostic (1.92e-1)" "unprognostic (2.15e-1)" "unprognostic (3.35e-1)" 0.0 0.0 0.0 7.1 0.9 3.4 0.0 0.0 0.2 0.1 1.1 0.0 0.0 1.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 2.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0 1.0 0.4 5.0 0.0 12.0 0.0 0.0 2.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 31.3 62.6 0.5 0.0 23.8 4.3 8.0 0.1 0.1 0.7 0.0 59.4 0.0 0.0 0.2 120.8 5.1 0.0 0.3 0.0 0.0 0.1 0.0 0.3 0.3 0.0 3.1 76.3 0.8 0.1 0.2 0.5 0.6 0.1 34.4 0.0 0.2 1.7 0.4 0.0 0.2 0.9 0.0 0.8 3.5 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 98.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.9 0.0 0.0 0.0 0.2 0.0 TET1 "bA119F7.1, CXXC6, KIAA1676, LCX" ENSG00000138336 "Tet methylcytosine dioxygenase 1" Q8NFU7 10 68560656-68694482 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 10 "Extravillous trophoblasts: 59.1;Horizontal cells: 33.4;Leydig cells: 23.9" "Cancer enriched" "Detected in some" 15 "testis cancer: 10.4" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BEWO: 15.3;HAP1: 17.4;K-562: 9.7;NTERA-2: 10.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019032, HPA057273" Supported "Nucleoplasm,Nuclear membrane" NA NA Nucleoplasm "Nuclear membrane" "HPA019032: AB_1847363, HPA057273: AB_2683391" "unprognostic (1.60e-1)" "unprognostic (8.30e-2)" "unprognostic (9.85e-2)" "unprognostic (1.67e-2)" "unprognostic (1.27e-1)" "unprognostic (8.15e-2)" "unprognostic (3.60e-3)" "unprognostic (1.12e-1)" "unprognostic (2.00e-1)" "unprognostic (7.90e-3)" "unprognostic (1.83e-1)" "unprognostic (1.71e-1)" "unprognostic (1.18e-3)" "unprognostic (2.88e-4)" "unprognostic (4.02e-2)" "unprognostic (2.54e-1)" "unprognostic (9.52e-3)" 4.4 1.6 3.3 4.3 2.6 1.6 3.1 4.4 4.3 5.1 2.4 5.8 3.2 1.2 6.0 3.4 2.4 2.9 3.5 2.4 3.5 2.3 1.8 1.5 1.6 1.7 2.5 2.6 6.1 1.6 7.4 2.2 5.8 2.9 3.2 2.0 8.1 15.9 4.8 4.0 2.2 1.8 6.5 3.6 1.7 2.2 1.4 5.9 1.2 3.2 3.2 1.8 5.1 5.4 1.3 1.1 1.0 0.0 0.9 2.3 0.2 0.6 0.7 6.9 7.8 0.7 0.6 15.3 0.4 0.8 0.6 1.1 4.6 0.2 0.0 0.2 0.7 0.1 0.0 17.4 0.0 0.7 0.2 2.8 1.8 0.0 4.1 1.0 1.6 0.9 0.9 0.1 0.4 0.0 1.4 0.1 2.9 9.7 1.2 0.6 0.5 2.7 1.2 10.2 0.0 0.9 2.7 2.2 0.2 0.3 0.7 1.9 3.1 0.3 0.4 1.4 7.2 0.9 1.2 0.2 0.6 1.4 0.0 0.5 0.5 0.5 2.7 0.1 0.0 0.1 0.0 0.0 1.0 1.5 0.0 2.0 1.3 0.8 1.3 0.2 0.5 1.4 1.1 0.0 0.9 0.0 1.1 2.3 0.2 3.3 2.6 4.4 2.6 3.5 2.3 2.5 2.6 2.9 5.9 3.0 3.8 0.0 1.9 1.0 2.2 4.5 2.5 1.4 4.5 0.0 9.8 16.6 0.0 1.4 0.4 3.3 0.0 0.0 0.3 59.1 11.8 2.1 0.0 2.1 3.3 33.4 13.2 7.4 0.0 0.6 23.9 0.1 1.7 0.0 0.0 17.3 0.9 0.0 19.4 0.8 10.8 6.5 3.8 0.5 0.7 1.0 23.3 1.7 0.4 0.3 TET2 "FLJ20032, KIAA1546" ENSG00000168769 "Tet methylcytosine dioxygenase 2" Q6N021 4 105145875-105279816 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle" "Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 29.0" "Lineage enriched" "Detected in all" 4 "granulocytes: 29.0" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA043135 Supported Approved Nucleoplasm NA NA Nucleoplasm "HPA043135: AB_10794177" "unprognostic (6.83e-2)" "unprognostic (3.52e-2)" "unprognostic (1.69e-2)" "unprognostic (9.42e-2)" "unprognostic (4.15e-2)" "unprognostic (5.88e-2)" "unprognostic (6.12e-2)" "unprognostic (1.19e-3)" "unprognostic (1.15e-2)" "unprognostic (1.57e-2)" "unprognostic (5.77e-2)" "unprognostic (7.29e-2)" "unprognostic (2.70e-3)" "unprognostic (6.10e-2)" "unprognostic (1.89e-1)" "unprognostic (9.15e-2)" "unprognostic (7.84e-2)" 9.9 6.1 8.7 11.9 11.4 26.3 8.0 4.1 10.0 9.6 7.4 10.1 5.8 8.2 10.1 7.4 16.2 9.2 6.6 6.8 9.0 4.2 6.7 5.5 9.9 9.8 13.7 5.7 8.5 7.0 7.4 29.0 12.4 9.1 6.5 8.0 4.7 13.5 8.2 9.8 16.0 10.2 7.8 15.5 12.9 6.8 3.2 14.6 9.3 7.2 6.9 8.7 9.8 12.3 2.8 5.1 29.0 7.0 2.6 2.1 1.4 4.8 3.1 10.6 10.8 1.9 4.3 4.3 3.5 4.7 5.0 4.9 3.1 6.5 0.5 4.0 4.3 2.4 4.6 10.2 6.1 5.7 6.2 2.7 6.8 6.0 1.1 5.4 15.4 11.3 3.7 8.3 4.8 6.2 8.1 6.6 3.7 7.2 12.7 4.3 3.6 2.5 4.2 2.3 6.4 1.9 7.9 5.3 1.0 4.6 10.2 7.6 6.2 3.8 9.9 0.6 6.0 4.5 11.1 8.5 7.6 6.9 2.2 5.9 8.5 6.1 6.4 4.6 3.8 7.4 10.8 7.0 7.2 2.1 5.5 0.8 2.6 1.2 1.2 5.1 2.8 1.0 1.6 29.0 2.6 6.4 4.5 1.5 1.4 8.7 11.4 4.1 10.0 9.0 4.2 13.7 5.7 9.1 14.6 23.8 26.1 5.6 9.4 12.8 21.1 21.6 7.6 21.4 20.5 8.7 15.7 16.9 6.6 5.6 0.2 12.9 15.8 0.0 6.6 4.8 7.5 10.8 26.6 6.6 13.0 33.4 22.3 9.2 49.2 0.4 7.5 43.4 5.0 11.8 15.9 5.6 6.6 17.3 6.7 2.4 23.8 12.9 8.2 0.2 0.6 31.5 28.6 17.5 12.7 22.5 TFE3 "bHLHe33, TFEA" ENSG00000068323 "Transcription factor binding to IGHM enhancer 3" P19532 X 49028726-49043486 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 10.5" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023881 Approved Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "HPA023881: AB_1857931" "unprognostic (2.68e-2)" "unprognostic (2.89e-3)" "unprognostic (2.40e-2)" "unprognostic (5.36e-2)" "unprognostic (2.71e-2)" "unprognostic (1.81e-1)" "prognostic unfavorable (6.03e-5)" "unprognostic (2.40e-1)" "unprognostic (1.26e-1)" "unprognostic (4.32e-2)" "unprognostic (5.41e-2)" "unprognostic (1.16e-1)" "prognostic unfavorable (2.19e-8)" "unprognostic (1.93e-1)" "unprognostic (8.77e-2)" "unprognostic (4.19e-2)" "unprognostic (6.25e-1)" 31.3 20.9 12.6 18.2 14.4 22.6 53.1 16.5 18.1 22.6 17.7 16.6 30.0 9.9 22.8 21.9 20.5 18.8 16.4 15.1 11.3 11.8 21.6 14.1 22.8 10.3 13.2 9.4 24.4 15.9 16.5 16.3 22.0 15.9 21.2 10.4 15.7 12.6 30.6 13.6 14.1 13.5 21.2 14.8 23.0 14.7 10.4 15.2 4.2 21.7 10.8 10.5 28.6 20.5 1.2 1.9 10.5 4.4 0.4 1.4 1.6 11.8 15.3 5.1 14.7 16.6 15.1 5.1 15.7 18.2 16.0 13.7 9.3 9.5 4.5 6.7 23.0 17.7 9.8 9.6 14.1 13.0 9.8 5.2 4.1 11.3 8.7 22.4 4.3 10.2 13.0 9.1 26.3 18.8 14.9 7.7 3.1 7.9 19.6 13.6 7.0 2.8 4.0 13.9 3.5 13.8 4.3 8.8 10.1 10.2 5.5 4.9 4.8 16.7 7.2 5.5 18.0 10.2 3.9 16.2 17.6 18.8 17.5 8.6 12.1 11.3 3.7 21.0 5.3 12.0 0.0 3.5 1.6 0.5 4.3 0.9 0.6 0.9 0.5 1.9 1.2 0.6 0.4 10.5 0.4 4.4 0.4 1.4 1.6 12.6 14.4 16.5 14.9 11.3 11.8 13.2 9.4 15.9 15.2 14.9 9.1 5.2 18.6 17.5 6.5 6.2 17.8 4.0 11.4 19.2 3.9 13.6 8.3 16.6 0.6 14.6 11.8 0.0 13.7 7.4 16.4 16.4 5.7 13.9 19.2 17.5 12.0 9.8 23.8 1.3 25.3 13.0 8.5 10.0 8.5 9.6 17.6 14.0 23.0 8.6 5.3 12.9 13.3 2.6 0.9 19.3 31.0 8.6 6.5 15.8 TFEB "bHLHe35, TCFEB" ENSG00000112561 "Transcription factor EB" P19484 6 41683978-41736259 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Adaptive immunity, Autophagy, Immunity, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 9 "Syncytiotrophoblasts: 100.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 29.0" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "BEWO: 30.2;Daudi: 19.1;OE19: 25.5;U-698: 28.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA049532 Supported Nucleoplasm NA NA Nucleoplasm "HPA049532: AB_2680807" "unprognostic (3.63e-3)" "unprognostic (1.51e-3)" "unprognostic (1.75e-2)" "unprognostic (4.48e-3)" "unprognostic (1.95e-1)" "unprognostic (1.05e-1)" "unprognostic (1.64e-1)" "unprognostic (4.22e-3)" "unprognostic (1.39e-2)" "unprognostic (4.13e-2)" "prognostic favorable (4.77e-4)" "unprognostic (2.12e-2)" "prognostic favorable (1.06e-5)" "unprognostic (1.44e-1)" "unprognostic (3.51e-2)" "unprognostic (2.46e-1)" "unprognostic (1.31e-2)" 8.6 6.4 10.2 16.8 20.7 8.9 6.8 8.6 15.0 6.4 10.5 34.4 8.2 6.8 7.1 4.3 9.3 7.2 9.1 19.3 14.6 8.2 12.2 5.0 8.3 24.1 30.0 6.8 6.7 11.4 26.1 14.9 18.5 16.2 10.7 5.3 6.9 18.0 8.6 45.2 7.9 15.5 8.4 27.4 27.3 7.9 2.5 24.0 2.8 11.1 10.9 18.3 10.8 11.1 22.2 8.5 29.0 9.6 0.8 2.6 4.4 1.7 1.8 0.4 7.0 2.4 1.4 30.2 2.7 5.5 2.4 1.8 4.0 2.0 19.1 3.7 2.9 1.8 4.8 1.1 2.8 0.6 17.5 1.9 0.0 6.9 7.3 4.7 0.5 2.6 0.5 5.4 2.8 1.8 5.8 1.8 2.1 2.3 4.7 0.9 1.2 1.1 1.4 0.1 25.5 0.9 12.6 0.2 2.6 4.3 1.4 7.9 2.3 2.3 4.9 0.6 1.8 1.4 9.5 3.8 0.9 1.9 0.1 1.9 12.3 1.9 28.2 1.4 8.1 0.9 0.1 9.6 8.8 2.6 9.3 0.4 22.2 0.7 1.0 8.5 15.1 0.2 0.9 29.0 0.8 6.5 1.7 0.4 4.4 10.2 20.7 8.6 15.0 14.6 8.2 30.0 6.8 16.2 24.0 8.9 9.4 20.8 7.5 12.6 5.8 16.4 12.7 4.0 1.2 12.2 11.8 37.8 18.3 3.0 0.7 7.7 14.0 0.0 6.2 3.4 5.2 6.4 1.1 3.9 25.2 25.4 12.7 8.6 22.7 4.0 3.1 12.9 0.0 4.6 8.4 16.7 6.9 17.3 10.3 2.4 4.7 6.5 6.2 0.5 0.9 12.7 100.7 5.4 7.9 6.0 TFG "FLJ36137, SPG57, TF6" ENSG00000114354 "TRK-fused gene" Q92734 3 100709331-100748966 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "ER-Golgi transport, Transport" "Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration, Neuropathy, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019473, HPA052206" Approved Supported Vesicles,Cytosol No No Vesicles Cytosol "HPA019473: AB_1857936, HPA052206: AB_2681760" "unprognostic (1.14e-1)" "unprognostic (3.58e-2)" "unprognostic (1.46e-1)" "unprognostic (2.94e-2)" "unprognostic (1.46e-1)" "unprognostic (4.14e-2)" "prognostic unfavorable (5.48e-4)" "unprognostic (3.31e-3)" "unprognostic (1.42e-1)" "unprognostic (3.73e-2)" "prognostic unfavorable (1.50e-4)" "unprognostic (4.58e-3)" "unprognostic (3.72e-2)" "unprognostic (2.82e-1)" "unprognostic (8.55e-2)" "unprognostic (3.33e-1)" "unprognostic (8.45e-2)" 36.4 40.3 27.2 21.9 33.8 29.7 31.0 28.1 40.5 31.2 34.7 33.3 44.2 52.5 31.2 45.8 46.7 29.0 40.8 46.2 28.1 30.7 44.6 68.6 29.9 25.4 28.2 21.5 33.5 49.2 52.3 45.1 63.3 33.7 27.5 40.7 31.9 39.6 45.8 38.6 31.0 67.1 37.5 31.7 28.3 28.9 33.5 23.0 27.6 43.6 42.9 41.2 29.5 30.1 25.8 27.8 43.2 28.4 27.7 26.8 21.8 48.7 26.6 33.1 21.0 41.8 47.4 40.9 35.3 47.5 46.2 55.1 33.5 24.4 6.5 26.0 43.8 35.8 36.6 35.6 40.3 55.0 30.0 20.9 24.5 20.5 31.1 46.8 18.1 14.7 38.8 54.4 27.6 48.8 42.9 40.8 11.5 17.6 18.1 47.6 34.1 15.9 14.3 31.5 45.4 40.0 14.0 19.4 21.2 56.0 32.9 26.2 24.0 23.2 30.2 41.1 28.7 35.6 24.6 27.3 27.9 33.8 12.8 25.5 15.5 15.6 23.4 44.6 19.8 32.7 43.2 28.3 27.0 21.8 28.4 26.4 25.8 22.6 24.4 27.8 22.9 21.6 21.6 18.7 27.7 26.4 19.4 26.8 21.8 27.2 33.8 28.1 40.5 28.1 30.7 28.2 21.5 33.7 23.0 56.6 28.8 33.5 90.7 121.3 43.5 83.1 53.5 36.1 40.9 34.9 23.6 186.8 116.0 161.1 64.7 63.1 162.1 23.3 94.6 171.9 101.9 94.0 76.1 59.6 75.5 54.0 50.5 51.0 25.1 36.9 65.6 40.7 60.8 142.5 99.4 86.6 108.9 83.4 69.6 72.7 59.0 38.8 84.4 49.9 48.5 104.0 237.9 28.8 82.9 98.7 TGFBR2 "MFS2, TBR-ii, TBRII" ENSG00000163513 "Transforming growth factor beta receptor 2" P37173 3 30606502-30694142 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins" "Apoptosis, Differentiation, Growth regulation" "Kinase, Receptor, Serine/threonine-protein kinase, Transferase" "Aortic aneurysm, Cancer-related genes, Craniosynostosis, Disease mutation, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 14 "Endothelial cells: 188.8;Ito cells: 564.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC diff: 54.5;ASC TERT1: 82.2;HSkMC: 70.9;LHCN-M2: 67.2;TIME: 61.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB073537 Supported "Plasma membrane" NA NA 560000 "Plasma membrane" "CAB073537: " "unprognostic (1.74e-1)" "unprognostic (1.84e-2)" "unprognostic (3.70e-1)" "unprognostic (3.02e-2)" "unprognostic (1.92e-1)" "unprognostic (2.26e-1)" "unprognostic (1.96e-1)" "unprognostic (1.62e-1)" "unprognostic (1.40e-1)" "unprognostic (2.24e-2)" "unprognostic (7.36e-2)" "unprognostic (1.12e-1)" "unprognostic (1.65e-2)" "unprognostic (4.72e-2)" "unprognostic (1.81e-2)" "unprognostic (8.81e-2)" "unprognostic (8.02e-2)" 91.8 24.6 6.7 24.6 10.3 7.3 88.3 3.6 7.3 36.5 42.6 9.8 18.6 13.2 42.6 23.3 36.2 28.4 42.6 73.5 6.9 5.2 32.6 21.9 52.6 75.7 12.6 3.7 22.2 26.0 17.4 10.3 24.2 9.9 35.2 17.5 27.9 22.5 19.5 34.9 17.0 31.3 37.2 12.0 68.7 26.8 15.4 8.2 19.3 40.9 16.8 26.9 48.0 82.0 5.3 6.8 20.0 6.6 1.4 19.7 3.9 2.5 14.7 0.9 0.0 54.5 82.2 2.5 12.8 18.0 4.4 4.4 3.3 13.6 0.3 46.2 17.1 5.2 5.1 0.6 18.7 7.3 1.0 1.3 1.4 1.7 16.5 23.3 2.3 12.1 70.9 16.6 19.0 18.4 20.2 47.6 1.7 0.3 0.0 67.2 0.2 2.3 1.7 0.4 12.8 5.9 2.1 5.9 0.3 23.6 6.0 0.0 0.9 3.8 1.0 3.6 1.2 0.0 2.5 61.6 21.7 5.4 9.8 4.8 0.5 0.0 2.0 13.0 2.5 8.7 6.9 2.9 20.0 3.5 3.0 3.2 4.0 5.4 4.2 2.6 5.3 19.7 9.1 12.6 1.4 6.6 6.8 1.2 3.9 6.7 10.3 3.6 7.3 6.9 5.2 12.6 3.7 9.9 8.2 134.0 83.8 41.5 14.2 33.2 1.9 64.1 48.4 12.0 53.4 26.2 0.0 5.3 3.3 11.4 2.0 188.8 9.7 0.0 13.8 4.3 48.1 7.3 28.9 45.3 27.1 0.0 8.1 564.1 139.2 2.0 30.5 46.1 28.7 1.8 11.9 0.2 25.3 10.8 44.6 5.6 0.9 32.3 36.0 0.3 1.1 26.7 3.1 39.4 13.0 9.0 TLX1 "HOX11, TCL3" ENSG00000107807 "T cell leukemia homeobox 1" P31314 10 101130505-101137789 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "lymphoid tissue: 59.5;salivary gland: 19.5" "Not detected" "Not detected" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HAP1: 5.4;HEK 293: 3.0;K-562: 15.4;SCLC-21H: 2.6;SH-SY5Y: 3.8;SiHa: 2.5" "Region enriched" "Detected in single" 13 "pons and medulla: 0.5" "Not detected" "Not detected" NA NA "unprognostic (8.67e-2)" "unprognostic (2.23e-1)" "prognostic unfavorable (7.32e-4)" "unprognostic (1.06e-5)" "unprognostic (1.06e-1)" "unprognostic (1.60e-1)" "unprognostic (5.07e-1)" "unprognostic (1.57e-2)" "unprognostic (2.12e-2)" "unprognostic (2.69e-2)" "unprognostic (2.52e-3)" "unprognostic (1.81e-1)" "unprognostic (2.63e-1)" "unprognostic (3.26e-1)" "unprognostic (3.06e-1)" "unprognostic (7.35e-2)" 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.1 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.2 0.4 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.1 0.1 0.2 0.0 0.0 19.5 0.0 0.1 0.0 0.6 0.0 0.0 59.5 0.0 0.1 0.1 0.0 0.0 4.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.1 0.0 5.4 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.6 3.8 2.5 0.0 0.0 0.3 0.2 0.5 0.2 0.0 1.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 TLX3 "HOX11L2, RNX" ENSG00000164438 "T cell leukemia homeobox 3" O43711 5 171309284-171312134 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Developmental protein, DNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 59 "brain: 46.6" "Cell type enriched" "Detected in some" 5 "Extravillous trophoblasts: 5.2" "Cancer enhanced" "Detected in some" "cervical cancer: 1.7" "Region enriched" "Detected in some" 22 "cerebellum: 46.6" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "SH-SY5Y: 24.6" "Region enriched" "Detected in single" 7 "cerebellum: 2.5" "Region enriched" "Detected in some" 10 "cerebellum: 48.1" "HPA030504, HPA060957, HPA069359" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "HPA030504: AB_2732458, HPA060957: AB_2732655, HPA069359: AB_2732130" "unprognostic (3.52e-2)" "unprognostic (2.43e-2)" "unprognostic (2.09e-1)" "unprognostic (3.11e-1)" "unprognostic (9.80e-2)" "unprognostic (2.76e-2)" "unprognostic (4.48e-2)" 0.4 0.5 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.3 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.2 0.0 0.0 24.6 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.6 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 TMPRSS2 PRSS10 ENSG00000184012 "Transmembrane serine protease 2" O15393 21 41464551-41531116 "Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 75.6;pancreas: 64.5;prostate: 68.2" "Cell type enhanced" "Detected in many" 10 "Enterocytes: 190.3;Glandular cells: 290.4;Paneth cells: 127.7;Urothelial cells: 115.9" "Cancer enriched" "Detected in many" 7 "prostate cancer: 250.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 14.1;MCF7: 6.1;OE19: 20.6;RT4: 33.9;SK-BR-3: 6.9" "Not detected" "Not detected" "HPA034493, HPA035787" Enhanced Approved "Nucleoplasm,Plasma membrane" "Intracellular and membrane" NA NA "Plasma membrane" Nucleoplasm "HPA034493: , HPA035787: AB_2674782" "unprognostic (4.80e-3)" "unprognostic (3.49e-1)" "unprognostic (2.16e-1)" "prognostic favorable (2.56e-4)" "unprognostic (1.72e-1)" "unprognostic (1.05e-2)" "unprognostic (4.28e-2)" "unprognostic (1.51e-3)" "unprognostic (9.43e-2)" "unprognostic (9.02e-3)" "unprognostic (6.24e-2)" "unprognostic (6.43e-2)" "prognostic favorable (7.86e-6)" "unprognostic (2.00e-2)" "unprognostic (1.68e-1)" "unprognostic (1.41e-1)" "unprognostic (2.15e-2)" 0.2 0.1 0.2 15.5 0.4 0.0 6.1 0.2 0.5 1.3 38.7 0.4 24.4 17.5 0.5 0.9 10.7 2.2 17.3 0.2 0.3 0.1 19.4 18.4 20.7 0.2 0.2 0.2 0.7 64.5 0.0 1.3 1.0 0.4 68.2 18.5 0.3 52.3 35.7 0.2 2.1 75.6 0.9 0.2 0.3 36.7 0.8 0.3 0.5 19.9 3.9 10.2 5.9 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 14.1 1.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.1 0.5 1.2 20.6 0.0 0.0 0.0 1.3 0.5 33.9 0.0 0.4 0.0 6.9 0.1 0.2 5.2 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.4 0.2 0.5 0.3 0.1 0.2 0.2 0.4 0.3 47.6 88.6 0.0 31.0 0.2 0.0 0.6 25.5 14.7 38.7 45.4 0.0 0.5 19.9 30.0 19.4 0.0 190.3 0.0 52.6 0.1 0.6 290.4 6.9 28.7 0.1 0.0 17.3 0.0 0.8 3.5 0.0 1.5 10.1 1.0 79.6 0.0 53.4 127.7 0.0 3.7 0.0 0.0 1.0 0.2 0.0 0.1 0.2 0.0 73.2 115.9 TNFAIP3 "A20, OTUD7C" ENSG00000118503 "TNF alpha induced protein 3" P21580 6 137867188-137883312 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Apoptosis, Inflammatory response, Ubl conjugation pathway" "DNA-binding, Hydrolase, Multifunctional enzyme, Protease, Thiol protease, Transferase" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 112.4" "Cell type enhanced" "Detected in many" 10 "Basal keratinocytes: 688.4;Suprabasal keratinocytes: 651.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "GAMG: 31.8;Karpas-707: 48.1;REH: 41.8;U-266/84: 35.9" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA002116 Approved Approved Centrosome,Cytosol NA NA "Centrosome, Cytosol" "HPA002116: AB_1858162" "unprognostic (5.50e-3)" "unprognostic (9.98e-3)" "unprognostic (3.06e-2)" "unprognostic (1.01e-2)" "unprognostic (4.01e-2)" "unprognostic (9.47e-2)" "unprognostic (5.01e-3)" "unprognostic (4.40e-2)" "unprognostic (2.92e-2)" "unprognostic (2.58e-1)" "unprognostic (1.72e-1)" "unprognostic (2.06e-1)" "prognostic unfavorable (6.05e-4)" "unprognostic (6.06e-2)" "unprognostic (3.55e-3)" "unprognostic (1.27e-1)" "unprognostic (6.29e-2)" 27.4 6.0 1.5 58.6 1.8 112.4 17.2 0.4 1.5 7.7 15.7 3.2 2.6 5.1 9.7 7.3 12.7 12.1 17.0 11.7 2.1 1.3 6.8 8.1 45.1 38.8 2.1 2.6 37.5 7.2 2.1 3.7 14.5 4.6 13.8 6.3 7.2 8.2 3.5 10.7 20.5 17.2 8.2 3.8 25.9 8.0 9.3 2.1 38.6 5.7 9.2 31.4 23.3 9.5 7.1 18.6 10.0 9.7 7.5 20.5 9.0 8.9 1.4 0.5 0.8 3.0 5.1 2.1 5.1 19.9 1.4 1.8 9.9 2.9 2.0 13.1 5.8 31.8 6.8 0.3 14.7 2.6 14.5 0.5 2.0 5.1 5.8 3.3 2.7 3.6 4.6 2.1 16.8 16.0 1.7 0.8 5.3 4.0 48.1 2.4 0.5 14.7 11.5 0.3 0.6 0.4 41.8 10.4 1.4 4.3 4.3 0.2 0.0 1.0 1.5 4.3 2.1 1.0 3.3 4.0 14.4 1.7 12.9 2.9 15.5 35.9 4.1 5.2 3.4 1.7 5.6 9.7 5.5 14.8 7.1 20.5 6.2 15.1 13.3 10.3 7.1 10.0 7.4 10.0 7.5 3.7 18.6 14.7 9.0 1.5 1.8 0.4 1.5 2.1 1.3 2.1 2.6 4.6 2.1 35.7 83.1 25.1 141.6 688.4 1.0 4.2 30.6 41.5 26.1 0.0 27.5 5.5 1.7 50.3 2.3 27.0 39.0 0.0 23.4 88.6 55.5 117.9 248.4 10.2 45.4 0.0 11.3 45.4 74.2 2.4 6.4 241.1 123.2 82.0 12.5 1.7 27.9 8.2 5.6 2.2 13.3 6.5 87.3 0.9 2.3 651.8 19.3 101.2 8.5 60.3 TNFRSF14 "ATAR, CD270, HVEA, HVEM, LIGHTR, TR2" ENSG00000157873 "TNF receptor superfamily member 14" Q92956 1 2555639-2565382 "Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "CAPAN-2: 14.6;HDLM-2: 14.8;HHSteC: 17.3;Karpas-707: 13.6;SK-MEL-30: 28.5" "HPA006404, CAB026150, CAB030007" Approved NA NA "CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348" "prognostic favorable (4.39e-5)" "unprognostic (3.48e-2)" "unprognostic (1.53e-2)" "prognostic favorable (8.01e-6)" "unprognostic (1.11e-2)" "unprognostic (6.83e-3)" "unprognostic (9.62e-3)" "unprognostic (2.32e-1)" "unprognostic (3.25e-1)" "unprognostic (1.62e-1)" "unprognostic (2.31e-1)" "unprognostic (1.64e-1)" "unprognostic (1.86e-2)" "unprognostic (1.16e-2)" "unprognostic (2.72e-2)" "unprognostic (1.58e-1)" "prognostic favorable (7.79e-6)" 15.9 24.9 4.9 38.9 2.8 11.0 21.9 2.0 4.5 16.8 36.3 3.2 18.5 36.3 15.2 20.5 13.7 12.3 36.7 12.7 4.9 2.5 19.3 20.5 30.3 33.2 3.6 5.7 12.8 7.3 3.5 9.3 8.3 3.9 21.5 8.2 44.1 20.9 22.6 5.2 8.4 41.9 14.6 4.1 36.7 16.7 5.9 2.7 23.5 10.8 10.6 25.0 15.4 17.2 18.2 9.7 30.2 25.8 8.1 25.1 14.2 1.3 0.1 0.1 2.4 5.2 2.8 0.8 0.7 2.4 1.4 1.9 0.2 14.6 0.8 0.1 2.2 1.4 1.3 0.0 0.9 0.2 14.8 0.0 8.5 0.4 2.7 17.3 1.1 10.6 2.7 1.4 0.7 0.1 2.1 3.8 0.8 1.2 13.6 1.3 0.0 4.7 1.3 0.0 4.6 1.3 3.8 0.0 4.2 0.2 2.1 0.4 0.0 0.6 0.1 28.5 0.0 0.4 0.3 9.6 0.2 0.6 0.3 0.1 11.1 2.7 0.4 2.4 1.2 1.0 3.0 15.1 8.2 17.2 25.8 14.9 16.6 18.0 14.8 9.7 18.2 17.3 14.9 30.2 8.1 24.1 8.7 25.1 14.2 4.9 2.8 2.0 4.5 4.9 2.5 3.6 5.7 3.9 2.7 17.9 38.9 54.7 30.5 14.5 1.5 6.7 56.0 26.8 31.8 33.2 0.0 1.0 3.3 16.7 0.3 48.4 116.5 0.0 29.0 0.8 16.0 32.4 50.9 18.3 78.8 0.0 34.7 35.0 60.9 1.3 19.2 62.9 43.9 111.0 60.4 15.8 19.7 86.3 13.1 30.9 0.5 19.4 17.5 0.0 0.3 11.7 1.0 77.3 72.2 38.8 TNFRSF17 "BCM, BCMA, CD269, TNFRSF13A" ENSG00000048462 "TNF receptor superfamily member 17" Q02223 16 11965107-11968068 "Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Adaptive immunity, Immunity" Receptor "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8" "Group enriched" "Detected in some" 9 "B-cells: 29.3;Erythroid cells: 46.7;Melanocytes: 101.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 59 "memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9" "Group enriched" "Detected in many" 62 "B-cells: 34.1;dendritic cells: 27.9" "Cell line enhanced" "Detected in some" "Karpas-707: 25.9;RPMI-8226: 40.8;U-266/70: 121.4;U-266/84: 60.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA 2200000 "prognostic favorable (1.35e-5)" "unprognostic (3.41e-2)" "unprognostic (4.00e-3)" "unprognostic (1.41e-2)" "unprognostic (6.47e-2)" "prognostic favorable (1.58e-6)" "unprognostic (9.75e-3)" "unprognostic (5.93e-2)" "unprognostic (2.13e-2)" "unprognostic (7.96e-3)" "unprognostic (2.46e-1)" "unprognostic (2.58e-1)" "unprognostic (2.85e-6)" "unprognostic (2.06e-1)" "unprognostic (2.48e-1)" "unprognostic (3.54e-2)" "unprognostic (1.10e-1)" 0.6 0.4 0.4 24.0 0.9 0.3 5.4 0.5 0.4 1.5 17.8 0.2 0.2 12.3 0.5 0.2 3.7 1.1 4.9 0.7 0.4 0.4 1.3 0.8 3.0 22.4 0.4 0.2 0.9 3.1 0.0 0.5 0.3 0.2 1.0 9.4 0.6 14.2 0.2 0.4 0.4 11.7 0.2 0.4 22.2 9.4 2.2 0.3 3.1 1.1 1.4 28.8 7.6 0.7 34.1 27.9 0.5 0.1 0.2 0.1 3.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 25.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 40.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 121.4 60.3 9.4 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.1 34.1 0.0 0.0 0.0 26.9 0.0 0.0 0.5 0.2 0.0 27.9 0.0 3.7 0.4 0.9 0.5 0.4 0.4 0.4 0.4 0.2 0.2 0.3 0.0 0.0 29.3 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0 46.7 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 3.6 0.0 0.0 101.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.5 0.0 0.5 0.4 0.5 0.0 0.0 0.0 0.0 TOP1 ENSG00000198900 "DNA topoisomerase I" P11387 20 41028818-41124487 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 6 "Syncytiotrophoblasts: 670.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009058, HPA019039" Supported Supported "Nucleoplasm,Nucleoli fibrillar center" No Yes "Nucleoplasm, Nucleoli fibrillar center" "CAB009058: AB_2303554, HPA019039: AB_1858187" "unprognostic (1.46e-1)" "unprognostic (8.65e-2)" "unprognostic (1.33e-2)" "unprognostic (1.92e-3)" "unprognostic (5.05e-2)" "unprognostic (1.49e-3)" "prognostic unfavorable (6.42e-4)" "unprognostic (5.86e-2)" "unprognostic (1.51e-1)" "unprognostic (4.60e-2)" "unprognostic (3.74e-3)" "unprognostic (6.51e-2)" "unprognostic (8.65e-2)" "unprognostic (4.70e-2)" "unprognostic (5.14e-1)" "unprognostic (3.64e-1)" "unprognostic (1.29e-1)" 26.6 31.0 24.6 46.3 25.3 55.3 37.4 39.6 31.1 21.3 30.0 11.1 26.7 29.7 22.9 22.5 36.0 20.5 29.2 21.0 23.0 18.3 31.8 32.7 37.9 38.6 21.9 20.9 25.5 22.5 22.2 39.9 43.9 25.2 23.3 27.2 13.6 25.3 34.3 26.2 24.6 48.4 23.1 27.4 36.9 26.7 14.2 24.2 54.2 31.5 25.1 40.6 25.2 41.7 9.0 17.2 18.4 11.1 5.8 8.2 4.6 22.0 15.4 28.9 23.7 11.7 14.0 28.7 20.0 17.6 23.2 21.2 40.5 27.8 62.9 21.4 10.3 24.8 21.5 34.7 31.9 34.1 13.6 17.7 80.2 12.4 28.7 30.6 34.5 27.6 15.8 17.0 22.6 37.2 20.8 24.2 23.0 34.7 21.9 26.2 49.0 48.8 21.9 23.3 22.1 28.8 41.7 27.2 33.4 24.8 20.5 24.1 16.7 31.3 19.4 20.3 21.8 21.6 30.9 23.7 18.8 16.0 17.4 21.4 13.9 15.6 73.3 25.3 19.4 17.8 9.1 9.2 14.3 6.5 9.2 8.2 9.0 7.2 6.8 8.6 8.7 7.7 6.9 18.4 5.8 11.1 17.2 7.9 4.6 24.6 25.3 39.6 31.1 23.0 18.3 21.9 20.9 25.2 24.2 110.2 181.3 71.6 274.4 218.4 93.3 38.9 84.1 73.6 228.6 94.2 56.9 139.0 63.0 78.8 6.3 78.8 108.1 210.2 57.1 149.4 129.3 136.7 76.2 114.3 86.4 68.3 88.0 63.8 84.7 6.5 55.3 93.8 69.2 72.1 73.8 94.4 93.7 112.2 65.4 91.4 80.4 84.1 77.1 95.2 57.3 187.2 670.2 61.2 78.0 206.2 TP53 "LFS1, p53" ENSG00000141510 "Tumor protein p53" P04637 17 7661779-7687550 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters" "Apoptosis, Biological rhythms, Cell cycle, Host-virus interaction, Necrosis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 102.6" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002973, CAB039238, CAB039239, HPA051244, HPA063532, CAB072876" Enhanced Enhanced Nucleoplasm Yes No Nucleoplasm "CAB002973: AB_2206626, CAB039238: , CAB039239: , CAB072876: AB_2665731, HPA051244: AB_2681403, HPA063532: " "unprognostic (2.29e-2)" "unprognostic (8.83e-3)" "unprognostic (1.26e-2)" "prognostic favorable (1.35e-4)" "unprognostic (9.95e-2)" "unprognostic (4.00e-2)" "unprognostic (2.79e-3)" "unprognostic (4.99e-2)" "unprognostic (2.75e-2)" "unprognostic (2.55e-1)" "unprognostic (1.30e-1)" "prognostic unfavorable (5.01e-4)" "unprognostic (1.86e-3)" "unprognostic (7.89e-3)" "unprognostic (8.05e-2)" "unprognostic (2.74e-1)" "unprognostic (1.08e-1)" 18.5 11.1 6.0 28.6 6.8 9.0 17.5 2.5 7.3 18.5 14.6 6.8 8.3 9.7 20.3 15.0 25.3 16.7 22.6 8.1 5.0 3.8 10.6 20.8 11.2 26.0 6.6 3.1 33.8 13.8 4.9 6.0 22.8 6.9 16.5 14.5 9.9 15.3 16.1 12.5 24.6 14.0 12.8 6.2 24.2 12.0 14.1 6.9 102.6 13.2 23.5 31.2 16.9 15.0 15.2 19.6 2.2 14.1 11.0 11.3 8.2 19.4 36.0 19.7 14.2 9.2 11.0 20.8 7.0 15.8 19.4 24.6 1.0 10.0 45.8 31.9 13.8 18.9 43.0 28.5 19.3 18.2 10.2 19.1 18.5 20.2 17.1 27.7 0.4 9.6 13.9 22.5 9.4 26.1 11.2 19.0 6.2 0.9 1.8 9.9 34.6 31.1 22.7 19.8 2.5 0.7 60.4 13.9 15.9 14.5 21.6 11.7 20.3 23.1 15.6 5.9 10.2 27.0 1.7 24.6 23.3 7.7 0.3 11.8 12.1 8.8 19.7 6.0 2.4 19.6 0.8 13.3 2.2 9.1 14.1 11.1 15.2 9.4 10.2 19.6 14.5 9.9 10.8 1.7 11.0 11.9 17.9 11.3 8.2 6.0 6.8 2.5 6.4 5.0 3.8 6.6 3.1 6.9 6.9 8.9 10.9 24.4 8.9 25.4 2.3 2.0 22.9 8.1 12.5 19.2 0.0 30.5 8.3 19.1 7.8 19.6 10.2 0.0 15.7 35.3 17.1 11.3 1.1 16.1 21.7 0.0 29.6 20.3 27.8 2.1 21.3 14.4 11.8 15.4 37.2 6.1 19.5 0.0 15.9 6.5 2.2 12.9 20.1 0.5 4.2 28.7 18.8 15.7 50.6 7.4 TP63 "EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L" ENSG00000073282 "Tumor protein p63" Q9H3D4 3 189631416-189897279 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Notch signaling pathway, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding" "Cancer-related genes, Disease mutation, Ectodermal dysplasia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 83.2;skin 1: 54.2" "Group enriched" "Detected in many" 12 "Basal keratinocytes: 244.6;Suprabasal keratinocytes: 247.4" "Group enriched" "Detected in many" 11 "cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 5 "HaCaT: 23.8;HBEC3-KT: 45.6;hTCEpi: 34.6;hTERT-HME1: 33.1;RT4: 50.1" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000083, HPA006288, HPA006289, HPA007009, HPA007010" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336" "prognostic favorable (1.07e-4)" "unprognostic (1.30e-1)" "unprognostic (1.44e-1)" "unprognostic (3.02e-1)" "unprognostic (4.38e-2)" "unprognostic (3.50e-1)" "unprognostic (1.29e-1)" "unprognostic (5.17e-2)" "unprognostic (2.78e-1)" "unprognostic (5.37e-2)" "unprognostic (2.09e-3)" "unprognostic (1.54e-1)" "unprognostic (1.87e-5)" "unprognostic (1.86e-1)" "unprognostic (1.05e-1)" "unprognostic (1.62e-1)" "unprognostic (2.74e-3)" 2.9 0.1 0.2 0.7 0.1 0.0 7.2 0.1 0.2 9.5 0.1 0.1 5.7 0.0 0.3 8.0 33.7 0.3 0.0 0.2 0.1 0.1 0.4 0.1 1.2 0.2 0.1 0.2 0.1 0.1 0.0 0.3 7.8 0.8 9.6 0.0 0.3 9.0 7.8 83.2 54.2 0.1 2.7 0.6 0.1 0.1 1.2 0.0 9.0 0.4 36.7 26.1 9.6 19.2 3.7 1.3 3.0 0.9 1.2 1.2 0.2 0.6 1.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.1 0.0 0.0 23.8 0.0 45.6 0.0 0.3 0.0 0.5 0.3 0.1 0.0 0.0 0.1 0.0 34.6 0.0 33.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 50.1 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.1 0.3 0.1 0.0 0.2 2.0 0.4 1.1 0.9 0.5 0.7 3.7 1.2 1.0 0.4 1.7 0.8 0.7 3.0 1.2 0.9 1.3 0.8 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.8 0.0 0.0 4.0 0.0 20.4 244.6 0.0 0.6 0.0 1.4 5.7 0.0 0.0 18.7 0.0 0.2 0.7 0.3 0.0 0.0 0.2 1.8 1.0 2.6 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 8.5 1.0 0.0 0.0 1.2 0.0 1.1 0.0 0.0 0.0 0.5 0.3 2.6 247.4 7.4 0.0 0.0 10.1 TPM3 "NEM1, TRK" ENSG00000143549 "Tropomyosin 3" P06753 1 154155304-154194648 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes, Disease mutation, Nemaline myopathy, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 738.4;tongue: 203.6" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000261, HPA009066, HPA047089, HPA053624" Approved Approved "Actin filaments,Cytosol" NA NA 410000000 "Actin filaments" Cytosol "HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: AB_2679928, HPA053624: AB_2682210" "unprognostic (1.64e-1)" "unprognostic (2.11e-2)" "unprognostic (3.01e-3)" "unprognostic (1.07e-1)" "unprognostic (2.39e-1)" "unprognostic (2.69e-3)" "prognostic unfavorable (6.73e-6)" "prognostic unfavorable (4.01e-4)" "unprognostic (2.80e-1)" "prognostic favorable (2.39e-5)" "prognostic unfavorable (3.65e-4)" "unprognostic (3.31e-2)" "prognostic unfavorable (3.12e-5)" "unprognostic (3.52e-2)" "unprognostic (1.67e-1)" "unprognostic (1.98e-2)" "unprognostic (1.00e-2)" 10.1 7.3 10.8 10.8 10.5 26.5 6.2 6.4 11.2 4.6 9.6 3.9 3.2 7.9 4.1 27.9 18.3 4.4 6.7 29.7 7.7 8.1 7.2 6.8 9.6 12.9 8.9 5.8 4.8 23.2 3.6 3.2 6.7 5.0 5.7 10.7 4.4 20.5 2.5 738.4 5.9 8.2 5.2 7.7 11.7 6.9 5.4 4.4 6.7 9.3 203.6 28.6 6.8 4.9 38.9 72.6 154.8 95.9 35.4 54.4 146.1 66.5 33.2 42.5 27.9 36.0 47.1 42.9 57.2 52.9 75.9 57.3 61.8 62.4 50.1 46.6 64.5 30.5 61.7 42.1 60.2 81.0 34.7 22.9 61.7 32.4 41.6 28.6 90.2 82.0 35.5 33.0 66.9 51.5 34.2 116.7 36.9 46.3 53.9 93.7 39.9 70.2 93.1 95.7 113.6 72.2 60.2 29.5 71.0 54.8 50.8 29.9 56.1 43.5 57.9 56.7 59.2 80.8 107.9 87.2 66.5 48.1 63.7 89.6 45.9 75.4 67.0 60.1 68.0 105.0 70.8 64.7 154.8 54.4 87.8 48.6 38.9 48.5 51.1 72.6 30.1 36.6 47.3 74.9 35.4 95.9 36.0 52.1 146.1 10.8 10.5 6.4 11.2 7.7 8.1 8.9 5.8 5.0 4.4 577.7 334.3 245.8 179.3 132.8 84.5 62.7 104.4 335.9 395.8 92.5 29.5 101.3 89.5 278.9 51.0 357.1 327.9 0.0 302.5 278.2 125.9 137.0 499.8 99.0 485.9 287.6 135.3 175.6 320.5 131.0 43.1 444.6 145.1 764.7 164.6 45.8 384.6 230.6 28.0 130.8 59.1 19.4 73.4 34.9 54.6 125.3 85.2 233.3 208.9 254.0 TPM4 ENSG00000167460 "Tropomyosin 4" P67936 19 16067021-16103005 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Actin-binding, Muscle protein" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "U-2197: 230.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004685, HPA047089, HPA053624" Approved Approved "Actin filaments,Cytosol" NA NA 950000000 "Actin filaments" Cytosol "CAB004685: AB_425723, HPA047089: AB_2679928, HPA053624: AB_2682210" "unprognostic (1.27e-1)" "unprognostic (1.53e-2)" "unprognostic (3.62e-3)" "unprognostic (7.38e-3)" "unprognostic (3.80e-1)" "unprognostic (2.40e-2)" "unprognostic (3.11e-2)" "unprognostic (2.75e-3)" "unprognostic (1.38e-2)" "unprognostic (3.61e-1)" "prognostic unfavorable (3.07e-4)" "unprognostic (1.03e-1)" "prognostic unfavorable (1.26e-10)" "unprognostic (3.85e-2)" "unprognostic (2.25e-1)" "unprognostic (1.48e-1)" "unprognostic (1.78e-1)" 66.2 17.9 13.3 60.0 13.7 10.8 47.4 46.2 11.5 90.2 40.5 14.6 56.4 17.4 87.1 63.3 149.3 49.4 108.4 39.2 14.5 12.4 32.4 12.2 69.7 27.1 16.0 10.5 102.4 15.4 8.4 16.2 65.0 19.7 84.1 31.8 18.6 47.6 64.6 29.9 39.0 25.2 127.2 22.5 99.7 37.5 30.6 11.7 11.5 20.0 92.2 60.1 177.3 70.5 22.2 35.0 40.7 32.7 24.7 52.5 48.6 59.8 23.7 46.0 28.0 106.9 159.3 57.6 83.9 101.8 71.1 73.4 24.6 62.6 2.7 65.6 104.6 52.4 32.3 19.2 48.1 93.0 39.4 11.0 30.2 34.1 19.7 58.8 5.4 72.2 98.6 15.6 58.1 66.8 82.3 81.3 14.1 3.4 38.0 98.1 20.3 16.2 19.0 24.0 54.9 28.9 22.2 39.5 13.0 16.4 51.3 8.3 26.3 56.4 25.3 29.7 46.3 0.5 8.3 95.2 123.9 15.7 230.2 77.5 6.6 15.6 13.3 85.9 15.9 41.9 40.7 30.1 2.2 34.8 32.7 26.3 22.2 26.9 31.2 35.0 18.8 7.8 18.3 35.2 24.7 16.2 27.4 52.5 48.6 13.3 13.7 46.2 11.5 14.5 12.4 16.0 10.5 19.7 11.7 372.2 149.0 112.7 891.9 382.9 46.3 46.3 96.8 158.0 326.4 230.3 9.8 212.0 11.6 660.1 53.8 384.6 203.3 0.0 501.5 677.9 318.1 567.0 235.4 1.9 313.9 4.8 90.0 275.0 103.4 37.2 160.2 324.4 135.0 331.0 106.2 5.7 698.7 90.9 514.4 15.6 10.7 329.8 423.9 12.0 11.3 300.5 475.8 117.4 88.9 901.5 TPR ENSG00000047410 "Translocated promoter region, nuclear basket protein" P12270 1 186311652-186375693 "Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters" "Cell cycle, Cell division, Mitosis, mRNA transport, Protein transport, Translocation, Transport" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 7 "Spermatocytes: 640.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019661, HPA019663, HPA024336" Enhanced Enhanced "Nuclear membrane" NA NA "Nuclear membrane" "HPA019661: AB_1858215, HPA019663: AB_1858216, HPA024336: AB_1858217" "unprognostic (4.51e-2)" "unprognostic (9.87e-3)" "unprognostic (2.48e-1)" "unprognostic (7.56e-2)" "unprognostic (9.88e-3)" "prognostic favorable (4.71e-4)" "prognostic unfavorable (1.06e-4)" "unprognostic (1.71e-1)" "unprognostic (3.71e-2)" "unprognostic (1.14e-1)" "unprognostic (1.45e-2)" "unprognostic (3.63e-2)" "unprognostic (1.31e-3)" "unprognostic (3.75e-1)" "unprognostic (4.19e-2)" "unprognostic (5.06e-2)" "unprognostic (1.98e-2)" 21.5 17.3 14.3 26.7 21.3 21.6 19.0 24.4 17.1 21.7 24.2 7.3 27.1 12.9 20.8 23.5 18.5 16.9 16.8 28.3 13.8 10.5 18.7 20.6 17.9 20.4 14.1 16.6 24.7 17.8 44.2 29.1 29.7 15.1 22.2 17.7 9.1 20.2 30.1 33.1 20.5 21.1 21.2 16.4 26.1 18.8 35.0 17.8 39.5 21.7 19.7 21.4 25.1 19.1 19.1 19.8 50.3 15.2 10.7 16.9 5.2 21.6 18.7 28.1 16.3 22.6 20.2 29.6 24.9 16.7 17.6 16.4 28.2 18.5 25.4 19.3 16.9 12.1 28.4 21.1 17.0 21.8 19.0 23.1 33.8 30.3 19.7 12.1 36.0 22.2 15.4 10.3 26.5 20.6 16.3 20.7 14.6 40.7 22.9 18.7 18.7 17.9 9.6 30.9 19.8 6.5 21.2 22.0 22.0 14.4 26.1 15.3 24.3 29.0 19.3 15.6 40.1 21.4 23.0 29.1 17.6 16.8 19.4 30.1 25.1 29.3 23.2 11.3 18.4 15.7 29.5 12.0 21.9 15.8 10.0 13.3 15.2 13.8 12.7 6.8 19.1 16.9 11.7 50.3 10.7 15.2 19.8 15.3 5.2 14.3 21.3 24.4 17.1 13.8 10.5 14.1 16.6 15.1 17.8 202.5 98.3 78.9 89.1 89.9 87.4 160.6 35.7 133.8 120.6 55.8 74.6 117.3 19.9 88.2 106.7 100.9 41.3 23.3 65.3 89.1 87.0 62.9 77.5 34.3 63.0 93.8 65.1 57.1 60.2 23.6 116.2 74.5 52.3 147.9 49.2 93.4 74.7 52.6 110.3 23.7 104.0 129.4 82.9 640.0 239.5 86.7 126.1 97.0 64.6 75.6 TRAF7 "DKFZp586I021, MGC7807, RFWD1, RNF119" ENSG00000131653 "TNF receptor associated factor 7" Q6Q0C0 16 2155698-2178129 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway" Transferase "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041229 Approved Supported "Vesicles,Plasma membrane" NA NA Vesicles "Plasma membrane" "HPA041229: AB_10794194" "unprognostic (1.94e-1)" "unprognostic (5.97e-2)" "unprognostic (1.13e-1)" "unprognostic (4.23e-2)" "unprognostic (1.09e-1)" "unprognostic (1.03e-1)" "unprognostic (1.65e-2)" "unprognostic (2.77e-3)" "unprognostic (7.08e-2)" "unprognostic (3.52e-2)" "unprognostic (1.52e-2)" "unprognostic (1.08e-1)" "unprognostic (9.23e-2)" "unprognostic (6.07e-2)" "unprognostic (2.99e-2)" "unprognostic (2.43e-1)" "unprognostic (8.48e-2)" 16.0 18.2 18.3 22.3 20.6 28.5 39.1 28.7 25.6 22.1 29.4 9.1 21.1 37.3 20.4 18.3 32.9 21.9 36.9 21.0 18.3 14.8 21.3 47.3 18.3 40.9 13.4 14.7 19.3 41.6 17.7 20.3 19.5 12.8 16.2 16.9 13.0 24.4 23.1 25.5 32.2 37.8 28.8 14.1 21.4 25.1 13.2 10.6 26.1 20.3 30.9 21.9 21.9 28.9 6.7 12.3 7.7 13.9 3.0 7.1 5.2 20.7 26.6 15.2 27.2 15.8 29.8 17.9 16.0 20.2 18.9 17.1 32.3 26.8 13.3 19.0 20.4 12.1 24.4 14.2 28.4 7.2 21.0 18.2 19.0 35.4 24.7 20.9 20.2 27.6 29.5 23.8 18.2 23.9 15.6 36.5 26.4 20.3 18.0 18.0 47.5 20.7 23.5 29.9 28.7 13.0 38.7 25.3 26.7 15.2 11.2 30.7 25.5 13.4 25.8 17.5 8.3 29.3 24.9 27.5 23.0 32.4 21.4 17.4 26.1 19.3 17.6 13.1 13.1 17.8 3.7 10.0 7.7 5.4 13.9 5.0 6.7 5.3 5.7 12.3 4.9 3.8 4.5 6.9 3.0 9.4 6.0 7.1 5.2 18.3 20.6 28.7 25.6 18.3 14.8 13.4 14.7 12.8 10.6 0.0 8.6 11.9 15.5 25.5 14.6 3.4 17.8 4.0 4.5 14.0 5.9 20.5 14.9 35.4 3.8 23.9 60.0 0.0 51.6 30.1 20.0 27.8 9.2 26.1 37.6 35.0 32.6 23.4 38.3 9.1 23.0 18.8 10.1 35.1 35.9 10.5 45.1 40.3 20.8 18.9 8.9 6.5 16.0 4.8 21.5 28.4 22.3 12.9 33.8 29.6 TRIM24 "hTIF1, RNF82, TIF1, Tif1a" ENSG00000122779 "Tripartite motif containing 24" O15164 7 138460334-138589993 "Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "AF22: 43.3;HMC-1: 58.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA043495, HPA061717" Approved Enhanced Nucleoplasm "Intracellular and membrane" NA NA Nucleoplasm "HPA043495: AB_10962915, HPA061717: AB_2684592" "unprognostic (2.40e-1)" "unprognostic (9.52e-3)" "unprognostic (2.23e-1)" "unprognostic (3.96e-2)" "unprognostic (1.20e-1)" "unprognostic (1.15e-1)" "prognostic unfavorable (9.94e-4)" "prognostic favorable (6.57e-4)" "unprognostic (4.01e-2)" "unprognostic (8.93e-2)" "unprognostic (2.53e-1)" "unprognostic (2.02e-1)" "unprognostic (4.62e-2)" "unprognostic (1.62e-1)" "unprognostic (2.25e-2)" "unprognostic (5.54e-2)" "unprognostic (6.34e-2)" 10.3 31.4 10.4 11.2 10.6 8.8 8.8 8.5 10.7 9.4 9.2 14.6 5.7 9.4 9.0 8.5 11.3 7.0 10.3 9.7 8.4 8.5 9.6 21.5 10.7 8.5 10.5 8.0 29.9 11.6 20.7 7.3 13.5 8.4 13.6 9.1 7.5 10.1 7.1 16.0 9.8 14.1 9.4 8.0 8.5 10.8 24.1 11.3 34.8 8.8 9.2 8.9 11.3 11.2 1.3 1.9 3.7 2.5 2.2 2.7 0.8 4.2 5.2 43.3 12.5 2.9 2.7 3.3 3.9 4.2 3.1 3.0 8.2 3.9 8.1 3.9 3.8 6.4 2.3 21.0 3.3 4.6 6.2 5.2 17.9 3.9 25.2 3.9 13.9 58.5 2.4 3.5 2.6 4.1 2.2 7.3 4.5 20.2 5.0 3.7 8.2 23.7 12.6 16.5 22.1 4.7 18.8 5.1 6.8 6.9 12.6 9.0 20.5 7.3 6.6 2.1 15.7 4.5 9.2 3.1 3.6 3.0 6.3 5.4 4.6 5.0 13.8 6.0 9.2 5.2 1.1 2.3 3.6 2.2 2.5 0.4 0.9 1.9 1.2 1.9 1.3 1.8 2.0 3.7 2.2 1.1 1.4 2.7 0.8 10.4 10.6 8.5 9.7 8.4 8.5 10.5 8.0 8.4 11.3 47.6 42.2 4.5 11.6 12.4 13.3 38.8 15.3 17.4 20.5 7.0 15.7 25.9 5.0 6.3 45.5 13.2 8.0 0.0 10.6 11.7 11.8 10.1 38.3 28.4 9.2 38.1 9.7 14.1 11.2 28.3 13.0 12.4 13.5 4.6 8.2 28.0 10.1 9.3 15.2 7.7 20.8 12.9 9.9 43.1 8.5 10.3 18.5 10.2 15.5 12.2 TRIM27 "RFP, RNF76" ENSG00000204713 "Tripartite motif containing 27" P14373 6 28903002-28923989 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Transport, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048684, HPA053408" Approved Approved Nucleoplasm,Nucleoli NA NA Nucleoli Nucleoplasm "HPA048684: AB_2680493, HPA053408: AB_2682139" "unprognostic (1.57e-1)" "unprognostic (1.48e-2)" "unprognostic (2.36e-1)" "unprognostic (1.14e-2)" "unprognostic (1.70e-2)" "unprognostic (2.56e-1)" "unprognostic (2.00e-3)" "unprognostic (1.17e-2)" "unprognostic (1.01e-2)" "unprognostic (1.12e-3)" "unprognostic (4.76e-3)" "unprognostic (1.16e-2)" "prognostic unfavorable (3.50e-6)" "unprognostic (1.27e-1)" "unprognostic (1.41e-1)" "unprognostic (1.47e-1)" "prognostic favorable (2.71e-4)" 11.5 10.6 8.8 25.5 9.7 7.9 9.3 10.1 12.2 11.2 10.2 8.7 20.2 23.8 12.1 13.2 7.8 12.1 11.4 8.1 8.2 9.6 10.1 22.5 10.4 17.4 12.6 8.3 14.7 31.0 7.4 13.9 13.7 10.6 13.7 4.6 7.7 17.0 25.2 12.2 9.7 19.4 9.2 8.4 18.6 18.5 9.2 9.2 16.7 12.5 7.9 12.1 9.9 11.8 12.5 12.5 13.8 13.9 11.2 15.9 13.8 3.3 2.3 1.0 6.1 0.8 1.7 0.7 4.6 1.1 1.4 1.7 1.7 1.4 7.7 8.0 1.3 3.0 7.4 1.1 2.7 0.1 3.0 13.1 11.0 0.5 2.3 1.3 4.6 1.7 1.3 1.7 1.2 0.5 0.1 1.2 8.0 10.6 3.3 0.4 1.3 6.4 2.4 0.0 2.1 7.4 9.1 7.0 14.3 1.1 1.1 3.3 13.1 5.6 3.4 7.4 0.3 3.3 3.6 4.0 3.5 7.1 6.3 2.7 12.2 14.6 12.2 1.8 11.7 5.2 12.6 13.8 8.8 12.7 13.9 15.9 12.5 12.6 14.4 12.5 10.5 11.8 12.1 13.8 11.2 12.1 9.8 10.4 13.8 8.8 9.7 10.1 12.2 8.2 9.6 12.6 8.3 10.6 9.2 14.9 21.9 30.9 26.1 25.2 11.0 14.9 30.6 24.1 19.4 27.9 15.7 41.3 18.3 35.7 9.4 29.1 15.7 23.3 37.7 49.1 24.4 31.4 20.8 36.5 36.4 7.9 26.5 25.2 23.8 4.4 22.2 24.5 8.5 25.2 24.4 9.8 42.8 19.5 17.3 24.1 13.1 19.4 21.1 5.1 11.2 17.1 38.1 26.2 24.4 24.0 TRIM33 "FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA" ENSG00000197323 "Tripartite motif containing 33" Q9UPN9 1 114392777-114511160 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor, Transferase" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" 4 "Early spermatids: 155.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 49.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004345 Supported Approved Nucleoplasm,Vesicles NA NA Vesicles Nucleoplasm "HPA004345: AB_1858287" "unprognostic (8.90e-2)" "unprognostic (5.86e-2)" "prognostic favorable (6.20e-4)" "unprognostic (1.09e-2)" "unprognostic (8.42e-3)" "prognostic favorable (8.93e-4)" "unprognostic (1.34e-2)" "unprognostic (1.83e-1)" "unprognostic (6.75e-2)" "unprognostic (4.58e-2)" "unprognostic (2.14e-1)" "unprognostic (1.08e-1)" "unprognostic (2.27e-2)" "unprognostic (4.84e-2)" "unprognostic (1.99e-1)" "unprognostic (1.40e-1)" "unprognostic (1.68e-1)" 15.2 12.8 16.9 18.4 19.9 27.1 17.1 38.3 21.8 16.9 14.3 11.0 21.9 10.9 19.8 38.3 16.4 15.0 15.6 10.8 18.1 12.5 17.3 15.0 14.3 15.2 12.1 18.0 19.8 15.7 21.8 22.4 27.2 15.2 16.5 13.0 10.7 16.4 19.1 14.3 19.5 14.8 20.2 12.9 14.9 14.1 29.0 16.3 20.5 17.9 9.8 16.6 17.9 28.7 3.4 4.0 12.2 2.8 4.7 4.4 1.0 13.1 7.1 13.4 10.0 5.7 6.0 22.9 6.7 7.2 9.4 10.0 8.0 5.6 14.1 7.0 7.8 6.1 7.6 12.2 7.8 13.0 10.6 7.2 13.6 9.4 9.3 6.3 17.1 11.3 5.7 5.8 11.1 11.4 7.2 7.8 12.0 16.9 10.0 8.9 49.4 17.2 7.3 18.1 5.0 7.2 14.9 20.5 4.6 6.7 20.7 9.3 9.8 12.7 15.4 12.1 9.0 7.0 9.4 8.8 6.5 10.6 15.1 9.4 7.0 6.5 14.7 9.2 10.0 18.5 12.2 1.6 7.4 3.5 1.8 3.1 3.4 3.7 3.7 2.0 2.2 2.9 4.4 4.8 4.7 2.8 4.0 2.0 1.0 16.9 19.9 38.3 21.8 18.1 12.5 12.1 18.0 15.2 16.3 17.9 29.5 19.1 25.9 46.9 71.6 22.0 25.5 10.7 25.0 52.4 92.3 49.7 1.7 18.3 155.1 31.1 23.6 23.3 20.5 27.8 32.1 38.2 36.9 40.5 26.3 25.4 50.1 37.4 44.7 78.9 45.5 39.2 18.6 17.2 31.4 33.5 25.3 32.6 34.6 12.6 58.2 32.3 23.7 54.0 29.6 48.4 73.3 35.5 28.9 48.8 TRIP11 "CEV14, GMAP-210, GMAP210, Trip230" ENSG00000100815 "Thyroid hormone receptor interactor 11" Q15643 14 91965991-92040896 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cancer-related genes, Disease mutation, Dwarfism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002570, HPA070684" Supported Enhanced "Nucleoplasm,Golgi apparatus" NA NA "Golgi apparatus" Nucleoplasm "HPA002570: AB_1078995, HPA070684: AB_2686295" "unprognostic (1.65e-1)" "unprognostic (2.81e-2)" "unprognostic (7.14e-2)" "unprognostic (1.12e-1)" "unprognostic (6.89e-2)" "unprognostic (1.39e-1)" "unprognostic (3.49e-3)" "unprognostic (1.60e-1)" "unprognostic (1.46e-1)" "unprognostic (7.33e-3)" "unprognostic (2.04e-1)" "unprognostic (1.21e-1)" "prognostic favorable (1.78e-6)" "unprognostic (1.78e-1)" "unprognostic (5.08e-1)" "unprognostic (7.74e-2)" "unprognostic (5.55e-2)" 13.0 15.0 10.5 10.8 12.5 7.7 12.1 18.5 14.1 17.4 13.0 8.8 15.2 11.1 13.3 12.7 14.7 11.4 11.2 12.9 9.2 6.7 15.5 16.1 10.6 9.4 12.2 11.1 16.0 27.1 27.1 34.9 24.4 15.2 14.5 11.0 9.4 15.1 15.3 24.0 12.4 15.9 11.2 10.7 15.2 16.2 14.0 13.5 16.4 18.4 11.1 11.9 15.8 12.5 20.0 12.7 17.0 13.0 12.1 14.1 3.9 12.5 12.8 8.3 8.8 14.7 22.8 12.6 20.0 15.4 10.0 11.4 7.7 20.5 8.8 14.8 17.6 7.8 16.6 10.9 9.7 21.8 13.4 3.3 9.9 11.5 7.3 11.2 11.6 9.9 8.7 11.9 17.6 15.1 11.1 15.8 4.9 6.5 10.2 15.5 17.6 6.6 2.9 3.8 12.3 9.2 8.2 16.0 4.4 8.9 20.6 6.1 5.5 16.2 9.5 6.2 8.8 20.8 5.9 20.9 11.6 8.2 12.0 9.0 9.1 13.9 8.0 13.6 6.6 14.5 8.2 8.8 17.0 13.3 8.0 12.8 11.8 14.1 12.1 6.9 20.0 13.5 14.1 8.7 12.1 13.0 12.7 12.2 3.9 10.5 12.5 18.5 14.1 9.2 6.7 12.2 11.1 15.2 13.5 50.6 65.6 24.1 27.5 14.7 56.7 99.6 35.7 71.0 62.6 36.6 68.7 34.2 14.9 55.0 10.9 42.7 24.5 0.0 40.6 23.8 31.0 32.3 35.9 30.6 22.0 41.3 30.9 30.7 25.7 8.5 57.5 21.2 6.8 33.3 38.0 54.1 40.4 28.1 50.9 21.4 64.7 58.2 23.7 107.2 64.1 14.9 60.6 21.0 28.1 33.1 TRRAP "PAF400, TR-AP, Tra1" ENSG00000196367 "Transformation/transcription domain associated protein" Q9Y4A5 7 98877933-99050831 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Activator, Chromatin regulator" "Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054376 Supported "Nucleoplasm,Golgi apparatus" NA NA Nucleoplasm "Golgi apparatus" "HPA054376: AB_2682467" "unprognostic (2.10e-1)" "unprognostic (7.79e-2)" "unprognostic (2.21e-1)" "unprognostic (4.35e-2)" "unprognostic (2.02e-1)" "unprognostic (2.02e-1)" "prognostic unfavorable (8.77e-4)" "unprognostic (1.40e-2)" "unprognostic (2.39e-2)" "unprognostic (3.99e-2)" "unprognostic (9.45e-2)" "unprognostic (7.02e-2)" "unprognostic (2.21e-3)" "unprognostic (1.59e-1)" "unprognostic (1.98e-1)" "unprognostic (1.04e-1)" "unprognostic (2.96e-1)" 9.6 14.2 10.7 18.4 13.4 18.8 14.9 22.8 14.4 14.1 11.3 15.4 10.0 10.6 15.1 10.1 11.3 17.1 11.4 11.4 10.7 9.5 10.8 11.0 13.1 17.1 12.4 9.4 22.4 16.2 26.7 29.9 12.2 9.6 11.8 10.2 13.7 11.8 16.7 11.7 16.9 13.3 16.9 14.2 14.5 11.5 19.3 12.1 37.1 16.6 7.7 19.3 12.8 11.5 2.7 3.1 5.7 0.9 1.3 2.7 0.3 12.3 14.4 15.0 12.7 7.4 7.6 7.5 5.4 7.3 8.6 8.3 11.2 5.5 17.2 8.7 10.1 16.6 6.4 15.5 7.5 9.5 9.9 15.2 10.5 10.5 6.5 5.5 18.8 7.8 7.1 4.4 14.0 12.0 6.0 11.0 15.6 17.9 32.7 8.0 23.8 23.0 7.5 11.4 7.5 8.9 17.0 8.6 13.1 4.5 13.8 11.9 14.8 13.8 9.1 4.6 12.8 4.6 8.5 11.5 11.6 16.9 15.3 12.7 13.5 15.3 25.5 8.2 9.7 11.4 5.7 0.9 0.6 1.5 0.6 2.7 2.0 2.7 1.3 0.9 2.7 1.9 1.8 2.9 1.3 0.9 3.1 2.0 0.3 10.7 13.4 22.8 14.4 10.7 9.5 12.4 9.4 9.6 12.1 14.9 13.9 4.5 3.7 14.1 13.1 9.2 5.1 4.0 10.3 14.0 25.5 7.7 0.0 6.7 3.0 9.0 6.1 0.0 5.7 4.3 8.0 6.5 5.7 10.9 7.0 20.6 12.1 9.2 8.7 4.0 8.1 8.4 8.5 5.4 10.6 5.8 7.9 3.5 8.1 4.3 8.5 0.0 6.1 14.4 8.0 18.6 9.2 9.2 9.5 6.0 TSC1 "hamartin, KIAA0243, LAM, TSC" ENSG00000165699 "TSC complex subunit 1" Q92574 9 132891348-132946874 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Chaperone "Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 7 "Late spermatids: 99.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011568, CAB012481, HPA074132" Supported Enhanced Cytosol NA NA Cytosol "CAB011568: AB_732752, CAB012481: , HPA074132: AB_2686666" "unprognostic (1.88e-1)" "unprognostic (1.51e-1)" "unprognostic (1.40e-2)" "unprognostic (2.56e-1)" "unprognostic (6.67e-2)" "unprognostic (4.23e-3)" "prognostic unfavorable (6.03e-6)" "unprognostic (1.96e-2)" "unprognostic (3.48e-2)" "unprognostic (1.24e-1)" "prognostic favorable (8.01e-4)" "unprognostic (1.84e-2)" "prognostic favorable (7.91e-4)" "unprognostic (9.49e-2)" "unprognostic (1.46e-1)" "unprognostic (2.35e-1)" "unprognostic (1.16e-1)" 10.4 13.6 15.8 8.8 26.8 13.6 11.4 32.1 28.3 12.7 10.8 22.6 7.9 9.1 14.6 12.3 10.9 12.4 9.7 17.6 13.0 12.1 13.1 9.4 11.6 10.2 12.5 15.1 21.2 12.1 15.9 19.5 15.8 21.1 11.8 12.6 13.1 11.6 10.4 20.0 13.8 11.2 14.2 12.4 13.7 10.6 36.2 14.9 10.5 16.2 8.6 14.2 10.9 11.1 2.8 3.1 4.8 7.0 4.9 7.1 2.6 6.2 7.4 10.1 8.3 10.4 9.9 19.0 8.4 13.6 8.8 8.7 12.5 7.3 14.6 3.7 16.0 13.4 16.2 11.9 8.5 9.0 7.0 6.3 4.6 14.7 10.2 12.4 6.8 6.3 10.7 6.4 11.2 13.8 8.8 10.1 13.0 8.1 8.0 10.0 11.5 6.1 5.8 13.9 9.2 6.2 7.4 19.1 8.2 3.9 8.2 5.1 7.8 9.8 6.1 4.8 12.5 11.1 4.0 10.4 14.4 8.7 8.6 5.7 4.5 10.0 14.2 8.2 4.0 6.4 4.1 4.4 4.8 6.5 7.0 7.1 1.9 3.6 5.7 3.1 2.8 5.9 5.3 1.7 4.9 3.2 1.8 5.7 2.6 15.8 26.8 32.1 28.3 13.0 12.1 12.5 15.1 21.1 14.9 20.8 25.6 10.8 4.8 6.6 26.0 26.6 7.6 21.4 12.5 10.4 35.3 12.8 11.6 9.5 39.6 8.7 6.3 0.0 6.2 19.5 9.1 6.5 8.1 5.0 7.8 23.8 16.1 12.3 8.7 99.6 14.4 7.4 11.8 8.2 7.9 10.4 10.9 8.4 10.6 7.5 25.2 19.4 8.0 18.9 17.8 7.5 17.6 7.1 9.9 6.5 TSC2 "LAM, PPP1R160, TSC4, tuberin" ENSG00000103197 "TSC complex subunit 2" P49815 16 2047465-2089487 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Host-virus interaction" "GTPase activation" "Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 4 "Cone photoreceptor cells: 88.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002225, HPA030409, HPA049679" Approved Enhanced Cytosol NA NA Cytosol "CAB002225: AB_564043, HPA030409: AB_10602483, HPA049679: AB_2680848" "unprognostic (2.80e-1)" "unprognostic (1.01e-1)" "unprognostic (1.60e-2)" "unprognostic (2.24e-1)" "unprognostic (1.02e-1)" "unprognostic (1.03e-3)" "unprognostic (2.04e-2)" "unprognostic (6.05e-3)" "unprognostic (3.43e-1)" "unprognostic (8.94e-2)" "prognostic favorable (5.06e-4)" "unprognostic (4.32e-2)" "unprognostic (3.91e-2)" "unprognostic (2.14e-2)" "unprognostic (2.54e-1)" "unprognostic (1.51e-2)" "unprognostic (8.96e-2)" 13.9 11.9 16.9 12.4 20.0 10.9 13.2 35.1 26.9 20.5 17.0 19.4 17.9 14.0 20.1 12.2 13.0 18.6 15.0 14.0 13.3 8.8 11.8 9.8 12.7 10.1 13.8 14.7 21.1 16.1 20.0 18.1 10.6 14.6 13.8 10.8 16.7 22.9 19.6 31.7 14.5 13.2 13.5 11.4 12.9 16.6 21.4 12.9 14.1 20.1 11.3 10.9 18.0 14.0 4.7 5.6 7.7 4.9 3.6 7.0 3.7 7.2 11.6 16.1 18.2 19.2 16.2 13.6 17.4 11.9 13.1 11.2 13.9 13.8 10.9 15.5 14.3 6.1 12.0 9.6 12.6 9.8 8.3 15.8 10.3 22.5 5.7 13.2 12.8 12.5 19.1 8.0 10.6 7.9 15.8 12.3 7.9 10.0 9.8 11.6 14.4 15.2 3.7 16.7 5.4 11.4 24.2 17.6 13.9 5.3 6.5 12.2 23.1 24.8 16.4 8.8 16.7 15.0 9.5 19.4 13.8 9.4 12.3 8.8 21.9 21.8 21.8 5.7 5.2 16.3 6.2 4.9 5.4 7.0 4.7 6.7 4.4 4.4 4.1 5.6 4.7 3.1 4.8 7.7 3.6 3.7 1.5 3.2 3.7 16.9 20.0 35.1 26.9 13.3 8.8 13.8 14.7 14.6 12.9 23.8 17.6 14.9 7.2 8.1 44.2 38.9 20.4 9.4 10.3 19.2 88.4 10.1 3.3 12.8 11.0 19.5 25.8 0.0 12.2 6.5 14.6 9.4 8.1 29.2 9.8 42.9 31.2 34.4 10.5 22.4 26.2 16.6 8.5 7.2 23.8 24.1 15.9 17.5 24.4 6.7 69.1 12.9 11.8 19.4 39.6 8.5 7.8 20.0 24.7 9.2 TSHR LGR3 ENSG00000165409 "Thyroid stimulating hormone receptor" P16473 14 80954989-81146302 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "thyroid gland: 158.0" "Cell type enhanced" "Detected in some" 15 "Club cells: 2.3;Intestinal endocrine cells: 1.7" "Cancer enriched" "Detected in some" 116 "thyroid cancer: 100.4" "Not detected" "Not detected" "Cell type enriched" "Detected in some" 5 "T-reg: 9.9" "Lineage enriched" "Detected in many" 5 "T-cells: 9.9" "Cell line enhanced" "Detected in some" "JURKAT: 34.0;MOLT-4: 13.3;SCLC-21H: 13.7;U-266/70: 6.7" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB000473 Approved "Intracellular and membrane" NA NA "CAB000473: AB_2303782" "unprognostic (3.36e-3)" "unprognostic (1.31e-3)" "unprognostic (1.02e-2)" "unprognostic (4.17e-6)" "unprognostic (3.01e-3)" "unprognostic (1.85e-3)" "unprognostic (1.83e-1)" "unprognostic (2.66e-2)" "unprognostic (3.39e-2)" "unprognostic (2.60e-2)" "unprognostic (1.70e-1)" "unprognostic (7.11e-3)" "unprognostic (5.08e-7)" "unprognostic (1.32e-1)" "unprognostic (7.40e-2)" "unprognostic (1.19e-1)" "unprognostic (1.66e-1)" 0.1 0.2 0.1 0.2 0.4 0.3 0.2 0.1 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.3 0.3 0.5 0.1 0.0 0.8 0.2 0.0 0.1 0.3 0.1 0.0 0.2 0.2 0.1 0.1 0.1 27.3 158.0 0.2 0.4 0.1 0.1 1.8 0.8 1.3 0.3 0.1 9.9 0.1 0.2 0.1 0.4 0.3 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.2 0.3 0.4 0.1 0.1 0.2 0.1 0.5 0.0 0.1 0.2 0.1 0.2 0.4 0.2 0.0 0.1 0.2 0.2 0.0 0.1 0.2 0.1 0.0 34.0 0.2 0.4 0.1 0.3 13.3 0.3 0.3 0.1 0.1 0.5 0.1 0.5 0.0 0.3 13.7 0.2 0.1 0.1 0.1 0.3 0.2 0.0 0.1 0.4 0.3 0.3 0.2 6.7 3.5 0.3 0.2 0.1 0.2 0.6 0.2 0.2 0.2 0.1 0.2 1.0 0.8 0.5 0.1 1.8 0.3 0.2 1.3 0.1 0.3 0.8 9.9 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.5 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 U2AF1 "RN, RNU2AF1, U2AF35, U2AFBP" ENSG00000160201 "U2 small nuclear RNA auxiliary factor 1" Q01081 21 43092956-43107587 "Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins" "mRNA processing, mRNA splicing" RNA-binding "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 6 "Basal keratinocytes: 437.9;Melanocytes: 192.3;Suprabasal keratinocytes: 379.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "HPA044833, HPA052083" Supported Enhanced Nucleoplasm NA NA Nucleoplasm "HPA044833: AB_10960990, HPA052083: AB_2681720" "unprognostic (1.10e-1)" "unprognostic (1.28e-1)" "unprognostic (5.98e-2)" "unprognostic (2.87e-2)" "unprognostic (1.36e-1)" "unprognostic (8.06e-2)" "unprognostic (2.76e-2)" "unprognostic (4.29e-4)" "unprognostic (4.81e-4)" "unprognostic (3.42e-2)" "unprognostic (2.31e-3)" "unprognostic (8.85e-2)" "unprognostic (2.14e-6)" "unprognostic (1.08e-1)" "unprognostic (1.40e-2)" "unprognostic (1.72e-1)" "unprognostic (1.26e-2)" 20.0 15.1 20.8 19.2 21.1 48.5 61.0 25.6 20.8 16.1 21.5 9.7 12.3 17.6 28.8 26.5 19.3 27.6 17.1 19.5 19.7 15.8 14.6 17.1 35.2 33.5 25.7 2.9 22.1 48.3 15.3 27.8 21.2 20.8 23.9 13.7 9.6 44.5 19.8 33.0 16.6 20.4 38.7 23.9 21.0 17.5 33.9 22.7 20.6 27.3 26.5 20.0 22.9 31.7 58.4 82.8 81.2 54.1 33.1 55.5 53.8 25.3 27.8 15.1 11.4 8.9 6.4 35.5 22.0 15.3 18.0 16.1 64.6 9.3 43.4 12.0 14.3 24.7 12.4 31.6 23.4 9.3 34.0 71.5 70.2 14.2 24.3 21.7 30.2 17.3 8.8 14.4 29.1 18.6 6.5 14.8 26.6 38.5 19.6 12.5 47.7 24.9 33.5 32.1 21.7 32.1 41.2 14.6 21.8 12.0 10.7 23.0 17.6 23.6 14.3 11.7 4.3 17.4 17.6 18.5 15.0 20.4 13.5 23.0 26.3 30.9 35.9 14.4 55.6 23.1 48.4 52.6 50.9 42.2 52.5 41.4 55.9 46.4 42.1 54.1 58.4 46.4 44.8 81.2 33.1 54.1 82.8 55.5 53.8 20.8 21.1 25.6 20.8 19.7 15.8 25.7 2.9 20.8 22.7 17.9 17.8 8.9 29.0 437.9 21.8 2.8 7.6 21.4 27.3 1.8 41.2 16.3 1.7 4.5 1.9 22.2 22.9 0.0 5.1 15.6 26.8 31.7 26.7 17.8 19.6 17.5 17.5 28.8 21.4 2.0 17.0 27.1 192.3 2.8 16.7 13.0 4.0 17.5 21.2 2.8 59.6 6.5 29.2 14.4 17.7 379.0 19.9 20.0 22.2 30.1 UBR5 "DD5, EDD, EDD1, HYD, KIAA0896" ENSG00000104517 "Ubiquitin protein ligase E3 component n-recognin 5" O95071 8 102253012-102412841 "Cancer-related genes, Enzymes, Predicted intracellular proteins" "DNA damage, DNA repair, Host-virus interaction, Ubl conjugation pathway" Transferase "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053688 Supported Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "HPA053688: AB_2682230" "unprognostic (3.79e-3)" "unprognostic (7.44e-3)" "unprognostic (1.25e-1)" "unprognostic (2.10e-2)" "unprognostic (2.44e-2)" "unprognostic (1.41e-1)" "prognostic unfavorable (1.26e-4)" "unprognostic (2.50e-1)" "unprognostic (1.75e-2)" "unprognostic (7.54e-3)" "unprognostic (8.29e-3)" "unprognostic (3.84e-2)" "unprognostic (6.64e-2)" "unprognostic (3.16e-1)" "unprognostic (1.94e-1)" "unprognostic (1.69e-2)" "unprognostic (2.45e-1)" 27.0 16.7 27.1 29.5 31.7 30.3 29.2 40.8 32.8 24.9 25.0 19.1 21.1 14.4 26.8 24.0 23.8 22.0 17.6 22.7 25.5 15.3 17.9 17.0 24.2 29.6 21.9 20.6 29.7 22.2 32.4 25.5 25.0 23.6 20.2 17.1 19.7 22.9 21.8 39.9 29.7 22.4 29.3 17.5 21.9 21.1 39.7 28.3 37.9 20.3 15.9 27.0 27.5 28.6 5.0 4.0 6.3 5.5 2.4 7.1 2.1 23.6 10.6 20.5 10.4 20.2 20.6 18.9 17.9 15.8 14.0 12.3 10.6 15.9 47.1 15.5 16.7 9.2 14.4 17.5 15.5 19.7 20.4 8.6 39.3 14.5 19.0 18.0 12.2 21.7 23.6 15.5 14.4 25.2 16.0 16.8 13.5 18.9 26.8 13.7 21.4 31.0 14.6 15.4 22.9 12.0 18.1 12.1 22.3 12.8 23.2 15.1 12.6 12.5 12.1 12.4 18.6 19.6 13.0 16.8 15.0 17.5 13.4 12.4 14.4 13.8 48.5 14.8 19.1 12.1 3.1 3.4 5.0 5.6 3.4 5.6 5.0 6.0 5.9 4.0 3.9 4.8 7.1 6.3 2.4 5.5 3.6 7.1 2.1 27.1 31.7 40.8 32.8 25.5 15.3 21.9 20.6 23.6 28.3 23.8 27.7 29.8 38.5 46.4 48.4 35.8 5.1 40.2 63.7 29.6 64.8 19.1 8.3 15.1 25.0 38.3 17.3 0.0 13.1 14.9 48.2 37.7 28.9 15.8 15.4 54.0 32.0 23.4 29.4 20.2 36.8 28.9 42.2 27.1 17.9 31.5 16.2 17.3 34.3 6.7 44.0 12.9 38.7 64.7 30.4 53.3 58.2 30.5 17.7 46.9 USP6 "HRP1, Tre-2, TRE17, Tre2, TRESMCR" ENSG00000129204 "Ubiquitin specific peptidase 6" P35125 17 5116438-5175034 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Ubl conjugation pathway" "Calmodulin-binding, Hydrolase, Protease, Thiol protease" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "skeletal muscle: 18.2;testis: 29.0" "Cell type enhanced" "Detected in many" 5 "Early spermatids: 19.3;Erythroid cells: 23.3;Spermatocytes: 19.2" "Cancer enriched" "Detected in single" 14 "testis cancer: 2.8" "Not detected" "Not detected" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" HPA046969 Uncertain Vesicles NA NA Vesicles "HPA046969: " "unprognostic (3.89e-2)" "unprognostic (3.79e-3)" "unprognostic (2.50e-1)" "unprognostic (1.85e-1)" "unprognostic (9.32e-2)" "unprognostic (3.50e-3)" "unprognostic (1.29e-1)" "unprognostic (1.67e-2)" "unprognostic (3.45e-2)" "unprognostic (2.46e-2)" "unprognostic (7.91e-4)" "unprognostic (6.28e-3)" "unprognostic (3.24e-4)" "unprognostic (3.75e-2)" "unprognostic (3.13e-1)" "unprognostic (2.71e-1)" "unprognostic (7.09e-4)" 0.3 0.3 0.3 0.3 0.6 0.2 0.4 0.5 0.5 0.3 0.5 0.3 1.2 0.0 0.6 0.6 0.3 0.5 0.4 0.3 0.3 0.1 0.3 0.3 0.3 0.3 0.3 0.3 2.6 0.3 0.0 0.4 0.4 0.3 0.4 0.1 0.3 0.3 0.3 18.2 0.6 0.7 0.9 0.3 0.3 0.0 29.0 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.9 1.2 1.9 1.0 0.2 0.4 0.1 2.2 0.9 2.2 1.6 0.4 0.2 2.3 1.9 0.1 0.6 0.4 0.8 1.0 2.2 1.6 1.2 1.9 1.0 0.7 0.8 0.5 1.5 1.3 1.7 1.3 0.9 1.2 0.5 2.8 1.1 0.5 0.1 0.2 2.5 0.3 1.8 0.5 0.3 0.5 2.5 1.8 0.7 1.5 0.7 0.1 1.4 1.9 0.2 0.5 0.7 0.9 2.1 1.0 0.1 3.3 3.7 2.1 2.2 1.2 0.9 3.2 2.0 1.4 2.0 1.6 1.5 0.0 0.1 2.6 0.1 0.4 0.9 0.4 0.3 0.2 0.6 0.3 0.3 0.3 0.9 0.3 0.4 1.9 0.2 1.0 1.2 0.1 0.1 0.3 0.6 0.5 0.3 0.3 0.1 0.3 0.3 0.3 0.3 6.0 9.6 0.5 0.9 9.6 7.9 1.6 7.6 5.3 5.7 3.5 11.8 0.5 3.3 0.0 19.3 2.9 0.0 23.3 0.0 0.8 1.5 2.4 0.0 2.6 2.3 1.6 0.0 4.9 4.9 9.4 1.7 5.7 3.3 0.0 0.0 4.7 0.1 0.0 2.5 2.8 9.8 6.5 0.6 19.2 5.5 9.2 0.6 0.7 0.0 0.9 USP8 "HumORF8, KIAA0055, SPG59, UBPY" ENSG00000138592 "Ubiquitin specific peptidase 8" P40818 15 50424380-50514419 "Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Cell cycle, Ubl conjugation pathway" "Hydrolase, Protease, Thiol protease" "Cancer-related genes, Cushing syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA050215 Approved Supported "Golgi apparatus,Cytosol" NA NA "Golgi apparatus" Cytosol "HPA050215: AB_2681054" "unprognostic (5.81e-2)" "unprognostic (1.34e-1)" "unprognostic (1.46e-1)" "unprognostic (9.58e-2)" "unprognostic (2.35e-2)" "unprognostic (2.91e-1)" "unprognostic (1.42e-1)" "unprognostic (3.96e-1)" "unprognostic (1.68e-2)" "unprognostic (5.08e-2)" "unprognostic (2.94e-1)" "unprognostic (3.99e-2)" "prognostic favorable (1.29e-5)" "unprognostic (4.89e-2)" "unprognostic (1.13e-1)" "unprognostic (3.79e-1)" "unprognostic (1.58e-1)" 19.4 21.9 21.0 20.6 20.6 21.6 18.1 27.3 21.6 21.4 23.9 13.8 19.5 20.2 22.1 17.4 22.3 17.4 15.5 17.4 19.7 18.2 28.2 26.4 17.0 25.4 21.8 15.2 21.9 16.7 42.6 43.2 29.1 29.7 16.7 18.9 10.7 19.9 17.9 24.3 17.8 32.1 19.2 29.3 30.3 17.7 27.5 26.1 28.9 24.1 12.7 20.9 22.3 18.4 16.7 10.6 38.1 15.1 9.5 11.9 6.9 11.2 16.2 9.1 16.0 16.6 18.7 12.6 16.2 19.2 15.8 18.7 10.8 7.5 11.9 12.5 18.5 17.8 21.8 12.4 12.1 18.7 10.4 8.2 21.9 15.1 11.0 17.1 14.7 14.9 14.4 14.6 13.9 23.6 14.7 15.3 8.5 12.5 14.5 14.8 23.1 9.4 5.8 10.4 12.9 7.5 8.5 16.9 17.8 15.0 26.5 11.6 10.6 17.0 25.5 21.2 20.1 14.0 18.0 17.3 16.4 9.2 50.5 21.3 11.3 23.4 13.1 13.1 29.7 15.8 38.1 13.3 22.4 11.1 12.4 10.7 16.5 11.4 11.1 10.6 16.7 11.9 10.7 22.7 9.5 15.1 9.9 8.5 6.9 21.0 20.6 27.3 21.6 19.7 18.2 21.8 15.2 29.7 26.1 89.3 104.5 61.4 35.4 25.6 51.6 61.8 48.4 147.2 88.7 45.4 64.8 49.9 21.6 44.4 53.0 44.9 70.6 23.3 44.6 38.3 35.3 38.8 83.3 45.5 40.2 31.8 51.2 53.4 59.1 12.4 49.8 49.2 38.8 52.3 54.2 53.3 45.7 54.3 58.0 40.7 75.6 45.3 42.6 86.1 47.1 36.3 88.0 47.9 55.0 52.6 VHL VHL1 ENSG00000134086 "Von Hippel-Lindau tumor suppressor" P40337 3 10141008-10152220 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Ubl conjugation pathway" "Cancer-related genes, Congenital erythrocytosis, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "BEWO: 54.7" "CAB005430, HPA031631, HPA031632" Uncertain Enhanced Nucleoplasm,Cytosol NA NA Nucleoplasm Cytosol "CAB005430: AB_2241850, HPA031631: AB_2673968, HPA031632: AB_2673969" "prognostic unfavorable (9.02e-5)" "unprognostic (1.10e-1)" "unprognostic (4.46e-3)" "unprognostic (1.52e-1)" "unprognostic (1.10e-1)" "unprognostic (1.33e-1)" "prognostic unfavorable (1.32e-5)" "unprognostic (3.55e-1)" "unprognostic (3.03e-2)" "unprognostic (4.36e-2)" "unprognostic (5.82e-3)" "unprognostic (1.81e-2)" "unprognostic (2.51e-1)" "prognostic favorable (7.84e-4)" "unprognostic (1.46e-1)" "unprognostic (2.92e-2)" "unprognostic (1.28e-3)" 13.8 17.4 18.1 29.2 18.4 24.3 15.4 25.8 21.4 13.3 19.8 19.3 14.5 15.9 15.1 13.6 16.4 14.3 18.9 10.5 17.1 18.5 13.7 16.3 14.6 27.9 13.5 12.3 15.2 22.5 13.8 14.6 18.8 12.8 15.1 16.6 12.5 21.8 13.7 14.8 14.0 22.3 13.4 17.0 22.6 16.2 17.9 11.2 39.2 16.9 11.5 29.3 15.4 19.1 5.4 3.9 8.0 4.1 4.4 4.3 1.7 6.8 6.6 14.6 8.9 13.6 10.5 54.7 6.1 8.7 7.8 9.2 7.8 8.6 24.3 8.3 8.2 11.0 5.9 13.5 8.5 9.6 11.6 12.2 18.9 10.8 10.7 12.9 16.6 15.2 10.6 9.7 10.3 13.0 10.4 8.9 15.3 16.8 18.5 7.6 12.4 15.8 12.2 9.8 7.4 8.5 20.1 12.9 12.2 9.5 17.8 5.5 18.3 12.8 6.8 7.3 9.2 13.4 21.1 7.7 7.7 10.4 7.2 9.5 13.2 26.9 38.8 8.6 20.0 7.0 2.6 4.1 3.3 3.8 2.5 3.6 4.1 2.9 4.3 3.9 5.4 2.5 2.7 8.0 4.4 3.2 2.4 3.1 1.7 18.1 18.4 25.8 21.4 17.1 18.5 13.5 12.3 12.8 11.2 11.9 12.2 25.5 15.5 13.1 15.6 5.0 20.4 5.3 5.7 15.7 17.7 13.9 6.6 9.9 7.6 12.1 10.5 0.0 4.5 15.8 9.5 19.0 4.7 12.3 12.9 17.5 13.8 17.2 20.2 6.1 13.0 18.5 11.8 15.4 9.3 10.4 8.5 9.3 10.6 7.3 13.9 6.5 6.2 14.4 25.6 17.9 14.4 17.5 10.7 19.5 WDCP "C2orf44, FLJ21945" ENSG00000163026 "WD repeat and coiled coil containing" Q9H6R7 2 24029340-24049575 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in some" 12 "Collecting duct cells: 8.7;Distal tubular cells: 6.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041054 Approved Approved Nucleoli,Cytosol NA NA Nucleoli Cytosol "HPA041054: AB_10796566" "unprognostic (1.07e-1)" "unprognostic (3.19e-2)" "unprognostic (3.36e-1)" "prognostic unfavorable (6.53e-4)" "unprognostic (1.32e-1)" "unprognostic (1.35e-1)" "prognostic unfavorable (5.14e-8)" "unprognostic (7.69e-2)" "unprognostic (9.01e-3)" "unprognostic (2.05e-1)" "unprognostic (1.07e-1)" "unprognostic (5.19e-2)" "unprognostic (2.76e-3)" "unprognostic (1.85e-1)" "unprognostic (1.97e-1)" "unprognostic (7.76e-2)" "unprognostic (3.00e-1)" 11.7 9.6 8.3 7.6 9.4 2.4 9.2 14.6 9.8 9.6 9.3 11.5 8.4 5.3 10.7 8.0 7.4 7.2 5.6 6.8 7.1 6.9 7.5 8.9 5.4 12.4 8.3 4.8 11.6 7.7 11.2 9.4 8.5 8.7 8.7 6.2 7.8 7.1 12.9 13.8 5.9 7.5 7.4 8.0 9.4 7.0 12.5 9.2 17.9 8.9 5.5 13.7 9.4 6.4 4.9 4.3 1.5 3.8 5.0 7.8 4.2 7.3 11.4 12.6 8.7 8.6 6.9 4.5 9.0 4.8 9.4 9.0 10.3 3.4 19.4 3.9 4.6 7.9 5.4 17.8 6.1 9.8 11.6 10.2 11.8 5.7 10.7 5.9 10.7 8.2 4.1 4.8 9.6 4.8 4.9 8.8 11.3 16.3 5.4 9.8 3.3 13.9 6.4 15.1 7.4 8.9 15.4 21.2 7.8 4.4 3.6 9.7 13.4 4.4 4.3 5.5 9.2 3.3 4.8 8.4 7.6 8.4 4.5 8.1 8.9 11.2 27.4 4.8 11.5 5.9 0.0 2.4 1.5 7.5 3.8 7.8 4.9 5.0 5.5 4.3 4.7 6.8 7.5 0.7 5.0 2.6 1.6 7.1 4.2 8.3 9.4 14.6 9.8 7.1 6.9 8.3 4.8 8.7 9.2 3.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.2 8.7 0.0 2.6 6.6 2.1 0.0 0.0 0.0 0.0 1.7 2.1 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 1.4 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 WIF1 ENSG00000156076 "WNT inhibitory factor 1" Q9Y5W5 12 65050626-65121566 "Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins" "Wnt signaling pathway" "Developmental protein" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.2;lung: 67.7;retina: 29.6" "Cell type enriched" "Detected in many" 15 "Muller glia cells: 2337.6" "Cancer enhanced" "Detected in many" "endometrial cancer: 16.9" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEK 293: 5.4;LHCN-M2: 2.5;NTERA-2: 7.0;SCLC-21H: 1.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Secreted to extracellular matrix" NA NA "unprognostic (5.96e-3)" "unprognostic (2.00e-1)" "unprognostic (4.29e-3)" "unprognostic (3.26e-3)" "unprognostic (9.66e-2)" "unprognostic (1.91e-1)" "unprognostic (1.26e-2)" "unprognostic (7.94e-2)" "unprognostic (2.44e-1)" "unprognostic (2.92e-2)" "unprognostic (3.17e-1)" "unprognostic (2.30e-5)" "unprognostic (3.02e-1)" "unprognostic (2.02e-1)" "unprognostic (1.22e-1)" "unprognostic (7.24e-3)" 0.9 2.4 23.3 0.8 35.2 0.6 14.2 1.6 20.6 1.6 0.8 1.0 1.9 0.6 5.5 14.5 3.4 1.5 0.6 0.7 10.4 3.9 1.0 0.6 67.7 0.7 1.4 8.2 0.8 0.8 0.6 21.4 0.6 0.4 9.5 0.8 29.6 24.8 2.3 0.6 4.2 1.8 1.2 0.7 0.7 0.9 1.0 3.5 0.0 0.6 3.6 0.6 0.8 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 2.5 0.1 0.0 0.9 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.3 35.2 1.6 20.6 10.4 3.9 1.4 8.2 0.4 3.5 32.8 159.2 0.0 31.4 11.2 20.4 1.1 0.0 62.9 48.9 1.8 7.9 0.0 0.0 0.0 0.1 1.2 0.0 0.0 0.0 0.0 1.9 16.0 7.0 0.0 0.0 14.3 0.0 0.0 0.0 0.0 0.0 3.1 21.9 0.0 0.0 2337.6 0.0 0.0 0.4 0.8 66.4 0.0 3.6 0.5 0.2 9.3 0.0 0.0 0.0 0.5 WT1 "AWT1, GUD, NPHS4, WAGR, WIT-2" ENSG00000184937 "Wilms tumor 1" P19544 11 32387775-32435630 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, RNA-binding" "Cancer-related genes, Disease mutation, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 69.0;fallopian tube: 34.5;ovary: 53.4" "Cell type enhanced" "Detected in some" 18 "Collecting duct cells: 19.2;Late spermatids: 5.9;Leydig cells: 7.8;Sertoli cells: 6.5" "Cancer enriched" "Detected in many" 14 "ovarian cancer: 55.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEL: 13.5;HMC-1: 17.4;K-562: 12.2;NB-4: 32.6;THP-1: 15.6" "Region enhanced" "Detected in single" "pons and medulla: 0.5" "Not detected" "Not detected" "CAB000327, HPA035717, HPA053848" Enhanced Enhanced Nucleoplasm NA NA Nucleoplasm "CAB000327: AB_2304486, HPA035717: AB_2674748, HPA053848: AB_2682279" "unprognostic (3.09e-3)" "unprognostic (9.97e-4)" "unprognostic (3.32e-1)" "unprognostic (8.24e-3)" "unprognostic (5.20e-2)" "unprognostic (1.98e-3)" "unprognostic (2.94e-2)" "unprognostic (1.59e-2)" "unprognostic (1.23e-2)" "unprognostic (4.15e-2)" "unprognostic (1.86e-2)" "unprognostic (1.36e-1)" "unprognostic (1.31e-10)" "unprognostic (2.65e-3)" "unprognostic (1.87e-1)" "unprognostic (1.96e-3)" "unprognostic (1.30e-2)" 10.3 0.0 0.2 1.8 0.6 0.0 0.2 0.2 0.5 20.3 1.5 0.2 3.7 0.0 69.0 9.3 0.4 34.5 0.8 2.1 0.9 0.0 5.3 0.2 0.8 0.5 0.2 0.2 53.4 0.2 0.0 0.2 6.9 0.3 0.9 0.0 0.2 0.2 4.2 0.2 0.0 0.4 23.7 0.2 14.6 0.0 24.5 0.2 0.2 0.3 0.2 0.2 1.3 4.1 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.1 0.1 0.0 0.0 0.0 6.3 0.0 0.0 0.0 4.7 13.5 0.0 1.2 3.8 9.0 17.4 0.0 0.0 2.8 0.0 0.0 0.0 2.8 12.2 0.1 2.7 0.0 7.9 32.6 0.7 0.0 3.8 1.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 1.8 15.6 0.1 0.0 2.4 0.0 0.3 0.0 0.0 0.0 0.1 2.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.6 0.2 0.5 0.9 0.0 0.2 0.2 0.3 0.2 0.0 0.0 0.0 0.2 0.0 0.0 1.4 0.0 0.0 0.0 19.2 0.0 0.9 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.7 0.2 0.1 0.0 0.0 0.3 0.0 0.0 2.5 0.0 5.9 7.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 1.2 0.0 6.5 0.0 1.9 0.9 0.0 0.7 0.0 0.0 0.1 WWTR1 "DKFZp586I1419, TAZ" ENSG00000018408 "WW domain containing transcription regulator 1" Q9GZV5 3 149517235-149736714 "Cancer-related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" Activator "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Basal glandular cells: 158.0;Endothelial cells: 172.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "gdT-cell: 2.6;memory CD8 T-cell: 2.8" "Lineage enriched" "Detected in single" 4 "T-cells: 2.8" "Cell line enhanced" "Detected in many" "EFO-21: 60.9;SK-MEL-30: 42.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007415, CAB017483, CAB068248" Enhanced Supported "Nucleoplasm,Nuclear bodies,Cytosol" NA NA "Nucleoplasm, Nuclear bodies" Cytosol "CAB017483: AB_2216639, CAB068248: AB_2665648, HPA007415: AB_1080602" "unprognostic (1.85e-2)" "unprognostic (2.24e-2)" "unprognostic (3.41e-3)" "unprognostic (1.33e-2)" "unprognostic (7.94e-2)" "unprognostic (1.37e-1)" "unprognostic (2.41e-2)" "unprognostic (2.22e-1)" "unprognostic (1.74e-2)" "unprognostic (2.34e-1)" "unprognostic (1.63e-2)" "unprognostic (3.32e-1)" "unprognostic (1.17e-3)" "unprognostic (2.76e-2)" "unprognostic (2.53e-1)" "unprognostic (3.98e-2)" "unprognostic (1.01e-3)" 25.1 9.9 9.3 16.0 18.6 0.2 20.4 7.7 10.5 27.2 38.5 18.4 15.0 5.6 27.2 17.6 41.2 16.4 25.8 20.6 14.7 9.0 31.0 13.1 29.8 6.2 15.2 5.6 30.9 21.7 10.4 8.5 29.0 20.7 34.6 9.1 29.4 15.8 22.4 12.1 13.4 11.7 81.5 25.8 13.8 20.8 12.0 16.4 0.7 18.2 13.2 7.1 68.4 31.0 0.2 0.1 0.6 0.1 0.1 2.8 0.4 16.8 20.0 10.6 14.2 12.7 22.7 11.2 9.8 14.4 4.4 4.7 11.2 14.3 0.0 60.9 11.0 13.6 10.0 6.9 7.1 4.4 4.7 5.3 0.0 5.2 9.3 7.2 0.0 0.0 12.0 1.8 15.4 6.8 17.0 34.5 0.0 0.0 0.0 15.3 2.2 0.0 0.0 2.4 0.0 25.3 0.0 14.3 0.1 37.8 2.5 0.0 0.1 6.5 4.6 42.0 8.3 7.8 0.3 28.0 8.7 4.2 7.0 19.1 0.2 0.1 0.2 18.7 0.0 22.2 0.4 0.1 0.1 2.6 0.0 0.0 0.0 0.3 2.8 0.0 0.2 0.1 1.3 0.6 0.1 0.0 0.1 1.9 0.4 9.3 18.6 7.7 10.5 14.7 9.0 15.2 5.6 20.7 16.4 59.6 79.0 0.0 158.0 45.9 2.0 42.0 147.7 60.2 128.5 47.1 3.9 10.5 6.6 55.4 14.8 172.1 0.7 0.0 23.5 70.1 58.9 72.2 7.0 20.3 3.7 0.0 0.0 92.7 6.4 3.6 53.5 8.0 28.7 3.6 0.0 10.4 31.6 0.0 118.8 48.8 2.0 58.2 48.4 1.7 0.7 31.0 12.4 5.3 0.0 80.1 XPO1 "CRM1, emb" ENSG00000082898 "Exportin 1" O14980 2 61477849-61538626 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Transport" RNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010184, HPA042933" Supported Enhanced "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" NA NA 170000 "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "CAB010184: AB_2215817, HPA042933: AB_2678229" "unprognostic (7.34e-2)" "unprognostic (7.04e-2)" "unprognostic (6.37e-2)" "unprognostic (1.67e-2)" "unprognostic (5.61e-2)" "unprognostic (1.28e-1)" "prognostic unfavorable (1.84e-5)" "unprognostic (1.84e-1)" "unprognostic (1.99e-3)" "unprognostic (4.43e-1)" "unprognostic (3.53e-3)" "unprognostic (4.90e-2)" "prognostic unfavorable (3.74e-4)" "unprognostic (5.69e-2)" "unprognostic (2.08e-1)" "unprognostic (2.43e-1)" "unprognostic (5.55e-2)" 20.7 27.9 36.1 28.1 39.6 21.6 35.1 41.5 36.3 28.2 23.2 19.5 26.0 16.5 35.7 35.3 26.1 36.0 20.3 20.1 33.0 19.2 19.5 22.2 22.0 34.5 42.0 19.5 45.0 34.6 33.4 27.6 30.8 33.6 25.8 24.5 18.0 20.2 29.9 34.9 29.8 25.0 28.4 32.1 24.5 21.9 32.1 39.3 51.1 28.2 16.4 35.7 26.0 57.8 6.1 5.4 12.6 5.1 6.2 5.1 2.5 39.4 35.3 47.9 35.9 21.7 29.2 35.3 43.7 28.2 46.0 39.4 46.9 29.7 57.9 30.6 29.9 46.8 33.5 73.0 30.3 67.7 35.3 26.9 57.0 36.3 29.3 15.7 57.4 39.0 16.4 22.7 36.3 39.6 34.9 37.5 29.2 65.7 33.8 42.3 20.8 47.7 25.2 55.7 47.2 27.1 42.8 54.7 35.2 20.9 30.0 38.3 20.4 42.5 35.9 21.3 50.4 29.4 28.4 25.0 43.2 49.1 35.1 42.9 27.5 45.3 84.0 26.8 49.3 38.9 12.6 5.1 5.8 5.1 5.0 4.7 4.3 3.6 4.5 3.9 6.1 4.3 3.7 12.4 6.2 3.2 5.4 3.2 2.5 36.1 39.6 41.5 36.3 33.0 19.2 42.0 19.5 33.6 39.3 38.7 36.3 31.8 27.6 46.2 69.7 57.0 43.3 46.8 28.4 29.6 90.3 46.3 11.6 24.4 3.2 40.7 19.3 70.0 22.5 42.3 40.9 34.4 40.5 48.0 49.4 68.3 43.4 42.4 46.3 8.0 31.1 53.2 35.4 49.5 31.2 34.0 26.3 17.5 29.0 20.8 102.5 19.4 43.7 64.6 88.2 49.7 25.2 42.9 37.6 38.3 YWHAE FLJ45465 ENSG00000108953 "Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon" P62258 17 1344272-1400378 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008445, CAB016200, CAB021109, CAB047350, HPA061603" Approved Supported "Nucleoplasm,Nucleoli rim,Cytosol" NA NA 160000000 Cytosol "Nucleoplasm, Nucleoli rim" "CAB016200: AB_626619, CAB021109: AB_10060396, CAB047350: , HPA008445: AB_1844336, HPA061603: " "unprognostic (1.29e-1)" "unprognostic (1.50e-1)" "unprognostic (3.99e-2)" "prognostic favorable (6.48e-6)" "unprognostic (1.59e-1)" "unprognostic (2.91e-2)" "unprognostic (2.73e-2)" "unprognostic (4.77e-3)" "unprognostic (4.53e-2)" "unprognostic (5.14e-2)" "unprognostic (1.59e-1)" "unprognostic (2.73e-1)" "unprognostic (1.92e-3)" "unprognostic (8.33e-2)" "unprognostic (2.57e-1)" "unprognostic (3.24e-2)" "unprognostic (8.94e-2)" 55.2 54.3 107.5 35.3 87.1 32.7 37.3 71.5 118.4 28.4 40.2 60.9 23.8 40.2 35.9 54.1 43.1 44.2 23.4 57.7 92.3 81.9 64.5 50.9 32.8 25.4 94.1 77.9 40.2 40.2 41.0 37.9 45.1 73.7 35.0 42.5 27.9 42.4 27.7 135.9 36.8 36.2 32.2 101.1 26.2 38.5 46.0 53.6 30.9 47.5 36.5 37.2 31.6 32.1 19.2 41.5 17.2 36.2 15.0 23.3 31.5 79.3 59.3 71.9 60.4 31.8 36.8 69.1 51.3 30.3 45.8 35.6 106.0 32.6 53.9 60.4 42.5 36.3 55.2 60.9 51.9 65.1 37.2 113.5 37.6 49.5 45.3 38.0 36.0 38.6 33.3 38.3 45.9 70.4 41.5 55.1 39.3 43.1 39.0 58.9 38.6 47.6 28.7 65.9 49.5 38.5 57.9 34.0 38.2 46.6 46.0 40.1 60.8 61.8 25.3 40.2 42.5 48.1 33.3 52.1 44.5 37.9 56.2 90.6 24.5 45.2 45.2 53.4 43.1 64.3 17.2 31.8 8.6 12.4 36.2 15.6 19.2 18.7 13.9 41.5 16.1 17.0 14.3 10.8 15.0 30.9 28.8 23.3 31.5 107.5 87.1 71.5 90.2 92.3 81.9 94.1 77.9 73.7 53.6 276.9 161.5 157.1 381.2 509.9 135.0 437.9 257.4 539.4 243.4 352.4 47.1 418.8 631.6 405.9 192.2 338.4 245.3 70.0 366.4 587.8 367.2 359.0 204.6 255.7 335.2 104.9 338.5 239.4 235.4 296.2 260.1 221.5 403.2 401.2 274.5 253.1 384.5 266.5 277.2 497.3 121.5 239.3 263.7 441.4 573.9 512.8 434.5 126.4 277.6 415.5 ZBTB16 "PLZF, ZNF145" ENSG00000109906 "Zinc finger and BTB domain containing 16" Q05516 11 114059593-114250676 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation, Ubl conjugation pathway" "DNA-binding, Repressor" "Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Leydig cells: 83.1;Peritubular cells: 86.7;Sertoli cells: 103.5" "Cancer enhanced" "Detected in many" "prostate cancer: 5.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "gdT-cell: 13.7;MAIT T-cell: 23.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "ASC diff: 30.6;ASC TERT1: 17.7;HEL: 18.2;HHSteC: 13.2;HSkMC: 14.1;hTCEpi: 13.1;hTERT-HME1: 11.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001499, CAB004540" Uncertain NA NA "CAB004540: AB_2218941, HPA001499: AB_1079640" "unprognostic (2.21e-1)" "unprognostic (2.17e-1)" "unprognostic (7.30e-2)" "unprognostic (1.18e-1)" "unprognostic (2.53e-1)" "unprognostic (3.05e-1)" "unprognostic (1.25e-2)" "unprognostic (1.40e-1)" "unprognostic (1.09e-1)" "unprognostic (8.79e-4)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "prognostic favorable (2.21e-4)" "unprognostic (2.57e-3)" "unprognostic (2.67e-1)" "unprognostic (1.00e-1)" "unprognostic (5.90e-2)" 38.0 16.0 10.0 6.3 14.6 6.3 20.5 18.0 22.8 18.7 14.9 6.7 15.7 1.8 19.6 8.5 24.0 17.3 11.8 25.5 11.8 4.5 8.3 9.3 17.3 6.2 16.1 8.9 41.6 51.5 14.5 9.5 8.3 12.6 10.0 3.0 7.8 10.4 15.1 58.8 17.5 10.4 15.1 10.8 11.1 12.8 4.6 14.2 0.0 24.1 10.9 2.5 21.9 27.5 6.9 0.0 0.6 2.4 5.5 23.5 2.7 0.0 0.0 6.2 0.0 30.6 17.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 18.2 0.0 0.0 13.2 0.3 0.2 14.1 13.1 0.0 11.5 0.0 2.2 2.7 0.0 0.0 0.1 0.0 1.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 2.4 0.6 13.7 0.6 23.5 0.1 0.6 2.0 0.0 6.9 0.8 0.4 0.2 5.5 0.5 0.0 0.2 2.7 10.0 14.6 18.0 22.8 11.8 4.5 16.1 8.9 12.6 14.2 20.8 4.8 11.1 63.9 9.8 23.7 31.3 25.5 10.7 7.9 8.7 0.0 0.1 1.7 0.7 18.8 27.5 2.0 0.0 0.8 0.2 13.1 36.9 13.9 45.2 0.7 0.0 6.9 57.7 19.6 16.8 83.1 5.8 6.8 2.8 0.7 21.4 0.5 0.0 86.7 5.3 1.9 103.5 50.5 0.3 5.7 5.9 0.2 29.3 0.8 6.3 ZFHX3 "ATBF1, ZNF927" ENSG00000140836 "Zinc finger homeobox 3" Q15911 16 72782885-73891871 "Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Myogenesis, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" 6 "Smooth muscle cells: 198.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "NK-cell: 2.5" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA059353 Uncertain Supported Nucleoplasm NA NA Nucleoplasm "HPA059353: AB_2683987" "prognostic unfavorable (1.55e-4)" "unprognostic (3.57e-2)" "unprognostic (1.68e-1)" "unprognostic (2.03e-2)" "unprognostic (2.81e-2)" "unprognostic (3.12e-1)" "unprognostic (4.24e-2)" "unprognostic (6.36e-2)" "unprognostic (9.94e-3)" "unprognostic (2.85e-1)" "unprognostic (1.06e-1)" "unprognostic (4.16e-2)" "prognostic favorable (1.37e-5)" "unprognostic (6.76e-2)" "unprognostic (1.10e-1)" "unprognostic (2.11e-1)" "unprognostic (2.15e-2)" 7.9 6.0 2.5 2.3 4.6 1.1 11.3 1.5 4.1 7.5 7.7 5.4 14.5 2.0 7.4 7.3 4.5 4.9 18.2 4.9 4.3 4.8 4.4 6.5 6.1 1.4 4.0 2.6 4.4 5.7 23.8 6.3 8.1 5.5 12.0 3.5 10.5 5.0 19.5 16.9 3.6 3.6 15.5 9.7 3.9 5.0 2.3 5.2 0.5 10.8 4.0 1.0 16.7 14.7 0.8 1.0 0.2 1.6 2.5 0.1 0.2 4.4 7.9 12.9 10.7 4.8 6.1 13.3 3.4 3.7 2.2 2.5 9.0 2.5 1.9 6.0 6.4 3.0 3.1 8.1 4.0 3.0 7.8 2.0 0.3 10.8 12.8 4.4 1.3 3.2 2.2 2.4 6.4 5.8 2.0 4.1 0.9 0.9 0.5 5.4 9.2 0.4 2.6 2.3 2.3 1.3 5.9 3.5 0.6 3.5 7.5 9.6 3.4 6.0 1.9 4.3 6.2 2.6 0.6 8.8 5.4 6.4 5.7 4.5 4.9 1.6 1.4 2.6 1.2 4.1 0.2 1.6 0.2 0.1 0.9 0.1 0.5 0.0 0.0 0.7 0.8 0.0 0.1 0.2 2.5 1.1 1.0 0.1 0.2 2.5 4.6 1.5 4.1 4.3 4.8 4.0 2.6 5.5 5.2 65.5 26.1 8.1 52.4 15.0 87.0 16.5 43.3 32.1 48.9 45.4 21.6 35.9 5.0 23.2 1.9 28.2 6.0 0.0 20.2 18.1 50.1 96.3 20.7 30.0 55.1 22.3 25.8 42.4 67.6 1.3 9.8 55.4 20.3 24.4 18.0 18.0 20.8 21.0 18.7 6.1 31.2 122.9 198.8 3.4 17.7 15.1 51.9 3.2 29.3 41.2 ZMYM2 "FIM, MYM, RAMP, ZNF198" ENSG00000121741 "Zinc finger MYM-type containing 2" Q9UBW7 13 19958670-20091829 "Cancer-related genes, Disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031765 Approved Approved "Nucleoplasm,Endoplasmic reticulum" NA NA "Nucleoplasm, Endoplasmic reticulum" "HPA031765: AB_10601927" "unprognostic (2.96e-1)" "unprognostic (3.42e-3)" "unprognostic (1.85e-1)" "unprognostic (1.69e-1)" "unprognostic (7.71e-2)" "unprognostic (2.33e-1)" "unprognostic (2.66e-3)" "unprognostic (1.16e-1)" "unprognostic (6.78e-2)" "unprognostic (5.88e-2)" "unprognostic (4.60e-2)" "unprognostic (2.80e-2)" "unprognostic (6.65e-3)" "unprognostic (2.05e-1)" "unprognostic (8.74e-2)" "unprognostic (1.06e-1)" "prognostic favorable (6.07e-4)" 15.0 17.3 15.9 18.1 23.3 22.2 16.1 23.9 26.8 18.3 16.8 14.0 13.7 13.3 20.0 14.0 18.5 16.1 15.7 17.1 14.4 12.0 17.3 13.7 15.4 14.2 12.9 20.2 21.7 16.2 17.1 32.1 14.0 23.2 19.4 13.8 13.8 18.2 17.6 19.7 18.3 14.5 15.3 16.2 16.3 16.0 44.5 16.5 38.0 24.3 10.4 19.7 19.5 17.2 5.5 6.3 7.4 5.9 5.4 7.9 3.5 6.4 5.8 22.3 9.6 9.9 10.6 10.6 6.7 10.8 8.7 10.4 8.9 13.3 15.4 6.2 9.4 8.3 10.3 16.4 7.2 11.8 6.1 4.6 27.2 8.7 4.4 9.9 22.9 8.3 10.5 13.5 6.9 7.1 13.8 14.7 15.9 10.3 11.0 11.9 9.1 22.1 6.5 20.6 19.5 3.6 24.7 24.3 7.2 6.7 9.4 26.1 26.0 13.0 9.3 12.2 15.7 12.3 16.4 8.6 4.3 6.9 5.2 3.5 8.7 6.8 15.9 3.7 5.4 10.3 0.2 5.2 4.0 5.5 5.9 6.7 5.5 7.5 5.6 6.1 4.5 7.9 6.9 7.4 5.4 4.9 6.3 5.4 3.5 15.9 23.3 23.9 26.8 14.4 12.0 12.9 20.2 23.2 16.5 41.7 35.3 47.7 40.3 48.9 111.9 33.0 28.1 36.1 46.6 48.8 106.0 13.1 5.0 20.1 90.8 35.1 23.6 0.0 15.4 10.5 38.8 45.9 45.1 28.4 19.1 68.3 53.6 43.6 57.0 140.1 51.8 45.1 32.1 20.8 31.0 48.9 25.9 31.6 38.5 13.7 112.6 32.3 39.3 94.3 48.9 39.0 9.5 45.9 27.6 70.2 ZNF331 "RITA, ZNF361, ZNF463" ENSG00000130844 "Zinc finger protein 331" Q9NQX6 19 53520981-53580269 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 66.4;ovary: 86.4" "Cell type enhanced" "Detected in many" 7 "granulocytes: 234.6;Smooth muscle cells: 196.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HEK 293: 36.4;RT4: 27.8" "Low region specificity" "Detected in all" HPA063157 Approved Nucleoplasm NA NA Nucleoplasm "HPA063157: AB_2684951" "unprognostic (2.19e-1)" "unprognostic (1.79e-1)" "unprognostic (5.18e-2)" "unprognostic (1.55e-2)" "unprognostic (4.24e-1)" "unprognostic (8.16e-2)" "unprognostic (7.62e-3)" "unprognostic (3.25e-2)" "unprognostic (1.84e-2)" "unprognostic (4.40e-2)" "unprognostic (5.68e-3)" "unprognostic (2.69e-1)" "unprognostic (4.73e-2)" "prognostic unfavorable (4.79e-4)" "unprognostic (2.08e-1)" "prognostic unfavorable (7.43e-4)" "unprognostic (6.74e-2)" 19.1 66.4 6.8 9.0 8.2 18.6 10.5 11.4 9.5 9.4 5.3 8.4 8.9 2.1 9.5 11.6 4.9 19.5 23.8 15.5 5.1 7.7 6.6 6.1 15.6 4.0 6.8 5.5 86.4 9.9 11.3 29.0 23.3 7.2 10.2 4.2 9.9 4.7 31.5 6.3 5.2 4.8 8.5 9.1 4.5 6.3 8.1 6.0 3.8 7.8 4.4 4.8 25.7 9.2 8.1 4.1 6.5 7.4 4.6 14.7 5.2 0.1 5.1 10.3 11.8 8.0 5.9 17.2 7.3 6.5 5.6 10.2 5.5 2.6 4.1 1.9 4.3 2.6 3.0 7.4 5.5 10.0 0.0 36.4 5.1 8.7 3.3 5.8 3.2 7.2 5.9 3.6 6.2 3.0 3.1 2.5 6.4 0.2 1.6 5.5 3.6 7.2 6.8 4.6 0.1 7.6 8.9 6.5 4.2 3.3 27.8 7.3 7.4 3.4 9.7 2.4 21.4 1.7 2.9 2.6 7.9 7.0 4.6 4.8 20.3 13.2 7.7 0.1 0.4 6.1 0.5 4.9 6.5 8.7 3.8 13.4 8.1 9.4 8.8 3.6 8.1 14.7 9.7 0.7 4.6 7.4 4.1 9.4 5.2 6.8 8.2 11.4 9.5 5.1 7.7 6.8 5.5 7.2 6.0 17.9 70.7 15.9 15.3 39.8 52.9 16.5 7.6 17.4 20.5 73.3 27.5 32.9 8.3 2.9 128.2 19.9 2.1 0.0 3.6 30.4 36.8 11.9 234.6 3.9 60.1 28.6 22.5 14.7 33.7 61.5 22.5 79.8 43.9 3.6 5.1 25.1 2.3 3.5 18.4 3.7 35.8 0.0 196.7 34.4 19.8 44.3 37.2 74.7 3.2 9.4 ZNF384 "CAGH1A, CIZ, NMP4, NP, TNRC1" ENSG00000126746 "Zinc finger protein 384" Q8TF68 12 6666477-6689572 "Cancer-related genes, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" DNA-binding "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004051 Supported Approved Nucleoplasm NA NA Nucleoplasm "HPA004051: AB_1859228" "unprognostic (1.90e-1)" "unprognostic (5.11e-3)" "unprognostic (1.76e-1)" "unprognostic (6.16e-2)" "unprognostic (1.79e-1)" "unprognostic (3.04e-2)" "unprognostic (1.87e-2)" "unprognostic (9.94e-2)" "unprognostic (1.35e-2)" "unprognostic (2.57e-2)" "unprognostic (3.51e-2)" "unprognostic (4.25e-1)" "unprognostic (1.24e-2)" "unprognostic (1.01e-1)" "unprognostic (2.22e-1)" "unprognostic (2.06e-1)" "unprognostic (8.13e-2)" 20.5 22.8 18.9 30.9 19.9 33.4 22.1 36.1 23.0 23.2 23.3 19.5 16.8 22.1 29.8 17.6 21.1 24.2 25.3 16.1 16.0 10.8 20.7 19.9 19.7 21.9 19.7 17.7 31.3 25.8 25.8 20.5 23.9 14.8 22.7 21.4 18.6 22.4 20.6 22.7 24.1 29.4 24.8 14.2 33.6 21.3 20.5 18.7 39.7 27.0 17.5 29.7 25.2 28.9 10.2 11.1 14.2 13.3 15.6 17.3 7.3 10.5 20.3 25.0 16.7 17.7 12.6 33.6 15.3 14.3 14.9 15.9 22.2 22.7 25.0 5.8 17.2 21.6 14.3 18.4 14.1 17.0 45.1 16.7 28.6 26.9 11.5 12.5 27.1 21.2 13.8 13.7 18.3 28.6 28.1 12.8 17.7 14.9 8.7 16.2 16.4 24.4 17.5 48.4 19.3 8.9 24.3 26.8 9.6 13.2 28.5 7.8 25.3 15.9 21.3 13.7 44.0 5.6 22.5 15.9 16.4 22.9 12.8 18.0 12.1 11.4 45.6 16.1 9.8 18.5 3.3 8.0 14.2 17.3 9.7 13.8 10.2 11.0 13.6 11.1 8.8 10.8 12.1 14.2 15.6 13.3 7.4 13.2 7.3 18.9 19.9 36.1 23.0 16.0 10.8 19.7 17.7 14.8 18.7 0.0 8.3 8.0 2.9 7.0 4.7 2.3 12.7 4.0 3.4 1.8 9.8 5.8 0.0 3.8 3.4 5.8 9.7 0.0 4.3 4.4 6.1 4.4 5.7 5.8 6.1 0.0 3.5 9.2 14.1 1.8 7.8 7.2 5.0 6.4 13.6 6.0 5.7 14.1 8.1 3.1 7.6 0.0 3.4 6.7 6.3 8.5 6.1 10.2 11.2 3.8 ZNF521 "EHZF, Evi3" ENSG00000198795 "Zinc finger protein 521" Q96K83 18 25061926-25352190 "Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors" "Differentiation, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Repressor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 69.1" "Cell type enhanced" "Detected in many" 8 "Bipolar cells: 27.9;Endothelial cells: 22.4;Horizontal cells: 14.3;Ito cells: 14.1" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 6 "cerebellum: 69.1" "Group enriched" "Detected in some" 5 "basophil: 8.8;plasmacytoid DC: 9.8" "Group enriched" "Detected in many" 5 "dendritic cells: 9.8;granulocytes: 8.8" "Cell line enhanced" "Detected in many" "AF22: 32.0;fHDF/TERT166: 15.0;HUVEC TERT2: 21.9;THP-1: 17.8" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 6 "cerebellum: 105.4" "HPA023056, HPA023849" Enhanced Approved Nucleoplasm NA NA Nucleoplasm "HPA023056: AB_1859315, HPA023849: AB_1859316" "unprognostic (8.80e-3)" "unprognostic (9.68e-2)" "unprognostic (2.05e-1)" "unprognostic (3.40e-2)" "unprognostic (5.43e-2)" "unprognostic (3.73e-3)" "unprognostic (1.52e-3)" "unprognostic (6.17e-2)" "unprognostic (1.72e-1)" "unprognostic (1.57e-1)" "unprognostic (8.18e-2)" "unprognostic (1.83e-1)" "unprognostic (1.19e-3)" "unprognostic (1.16e-3)" "unprognostic (2.43e-1)" "unprognostic (2.52e-3)" "unprognostic (7.82e-4)" 9.2 11.3 5.2 2.8 7.0 1.9 9.1 69.1 11.5 11.0 3.4 9.1 4.7 1.7 19.8 5.9 3.8 9.0 10.0 7.0 5.8 5.1 3.1 1.2 6.4 4.0 8.4 2.8 20.5 1.4 1.4 16.8 8.0 12.2 4.4 3.5 6.7 8.7 3.0 3.8 4.6 3.2 13.3 12.2 18.5 2.4 3.4 8.9 0.5 5.3 6.9 2.6 7.4 5.4 0.0 9.8 8.8 0.1 1.7 0.0 0.1 0.0 0.0 32.0 0.0 5.1 9.0 0.1 4.6 6.7 1.6 1.0 0.0 0.0 0.0 0.0 15.0 0.0 0.1 0.0 0.0 1.3 0.0 1.9 6.3 0.3 0.2 0.9 0.0 9.6 11.1 0.0 0.1 0.0 0.0 21.9 7.6 0.1 0.0 2.8 0.0 4.1 0.0 2.2 0.0 0.0 0.0 7.2 0.5 0.0 0.0 4.1 2.6 0.4 0.0 0.0 3.0 0.0 17.8 12.4 12.7 1.0 3.7 0.7 0.0 0.0 0.1 4.8 0.0 10.4 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.1 9.8 0.0 0.1 5.2 7.0 69.1 4.3 5.8 5.1 8.4 2.8 12.2 8.9 0.0 4.8 0.0 0.1 3.3 27.9 9.1 0.0 2.7 1.2 0.0 2.0 0.0 0.0 0.0 1.6 22.4 0.0 0.0 0.0 0.0 7.2 0.2 12.7 0.0 0.1 14.3 1.2 14.1 1.6 3.6 9.2 0.9 13.5 0.0 0.0 0.7 0.0 0.0 7.4 3.1 2.7 0.0 3.3 0.1 1.5 3.9 0.1 0.0 0.0 0.1 ZRSR2 "U2AF1-RS2, U2AF1L2, URP, ZC3H22" ENSG00000169249 "Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2" Q15696 X 15790472-15823260 "Cancer-related genes, Predicted intracellular proteins" "mRNA processing, mRNA splicing" "Ribonucleoprotein, RNA-binding" "Cancer-related genes" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "prognostic favorable (7.96e-4)" "unprognostic (1.54e-2)" "unprognostic (7.31e-2)" "prognostic favorable (8.50e-5)" "unprognostic (8.08e-2)" "unprognostic (1.69e-1)" "unprognostic (6.14e-3)" "unprognostic (5.72e-3)" "unprognostic (8.46e-2)" "unprognostic (3.47e-3)" "unprognostic (6.90e-2)" "unprognostic (2.85e-2)" "prognostic unfavorable (4.87e-5)" "unprognostic (8.14e-2)" "unprognostic (3.04e-1)" "unprognostic (1.65e-2)" "prognostic favorable (2.97e-4)" 11.4 9.7 16.7 13.4 21.7 32.5 14.2 22.5 22.1 20.7 13.6 7.6 11.2 9.1 17.1 17.7 10.9 11.8 8.8 12.8 16.1 14.4 11.5 8.2 13.9 21.7 18.1 11.6 16.7 9.2 15.7 31.1 9.8 16.0 11.8 10.9 9.4 10.6 10.6 31.7 12.3 12.4 14.5 20.1 21.1 9.5 4.8 17.5 7.9 12.8 5.6 16.5 21.8 16.7 23.8 17.8 22.0 18.8 10.2 20.3 7.6 9.5 6.4 11.0 10.3 15.6 13.5 4.4 7.9 7.4 7.7 7.8 7.5 7.9 10.9 13.6 7.3 19.7 9.4 10.6 13.7 8.0 8.1 14.0 7.2 15.1 7.0 10.7 16.4 16.9 6.7 12.6 14.1 23.0 15.1 13.3 10.5 11.3 10.8 9.2 11.7 8.7 17.3 14.0 5.0 8.9 10.1 15.4 11.1 9.1 7.6 7.7 8.4 18.5 16.5 11.5 15.7 13.0 9.5 9.3 7.7 5.5 20.2 7.4 9.2 7.7 10.4 5.9 11.9 9.9 22.0 18.8 16.6 13.5 16.6 13.1 21.6 17.1 18.0 10.9 23.8 20.3 14.8 21.0 10.2 15.6 17.8 16.0 7.6 16.7 21.7 22.5 22.1 16.1 14.4 18.1 11.6 16.0 17.5 8.9 19.5 19.6 9.7 10.1 13.0 20.2 5.1 25.4 17.0 15.7 13.7 6.1 19.9 11.9 1.0 13.5 12.1 0.0 12.9 6.7 11.0 6.3 31.2 12.5 17.3 7.9 16.1 8.6 25.9 1.1 12.7 29.4 11.8 22.6 11.2 9.0 11.1 9.1 15.6 11.0 18.4 19.4 17.9 3.8 3.8 9.3 6.1 30.8 11.5 6.5